0001297184-24-00005810-Q Amphastar Pharmaceuticals, Inc. 20241107202411071618471618471618471 0 0001297184-24-000058 10-Q 99 20240930 20241107 20241107 Amphastar Pharmaceuticals, Inc. 0001297184 2834 330702205 1231 10-Q 34 001-36509 241436100 11570 SIXTH STREET RANCHO CUCAMONGA CA 91730 909-980-9484 11570 SIXTH STREET RANCHO CUCAMONGA CA 91730 10-Q 1 amph-20240930x10q.htm 10-Q 0000http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsP0Y440000Large Accelerated Filerfalse0000falseAmphastar Pharmaceuticals, Inc.--12-31false0001297184Q3falseYestrueDEfalse2024-09-30000P30D0000000001297184us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001297184amph:November2014ShareRepurchasePlanMember2024-07-012024-09-300001297184amph:November2014ShareRepurchasePlanMember2024-01-012024-09-300001297184us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001297184amph:November2014ShareRepurchasePlanMember2023-07-012023-09-300001297184amph:November2014ShareRepurchasePlanMember2023-01-012023-09-300001297184us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001297184amph:November2014ShareRepurchasePlanMemberus-gaap:SubsequentEventMember2024-11-040001297184amph:November2014ShareRepurchasePlanMember2024-06-030001297184us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001297184us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001297184us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001297184us-gaap:CommonStockMember2024-07-012024-09-300001297184us-gaap:CommonStockMember2024-04-012024-06-300001297184us-gaap:CommonStockMember2024-01-012024-03-310001297184us-gaap:CommonStockMember2023-07-012023-09-300001297184us-gaap:CommonStockMember2023-04-012023-06-300001297184us-gaap:CommonStockMember2023-01-012023-03-3100012971842024-06-3000012971842024-03-3100012971842023-06-3000012971842023-03-310001297184us-gaap:RetainedEarningsMember2024-09-300001297184us-gaap:AdditionalPaidInCapitalMember2024-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001297184us-gaap:RetainedEarningsMember2024-06-300001297184us-gaap:AdditionalPaidInCapitalMember2024-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001297184us-gaap:RetainedEarningsMember2024-03-310001297184us-gaap:AdditionalPaidInCapitalMember2024-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001297184us-gaap:RetainedEarningsMember2023-12-310001297184us-gaap:AdditionalPaidInCapitalMember2023-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001297184us-gaap:RetainedEarningsMember2023-09-300001297184us-gaap:AdditionalPaidInCapitalMember2023-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001297184us-gaap:RetainedEarningsMember2023-06-300001297184us-gaap:AdditionalPaidInCapitalMember2023-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001297184us-gaap:RetainedEarningsMember2023-03-310001297184us-gaap:AdditionalPaidInCapitalMember2023-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001297184us-gaap:RetainedEarningsMember2022-12-310001297184us-gaap:AdditionalPaidInCapitalMember2022-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001297184amph:EmployeeStockPurchasePlan2014Member2024-09-300001297184amph:The2015EquityIncentivePlanMember2024-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2023-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember2024-07-012024-09-300001297184amph:AnpMemberamph:ResearchAndDevelopmentServicesMember2024-07-012024-09-300001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2024-07-012024-09-300001297184us-gaap:ProductMember2024-07-012024-09-300001297184us-gaap:ProductAndServiceOtherMember2024-07-012024-09-300001297184country:US2024-07-012024-09-300001297184country:FR2024-07-012024-09-300001297184country:CN2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember2024-01-012024-09-300001297184amph:AnpMemberamph:ResearchAndDevelopmentServicesMember2024-01-012024-09-300001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2024-01-012024-09-300001297184us-gaap:ProductMember2024-01-012024-09-300001297184us-gaap:ProductAndServiceOtherMember2024-01-012024-09-300001297184country:US2024-01-012024-09-300001297184country:FR2024-01-012024-09-300001297184country:CN2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember2023-07-012023-09-300001297184amph:AnpMemberamph:ResearchAndDevelopmentServicesMember2023-07-012023-09-300001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-07-012023-09-300001297184us-gaap:ProductMember2023-07-012023-09-300001297184us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001297184country:US2023-07-012023-09-300001297184country:FR2023-07-012023-09-300001297184country:CN2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember2023-01-012023-09-300001297184amph:AnpMemberamph:ResearchAndDevelopmentServicesMember2023-01-012023-09-300001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-01-012023-09-300001297184us-gaap:ProductMember2023-01-012023-09-300001297184us-gaap:ProductAndServiceOtherMember2023-01-012023-09-300001297184country:US2023-01-012023-09-300001297184country:FR2023-01-012023-09-300001297184country:CN2023-01-012023-09-300001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2024-07-012024-09-300001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2024-01-012024-09-300001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2023-07-012023-09-300001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-07-012023-09-300001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2023-01-012023-09-300001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-01-012023-09-300001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2022-11-012022-11-300001297184us-gaap:MachineryAndEquipmentMember2024-09-300001297184us-gaap:LeaseholdImprovementsMember2024-09-300001297184us-gaap:LandMember2024-09-300001297184us-gaap:ConstructionInProgressMember2024-09-300001297184us-gaap:BuildingMember2024-09-300001297184amph:FurnitureFixturesAndVehiclesMember2024-09-300001297184us-gaap:MachineryAndEquipmentMember2023-12-310001297184us-gaap:LeaseholdImprovementsMember2023-12-310001297184us-gaap:LandMember2023-12-310001297184us-gaap:ConstructionInProgressMember2023-12-310001297184us-gaap:BuildingMember2023-12-310001297184amph:FurnitureFixturesAndVehiclesMember2023-12-310001297184amph:BaqsimiAcquisitionsMember2024-06-012024-06-300001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2024-09-300001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2024-09-300001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2024-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001297184country:US2024-09-300001297184country:FR2024-09-300001297184country:CN2024-09-300001297184country:US2023-12-310001297184country:FR2023-12-310001297184country:CN2023-12-310001297184us-gaap:RetainedEarningsMember2024-07-012024-09-300001297184us-gaap:RetainedEarningsMember2024-04-012024-06-300001297184us-gaap:RetainedEarningsMember2024-01-012024-03-310001297184us-gaap:RetainedEarningsMember2023-07-012023-09-300001297184us-gaap:RetainedEarningsMember2023-04-012023-06-300001297184us-gaap:RetainedEarningsMember2023-01-012023-03-310001297184amph:CommitmentsToPurchaseEquipmentAndRawMaterialsMember2024-07-012024-09-300001297184us-gaap:RevolvingCreditFacilityMemberamph:RevlovingLineOfCreditDueAugust2026Memberamph:CapitalOneNationalAssociationMember2024-09-300001297184us-gaap:LineOfCreditMemberamph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember2024-09-300001297184amph:TermLoanDueJune2028Memberamph:WellsFargoBankMember2024-09-300001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2024-09-300001297184us-gaap:RevolvingCreditFacilityMemberamph:RevlovingLineOfCreditDueAugust2026Memberamph:CapitalOneNationalAssociationMember2023-12-310001297184us-gaap:LineOfCreditMemberamph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember2023-12-310001297184amph:TermLoanDueJune2028Memberamph:WellsFargoBankMember2023-12-310001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2023-12-310001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2023-12-310001297184amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember2023-12-310001297184amph:PropertyAndCasualtyClaimMemberus-gaap:PendingLitigationMember2024-09-300001297184us-gaap:LineOfCreditMemberamph:LineOfCreditDueNovember2033Memberamph:ICBCBankMember2024-01-310001297184us-gaap:TrademarksMember2024-09-300001297184us-gaap:TrademarksMember2023-12-310001297184amph:CorporateBondsShortTermMember2024-09-300001297184us-gaap:MunicipalBondsMember2023-12-310001297184us-gaap:CorporateBondSecuritiesMember2023-12-310001297184amph:CorporateBondsShortTermMember2023-12-3100012971842023-01-012023-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2023-12-310001297184us-gaap:UseRightsMember2024-09-300001297184us-gaap:PatentsMember2024-09-300001297184amph:BaqsimiAcquisitionsMember2024-09-300001297184us-gaap:UseRightsMember2023-12-310001297184us-gaap:PatentsMember2023-12-310001297184amph:BaqsimiAcquisitionsMember2023-12-310001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2024-09-300001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2024-01-012024-09-300001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2024-07-012024-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2024-01-012024-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2023-07-012023-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2023-01-012023-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2023-01-012023-09-300001297184us-gaap:LineOfCreditMemberamph:LineOfCreditDueNovember2033Memberamph:ICBCBankMember2024-09-300001297184amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember2024-09-300001297184amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember2023-09-120001297184amph:McKessonMemberus-gaap:SalesRevenueNetMember-

gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001297184amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001297184amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:EliLillyAndCoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:CencoraMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001297184amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001297184amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001297184amph:EliLillyAndCoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001297184amph:CencoraMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001297184amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001297184amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001297184us-gaap:TreasuryStockCommonMember2024-09-300001297184us-gaap:CommonStockMember2024-09-300001297184us-gaap:TreasuryStockCommonMember2024-06-300001297184us-gaap:CommonStockMember2024-06-300001297184us-gaap:TreasuryStockCommonMember2024-03-310001297184us-gaap:CommonStockMember2024-03-310001297184us-gaap:TreasuryStockCommonMember2023-12-310001297184us-gaap:CommonStockMember2023-12-310001297184us-gaap:TreasuryStockCommonMember2023-09-300001297184us-gaap:CommonStockMember2023-09-300001297184us-gaap:TreasuryStockCommonMember2023-06-300001297184us-gaap:CommonStockMember2023-06-300001297184us-gaap:TreasuryStockCommonMember2023-03-310001297184us-gaap:CommonStockMember2023-03-310001297184us-gaap:TreasuryStockCommonMember2022-12-310001297184us-gaap:CommonStockMember2022-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184amph:BaqsimiAcquisitionsMember2023-04-210001297184us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:FairValueMeasurementsRecurringMember2024-09-300001297184us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184us-gaap:FairValueMeasurementsRecurringMember2023-12-310001297184amph:BaqsimiAcquisitionsMember2023-04-212023-04-210001297184amph:EmployeeAndNonEmployeeStockOptionsMember2023-07-012023-09-300001297184us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001297184us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001297184us-gaap:CostOfSalesMember2024-07-012024-09-300001297184amph:EmployeeStockPurchasePlan2014Member2024-07-012024-09-300001297184us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001297184us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001297184us-gaap:CostOfSalesMember2024-01-012024-09-300001297184amph:EmployeeStockPurchasePlan2014Member2024-01-012024-09-300001297184us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001297184us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001297184us-gaap:CostOfSalesMember2023-07-012023-09-300001297184amph:EmployeeStockPurchasePlan2014Member2023-07-012023-09-300001297184us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001297184us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001297184us-gaap:CostOfSalesMember2023-01-012023-09-300001297184amph:EmployeeStockPurchasePlan2014Member2023-01-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2024-07-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2024-01-012024-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2023-07-012023-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2023-01-012023-09-300001297184amph:November2014ShareRepurchasePlanMember2024-11-04000129718420241-11-010001297184us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001297184us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001297184202-04-012024-06-300001297184us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001297184202-01-012024-03-310001297184us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001297184us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001297184202-04-012023-06-300001297184us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001297184202-01-012023-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2024-09-300001297184amph:RestrictedStockUnitsIssuedAsCompensationMember2024-01-012024-09-300001297184us-gaap:AccountsReceivableMember2024-09-300001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300001297184us-gaap:AccountsReceivableMember2023-12-310001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310001297184202-09-300001297184202-12-310001297184srt:MinimumMember2024-01-012024-09-300001297184srt:MaximumMember2024-01-012024-09-300001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2024-01-012024-09-300001297184us-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001297184202-07-012024-09-300001297184us-gaap:InterestRateSwapMember2024-01-012024-09-300001297184us-gaap:InterestRateSwapMember2023-07-012023-09-300001297184us-gaap:InterestRateSwapMember2023-01-012023-09-300001297184amph:EmployeeStockPurchasePlan2014Member2024-05-012024-05-310001297184202-01-012023-09-300001297184amph:BaqsimiAcquisitionsMember2024-01-012024-09-300001297184amph:BaqsimiAcquisitionsMember2023-07-012023-09-300001297184amph:BaqsimiAcquisitionsMember2023-01-012023-09-300001297184amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember2023-09-300001297184amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember2023-09-012023-09-300001297184amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember2023-09-122023-09-120001297184us-gaap:LineOfCreditMemberamph:LineOfCreditDueNovember2033Memberamph:ICBCBankMember2024-01-012024-09-300001297184amph:BaqsimiAcquisitionsMember2023-06-302023-06-300001297184amph:EmployeeAndNonEmployeeStockOptionsMember2024-07-012024-09-300001297184amph:EmployeeAndNonEmployeeStockOptionsMember2024-01-012024-09-300001297184amph:EmployeeAndNonEmployeeStockOptionsMember2023-01-012023-09-300001297184srt:MaximumMemberamph:BaqsimiAcquisitionsMemberamph:TransitionServicesAgreementMember2023-06-302023-06-300001297184srt:MaximumMemberamph:BaqsimiAcquisitionsMemberamph:ManufacturingServicesAgreementMember2023-06-302023-06-300001297184202-01-012024-09-300001297184202-09-300001297184202-12-31iso4217:USDiso4217:USDxbrli:sharesxbrli:pureamph:Damph:itemxbrli:sharesamph:segmentTable of Contentsâ€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549â€‹â€‹FORM 10-Qâ€‹â€‹âŒ§QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024orâ€‹â€”»TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from Â Â Â Â Â Â Â Â Â Â Â Â to Â Â Â Â Â Â Â Â Â Â Â Â Commission file number 001-36509â€‹â€‹AMPHASTAR PHARMACEUTICALS, INC.(Exact name of Registrant as specified in its charter)â€‹â€‹â€‹â€‹â€‹DelawareÂ 33-0702205(State or other jurisdiction ofincorporation or organization)Â (I.R.S. EmployerIdentification No.)â€‹â€‹â€‹â€‹11570 6th StreetÂ â€‹Rancho Cucamonga, CAÂ 91730(Address of principal executive offices)â€‹(zip code)â€‹ (909) 980-9484(Registrantâ€™s telephone number, including area code)â€‹â€‹Indicate by check mark whether the registrant (1) has filed all reports required to be filed by SectionÂ 13Â orÂ 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Â Â Â Â YesÂ Â âŒ§Â Â Â Â NoÂ Â â—»â€‹Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â Â YesÂ Â âŒ§Â Â Â Â NoÂ Â â—»â€‹Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹LargeÂ acceleratedÂ filerâ€‹âŒ§â€‹Accelerated filerâ€‹â—»â€‹â€‹â€‹â€‹â€‹Non-accelerated filerâ€‹â—»â€‹SmallerÂ reportingÂ companyâ€‹â—»â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

claims;â—our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions, divestitures or investments, including the anticipated benefits of such acquisitions, divestitures or investments;â—our ability to expand internationally;â—economic and industry trends and trend analysis;â—our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business both in the United States and internationally;â—the impact of trade tariffs, export or import restrictions, or other trade barriers;â—the impact of Patient Protection and Affordable Care Act (as amended) and other legislative and regulatory healthcare reforms in the countries in which we operate including the potential for drug price controls;â—the impact of global and domestic tax reforms;â—the timing for completion and the validation of the new construction at our ANP and Amphastar facilities;â—the timing and extent of share buybacks; andâ—our financial performance expectations, including our expectations regarding our backlog, revenue, cost of revenue, gross profit or gross margin, operating expenses, including changes in research and development, sales and marketing and general and administrative expenses, and our ability to achieve and maintain future profitability.â€‹ Table of ContentsYou should read this Quarterly Report and the documents that we reference elsewhere in this Quarterly Report completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We discuss many of these risks and uncertainties in greater detail in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2023, particularly in Item 1A. â€œRisk Factors.â€ These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report regardless of the time of delivery of this Quarterly Report, and such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report.Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to â€œAmphastar,â€ â€œthe Company,â€ â€œwe,â€ â€œour,â€ and â€œusâ€ refer to Amphastar Pharmaceuticals, Inc. and our subsidiaries.â€‹â€‹â€‹â€‹â€‹ Table of ContentsPART I â€“ FINANCIAL INFORMATIONITEM 1. FINANCIAL STATEMENTSAMPHASTAR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share data)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹2024â€‹2023â€‹(unaudited)â€‹â€‹ASSETSâ€‹â€‹â€‹Current assets:â€‹â€‹â€‹â€‹â€‹Cash and cash equivalentsâ€‹$ 192,116â€‹$ 144,296Restricted cashâ€‹ 235â€‹ 235Short-term investmentsâ€‹ 58,375â€‹ 112,510Restricted short-term investmentsâ€‹Â 2,200â€‹Â 2,200Accounts receivable, netâ€‹Â 139,635â€‹Â 114,943Inventoriesâ€‹Â 130,316â€‹Â 105,833Income tax refunds and depositsâ€‹Â 5,349â€‹Â 526Prepaid expenses and other assetsâ€‹Â 17,723â€‹Â 9,057Total current assetsâ€‹Â 545,949â€‹Â 489,600â€‹â€‹â€‹â€‹â€‹Property, plant, and equipment, netâ€‹Â 295,384â€‹Â 282,746Finance lease right-of-use assetsâ€‹â€‹ 426â€‹â€‹ 564Operating lease right-of-use assetsâ€‹ 31,708â€‹ 32,333Investment in unconsolidated affiliateâ€‹â€‹ â€”â€‹â€‹ 527Goodwill and intangible assets, netâ€‹Â 594,796â€‹Â 613,295Long-term investmentsâ€‹â€‹ â€”â€‹â€‹ 14,685Other assetsâ€‹Â 23,663â€‹Â 25,910Deferred tax assetsâ€‹Â 53,252â€‹Â 53,252Total assetsâ€‹$ 1,545,178â€‹$ 1,512,912â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹LIABILITIES AND STOCKHOLDERS' EQUITYâ€‹â€‹â€‹â€‹â€‹Current liabilities:â€‹â€‹â€‹â€‹â€‹Accounts payable and accrued liabilitiesâ€‹$ 153,268â€‹$ 93,366Accrued payments for BAQSIMIÂ® (see Note 3)â€‹â€‹ â€”â€‹â€‹ 126,090Income taxes payableâ€‹Â 1,281â€‹Â 1,609Current portion of long-term debtâ€‹Â 252â€‹Â 436Current portion of operating lease liabilitiesâ€‹â€‹ 4,209â€‹â€‹ 3,906Total current liabilitiesâ€‹Â 159,010â€‹Â 225,407â€‹â€‹â€‹â€‹â€‹Long-term reserve for income tax liabilitiesâ€‹Â 6,066â€‹Â 6,066Long-term debt, net of current portion and unamortized debt issuance costsâ€‹Â 596,446â€‹Â 589,579Long-term operating lease liabilities, net of current portionâ€‹â€‹ 28,941â€‹â€‹ 29,721Other long-term liabilitiesâ€‹Â 27,037â€‹Â 22,718Total liabilitiesâ€‹Â 817,500â€‹Â 873,491Commitments and contingenciesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Stockholdersâ€™ equity:â€‹â€‹â€‹â€‹â€‹â€‹Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstandingâ€‹Â â€”â€‹Â â€”Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023â€‹Â 6â€‹Â 6Additional paid-in capitalâ€‹Â 496,427â€‹Â 486,056Retained earningsâ€‹Â 530,823â€‹Â 409,268Accumulated other comprehensive lossâ€‹Â (8,821)â€‹Â (8,478)Treasury stockâ€‹Â (290,757)â€‹Â (247,431)Total equityâ€‹â€‹ 727,678â€‹â€‹ 639,421Total liabilities and stockholdersâ€™ equityâ€‹$ 1,545,178â€‹$ 1,512,912See Accompanying Notes to Condensed Consolidated Financial Statements.â€‹-1- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited; in thousands, except per share data)â€‹Three Months Ended â€‹Nine Months Ended Â â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Net revenues:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

adjustments are of a normal, recurring nature. The Companyâ€™s results of operations, comprehensive income and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.â€‹Note 2. Summary of Significant Accounting Policiesâ€‹Basis of Presentationâ€‹The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with GAAP. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.â€‹The Companyâ€™s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals,Â Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Amphastar France Pharmaceuticals, S.A.S., or AFP, (5) Amphastar UK Ltd., or AUK, (6) International Medication Systems (UK) Limited, or IMS UK, and (7) Amphastar Medication Co., LLC, or Amphastar Medication.â€‹Investment in Unconsolidated Affiliate â€‹The Company applies the equity method of accounting for investments when it has significant influence, but not controlling interest in the investee. The Companyâ€™s proportionate share of the earnings or losses resulting from these investments is reported as â€œEquity in losses of unconsolidated affiliateâ€ in the accompanying condensed consolidated statements of operations. Investments accounted for using the equity method may be reported on a lag of up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date.â€‹-6- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹The carrying value of equity method investments is reported as â€œInvestment in unconsolidated affiliateâ€ in the accompanying condensed consolidated balance sheets. The Companyâ€™s equity method investments are reported at cost and adjusted each period for the Companyâ€™s share of the investeeâ€™s earnings or losses and dividends paid, if any.â€‹Use of Estimatesâ€‹The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: fair value of acquired assets, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.â€‹Foreign Currency â€‹The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the U.S. Dollar, or USD. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Companyâ€™s condensed consolidated statements of operations. â€‹The Companyâ€™s French subsidiary, AFP, maintains its books of record in euros. AUKâ€™s subsidiary, IMS UK, maintains its books of record in British pounds. These local currencies have been determined to be the subsidiariesâ€™ respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholdersâ€™ equity and are included as a component of other comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). â€‹The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $1.4 million gain and a $0.4 million gain for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $0.9 million loss and a $0.4 million loss, respectively. â€‹Comprehensive Incomeâ€‹The Companyâ€™s comprehensive income includes its foreign currency translation gains and losses as well as its share of other comprehensive income from its equity method investments. â€‹Acquisitions â€‹The Company evaluates acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and substantive processes that have the ability to create outputs, which would meet the definition of a business.-7- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹â€‹Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.â€‹For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis, with the exception of non-qualifying assets. Goodwill is not recognized in an asset acquisition. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR&D, asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration, including assumed contingent considerations, is not recognized until all contingencies are resolved and the consideration is paid or becomes payable (unless contingent considerations meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired), at which point the consideration is allocated to the assets acquired based on their relative fair values at the acquisition date, with the exception of non-qualifying assets.â€‹Judgments are used in determining estimates of useful lives of long-lived assets. Useful life estimates are based on, among other factors, estimates of expected future net cash flows, the assessment of each assetâ€™s life cycle, and the impact of competitive trends on each assetâ€™s life cycle and other factors. These judgments can materially impact the estimates used to allocate purchase consideration to assets acquired and liabilities assumed, and the resulting timing and amounts charged to or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.â€‹Advertising Expenseâ€‹Advertising expenses, primarily associated with Primatene MISTÂ®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Companyâ€™s condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, advertising expenses were $2.5 million and $7.8 million, respectively. For the three and nine months ended September 30, 2023, advertising expenses were $1.9 million and $8.1 million, respectively.â€‹Financial Instrumentsâ€‹The Companyâ€™s accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses, short-term borrowings, and long-term obligations. The Company considers the carrying amounts of current assets and liabilities on the condensed consolidated balance sheets to approximate the fair value of these financial instruments due to the short maturity of these items. The carrying value of the Companyâ€™s long-term obligations, with the exception of the convertible debt (see Note 14), approximates their fair value, as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. Investments and short-term investments are recorded at fair value based on quoted prices from recognized security exchanges and other methods (see Note 9). The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt. The Companyâ€™s interest rate swap contracts exchange the variable interest rates for fixed interest rates. -8- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹Cash and Cash Equivalentsâ€‹Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments with original maturities of three months or less.â€‹Investmentsâ€‹Investments as of September 30, 2024 and December 31, 2023 consisted of certificates of deposit and investment grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months.â€‹Restricted Cash â€‹Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of September 30, 2024 and December 31, 2023, the restricted cash balance was $0.2 million.â€‹Restricted Short-Term Investmentsâ€‹Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workersâ€™ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of September 30, 2024 and December 31, 2023, the balance of restricted short-term investments was $2.2 million.â€‹Deferred Income Taxesâ€‹The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized.â€‹Debt Issuance Costsâ€‹Debt issuance costs related to non-revolving debt are recognized as a reduction to the related debt balance in the accompanying condensed consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Debt issuance costs associated with revolving debt are capitalized within other long-term assets on the condensed consolidated balance sheets and are amortized to interest expense over the term of the related revolving debt.â€‹Convertible Debtâ€‹The Company accounts for its convertible debt instruments as a single unit of accounting, a liability, because the Company concluded that the conversion features do not require bifurcation as a derivative under Accounting Standards Codification, or ASC, 815-15, Derivatives and Hedging and the Company did not issue its convertible debt instruments at a substantial premium. The Company records debt issuance costs as contra-liabilities in its condensed consolidated balance sheets at issuance and amortizes them over the contractual term of the convertible debt instrument using the effective interest rate.â€‹In accordance with Accounting Standards Update, or ASU,Â 2020-06,Â Debtâ€”Debt with Conversion and Other Options (SubtopicÂ 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (SubtopicÂ 815-40): Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, the Company evaluates convertible debt instruments to determine if the conversion feature is freestanding or embedded. If the conversion feature is embedded, the conversion -9- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹feature is not bifurcated from the host instrument. If the conversion feature does not require derivative treatment underÂ ASC 815, the instrument is evaluated underÂ ASC 470-20,Â â€œDebt with Conversion and Other Optionsâ€ for consideration of any beneficial conversion features. If no beneficial conversion features exist that require separate recognition, convertible debt instruments are accounted for as a single liability measured at its amortized cost as long asÂ noÂ other features require separation and recognition as derivatives.â€‹Litigation, Commitments and Contingenciesâ€‹Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized.â€‹Recent Accounting Pronouncementsâ€‹In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the disclosure requirements related to the new standard.â€‹In December 2023, the FASB issued Accounting Standard Update 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures which requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to the new standard.â€‹Note 3. BAQSIMIÂ® Asset Acquisitionâ€‹On June 30, 2023, the Company completed its acquisition of BAQSIMIÂ® glucagon nasal powder, or BAQSIMIÂ®, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli Lilly & Company, or Lilly, dated April 21, 2023. â€‹The Company accounted for the BAQSIMIÂ® acquisition as an asset acquisition in accordance with ASC 805, Business Combinations, as substantially all the fair value of the assets acquired was concentrated in a single identifiable asset, BAQSIMIÂ® product rights. The BAQSIMIÂ® product rights include the license for the BAQSIMIÂ® intellectual property, regulatory documentation, marketing authorizations, and domain names, which are considered a single asset as they are inextricably linked. â€‹â€‹-10- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹The total purchase price was allocated to the acquired assets based on their relative fair values, as follows: â€‹â€‹â€‹â€‹â€‹â€‹â€‹Fair Valueâ€‹â€‹(in thousands)Property, plant, and equipmentÂ Â Â Â $ 34,426BAQSIMIÂ® product rightsâ€‹Â 591,338Deferred tax assetsâ€‹â€‹ 2,341Total assets acquiredâ€‹$ 628,105â€‹The Company amortizes the acquired intangible asset to cost of revenues on a straight line basis over its estimated useful life of 24 years (see Note 10 for additional information).A portion of the consideration for the asset acquisition was a deferred cash payment. The fair value of the deferred cash payment was accreted to its full $129.0 million amount over a one-year period from the date of acquisition through interest expense. During the nine months ended September 30, 2024, the Company recognized $3.6 million of interest expense related to accretion of the deferred cash payment. During the three and nine months ended September 30, 2023, $1.8 million of interest expense was recognized related to the accretion of the deferred cash payment. The Company made the $129.0 million deferred cash payment in June 2024.â€‹The Company may also be required to pay additional contingent consideration of up to an aggregate of $575.0 million in cash as part of the BAQSIMIÂ® acquisition, based on the achievement of certain net sales milestones. Through September 30, 2024, the Company has not triggered any milestones and therefore no amounts have been recognized or paid.â€‹Manufacturing Services Agreementâ€‹In connection with the closing of the acquisition, the Company entered into a Manufacturing Services Agreement, or the MSA, with Lilly, pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain manufacturing, packaging, labeling and supply services for BAQSIMIÂ® directly or through third-party contractors to the Company in connection with its operation of the development, manufacture, and commercialization of BAQSIMIÂ®. Upon termination of the MSA, the Company will be obligated to purchase all API, components, and finished goods on hand at prices agreed upon in the MSA.â€‹Transition Services Agreementâ€‹In connection with the closing of the acquisition, the Company also entered into a Transition Services Agreement, or the TSA, with Lilly pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain services to the Company to support the transition of BAQSIMIÂ® operations to the Company, including with respect to the conduct of certain clinical, regulatory, medical affairs, and commercial sales channel activities. â€‹Throughout 2024, the Company assumed distribution responsibilities, from Lilly, to its customers in the United States, and certain other countries. As a result, the Company has recorded the sales and related cost of BAQSIMIÂ® in these countries as product revenue, net and cost of revenues, respectively. The Company will continue to assume distribution of BAQSIMIÂ® for the remaining territories on a country by country basis throughout 2024.â€‹-11- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹Note 4. Revenue Recognitionâ€‹Product revenues, netâ€‹In accordance with ASC 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Companyâ€™s customers obtain control of the promised goods. â€‹Generally, revenue is recognized at the time of product delivery to the Companyâ€™s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. â€‹The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration including provision for chargebacks and rebates, accrual for product returns, prompt pay discounts, distributor fees, patient co-pay assistance, and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Payment terms offered to customers generally range from 30 to 75 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If the Company expects, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, the amount of consideration is

not adjusted for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, distribution and marketing expenses in the accompanying condensed consolidated statements of operations.â€‹Provision for Chargebacks and Rebates: The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Companyâ€™s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historical chargeback and rebate rates, and current contract pricing.â€‹The provision for chargebacks and rebates is reflected as a component of product revenues, net. The following table is an analysis of the chargeback and rebate provision:
â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)Beginning balanceÂ Â Â Â $ 27,920Â Â Â Â $ 26,606Provision for chargebacks and rebatesâ€‹Â 218,312â€‹Â 200,317Credits and payments issued to third partiesâ€‹Â (181,216)â€‹Â (201,650)Ending balanceâ€‹$ 65,016â€‹$ 25,273â€‹Changes in the chargeback provision from period to period are primarily dependent on the Companyâ€™s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalersâ€™ customer mix. Changes in the rebate provision from period to period are primarily dependent on retailersâ€™ and other indirect customersâ€™ purchases. The approach that the Company uses to estimate chargebacks and rebates has been consistently applied for all periods -12- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 20 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer.â€‹The provision for chargebacks and rebates is included in the following balance sheet
accounts:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹2024â€‹2023â€‹(in thousands)Reduction to accounts receivable, net$ 21,355Â Â Â Â $ 21,861Accounts payable and accrued liabilitiesÂ 43,661â€‹Â 6,059Total$ 65,016â€‹$ 27,920â€‹Accrual for Product Returns: The Company offers certain customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Companyâ€™s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and new competition.â€‹Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized.â€‹Distributor Fees: The Company engages with wholesalers to distribute its products to end customers. The Company pays the wholesalers a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.â€‹Patient Co-Pay Assistance: Co-pay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The accrual for co-pay is based on an estimate of claims and the cost per claim that the Company expects to receive associated with inventory that exists in the distribution channel at period end.â€‹Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers. The Companyâ€™s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit.â€‹Service revenues derived from research and development contracts are recognized over time based on progress toward satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation. For the three and -13- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹nine months ended September 30, 2024, revenues from research and development services were $0.1 million and $2.0 million, respectively. For the three and nine months ended September 30, 2023, revenues from research and development services were $0.8 million and $2.1 million, respectively.â€‹Other revenuesâ€‹Revenues related to sales of BAQSIMIÂ®, which was supplied and sold by Lilly under the TSA during the three and nine months ended September 30, 2024 and 2023, or BAQSIMIÂ® NEB, were recorded on a net basis, similar to a royalty arrangement. This includes revenues in the United States and certain other countries for a portion of the period.â€‹â€‹Note 5. Net Income per Shareâ€‹Basic net income per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share gives effect to all potentially dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Companyâ€™s Employee Stock Purchase Plan, or ESPP, and potential shares of common stock issuable upon conversion of Convertible Notes of the Company, due March 2029, or the 2029 Convertible Notes.â€‹For the three and nine months ended September 30, 2024, options to purchase 619,847 shares of stock with a weighted-average exercise price of $46.63 per share, were excluded in the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price.â€‹For the three months ended September 30, 2023, none of the Companyâ€™s options were excluded from the computation of diluted net income per share. For the nine months ended September 30, 2023, options to purchase 45,934 shares of stock with a weighted-average exercise price of $46.01 per share, were excluded from the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price.â€‹The following table provides the calculation of basic and diluted net income per share for each of the periods presented:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

assets and liabilities measured at fair value as of SeptemberÂ 30,Â 2024â€<$ 165,513â€<$ 143,872â€<$ 21,641â€<$
â€”â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Â Â Â Â TotalÂ Â Â Â (Level 1)Â Â Â Â (Level 2)Â Â Â Â (Level 3)â€<â€<(in thousands)Cash equivalentsâ€<$ 116,441â€<$ 116,441â€<$
â€”â€<$ â€”Restricted cashâ€<â€< 235â€<â€< 235â€<â€< â€”â€<â€< â€”Short-term investmentsâ€<â€< 37,142â€<â€< â€”â€<â€< 37,142â€<â€< â€”Restricted short-term investmentsâ€<Â 2,200â€<Â â€”â€<Â 2,200â€<Â â€”Interest rate swaps related to variable rate loansâ€<â€< (5,243)â€<â€< â€”â€<â€< (5,243)â€<â€< â€”Total assets and liabilities measured at fair value as of DecemberÂ 31,Â 2023â€<$ 150,775â€<$ 116,676â€<$ 34,099â€<$ â€”â€<The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.â€<Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include investments in unconsolidated affiliates, long-lived assets, goodwill, and intangible assets for which the fair value is determined as part of an impairment test. As of September 30, 2024, and December 31, 2023, there were no significant adjustments to fair value for nonfinancial assets or liabilities.â€<The Companyâ€™s deferred compensation plan assets are valued using the cash surrender value of the life insurance policies and are not included in the table above.â€<â€<-18- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<Note 9. Investmentsâ€<The following is a summary of the Companyâ€™s investments that are classified as held-to-maturity:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Grossâ€<Grossâ€<â€<â€<â€<Amortizedâ€<Unrealizedâ€<Unrealizedâ€<Fairâ€<Â Â Â Â CostÂ Â Â Â GainsÂ Â Â Â LossesÂ Â Â Â Va thousands)Corporate and agency bonds (due within 1 year)â€<$ 31,903â€<$ 67â€<$ (2)â€<$ 31,968Total investments as of SeptemberÂ 30,Â 2024â€<$ 31,903â€<$ 67â€<$ (2)â€<$ 31,968â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Corporate and agency bonds (due within 1 to 3 years)â€<$ 73,815â€<$ 7â€<$ (21)â€<$ 73,801Corporate and agency bonds (due within 1 to 3 years)â€<â€< 14,621â€<â€< 56â€<â€< (1)â€<â€< 14,676Municipal bonds (due within 1 year)â€<â€< 1,081â€<â€< 1â€<â€< â€”â€<â€< 1,082Total investments as of DecemberÂ 31,Â 2023â€<$ 89,517â€<$ 64â€<$ (22)â€<$ 89,559â€<At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, identifying neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.â€<The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Companyâ€™s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements. â€<â€<â€<â€<â€<â€<â€<Note 10. Goodwill and Intangible Assetsâ€<The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification: â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Weighted-Averageâ€<â€<â€<â€<Accumulatedâ€<â€<â€<Â â€<Â Â Â Â Life (Years)Â Â Â Â Original CostÂ Â Â Â AmortizationÂ Â Â Â Net Book ValueÂ â€<â€<(in thousands)Â Definite-lived intangible assetsâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<BAQSIMIÂ® product rights(1)â€<24â€<$ 591,338â€<$ 30,799â€<$ 560,539â€<PatentsÂ 15â€<Â 193â€<â€< 92â€<Â 101â€<Land-use rightsÂ 39â€<Â 2,540â€<â€< 865â€<Â 1,675â€<SubtotalÂ 24â€<Â 594,071â€<Â 31,756â€<Â 562,315â€<Indefinite-lived intangible assetsâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<TrademarkÂ *â€<Â 29,225â€<Â â€”â€<Â 29,225â€<Goodwill - Finished pharmaceutical productsÂ *â€<Â 3,256â€<Â â€”â€<Â 3,256â€<SubtotalÂ *â€<Â 32,481â€<Â â€”â€<Â 32,481â€< As of SeptemberÂ 30,Â 2024Â *â€<$ 626,552â€<$ 31,756â€<$ 594,796â€<â€<-19- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Weighted-Averageâ€<â€<â€<â€<Accumulatedâ€<â€<â€<Â â€<Â Â Â Â Life (Years)Â Â Â Â Original CostÂ Â Â Â AmortizationÂ Â Â Â Net Book ValueÂ â€<â€<(in thousands)Â Definite-lived intangible assetsâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<BAQSIMIÂ® product rights(1)â€<24â€<$ 591,338â€<$ 12,319â€<$ 579,019â€<PatentsÂ 12â€<Â 486â€<â€< 376â€<Â 110â€<Land-use rightsÂ 39â€<Â 2,540â€<â€< 815â€<Â 1,725â€<SubtotalÂ 24â€<Â 594,364â€<Â 13,510â€<Â 580,854â€<Indefinite-lived intangible assetsâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<TrademarkÂ *â€<Â 29,225â€<Â â€”â€<Â 29,225â€<Goodwill - Finished pharmaceutical productsÂ *â€<Â 3,216â€<Â â€”â€<Â 3,216â€<SubtotalÂ *â€<Â 32,441â€<Â â€”â€<Â 32,441â€< As of DecemberÂ 31,Â 2023Â *â€<$ 626,805â€<$ 13,510â€<$ 613,295â€<* Intangible assets with indefinite lives have an indeterminable average life.(1) See Note 3. â€<Goodwillâ€<The changes in the carrying amounts of goodwill are as follows:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<SeptemberÂ 30,Â â€<DecemberÂ 31,Â Â â€<â€<2024â€<2023Â â€<â€<(inÂ thousands)Â Beginning balanceÂ Â Â Â $ 3,216Â Â Â Â $ 3,126â€<Currency translationâ€<Â 40â€<Â 90â€<Ending balanceâ€<$ 3,256â€<$ 3,216â€<â€<â€<Note 11. Inventoriesâ€<Inventories consist of the following:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<SeptemberÂ 30,Â â€<DecemberÂ 31,Â Â â€<â€<2024â€<2023Â â€<â€<(in thousands)Â Raw materials and suppliesÂ Â Â Â $ 60,536Â Â Â Â $ 50,082â€<Work in processâ€<Â 36,016â€<Â 30,822â€<Finished goodsâ€<Â 33,764â€<Â 24,929â€<Total inventoriesâ€<$ 130,316â€<$ 105,833â€<â€<â€<â€<â€<Charges of $0.9 million and $10.1 million were included in the cost of revenues in the Companyâ€™s condensed consolidated statements of operations for the three and nine months ended September 30, 2024, respectively, to adjust the Companyâ€™s inventory and related firm purchase commitments to its net realizable value. For the three months ended September 30, 2023, the Company had an immaterial amount that was included in cost of revenues to adjust the Companyâ€™s inventory and related firm purchase commitments to its net realizable value. For the nine months ended September 30, 2023, charges of $9.6 million were included in the cost of revenues to adjust the Companyâ€™s inventory and related firm purchase commitments to its net realizable value.â€<â€<-20- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<Note 12. Property, Plant, and Equipmentâ€<Property, plant, and equipment consist of the following:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<SeptemberÂ 30,Â â€<DecemberÂ 31,Â Â â€<â€<2024â€<2023Â â€<â€<(in thousands)Â BuildingsÂ Â Â Â $ 170,203Â Â Â Â $ 168,771â€<Leasehold improvementsâ€<Â 42,012â€<Â 41,686â€<Landâ€<Â 7,499â€<Â 7,484â€<Machinery and equipmentâ€<Â 278,200â€<Â 259,484â€<Furniture, fixtures, and automobilesâ€<Â 34,795â€<Â 31,943â€<Construction in progressâ€<Â 28,864â€<Â 18,676â€<Total property, plant, and equipmentâ€<Â 561,573â€<Â 528,044â€<Less accumulated depreciationâ€<Â (266,189)â€<Â (245,298)â€<Total property, plant, and equipment, netâ€<$ 295,384â€<$ 282,746â€<â€<â€<â€<Note 13. Accounts Payable and Accrued Liabilitiesâ€<Accounts payable and accrued liabilities consisted of the following:â€<â€<â€<â€<â€<â€<â€<â€<â€<SeptemberÂ 30,Â â€<DecemberÂ 31,Â â€<2024â€<2023â€<(in thousands)Accrued customer fees and rebates$ 59,949â€<$ 16,702Accrued payroll and related benefitsâ€< 29,207â€<â€< 25,203Accrued product returns, current portionâ€< 13,480â€<â€< 12,263Accrued loss on firm purchase commitmentsâ€< 812â€<â€< 918Other accrued liabilitiesâ€< 15,732â€<â€< 12,842Total accrued liabilitiesÂ 119,180â€<Â 67,928Accounts payableÂ 34,088â€<Â 25,438Total accounts payable and accrued liabilities$ 153,268â€<$ 93,366â€<â€<-21- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<Note 14. Debtâ€<Debt consists of the following:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<SeptemberÂ 30,Â â€<DecemberÂ 31,Â â€<â€<2024â€<2023â€<â€<(in thousands)Convertible Debtâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<2029 Convertible Notesâ€<$ 345,000â€<$ 345,000â€<â€<â€<â€<â€<â€<â€<â€<â€<Term Loanâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Wells Fargo Term Loan due June 2028â€<â€< 250,000â€<â€< 250,000â€<â€<â€<â€<â€<â€<â€<â€<â€<Mortgage Loansâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Mortgage payable with East West Bank paid off June 2024â€<â€< â€”â€<â€< 8,016â€<â€<â€<â€<â€<â€<â€<â€<â€<Other Loans and Payment Obligationsâ€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<French government loans due December 2026â€<â€< 168â€<â€< 158â€<â€<â€<â€<â€<â€<â€<â€<Line of Credit FacilitiesÂ Â Â Â â€<â€<Â Â Â Â Â â€<Â Â Â Â Â â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Line of credit facility with China Merchant Bank due October 2026â€< â€< â€”â€<â€< â€< â€”Wells Fargo Revolving line of credit facility due June 2028â€<â€< â€”â€<â€< â€”Line of credit facility with ICBC Bank due November 2033â€<â€< 13,565â€<â€< â€”â€<â€<â€<â€<â€<â€<â€<â€<â€<Equipment under Finance Leasesâ€<Â 485â€<Â 616Total debtâ€<Â 609,218â€<Â 603,790Less current portion of long-term debtâ€<Â 252â€<Â 436Less: Loan issuance costsâ€<â€< 12,520â€<â€< 13,775Long-term debt, net of current portion and unamortized debt issuance costsâ€<$ 596,446â€<$ 589,579â€<Credit Agreementâ€<2029 Convertible Notesâ€<In September 2023, the Company issued the 2029 Convertible Notes, in the aggregate principal amount of $345.0 million in a private offering pursuant to Section 4(a)(2) and Rule 144A under the Securities Act of 1933, as amended. The Company used portions of the net proceeds from the 2029 Convertible Notes to (i) repay approximately $200.0 million of the Companyâ€™s borrowings under the Wells Fargo Term Loan and (ii) repurchase $50.0 million of the Companyâ€™s common stock.â€<In connection with the issuance of the 2029 Convertible Notes, the Company incurred approximately $10.8 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees. Unamortized debt issuance costs related to the 2029 Convertible Notes were $8.8 million as of September 30, 2024. The fair value of the 2029 Convertible Notes was approximately $365.4 million as of September 30, 2024 based on level 2 inputs.The 2029 Convertible Notes are general senior, unsecured obligations and bear an interest rate of 2.0% per year. The -22- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<2029 Convertible Notes were issued pursuant to an indenture, dated September 15, 2023, or the Indenture, between the Company and U.S. Bank Trust Company, National Association, as trustee.â€<The 2029 Convertible Notes will rank senior in right of payment to all of the Companyâ€™s indebtedness that is expressly subordinated in right of payment to the 2029 Convertible Notes; equal in right of payment to all of the Companyâ€™s unsecured indebtedness that is not so subordinated; effectively junior to any of the Companyâ€™s secured indebtedness to the extent of the value of the assets securing such indebtedness, including any amount outstanding under the Companyâ€™s credit facilities; and structurally junior to all indebtedness and other liabilities of the Companyâ€™s current or future subsidiaries, including trade payables.â€<Interest is payable semi-annually in arrears on March 15 and September 15 of each year. The 2029 Convertible Notes may bear additional interest under specified circumstances relating to the Companyâ€™s failure to comply with its reporting obligations under the Indenture or if the 2029 Convertible Notes are not freely tradeable as required by the Indenture. â€<The 2029 Convertible Notes will mature on March 15, 2029, unless earlier converted, repurchased or redeemed. â€<Conversions of the 2029 Convertible Notes will be settled in cash up to the aggregate principal amount of the 2029 Convertible Notes to be converted, and cash, shares of common stock or a combination of cash and shares of common stock, at the Companyâ€™s election, with respect to the remainder, if any, of the Companyâ€™s conversion obligation in excess of the aggregate principal amount.â€<Holders may convert their 2029 Convertible Notes at their option prior to the close of business on the business day immediately preceding December 15, 2028, in multiples of $1,000 principal amount, only under the following circumstances; (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2029 Convertible Notes on each applicable trading day, (ii) during the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, per $1,000 principal amount of the 2029 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Companyâ€™s common stock and the conversion rate on each such trading day, (iii) if the Company calls the 2029 Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, and (iv) upon the occurrence of specified corporate events defined in the Indenture.â€<On or after December 15, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2029 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.â€<The Company may redeem the 2029 Convertible Notes, at its option, in whole or in part (subject to certain limitations), on or after September 20, 2026 and prior to the 41st scheduled trading day preceding the maturity date, if the last reported sale price of the Companyâ€™s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.â€<The initial conversion rate is 15.8821 shares of the Companyâ€™s common stock per $1,000 principal amount of the 2029 Convertible Notes, which represents an initial conversion price of approximately $62.96 per share of common stock. The initial conversion price of $62.96 represents a premium of approximately 35.0% over the last reported sale price of the -23- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<Companyâ€™s common stock on Nasdaq Global Select Market on September 12, 2023. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.â€<If a fundamental change, as defined in the Indenture, occurs at any time prior to the maturity date, then, subject to certain conditions, holders of the 2029 Convertible Notes may require the Company to repurchase for cash all or any portion of their 2029 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2029 Convertible Notes to be repurchased, plus any accrued and unpaid interest. In addition, following certain specified corporate events or if the Company issues a notice of redemption, the Company will, under certain circumstances, increase the conversion rate for holders who convert their 2029 Convertible Notes in connection with such corporate event or during a redemption period.â€<Syndicated Line of Credit Facility with ICBC Bank â€” Due November 2033â€<In January 2024, the Company entered into a credit agreement with Industrial and Commercial Bank of China Limited, or ICBC Bank, acting as a lender and as agent for other lenders. The credit agreement allows the Company to borrow up to $40.0 million secured by equipment and buildings at ANP. The interest rate and other terms will be determined at the time of the borrowing, depending on the type of loan requested. The credit agreement expires in November 2033.â€<As of September 30, 2024, the Company borrowed approximately $13.6 million under the credit agreement. The loan bears interest at the prime rate as published by The Peopleâ€™s Bank of China minus 0.2%. Interest payments are due quarterly and repayment of the principal amount is biannual and begins in May 2026. As of September 30, 2024, the Company had $13.6 million of principal outstanding under this loan, which is recorded net of loan issuance costs of $0.8 million.â€<Interest Rate Swap Contractâ€<As of September 30, 2024, the fair value of the loans listed above approximated their carrying amount based on Level 2 inputs, with the exception of the 2029 Convertible Notes. For the Wells Fargo Term Loan, the Company has entered into a fixed interest rate swap contract to exchange the variable interest rates for fixed interest rates. The interest rate swap contract is recorded at fair value in the other assets line in the condensed consolidated balance sheets. Changes in the fair values of interest rate swaps were $7.4 million loss and $1.6 million loss for the three and nine months ended September 30, 2024, respectively. Changes in the fair values of interest rate swaps were $4.9 million gain and $2.7 million gain for the three and nine months ended September 30, 2023, respectively.â€<Covenantsâ€<At September 30, 2024 and December 31, 2023, the Company was in compliance with all of its debt covenants.â€<-24- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€<â€<Note 15. Income Taxesâ€<The following table sets forth the Companyâ€™s income tax provision for the periods indicated:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Three Months Ended â€<Nine Months Ended
Â â€<â€<SeptemberÂ 30,Â â€<SeptemberÂ 30,Â Â â€<Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â â€<â€<(inÂ thousands)Â â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Income before taxesâ€<$ 47,683â€<$ 63,637â€<$ 145,802â€<$ 130,014â€<Income tax provisionâ€<â€< 7,254â€<Â 14,025â€<â€< 23,674â€<Â 27,160â€<Income before equity in losses of unconsolidated affiliateâ€<$ 40,429â€<$ 49,612â€<$ 122,128â€<$ 102,854â€<Income tax provision as a percentage of income before income taxesâ€<â€< 15.2%Â 22.0%â€< 16.2%Â 20.9%â€<Valuation Allowanceâ€<In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. Ultimately, realization depends on the existence of future taxable income. Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income.â€<The Company continues to record a full valuation allowance on the net deferred income tax assets of its France subsidiary, AFP, and its U.K. subsidiaries, AUK and IMS UK. The Company will continue to do so until the subsidiaries generate sufficient taxable income to realize their respective deferred income tax assets.â€<The Company records a valuation allowance on net deferred income tax assets in states where it files separately and will continue to do so until sufficient taxable income is generated to realize these state deferred income tax assets.â€<Note 16. Stockholders' Equityâ€<Share Buyback Programâ€<Pursuant to the Companyâ€™s existing share buyback program, the Company purchased 797,038 and 1,004,326 shares of its common stock, during the three and nine months ended September 30, 2024, for total consideration of $35.0 million and $43.5 million, respectively. The Company purchased 1,072,041 and 1,338,757 shares of its common stock during the three and nine months ended September 30, 2023, for total consideration of $50.0 million and $58.1 million, respectively.â€<The Companyâ€™s Board of Directors authorized a $50.0 million increase to the Companyâ€™s share buyback program in June 2024, and an additional $50.0 million increase in November 2024, which is expected to continue for an indefinite period of time. Since the inception of the program,

the Companyâ€™s Board of Directors has authorized a total of $385.0 million in the share buyback program. The primary goal of the program is to offset dilution created by the Companyâ€™s equity compensation programs.â€‹Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Companyâ€™s management and in accordance with the requirements of theÂ SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Companyâ€™s condensed consolidated balance sheets.â€‹-25- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹Amended and Restated 2015 Equity Incentive Planâ€‹In February 2024, the Board of Directors approved the Companyâ€™s amended and restated 2015 Equity Incentive Plan, or the Amended 2015 Plan, which was subsequently approved by the Companyâ€™s stockholders, and accordingly, adopted by the Company in June 2024. The Amended 2015 Plan extends the terms of the 2015 Equity Incentive Plan, or the Original 2015 Plan, and makes certain other changes. The term of the Amended 2015 Plan will be extended indefinitely, however, the Companyâ€™s ability to grant incentive stock options thereunder will continue through February 2034.â€‹As of September 30, 2024, the Company reserved an aggregate of 7,817,319 shares of common stock for future issuance under the Amended 2015 Plan.â€‹2014 Employee Stock Purchase Plan â€‹As of September 30, 2024, the Company has issued 1,246,323 shares of common stock under the ESPP and 753,677 shares of its common stock remain available for issuance under the ESPP.â€‹In May 2024, the Company issued 54,189 shares at a purchase price of $35.98 per share under the ESPP. For the three and nine months ended September 30, 2024, the Company recorded ESPP expense of $0.2 million and $0.9 million, respectively. For the three and nine months ended September 30, 2023, the Company recorded ESPP expense of $0.2 million and $0.8 million, respectively.â€‹Share-Based Award Activity and Balancesâ€‹The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the ESPP awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Companyâ€™s common share price. Compensation cost for all share-based payments granted with service-based graded vesting schedules is recognized using the straight-line method over the requisite service period.â€‹The weighted-averages for key assumptions used in determining the fair value of options granted are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â â€‹Average volatilityÂ â€”%Â Â 40.2%Â Â 41.3% 41.4%â€‹Average risk-free interest rateÂ â€”%Â Â 4.4%Â Â 4.2% 4.1%â€‹Weighted-average expected life in yearsÂ â€”â€‹ 6.3â€‹ 6.2â€‹ 6.2â€‹â€‹Dividend yield rateÂ â€”%Â Â â€”%Â Â â€”% â€”%â€‹â€‹-26- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹A summary of option activity under all plans for the nine months ended September 30, 2024, is presented below:â€‹Weighted-Averageâ€‹â€‹â€‹â€‹Â â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹Remainingâ€‹AggregateÂ â€‹â€‹â€‹â€‹Exerciseâ€‹Contractualâ€‹IntrinsicÂ â€‹â€‹â€‹Optionsâ€‹Priceâ€‹TermÂ (Years)â€‹Value(1)Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)Â Outstanding as of DecemberÂ 31,Â 2023â€‹Â 7,762,298â€‹$ 19.70Â Â Â Â Â Â Â Â â€‹Â Â Â Â â€‹Options grantedÂ 642,985â€‹â€‹ 46.27â€‹â€‹â€‹â€‹â€‹â€‹Options exercisedÂ (1,611,117)â€‹â€‹ 13.66â€‹â€‹â€‹â€‹â€‹â€‹Options forfeitedÂ (21,138)â€‹â€‹ 35.10â€‹â€‹â€‹â€‹â€‹â€‹Options expiredÂ â€”â€‹â€‹ â€”â€‹â€‹â€‹â€‹â€‹â€‹Outstanding as of SeptemberÂ 30,Â 2024Â 6,773,028â€‹$ 23.61â€‹ 5.12â€‹$ 168,760â€‹Exercisable as of SeptemberÂ 30,Â 2024Â 4,968,365â€‹â€‹ 19.02â€‹ 3.97â€‹$ 146,600â€‹Vested and expected to vest as of SeptemberÂ 30,Â 2024â€‹ 6,617,113â€‹â€‹ 23.24â€‹ 5.04â€‹$ 167,346â€‹(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Companyâ€™s stock for those awards that have an exercise price below the estimated fair value at September 30, 2024.â€‹For the three and nine months ended September 30, 2024, the Company recorded expense of $2.7 million and $9.0 million, respectively, related to stock options granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expense of $2.2 million and $7.5 million, respectively, related to stock options granted under all plans.â€‹Information relating to option grants and exercises is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â â€‹â€‹(in thousands, except per share data)Â Weighted-average grant date fair value per shareâ€‹$ â€”â€‹$ 21.49â€‹$ 21.89â€‹$ 16.76â€‹Intrinsic value of options exercisedâ€‹Â 6,218â€‹Â 5,628â€‹Â 48,381â€‹Â 24,544â€‹Cash received from options exercisedâ€‹Â 3,332â€‹Â 2,277â€‹Â 9,154â€‹Â 12,015â€‹Total fair value of the options vested during the periodâ€‹Â 111â€‹Â 167â€‹Â 9,815â€‹Â 8,887â€‹â€‹A summary of the status of the Companyâ€™s non-vested options as of September 30, 2024, and changes during the nine months ended September 30, 2024, are presented below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â Weighted-AverageÂ â€‹â€‹â€‹â€‹GrantÂ DateÂ â€‹â€‹Optionsâ€‹FairÂ ValueÂ Non-vested as of DecemberÂ 31,Â 2023â€‹Â 2,076,355â€‹$ 12.68â€‹Options grantedÂ 642,985â€‹â€‹ 21.89â€‹Options vestedÂ (893,539)â€‹â€‹ 10.98â€‹Options forfeitedÂ (21,138)â€‹â€‹ 16.19â€‹Non-vested as of SeptemberÂ 30,Â 2024Â 1,804,663â€‹Â 16.76â€‹â€‹As of September 30 2024, there was $21.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures. â€‹-27- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹Restricted Stock Unitsâ€‹The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to four years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until vested. The RSUs do not have any voting or dividend rights prior to the issuance of the underlying common stock. The share-based expense associated with these grants was based on the Companyâ€™s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. For the three and nine months ended September 30, 2024, the Company recorded total expenses of $2.7 million and $8.8 million, respectively, related to RSU awards granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expenses of $2.2 million and $7.3 million, respectively, related to RSU awards granted under all plans.â€‹As of September 30, 2024, there was $22.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures.â€‹Information relating to RSU grants and deliveries is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TotalÂ FairÂ MarketÂ â€‹â€‹TotalÂ RSUsâ€‹ValueÂ ofÂ RSUsÂ â€‹Â Â Â Â IssuedÂ Â Â Â Issued(1)Â â€‹â€‹â€‹â€‹(inÂ thousands)Â RSUs outstanding at DecemberÂ 31,Â 2023Â 920,376â€‹â€‹â€‹â€‹RSUs grantedÂ 303,788â€‹$ 14,060â€‹RSUs forfeitedÂ (9,620)â€‹â€‹â€‹â€‹RSUs vested(2)Â (388,668)â€‹â€‹â€‹â€‹RSUs outstanding at SeptemberÂ 30,Â 2024Â 825,876â€‹â€‹â€‹â€‹(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.(2)Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations.â€‹Share-based Compensation Expenseâ€‹The Company recorded share-based compensation expense, which is included in the Companyâ€™s condensed consolidated statement of operations as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024Â 2023Â â€‹â€‹(in thousands)Â Cost of revenuesÂ Â Â $ 1,133Â Â Â Â $ 1,004Â Â Â Â $ 4,583Â Â Â Â $ 3,868â€‹Operating expenses:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Selling, distribution, and marketingâ€‹Â 249â€‹Â 213â€‹Â 777â€‹Â 649â€‹General and administrativeâ€‹Â 3,710â€‹Â 2,975â€‹Â 11,239â€‹Â 9,323â€‹Research and developmentâ€‹Â 504â€‹Â 452â€‹Â 2,137â€‹Â 1,780â€‹Total share-based compensationâ€‹$ 5,596â€‹$ 4,644â€‹$ 18,736â€‹$ 15,620â€‹â€‹â€‹â€‹-28- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹Note 17. Employee Benefitsâ€‹401(k) Planâ€‹The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three and nine months ended September 30, 2024 were approximately $0.6Â million and $2.0Â million, respectively, compared to the prior year expense of $0.5 million and $1.7 million for the three and nine months ended September 30, 2023, respectively.â€‹Defined Benefit Pension Planâ€‹The Companyâ€™s subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employeeâ€™s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employeeâ€™s age, length of service, and AFP employee turnover rate.â€‹The liability under the plan is based on a discount rate of 3.25% as of September 30, 2024 and December 31, 2023. The liability is included in other long-term liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.8 million and $2.6 million at September 30, 2024 and December 31, 2023, respectively. The Company recorded an immaterial amount of expense under the plan for each of the three and nine months ended September 30, 2024 and 2023.â€‹Non-qualified Deferred Compensation Planâ€‹In December 2019, the Company established a non-qualified deferred compensation plan. The plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. The plan assets were valued at approximately $9.4 million and $6.8 million as of September 30, 2024 and December 31, 2023, respectively. The plan liabilities were valued at approximately $9.8 million and $7.1 million as of September 30, 2024, and December 31, 2023, respectively. The plan assets and liabilities are included in other long-term assets and other long-term liabilities, respectively, on the Companyâ€™s condensed consolidated balance sheets.â€‹Note 18. Commitments and Contingenciesâ€‹Purchase Commitmentsâ€‹As of September 30, 2024, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $95.9 million.â€‹Note 19. Related Party Transactionsâ€‹Investment in Hanxin Pharmaceutical Technology, Co., Ltd.â€‹The Company has an 11.5% ownership in Hanxin Pharmaceutical Technology Co., Ltd, or Hanxin, that is accounted for as an equity method investment. The Company maintains a seat on Hanxinâ€™s board of directors, and Henry Zhang, the -29- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹son of Dr. Jack Zhang, is an equity holder, the general manager, and the chairman of the board of directors of Hanxin. Additionally, Dr. Mary Luo and Dr. Jack Zhang, have an ownership interest in Hanxin through an affiliated entity. As a result, Hanxin is a related party.â€‹Contract manufacturing agreement with Hanxinâ€‹The Company, has various contract manufacturing agreements with Hanxin and its subsidiaries, whereby Hanxin will develop several active pharmaceutical ingredients and finished products for the Chinese market and will engage the Company to manufacture the products on a cost-plus basis.â€‹During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.5 million, respectively, of revenue from manufacturing services provided to Hanxin. During the three and nine months ended September 30, 2023, the Company recognized an immaterial amount of revenue from manufacturing services provided to Hanxin. As of September 30, 2024, the Company had $0.4 million of receivables from Hanxin.â€‹Contract Research Agreement with Hanxinâ€‹In July 2022, the Company entered into a three-year contract research agreement with Hanxin, a related party, whereby Hanxin will develop Recombinant Human Insulin Research Cell Banks, or RCBs, for the Company and license the RCBs to the Company subject to a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license. Hanxin will also perform scale-up manufacturing process development using the RCBs for the Company.â€‹During the three months ended September 30, 2024, the Company did not have any payments under the amended agreement and during the nine months ended September 30 2024, the Company paid $0.2 million under the amended agreement. During the three and nine months ended September 30, 2023, the Company paid $0.4 million and $1.0 million, respectively, under the amended agreement. As of September 30, 2024, the Company had an immaterial amount payable to Hanxin.â€‹Supply Agreement with Letopâ€‹In November 2022, the Company, entered into a supply agreement with Nanjing Letop Biotechnology Co., Ltd., or Letop, which is considered a related-party due to an ownership stake of Henry Zhang. Under the terms of the supply agreement Letop will manufacture and deliver chemical intermediates to the Company on a cost-plus basis. The agreement is effective for three years and the total cost of the agreement shall not exceed $1.5 million, with payments adjusted based on the then current exchange rates.â€‹During the three and nine months ended September 30, 2024, the Company paid an immaterial amount under this agreement. During the three months ended September 30, 2023, the Company did not have any payments under this agreement. During the nine months ended September 30, 2023, the Company paid $0.7 million, under this agreement. As of September 30, 2024, the Company did not have any amounts payable to Letop.â€‹Primatene MISTÂ® Distribution agreement with Hong Kong Genreach Limitedâ€‹In August 2024, the Company entered into a distribution agreement with Hong Kong Genreach Limited, or Genreach, a wholly owned subsidiary of Hanxin, a related party. Per the terms of the agreement, the Company has appointed Genreach as the exclusive distributor to market and sell Primatene MISTÂ® in Mainland China, Taiwan, Hong Kong, and Macau in the Greater China region. Genreach will be responsible for obtaining any and all regulatory approvals in the region for Primatene MISTÂ®. â€‹The term of the agreement is ten years, with both parties having termination rights without cause after the completion of the second contract year. -30- Table of ContentsAMPHASTAR PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)â€‹â€‹Note 20. Litigationâ€‹Employment Litigationâ€‹On April 15, 2024, a former employee (â€œPlaintiffâ€) initiated an employment litigation against Amphastar and IMS by filing a complaint, as amended, having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the class action complaint.â€‹On June 20, 2024, a former employee (â€œPlaintiffâ€) initiated an employment litigation against Amphastar, IMS and Roth Staffing Companies L.P. by filing a complaint having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the complaint.â€‹Albuterol sulfate Inhalation Aerosol Patent Litigation â€‹On July 25, 2024, Teva Branded Pharmaceutical Products R&D, Inc. (â€œTeva Brandedâ€), Norton (Waterford) Ltd. (â€œNortonâ€), and Teva Pharmaceuticals USA, Inc. (â€œTeva USAâ€), collectively referred to as (â€œPlaintiffâ€) filed a Complaint in the United States District Court for the District of Delaware (â€œDelaware Courtâ€) against the Company for infringement of U.S. Patent No. 9,463,289, with regard to Amphastarâ€™s ANDA No. 212447, for approval to manufacture and sell generic version of ProAirÂ® HFA (albuterol sulfate) Inhalation Aerosol. On October 21, 2024, Plaintiff amended its complaint against the Company to include additional claims for infringement of U.S. Patent No. 9,808,587 and 10,561,808, with regard to Amphastarâ€™s ANDA No. 212447, for approval to manufacture and sell generic version of ProAirÂ® HFA (albuterol sulfate) Inhalation Aerosol. The Company intends to vigorously defend this patent lawsuit.â€‹Other litigationâ€‹The Company is subject to various claims, arbitrations, investigations, and lawsuits from time to time arising in the ordinary course of business. In addition, third parties may, from time to time, assert claims against the Company in the forms of letters and other communications. Currently, the Company is subject to a lawsuit for a property and casualty claim, for which it has recorded an estimated liability of $6.0 million within accounts payable and other accrued liabilities on the condensed balance sheet as of September 30, 2024. This estimated liability is fully covered by the Companyâ€™s insurance policies. The $6.0 million insurance recovery related to this claim is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheet as of September 30, 2024.â€‹The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Companyâ€™s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.â€‹â€‹-31- Table of Contentsâ€‹ITEMÂ 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSâ€‹The following is a discussion and analysis of the consolidated operating

results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the â€œCondensed Consolidated Financial Statementsâ€ and the related notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the â€œSpecial Note About Forward-Looking Statements,â€ above and described in greater detail elsewhere in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2023, particularly in Item 1A. â€œRisk Factorsâ€.â€‹Overviewâ€‹We are a bio-pharmaceutical company focusing primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. We currently manufacture and sell over 25 products. â€‹Our largest products by net revenues currently include BAQSIMIÂ®, Primatene MISTÂ®, glucagon, epinephrine, lidocaine, enoxaparin sodium, and phytonadione.â€‹We are currently developing a portfolio of generic abbreviated new drug applications, or ANDAs, biosimilar insulin product candidates and proprietary product candidates, which are in various stages of development and target a variety of indications. Four of the ANDAs are currently on file with the FDA. â€‹To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our injectable, inhalation, and intra-nasal product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities, including the ability to manufacture raw materials, API, and other components for our products.â€‹Macroeconomic Trends and Uncertainties â€‹Recent uncertain macroeconomic conditions and worldwide events, including extended periods of heightened inflation, fluctuating interest rates and instability in the financial systems, ongoing geopolitical conflicts such as the Russia-Ukraine and Middle East conflicts, as well as rising healthcare costs continue to pose challenges to our business.â€‹See the section titled â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, for further discussion of the potential adverse impact of unfavorable global and geopolitical economic conditions on our business, results of operations and financial conditions.â€‹Recent Developmentsâ€‹BAQSIMIÂ® Acquisitionâ€‹In connection with the acquisition of BAQSIMIÂ® in June 2023, we entered into a Transition Service Agreement, or the TSA, with Eli Lilly & Company, or Lilly, pursuant to which Lilly agreed, for a period of time not to exceed 18 months to provide certain services to us to support the transition of the BAQSIMIÂ® operations, including with respect to the conduct of certain clinical, regulatory, medical affairs, and commercial sales channel activities. Revenues from the sales of BAQSIMIÂ® under the TSA with Lilly during the transition period were recognized on a net basis, similar to a royalty arrangement. The impact of this revenue recognition method resulted in lower reported revenues relative to the revenue that would have been reported had we recognized gross revenues from sales of BAQSIMIÂ®.â€‹-32- Table of ContentsThroughout 2024, we assumed distribution responsibilities from Lilly to our customers in the United States, which comprises approximately 80% of BAQSIMIÂ® worldwide revenues, as well as certain other countries. As a result, we started recognizing gross revenues and cost of revenues from the sales of BAQSIMIÂ® in these countries, which is classified as product revenue, net and cost of revenue, respectively on the condensed consolidated statement of operations. The assumption of distribution in countries outside the United States will occur on a country-by-country basis once the marketing authorizations for each territory have been transferred to us, we have set up distribution agreements, and we have obtained sufficient inventory.â€‹For more information regarding our acquisition of BAQSIMIÂ®, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 3. BAQSIMIÂ® Acquisition.â€â€‹Business Segments â€‹As of September 30, 2024, our performance is assessed and resources are allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) Active Pharmaceutical Ingredient, or API, products. The finished pharmaceutical products segment manufactures, markets and distributes BAQSIMIÂ®, Primatene MISTÂ®, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes Recombinant Human Insulin, or RHI API, and porcine insulin API for external customers and internal product development. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products.â€‹For more information regarding our segments, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 6. Segment Reporting.â€â€‹Results of Operationsâ€‹Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023â€‹Net revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Net revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Finished pharmaceutical productsâ€‹$ 187,357â€‹$ 147,665â€‹$ 39,692â€‹ 27%â€‹APIâ€‹Â 1,462â€‹Â 4,190â€‹Â (2,728)Â (65)%â€‹Total product revenues, netâ€‹â€‹ 188,819â€‹â€‹ 151,855â€‹â€‹ 36,964Â 24%â€‹Other revenuesâ€‹â€‹ 2,395â€‹â€‹ 28,701â€‹â€‹ (26,306)â€‹ (92)%â€‹Total net revenuesâ€‹$ 191,214â€‹$ 180,556â€‹$ 10,658Â 6%â€‹Cost of revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Finished pharmaceutical productsâ€‹$ 84,208â€‹$ 66,867â€‹$ 17,341Â 26%â€‹APIâ€‹Â 5,065â€‹Â 5,286â€‹Â (221)Â (4)%â€‹Total cost of revenuesâ€‹$ 89,273â€‹$ 72,153â€‹$ 17,120Â 24%â€‹Gross profitâ€‹$ 101,941â€‹$ 108,403â€‹$ (6,462)â€‹ (6)%â€‹as % of net revenuesâ€‹Â 53%Â Â Â 60%Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹-33- Table of ContentsThe increase in net revenues of the finished pharmaceutical products for the three months ended September 30, 2024 was due to the following changes:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Finished pharmaceutical products net revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹BAQSIMIÂ®â€‹$ 40,409â€‹$ â€”â€‹$ 40,409â€‹N/Aâ€‹â€‹Glucagonâ€‹â€‹ 26,792â€‹â€‹ 29,514â€‹â€‹ (2,722)â€‹ (9)%â€‹Primatene MISTÂ®â€‹â€‹ 26,055â€‹â€‹ 24,834â€‹â€‹ 1,221â€‹ 5%â€‹Epinephrineâ€‹â€‹ 21,341â€‹â€‹ 20,199â€‹â€‹ 1,142â€‹ 6%â€‹Lidocaineâ€‹â€‹ 15,884â€‹â€‹ 15,522â€‹â€‹ 362â€‹ 2%â€‹Phytonadioneâ€‹â€‹ 11,721â€‹â€‹ 7,449â€‹â€‹ 4,272â€‹ 57%â€‹Enoxaparin â€‹â€‹ 5,615â€‹â€‹ 7,702â€‹â€‹ (2,087)â€‹ (27)%â€‹Naloxone â€‹â€‹ 4,037â€‹â€‹ 4,715â€‹â€‹ (678)â€‹ (14)%â€‹Other finished pharmaceutical productsâ€‹Â 35,503â€‹Â 37,730â€‹Â (2,227)Â (6)%â€‹Total finished pharmaceutical products net revenuesâ€‹$ 187,357â€‹$ 147,665â€‹$ 39,692Â 27%â€‹â€‹Product Revenues, netâ€‹Throughout 2024, we assumed distribution responsibilities for BAQSIMIÂ® from Lilly to our customers in the United States, and certain other countries. As a result, $40.4 million of our third quarter BAQSIMIÂ® sales were recognized separate from the cost of revenues, similar to our other products. During the third quarter of 2024, while the Company was transitioning from Lilly labeled product to Amphastar labeled product, our supplier was unable to supply Amphastar labeled product in 14 European countries on a timely basis, which limited sales by approximately $2.0 million to $3.0 million.â€‹For more information, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to the Condensed Consolidated Financial Statements â€“ Note 4. Revenue Recognition.â€â€‹Primatene MISTÂ® sales increased primarily due to an increase in unit volumes. The increase in sales of epinephrine was primarily due to sales of epinephrine pre-filled syringes in Canada, which we began this quarter. The increase in sales of phytonadione was primarily driven by an increase in unit volume, as a result of an increase in demand. The decrease in sales of glucagon was due to a decrease in unit volumes as a result of a move to ready to use glucagon products such as BAQSIMIÂ®, as well as a decrease in average selling price. The decrease in sales of enoxaparin and naloxone was primarily due to a decrease in unit volumes. The decrease in other finished pharmaceutical products was primarily due to lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels. This decrease was partially offset by higher unit volumes of sodium bicarbonate due to an increase in capacity at our subsidiary, International Medication Systems, Limited, as well as the launch of albuterol in August 2024. Between $2.0 million and $4.0 million in sales expected to be recognized in the third quarter were not recognized due to delayed shipments caused by the aftermath of Hurricane Helene. Revenues for these shipments are expected to be recognized in the fourth quarter.â€‹We anticipate that sales of naloxone and enoxaparin will continue to fluctuate in the future due to competitive dynamics. We also anticipate that sales of epinephrine and other finished pharmaceutical products will continue to fluctuate depending on the ability of our competitors to supply market demands.â€‹Sales of API primarily depend on the timing of customer purchases, and will be lower for the next two years because MannKind, our largest RHI customer, is in the process of qualifying our upgraded RHI, which uses our internally produced inclusion bodies made at AFP. Until they complete this process, we anticipate sales of RHI will be at levels lower than historical.â€‹-34- Table of ContentsOther Revenuesâ€‹Other revenues include the portion of BAQSIMIÂ® sales made by Lilly on our behalf under the TSA which amounted to $2.4 million and $28.7 million during the three months ended September 30, 2024 and 2023, respectively, based on total BAQSIMIÂ® sales of $6.4 million and $48.7 million, respectively, as reported to us by Lilly, which was recognized on a net basis, similar to a royalty arrangement. The BAQSIMIÂ® sales made by Lilly on our behalf under the TSA have decreased throughout 2024, due to our assumption of distribution responsibilities for BAQSIMIÂ® from Lilly to our customers in the United States, and certain other countries. We recognized these sales within product net revenues.â€‹Backlogâ€‹A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. As of September 30, 2024, we experienced an immaterial amount of backlog for various products, primarily as a result of competitor shortages and supplier constraints. Historically, our backlog has not been a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.â€‹Gross marginsâ€‹The decrease in gross margins during the three months ended September 30, 2024, is primarily due to an increase in labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value. As a result of the TSA with Lilly, the portion of revenues relating to BAQSIMIÂ® sales made by Lilly on our behalf are reported on a net basis, similar to a royalty arrangement with no amount reported as cost of revenues. Therefore, in the prior year, BAQSIMIÂ® sales did not have any associated cost of revenues, which increased the gross margins.â€‹The decrease in gross margins was partially offset by an increase in sales of Primatene MISTÂ® and epinephrine, which are higher-margin products.â€‹We are currently experiencing increased costs for labor as well as certain APIs and purchased components. However, we believe that this trend will be offset longer term by increased sales of our higher-margin products, including BAQSIMIÂ®, Primatene MISTÂ®, vasopressin, ganirelix, and albuterol, and new products we anticipate launching.â€‹Selling, distribution and marketing, and general and administrativeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹â€‹2024â€‹2023â€‹Dollarsâ€‹%Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Selling, distribution, and marketingÂ Â Â Â $ 8,995Â Â Â Â $ 6,407Â Â Â Â $ 2,588Â Â Â Â 40%â€‹General and administrativeâ€‹$ 14,821â€‹$ 12,654â€‹$ 2,167Â 17%â€‹â€‹The increase in selling, distribution and marketing expenses was primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMIÂ®. The increase in general and administrative expense was primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMIÂ®.â€‹We expect that selling, distribution and marketing expenses will continue to increase due to the increase in marketing expenditures for BAQSIMIÂ® and Primatene MISTÂ®. Legal fees may fluctuate from period to period due to the timing of patent challenges and other litigation matters.â€‹â€‹-35- Table of ContentsResearch and developmentâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Salaries and personnel-related expensesâ€‹$ 7,768â€‹$ 7,007â€‹$ 761Â 11%â€‹Pre-launch inventoryâ€‹Â 222â€‹Â 460â€‹Â (238)Â (52)%â€‹Clinical trialsâ€‹Â 9â€‹Â 673â€‹Â (664)Â (99)%â€‹FDA feesâ€‹Â 34â€‹Â 45â€‹Â (11)Â (24)%â€‹Materials and suppliesâ€‹Â 5,852â€‹Â 3,664â€‹Â 2,188Â 60%â€‹Depreciationâ€‹Â 3,278â€‹Â 2,452â€‹Â 826Â 34%â€‹Other expensesâ€‹Â 3,914â€‹Â 2,363â€‹Â 1,551Â 66%â€‹Total research and development expensesâ€‹$ 21,077â€‹$ 16,664â€‹$ 4,413â€‹ 26%â€‹â€‹The increase in research and development expenses is primarily due to an increase in expenditure on raw materials and components for our insulin pipeline products, as well as an increase in salary and personnel-related expenses. This was partially offset by a decrease in clinical trial expense, due to the timing of clinical trials.â€‹Research and development expenses consist primarily of costs associated with the research and development of our product candidates including the cost of developing APIs. We expense research and development costs as incurred. â€‹We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.â€‹Non-operating income (expenses), netâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹â€‹2024â€‹2023â€‹Dollarsâ€‹%Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Non-operating income (expenses)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Interest incomeâ€‹$ 2,427â€‹$ 1,202â€‹$ 1,225â€‹ 102%â€‹Interest expenseâ€‹â€‹ (6,698)â€‹â€‹ (13,702)â€‹â€‹ 7,004â€‹ (51)%â€‹Other income (expenses), netÂ Â Â Â â€‹ (5,094)Â Â Â Â â€‹ 3,459Â Â Â Â â€‹ (8,553)Â Â Â Â (247)%â€‹Total non-operating income (expenses), netâ€‹$ (9,365)â€‹$ (9,041)â€‹$ (324)â€‹ 4%â€‹â€‹The change in non-operating income (expenses), net is primarily a result of:â€‹â—An increase in interest income resulting from an increase in cash and investments.â€‹â—A decrease in interest expense was primarily due to the $250.0 million repayment of the principal balance of the Wells Fargo Term Loan in September 2023, along with the write-off of the associated unamortized debt issuance costs related to the Term Loan in 2023. â€‹â—A change to Other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended September 30, 2024.â€‹-36- Table of ContentsIncome tax provisionâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Income tax provisionâ€‹$ 7,254â€‹$ 14,025â€‹$ (6,771)â€‹ (48)%â€‹Effective tax rateâ€‹â€‹ 15%Â Â Â 22%Â Â â€‹â€‹â€‹â€‹â€‹â€‹Our effective tax rate for the three months ended September 30, 2024 decreased in comparison to the three months ended September 30, 2023, primarily due to differences in pre-tax income positions and timing of discrete tax items. For more information regarding our income taxes, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 15. Income Taxes.â€â€‹Beginning in 2024, many countries are implementing some or all of the Organization for Economic Co-operation and Developmentâ€™s Inclusive Framework on Base Erosion and Profit Shifting Two-Pillar in response to tax challenges arising from the digitalization of the global economy. While we continue to evaluate those countriesâ€™ implementations, we do not expect those implementations to have a material impact on our consolidated financial statements in 2024.â€‹Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023â€‹Net revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Net revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Finished pharmaceutical productsâ€‹$ 519,147â€‹$ 426,541â€‹$ 92,606Â 22%â€‹APIâ€‹Â 6,689â€‹Â 11,048â€‹Â (4,359)Â (39)%â€‹Total product revenues, netâ€‹â€‹ 525,836â€‹â€‹ 437,589â€‹â€‹ 88,247Â 20%â€‹Other revenuesâ€‹â€‹ 19,608â€‹â€‹ 28,701â€‹â€‹ (9,093)Â (32)%â€‹Total net revenuesâ€‹$ 545,444â€‹$ 466,290â€‹$ 79,154Â 17%â€‹Cost of revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Finished pharmaceutical productsâ€‹$ 236,433â€‹$ 192,500â€‹$ 43,933Â 23%â€‹APIâ€‹Â 21,804â€‹Â 18,809â€‹Â 2,995Â 16%â€‹Total cost of revenuesâ€‹$ 258,237â€‹$ 211,309â€‹$ 46,928Â 22%â€‹Gross profitâ€‹$ 287,207â€‹$ 254,981â€‹$ 32,226â€‹ 13%â€‹as % of net revenuesâ€‹Â 53%Â Â Â 55%Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹-37- Table of ContentsThe increase in net revenues of the finished pharmaceutical products for the nine months ended September 30, 2024, was due to the following changes:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Finished pharmaceutical products net revenuesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹BAQSIMIÂ®â€‹$ 85,106â€‹$ â€”â€‹$ 85,106â€‹N/Aâ€‹â€‹Glucagonâ€‹â€‹ 82,700â€‹â€‹ 82,486â€‹â€‹ 214â€‹ 0%â€‹Epinephrineâ€‹â€‹ 75,392â€‹â€‹ 57,004â€‹â€‹ 18,388â€‹ 32%â€‹Primatene MISTÂ®â€‹â€‹ 73,077â€‹â€‹ 64,837â€‹â€‹ 8,240â€‹ 13%â€‹Lidocaineâ€‹â€‹ 41,457â€‹â€‹ 43,174â€‹â€‹ (1,717)â€‹ (4)%â€‹Phytonadioneâ€‹â€‹ 31,998â€‹â€‹ 33,017â€‹â€‹ (1,019)â€‹ (3)%â€‹Enoxaparin â€‹â€‹ 17,984â€‹â€‹ 25,441â€‹â€‹ (7,457)â€‹ (29)%â€‹Naloxone â€‹â€‹ 12,124â€‹â€‹ 14,774â€‹â€‹ (2,650)â€‹ (18)%â€‹Other finished pharmaceutical productsâ€‹Â 99,309â€‹Â 105,808â€‹Â (6,499)Â (6)%â€‹Total finished pharmaceutical products net revenuesâ€‹$ 519,147â€‹$ 426,541â€‹$ 92,606Â 22%â€‹â€‹Product Revenues, netâ€‹Throughout 2024, we assumed distribution responsibilities for BAQSIMI Â® from Lilly to our customers in the United States, and certain other countries. As a result, $85.1 million of our BAQSIMIÂ® sales for the nine months ended September 30, 2024, are recognized separate from the cost of revenues, similar to our other

products.â€‹For more information, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to the Condensed Consolidated Financial Statements â€“ Note 4. Revenue Recognition.â€â€‹The increase in sales of epinephrine was primarily due to an increase in unit volumes, as a result of an increase in demand caused by other supplier shortages. Primatene MISTÂ® sales increased primarily due to an increase in unit volumes. The decrease in sales of enoxaparin and naloxone was primarily due to a decrease in unit volumes. The decrease in other finished pharmaceutical products was primarily due to lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels, as well as lower unit sales of medroxyprogesterone, as our API supplier discontinued making the active ingredient, which resulted in a halt of sales of medroxyprogesterone after the third quarter of 2023. Subsequently, we qualified our subsidiary, ANP, to manufacture this API, and in September 2024, we re-launched the product. This decrease was partially offset by higher unit volumes of dextrose and sodium bicarbonate due to an increase in demand caused by other supplier shortages, as well as the launch of albuterol in August 2024.â€‹We anticipate that sales of naloxone and enoxaparin will continue to fluctuate in the future due to competitive dynamics. We also anticipate that sales of epinephrine and other finished pharmaceutical products will continue to fluctuate depending on the ability of our competitors to supply market demands.â€‹Sales of API primarily depend on the timing of customer purchases, and will be lower for the next two years because MannKind, our largest RHI customer, is in the process of qualifying our upgraded Recombinant Human Insulin, or RHI, which uses our internally produced inclusion bodies made at AFP. Until they complete this process, we anticipate sales of RHI will be at levels lower than historical.â€‹Other Revenuesâ€‹Other revenues include the portion of BAQSIMIÂ® sales made by Lilly on our behalf under the TSA which amounted to $19.6 million and $28.7 million during the nine months ended September 30, 2024 and 2023, respectively, based on total BAQSIMIÂ® sales of $38.6 million and $48.7 million, respectively, as reported to us by Lilly, which was recognized on a net basis, similar to a royalty arrangement. The BAQSIMIÂ® sales made by Lilly on our behalf under the TSA have -38- Table of Contentsdecreased throughout 2024, due to our assumption of distribution responsibilities for BAQSIMIÂ® from Lilly to our customers in the United States, and certain other countries. We recognized these sales within product net revenues.â€‹Gross marginsâ€‹The decrease in gross margins during the nine months ended September 30, 2024, is primarily due to an increase in depreciation and amortization expenses related to the acquired BAQSIMIÂ® assets, an increase in labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value. As a result of the TSA with Lilly, the portion of revenues relating to BAQSIMIÂ® sales made by Lilly on our behalf are reported on a net basis, similar to a royalty arrangement with no amount reported as cost of revenues. Therefore, in the prior year, BAQSIMIÂ® sales did not have any associated cost of revenues, which increased the gross margins.â€‹The decrease in gross margins was partially offset by the increase in sales of Primatene MISTÂ® and epinephrine, which are higher-margin products.â€‹We are currently experiencing increased costs for labor as well as certain APIs and purchased components. However, we believe that this trend will be offset longer term by increased sales of our higher-margin products, including BAQSIMIÂ®, Primatene MISTÂ®, vasopressin, ganirelix, albuterol, and new products we anticipate launching.â€‹Selling, distribution and marketing, and general and administrativeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended Â Â Â Â â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Selling, distribution, and marketingâ€‹$ 27,378â€‹$ 20,234â€‹$ 7,144Â Â Â Â 35%â€‹General and administrativeâ€‹$ 43,782â€‹$ 38,418â€‹$ 5,364Â 14%â€‹â€‹The increase in selling, distribution and marketing expenses was primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMIÂ®. The increase in general and administrative expense was primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMIÂ®.â€‹We expect that selling, distribution and marketing expenses will continue to increase due to the increase in marketing expenditures for BAQSIMIÂ® and Primatene MISTÂ®. Legal fees may fluctuate from period to period due to the timing of patent challenges and other litigation matters.â€‹Research and developmentâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Salaries and personnel-related expensesâ€‹$ 23,898â€‹$ 21,653â€‹$ 2,245Â 10%â€‹Pre-launch inventoryâ€‹Â 222â€‹Â 460â€‹Â (238)Â (52)%â€‹Clinical trialsâ€‹Â 292â€‹Â 3,430â€‹Â (3,138)Â (91)%â€‹FDA feesâ€‹Â 1,333â€‹Â 142â€‹Â 1,191Â NMâ€‹â€‹Materials and suppliesâ€‹Â 12,334â€‹Â 13,556â€‹Â (1,222)Â (9)%â€‹Depreciationâ€‹Â 9,206â€‹Â 7,282â€‹Â 1,924Â 26%â€‹Other expensesâ€‹Â 8,487â€‹Â 6,799â€‹Â 1,688Â 25%â€‹Total research and development expensesâ€‹$ 55,772â€‹$ 53,322â€‹$ 2,450â€‹ 5%â€‹â€‹The increase in research and development expenses is primarily due to an increase in salary and personnel-related expenses, as well as an increase in FDA filing fees as we filed the ANDA for AMP-018 in the second quarter of 2024. -39- Table of ContentsThis was partially offset by a decrease in clinical trials expense, as well as a decrease in materials and supply expense, as a result of a ramp-up of expenses in 2023 for our insulin and inhalation pipeline products.â€‹Research and development expenses consist primarily of costs associated with the research and development of our product candidates including the cost of developing APIs. We expense research and development costs as incurred. â€‹We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.â€‹Non-operating income (expenses), netâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Non-operating income (expenses)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Interest incomeâ€‹$ 8,320â€‹$ 3,156â€‹$ 5,164â€‹ 164%â€‹Interest expenseâ€‹â€‹ (23,918)â€‹â€‹ (17,702)â€‹â€‹ (6,216)â€‹ 35%â€‹Other income (expenses), netâ€‹â€‹ 1,125â€‹â€‹ 1,553â€‹â€‹ (428)Â Â Â Â (28)%â€‹Total non-operating income (expense), netâ€‹$ (14,473)â€‹$ (12,993)â€‹$ (1,480)â€‹ 11%â€‹â€‹The change in non-operating income (expenses), net is primarily a result of:â€‹â—An increase in interest income resulting from an increase in cash and investments.â€‹â—An increase in interest expense resulting from the Term Loan used to finance the acquisition of BAQSIMIÂ®, as well as the 2029 Convertible Notes, which we entered into in the second half of 2023. For more information regarding our debt, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 14. Debt.â€â€‹â—A change to Other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the nine months ended September 30, 2024. â€‹Income tax provisionâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹Â â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Changeâ€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarsÂ Â Â Â %Â â€‹â€‹â€‹(inÂ thousands)â€‹â€‹Â â€‹Income tax provisionâ€‹$ 23,674â€‹$ 27,160â€‹$ (3,486)â€‹ (13)%â€‹Effective tax rateâ€‹Â 16%Â Â Â 21%Â Â â€‹â€‹â€‹â€‹â€‹â€‹Our effective tax rate for the nine months ended September 30, 2024 decreased in comparison to the nine months ended September 30, 2023, primarily due to the timing of discrete tax items partially offset by differences in pre-tax income positions. For more information regarding our income taxes, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 15. Income Taxes.â€â€‹-40- Table of ContentsLiquidity and Capital Resourcesâ€‹Cash Requirements and Sourcesâ€‹We need capital resources to maintain and expand our business. We expect our cash requirements to increase significantly in the foreseeable future as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development stage product candidates and pursue strategic acquisitions of businesses or assets. Our future capital expenditures include projects to upgrade, expand, and improve our manufacturing facilities in the United States and China, including a significant increase in capital expenditures over the next few years. We plan to fund this facility expansion primarily with cash flows from operations. We may also become subject to cash obligations of up to an aggregate of $575.0 million that are contingent upon certain net sales milestones related to the BAQSIMIÂ® acquisition. No milestone payments have been made through the date of this filing. Our cash obligations include the principal and interest payments due on our existing loans and lease payments, as described below and throughout this Quarterly Report. â€‹As of September 30, 2024, our foreign subsidiaries collectively held $9.5 million in cash and cash equivalents. Cash or cash equivalents held at foreign subsidiaries are not available to fund the parent companyâ€™s operations in the United States. We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. We expect additional cash flows to be generated in the longer term from future product introductions, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product introductions, which could be lengthy or ultimately unsuccessful.â€‹Working capital increased $122.7 million to $386.9 million at September 30, 2024, compared to $264.2 million at December 31, 2023.â€‹Cash Flows from Operationsâ€‹The following table summarizes our cash flows used in operating, investing, and financing activities for the nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024â€‹2023â€‹â€‹(inÂ thousands)Â â€‹Statement of Cash Flow Data:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net cash provided by (used in)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating activitiesâ€‹$ 184,362â€‹$ 159,639â€‹Investing activitiesâ€‹Â (89,252)â€‹Â (546,067)â€‹Financing activitiesâ€‹Â (47,111)â€‹Â 501,176â€‹Effect of exchange rate changes on cashâ€‹Â (179)â€‹Â (44)â€‹Net increase in cash, cash equivalents, and restricted cashâ€‹$ 47,820â€‹$ 114,704â€‹â€‹Sources and Use of Cashâ€‹Operating Activitiesâ€‹Net cash provided by operating activities was $184.4 million for the nine months ended September 30, 2024, which included net income of $121.6 million. Non-cash items comprised primarily of $47.8 million of depreciation and amortization, which includes $21.0 million related to depreciation of property, plant and equipment; $18.5 million related to amortization of product rights, trademarks and patents; $3.0 million related to amortization of operating lease right-of-use assets; $5.3 million related to amortization of discounts, premiums, and debt issuance costs; and share-based compensation expense of $18.7 million.â€‹-41- Table of ContentsAdditionally, for the nine months ended September 30, 2024, there was a net cash outflow from changes in operating assets and liabilities of $6.0 million, which resulted primarily from an increase in accounts receivables, an increase in inventories, as well as an increase in prepaid expenses and other assets, which was partially offset by an increase in accounts payable and accrued liabilities. The increase in accounts receivables was primarily due to the increase in sales. The increase in inventories was primarily due to the increased purchases of certain raw materials and components. Accounts payable and accrued liabilities increased primarily due to the increase in accrued customer fees and rebates associated with BAQSIMIÂ® sales, as we continue to assume distribution responsibilities for BAQSIMIÂ® from Lilly to our customers in the United States and certain other countries. â€‹Net cash provided by operating activities was $159.6 million for the nine months ended September 30, 2023, which included net income of $101.4 million. Non-cash items comprised primarily of $36.5 million of depreciation and amortization, $15.6 million of share-based compensation expense, and an impairment charge of $2.7 million relating to the impairment of the IMS (UK) international product rights. Additionally, for the nine months ended September 30, 2023, there was a net cash inflow from changes in operating assets and liabilities of $2.5 million, which resulted from an increase in accounts payable and accrued liabilities, which was partially offset by an increase in accounts receivables and inventories. Accounts payable and accrued liabilities increased primarily due to the timing of payments. The increase in accounts receivables was primarily due to the timing of the payment from Lilly for BAQSIMIÂ® during the quarter, which was received subsequent to the quarter end.â€‹Investing Activitiesâ€‹Net cash used in investing activities was $89.3 million for the nine months ended September 30, 2024, primarily due to the payment of $129.0 million relating to the BAQSIMIÂ® acquisition, $28.6 million in purchases of property, plant, and equipment, which included $10.2 million incurred in the United States, $2.4 million in France, and $15.9 million in China. This was partially offset by a net cash inflow of $71.0 million from sales and purchases of investments during the period.â€‹Net cash used in investing activities was $546.1 million for the nine months ended September 30, 2023, primarily as a result of $506.4 million relating to the BAQSIMIÂ® acquisition, $28.7 million in purchases of property, plant, and equipment, which included $19.5 million incurred in the United States, $1.7 million in France, and $7.5 million in China.â€‹Financing Activitiesâ€‹Net cash used in financing activities was $47.1 million for the nine months ended September 30, 2024, primarily as a result of $43.5 million used to purchase treasury stock and $8.2 million used to settle share-based compensation awards under our equity plan and for tax payments related to the net share settlement of options exercised. Additionally, we made $8.1 million in principal payments on our long-term debt, primarily as a result of paying off the mortgage loan with East West Bank. This was partially offset by $13.6 million of net proceeds from borrowings on our line of credit in China.â€‹Net cash provided by financing activities was $501.2 million for the nine months ended September 30, 2023, primarily due to our entry into the Credit Agreement with Wells Fargo and the issuance of the 2029 Convertible Notes, which waspartially offset by $268.5 million in principal payments of our long-term debt and $24.6 million in debt issuance cost. Additionally, we received $7.4 million in net proceeds from the settlement of share-based compensation awards under our equity plan, which was partially offset by the $58.4 million used to purchase treasury stock. â€‹Indebtednessâ€‹For more information regarding our outstanding indebtedness, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 14. Debtâ€.â€‹-42- Table of ContentsCritical Accounting Policiesâ€‹The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our critical accounting policies as compared to the critical accounting policies as described in our Annual Report on Form 10-K for the year ended December 31, 2023.â€‹Recent Accounting Pronouncementsâ€‹For information regarding recent accounting pronouncements, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 2. Summary of Significant Accounting Policiesâ€.â€‹Government Regulationâ€‹Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The Drug Enforcement Administration, or DEA, maintains oversight over our products that are considered controlled substances.â€‹From February 20 through March 1, 2024, our Amphastar facility in Rancho Cucamonga, California was subject to pre-approval and cGMP inspection by the FDA. The inspection included a review of compliance with FDA regulations to support one of our pending applications as well as to compliance with Good Manufacturing Practices. The inspection resulted in several observations on Form 483. We responded to those observations. We believe that our response to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.â€‹From July 15 through July 19, 2024, our Armstrong facility in Canton, Massachusetts was subject to a pre-approval inspection by the FDA. The inspection included review of compliance of our analytical laboratory with FDA regulations to support one of our pending applications. The inspection resulted in several observations on Form 483. We responded to those observations. We believe that our response to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.â€‹-43- Table of Contentsâ€‹ITEMÂ 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKâ€‹Except for the broad, ongoing macroeconomic challenges facing the global economy and financial markets, there have been no material changes in market risk from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2023. We are exposed to market risk in the ordinary course of business.Â Market risk represents the potential loss arising from adverse changes in the value of financial instruments.Â The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).â€‹ITEMÂ 4. CONTROLS AND PROCEDURESâ€‹Evaluation of Disclosure Controls and Proceduresâ€‹Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the â€œExchange Actâ€), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. â€‹Changes in Internal Control Over Financial Reportingâ€‹There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal

control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).â€‹Inherent Limitations of Internal Controls â€‹Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.â€‹-44- Table of ContentsPART II. OTHER INFORMATIONâ€‹ITEMÂ 1. LEGAL PROCEEDINGSâ€‹For information regarding legal proceedings, see â€œPart I â€“ Item 1. Financial Statements â€“ Notes to Condensed Consolidated Financial Statements â€“ Note 20. Litigation.â€‹ITEMÂ 1A. RISK FACTORSâ€‹Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024.â€‹We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.The facilities we use for our headquarters, laboratory and research and development activities are located in earthquake-prone areas of California. A significant percentage of the facilities we use for our manufacturing, packaging, warehousing, distribution and administration offices are also located in these areas. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. Additionally, we currently rely on third parties whose operations may be disrupted by natural disasters. For example, the aftermath of Hurricane Helene caused us to experience delays in shipments of certain products.â€‹If a natural disaster, power outage or other event occurred that prevented us or the third parties upon whom we depend from using all or a significant portion of our facilities, that damaged critical infrastructure, such as our or third parties' manufacturing facilities, or that otherwise disrupted operations of ours or those of third parties, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans.â€‹Jack Y. Zhang and Mary Z. Luo have each pledged shares of our common stock to secure funds borrowed under existing credit lines from three financial institutions. Each of the lenders has varying rights as a lender, including one which has the right to conduct a forced sale at its sole discretion. An action by one of the lenders could include a sale of certain shares of our common stock pledged as collateral, the sale of which could cause the price of our common stock to decline. An action to cure and cover indebtedness by any one of the lenders could also have other negative impacts on our business.â€‹Since September 2015, UBS Bank USA, or UBS, has made extensions of credit up to the amount of $8.0 million to Applied Physics & Chemistry Laboratories, Inc., or APCL, which is controlled by Jack Y. Zhang and Mary Z. Luo. In May 2019, the credit amount was increased to $11.0 million. Since February 2017, UBS Group AG, or UBS AG, has also provided an extension of credit up to the amount of $8.0 million to APCL. In 2021, the outstanding UBS AG credit line was transferred to UBS's Utah location due to an organizational change and in June 2021 the credit line with UBS was increased to $11.9 million. As of September 30, 2024, the total outstanding UBS combined credit lines were $11.9 million. The UBS credit lines are secured by a pledge of 400,000 shares of our common stock currently held by APCL. Interest on the loans accrues at market rates. UBS has an unlimited and unilateral right to call each of the credit lines for any reason whatsoever.â€‹In October 2017, East West Bank, or East West, entered into an agreement with Drs. Zhang and Luo whereby East West would loan them up to $5.0 million. In March 2023, East West amended the loan to increase the loan amount to $8.0 million. As of September 30, 2024, the loan is secured by a pledge of 500,000 shares of our common stock held by Dr. Zhang. Interest on the loan accrues at market rates. East West has acceleration rights to protect itself in the event of a default.â€‹-45- Table of ContentsIn June 2024, Cathay Bank entered into an agreement with APCL and Dr. Luo, whereby Cathay Bank would loan them up to $20.0 million. As of September 30, 2024, the loan is secured by a pledge of 1,000,000 shares of our common stock held by APCL and Dr. Luo. Interest on the loan accrues at market rates. Cathay Bank has acceleration rights to protect itself in the event of a default.â€‹We are not a party to these loans, which are full recourse against APCL and each of Drs. Zhang and Luo, respectively, and are secured by pledges of a portion of the shares of our common stock currently held by APCL and each of Drs. Zhang and Luo. â€‹In 2021, we created a pledging policy to restrict the pledging of shares by our executive officers and directors. The policy prohibits our executive officers and directors from entering into any transaction whereby the executive officer or director, directly or indirectly, pledges, hypothecates, or otherwise encumbers more than twenty (20) percent of shares of common stock held by the individual or more than five (5) percent of our total outstanding shares of common stock as of the date of the transaction, whichever is lower, as collateral for indebtedness. This restriction extends to any hedging or similar transaction designed to decrease the risks associated with holding our securities. For already existing pledges made by executive officers and directors, those existing pledges must be reduced to no more than twenty (20) percent of the shares of our common stock held by such individual as collateral for indebtedness within three (3) years of December 31, 2021. As a result of this policy, Drs. Zhang and Luo reduced their total number of pledged shares to 1,900,000 in June 2024 from 2,350,000 in May 2022, 3,182,898 in February 2022, and 8,582,898 in February 2021.â€‹If the price of our common stock declines, Drs. Zhang and Luo may be forced by these financial institutions to provide additional collateral for the loans or to sell shares of our common stock held by them in order to remain within the margin limitations imposed under the terms of their loans. Furthermore, the pledged shares of our common stock may be acquired and sold by the lenders. These factors may limit Drs. Zhang and Luoâ€™s ability to either pledge additional shares of our common stock or sell shares of our common stock held by them as a means to avoid or satisfy a margin call with respect to their pledged shares of our common stock in the event of a decline in our stock price that is large enough to trigger a margin call. Any significant sales of shares of our common stock by one or more of these three lenders could cause the price of our common stock to decline further.â€‹ITEMÂ 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSâ€‹(c)Issuer Purchases of Equity Securitiesâ€‹The table below provides information with respect to repurchases of our common stock.â€‹â€‹â€‹

å¯¹ARMSTRONGçš„äçº¯ã€å£°æ˜æ‰¿è¯ºä¾›è´§ã€‚(5)accept reasonable advices from ARMSTRONG on the sales and distribution of Product P;æŽ¥å—ARMSTRONGå¯¹äºŽé”€å”®å'Œç»é”€ä»§å"Pçš„å¯ç†å»ºè®®ï¼›(6)promptly notify ARMSTRONG upon becoming aware of any breach of its obligations under this Agreement, or any circumstances or matters that are reasonably likely to give rise to any such breach;åœ¨æ„è¯†å°ä»»ä½•è¿åå…¶æ ¹æ®æœ¬åè®®çš„ä¹‰åŠ¡çš„æƒ…å†µæˆ–å¯èƒ½å¯¼è‡´æ¤ç±»è¿åçš„æƒ…å†µæˆ–事项后，(7)not sell or distribute any products that infringe on any ARMSTRONG Intellectual Property, promptly notify ARMSTRONG upon becoming aware of any such products or infringement on any ARMSTRONG Intellectual Property and, upon ARMSTRONGâ€™s request, promptly provide all necessary information, cooperation and assistance for defense of infringement; andä¸€æ¦‚ä»¥ARMSTRONGçŸ¥è¯†äº§æƒçš„ä¸ä¾µçŠ¯ARMSTRONGçŸ¥è¯†äº§æƒçš„ä»»ä½•äº§å"æˆ–å¯¼è‡´æ¤ç±»ä¾µçŠ¯çš„æƒ…å†µæˆ–事项后，(8)cooperate fully with and provide any necessary assistance and information to ARMSTRONG in implementing any recall, withdrawal, seizure or destruction of Product P initiated by ARMSTRONG. Â ä¸ŽARMSTRONGå……..å¯†åˆ¥æ´»åŠ¨çš„æ¯ä»½æ–‡ä»¶ã€æ•°æ®ã€ä¿¡æ¯ã€ç»éªŒå’ŒçŸ¥è¯†ï¼Œä»¥åŠARMSTRONGæä¾›çš„æ‰€æœ‰å¸®åŠ©ã€åˆä½œå’Œæ”¯æŒï¼Œç”¨äºŽARMSTRONGå¯¹äºŽæ¬¡äº§å"çš„å¬å›žã€æ’¤å›žã€æ‰£æ¼æˆ–é”€æ¯ã€(9)Comply with Safety Data Exchange Agreement (SDEA) as set forth in Appendix A.é¡µå¤´æœ¬åè®®ä¸çº¦å®šçš„ä¸Žå®‰å…¨æ•°æ®äº¤æ¢åè®®ï¼ˆSDEAï¼‰ã€(10)Comply with Quality Agreement (Quality Agreement) as set forth in Appendix B.é¡µå¤´æœ¬åè®®ä¸çº¦å®šçš„è´¨éœ€åè®®ï¼ˆQuality Agreementï¼‰ã€3No Employment or Representationéžé›‡ä½£æ˜¯æ–¹ã€‚Ç3.1Nothing in this Agreement shall be construed as to create an employment relationship between ARMSTRONG and the Distributor. The Distributor has no authority or power to bind ARMSTRONG or contract in the name of ARMSTRONG.æœ¬åè®®çš„ä¸ä»»ä½•å†…å®¹å‡ä¸è§£é‡Šä¸ºåœ¨ARMSTRONGä¸Žç»é”€å•†ä¹‹é—´åˆ›å»ºé›‡ä½£å…³ç³»ã€‚ç»é”€å•†æ²¡æœ‰æƒåˆ©æˆ–æƒåŠ›ä»¥ARMSTRONGçš„åä¹‰è¿›è¡Œä»»ä½•æ´»åŠ¨æˆ–è®¢ç«‹ä»»ä½•åˆåŒã€‚3.2The Distributor, its employees and its representatives must refrain from any act that might create the false impression that they are employees or agents or representatives of ARMSTRONG. Whenever the Distributor describes its 4â€<â€<relationship with ARMSTRONG it shall make it clear that it is an independent distributor and not an agent, representative or person having the authority to enter into contracts on behalf of ARMSTRONG or incur obligations binding on ARMSTRONG.ç»é”€å•†åŠå…¶å¯¹äºŽä»£è¡¨å¿…é¡»é¿å…ä»»ä½•å¯èƒ½äº§ç”Ÿè™šå‡å°è±¡ARMSTRONGçš„è¡Œä¸ºæˆ–æ´»åŠ¨çš„æ–¹å¼ã€‚ç»é”€å•†åœ¨æ述其对ARMSTRONG的4â€<â€<关系时，应当明确表示其为独立经销商，而非代理、代表或有权代表ARMSTRONG签订合同或承担对ARMSTRONG有约束力义务的人。3.3Product P is exclusively distributed by ARMSTRONG in Hainan free trade port during such period.ç¬¬ä¸€æ¥ä¾›é"€å•†å¤"æ ¹æ®é¢„ç"¨æ³•å¾‹åŽŸåˆ™ä¸Žæ¸¯æ¾³å°åœ°åŒºæ¶‰å¤–è´¢åŠ¡ä¸Žä¼šè®¡å‡†åˆ™ï¼Œé"€å•†åº"è´Ÿè´£å®Œæˆç›¸å…³æ³¨å†Œç¨‹åºï¼Œå…¶ä¸æ³¨å†Œè¯ä¹¦ç”±ARMSTRONGè®¤å¯¹çš„ä¸ºæ¬¡äº§å"æ³¨å†Œäººæ‰€æœ‰ã€‚3.3During such period, Product P is exclusively distributed by ARMSTRONG in Hainan free trade port. The registration certificate of Product P is held by ARMSTRONG's approved registrant for Product P.ç¬¬ä¸€æ¥ä¾›é"€å•†åº"æ ¹æ®æœ¬åè®®çš„ä¸ºæ¬¡äº§å"æ供ç»é”€å•†ä¹‹é—´ç‹¬å®¶åˆ†é"€ã€‚ç»é”€å•†åº"è´Ÿè´£å®Œæˆç›¸å…³æ³¨å†Œç¨‹åºï¼Œå…¶ä¸æ³¨å†Œè¯ä¹¦ç”±ARMSTRONGè®¤å¯¹çš„Product P注册人所有。3.4The Distributor shall not sell or distribute Product P to any other territories or jurisdictions other than Hainan free trade port during such period.ç¬¬ä¸€æ¥ä¾›é"€å•†åº"æ ¹æ®æœ¬åè®®çš„ä¸ºæ¬¡äº§å"æ供ç»é”€å•†ä¹‹é—´ç‹¬å®¶åˆ†é"€ä»¥å¤–çš„å…¶ä»–åœ°åŒºæˆ–管辖区销售或分销Product P。3.4 Product P is exclusively distributed by ARMSTRONG in Hainan free trade port during such period.ç¬¬ä¸€æ¥ä¾›é"€å•†åº"æ ¹æ®æœ¬åè®®çš„ä¸ºæ¬¡äº§å"æ供ç»é”€å•†ä¹‹é—´ç‹¬å®¶åˆ†é"€ã€‚3.4The Distributor shall not sell or distribute Product P to any other territories or jurisdictions other than Hainan free trade port during such period.ç¬¬ä¸€æ¥ä¾›é"€å•†åº"æ ¹æ®æœ¬åè®®çš„ä¸ºæ¬¡äº§å"æ供ç»é”€å•†ä¹‹é—´ç‹¬å®¶åˆ†é"€ä»¥å¤–çš„å…¶ä»–åœ°åŒºæˆ–管辖区销售或分销Product P。

[illegible] ARMSTRONG [illegible] GENREACH [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] GENREACH [illegible] GENREACH [illegible] 6.7Returns. Distributer will not be allowed to make returns of Product P. [illegible] 6.8Residual Validity. Product P delivered by Armstrong shall have a residual validity period of not less than 21 months. [illegible] Armstrong [illegible] P [illegible] 21 [illegible] 7Distribution Costs and Additional Fees [illegible] 7.1Distribution Costs. The Distributor shall itself bear all the distribution costs of Product P (â€œDistribution Costsâ€), including all the costs and expenses incurred for the purpose of (i) obtaining any Regulatory Approval required for the Development Plan, (ii) marketing and clinical costs of Product P in the Collaboration Region, (iii) warehousing and transportation costs, and (iv) other costs incurred for or in relation to the sales and distribution of Product P. For avoidance of doubt, the Distribution Costs are not included in the Supply Price paid to ARMSTRONG. [illegible] P [illegible] (i) [illegible] (ii) [illegible] P [illegible] (iii) [illegible] (iv) [illegible] P [illegible] ARMSTRONG [illegible] 11 [illegible] 7.2Additional Fees. In the case the Distributor requires additional supports from ARMSTRONG, such as personnel supports, the Distributor shall pay additional fees to ARMSTRONG, which will be negotiated separately. [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] 8Intellectual Property, License and Trademarks [illegible] 8.1ARMSTRONG Intellectual Property. The Distributor hereby acknowledges that (i) all Intellectual Property in relation to and developed for Product P, and (ii) any Intellectual Property further generated in the context of Product P, including but not limited to those generated or improved during any clinical trials or marketing activities on behalf of the Distributor, and any other peripheral technologies shall solely belong to ARMSTRONG, regardless of whether such Intellectual Property have been registered or not (the â€œARMSTRONG Intellectual Propertyâ€). ARMSTRONG [illegible] (i) [illegible] P [illegible] P [illegible] (ii) [illegible] P [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] 8.2License to the Distributor. ARMSTRONG hereby grants to the Distributor and the Distributor hereby accepts a non-exclusive license to use ARMSTRONG Intellectual Property solely in connection with (i) the distribution and promotion of Product P in the Collaboration Region within the term of this Agreement, and (ii) application for necessary Regulatory Approval for the Development Plan, with the right to sublicense to permitted Sub-Distributors to use ARMSTRONG Intellectual Property solely in connection with the distribution and promotion of Product P in the Collaboration Region within the term of this Agreement.

Â [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] (i) [illegible] P [illegible] (ii) [illegible] ARMSTRONG [illegible] 8.3Limitation of Use of ARMSTRONG Intellectual Property. Without the express written consent from ARMSTRONG, the Distributor shall not manufacture, market or sell any product that contains Product P or embodies any of ARMSTRONGâ€™s Intellectual Property for purposes other than to perform this Agreement. Â The Distributor shall not use (other than pursuant to this Agreement) or seek to register or apply for statutory protection any of ARMSTRONGâ€™s Intellectual Property, or any Intellectual Property that may impair the protection of ARMSTRONG Intellectual Property. The 12â€‹â€‹Distributor shall immediately notify ARMSTRONG if it becomes aware of a possible infringement of ARMSTRONGâ€™s Intellectual Property.ARMSTRONG [illegible] ARMSTRONG [illegible] P [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] 8.4No Exclusiveness When Breach. Notwithstanding the foregoing, the exclusive license granted under this Agreement is suspended and ARMSTRONG shall retain the right to market and sell the Product P anywhere in the world through third parties in the event that the Distributor is in violation of this Agreement. [illegible] ARMSTRONG [illegible] P [illegible] 9Representations, Warranties and Liabilities [illegible] 9.1General Representations and Warranties. Each Party respectively represents and warrants to the other Party that: (i) it is a corporation duly incorporated, validly existing, and in good standing under the applicable law; (ii) it has full right, power, and authority to enter into this Agreement and to perform its obligations hereunder; no consent of, approval from, authorization of, designation of, declaration from or filing with any governmental authority is required in connection with the valid execution, delivery and performance of this Agreement; and it has no current legal arrangement with any other party that would conflict with this Agreement; (iii) the representative entrusted by it to execute this Agreement has been duly authorized to do so; (iv) upon execution, this Agreement shall become a lawful, valid, and binding obligation of such Party, enforceable against it in accordance with its terms; and (v) it shall not enter into any agreement or make any commitment or take any other action that would impair its ability to perform its obligations under this Agreement. [illegible] (i) [illegible] (ii) [illegible] (iii) [illegible] (iv) [illegible] (v) [illegible] 9.2Compliance with Law. The Distributor shall comply with all legislations, rules, regulations and statutory requirements existing from time to time in the jurisdiction where Product P is being sold that are applicable to the sale 13â€‹â€‹and distribution of Product P. The Distributor shall be responsible for obtaining all necessary authorizations, consents, approvals, licenses and permits in relation to the performance by them of their obligations under this Agreement and for making any necessary filling, record or registration of this Agreement and shall, upon request, provide ARMSTRONG satisfactory evidence thereof as reasonably required by ARMSTRONG from time to time. The Distributor shall indemnify ARMSTRONG and its Affiliates and their respective employees, servants and agents and hold them harmless from and against any loss, suit, claim, liability, expense (including and without limitation reasonable attorneyâ€™s fees), proceeding or damage (on an after-tax basis) to persons or property arising out of or related to warehousing, transportation, distribution, sale, marketing of Product P in the Collaboration Region. [illegible] P [illegible] P [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] ARMSTRONG [illegible] 9.3LIMITED WARRANTIES AND DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ARMSTRONG MAKES NO WARRANTY TO THE DISTRIBUTOR WITH RESPECT TO PRODUCT P AND EXCLUDES ALL OTHER EXPRESS AND IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, NONINFRINGEMENT, QUIET ENJOYMENT, AND ANY IMPLIED WARRANTY ARISING FROM THE COURSE OF DEALING OR THE COURSE OF PERFORMANCE. [illegible] ARMSTRONG [illegible] P [illegible] 10Indemnification [illegible] 10.1Indemnity. Â Each Party (the â€œIndemnifying Partyâ€) shall indemnify and defend the other Party and its Affiliates and their respective employees, servants and agents and hold them harmless from and against any loss, suit, claim, liability, expense (including and without limitation reasonable attorneyâ€™s fees), proceeding or damage (on an after-tax basis) to persons or property arising out of or related to (a) any acts, whether of omission or commission, that may be committed by the Indemnifying Party; and (b) any alleged or actual breach by the Indemnifying Party of its warranties, representations, covenants and obligations under this Agreement. Â The 14â€‹â€‹provisions of this Section 10.1 shall survive the termination of this Agreement. [illegible] (a) [illegible] (b) [illegible] 10.1 [illegible] 11Term and Termination [illegible] 11.1Term. Â This Agreement shall be effective upon the Effective Date, and shall be binding upon and inure to the benefit of the Parties and their respective assigns and successors in interest. The term of this Agreement (the â€œTermâ€) shall be ten (10) years commencing on the Effective Date herein. The Parties may negotiate on extension of this Agreement commencing six (6) months prior to the expiration. [illegible] 10 [illegible] 6 [illegible] 10 [illegible] 6 [illegible] 11.2Termination. This Agreement may be terminated before the expiration in any of the following events: [illegible] (1)After the completion of Contract Year 2, either party is entitled to terminate this Agreement without cause by giving a six (6) monthsâ€™ prior written notice; [illegible] 2 [illegible] 6 [illegible] (2)If any party breaches this Agreement, the other party is entitled to terminate this Agreement by giving a two (2) monthsâ€™ prior written notice; [illegible] 2 [illegible] (3)If the Distributor fails to reach the sales forecasts in Section 5.1 herein for two (2) consecutive Contract Years, ARMSTRONG is entitled to terminate this Agreement immediately; and [illegible] 2 [illegible] 5.1 [illegible] ARMSTRONG [illegible] 15â€‹â€‹(4)If the Distributor fails to purchase [***] units of Product P from ARMSTRONG in any Contract Year, ARMSTRONG is entitled to terminate this Agreement immediately. [illegible] ARMSTRONG [illegible] [***] [illegible] P [illegible] ARMSTRONG [illegible] 11.3Effect of Termination for Parties. Â Except as expressly provided herein, no Party shall incur any liability to the other party for terminating this Agreement in accordance with this Section 11, and no such termination shall limit the contemporaneous or subsequent exercise of any other rights and remedies such Party may have. Nothing herein shall be construed to release any Party from any obligation that accrued prior to the date of termination, except as expressly provided in this Agreement. Without limitation, (i) all accrued but unpaid amounts that may be owing from a Party to the other Party shall survive termination and (ii) any claim for breach or damages arising prior to or as a result of the termination shall survive (including an claim for any breach or damages continuing after termination). [illegible] 11 [illegible] (i) [illegible] (ii) [illegible] Upon termination of this Agreement, ARMSTRONG may, without limiting any other right or remedy: [illegible] ARMSTRONG [illegible] (1)suspend the supply of all Product P (including under purchase orders not yet fulfilled) to Distributor; [illegible] P [illegible] (2)require Distributor and its Affiliates to promptly return to ARMSTRONG all Product P in the possession, custody or control of Distributor or its Affiliates; and [illegible] P [illegible] ARMSTRONG [illegible] (3)sell, or engage a third party distributor to sell, all Product P manufactured under purchase order of Distributor to a third party, and recover from Distributor any costs and expenses reasonably incurred by ARMSTRONG in doing so. [illegible] P [illegible] ARMSTRONG [illegible] 16â€‹â€‹12Confidentiality. [illegible] 12.1The receiving party shall treat as confidential and secret all information which has been or may hereafter be disclosed by the disclosing party, directly or indirectly, to the receiving party, either orally, in writing or through inspection. The receiving party shall use the Confidential Information received only to the extent necessary to execute the Purpose of this Agreement. The receiving party shall not disclose to anyone any Confidential Information received from the disclosing party, and shall use the same degree of care, but no less than a reasonable degree of care, to prevent the disclosure of the Confidential Information to others as it uses to prevent the disclosure of its own Confidential Information. Upon request from the disclosing party, the receiving party shall promptly return to the disclosing party or destroy all drawings, data, memoranda and information in physical form relating to the Confidential Information. [illegible] â€œConfidential Informationâ€ means technical and business information relating to inventions, proprietary ideas and/or patentable ideas, patent applications, background intellectual property, techniques, scientific knowledge, know-how processes, existing and/or contemplated products and services, software, biological material, schematics, research and development, production, costs, profit and margin information, finances and financial projections, customers, clients, licensees, marketing, and current or future business plans and models, or other subject matters of this Agreement, regardless of whether such information is designated as â€œConfidential Informationâ€ at the time of disclosure. Â The term â€œConfidential Informationâ€ does not include such information which: [illegible] (i)is or becomes generally available to the public, other than through the receiving partyâ€™s disclosure, [illegible] (ii)was within the receiving partyâ€™s possession prior to it being furnished by or on

behalf of the disclosing party, provided that receiving partyâ€™s source had no obligation of confidentiality to the disclosing party,17â€‹â€‹åœ¨ç”±æŠ«éœ²æ–¹æ¾æˆ–ä»£è¡¨æŠ«éœ²æ–¹æä¾›ä¹‹å‰ï¼ŒæŽ¥æ”¶æ–¹å·²ç»Ž·å¾—çš„ï¼›ä¸”æŽ¥æ”¶æ–¹çš„ä¿¡æ¯æ¥æº(iii)becomes available to the receiving party on a non-confidential basis from an information provider other than the disclosing party, provided that the information provider did not have a duty of confidentiality to the disclosing party, or æŽ¥æ”¶æ–¹ä»Žä¿¡æ¯æä¾›è€…å¤„ä»¥éžä¿å¯†çš„æ–¹å¼èŽ·å¾—ï¼ŒåŽŸå› æ˜¯è¯¥ä¿¡æ¯æä¾›è€…éžæŠ«éœ²æ–¹ä¸”æ²¡æœ‰å¯¹æŠ«éœ²æ–¹è´Ÿæœ‰ä¿å¯†ä¹‰åŠ¡ï¼›æˆ–-(iv)is or becomes independently developed the receiving party without access to the Confidential Information and without violating any of the receiving partyâ€™s obligations under this Agreement, as can be demonstrated by the receiving partyâ€™s written records.æŽ¥æ”¶æ–¹åœ¨æœªèŽ·å¾—ä¿å¯†ä¿¡æ¯ä¸”æœªè¿åæœ¬åè®®ä¸‹ä»»ä½•ä¹‰åŠ¡çš„æƒ…å†µä¸‹ç‹¬ç«‹å¼€å‘çš„ï¼Œä¸”ç”±æŽ¥æ”¶æ–¹çš„ä¹¦é¢è®°å½•è¯æ˜Žã€‚12.2Each Party agrees to keep the Confidential Information confidential, which includes (but is not limited to) not disclosing the disclosing partyâ€™s Confidential Information, or any part thereof (except as otherwise may be provided herein), absent the disclosing partyâ€™s prior written consent, unless required to do so by Applicable Law, act or a valid order of a court or other governing, regulatory body with authority over the receiving party (â€œRequired Disclosureâ€); provided that the receiving party shall first give reasonable written notice to the disclosing party prior to any Required Disclosure and shall exercise its best efforts to obtain an order or other reliable assurance that the Confidential Information disclosed will be treated at the highest level of confidentiality. Upon receipt of notice from the receiving party of any Required Disclosure, the disclosing party may, at the disclosing partyâ€™s expense, seek to quash or restrict the disclosure of the disclosing partyâ€™s Confidential Information and the receiving party shall not oppose or seek to impede the disclosing partyâ€™s efforts to obtain such relief.åŒæ–¹åŒæ„å¯¹ä¿å¯†ä¿¡æ¯è¿›è¡Œä¿å¯†ï¼ŒåŒ…æ‹¬ï¼ˆä½†ä¸é™äºŽï¼‰æœªç»æŠ«éœ²æ–¹äº‹å…ˆä¹¦é¢åŒæ„ï¼Œä¸å¾—æŠ«éœ²æŠ«éœ²æ–¹çš„ä¿å¯†ä¿¡æ¯æˆ–å…¶ä»»ä½•éƒ¨åˆ†ï¼ˆæœ¬åè®®å¦æœ‰è§„å®šçš„é™¤å¤–ï¼‰ï¼Œé™¤éžé€‚ç”¨æ³•å¾‹ã€æ³•ä»¤æˆ–æ³•é™¢æˆ–å¯¹æŽ¥æ”¶æ–¹æœ‰ç®¡è¾–æƒçš„å…¶ä»–ç®¡ç†ã€ç›‘ç®¡æœºæž„çš„æœ‰æ•ˆå‘½ä»¤è¦æ±‚æŠ«éœ²ï¼ˆ"è¦æ±‚æŠ«éœ²"ï¼‰ï¼›ä½†æŽ¥æ”¶æ–¹åº”åœ¨ä»»ä½•è¦æ±‚æŠ«éœ²ä¹‹å‰å…ˆå‘æŠ«éœ²æ–¹å‘å‡ºåˆç†çš„ä¹¦é¢é€šçŸ¥ï¼Œå¹¶å°½æœ€å¤§åŠªåŠ›èŽ·å¾—å‘½ä»¤æˆ–å…¶ä»–å¯é ä¿è¯ï¼Œç¡®ä¿æ‰€æŠ«éœ²çš„ä¿å¯†ä¿¡æ¯å°†å¾—åˆ°æœ€é«˜çº§åˆ«çš„ä¿å¯†å¤„ç†ã€‚åœ¨æ”¶åˆ°æŽ¥æ”¶æ–¹å…³äºŽä»»ä½•è¦æ±‚æŠ«éœ²çš„é€šçŸ¥åŽï¼ŒæŠ«éœ²æ–¹å¯è‡ªè´¹å¯»æ±‚æ’¤é”€æˆ–é™åˆ¶æŠ«éœ²æ–¹ä¿å¯†ä¿¡æ¯çš„æŠ«éœ²ï¼ŒæŽ¥æ”¶æ–¹ä¸å¾—åå¯¹æˆ–è¯•å›¾é˜»ç¢æŠ«éœ²æ–¹èŽ·å¾—æ¤ç±»æ•‘æµŽçš„åŠªåŠ›ã€‚â€‹â€‹13Noticeé€šçŸ¥13.1All notices and communications between the parties must be in writing and addressed to the receiving party as follows:18â€‹â€‹åŒæ–¹ä¹‹é—´çš„æ‰€æœ‰é€šçŸ¥å'Œé€šè®¯å¿…é¡»ä»¥ä¹¦é¢å½¢å¼å‘é€ç»™æŽ¥æ”¶æ–¹ï¼šIf to ARMSTRONG:ARMSTRONGï¼šAddress:11570 Sixth Street, Rancho Cucamonga, CA 91730, U.S.A.åœ°å€ï¼š11570 Sixth Street, Rancho Cucamonga, CA 91730, U.S.A.Email: [***]é‚®ç®±ï¼š[***]Tel:1-909-980-9484ç”µè¯ï¼š1-909-980-9484If to the Distributor:ç»é”€å•†ï¼šGENREACHAddress: RM 1007B,10/F.,HO KING COMMERCIAL CTR.,NO.2-16 FA YUEN STREET, MONGKOK HONG KONG, CHINAåœ°å€ï¼šä¸å›½é¦™æ¸¯æ—ºè§’èŠ±å›è¡—2-16å·å¥½æ™¯å•†ä¸šä¸å¿ƒ10æ¥¼1007B室Email: [***]é‚®ç®±ï¼š[***]Tel: [***]ç”µè¯ï¼š[***]14Governing Law and Dispute Resolutioné€‚ç”¨æ³•å¾‹å'Œäº‰è®®è§£å†³14.1Governing Law. Â This Agreement shall be governed by, and construed in accordance with the laws of Hong Kong, excluding provisions relating to conflict of laws or rules that would require the application of the laws of any other jurisdiction and the Convention on Contracts for the International Sale of Goods. Â é€‚ç"¨æ³•å¾‹ã€‚æœ¬åè®®åº"å—é¦™æ¸¯æ³•å¾‹ç®¡è¾–å¹¶æ®æ¤è§£é‡Šï¼Œä½†ä¸åŒ…æ‹¬æ¶‰åŠæ³•å¾‹å†²çªçš„æ¡æ¬¾æˆ–è¦æ±‚é€‚ç"¨ä»»ä½•å…¶ä»–å¸æ³•ç®¡è¾–åŒºæ³•å¾‹çš„è§„åˆ™ä»¥åŠã€Šè"åˆå›½å›½é™…è´§ç‰©é”€å"®åˆåŒå…¬çº¦ã€‹ã€‚14.2Dispute Resolution. Â This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) (the â€œDisputesâ€) shall first be resolved through consultation. If the Disputes cannot be resolved through negotiation, the Disputes (including a Dispute in connection with the validity or continuity of this Agreement) shall be submitted to arbitration in Hong Kong International Arbitration Centre (HKIAC) with its then effective arbitration rules. The arbitration tribunal shall be consisted by three (3) members. One (1) arbitrator shall be appointed by the Party initiating the arbitration, one (1) arbitrator shall be appointed by the other Party, and the third arbitrator shall be jointly selected by the two (2) appointed arbitrators. The award of the 19â€‹â€‹arbitration tribunal shall be final and binding upon the Parties, and each Party may apply to a court of competent jurisdiction for enforcement of such award. Â Except for matters in the Dispute during a Dispute which is being resolved in accordance with this Agreement, the Parties shall continue to perform their obligations hereunder.äº‰è®®è§£å†³ã€‚æœ¬åè®®åŠ æœ¬åè®®æˆ–å…¶æ ‡çš„ç‰©æˆ–è®¢ç«‹æ‰€äº§ç"Ÿçš„æˆ–ä¸Žä¹‹ç›¸å…³çš„ä»»ä½•äº‰è®®æˆ–ç´¢èµ"ï¼ˆåŒ…æ‹¬éžåˆåŒæ€§äº‰è®®æˆ–ç´¢èµ"ï¼‰ï¼ˆ"äº‰è®®"ï¼‰åº"é¦–å…ˆé€šè¿‡åå•†è§£å†³ã€‚å¦‚æžœäº‰è®®æ— æ³•é€šè¿‡åå•†è§£å†³ï¼Œäº‰è®®ï¼ˆåŒ…æ‹¬ä¸Žæœ¬åè®®çš„æœ‰æ•ˆæ€§æˆ–æŒç»æ€§ç›¸å…³çš„äº‰è®®ï¼‰åº"æäº¤é¦™æ¸¯å›½é™…ä»²è£ä¸å¿ƒï¼ˆHKIACï¼‰æ ¹æ®å…¶å½"æ—¶æœ‰æ•ˆçš„ä»²è£è§„åˆ™è¿›è¡Œä»²è£ã€‚ä»²è£åºç"±ä¸‰ï¼ˆ3ï¼‰åä»²è£å‘˜ç»„æˆã€‚å…¶ä¸ä¸€ï¼ˆ1ï¼‰åä»²è£å‘˜ç"±å‘èµ·ä»²è£çš„ä¸€æ–¹æŒ‡å®šï¼Œä¸€ï¼ˆ1ï¼‰åä»²è£å‘˜ç"±å¦ä¸€æ–¹æŒ‡å®šï¼Œç¬¬ä¸‰åä»²è£å‘˜ç"±ä¸¤ï¼ˆ2ï¼‰åè¢«æŒ‡å®šçš„ä»²è£å‘˜å…±åŒé€‰å®šã€‚ä»²è£åºçš„è£å†³ä¸ºç»ˆå±€è£å†³ï¼Œå¯¹åŒæ–¹å‡æœ‰çº¦æŸåŠ›ï¼Œå„æ–¹å‡å¯å'æœ‰ç®¡è¾–æƒçš„æ³•é™¢ç"³è¯·æ‰§è¡Œè¯¥è£å†³ã€‚é™¤äº‰è®®äº‹é¡¹å¤–ï¼Œåœ¨æ ¹æ®æœ¬åè®®è§£å†³äº‰è®®æœŸé—´ï¼ŒåŒæ–¹åº"ç»§ç»å±¥è¡Œå…¶åœ¨æœ¬åè®®é¡¹ä¸‹çš„ä¹‰åŠ¡ã€‚15General Provisionsä¸€èˆ¬æ¡æ¬¾15.1Taxes. Â Each Party shall assume full responsibility for the proper reporting and payment of all national, state or local taxes, value-added or other taxes, contributions and/or special levies imposed or required under income tax and/or other laws or regulations, with respect to its performance under this Agreement. ç¨Žè´¹ã€‚åŒæ–¹åº"å°±å…¶åœ¨æœ¬åè®®é¡¹ä¸‹çš„å±¥è¡Œï¼Œå…¨æƒè´Ÿè´£å¦¥å–„ç"³æŠ¥å'Œç¼´çº³æ‰€å¾—ç¨Žæ³•å'Œ/æˆ–å…¶ä»–æ³•å¾‹æˆ–æ³•è§„è§„å®šå¾æ"¶çš„æ‰€æœ‰å›½å®¶ã€å·žæˆ–åœ°æ–¹ç¨Žã€å¢žå€¼ç¨Žæˆ–å…¶ä»–ç¨Žè´¹ã€ä¾›æ¬¾å'Œ/æˆ–ç‰¹åˆ«å¾æ"¶æ¬¾é¡¹ã€‚15.2Amendment. Â This Agreement may be amended only in writing signed by both Parties. Â Any term or condition in other contracts or agreements between the Parties that conflict in whole or in part with the provisions in this Agreement shall be of no force or effect and the provisions of this Agreement shall prevail in any such circumstance. ä¿®æ"¹ã€‚æœ¬åè®®åªèƒ½ä»¥åŒæ–¹ç¾ç½²çš„ä¹¦é¢å½¢å¼è¿›è¡Œä¿®æ"¹ã€‚åŒæ–¹ä¹‹é—´çš„å…¶ä»–åˆåŒæˆ–åè®®ä¸ä¸Žæœ¬åè®®æ¡æ¬¾å…¨éƒ¨æˆ–éƒ¨åˆ†å†²çªçš„ä»»ä½•æ¡æ¬¾æˆ–æ¡ä»¶å‡æ— æ•ˆï¼Œåœ¨ä»»ä½•æ¤ç±»æƒ…å†µä¸‹ï¼Œå‡ä»¥æœ¬åè®®æ¡æ¬¾ä¸ºå‡†ã€‚15.3Assignment. Â Each Partyâ€™s rights and obligations under this Agreement are not transferable and assignable without the prior written consent of the other Party. Â è½¬è®©ã€‚æœªç»å¦ä¸€æ–¹äº‹å…ˆä¹¦é¢åŒæ„ï¼Œå„æ–¹åœ¨æœ¬åè®®é¡¹ä¸‹çš„æƒåˆ©å'Œä¹‰åŠ¡ä¸å¾—è½¬è®©ã€‚15.4Severability. Â If any term, provision, covenant, or condition of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the provisions shall remain in full force and effect and shall in no way be affected, impaired or invalidated, provided that the Agreement remains substantially capable of performance without adversely affecting the rights of the Parties.20â€‹â€‹å¯åˆ†å‰²æ€§ã€‚å¦‚æžœæœ¬åè®®çš„ä»»ä½•æ¡æ¬¾ã€è§„å®šã€å¥‘çº¦æˆ–æ¡ä»¶è¢«æœ‰ç®¡è¾–æƒçš„æ³•é™¢è®¤å®šä¸ºæ— æ•ˆã€æ— æ•ˆæˆ–ä¸å¯æ‰§è¡Œï¼Œåˆ™å…¶ä½™æ¡æ¬¾ä»åº"å®Œå…¨æœ‰æ•ˆï¼Œä¸å—ä»»ä½•å½±å"ã€æŸå®³æˆ–å¤±æ•ˆï¼Œå‰æ˜¯æœ¬åè®®ä»åŸºæœ¬èƒ½å¤Ÿå±¥è¡Œï¼Œä¸"ä¸ä¼šå¯¹åŒæ–¹çš„æƒåˆ©äº§ç"Ÿä¸åˆ©å½±å"ã€‚15.5Survival. Sections 10, 11.3, 12, 14 and 15 shall survive the termination of this Agreement.å˜ç»ã€‚æœ¬åè®®ç¬¬10æ¡ã€11.3æ¡ã€12æ¡ã€14æ¡å'Œ15æ¡åœ¨æœ¬åè®®ç»ˆæ¢åŽç»§ç»æœ‰æ•ˆã€‚15.6Waiver. Â The failure of a Party to enforce, at any time or for any period of time, any provision of this Agreement shall not be construed as a waiver of such provision or the right of such a Party to enforce such provision thereafter.æ"¾å¼ƒã€‚ä¸€æ–¹æœªèƒ½åœ¨ä»»ä½•æ—¶å€™æˆ–ä»»ä½•æ—¶æœŸå†…æ‰§è¡Œæœ¬åè®®çš„ä»»ä½•æ¡æ¬¾ï¼Œä¸åº"è¢«è§£é‡Šä¸ºæ"¾å¼ƒè¯¥æ¡æ¬¾æˆ–è¯¥æ–¹æ¤åŽæ‰§è¡Œè¯¥æ¡æ¬¾çš„æƒåˆ©ã€‚15.7Force Majeure. Â A Party shall not be responsible for any default in performing this Agreement due to unforeseen circumstances or causes beyond its reasonable control (the â€œForce Majeureâ€), including but not limited to earthquake, typhoon, flood, or other acts of nature, pandemic (excluding those related to the COVID-19 pandemic subsisting as at the date of this Agreement which have not materially escalated afterwards), fire, terrorism, war and riots. Â The Party claiming Force Majeure shall notify the other Party in writing within thirty (30) days after the occurrence of such event, take appropriate means to minimize or remove the effects of Force Majeure and make attempts to resume performance of its obligations affected by the Force Majeure. If the Party claiming Force Majeure is unable to perform all or part of this Agreement for three (3) months after the occurrence of such event, the other Party may terminate this Agreement. ä¸å¯æŠ—åŠ›ã€‚ç"±äºŽä¸å¯é¢„è§çš„æƒ…å†µæˆ–è¶…å‡ºå…¶åˆç†æŽ§åˆ¶èŒƒå›´çš„åŽŸå› ï¼ˆ"ä¸å¯æŠ—åŠ›"ï¼‰ï¼ŒåŒ…æ‹¬ä½†ä¸é™äºŽåœ°éœ‡ã€å°é£Žã€æ´ªæ°´æˆ–å…¶ä»–è‡ªç„¶ç¾å®³ã€æµè¡Œç—…ï¼ˆä¸åŒ…æ‹¬ä¸Žæœ¬åè®®ç¾ç½²ä¹‹æ—¥å˜åœ¨ä¸"æ¤åŽæœªæ˜¾è'—å‡çº§çš„COVID-19æµè¡Œç—…ç›¸å…³çš„æµè¡Œç—…ï¼‰ã€ç«ç¾ã€ææ€–ä¸»ä¹‰ã€æˆ˜äº‰å'Œæš´ä¹±ï¼Œä¸€æ–¹ä¸å¯¹æœªèƒ½å±¥è¡Œæœ¬åè®®æ‰¿æ‹…è´£ä»»ã€‚ä¸»å¼ ä¸å¯æŠ—åŠ›çš„ä¸€æ–¹åº"åœ¨æ¤ç±»äº‹ä»¶å‘ç"Ÿåä¸‰åï¼ˆ30ï¼‰å¤©å†…ä»¥ä¹¦é¢å½¢å¼é€šçŸ¥å¦ä¸€æ–¹ï¼Œé‡‡å–é€‚å½"æŽªæ–½å°½é‡å‡å°'æˆ–æ¶ˆé™¤ä¸å¯æŠ—åŠ›çš„å½±å"ï¼Œå¹¶åŠªåŠ›æ¢å¤å±¥è¡Œå—ä¸å¯æŠ—åŠ›å½±å"çš„ä¹‰åŠ¡ã€‚å¦‚æžœä¸»å¼ ä¸å¯æŠ—åŠ›çš„ä¸€æ–¹åœ¨è¯¥äº‹ä»¶å‘ç"Ÿåä¸‰ï¼ˆ3ï¼‰ä¸ªæœˆå†…æ— æ³•å±¥è¡Œå…¨éƒ¨æˆ–éƒ¨åˆ†æœ¬åè®®ï¼Œå¦ä¸€æ–¹å¯ç»ˆæ¢æœ¬åè®®ã€‚15.8Execution in Counterparts. Â This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Â This Agreement shall become binding when any one or more counterparts thereof, individually or taken together, bear the signature of both Parties thereto. Â For the purposes hereof, a facsimile copy of this Agreement, including the signature pages thereto, shall be deemed an original.ä»½æ•°ã€‚æœ¬åè®®å¯ç¾ç½²ä¸€ä»½æˆ–å¤šä»½å‰¯æœ¬ï¼Œæ¯ä»½å‰¯æœ¬å‡è¢«è§†ä¸ºåŽŸä»¶ï¼Œæ‰€æœ‰å‰¯æœ¬å…±åŒæž„æˆåŒä¸€æ–‡ä»¶ã€‚å½"æœ¬åè®®çš„ä»»ä½•ä¸€ä»½æˆ–å¤šä»½å‰¯æœ¬å•ç‹¬æˆ–åˆå¹¶å¸¦æœ‰åŒæ–¹çš„ç¾å—æ—¶ï¼Œæœ¬åè®®å³å…·æœ‰çº¦æŸåŠ›ã€‚ä¸ºæœ¬åè®®ä¹‹ç›®çš„ï¼Œæœ¬åè®®çš„ä¼ çœŸå‰¯æœ¬ï¼ŒåŒ…æ‹¬å…¶ç¾å—é¡µï¼Œåº"è¢«è§†ä¸ºåŽŸä»¶ã€‚21â€‹â€‹15.9Language. Â This Agreement is written in English and Chinese. Should there be any discrepancy between the English version and Chinese version, the English version shall prevail.è¯è¨€ã€‚æœ¬åè®®ä»¥è‹±æ–‡å'Œä¸æ–‡ä¹¦å†™ã€‚å¦‚è‹±æ–‡ç‰ˆæœ¬ä¸Žä¸æ–‡ç‰ˆæœ¬ä¹‹é—´å˜åœ¨ä»»ä½•å·®å¼‚ï¼Œä»¥è‹±æ–‡ç‰ˆæœ¬ä¸ºå‡†ã€‚â€‹[The below is intentionally left blank][ä»¥ä¸‹æ— æ£æ–‡]â€‹â€‹22â€‹â€‹â€‹IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be executed by their representatives, duly authorized hereunto, on the date first above written.æœ¬åè®®çš„æ¯ä¸€æ–¹å·²ä¿ƒä½¿ç»å…¶æ£å¼æŽˆæƒçš„ä»£è¡¨äºŽä¸Šæ–‡é¦–å†™ä¹‹æ—¥ç¾ç½²æœ¬åè®®ï¼Œä»¥èµ„è¯æ˜Žã€‚â€‹â€‹â€‹â€‹rmstrong Pharmaceuticals, Inc.:â€‹For and on behalf ofèº"ä»£è¡¨Armstrong Pharmaceuticals, Inc.:â€‹By/ç¾ç½²:/s/Tony MarrsName/å§"å:Tony MarrsTitle/èŒåŠ¡:Presidentâ€‹For and on behalf of èº"ä»£è¡¨Hong Kong Genreach Limited:(é¦™æ¸¯ç'ç'žé©°æœ‰é™å…¬å¸) (Seal):â€‹By/ç¾ç½²:/s/Xuefeng Yang Name/å§"å:Xuefeng Yang Title/èŒåŠ¡:Legal Representative â€‹Signature pages of Distribution Agreementç»é"€åè®®ç¾å—é¡µâ€‹ EX-31.1 3 amph-20240930xex31d1.htm EX-31.1 ExhibitÂ 31.1â€‹CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OFTHE SECURITIES EXCHANGE ACT OF 1934AS ADOPTED PURSUANT TO SECTION 302OF THE SARBANES OXLEY ACT OF 2002I, Jack Y. Zhang, Ph.D., certify that:â€‹1.I have reviewed this Quarterly Report on Form 10-Q of Amphastar Pharmaceuticals, Inc.;â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹â€‹Date: November 7, 2024By:/s/ JACK Y. ZHANGâ€‹â€‹â€‹Jack Y. Zhangâ€‹â€‹â€‹Chief Executive Officerâ€‹â€‹â€‹(Principal Executive Officer)â€‹â€‹â€‹ EX-31.2 4 amph-20240930xex31d2.htm EX-31.2 ExhibitÂ 31.2â€‹CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OFTHE SECURITIES EXCHANGE ACT OF 1934AS ADOPTED PURSUANT TO SECTION 302OF THE SARBANES OXLEY ACT OF 2002I, William J. Peters, certify that:â€‹1.I have reviewed this Quarterly Report on Form 10-Q of Amphastar Pharmaceuticals, Inc.;â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹Date: November 7, 2024By:/s/ WILLIAM J. PETERSâ€‹â€‹â€‹William J. Petersâ€‹â€‹â€‹Chief Financial Officerâ€‹â€‹â€‹(Principal Financial and Accounting Officer)â€‹â€‹â€‹ EX-32.1 5 amph-20240930xex32d1.htm EX-32.1 ExhibitÂ 32.1â€‹CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906OF THE SARBANES-OXLEY ACT OF 2002â€‹The undersigned officer of Amphastar Pharmaceuticals, Inc. (the â€œCompanyâ€), hereby certifies, to the best of such officerâ€™s knowledge, that:â€‹(i)Â the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Securities Exchange Act of 1934 andâ€‹(ii)Â the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.â€‹â€‹â€‹Date: November 7, 2024By:/s/ JACK Y. ZHANGâ€‹â€‹â€‹Jack Y. Zhangâ€‹â€‹â€‹Chief Executive Officerâ€‹â€‹â€‹(Principal Executive Officer)â€‹â€‹The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Â§1350, and is not being filed for purposes of SectionÂ 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into

any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.â€‹ EX-32.2 6 amph-20240930xex32d2.htm EX-32.2 ExhibitÂ 32.2â€‹CERTIFICATIONS OF PRINCIPAL FINANCIAL OFFICERPURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906OF THE SARBANES-OXLEY ACT OF 2002â€‹The undersigned officer of Amphastar Pharmaceuticals, Inc. (the â€œCompanyâ€), hereby certifies, to the best of such officerâ€™s knowledge, that:â€‹(i)Â the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Securities Exchange Act of 1934 andâ€‹(ii)Â the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.â€‹â€‹â€‹â€‹â€‹Date: November 7, 2024By:/s/ WILLIAM J. PETERSâ€‹â€‹â€‹William J. Petersâ€‹â€‹â€‹Chief Financial Officerâ€‹â€‹â€‹(Principal Financial and Accounting Officer)â€‹â€‹The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Â§1350, and is not being filed for purposes of SectionÂ 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.â€‹ EX-101.SCH 7 amph-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 995200500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - BAQSIMI Acquisition (Purchase Price Allocated to Acquired Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Net Income per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Investments (Held-to-Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - BAQSIMI Acquisition link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Net Income per Share link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Customer and Supplier Concentration link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Property, Plant, and Equipment link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211601 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995211701 - Disclosure - Employee Benefits link:presentationLink link:calculationLink link:definitionLink 995211801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211901 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 995212001 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - BAQSIMI Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Customer and Supplier Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 99931403 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99931503 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 99931603 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - BAQSIMI Acquisition (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Revenue Recognition (Analysis of the Chargeback Provision) (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Revenue Recognition (Chargebacks and Rebates Balance Sheet Accounts) (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Net Income per Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Segment Reporting (Selected Financial Information by Reporting Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Segment Reporting (Summary of Net Revenues by Product Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Customer and Supplier Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Debt (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 99941402 - Disclosure - Debt (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - Income Taxes (Summary of Income (Loss) Before Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 99941601 - Disclosure - Stockholders' Equity (Share Buyback Program) (Details) link:presentationLink link:calculationLink link:definitionLink 99941602 - Disclosure - Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 99941603 - Disclosure - Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 99941604 - Disclosure - Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details) link:presentationLink link:calculationLink link:definitionLink 99941605 - Disclosure - Stockholders' Equity (Summary of Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 99941606 - Disclosure - Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) link:presentationLink link:calculationLink link:definitionLink 99941607 - Disclosure - Stockholders' Equity (Summary of Nonvested Options) (Details) link:presentationLink link:calculationLink link:definitionLink 99941608 - Disclosure - Stockholders' Equity (Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 99941609 - Disclosure - Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) link:presentationLink link:calculationLink link:definitionLink 99941610 - Disclosure - Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 99941701 - Disclosure - Employee Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 99941801 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details) link:presentationLink link:calculationLink link:definitionLink 99941901 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 99942001 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 amph-20240930_cal.xml EX-101.CAL EX-101.DEF 9 amph-20240930_def.xml EX-101.DEF EX-101.LAB 10 amph-20240930_lab.xml EX-101.LAB Document and Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Restricted Cash, Current Restricted cash Short-Term Investments Short-term investments Restricted Investments, Current Restricted short-term investments Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net Inventory, Net Inventories Total inventory, net Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds and deposits of overpayments or recoveries based on agreed-upon resolutions of disputes. Income Tax Refund And deposits Income tax refunds and deposits Prepaid Expense and Other Assets, Current Prepaid expenses and other assets Assets, Current Total current assets Property, Plant and Equipment, Net Total property, plant, and equipment, net Property, plant, and equipment, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Finance lease right-of-use assets Operating Lease, Right-of-Use Asset This item represents the carrying amount on the entity's balance sheet of its investment in unconsolidated affiliate. Investment In Unconsolidated Affiliate Investment in unconsolidated affiliate Intangible Assets, Net (Including Goodwill) Balance, Net Book Value Goodwill and intangible assets, net Long-Term Investments Long-term investments Other Assets, Noncurrent Other assets Deferred Income Tax Assets, Net Deferred tax assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Total accounts payable and accrued liabilities The amount of accrued payments for assets acquisitions. Accrued Payments For Asset Acquisitions Accrued payments for BAQSIMI Accrued Income Taxes, Current Income taxes payable Long-Term Debt and Lease Obligation, Current Less current portion of long-term debt and finance leases Current portion of long-term debt Operating Lease, Liability, Current Current portion of operating lease liabilities Liabilities, Current Total current liabilities Accrued Income Taxes, Noncurrent Long-term reserve for income tax liabilities Long-Term Debt and Lease Obligation Long-term debt, net of current portion and unamortized debt issuance costs Operating Lease, Liability, Noncurrent Long-term operating lease liabilities, net of current portion Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023 Additional Paid in Capital Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury Stock, Value Treasury stock Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock; shares authorized Common Stock, Shares, Issued Common stock; shares issued Common Stock, Shares, Outstanding Balance Balance Common stock; shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Product and Service [Axis] Product and Service [Domain] Product [Member] Product and Service, Other [Member] Revenues [Abstract] Net revenues: Net Revenues: Revenues Revenue Cost of Revenue Cost of revenues Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: Selling and Marketing Expense General and Administrative Expense General and administrative Research and Development Expense Research and development Operating Expenses Total operating expenses Operating Income (Loss) Income from operations Nonoperating Income (Expense) [Abstract] Non-operating income (expenses): Investment Income, Interest Interest Expense, Nonoperating Interest expense Other Nonoperating Income (Expense) Nonoperating Income (Expense) Non-operating income (expenses) Total non-operating income (expenses), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) before income taxes Income (loss) before income taxes Income Tax Expense (Benefit) Income tax provision Amount after tax of income (loss) from continuing operations. Income Loss From Continuing Operations After Income Taxes Income before equity in losses of unconsolidated affiliate Income before equity in losses of unconsolidated affiliate Income (Loss) from Equity Method Investments Equity in losses of unconsolidated affiliate Equity in losses of unconsolidated affiliates Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income attributable to Amphastar Pharmaceuticals, Inc. Net income Net income attributable to Amphastar Pharmaceuticals, Inc. Net income Net Income per Share Net income per share Earnings Per Share, Basic Net income (loss) per share - basic Earnings Per Share, Diluted Net income (loss) per share - diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average shares used to compute net income per share: Weighted Average Number of Shares Outstanding, Basic Weighted-average shares outstanding-basic Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares outstanding - diluted Diluted (in Shares) CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss), net of income taxes Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive income (loss) Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive income CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock, Common [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in Stockholders' Equity Equity, Attributable to Parent Balance Balance Treasury Stock, Value, Acquired, Cost Method Purchase of treasury stock Treasury Stock, Shares, Acquired Purchase of treasury stock (in Shares) Stock Issued During Period, Value, Treasury Stock Reissued Issuance of treasury stock in connection with the Company's equity plans Stock Issued During Period, Shares, Treasury Stock Reissued Issuance of treasury stock in connection with the Company's equity plans (in Shares) Value of shares issued under equity plans. Stock Issued During Period Value Equity Plans Issuance of common stock in connection with the Company's equity plans Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Issuance of common stock in connection with the Company's equity plans (in Shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash Flows From Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation to net cash provided by operating activities: Gain (Loss) on Disposition of Assets Loss (gain) on disposal of assets Impairment of Long-Lived Assets to be Disposed of Impairment of long-lived assets The amount of net gain or loss on interest rate swaps and foreign currency transactions. Gain Loss On Interest Rate Swaps And Foreign Currency Transactions Net Gain on interest rate swaps and foreign currency transactions, net Depreciation Depreciation of property, plant, and equipment Amortization of Intangible Assets Amortization of product rights, trademarks, and patents Operating Lease, Right-of-Use Asset, Periodic Reduction Operating lease right-of-use asset amortization Amortization of Debt

Issuance Costs Amortization of discounts, premium, and debt issuance costs Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable, net Increase (Decrease) in Inventories Inventories Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase Decrease In Income Tax Refund, Deposits, and Payable Increase Decrease In Income Tax Refund, Deposits, and Payable Income tax refunds, deposits, and payable, net Amount of lessee's right to use underlying asset under operating lease, net of present value of lessee's discounted obligation for lease payments from operating lease. Operating Lease Right Of Use Assets And Liabilities Net Operating lease liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash Flows From Investing Activities: The cash outflow for acquisitions of assets. Payments Acquisitions Of Assets BAQSIMI acquisition Payments to Acquire Property, Plant, and Equipment Purchases and construction of property, plant, and equipment Payments to Acquire Marketable Securities Purchase of investments Proceeds from Sale and Maturity of Marketable Securities Maturity of investments Cash outflow related to payments and other deposits not otherwise defined in the taxonomy. Payments For Deposits And Other Assets Deposits and other assets Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows From Financing Activities: Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds from equity plans, net of withholding tax payments The total cash inflow or outflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises, net of withholding tax payments upon issuance to employees. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Proceeds From Payments For Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options, Net Of Withholding Tax Payments Proceeds from equity plans, net of withholding tax payments Payments for Repurchase of Common Stock Purchase of treasury stock Payments for repurchase of common stock Payments of Debt Issuance Costs Debt issuance costs Proceeds from Lines of Credit Proceeds from Issuance of Long-Term Debt Repayments of Long-Term Debt Principal payments on long-term debt Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash at beginning of period Noncash Investing and Financing Items [Abstract] Noncash Investing and Financing Activities: The amount of deferred payments for acquisitions. Deferred Payment For Acquisition Deferred payment for BAQSIMI acquisition Capital Expenditures Incurred but Not yet Paid Capital expenditures included in accounts payable Amount of lessee's right to use underlying asset under operating lease in noncash investing or financing activities. Noncash Operating Lease Right Of Use Asset Operating lease right-of-use assets in exchange for operating lease liabilities Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: Interest Paid, Excluding Capitalized Interest, Operating Activities Income Taxes Paid General Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] General Summary of Significant Accounting Policies Disclosure of the reporting entity's significant accounting policies, excluding its policy for revenue recognition. Significant Accounting Policies Excluding Revenue Recognition Policy Text Block Summary of Significant Accounting Policies BAQSIMI Acquisition Asset Acquisition [Table] Asset Acquisition [Line Items] Asset Acquisition [Text Block] BAQSIMI Acquisition Revenue Recognition The entire disclosure for revenue recognition. Revenue Recognition Disclosure [Text Block] Revenue Recognition Earnings Per Share [Text Block] Net Income per Share Segment Reporting Segment Reporting Disclosure [Text Block] Segment Reporting Customer and Supplier Concentration Concentration Risk Disclosure [Text Block] Customer and Supplier Concentration Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Inventories Inventory Disclosure [Text Block] Inventories Property, Plant, and Equipment. Property, Plant and Equipment Disclosure [Text Block] Property, Plant, and Equipment Accounts Payable and Accrued Liabilities. Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Liabilities Debt Debt Disclosure [Text Block] Debt Income Taxes Income Tax Disclosure [Text Block] Income Taxes Stockholders' Equity Equity [Text Block] Stockholders' Equity Employee Benefits Retirement Benefits [Text Block] Employee Benefits Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related-Party Transactions Related Party Transactions Disclosure [Text Block] Related-Party Transactions Litigation Legal Matters and Contingencies [Text Block] Litigation Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Equity Method Investments [Policy Text Block] Investment in Unconsolidated Affiliates Use of Estimates, Policy [Policy Text Block] Use of Estimates Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (loss) Disclosure of accounting policy for acquisitions. Acquisitions Policy Policy Text Block Acquisitions Advertising Cost [Policy Text Block] Advertising Expense Fair Value of Financial Instruments, Policy [Policy Text Block] Financial Instruments Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Investment, Policy [Policy Text Block] Investments Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Disclosure of accounting policy for restricted short-term investments. Restricted Short-term Investments [Policy Text Block] Restricted Short-Term Investments Income Tax, Policy [Policy Text Block] Deferred Income Taxes Debt, Policy [Policy Text Block] Debt Issuance Costs Disclosure of accounting policy related to convertible debt. Convertible Debt Policy Text Block Convertible Debt Commitments and Contingencies, Policy [Policy Text Block] Litigation, Commitments and Contingencies New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Asset Acquisition [Table Text Block] Schedule of purchase price allocated to acquired assets The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing. Schedule of Chargeback Liability [Table Text Block] Schedule of chargeback and rebates provision analysis Tabular disclosure of the amounts that are recognized in the balance sheet for chargebacks and rebates. Schedule Of Provision For Chargebacks And Rebates Amounts Recognized In Balance Sheet Table Text Block Schedule of provision of chargebacks and rebates as reflected in the balance sheets Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net income (loss) per share calculation Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of financial information by reporting segment Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Schedule of net revenues in the finished pharmaceutical products segment Tabular disclosure of depreciation, depletion, and amortization of property and equipment costs. Schedule Of Depreciation Depletion And Amortization [Table Text Block] Schedule of depreciation and amortization expense by reporting segment Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of net revenues and carrying values of long-lived assets by geographic region Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Schedule of accounts receivable and net revenues by major customer Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities measured on a recurring basis Debt Securities, Held-to-Maturity [Table Text Block] Schedule of securities classified as held-to-maturity Tabular disclosure of amortizable finite-lived intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Schedule Of Finite Lived And Indefinite Lived Intangible Assets By Major Class Table Text Block Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class Schedule of Goodwill [Table Text Block] Schedule of changes in carrying amounts of goodwill Schedule of Inventory, Current [Table Text Block] Schedule of inventories Property, Plant and Equipment [Table Text Block] Schedule of property, plant, and equipment Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued liabilities Schedule of Debt [Table Text Block] Schedule of debt Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Summary of provision (benefit) for income taxes Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of key assumptions to determine fair value of options Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of the summary of option activity under all plans Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of information relating to options grants Schedule of Nonvested Share Activity [Table Text Block] Schedule of the summary of nonvested options status Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block] Schedule of information relating to RSU grants and deliveries Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of recorded share-based compensation expense under all plans Segments [Axis] Segments [Domain] Represents the finished pharmaceutical products segments of the business. Finished Pharmaceutical Products Segment Subsegments [Axis] Subsegments [Domain] Represents Primatene MIST. Primatene MIST Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Gains and (losses) of intercompany foreign currency transactions Advertising Expense Advertising expense Certificates of Deposit, at Carrying Value Asset Acquisition [Axis] Asset Acquisition [Domain] Represents information pertaining to BAQSIMI acquisitions. BAQSIMI product rights Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents Manufacturing Services Agreement. Manufacturing Services Agreement Represents Transition Services Agreement. Transition Services Agreement Payments to Acquire Productive Assets Cash payment Payment to acquire assets Asset Acquisition, Consideration Transferred, Contingent Consideration Contingent consideration Period of time for agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Term Agreement term The amount of consideration payable including accrued interest as part of consideration transferred in asset acquisition. Asset Acquisition Consideration Deferred Payment Including Accrued Interest Deferred payment including accrued interest Period of time, typically for liabilities, that have been discounted to their net present values, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Interest Expense Accretion Term Interest expense accretion period Amount of interest expense recognized related to accretion of deferred payment. Deferred Payment Accretion Interest Expense Recognized Interest expense recognized related to accretion of deferred payment Debt Instrument, Face Amount Principal amount Aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Intangible Assets, Net (Excluding Goodwill) BAQSIMI product rights Deferred Tax Assets, Goodwill and Intangible Assets Deferred tax assets Net Assets Total assets acquired Minimum [Member] Services for research and development. Research and development services Legal Entity [Axis] All Entities [Member] ANP [Member] ANP Payment terms in contract with customer, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration. Revenue Performance Obligation Payment Terms Payment terms Represents the amount the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. Revenue Recognition Wholesaler Chargebacks Ending balance Beginning balance Total Represents the wholesaler chargeback provision related to sales made in the current period. Provision for chargebacks and rebates Represents wholesaler chargeback credits issued to third parties during the period. RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties Credits and payments issued to third parties The settlement of chargebacks and rebate terms, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Settlement Of Chargebacks And Rebates Terms Settlement of chargebacks and rebates terms Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Accounts Receivable [Member] Accounts Payable and Accrued Liabilities [Member] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. Employee and non-employee stock options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares Represents the weighted-average exercise price of the excluded securities, per share. Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Basic and dilutive numerator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted-average shares outstanding - basic Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Net effect of dilutive securities: Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Incremental shares from equity awards Schedule of Segment Reporting Information, by Segment [Table] Represents the active pharmaceutical ingredient or API segment of the business. Active Pharmaceutical Ingredient Segment Segment Reporting Information [Line Items] Number of Reportable Segments Gross Profit [Abstract] Gross profit (loss): Represents Glucagon. Glucagon Represents BAQSIMI. BAQSIMI Represents Epinephrine. Epinephrine Represents Lidocaine. Lidocaine Represents Phytonadione. Phytonadione Represents Enoxaparin. Enoxaparin Represents Naloxone. Naloxone Other Finished Pharmaceutical Products [Member] Other Finished Pharmaceutical Products Finished pharmaceutical products net revenues Total finished pharmaceutical products net revenues Represents BAQSIMI NEB. BAQSIMI NEB Segment Reporting Information, Revenue for Reportable Segment [Abstract] Depreciation, Depletion and Amortization Depreciation and amortization expense Schedule of Revenues from External Customers and Long-Lived Assets [Table] Geographical [Axis] Geographical [Domain] UNITED STATES CHINA FRANCE Revenues from External Customers and Long-Lived Assets [Line Items] Long-Lived Assets Schedule of Revenue by Major Customers, by Reporting Segments [Table] Customer [Axis] Customer [Domain] The major customer McKesson. McKesson [Member] The major customer Cencora Inc. Cencora [Member] The major customer Cardinal Health. Cardinal Health [Member] Eli Lilly and Co. Lilly [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue Benchmark [Member] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Revenue, Major Customer [Line Items] Number of major customers that are wholesale distributors of the reporting entity's products. Number Of Major Customers, Wholesale Drug Distributors Number of major customers that are wholesale distributors Number of major customers. Number Of Major Customers Number of major customers Concentration Risk, Percentage Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Certificates of Deposit [Member] Money Market Funds [Member] Derivative Instrument [Axis] Derivative Contract [Domain] Interest Rate Swap [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Restricted Cash and Investments Restricted cash Investments, Fair Value Disclosure Short-term investments Restricted Investments, at Fair Value Restricted short-term investments Assets, Fair Value Disclosure Total assets measured at fair value Derivative Liability, Subject to Master Netting Arrangement, before Offset Interest rate swaps related to variable rate loans Interest rate swaps related to variable rate loans Debt Securities, Held-to-Maturity [Table] Financial Instrument [Axis] Financial Instruments [Domain] This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount). Corporate and agency bonds (due within 1 year) Corporate Bond Securities [Member] Municipal Bonds [Member] Schedule of Held-to-Maturity Securities [Line Items] Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Amortized Cost Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Gross Unrealized Gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Gross Unrealized Losses Debt Securities, Held-to-Maturity, Fair Value Fair Value Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class. Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Use Rights [Member] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major

Class Name [Domain] Trademarks [Member] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Asset, Useful Life Weighted-Average Life (Years) Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived intangible assets Goodwill Ending balance Beginning balance Goodwill recognized Gross amount of indefinite-lived intangible assets and goodwill. Indefinite Lived Intangible Assets Including Goodwill Gross Subtotal, Original Cost Carrying amount of indefinite-lived intangible assets and goodwill. Indefinite Lived Intangible Assets Including Goodwill Net Subtotal, Net Book Value Amount before accumulated amortization of intangible assets, including goodwill. Balance, Original Cost Balance, Original Cost Goodwill, Translation and Measurement Period Adjustments Inventory, Raw Materials and Supplies, Gross Inventory, Work in Process, Gross Inventory, Finished Goods, Gross Inventory Write-down Inventory adjustment to reflect net realizable value Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Building [Member] Leasehold Improvements [Member] Land [Member] Machinery and Equipment [Member] Total of 1) equipment such as desks, chairs) commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and 2) vehicles. Furniture, fixtures, and automobiles Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Total property, plant, and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Accrued customer fees and rebates Accrued customer fees and rebates Employee-related Liabilities, Current Accrued payroll and related benefits Carrying value as of the balance sheet date of obligations incurred through that date for estimated refunds due to goods returned by customers (other than under warranty provisions). For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Product Return Accrual, Current Accrued product returns, current portion Accrued loss on firm purchase commitments Accrued loss on firm purchase commitments Estimated Litigation Liability Accrued litigation settlement Other Accrued Liabilities, Current Other accrued liabilities Accrued Liabilities, Current Total accrued liabilities Accounts Payable, Current Accounts payable Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents 2.0% convertible senior notes due 2029. Two Percent Convertible Senior Notes Due Two Thousand Twenty Nine Member 2029 Convertible Notes Line of Credit Facility with China Merchant Bank due October 2026 Line of Credit - Due October 2026 Term loan with Wells Fargo Bank due June 2028 Term Loan - Due June 2028 Mortgage Payable - Paid off June 2024 [Member] Mortgage Payable - Paid off June 2024 Represents the French Government loan due December 2026. French Government Loan 4 - Due December 2026 Revolving line of credit with Captial One N.A. due August 2026 Revolving line of credit - closed in June 2023 Lender Name [Axis] Line of Credit Facility, Lender [Domain] Represents East West Bank. East West Bank [Member] Loans/Agreements with China Merchant Bank China Merchant Bank Represents the Seine-Normandie water agency. Seine-Normandie Water Agency [Member] Represents Capital One, National Association. Capital One, N.A. Represents Loans with Wells Fargo Bank Wells Fargo Bank Credit Facility [Axis] Credit Facility [Domain] Line of Credit [Member] Revolving Credit Facility [Member] Debt Instrument [Line Items] Debt Long-Term Debt Unamortized Debt Issuance Expense Unamortized debt issuance costs Finance Lease, Liability, Noncurrent Equipment under Finance Leases Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Contractual Obligation Total debt Line of Credit Facility with ICBC Bank due November 2033 Line of Credit Due November 2033 Represents loans with ICBC bank. ICBC Bank Debt Instrument, Interest Rate, Stated Percentage Debt interest rate Repayments of Senior Debt Repayment of debt Debt Issuance Costs, Net Debt issuance costs Debt Instrument, Convertible, Conversion Ratio Debt conversion ratio Represents the denomination of the principal amount of debt that is used in conversion calculations. Debt Instrument Principal Amount Denomination For Conversion Into Common Stock Debt principle amount converted into common stock Debt Instrument, Convertible, Conversion Price Debt conversion price per share Percentage of premium over the last reported sale price in a convertible debt instrument. Debt Instrument, Convertible, Premium Percentage over Last Reported Sale Price percent Convertible debt, percentage of premium over the last reported sale price Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Convertible debt threshold percentage Debt Instrument, Convertible, Threshold Trading Days Convertible debt, threshold trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Convertible debt, threshold consecutive trading days Threshold number of business days after consecutive trading days that trading price is less than the product of threshold sale price of the common stock and the conversion rate on each trading day to trigger conversion feature. Debt Instrument, Convertible, Threshold Business Days After Consecutive Trading Period Threshold business days after consecutive trading period Threshold period of specified consecutive trading days within which trading price is less than the product of threshold sale price of the common stock and the conversion rate on each trading day to trigger conversion feature. Debt Instrument, Convertible, Threshold Consecutive Trading Period Threshold consecutive trading period Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Percentage of principal amount redeemed Represents the trading price as a maximum percentage of product of sale price of common stock and conversion rate on each trading day to determine eligibility of conversion. Debt Instrument, Convertible, Threshold Trading Price As a Percentage of Product of Sale Price of Common Stock and Conversion Rate Percentage of product sale price Debt Instrument, Fair Value Disclosure Percentage points added to the reference rate to compute the variable rate on the debt instrument. Debt Instrument Basis Spread Discount On Variable Rate Prime rate discount percentage Line of Credit Facility, Fair Value of Amount Outstanding Borrowings The amount of net gains (losses) from changes in fair value of interest rate cash flow hedges. Gain Loss From Change In Fair Value Of Interest Rate Cash Flow Hedges Gains (losses) from changes in fair values of interest rate swaps Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Income (loss) before income taxes: Effective Income Tax Rate Reconciliation, Percent Income tax provision as a percentage of income before income taxes Class of Treasury Stock [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Share Repurchase Program [Axis] Share Repurchase Program [Domain] November 2014 share repurchase plan. November 2014 Share Repurchase Plan Equity, Class of Treasury Stock [Line Items] Share Repurchase Program, Authorized, Amount Stock buyback program, authorized amount Share Repurchase Program, Remaining Authorized, Amount Increase authorized for share buyback program Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Information related to the 2015 Equity Incentive Plan. The 2015 Equity Incentive Plan [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Information related to the 2014 Employee Stock Purchase Plan. 2014 Employee Stock Purchase Plan [Member] Stock Issued During Period, Shares, Employee Stock Purchase Plans Weighted average purchase price of shares purchased through an employee stock purchase plan. Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased Weighted-Average Purchase Price (In Dollars per Share) Share-Based Payment Arrangement, Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding Options, End of period Outstanding Options, Beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Options forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable at the end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest, at the end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Exercise Price (in dollars per share) Outstanding Exercise Price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at the end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable remaining contractual term (in Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Exercisable aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options granted (in dollars per share) Weighted-average grant date fair value (in Dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Proceeds from Stock Options Exercised Cash received from options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value An arrangement whereby an employee, consultant or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Employee Stock Options [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Nonvested at end of period Nonvested at beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Options forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Nonvested at end of period (in dollars per share) Nonvested at beginning of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Options forfeited (in dollars per share) Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Restricted Stock Units (RSUs) [Member] Represents the number of common shares the grantee is to receive at a specified future date for each Restricted Stock Unit ("RSU") awarded. Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares) Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Represents Restricted Stock Units (RSUs) issued as compensation. Restricted Stock Units Issued as Compensation [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Total RSUs outstanding at the end of the period Total RSUs outstanding at the beginning of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSUs forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period RSUs vested Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Stock surrendered to fulfill tax withholding obligations Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Total Fair Market Value of RSUs Issued Fair value of share-based awards granted during the period. RSUs granted (in Dollars) Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Cost of Sales [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Defined Contribution Plan, Employer Matching Contribution, Percent of Match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Defined Contribution Plan, Cost Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Benefit Obligation Pension Cost (Reversal of Cost) Pension Cost Deferred Compensation Plan Assets Deferred compensation plan assets Deferred Compensation Liability, Current and Noncurrent Deferred compensation plan liabilities Purchase Commitment, Excluding Long-Term Purchase Commitment [Table] Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Domain] Represents commitments to purchase equipment and raw materials. Commitments to Purchase Equipment and Raw Materials [Member] Purchase Commitment, Excluding Long-Term Commitment [Line Items] Long-Term Purchase Commitment, Amount Related Party Transaction [Table] Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Represents Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin. Hanxin Nanjing Letop Biotechnology Technology Co. Ltd. [Member] Letop Related Party Transaction [Line Items] Related Party Transaction, Purchases from Related Party Payment to related party Other Liabilities, Current Other Receivables Receivables from Hanxin Percentage of ownership in investment after spin-off transaction. Ownership Percentage After Spinoff Transaction Ownership after transaction Related Party Transaction, Amounts of Transaction Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Domain] Pending Litigation [Member] Litigation Case [Axis] Litigation Case [Domain] Property and Casualty Claim Property and Casualty Claim Loss Contingencies [Line Items] Prepaid Expense and Other Assets EX-101.PRE 11 amph-20240930_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document and Entity Information [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Securities Act File Number 001-36509 Â Entity Registrant Name Amphastar Pharmaceuticals, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 33-0702205 Â Entity Address, Address Line One 11570 6th Street Â Entity Address, City or Town Rancho Cucamonga Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 91730 Â City Area Code 909 Â Local Phone Number 980-9484 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol AMPH Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 48,081,433 Entity Central Index Key 0001297184 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace

Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 192,116 $ 144,296 Restricted cash 235 235 Short-term investments 58,375 112,510 Restricted short-term investments 2,200 2,200 Accounts receivable, net 139,635 114,943 Inventories 130,316 105,833 Income tax refunds and deposits 5,349 526 Prepaid expenses and other assets 17,723 9,057 Total current assets 545,949 489,600 Property, plant, and equipment, net 295,384 282,746 Finance lease right-of-use assets 426 564 Operating Lease, Right-of-Use Asset 31,708 32,333 Investment in unconsolidated affiliate Â 527 Goodwill and intangible assets, net 594,796 613,295 Long-term investments Â 14,685 Other assets 23,663 25,910 Deferred tax assets 53,252 53,252 Total assets 1,545,178 1,512,912 Current liabilities: Â Â Accounts payable and accrued liabilities 153,268 93,366 Accrued payments for BAQSIMI Â 126,090 Income taxes payable 1,281 1,609 Current portion of long-term debt 252 436 Current portion of operating lease liabilities 4,209 3,906 Total current liabilities 159,010 225,407 Long-term reserve for income tax liabilities 6,066 6,066 Long-term debt, net of current portion and unamortized debt issuance costs 596,446 589,579 Long-term operating lease liabilities, net of current portion 28,941 29,721 Other long-term liabilities 27,037 22,718 Total liabilities 817,500 873,491 Stockholders' equity: Â Â Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023 6 6 Additional Paid in Capital 496,427 486,056 Retained Earnings (Accumulated Deficit) 530,823 409,268 Accumulated Other Comprehensive Income (Loss), Net of Tax (8,821) (8,478) Treasury stock (290,757) (247,431) Total equity 727,678 639,421 Total liabilities and stockholders' equity $ 1,545,178 $ 1,512,912 X - DefinitionThe amount of accrued payments for assets acquisitions. + ReferencesNo definition available. + Details Name: amph_AccruedPaymentsForAssetAcquisitions Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds and deposits of overpayments or recoveries based on agreed-upon resolutions of disputes. + ReferencesNo definition available. + Details Name: amph_IncomeTaxRefundAndDeposits Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in unconsolidated affiliate. + ReferencesNo definition available. + Details Name: amph_InvestmentInUnconsolidatedAffiliate Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1 + Details Name: us-gaap_IntangibleAssetsNetIncludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_RestrictedInvestmentsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-

2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized 20,000,000 20,000,000 Preferred stock, shares issued 0 0 Preferred Stock, Shares Outstanding 0 0 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock; shares authorized 300,000,000 300,000,000 Common stock; shares issued 60,690,076 59,390,194 Common stock; shares outstanding 48,372,997 48,068,881 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be

issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net Revenues: Â Â Â Â Revenues $ 191,214 $ 180,556 $ 545,444 $ 466,290 Cost of revenues 89,273 72,153 258,237 211,309 Gross profit 101,941 108,403 287,207 254,981 Operating expenses: Â Â Â Â Selling and Marketing Expense 8,995 6,407 27,378 20,234 General and administrative 14,821 12,654 43,782 38,418 Research and development 21,077 16,664 55,772 53,322 Total operating expenses 44,893 35,725 126,932 111,974 Income from operations 57,048 72,678 160,275 143,007 Non-operating income (expenses): Â Â Â Â Investment Income, Interest 2,427 1,202 8,320 3,156 Interest expense (6,698) (13,702) (23,918) (17,702) Other Nonoperating Income (Expense) (5,094) 3,459 1,125 1,553 Total non-operating income (expenses), net (9,365) (9,041) (14,473) (12,993) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 47,683 63,637 145,802 130,014 Income tax provision 7,254 14,025 23,674 27,160 Income before equity in losses of unconsolidated affiliate 40,429 49,612 122,128 102,854 Equity in losses of unconsolidated affiliates Â (390) (573) (1,476) Net income attributable to Amphastar Pharmaceuticals, Inc. Â Â 121,555 101,378 Net income attributable to Amphastar Pharmaceuticals, Inc. $ 40,429 $ 49,222 $ 121,555 $ 101,378 Net income per share Â Â Â Â Earnings Per Share, Basic $ 0.83 $ 1.01 $ 2.50 $ 2.10 Earnings Per Share, Diluted $ 0.78 $ 0.91 $ 2.32 $ 1.91 Weighted-average shares used to compute net income per share: Â Â Â Â Weighted Average Number of Shares Outstanding, Basic 48,621 48,701 48,580 48,368 Diluted (in Shares) 51,862 53,921 52,307 52,997 Product [Member] Â Â Â Â Net Revenues: Â Â Â Â Revenues $ 188,819 $ 151,855 $ 525,836 $ 437,589 Product and Service, Other [Member] Â Â Â Â Net Revenues: Â Â Â Â Revenues $ 2,395 $ 28,701 $ 19,608 $ 28,701 X - DefinitionAmount after tax of income (loss) from continuing operations. + ReferencesNo definition available. + Details Name: amph_IncomeLossFromContinuingOperationsAfterIncomeTaxes Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification - Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification - Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification - Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 - Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification - Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification - Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 - Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef - Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification - Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 - Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef - Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB - URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification - Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 - Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification - Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Â Â Â Â Net income $ 40,429 $ 49,222 $ 121,555 $ 101,378 Other comprehensive income (loss), net of income taxes Â Â Â Â Foreign currency translation adjustment 5 (87) (343) 213 Total other comprehensive income (loss) 5 (87) (343) 213 Total comprehensive income $ 40,434 $ 49,135 $ 121,212 $ 101,591 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. +

ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock, Common [Member] Total Balance at Dec. 31, 2022 $ 6 $ 455,077 $ 271,723 $ (8,624) $ (189,524) Â Balance at Dec. 31, 2022 Â Â Â Â Â $ 528,658 Balance at Dec. 31, 2022 58,110,231 Â Â Â (9,998,162) Â Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 26,032 Â Â 26,032 Other comprehensive income (loss) Â Â Â 356 Â 356 Purchase of treasury stock Â Â Â Â $ (8,015) (8,015) Purchase of treasury stock (in Shares) Â Â Â Â (263,131) Â Issuance of common stock in connection with the Company's equity plans Â (4,565) Â Â Â (4,565) Issuance of common stock in connection with the Company's equity plans (in Shares) 330,300 Â Â Â Â Â Share-based compensation expense Â 6,111 Â Â Â 6,111 Balance at Mar. 31, 2023 $ 6 456,623 297,755 (8,268) $ (197,539) Â Balance at Mar. 31, 2023 Â Â Â Â Â 548,577 Balance at Mar. 31, 2023 58,440,531 Â Â Â (10,261,293) Â Balance at Dec. 31, 2022 $ 6 455,077 271,723 (8,624) $ (189,524) Â Balance at Dec. 31, 2022 Â Â Â Â Â 528,658 Balance at Dec. 31, 2022 58,110,231 Â Â Â (9,998,162) Â Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 101,378 Â 101,378 Other comprehensive income (loss) Â Â Â Â Â 213 Balance at Sep. 30, 2023 $ 6 477,880 373,102 (8,411) $ (247,437) Â Balance at Sep. 30, 2023 Â Â Â Â Â 595,140 Balance at Sep. 30, 2023 59,220,178 Â Â Â (11,321,712) Â Balance at Mar. 31, 2023 $ 6 456,623 297,755 (8,268) $ (197,539) Â Balance at Mar. 31, 2023 Â Â Â Â Â 548,577 Balance at Mar. 31, 2023 58,440,531 Â Â Â (10,261,293) Â Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 26,124 Â Â 26,124 Other comprehensive income (loss) Â Â Â (56) Â (56) Purchase of treasury stock Â Â Â Â $ (129) (129) Purchase of treasury stock (in Shares) Â Â Â Â (3,585) Â Issuance of treasury stock in connection with the Company's equity plans Â (231) Â Â $ 231 Â Issuance of treasury stock in connection with the Company's equity plans (in Shares) Â Â Â Â 15,207 Â Issuance of common stock in connection with the Company's equity plans Â 9,853 Â Â Â 9,853 Issuance of common stock in connection with the Company's equity plans (in Shares) 627,946 Â Â Â Â Â Share-based compensation expense Â 4,865 Â Â Â 4,865 Balance at Jun. 30, 2023 $ 6 471,110 323,880 (8,324) $ (197,437) Â Balance at Jun. 30, 2023 Â Â Â Â Â 589,235 Balance at Jun. 30, 2023 59,068,477 Â Â Â (10,249,671) Â Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 49,222 Â Â 49,222 Other comprehensive income (loss) Â Â Â (87) Â (87) Purchase of treasury stock Â Â Â Â $ (50,000) (50,000) Purchase of treasury stock (in Shares) Â Â Â Â (1,072,041) Â Issuance of common stock in connection with the Company's equity plans Â 2,126 Â Â Â 2,126 Issuance of common stock in connection with the Company's equity plans (in Shares) 151,701 Â Â Â Â Â Share-based compensation expense Â 4,644 Â Â Â 4,644 Balance at Sep. 30, 2023 $ 6 477,880 373,102 (8,411) $ (247,437) Â Balance at Sep. 30, 2023 Â Â Â Â Â 595,140 Balance at Sep. 30, 2023 59,220,178 Â Â Â (11,321,712) Â Balance at Dec. 31, 2023 $ 6 486,056 409,268 (8,478) $ (247,431) Â Balance at Dec. 31, 2023 Â Â Â Â Â $ 639,421 Balance at Dec. 31, 2023 59,390,194 Â Â Â (11,321,313) 48,068,881 Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 43,177 Â Â $ 43,177 Other comprehensive income (loss) Â Â Â (291) Â (291) Issuance of treasury stock in connection with the Company's equity plans Â (33) Â Â $ 33 Â Issuance of treasury stock in connection with the Company's equity plans (in Shares) Â Â Â Â 2,197 Â Issuance of common stock in connection with the Company's equity plans Â (17,311) Â Â Â (17,311) Issuance of common stock in connection with the Company's equity plans (in Shares) 770,265 Â Â Â Â Â Share-based compensation expense Â 7,360 Â Â Â 7,360 Balance at Mar. 31, 2024 $ 6 476,072 452,445 (8,769) $ (247,398) Â Balance at Mar. 31, 2024 Â Â Â Â Â 672,356 Balance at Mar. 31, 2024 60,160,459 Â Â Â (11,319,116) Â Balance at Dec. 31, 2023 $ 6 486,056 409,268 (8,478) $ (247,431) Â Balance at Dec. 31, 2023 Â Â Â Â Â $ 639,421 Balance at Dec. 31, 2023 59,390,194 Â Â Â (11,321,313) 48,068,881 Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â Â Â Â $ 121,555 Other comprehensive income (loss) Â Â Â Â Â (343) Balance at Sep. 30, 2024 $ 6 496,427 530,823 (8,821) $ (290,757) Â Balance at Sep. 30, 2024 Â Â Â Â Â Â $ 727,678 Balance at Sep. 30, 2024 60,690,076 Â Â Â (12,317,079) 48,372,997 Balance at Mar. 31, 2024 $ 6 476,072 452,445 (8,769) $ (247,398) Â Balance at Mar. 31, 2024 Â Â Â Â Â $ 672,356 Balance at Mar. 31, 2024 60,160,459 Â Â Â (11,319,116) Â Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 37,949 Â Â 37,949 Other comprehensive income (loss) Â Â Â (57) Â (57) Purchase of treasury stock Â Â Â Â $ (8,498) (8,498) Purchase of treasury stock (in Shares) Â Â Â Â (207,288) Â Issuance of treasury stock in connection with the Company's equity plans Â (97) Â Â $ 97 Â Issuance of treasury stock in connection with the Company's equity plans (in Shares) Â Â Â Â 6,363 Â Issuance of common stock in connection with the Company's equity plans Â 5,816 Â Â Â 5,816 Issuance of common stock in connection with the Company's equity plans (in Shares) 321,996 Â Â Â Â Â Share-based compensation expense Â 5,780 Â Â Â 5,780 Balance at Jun. 30, 2024 $ 6 487,571 490,394 (8,826) $ (255,799) Â Balance at Jun. 30, 2024 Â Â Â Â Â 713,346 Balance at Jun. 30, 2024 60,482,455 Â Â Â (11,520,041) Â Changes in Stockholders' Equity Â Â Â Â Â Â Net income Â Â 40,429 Â Â 40,429 Other comprehensive income (loss) Â Â Â 5 Â 5 Purchase of treasury stock Â Â Â Â $ (34,958) (34,958) Purchase of treasury stock (in Shares) Â Â Â Â (797,038) Â Issuance of common stock in connection with the Company's equity plans Â 3,260 Â Â Â 3,260 Issuance of common stock in connection with the Company's equity plans (in Shares) 207,621 Â Â Â Â Â Share-based compensation expense Â 5,596 Â Â Â 5,596 Balance at Sep. 30, 2024 $ 6 $ 496,427 $ 530,823 $ (8,821) $ (290,757) Â Balance at Sep. 30, 2024 Â Â Â Â Â $ 727,678 Balance at Sep. 30, 2024 60,690,076 Â Â Â (12,317,079) 48,372,997 X - DefinitionValue of shares issued under equity plans. + ReferencesNo definition available. + Details Name: amph_StockIssuedDuringPeriodValueEquityPlans Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-

20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash Flows From Operating Activities: Â Â Net income $ 121,555 $ 101,378 Reconciliation to net cash provided by operating activities: Â Â Loss (gain) on disposal of assets 110 474 Impairment of long-lived assets Â 2,700 Gain on interest rate swaps and foreign currency transactions, net 1,496 (1,019) Depreciation of property, plant, and equipment 20,992 18,559 Amortization of product rights, trademarks, and patents 18,539 6,651 Operating lease right-of-use asset amortization 3,010 2,778 Amortization of discounts, premium, and debt issuance costs 5,308 8,486 Equity in losses of unconsolidated affiliate 573 1,476 Share-Based Payment Arrangement, Noncash Expense 18,736 15,620 Changes in operating assets and liabilities: Â Â Accounts receivable, net (24,577) (30,175) Inventories (24,329) (6,537) Prepaid expenses and other assets (10,489) 105 Income tax refunds, deposits, and payable, net (5,147) 25,185 Operating lease liabilities (2,866) (2,667) Accounts payable and accrued liabilities 61,451 16,625 Net cash provided by operating activities 184,362 159,639 Cash Flows From Investing Activities: Â Â BAQSIMI acquisition (129,000) (506,406) Purchases and construction of property, plant, and equipment (28,630) (28,724) Purchase of investments (47,507) (52,802) Maturity of investments 118,538 38,801 Deposits and other assets 2,653 (3,064) Net cash provided by (used in) investing activities (89,252) (546,067) Cash Flows From Financing Activities: Â Â Proceeds from equity plans, net of withholding tax payments Â 7,414 Proceeds from equity plans, net of withholding tax payments (8,234) Â Purchase of treasury stock (43,456) (58,144) Debt issuance costs (838) (24,589) Proceeds from Lines of Credit 13,565 Â Proceeds from Issuance of Long-Term Debt Â 845,000 Principal payments on long-term debt (8,148) (268,506) Net cash used in financing activities (47,111) 501,176 Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations (179) (44) Net increase in cash, cash equivalents, and restricted cash 47,820 114,704 Cash, cash equivalents, and restricted cash at beginning of period 144,531 156,333 Cash, cash equivalents, and restricted cash at end of period 192,351 271,037 Noncash Investing and Financing Activities: Â Â Deferred payment for BAQSIMI acquisition Â 121,699 Capital expenditures included in accounts payable 5,120 4,496 Operating lease right-of-use assets in exchange for operating lease liabilities 2,386 9,890 Supplemental Disclosures of Cash Flow Information: Â Â Interest Paid, Excluding Capitalized Interest, Operating Activities 22,389 12,098 Income Taxes Paid $ 29,000 $ 2,136 X - DefinitionThe amount of deferred payments for acquisitions. + ReferencesNo definition available. + Details Name: amph_DeferredPaymentForAcquisition Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net gain or loss on interest rate swaps and foreign currency transactions. + ReferencesNo definition available. + Details Name: amph_GainLossOnInterestRateSwapsAndForeignCurrencyTransactionsNet Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease Decrease In Income Tax Refund, Deposits, and Payable + ReferencesNo definition available. + Details Name: amph_IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease in noncash investing or financing activities. + ReferencesNo definition available. + Details Name: amph_NoncashOperatingLeaseRightOfUseAsset Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease, net of present value of lessee's discounted obligation for lease payments from operating lease. + ReferencesNo definition available. + Details Name: amph_OperatingLeaseRightOfUseAssetsAndLiabilitiesNet Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for acquisitions of assets. + ReferencesNo definition available. + Details Name: amph_PaymentsAcquisitionsOfAssets Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash outflow related to payments and other deposits not otherwise defined in the taxonomy. + ReferencesNo definition available. + Details Name: amph_PaymentsForDepositsAndOtherAssets Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe total cash inflow or outflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises, net of withholding tax payments upon issuance to employees. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. + ReferencesNo definition available. + Details Name: amph_ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate

value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 General 9 Months Ended Sep. 30, 2024 General Â General Note 1. Generalâ€‹Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the â€œCompanyâ€) is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Companyâ€™s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Companyâ€™s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Companyâ€™s inhalation product, Primatene MISTÂ®, is primarily distributed through drug retailers.â€‹The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the Companyâ€™s consolidated financial position, results of operations, comprehensive income, stockholdersâ€™ equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Companyâ€™s results of operations, comprehensive income and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies Note 2. Summary of Significant Accounting Policiesâ€‹Basis of Presentationâ€‹The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with GAAP. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.â€‹The Companyâ€™s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals,Â Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Amphastar France Pharmaceuticals, S.A.S., or AFP, (5) Amphastar UK Ltd., or AUK, (6) International Medication Systems (UK) Limited, or IMS UK, and (7) Amphastar Medication Co., LLC, or Amphastar Medication.â€‹Investment in Unconsolidated Affiliate â€‹The Company applies the equity method of accounting for investments when it has significant influence, but not controlling interest in the investee. The Companyâ€™s proportionate share of the earnings or losses resulting from these investments is reported as â€œEquity in losses of unconsolidated affiliateâ€ in the accompanying condensed consolidated statements of operations. Investments accounted for using the equity method may be reported on a lag of up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date.â€‹The carrying value of equity method investments is reported as â€œInvestment in unconsolidated affiliateâ€ in the accompanying condensed consolidated balance sheets. The Companyâ€™s equity method investments are reported at cost and adjusted each period for the Companyâ€™s share of the investeeâ€™s earnings or losses and dividends paid, if any.â€‹Use of Estimatesâ€‹The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: fair value of acquired assets, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.â€‹Foreign Currency â€‹The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the U.S. Dollar, or USD. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Companyâ€™s condensed consolidated statements of operations. â€‹The Companyâ€™s French subsidiary, AFP, maintains its books of record in euros. AUKâ€™s subsidiary, IMS UK, maintains its books of record in British pounds. These local currencies have been determined to be the subsidiariesâ€™ respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholdersâ€™ equity and are included as a component of other comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). â€‹The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $1.4 million gain and a $0.4 million gain for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $0.9 million loss and a $0.4 million loss, respectively. â€‹Comprehensive Incomeâ€‹The Companyâ€™s comprehensive income includes its foreign currency translation gains and losses as well as its share of other comprehensive income from its equity method investments. â€‹Acquisitions â€‹The Company evaluates acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and substantive processes that have the ability to create outputs, which would meet the definition of a business.â€‹Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.â€‹For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis, with the exception of non-qualifying assets. Goodwill is not recognized in an asset acquisition. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR&D, asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration, including assumed contingent considerations, is not recognized until all contingencies are resolved and the consideration is paid or becomes payable (unless contingent considerations meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired), at which point the consideration is allocated to the assets acquired based on their relative fair values at the acquisition date, with the exception of non-qualifying assets.â€‹Judgments are used in determining estimates of useful lives of long-lived assets. Useful life estimates are based on, among other factors, estimates of expected future net cash flows, the assessment of each assetâ€™s life cycle, and the impact of competitive trends on each assetâ€™s life cycle and other factors. These judgments can materially impact the estimates used to allocate purchase consideration to assets acquired and liabilities assumed, and the resulting timing and amounts charged to or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.â€‹Advertising Expenseâ€‹Advertising expenses, primarily associated with Primatene MISTÂ®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Companyâ€™s condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, advertising expenses were $2.5 million and $7.8 million, respectively. For the three and nine months ended September 30, 2023, advertising expenses were $1.9 million and $8.1 million, respectively.â€‹Financial Instrumentsâ€‹The Companyâ€™s accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses, short-term borrowings, and long-term obligations. The Company considers the carrying amounts of current assets and liabilities on the condensed consolidated balance sheets to approximate the fair value of these financial instruments due to the short maturity of these items. The carrying value of the Companyâ€™s long-term obligations, with the exception of the convertible debt (see Note 14), approximates their fair value, as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. Investments and short-term investments are recorded at fair value based on quoted prices from recognized security exchanges and other methods (see Note 9). The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt. The Companyâ€™s interest rate swap contracts exchange the variable interest rates for fixed interest rates. Cash and Cash Equivalentsâ€‹Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments with original maturities of three months or less.â€‹Investmentsâ€‹Investments as of September 30, 2024 and December 31, 2023 consisted of certificates of deposit and investment grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months.â€‹Restricted Cash â€‹Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of September 30, 2024 and December 31, 2023, the restricted cash balance was $0.2 million.â€‹Restricted Short-Term Investmentsâ€‹Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workersâ€™ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of September 30, 2024 and December 31, 2023, the balance of restricted short-term investments was $2.2 million.â€‹Deferred Income Taxesâ€‹The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized.â€‹Debt Issuance Costsâ€‹Debt issuance costs related to non-revolving debt are recognized as a reduction to the related debt balance in the accompanying condensed consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Debt issuance costs associated with revolving debt are capitalized within other long-term assets on the condensed consolidated balance sheets and are amortized to interest expense over the term of the related revolving debt.â€‹Convertible Debtâ€‹The Company accounts for its convertible debt instruments as a single unit of accounting, a liability, because the Company concluded that the conversion features do not require bifurcation as a derivative under Accounting Standards Codification, or ASC, 815-15, Derivatives and Hedging and the Company did not issue its convertible debt instruments at a substantial premium. The Company records debt issuance costs as contra-liabilities in its condensed consolidated balance sheets at issuance and amortizes them over the contractual term of the convertible debt instrument using the effective interest rate.â€‹In accordance with Accounting Standards Update, or ASU,Â 2020-06,Â Debtâ€”Debt with Conversion and Other Options (SubtopicÂ 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (SubtopicÂ 815-40): Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, the Company evaluates convertible debt instruments to determine if the conversion feature is freestanding or embedded. If the conversion feature is embedded, the conversion feature is not bifurcated from the host instrument. If the conversion feature does not require derivative treatment underÂ ASC 815, the instrument is evaluated underÂ ASC 470-20,Â â€œDebt with Conversion and Other Optionsâ€ for consideration of any beneficial conversion features. If no beneficial conversion features exist that require separate recognition, convertible debt instruments are accounted for as a single liability measured at its amortized cost as long asÂ noÂ other features require separation and recognition as derivatives.â€‹Litigation, Commitments and Contingenciesâ€‹Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized.â€‹Recent Accounting Pronouncementsâ€‹In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the disclosure requirements related to the new standard.â€‹In December 2023, the FASB issued Accounting Standard Update 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures which requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to the new standard. X - DefinitionDisclosure of the reporting entity's significant accounting policies, excluding its policy for revenue recognition. + ReferencesNo definition available. + Details Name: amph_SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3 BAQSIMI Acquisition 9 Months Ended Sep. 30, 2024 BAQSIMI Acquisition Â BAQSIMI Acquisition Note 3. BAQSIMIÂ® Asset Acquisitionâ€‹On June 30, 2023, the Company completed its acquisition of BAQSIMIÂ® glucagon nasal powder, or BAQSIMIÂ®, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli Lilly & Company, or Lilly, dated April 21, 2023. â€‹The Company accounted for the BAQSIMIÂ® acquisition as an asset acquisition in accordance with ASC 805, Business Combinations, as substantially all the fair value of the assets acquired was concentrated in a single identifiable asset, BAQSIMIÂ® product rights. The BAQSIMIÂ® product rights include the license for the BAQSIMIÂ® intellectual property, regulatory

documentation, marketing authorizations, and domain names, which are considered a single asset as they are inextricably linked. â€‹â€‹The total purchase price was allocated to the acquired assets based on their relative fair values, as follows: â€‹â€‹â€‹â€‹â€‹â€‹Fair Valueâ€‹â€‹(in thousands)Property, plant, and equipmentÂ Â Â Â $ 34,426BAQSIMIÂ® product rightsâ€‹Â 591,338Deferred tax assetsâ€‹â€‹ 2,341Total assets acquiredâ€‹$ 628,105â€‹The Company amortizes the acquired intangible asset to cost of revenues on a straight line basis over its estimated useful life of 24 years (see Note 10 for additional information).A portion of the consideration for the asset acquisition was a deferred cash payment. The fair value of the deferred cash payment was accreted to its full $129.0 million amount over a one-year period from the date of acquisition through interest expense. During the nine months ended September 30, 2024, the Company recognized $3.6 million of interest expense related to accretion of the deferred cash payment. During the three and nine months ended September 30, 2023, $1.8 million of interest expense was recognized related to the accretion of the deferred cash payment. The Company made the $129.0 million deferred cash payment in June 2024.â€‹The Company may also be required to pay additional contingent consideration of up to an aggregate of $575.0 million in cash as part of the BAQSIMIÂ® acquisition, based on the achievement of certain net sales milestones. Through September 30, 2024, the Company has not triggered any milestones and therefore no amounts have been recognized or paid.â€‹Manufacturing Services Agreementâ€‹In connection with the closing of the acquisition, the Company entered into a Manufacturing Services Agreement, or the MSA, with Lilly, pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain manufacturing, packaging, labeling and supply services for BAQSIMIÂ® directly or through third-party contractors to the Company in connection with its operation of the development, manufacture, and commercialization of BAQSIMIÂ®. Upon termination of the MSA, the Company will be obligated to purchase all API, components, and finished goods on hand at prices agreed upon in the MSA.â€‹Transition Services Agreementâ€‹In connection with the closing of the acquisition, the Company also entered into a Transition Services Agreement, or the TSA, with Lilly pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain services to the Company to support the transition of BAQSIMIÂ® operations to the Company, including with respect to the conduct of certain clinical, regulatory, medical affairs, and commercial sales channel activities. â€‹Throughout 2024, the Company assumed distribution responsibilities, from Lilly, to its customers in the United States, and certain other countries. As a result, the Company has recorded the sales and related cost of BAQSIMIÂ® in these countries as product revenue, net and cost of revenues, respectively. The Company will continue to assume distribution of BAQSIMIÂ® for the remaining territories on a country by country basis throughout 2024. X - ReferencesNo definition available. + Details Name: us-gaap_AssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition 9 Months Ended Sep. 30, 2024 Revenue Recognition Â Revenue Recognition Note 4. Revenue Recognitionâ€‹Product revenues, netâ€‹In accordance with ASC 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Companyâ€™s customers obtain control of the promised goods. â€‹Generally, revenue is recognized at the time of product delivery to the Companyâ€™s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. â€‹The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration including provision for chargebacks and rebates, accrual for product returns, prompt pay discounts, distributor fees, patient co-pay assistance, and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Payment terms offered to customers generally range from 30 to 75 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If the Company expects, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, the amount of consideration is not adjusted for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, distribution and marketing expenses in the accompanying condensed consolidated statements of operations.â€‹Provision for Chargebacks and Rebates: The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Companyâ€™s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historical chargeback and rebate rates, and current contract pricing.â€‹The provision for chargebacks and rebates is reflected as a component of product revenues, net. The following table is an analysis of the chargeback and rebate provision: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)Beginning balanceÂ Â Â Â $ 27,920Â Â Â Â $ 26,606Provision for chargebacks and rebatesâ€‹Â 218,312â€‹Â 200,317Credits and payments issued to third partiesâ€‹Â (181,216)â€‹Â (201,650)Ending balanceâ€‹$ 65,016â€‹$ 25,273â€‹Changes in the chargeback provision from period to period are primarily dependent on the Companyâ€™s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalersâ€™ customer mix. Changes in the rebate provision from period to period are primarily dependent on retailersâ€™ and other indirect customersâ€™ purchases. The approach that the Company uses to estimate chargebacks and rebates has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 20 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer.â€‹The provision for chargebacks and rebates is included in the following balance sheet accounts:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹2024â€‹2023â€‹(in thousands)Reduction to accounts receivable, net$ 21,355Â Â Â Â $ 21,861Accounts payable and accrued liabilitiesÂ 43,661â€‹Â 6,059Total$ 65,016â€‹$ 27,920â€‹Accrual for Product Returns: The Company offers certain customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Companyâ€™s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and new competition.â€‹Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized.â€‹Distributor Fees: The Company engages with wholesalers to distribute its products to end customers. The Company pays the wholesalers a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.â€‹Patient Co-Pay Assistance: Co-pay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The accrual for co-pay is based on an estimate of claims and the cost per claim that the Company expects to receive associated with inventory that exists in the distribution channel at period end.â€‹Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers. The Companyâ€™s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit.â€‹Service revenues derived from research and development contracts are recognized over time based on progress toward satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation. For the three and nine months ended September 30, 2024, revenues from research and development services were $0.1 million and $2.0 million, respectively. For the three and nine months ended September 30, 2023, revenues from research and development services were $0.8 million and $2.1 million, respectively.â€‹Other revenuesâ€‹Revenues related to sales of BAQSIMIÂ®, which was supplied and sold by Lilly under the TSA during the three and nine months ended September 30, 2024 and 2023, or BAQSIMIÂ® NEB, were recorded on a net basis, similar to a royalty arrangement. This includes revenues in the United States and certain other countries for a portion of the period. X - DefinitionThe entire disclosure for revenue recognition. + ReferencesNo definition available. + Details Name: amph_RevenueRecognitionDisclosureTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueRecognitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Share 9 Months Ended Sep. 30, 2024 Net Income per Share Â Net Income per Share Note 5. Net Income per Shareâ€‹Basic net income per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share gives effect to all potentially dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Companyâ€™s Employee Stock Purchase Plan, or ESPP, and potential shares of common stock issuable upon conversion of Convertible Notes of the Company, due March 2029, or the 2029 Convertible Notes.â€‹For the three and nine months ended September 30, 2024, options to purchase 619,847 shares of stock with a weighted-average exercise price of $46.63 per share, were excluded in the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price.â€‹For the three months ended September 30, 2023, none of the Companyâ€™s options were excluded from the computation of diluted net income per share. For the nine months ended September 30, 2023, options to purchase 45,934 shares of stock with a weighted-average exercise price of $46.01 per share, were excluded from the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price.â€‹The following table provides the calculation of basic and diluted net income per share for each of the periods presented:â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹2024â€‹2023â€‹â€‹â€‹(in thousands, except per share data)â€‹Basic and dilutive numerator:Â Â Â Â â€‹Â Â Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â Â Â Â Â â€‹Net incomeâ€‹$ 40,429â€‹$ 49,222â€‹$ 121,555â€‹$ 101,378â€‹Denominator:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

reporting segment is presented below:â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)â€‹Depreciation and amortization expense Â Â Â Â â€‹Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â Â Â â€‹Â Â Â Â Â Finished pharmaceutical productsâ€‹$ 8,755â€‹$ 8,616â€‹$ 26,086â€‹$ 13,143â€‹APIâ€‹Â 1,038â€‹Â 1,003â€‹Â 3,045â€‹â€‹ 2,938â€‹Total depreciation and amortization expense â€‹$ 9,793â€‹$ 9,619â€‹$ 29,131â€‹$ 16,081â€‹â€‹Net revenues and carrying values of long-lived assets, which includes property, plant and equipment, as well as finance and operating lease right-of-use assets, by geographic regions, based on where the Company conducts its operations are as follows:â€‹Net Revenuesâ€‹Long-Lived Assetsâ€‹â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023â€‹2024â€‹2023â€‹â€‹(in thousands)United States(1)Â Â Â Â $ 186,514Â Â Â Â $ 178,056Â Â Â Â $ 532,591Â Â Â Â $ 459,909Â Â Â Â $ 187,410Â Â Â Â $ 186,083Chinaâ€‹Â 178â€‹â€‹ 833â€‹â€‹ 2,145â€‹â€‹ 2,142â€‹Â 103,009â€‹Â 91,913Franceâ€‹Â 4,522â€‹â€‹ 1,667â€‹â€‹ 10,708â€‹â€‹ 4,239â€‹Â 37,099â€‹Â 37,647Totalâ€‹$ 191,214â€‹$ 180,556â€‹$ 545,444â€‹$ 466,290â€‹$ 327,518â€‹$ 315,643 (1) Includes Other revenues from the sales of BAQSIMIÂ®. X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Customer and Supplier Concentration 9 Months Ended Sep. 30, 2024 Customer and Supplier Concentration Â Customer and Supplier Concentration Note 7. Customer and Supplier Concentrationâ€‹Customer Concentrationsâ€‹Three large wholesale drug distributors, Cencora Inc., formally AmerisourceBergen, or Cencora, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Companyâ€™s products, as well as suppliers of a broad range of health care products. Lilly currently manufactures and sells BAQSIMIÂ® on the Companyâ€™s behalf pursuant to the terms of the TSA in certain jurisdictions (see Note 3 for additional information). The Company considers these four customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Companyâ€™s net revenue for the three and nine months ended September 30, 2024 and 2023, and accounts receivable as of September 30, 2024 and December 31, 2023, respectively. The following table provides accounts receivable and net revenue information for these major customers:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹% of Total Accountsâ€‹% of Netâ€‹â€‹Receivableâ€‹Revenuesâ€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â 2023Â McKessonÂ 29% 26% 26% 22% 25% 25%CencoraÂ 28% 16% 21% 17% 20% 20%Cardinal HealthÂ 17% 13% 20% 15% 20% 16%Lillyâ€‹ 2% 20% 1% 16% 4% 6%â€‹Supplier Concentrationsâ€‹The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Companyâ€™s business, financial condition, and results of operations. X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Measurements Â Fair Value Measurements Note 8. Fair Value Measurementsâ€‹GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:â€‹â—Level 1Â â€" Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;â€‹â—Level 2Â â€" Inputs to measure fair value are based on the following: (a) quoted prices in active markets on similar assets or liabilities, (b) quoted prices for identical or similar instruments in inactive markets, or (c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; andâ€‹â—Level 3Â â€" Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Companyâ€™s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.â€‹As of September 30, 2024 and December 31, 2023, cash equivalents include money market accounts and corporate and municipal bonds with original maturities of less than three months. Investments consist of certificates of deposit as well as investment-grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months. The certificates of deposit are carried at amortized cost in the Companyâ€™s condensed consolidated balance sheets, which approximates their fair value determined based on Level 2 inputs. The corporate, agency and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses. The fair value of such bonds is disclosed in Note 9 and was determined based on Level 2 inputs. The restrictions on restricted cash and investments have an immaterial effect on the fair value of these financial assets.â€‹The fair values of the Companyâ€™s financial assets and liabilities measured on a recurring basis as of September 30, 2024 and December 31, 2023, are as follows:â€‹Â Â Â Â TotalÂ Â Â Â (Level 1)Â Â Â Â (Level 2)Â Â Â Â (Level 3)Â â€‹â€‹(in thousands)Â Cash equivalentsâ€‹$ 143,637â€‹$ 143,637â€‹$ â€"â€‹$ â€"â€‹Restricted cashâ€‹â€‹ 235â€‹â€‹ 235â€‹â€‹ â€"â€‹â€‹ â€"â€‹Short-term investmentsâ€‹â€‹ 26,322â€‹â€‹ â€"â€‹â€‹ 26,322â€‹â€‹ â€"â€‹Restricted short-term investmentsâ€‹Â 2,200â€‹Â â€"â€‹Â 2,200â€‹Â â€"â€‹Interest rate swaps related to variable rate loansâ€‹â€‹ (6,881)â€‹â€‹ â€"â€‹â€‹ (6,881)â€‹â€‹ â€"â€‹Total assets and liabilities measured at fair value as of SeptemberÂ 30,Â 2024â€‹$ 165,513â€‹$ 143,872â€‹$ 21,641â€‹$ â€"â€‹Â Â Â Â TotalÂ Â Â Â (Level 1)Â Â Â Â (Level 2)Â Â Â Â (Level 3)â€‹â€‹(in thousands)Cash equivalentsâ€‹$ 116,441â€‹$ 116,441â€‹$ â€"â€‹$ â€"Restricted cashâ€‹â€‹ 235â€‹â€‹ 235â€‹â€‹ â€"â€‹â€‹ â€"Short-term investmentsâ€‹â€‹ 37,142â€‹â€‹ â€"â€‹â€‹ 37,142â€‹â€‹ â€"Restricted short-term investmentsâ€‹Â 2,200â€‹Â â€"â€‹Â 2,200â€‹Â â€"Interest rate swaps related to variable rate loansâ€‹â€‹ (5,243)â€‹â€‹ â€"â€‹â€‹ (5,243)â€‹â€‹ â€"Total assets and liabilities measured at fair value as of DecemberÂ 31,Â 2023â€‹$ 150,775â€‹$ 116,676â€‹$ 34,099â€‹$ â€"â€‹The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.â€‹Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include investments in unconsolidated affiliates, long-lived assets, goodwill, and intangible assets for which the fair value is determined as part of an impairment test. As of September 30, 2024, and December 31, 2023, there were no significant adjustments to fair value for nonfinancial assets or liabilities.â€‹The Companyâ€™s deferred compensation plan assets are valued using the cash surrender value of the life insurance policies and are not included in the table above. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Investments 9 Months Ended Sep. 30, 2024 Investments Â Investments Note 9. Investmentsâ€‹The following is a summary of the Companyâ€™s investments that are classified as held-to-

maturity:â€‹Grossâ€‹Grossâ€‹â€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹FairÂ Â Â Â CostÂ Â Â Â GainsÂ Â Â Â LossesÂ Â Â Â Va thousands)Corporate and agency bonds (due within 1 year)â€‹$ 31,903â€‹$ 67â€‹$ (2)â€‹$ 31,968Total investments as of SeptemberÂ 30,Â 2024â€‹$ 31,903â€‹$ 67â€‹$ (2)â€‹$ 31,968â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Corporate and agency bonds (due within 1 year)â€‹$ 73,815â€‹$ 7â€‹$ (21)â€‹$ 73,801Corporate and agency bonds (due within 1 to 3 years)â€‹â€‹ 14,621â€‹â€‹ 56â€‹â€‹ (1)â€‹â€‹ 14,676Municipal bonds (due within 1 year)â€‹â€‹ 1,081â€‹â€‹ 1â€‹â€‹ â€”â€‹â€‹ 1,082Total investments as of DecemberÂ 31,Â 2023â€‹$ 89,517â€‹$ 64â€‹$ (22)â€‹$ 89,559â€‹At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, identifying neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.â€‹The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Companyâ€™s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements. â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Â Goodwill and Intangible Assets Note 10. Goodwill and Intangible Assetsâ€‹The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹â€‹â€‹â€‹Accumulatedâ€‹â€‹â€‹Â â€‹Â Â Â Â Life (Years)Â Â Â Â Original CostÂ Â Â Â AmortizationÂ Â Â Â Net Book ValueÂ â€‹â€‹(in thousands)Â Definite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹BAQSIMIÂ® product rights(1)â€‹24â€‹$ 591,338â€‹$ 30,799â€‹$ 560,539â€‹PatentsÂ 15â€‹Â 193â€‹â€‹ 92â€‹Â 101â€‹Land-use rightsÂ 39â€‹Â 2,540â€‹â€‹ 865â€‹Â 1,675â€‹SubtotalÂ 24â€‹Â 594,071â€‹Â 31,756â€‹Â 562,315â€‹Indefinite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TrademarkÂ *â€‹Â 29,225â€‹Â â€”â€‹Â 29,225â€‹Goodwill - Finished pharmaceutical productsÂ *â€‹Â 3,256â€‹Â â€”â€‹Â 3,256â€‹SubtotalÂ *â€‹Â 32,481â€‹Â â€”â€‹Â 32,481â€‹ As of SeptemberÂ 30,Â 2024Â *â€‹$ 626,552â€‹$ 31,756â€‹$ 594,796â€‹Weighted-Averageâ€‹â€‹â€‹â€‹Accumulatedâ€‹â€‹â€‹Â â€‹Â Â Â Â Life (Years)Â Â Â Â Original CostÂ Â Â Â AmortizationÂ Â Â Â Net Book ValueÂ â€‹â€‹(in thousands)Â Definite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹BAQSIMIÂ® product rights(1)â€‹24â€‹$ 591,338â€‹$ 12,319â€‹$ 579,019â€‹PatentsÂ 12â€‹Â 486â€‹â€‹ 376â€‹Â 110â€‹Land-use rightsÂ 39â€‹Â 2,540â€‹â€‹ 815â€‹Â 1,725â€‹SubtotalÂ 24â€‹Â 594,364â€‹Â 13,510â€‹Â 580,854â€‹Indefinite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TrademarkÂ *â€‹Â 29,225â€‹Â â€”â€‹Â 29,225â€‹Goodwill - Finished pharmaceutical productsÂ *â€‹Â 3,216â€‹Â â€”â€‹Â 3,216â€‹SubtotalÂ *â€‹Â 32,441â€‹Â â€”â€‹Â 32,441â€‹ As of DecemberÂ 31,Â 2023Â *â€‹$ 626,805â€‹$ 13,510â€‹$ 613,295â€‹* Intangible assets with indefinite lives have an indeterminable average life.(1) See Note 3. â€‹Goodwillâ€‹The changes in the carrying amounts of goodwill are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â Â â€‹â€‹2024â€‹2023Â â€‹â€‹(inÂ thousands)Â Beginning balanceÂ Â Â Â $ 3,216Â Â Â Â $ 3,126â€‹Currency translationâ€‹Â 40â€‹Â 90â€‹Ending balanceâ€‹$ 3,256â€‹$ 3,216â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventories Â Inventories Note 11. Inventoriesâ€‹Inventories consist of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â Â â€‹DecemberÂ 31,Â Â â€‹â€‹2024â€‹2023Â â€‹â€‹(in thousands)Â Raw materials and suppliesÂ Â Â Â $ 60,536Â Â Â Â $ 50,082â€‹Work in processâ€‹Â 36,016â€‹Â 30,822â€‹Finished goodsâ€‹Â 33,764â€‹Â 24,929â€‹Total inventoriesâ€‹$ 130,316â€‹$ 105,833â€‹â€‹â€‹â€‹Charges of $0.9 million and $10.1 million were included in the cost of revenues in the Companyâ€™s condensed consolidated statements of operations for the three and nine months ended September 30, 2024, respectively, to adjust the Companyâ€™s inventory and related firm purchase commitments to its net realizable value. For the three months ended September 30, 2023, the Company had an immaterial amount that was included in cost of revenues to adjust the Companyâ€™s inventory and related firm purchase commitments to its net realizable value. For the nine months ended September 30, 2023, charges of $9.6 million were included in the cost of revenues to adjust the Companyâ€™s inventory and related firm purchase commitments to its net realizable value. X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Property, Plant, and Equipment 9 Months Ended Sep. 30, 2024 Property, Plant, and Equipment. Â Property, Plant, and Equipment Note 12. Property, Plant, and Equipmentâ€‹Property, plant, and equipment consist of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â Â â€‹DecemberÂ 31,Â Â â€‹â€‹2024â€‹2023Â â€‹â€‹(in thousands)Â BuildingsÂ Â Â Â $ 170,203Â Â Â Â $ 168,771â€‹Leasehold improvementsâ€‹Â 42,012â€‹Â 41,686â€‹Landâ€‹Â 7,499â€‹Â 7,484â€‹Machinery and equipmentâ€‹Â 278,200â€‹Â 259,484â€‹Furniture, fixtures, and automobilesâ€‹Â 34,795â€‹Â 31,943â€‹Construction in progressâ€‹Â 28,864â€‹Â 18,676â€‹Total property, plant, and equipmentâ€‹Â 561,573â€‹Â 528,044â€‹Less accumulated depreciationâ€‹Â (266,189)â€‹Â (245,298)â€‹Total property, plant, and equipment, netâ€‹$ 295,384â€‹$ 282,746â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Accrued Liabilities 9 Months Ended Sep. 30, 2024 Accounts Payable and Accrued Liabilities. Â Accounts Payable and Accrued Liabilities Note 13. Accounts Payable and Accrued Liabilitiesâ€‹Accounts payable and accrued liabilities consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹2024â€‹2023â€‹(in thousands)Accrued customer fees and rebates$ 59,949â€‹$ 16,702Accrued payroll and related benefitsâ€‹ 29,207â€‹â€‹ 25,203Accrued product returns, current portionâ€‹ 13,480â€‹â€‹ 12,263Accrued loss on firm purchase commitmentsâ€‹ 812â€‹â€‹ 918Other accrued liabilitiesâ€‹ 15,732â€‹â€‹ 12,842Total accrued liabilitiesÂ 119,180â€‹Â 67,928Accounts payableÂ 34,088â€‹Â 25,438Total accounts payable and accrued liabilities$ 153,268â€‹$ 93,366â€‹ X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Debt 9 Months Ended Sep. 30, 2024 Debt Â Debt Note 14. Debtâ€‹Debt consists of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)Convertible Debtâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2029 Convertible Notesâ€‹$ 345,000â€‹$ 345,000â€‹â€‹â€‹â€‹â€‹â€‹Term Loanâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Wells Fargo Term Loan due June 2028â€‹â€‹ 250,000â€‹â€‹ 250,000â€‹â€‹â€‹â€‹â€‹Mortgage Loansâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Mortgage payable with East West Bank paid off June 2024â€‹â€‹ â€”â€‹â€‹ 8,016â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Other Loans and Payment Obligationsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹French government loans due December 2026â€‹â€‹ 168â€‹â€‹ 158â€‹â€‹â€‹â€‹â€‹â€‹Line of Credit FacilitiesÂ Â Â Â â€‹â€‹Â Â Â Â â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹Line of credit facility with China Merchant Bank due October 2026â€‹â€‹ â€‹â€‹ â€”â€‹â€‹ â€‹â€‹ â€”Wells Fargo Revolving line of credit facility due June 2028â€‹â€‹ â€”â€‹â€‹ â€”Line of credit facility with ICBC Bank due November 2033â€‹â€‹ 13,565â€‹â€‹ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Equipment under Finance Leasesâ€‹Â 485â€‹Â 616Total debtâ€‹Â 609,218â€‹Â 603,790Less current portion of long-term debtâ€‹Â 252â€‹Â 436Less: Loan issuance costsâ€‹â€‹ 12,520â€‹â€‹ 13,775Long-term debt, net of current portion and unamortized debt issuance costsâ€‹$ 596,446â€‹$ 589,579â€‹Credit Agreementâ€‹2029 Convertible Notesâ€‹In September 2023, the Company issued the 2029 Convertible Notes, in the aggregate principal amount of $345.0 million in a private offering pursuant to Section 4(a)(2) and Rule 144A under the Securities Act of 1933, as amended. The Company used portions of the net proceeds from the 2029 Convertible Notes to (i) repay approximately $200.0 million of the Companyâ€™s borrowings under the Wells Fargo Term Loan and (ii) repurchase $50.0 million of the Companyâ€™s common stock.â€‹In connection with the issuance of the 2029 Convertible Notes, the Company incurred approximately $10.8 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees. Unamortized debt issuance costs related to the 2029 Convertible Notes were $8.8 million as of September 30, 2024. The fair value of the 2029 Convertible Notes was approximately $365.4 million as of September 30, 2024 based on level 2 inputs.The 2029 Convertible Notes are general senior, unsecured obligations and bear an interest rate of 2.0% per year. The 2029 Convertible Notes were issued pursuant to an indenture, dated September 15, 2023, or the Indenture, between the Company and U.S. Bank Trust Company, National Association, as trustee.â€‹The 2029 Convertible Notes will rank senior in right of payment to all of the Companyâ€™s indebtedness that is expressly subordinated in right of payment to the 2029 Convertible Notes; equal in right of payment to all of the Companyâ€™s unsecured indebtedness that is not so subordinated; effectively junior to any of the Companyâ€™s secured indebtedness to the extent of the value of the assets securing such indebtedness, including any amount outstanding under the Companyâ€™s credit facilities; and structurally junior to all indebtedness and other liabilities of the Companyâ€™s current or future subsidiaries, including trade payables.â€‹Interest is payable semi-annually in arrears on March 15 and September 15 of each year. The 2029 Convertible Notes may bear additional interest under specified circumstances relating to the Companyâ€™s failure to comply with its reporting obligations under the Indenture or if the 2029 Convertible Notes are not freely tradeable as required by the Indenture. â€‹The 2029 Convertible Notes will mature on March 15, 2029, unless earlier converted, repurchased or redeemed. â€‹Conversions of the 2029 Convertible Notes will be settled in cash up to the aggregate principal amount of the 2029 Convertible Notes to be converted, and cash, shares of common stock or a combination of cash and shares of common stock, at the Companyâ€™s election, with respect to the remainder, if any, of the Companyâ€™s conversion obligation in excess of the aggregate principal amount.â€‹Holders may convert their 2029 Convertible Notes at their option prior to the close of business on the business day immediately preceding December 15, 2028, in multiples of $1,000 principal amount, only under the following circumstances; (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2029 Convertible Notes on each applicable trading day, (ii) during the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, per $1,000 principal amount of the 2029 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Companyâ€™s common stock and the conversion rate on each such trading day, (iii) if the Company calls the 2029 Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, and (iv) upon the occurrence of specified corporate events defined in the Indenture.â€‹On or after December 15, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2029 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.â€‹The Company may redeem the 2029 Convertible Notes, at its option, in whole or in part (subject to certain limitations), on or after September 20, 2026 and prior to the 41st scheduled trading day preceding the maturity date, if the last reported sale price of the Companyâ€™s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.â€‹The initial conversion rate is 15.8821 shares of the Companyâ€™s common stock per $1,000 principal amount of the 2029 Convertible Notes, which represents an initial conversion price of approximately $62.96 per share of common stock. The initial conversion price of $62.96 represents a premium of approximately 35.0% over the last reported sale price of the Companyâ€™s common stock on Nasdaq Global Select Market on September 12, 2023. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.â€‹If a fundamental change, as defined in the Indenture, occurs at any time prior to the maturity date, then, subject to certain conditions, holders of the 2029 Convertible Notes may require the Company to repurchase for cash all or any portion of their 2029 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2029 Convertible Notes to be repurchased, plus any accrued and unpaid interest. In addition, following certain specified corporate events or if the Company issues a notice of redemption, the Company will, under certain circumstances, increase the conversion rate for holders who convert their 2029 Convertible Notes in connection with such

corporate event or during a redemption period.â€‹Syndicated Line of Credit Facility with ICBC Bank â€“ Due November 2033â€‹In January 2024, the Company entered into a credit agreement with Industrial and Commercial Bank of China Limited, or ICBC Bank, acting as a lender and as agent for other lenders. The credit agreement allows the Company to borrow up to $40.0 million secured by equipment and buildings at ANP. The interest rate and other terms will be determined at the time of the borrowing, depending on the type of loan requested. The credit agreement expires in November 2033.â€‹As of September 30, 2024, the Company borrowed approximately $13.6 million under the credit agreement. The loan bears interest at the prime rate as published by The Peopleâ€™s Bank of China minus 0.2%. Interest payments are due quarterly and repayment of the principal amount is biannual and begins in May 2026. As of September 30, 2024, the Company had $13.6 million of principal outstanding under this loan, which is recorded net of loan issuance costs of $0.8 million.â€‹Interest Rate Swap Contractâ€‹As of September 30, 2024, the fair value of the loans listed above approximated their carrying amount based on Level 2 inputs, with the exception of the 2029 Convertible Notes. For the Wells Fargo Term Loan, the Company has entered into a fixed interest rate swap contract to exchange the variable interest rates for fixed interest rates. The interest rate swap contract is recorded at fair value in the other assets line in the condensed consolidated balance sheets. Changes in the fair values of interest rate swaps were $7.4 million loss and $1.6 million loss for the three and nine months ended September 30, 2024, respectively. Changes in the fair values of interest rate swaps were $4.9 million gain and $2.7 million gain for the three and nine months ended September 30, 2023, respectively.â€‹Covenantsâ€‹At September 30, 2024 and December 31, 2023, the Company was in compliance with all of its debt covenants. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Taxes Â Income Taxes Note 15. Income Taxesâ€‹The following table sets forth the Companyâ€™s income tax provision for the periods indicated:â€‹â€‹â€‹

each RSU awarded. The RSUs may not be sold or otherwise transferred until vested. The RSUs do not have any voting or dividend rights prior to the issuance of the underlying common stock. The share-based expense associated with these grants was based on the Companyâ€™s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. For the three and nine months ended September 30, 2024, the Company recorded total expenses of $2.7 million and $8.8 million, respectively, related to RSU awards granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expenses of $2.2 million and $7.3 million, respectively, related to RSU awards granted under all plans.â€‹As of September 30, 2024, there was $22.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures.â€‹Information relating to RSU grants and deliveries is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TotalÂ FairÂ MarketÂ â€‹â€‹TotalÂ RSUsâ€‹ValueÂ ofÂ RSUsÂ â€‹Â Â Â Â IssuedÂ Â Â Â Issued(1)Â â€‹â€‹â€‹â€‹(inÂ thousands)Â RSUs outstanding at DecemberÂ 31,Â 2023Â 920,376â€‹â€‹â€‹â€‹RSUs grantedÂ 303,788â€‹$ 14,060â€‹RSUs forfeitedÂ (9,620)â€‹â€‹â€‹â€‹RSUs vested(2)Â (388,668)â€‹â€‹â€‹â€‹RSUs outstanding at SeptemberÂ 30,Â 2024Â 825,876â€‹â€‹â€‹(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.(2)Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations.â€‹Share-based Compensation Expenseâ€‹The Company recorded share-based compensation expense, which is included in the Companyâ€™s condensed consolidated statement of operations as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹2024Â 2023Â â€‹â€‹(in thousands)Â Cost of revenuesÂ Â Â Â $ 1,133Â Â Â Â $ 1,004Â Â Â Â $ 4,583Â Â Â Â $ 3,868â€‹Operating expenses:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Selling, distribution, and marketingâ€‹Â 249â€‹Â 213â€‹Â 777â€‹Â 649â€‹General and administrativeâ€‹Â 3,710â€‹Â 2,975â€‹Â 11,239â€‹Â 9,323â€‹Research and developmentâ€‹Â 504â€‹Â 452â€‹Â 2,137â€‹Â 1,780â€‹Total share-based compensationâ€‹$ 5,596â€‹$ 4,644â€‹$ 18,736â€‹$ 15,620â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefits 9 Months Ended Sep. 30, 2024 Employee Benefits Â Employee Benefits Note 17. Employee Benefitsâ€‹401(k) Planâ€‹The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three and nine months ended September 30, 2024 were approximately $0.6Â million and $2.0Â million, respectively, compared to the prior year expense of $0.5 million and $1.7 million for the three and nine months ended September 30, 2023, respectively.â€‹Defined Benefit Pension Planâ€‹The Companyâ€™s subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employeeâ€™s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employeeâ€™s age, length of service, and AFP employee turnover rate.â€‹The liability under the plan is based on a discount rate of 3.25% as of September 30, 2024 and December 31, 2023. The liability is included in other long-term liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.8 million and $2.6 million at September 30, 2024 and December 31, 2023, respectively. The Company recorded an immaterial amount of expense under the plan for each of the three and nine months ended September 30, 2024 and 2023.â€‹Non-qualified Deferred Compensation Planâ€‹In December 2019, the Company established a non-qualified deferred compensation plan. The plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. The plan assets were valued at approximately $9.4 million and $6.8 million as of September 30, 2024 and December 31, 2023, respectively. The plan liabilities were valued at approximately $9.8 million and $7.1 million as of September 30, 2024, and December 31, 2023, respectively. The plan assets and liabilities are included in other long-term assets and other long-term liabilities, respectively, on the Companyâ€™s condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for retirement benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (p) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 60 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3 + Details Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Â Commitments and Contingencies Note 18. Commitments and Contingenciesâ€‹Purchase Commitmentsâ€‹As of September 30, 2024, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $95.9 million. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Related-Party Transactions 9 Months Ended Sep. 30, 2024 Related-Party Transactions Â Related-Party Transactions Note 19. Related Party Transactionsâ€‹Investment in Hanxin Pharmaceutical Technology, Co., Ltd.â€‹The Company has an 11.5% ownership in Hanxin Pharmaceutical Technology Co., Ltd, or Hanxin, that is accounted for as an equity method investment. The Company maintains a seat on Hanxinâ€™s board of directors, and Henry Zhang, the son of Dr. Jack Zhang, is an equity holder, the general manager, and the chairman of the board of directors of Hanxin. Additionally, Dr. Mary Luo and Dr. Jack Zhang, have an ownership interest in Hanxin through an affiliated entity. As a result, Hanxin is a related party.â€‹Contract manufacturing agreement with Hanxinâ€‹The Company, has various contract manufacturing agreements with Hanxin and its subsidiaries, whereby Hanxin will develop several active pharmaceutical ingredients and finished products for the Chinese market and will engage the Company to manufacture the products on a cost-plus basis.â€‹During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.5 million, respectively, of revenue from manufacturing services provided to Hanxin. During the three and nine months ended September 30, 2023, the Company recognized an immaterial amount of revenue from manufacturing services provided to Hanxin. As of September 30, 2024, the Company had $0.4 million of receivables from Hanxin.â€‹Contract Research Agreement with Hanxinâ€‹In July 2022, the Company entered into a three-year contract research agreement with Hanxin, a related party, whereby Hanxin will develop Recombinant Human Insulin Research Cell Banks, or RCBs, for the Company and license the RCBs to the Company subject to a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license. Hanxin will also perform scale-up manufacturing process development using the RCBs for the Company.â€‹During the three months ended September 30, 2024, the Company did not have any payments under the amended agreement and during the nine months ended September 30 2024, the Company paid $0.2 million under the amended agreement. During the three and nine months ended September 30, 2023, the Company paid $0.4 million and $1.0 million, respectively, under the amended agreement. As of September 30, 2024, the Company had an immaterial amount payable to Hanxin.â€‹Supply Agreement with Letopâ€‹In November 2022, the Company, entered into a supply agreement with Nanjing Letop Biotechnology Co., Ltd., or Letop, which is considered a related-party due to an ownership stake of Henry Zhang. Under the terms of the supply agreement Letop will manufacture and deliver chemical intermediates to the Company on a cost-plus basis. The agreement is effective for three years and the total cost of the agreement shall not exceed $1.5 million, with payments adjusted based on the then current exchange rates.â€‹During the three and nine months ended September 30, 2024, the Company paid an immaterial amount under this agreement. During the three months ended September 30, 2023, the Company did not have any payments under this agreement. During the nine months ended September 30, 2023, the Company paid $0.7 million, under this agreement. As of September 30, 2024, the Company did not have any amounts payable to Letop.â€‹Primatene MISTÂ® Distribution agreement with Hong Kong Genreach Limitedâ€‹In August 2024, the Company entered into a distribution agreement with Hong Kong Genreach Limited, or Genreach, a wholly owned subsidiary of Hanxin, a related party. Per the terms of the agreement, the Company has appointed Genreach as the exclusive distributor to market and sell Primatene MISTÂ® in Mainland China, Taiwan, Hong Kong, and Macau in the Greater China region. Genreach will be responsible for obtaining any and all regulatory approvals in the region for Primatene MISTÂ®. â€‹The term of the agreement is ten years, with both parties having termination rights without cause after the completion of the second contract year. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -

SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Litigation 9 Months Ended Sep. 30, 2024 Litigation Â Litigation Note 20. Litigationâ€‹Employment Litigationâ€‹On April 15, 2024, a former employee (â€œPlaintiffâ€) initiated an employment litigation against Amphastar and IMS by filing a complaint, as amended, having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the class action complaint.â€‹On June 20, 2024, a former employee (â€œPlaintiffâ€) initiated an employment litigation against Amphastar, IMS and Roth Staffing Companies L.P. by filing a complaint having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the complaint.â€‹Albuterol sulfate Inhalation Aerosol Patent Litigation â€‹On July 25, 2024, Teva Branded Pharmaceutical Products R&D, Inc. (â€œTeva Brandedâ€), Norton (Waterford) Ltd. (â€œNortonâ€), and Teva Pharmaceuticals USA, Inc. (â€œTeva USAâ€), collectively referred to as (â€œPlaintiffâ€) filed a Complaint in the United States District Court for the District of Delaware (â€œDelaware Courtâ€) against the Company for infringement of U.S. Patent No. 9,463,289, with regard to Amphastarâ€™s ANDA No. 212447, for approval to manufacture and sell generic version of ProAirÂ® HFA (albuterol sulfate) Inhalation Aerosol. On October 21, 2024, Plaintiff amended its complaint against the Company to include additional claims for infringement of U.S. Patent No. 9,808,587 and 10,561,808, with regard to Amphastarâ€™s ANDA No. 212447, for approval to manufacture and sell generic version of ProAirÂ® HFA (albuterol sulfate) Inhalation Aerosol. The Company intends to vigorously defend this patent lawsuit.â€‹Other litigationâ€‹The Company is subject to various claims, arbitrations, investigations, and lawsuits from time to time arising in the ordinary course of business. In addition, third parties may, from time to time, assert claims against the Company in the forms of letters and other communications. Currently, the Company is subject to a lawsuit for a property and casualty claim, for which it has recorded an estimated liability of $6.0 million within accounts payable and other accrued liabilities on the condensed balance sheet as of September 30, 2024. This estimated liability is fully covered by the Companyâ€™s insurance policies. The $6.0 million insurance recovery related to this claim is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheet as of September 30, 2024.â€‹The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Companyâ€™s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. X - DefinitionThe entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent + Details Name: us-gaap_LegalMattersAndContingenciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LossContingencyInformationAboutLitigationMattersAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ 40,429 $ 37,949 $ 43,177 $ 49,222 $ 26,124 $ 26,032 $ 121,555 $ 101,378 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Basis of Presentation Basis of Presentationâ€‹The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with GAAP. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.â€‹The Companyâ€™s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals,Â Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Amphastar France Pharmaceuticals, S.A.S., or AFP, (5) Amphastar UK Ltd., or AUK, (6) International Medication Systems (UK) Limited, or IMS UK, and (7) Amphastar Medication Co., LLC, or Amphastar Medication.â€‹ Investment in Unconsolidated Affiliates Investment in Unconsolidated Affiliate â€‹The Company applies the equity method of accounting for investments when it has significant influence, but not controlling interest in the investee. The Companyâ€™s proportionate share of the earnings or losses resulting from these investments is reported as â€œEquity in losses of unconsolidated affiliateâ€ in the accompanying condensed consolidated statements of operations. Investments accounted for using the equity method may be reported on a lag of up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date.â€‹The carrying value of equity method investments is reported as â€œInvestment in unconsolidated affiliateâ€ in the accompanying condensed consolidated balance sheets. The Companyâ€™s equity method investments are reported at cost and adjusted each period for the Companyâ€™s share of the investeeâ€™s earnings or losses and dividends paid, if any. Use of Estimates Use of Estimatesâ€‹The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.

Actual results could differ from those estimates. The principal accounting estimates include: fair value of acquired assets, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions. Foreign Currency Foreign Currency â€‹The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the U.S. Dollar, or USD. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Companyâ€™s condensed consolidated statements of operations. â€‹The Companyâ€™s French subsidiary, AFP, maintains its books of record in euros. AUKâ€™s subsidiary, IMS UK, maintains its books of record in British pounds. These local currencies have been determined to be the subsidiariesâ€™ respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholdersâ€™ equity and are included as a component of other comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). â€‹The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $1.4 million gain and a $0.4 million gain for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $0.9 million loss and a $0.4 million loss, respectively. â€‹ Comprehensive Income (loss) Comprehensive Incomeâ€‹The Companyâ€™s comprehensive income includes its foreign currency translation gains and losses as well as its share of other comprehensive income from its equity method investments. Acquisitions Acquisitions â€‹The Company evaluates acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and substantive processes that have the ability to create outputs, which would meet the definition of a business.â€‹Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.â€‹For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis, with the exception of non-qualifying assets. Goodwill is not recognized in an asset acquisition. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR&D, asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration, including assumed contingent considerations, is not recognized until all contingencies are resolved and the consideration is paid or becomes payable (unless contingent considerations meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired), at which point the consideration is allocated to the assets acquired based on their relative fair values at the acquisition date, with the exception of non-qualifying assets.â€‹Judgments are used in determining estimates of useful lives of long-lived assets. Useful life estimates are based on, among other factors, estimates of expected future net cash flows, the assessment of each assetâ€™s life cycle, and the impact of competitive trends on each assetâ€™s life cycle and other factors. These judgments can materially impact the estimates used to allocate purchase consideration to assets acquired and liabilities assumed, and the resulting timing and amounts charged to or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results. Advertising Expense Advertising Expenseâ€‹Advertising expenses, primarily associated with Primatene MISTÂ®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Companyâ€™s condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, advertising expenses were $2.5 million and $7.8 million, respectively. For the three and nine months ended September 30, 2023, advertising expenses were $1.9 million and $8.1 million, respectively. Financial Instruments Financial Instrumentsâ€‹The Companyâ€™s accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses, short-term borrowings, and long-term obligations. The Company considers the carrying amounts of current assets and liabilities on the condensed consolidated balance sheets to approximate the fair value of these financial instruments due to the short maturity of these items. The carrying value of the Companyâ€™s long-term obligations, with the exception of the convertible debt (see Note 14), approximates their fair value, as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. Investments and short-term investments are recorded at fair value based on quoted prices from recognized security exchanges and other methods (see Note 9). The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt. The Companyâ€™s interest rate swap contracts exchange the variable interest rates for fixed interest rates. Cash and Cash Equivalents Cash and Cash Equivalentsâ€‹Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments with original maturities of three months or less. Investments Investmentsâ€‹Investments as of September 30, 2024 and December 31, 2023 consisted of certificates of deposit and investment grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months. Restricted Cash Restricted Cash â€‹Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of September 30, 2024 and December 31, 2023, the restricted cash balance was $0.2 million. Restricted Short-Term Investments Restricted Short-Term Investmentsâ€‹Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workersâ€™ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of September 30, 2024 and December 31, 2023, the balance of restricted short-term investments was $2.2 million. Deferred Income Taxes Deferred Income Taxesâ€‹The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. Debt Issuance Costs Debt Issuance Costsâ€‹Debt issuance costs related to non-revolving debt are recognized as a reduction to the related debt balance in the accompanying condensed consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Debt issuance costs associated with revolving debt are capitalized within other long-term assets on the condensed consolidated balance sheets and are amortized to interest expense over the term of the related revolving debt. Convertible Debt Convertible Debtâ€‹The Company accounts for its convertible debt instruments as a single unit of accounting, a liability, because the Company concluded that the conversion features do not require bifurcation as a derivative under Accounting Standards Codification, or ASC, 815-15, Derivatives and Hedging and the Company did not issue its convertible debt instruments at a substantial premium. The Company records debt issuance costs as contra-liabilities in its condensed consolidated balance sheets at issuance and amortizes them over the contractual term of the convertible debt instrument using the effective interest rate.â€‹In accordance with Accounting Standards Update, or ASU,Â 2020-06,Â Debtâ€”Debt with Conversion and Other Options (SubtopicÂ 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (SubtopicÂ 815-40): Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, the Company evaluates convertible debt instruments to determine if the conversion feature is freestanding or embedded. If the conversion feature is embedded, the conversion feature is not bifurcated from the host instrument. If the conversion feature does not require derivative treatment underÂ ASC 815, the instrument is evaluated underÂ ASC 470-20,Â â€œDebt with Conversion and Other Optionsâ€ for consideration of any beneficial conversion features. If no beneficial conversion features exist that require separate recognition, convertible debt instruments are accounted for as a single liability measured at its amortized cost as long asÂ noÂ other features require separation and recognition as derivatives. Litigation, Commitments and Contingencies Litigation, Commitments and Contingenciesâ€‹Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized. Recent Accounting Pronouncements Recent Accounting Pronouncementsâ€‹In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the disclosure requirements related to the new standard.â€‹In December 2023, the FASB issued Accounting Standard Update 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures which requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to the new standard. X - DefinitionDisclosure of accounting policy for acquisitions. + ReferencesNo definition available. + Details Name: amph_AcquisitionsPolicyPolicyTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to convertible debt. + ReferencesNo definition available. + Details Name: amph_ConvertibleDebtPolicyTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for restricted short-term investments. + ReferencesNo definition available. + Details Name: amph_RestrictedShortTermInvestmentsPolicyTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 450 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 21D -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D + Details Name: us-gaap_EquityMethodInvestmentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -

DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 BAQSIMI Acquisition (Tables) 9 Months Ended Sep. 30, 2024 BAQSIMI Acquisition Â Schedule of purchase price allocated to acquired assets â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Fair Valueâ€‹â€‹(in thousands)Property, plant, and equipmentÂ Â Â Â $ 34,426BAQSIMIÂ® product rightsâ€‹Â 591,338Deferred tax assetsâ€‹â€‹ 2,341Total assets acquiredâ€‹$ 628,105 X - ReferencesNo definition available. + Details Name: us-gaap_AssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition (Tables) 9 Months Ended Sep. 30, 2024 Revenue Recognition Â Schedule of chargeback and rebates provision analysis â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)Beginning balanceÂ Â Â Â $ 27,920Â Â Â Â $ 26,606Provision for chargebacks and rebatesâ€‹Â 218,312â€‹Â 200,317Credits and payments issued to third partiesâ€‹Â (181,216)â€‹Â (201,650)Ending balanceâ€‹$ 65,016â€‹$ 25,273 Schedule of provision of chargebacks and rebates as reflected in the balance sheets â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹2024â€‹2023â€‹(in thousands)Reduction to accounts receivable, net$ 21,355Â Â Â Â $ 21,861Accounts payable and accrued liabilitiesÂ 43,661â€‹Â 6,059Total$ 65,016â€‹$ 27,920 X - DefinitionThe provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing. + ReferencesNo definition available. + Details Name: amph_ScheduleOfChargebackLiabilityTableTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts that are recognized in the balance sheet for chargebacks and rebates. + ReferencesNo definition available. + Details Name: amph_ScheduleOfProvisionForChargebacksAndRebatesAmountsRecognizedInBalanceSheetTableTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueRecognitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Share (Tables) 9 Months Ended Sep. 30, 2024 Net Income per Share Â Schedule of basic and diluted net income (loss) per share calculation â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Measurements Â Schedule of financial assets and liabilities measured on a recurring basis â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â TotalÂ Â Â Â (Level 1)Â Â Â Â (Level 2)Â Â Â Â (Level 3)Â â€‹â€‹(in thousands)Â Cash equivalentsâ€‹$ 143,637â€‹$ 143,637â€‹$ â€”â€‹$ â€”â€‹Restricted cashâ€‹â€‹ 235â€‹â€‹ 235â€‹â€‹ â€”â€‹â€‹ â€”â€‹Short-term investmentsâ€‹â€‹ 26,322â€‹â€‹ â€”â€‹â€‹ 26,322â€‹â€‹ â€”â€‹Restricted short-term investmentsâ€‹Â 2,200â€‹Â â€”â€‹Â 2,200â€‹Â â€”â€‹Interest rate swaps related to variable rate loansâ€‹â€‹ (6,881)â€‹â€‹ â€”â€‹â€‹ (6,881)â€‹â€‹ â€”â€‹Total assets and liabilities measured at fair value as of SeptemberÂ 30,Â 2024â€‹$ 165,513â€‹$ 143,872â€‹$ 21,641â€‹$ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â TotalÂ Â Â Â (Level 1)Â Â Â Â (Level 2)Â Â Â Â (Level 3)â€‹â€‹(in thousands)Cash equivalentsâ€‹$ 116,441â€‹$ 116,441â€‹$ â€”â€‹$ â€”Restricted cashâ€‹â€‹ 235â€‹â€‹ 235â€‹â€‹ â€”â€‹â€‹ â€”Short-term investmentsâ€‹â€‹ 37,142â€‹â€‹ â€”â€‹â€‹ 37,142â€‹â€‹ â€”Restricted short-term investmentsâ€‹Â 2,200â€‹Â â€”â€‹Â 2,200â€‹Â â€”Interest rate swaps related to variable rate loansâ€‹â€‹ (5,243)â€‹â€‹ â€”â€‹â€‹ (5,243)â€‹â€‹ â€”Total assets and liabilities measured at fair value as of DecemberÂ 31,Â 2023â€‹$ 150,775â€‹$ 116,676â€‹$ 34,099â€‹$ â€” X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Investments (Tables) 9 Months Ended Sep. 30, 2024 Investments Â Schedule of securities classified as held-to-maturity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Grossâ€‹Grossâ€‹â€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fairâ€‹Â Â Â Â CostÂ Â Â Â GainsÂ Â Â Â LossesÂ Â Â Â Valueâ€‹â€‹(in thousands)Corporate and agency bonds (due within 1 year)â€‹$ 31,903â€‹$ 67â€‹$ (2)â€‹$ 31,968Total investments as of SeptemberÂ 30,Â 2024â€‹$ 31,903â€‹$ 67â€‹$ (2)â€‹$ 31,968â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Corporate and agency bonds (due within 1 year)â€‹$ 73,815â€‹$ 7â€‹$ (21)â€‹$ 73,801Corporate and agency bonds (due within 1 to 3 years)â€‹â€‹ 14,621â€‹â€‹ 56â€‹â€‹ (1)â€‹â€‹ 14,676Municipal bonds (due within 1 year)â€‹â€‹ 1,081â€‹â€‹ 1â€‹â€‹ â€”â€‹â€‹ 1,082Total investments as of DecemberÂ 31,Â 2023â€‹$ 89,517â€‹$ 64â€‹$ (22)â€‹$ 89,559 X - DefinitionTabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 15: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B + Details Name: us-gaap_HeldToMaturitySecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Â Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹â€‹â€‹â€‹Accumulatedâ€‹â€‹â€‹Â â€‹Â Â Â Â Life (Years)Â Â Â Â Original CostÂ Â Â Â AmortizationÂ Â Â Â Net Book ValueÂ â€‹â€‹(in thousands)Â Definite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹BAQSIMIÂ® product rights(1)â€‹24â€‹$ 591,338â€‹$ 30,799â€‹$ 560,539â€‹PatentsÂ 15â€‹Â 193â€‹â€‹ 92â€‹Â 101â€‹Land-use rightsÂ 39â€‹Â 2,540â€‹â€‹ 865â€‹Â 1,675â€‹SubtotalÂ 24â€‹Â 594,071â€‹Â 31,756â€‹Â 562,315â€‹Indefinite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TrademarkÂ *â€‹Â 29,225â€‹Â â€”â€‹Â 29,225â€‹Goodwill - Finished pharmaceutical productsÂ *â€‹Â 3,256â€‹Â â€”â€‹Â 3,256â€‹SubtotalÂ *â€‹Â 32,481â€‹Â â€”â€‹Â 32,481â€‹ As of SeptemberÂ 30,Â 2024Â *â€‹$ 626,552â€‹$ 31,756â€‹$ 594,796â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹â€‹â€‹â€‹Accumulatedâ€‹â€‹â€‹Â â€‹Â Â Â Â Life (Years)Â Â Â Â Original CostÂ Â Â Â AmortizationÂ Â Â Â Net Book ValueÂ â€‹â€‹(in thousands)Â Definite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹BAQSIMIÂ® product rights(1)â€‹24â€‹$ 591,338â€‹$ 12,319â€‹$ 579,019â€‹PatentsÂ 12â€‹Â 486â€‹â€‹ 376â€‹Â 110â€‹Land-use rightsÂ 39â€‹Â 2,540â€‹â€‹ 815â€‹Â 1,725â€‹SubtotalÂ 24â€‹Â 594,364â€‹Â 13,510â€‹Â 580,854â€‹Indefinite-lived intangible assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TrademarkÂ *â€‹Â 29,225â€‹Â â€”â€‹Â 29,225â€‹Goodwill - Finished pharmaceutical productsÂ *â€‹Â 3,216â€‹Â â€”â€‹Â 3,216â€‹SubtotalÂ *â€‹Â 32,441â€‹Â â€”â€‹Â 32,441â€‹ As of DecemberÂ 31,Â 2023Â *â€‹$ 626,805â€‹$ 13,510â€‹$ 613,295â€‹* Intangible assets with indefinite lives have an indeterminable average life.(1) See Note 3. Schedule of changes in carrying amounts of goodwill â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â Â â€‹â€‹2024â€‹2023Â â€‹â€‹(inÂ thousands)Â Beginning balanceÂ Â Â Â $ 3,216Â Â Â Â $ 3,126â€‹Currency translationâ€‹Â 40â€‹Â 90â€‹Ending balanceâ€‹$ 3,256â€‹$ 3,216â€‹â€‹ X - DefinitionTabular disclosure of amortizable finite-lived intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. + ReferencesNo definition available. + Details Name: amph_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock Namespace Prefix: amph_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventories Â Schedule of inventories â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â Â â€‹â€‹2024â€‹2023Â â€‹â€‹(in thousands)Â Raw materials and suppliesÂ Â Â Â $ 60,536Â Â Â Â $ 50,082â€‹Work in processâ€‹Â 36,016â€‹Â 30,822â€‹Finished goodsâ€‹Â 33,764â€‹Â 24,929â€‹Total inventoriesâ€‹$ 130,316â€‹$ 105,833â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Property, Plant, and Equipment (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant, and Equipment. Â Schedule of property, plant, and equipment â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â Â â€‹â€‹2024â€‹2023Â â€‹â€‹(in thousands)Â BuildingsÂ Â Â Â $ 170,203Â Â Â Â $ 168,771â€‹Leasehold improvementsâ€‹Â 42,012â€‹Â 41,686â€‹Landâ€‹Â 7,499â€‹Â 7,484â€‹Machinery and equipmentâ€‹Â 278,200â€‹Â 259,484â€‹Furniture, fixtures, and automobilesâ€‹Â 34,795â€‹Â 31,943â€‹Construction in progressâ€‹Â 28,864â€‹Â 18,676â€‹Total property, plant, and equipmentâ€‹Â 561,573â€‹Â 528,044â€‹Less accumulated depreciationâ€‹Â (266,189)â€‹Â (245,298)â€‹Total property, plant, and equipment, netâ€‹$ 295,384â€‹$ 282,746â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Accrued Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Accounts Payable and Accrued Liabilities. Â Schedule of accounts payable and accrued liabilities â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹2024â€‹2023â€‹(in thousands)Accrued customer fees and rebates$ 59,949â€‹$ 16,702Accrued payroll and related benefitsâ€‹ 29,207â€‹â€‹ 25,203Accrued product returns, current portionâ€‹ 13,480â€‹â€‹ 12,263Accrued loss on firm purchase commitmentsâ€‹ 812â€‹â€‹ 918Other accrued liabilitiesâ€‹ 15,732â€‹â€‹ 12,842Total accrued liabilitiesÂ 119,180â€‹Â 67,928Accounts payableÂ 34,088â€‹Â 25,438Total accounts payable and accrued liabilities$ 153,268â€‹$ 93,366â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect

the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Â Schedule of debt â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹â€‹2023â€‹â€‹(in thousands)Convertible Debtâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2029 Convertible Notesâ€‹$ 345,000â€‹$ 345,000â€‹â€‹â€‹â€‹Term Loanâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Wells Fargo Term Loan due June 2028â€‹â€‹ 250,000â€‹â€‹ 250,000â€‹â€‹â€‹â€‹â€‹â€‹Mortgage Loansâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Mortgage payable with East West Bank paid off June 2024â€‹â€‹ â€"â€‹â€‹ 8,016â€‹â€‹â€‹â€‹â€‹â€‹Other Loans and Payment Obligationsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹French government loans due December 2026â€‹â€‹ 168â€‹â€‹ 158â€‹â€‹â€‹â€‹â€‹â€‹Line of Credit FacilitiesÂ Â Â â€‹â€‹Â Â Â â€‹â€‹Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹Line of credit facility with China Merchant Bank due October 2026â€‹ â€‹ â€"â€‹ â€‹ â€"Wells Fargo Revolving line of credit facility due June 2028â€‹â€‹ â€"â€‹â€‹ â€"Line of credit facility with ICBC Bank due November 2033â€‹â€‹ 13,565â€‹â€‹ â€"â€‹â€‹â€‹â€‹â€‹â€‹Equipment under Finance Leasesâ€‹Â 485â€‹Â 616Total debtâ€‹Â 609,218â€‹Â 603,790Less current portion of long-term debtâ€‹Â 252â€‹Â 436Less: Loan issuance costsâ€‹â€‹ 12,520â€‹â€‹ 13,775Long-term debt, net of current portion and unamortized debt issuance costsâ€‹$ 596,446â€‹$ 589,579 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Tables) 9 Months Ended Sep. 30, 2024 Income Taxes Â Summary of provision (benefit) for income taxes â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â Â â€‹Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023Â â€‹â€‹(inÂ thousands)Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Income before taxesâ€‹$ 47,683â€‹$ 63,637â€‹$ 145,802â€‹$ 130,014â€‹Income tax provisionâ€‹â€‹ 7,254â€‹Â 14,025â€‹â€‹ 23,674â€‹Â 27,160â€‹Income before equity in losses of unconsolidated affiliateâ€‹$ 40,429â€‹$ 49,612â€‹$ 122,128â€‹$ 102,854â€‹Income tax provision as a percentage of income before income taxesâ€‹â€‹ 15.2%Â 22.0%â€‹ 16.2%Â 20.9% X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Â Schedule of key assumptions to determine fair value of options â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023Â â€‹Average volatilityÂ â€"%Â Â 40.2%Â Â 41.3% 41.4%â€‹Average risk-free interest rateÂ â€"%Â Â 4.4%Â Â 4.2% 4.1%â€‹Weighted-average expected life in yearsÂ â€"â€‹ 6.3â€‹ 6.2â€‹ 6.2â€‹â€‹Dividend yield rateÂ â€"%Â Â â€"%Â â€"% â€"%â€‹ Schedule of the summary of option activity under all plans â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹â€‹Â â€‹â€‹â€‹Weighted-Averageâ€‹Remainingâ€‹AggregateÂ â€‹â€‹â€‹â€‹Exerciseâ€‹Contractualâ€‹IntrinsicÂ â€‹â€‹Optionsâ€‹Priceâ€‹TermÂ (Years)â€‹Value(1)Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)Â Outstanding as of DecemberÂ 31,Â 2023â€‹ 7,762,298â€‹$ 19.70Â Â Â Â Â Â Â Â Â â€‹Â Â Â Â â€‹Options grantedÂ 642,985â€‹â€‹ 46.27â€‹â€‹â€‹â€‹Options exercisedÂ (1,611,117)â€‹â€‹ 13.66â€‹â€‹â€‹â€‹â€‹Options forfeitedÂ (21,138)â€‹â€‹ 35.10â€‹â€‹â€‹â€‹Options expiredÂ â€"â€‹â€‹ â€"â€‹â€‹â€‹â€‹Outstanding as of SeptemberÂ 30,Â 2024Â 6,773,028â€‹$ 23.61â€‹ 5.12â€‹$ 168,760â€‹Exercisable as of SeptemberÂ 30,Â 2024Â 4,968,365â€‹â€‹ 19.02â€‹ 3.97â€‹$ 146,600â€‹Vested and expected to vest as of SeptemberÂ 30,Â 2024â€‹ 6,617,113â€‹â€‹ 23.24â€‹ 5.04â€‹$ 167,346â€‹(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Companyâ€™s stock for those awards that have an exercise price below the estimated fair value at September 30, 2024. Schedule of information relating to options grants â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023Â â€‹â€‹(in thousands, except per share data)Â Weighted-average grant date fair value per shareâ€‹$ â€"â€‹$ 21.49â€‹$ 21.89â€‹$ 16.76â€‹Intrinsic value of options exercisedâ€‹Â 6,218â€‹Â 5,628â€‹Â 48,381â€‹Â 24,544â€‹Cash received from options exercisedâ€‹Â 3,332â€‹Â 2,277â€‹Â 9,154â€‹Â 12,015â€‹Total fair value of the options vested during the periodâ€‹Â 111â€‹Â 167â€‹Â 9,815â€‹Â 8,887â€‹ Schedule of the summary of nonvested options status â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â â€‹Â Â Â Weighted-AverageÂ â€‹â€‹GrantÂ DateÂ â€‹â€‹Optionsâ€‹FairÂ ValueÂ Non-vested as of DecemberÂ 31,Â 2023â€‹ 2,076,355â€‹$ 12.68â€‹Options grantedÂ 642,985â€‹â€‹ 21.89â€‹Options vestedÂ (893,539)â€‹â€‹ 10.98â€‹Options forfeitedÂ (21,138)â€‹â€‹ 16.19â€‹Non-vested as of SeptemberÂ 30,Â 2024Â 1,804,663â€‹Â 16.76â€‹ Schedule of information relating to RSU grants and deliveries â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹TotalÂ FairÂ MarketÂ â€‹TotalÂ RSUsâ€‹ValueÂ ofÂ RSUsÂ â€‹Â Â Â Â IssuedÂ Â Â Â Issued(1)Â â€‹â€‹â€‹â€‹(inÂ thousands)Â RSUs outstanding at DecemberÂ 31,Â 2023Â 920,376â€‹â€‹RSUs grantedÂ 303,788â€‹$ 14,060â€‹RSUs forfeitedÂ (9,620)â€‹â€‹â€‹â€‹RSUs vested(2)Â (388,668)â€‹â€‹â€‹â€‹RSUs outstanding at SeptemberÂ 30,Â 2024Â 825,876â€‹â€‹â€‹â€‹(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.(2)Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations. Schedule of recorded share-based compensation expense under all plans â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹2024Â 2023Â â€‹â€‹(in thousands)Â Cost of revenuesÂ Â Â Â $ 1,133Â Â Â Â $ 1,004Â Â Â Â $ 4,583Â Â Â Â $ 3,868â€‹Operating expenses:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Selling, distribution, and marketingâ€‹Â 249â€‹Â 213â€‹Â 777â€‹Â 649â€‹General and administrativeâ€‹Â 3,710â€‹Â 2,975â€‹Â 11,239â€‹Â 9,323â€‹Research and developmentâ€‹Â 504â€‹Â 452â€‹Â 2,137â€‹Â 1,780â€‹Total share-based compensationâ€‹$ 5,596â€‹$ 4,644â€‹$ 18,736â€‹$ 15,620â€‹â€‹ X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Gains and (losses) of intercompany foreign currency transactions $ 1,400 $ (900) $ 400 $ (400) Â Restricted cash 235 Â 235 Â $ 235 Certificates of Deposit, at Carrying Value 2,200 Â 2,200 Â Â Finished Pharmaceutical Products Segment | Primatene MIST Â Â Â Â Â Advertising expense $ 2,500 $ 1,900 $ 7,800 $ 8,100 Â X - DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CertificatesOfDepositAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_FinishedPharmaceuticalProductsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_PrimatenemistMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3 BAQSIMI Acquisition (Narrative) (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jun. 30, 2023 Apr. 21, 2023 Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Asset Acquisition [Line Items] Â Â Â Â Â Â Proceeds from Lines of Credit Â Â Â Â $ 13,565 Â BAQSIMI product rights Â Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Â Cash payment Â Â $ 129,000 Â Â Â Contingent consideration Â $ 575,000 Â Â Â Â Deferred payment including accrued interest $ 129,000 Â Â Â Â Â Interest expense accretion period 1 year Â Â Â Â Â Interest expense recognized related to accretion of deferred payment Â Â $ 1,800 $ 3,600 $ 1,800 BAQSIMI product rights | Maximum [Member] | Manufacturing Services Agreement Â Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Â Agreement term 18 months Â Â Â Â

Â BAQSIMI product rights | Maximum [Member] | Transition Services Agreement Â Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Â Agreement term 18 months Â Â Â Â Â X - DefinitionPeriod of time for agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: amph_AgreementTerm Namespace Prefix: amph_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe amount of consideration payable including accrued interest as part of consideration transferred in asset acquisition. + ReferencesNo definition available. + Details Name: amph_AssetAcquisitionConsiderationDeferredPaymentIncludingAccruedInterest Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense recognized related to accretion of deferred payment. + ReferencesNo definition available. + Details Name: amph_DeferredPaymentAccretionInterestExpenseRecognized Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod of time, typically for liabilities, that have been discounted to their net present values, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: amph_InterestExpenseAccretionTerm Namespace Prefix: amph_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of contingent consideration recognized as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=amph_BaqsimiAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=amph_ManufacturingServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=amph_TransitionServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3 BAQSIMI Acquisition (Purchase Price Allocated to Acquired Assets) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Apr. 21, 2023 Asset Acquisition [Line Items] Â Â Â Property, Plant and Equipment, Net $ 295,384 $ 282,746 Â BAQSIMI product rights Â Â Â Asset Acquisition [Line Items] Â Â Â Property, Plant and Equipment, Net Â Â $ 34,426 BAQSIMI product rights Â Â 591,338 Deferred tax assets Â Â 2,341 Total assets acquired Â Â $ 628,105 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of net assets (liabilities). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479910/205-30-50-1 + Details Name: us-gaap_AssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AssetAcquisitionAxis=amph_BaqsimiAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition (Analysis of the Chargeback Provision) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue $ 191,214 $ 180,556 $ 545,444 $ 466,290 Beginning balance Â Â 27,920 26,606 Provision for chargebacks and rebates Â Â 218,312 200,317 Credits and payments issued to third parties Â Â (181,216) (201,650) Ending balance 65,016 25,273 65,016 25,273 Research and development services | ANP Â Â Â Â Revenue $ 100 $ 800 $ 2,000 $ 2,100 Minimum [Member] Â Â Â Â Payment terms Â Â 30 days Â Settlement of chargebacks and rebates terms Â Â 20 days Â Maximum [Member] Â Â Â Â Payment terms Â Â 75 days Â Settlement of chargebacks and rebates terms Â Â 60 days Â X - DefinitionPayment terms in contract with customer, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration. + ReferencesNo definition available. + Details Name: amph_RevenuePerformanceObligationPaymentTerms Namespace Prefix: amph_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the amount the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. + ReferencesNo definition available. + Details Name: amph_RevenueRecognitionWholesalerChargebacks Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents wholesaler chargeback credits issued to third parties during the period. + ReferencesNo definition available. + Details Name: amph_RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the wholesaler chargeback provision related to sales made in the current period. + ReferencesNo definition available. + Details Name: amph_RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe settlement of chargebacks and rebate terms, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: amph_SettlementOfChargebacksAndRebatesTerms Namespace Prefix: amph_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=amph_ResearchAndDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=amph_AnpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition (Chargebacks and Rebates Balance Sheet Accounts) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Total

$ 65,016 $ 27,920 $ 25,273 $ 26,606 Accounts Receivable [Member] Â Â Â Â Total 21,355 21,861 Â Â Accounts Payable and Accrued Liabilities [Member] Â Â Â Â Total $ 43,661 $ 6,059 Â Â X - DefinitionRepresents the amount the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. + ReferencesNo definition available. + Details Name: amph_RevenueRecognitionWholesalerChargebacks Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Share (Narrative) (Details) - Employee and non-employee stock options - $ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares 619,847 0 619,847 45,934 Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities $ 46.63 Â $ 46.63 $ 46.01 X - DefinitionRepresents the weighted-average exercise price of the excluded securities, per share. + ReferencesNo definition available. + Details Name: amph_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfExcludedSecurities Namespace Prefix: amph_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amph_EmployeeAndNonEmployeeStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Basic and dilutive numerator: Â Â Â Â Â Â Â Net Income (Loss) $ 40,429 $ 37,949 $ 43,177 $ 49,222 $ 26,124 $ 26,032 $ 121,555 $ 101,378 Weighted-average shares outstanding - basic Â Â Â Â Â Â Â Â Weighted-average shares outstanding-basic 48,621 Â Â 48,701 Â Â 48,580 48,368 Net effect of dilutive securities: Â Â Â Â Â Â Â Â Incremental shares from equity awards 3,241 Â Â 5,220 Â Â 3,727 4,629 Weighted-average shares outstanding - diluted 51,862 Â Â 53,921 Â Â 52,307 52,997 Net income (loss) per share - basic $ 0.83 Â Â $ 1.01 Â Â $ 2.50 $ 2.10 Net income (loss) per share - diluted $ 0.78 Â Â $ 0.91 Â Â $ 2.32 $ 1.91 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 44 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-44Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 51 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-51Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-52Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-53Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 54 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-54Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 48 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-48Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 48 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-48 + Details Name: us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -

Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Selected Financial Information by Reporting Segment) (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Segment Reporting Information [Line Items] Â Â Â Â Number of Reportable Segments Â Â 2 Â Net revenues: Â Â Â Â Revenues $ 191,214,000 $ 180,556,000 $ 545,444,000 $ 466,290,000 Gross profit (loss): Â Â Â Â Gross Profit 101,941,000 108,403,000 287,207,000 254,981,000 Operating Expenses 44,893,000 35,725,000 126,932,000 111,974,000 Income from operations 57,048,000 72,678,000 160,275,000 143,007,000 Non-operating income (expenses) (9,365,000) (9,041,000) (14,473,000) (12,993,000) Income (loss) before income taxes 47,683,000 63,637,000 145,802,000 130,014,000 Finished Pharmaceutical Products Segment Â Â Â Â Net revenues: Â Â Â Â Revenues 189,752,000 176,366,000 538,755,000 455,242,000 Gross profit (loss): Â Â Â Â Gross Profit 105,544,000 109,499,000 302,322,000 262,742,000 Active Pharmaceutical Ingredient Segment Â Â Â Â Net revenues: Â Â Â Â Revenues 1,462,000 4,190,000 6,689,000 11,048,000 Gross profit (loss): Â Â Â Â Gross Profit $ (3,603,000) $ (1,096,000) $ (15,115,000) $ (7,761,000) X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GrossProfitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_FinishedPharmaceuticalProductsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_ActivePharmaceuticalIngredientSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues $ 191,214 $ 180,556 $ 545,444 $ 466,290 Finished Pharmaceutical Products Segment Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 189,752 176,366 538,755 455,242 Finished Pharmaceutical Products Segment | Glucagon Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 40,409 Â 85,106 Â Finished Pharmaceutical Products Segment | Primatene MIST Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 21,341 20,199 75,392 57,004 Finished Pharmaceutical Products Segment | BAQSIMI Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 26,055 24,834 73,077 64,837 Finished Pharmaceutical Products Segment | Epinephrine Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 26,792 29,514 82,700 82,486 Finished Pharmaceutical Products Segment | Lidocaine Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 15,884 15,522 41,457 43,174 Finished Pharmaceutical Products Segment | Phytonadione Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 11,721 7,449 31,998 33,017 Finished Pharmaceutical Products Segment | Enoxaparin Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 5,615 7,702 17,984 25,441 Finished Pharmaceutical Products Segment | Naloxone Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 4,037 4,715 12,124 14,774 Finished Pharmaceutical Products Segment | Other Finished Pharmaceutical Products Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 35,503 37,730 99,309 105,808 Finished Pharmaceutical Products Segment | Total finished pharmaceutical products net revenues Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues 187,357 147,665 519,147 426,541 Finished Pharmaceutical Products Segment | BAQSIMI NEB Â Â Â Â Segment Reporting Information, Revenue for Reportable Segment [Abstract] Â Â Â Â Revenues $ 2,395 $ 28,701 $ 19,608 $ 28,701 X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationRevenueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_FinishedPharmaceuticalProductsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_GlucagonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_PrimatenemistMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_BaqsimiMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_EpinephrineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_LidocaineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_PhytonadioneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_EnoxaparinMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_NaloxoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_OtherFinishedPharmaceuticalProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_FinishedPharmaceuticalProductsNetRevenuesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=amph_BaqsimiNebMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting Information [Line Items] Â Â Â Â Depreciation and amortization expense $ 9,793 $ 9,619 $ 29,131 $ 16,081 Finished Pharmaceutical Products

Segment Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Depreciation and amortization expense 8,755 8,616 26,086 13,143 Active Pharmaceutical Ingredient Segment Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Depreciation and amortization expense $ 1,038 $ 1,003 $ 3,045 $ 2,938 X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_FinishedPharmaceuticalProductsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_ActivePharmaceuticalIngredientSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues $ 191,214 $ 180,556 $ 545,444 $ 466,290 Â Long-Lived Assets 327,518 Â 327,518 Â $ 315,643 UNITED STATES Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues 186,514 178,056 532,591 459,909 Â Long-Lived Assets 187,410 Â 187,410 Â 186,083 CHINA Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues 178 833 2,145 2,142 Â Long-Lived Assets 103,009 Â 103,009 Â 91,913 FRANCE Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues 4,522 $ 1,667 10,708 $ 4,239 Â Long-Lived Assets $ 37,099 Â $ 37,099 Â $ 37,647 X - DefinitionLong-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_NoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CN Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_FR Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Customer and Supplier Concentration (Details) - Customer Concentration Risk [Member] - item 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue, Major Customer [Line Items] Â Â Â Â Â Number of major customers that are wholesale distributors Â Â 3 Â Â Accounts Receivable [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Number of major customers Â Â 4 Â 4 Revenue Benchmark [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Number of major customers 4 4 4 4 Â McKesson [Member] | Accounts Receivable [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage Â Â 29.00% Â 26.00% McKesson [Member] | Revenue Benchmark [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage 26.00% 22.00% 25.00% 25.00% Â Cencora [Member] | Accounts Receivable [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage Â Â 28.00% Â 16.00% Cencora [Member] | Revenue Benchmark [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage 21.00% 17.00% 20.00% 20.00% Â Cardinal Health [Member] | Accounts Receivable [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage Â Â 17.00% Â 13.00% Cardinal Health [Member] | Revenue Benchmark [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage 20.00% 15.00% 20.00% 16.00% Â Lilly [Member] | Accounts Receivable [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage Â Â 2.00% Â 20.00% Lilly [Member] | Revenue Benchmark [Member] Â Â Â Â Â Revenue, Major Customer [Line Items] Â Â Â Â Â Concentration Risk, Percentage 1.00% 16.00% 4.00% 6.00% Â X - DefinitionNumber of major customers. + ReferencesNo definition available. + Details Name: amph_NumberOfMajorCustomers Namespace Prefix: amph_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of major customers that are wholesale distributors of the reporting entity's products. + ReferencesNo definition available. + Details Name: amph_NumberOfMajorCustomersWholesaleDrugDistributors Namespace Prefix: amph_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EntityWideRevenueMajorCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=amph_McKessonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=amph_CencoraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=amph_CardinalHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=amph_EliLillyAndCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Short-term investments $ 26,322 $ 37,142 Total assets measured at fair value 165,513 150,775 Interest Rate Swap [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Interest rate swaps related to variable rate loans (6,881) (5,243) Certificates of Deposit [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Restricted short-term investments 2,200 2,200 Money Market Funds [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents 143,637 116,441 Restricted cash 235 235 Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets measured at fair value 143,872 116,676 Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents 143,637 116,441 Restricted cash 235 235 Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Short-term investments 26,322 37,142 Total assets measured at fair value 21,641 34,099 Fair Value, Inputs, Level 2 [Member] | Interest Rate Swap [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Interest rate swaps related to variable rate loans (6,881) (5,243) Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Restricted short-term investments $ 2,200 $ 2,200 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash and investments whose use in whoīe or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2 + Details Name: us-gaap_RestrictedCashAndInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate value of all restricted investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2 + Details Name: us-gaap_RestrictedInvestmentsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Investments (Held-to-Maturity) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost $ 31,903 $ 89,517 Gross Unrealized Gains 67 64 Gross Unrealized Losses (2) (22) Fair Value 31,968 89,559 Corporate and agency bonds (due within 1 year) Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost 31,903 73,815 Gross Unrealized Gains 67 7 Gross Unrealized Losses (2) (21) Fair Value $ 31,968 73,801 Corporate Bond Securities [Member] Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost Â 14,621 Gross Unrealized Gains Â 56 Gross Unrealized Losses Â (1) Fair Value Â 14,676 Municipal Bonds [Member] Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost Â 1,081 Gross Unrealized Gains Â 1 Fair Value Â $ 1,082 X - DefinitionAmount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14 + Details Name: us-gaap_HeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_HeldToMaturitySecuritiesFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=amph_CorporateBondsShortTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) - USD ($) $ in Thousands 1 Months Ended 9 Months Ended Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2022 Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Weighted-Average Life (Years) Â Â 24 years 24 years Â Finite-Lived Intangible Assets, Gross Â Â $ 594,071 $ 594,364 Â Accumulated Amortization Â Â 31,756 13,510 Â Finite-Lived Intangible Assets, Net Â Â 562,315 580,854 Â Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Â Â Â Â Â Goodwill recognized Â Â 3,256 3,216 $ 3,126 Subtotal, Original Cost Â Â 32,481 32,441 Â Subtotal, Net Book Value Â Â 32,481 32,441 Â Balance, Original Cost Â Â 626,552 626,805 Â Balance, Net Book Value Â Â 594,796 613,295 Â Impairment of Long-Lived Assets to be Disposed of Â $ 2,700 Â Â Â Finished Pharmaceutical Products Segment Â Â Â Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Â Â Â Â Â Goodwill recognized Â Â 3,256 3,216 Â Trademarks [Member] Â Â Â Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Â Â Â Â Â Indefinite-lived intangible assets Â Â $ 29,225 $ 29,225 Â BAQSIMI product rights Â Â Â Â Â Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Weighted-Average Life (Years) Â Â 24 years 24 years Â Finite-Lived Intangible Assets, Gross Â Â $ 591,338 $ 591,338 Â Accumulated Amortization Â Â 30,799 12,319 Â Finite-Lived Intangible Assets, Net Â Â $ 560,539 $ 579,019 Â Patents [Member] Â Â Â Â Â Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Weighted-Average Life (Years) Â Â 15 years 12 years Â Finite-Lived Intangible Assets, Gross Â Â $ 193 $ 486 Â Accumulated Amortization Â Â 92 376 Â Finite-Lived Intangible Assets, Net Â Â $ 101 $ 110 Â Use Rights [Member] Â Â Â Â Â Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Weighted-Average Life (Years) Â Â 39 years 39 years Â Finite-Lived Intangible Assets, Gross Â Â $ 2,540 $ 2,540 Â Accumulated Amortization Â Â 865 815 Â Finite-Lived Intangible Assets, Net Â Â $ 1,675 $ 1,725 Â BAQSIMI product rights Â Â Â Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Â Â Â Â Â Payment to acquire assets $ 129,000 Â Â Â Â X - DefinitionGross amount of indefinite-lived intangible assets and goodwill. + ReferencesNo definition available. + Details Name: amph_IndefiniteLivedIntangibleAssetsIncludingGoodwillGross Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount of indefinite-lived intangible assets and goodwill. + ReferencesNo definition available. + Details Name: amph_IndefiniteLivedIntangibleAssetsIncludingGoodwillNet Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type:

debit Period Type: instant X - DefinitionAmount before accumulated amortization of intangible assets, including goodwill. + ReferencesNo definition available. + Details Name: amph_IntangibleAssetsGrossIncludingGoodwill Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1 + Details Name: us-gaap_IntangibleAssetsNetIncludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=amph_FinishedPharmaceuticalProductsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amph_BaqsimiAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=amph_BaqsimiAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Goodwill and Intangible Assets Â Â Beginning balance $ 3,216 $ 3,126 Goodwill, Translation and Measurement Period Adjustments 40 90 Ending balance $ 3,256 $ 3,216 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Inventories Â Â Â Â Â Inventory, Raw Materials and Supplies, Gross $ 60,536 Â $ 60,536 Â $ 50,082 Inventory, Work in Process, Gross 36,016 Â 36,016 Â 30,822 Inventory, Finished Goods, Gross 33,764 Â 33,764 Â 24,929 Total inventory, net 130,316 Â 130,316 Â $ 105,833 Inventory adjustment to reflect net realizable value $ 900 $ 0 $ 10,100 $ 9,600 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment $ 561,573 $ 528,044 Less accumulated depreciation and amortization (266,189) (245,298) Total property, plant, and equipment, net 295,384 282,746 Building [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment 170,203 168,771 Leasehold Improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment 42,012 41,686 Land [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment 7,499 7,484 Machinery and Equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment 278,200 259,484 Furniture, fixtures, and automobiles Â Â Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment 34,795 31,943 Construction in Progress [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total property, plant, and equipment $ 28,864 $ 18,676 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -

SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=amph_FurnitureFixturesAndVehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accounts Payable and Accrued Liabilities. Â Â Accrued customer fees and rebates $ 59,949 $ 16,702 Accrued payroll and related benefits 29,207 25,203 Accrued product returns, current portion 13,480 12,263 Accrued loss on firm purchase commitments 812 918 Other accrued liabilities 15,732 12,842 Total accrued liabilities 119,180 67,928 Accounts payable 34,088 25,438 Total accounts payable and accrued liabilities $ 153,268 $ 93,366 X - DefinitionAccrued customer fees and rebates + ReferencesNo definition available. + Details Name: amph_AccruedCustomerFeesAndRebates Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued loss on firm purchase commitments + ReferencesNo definition available. + Details Name: amph_AccruedLossOnFirmPurchaseCommitments Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date for estimated refunds due to goods returned by customers (other than under warranty provisions). For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: amph_ProductReturnAccrualCurrent Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 76 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Schedule of Debt) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Unamortized Debt Issuance Expense $ 12,520 $ 13,775 Equipment under Finance Leases $ 485 616 Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term debt, net of current portion and unamortized debt issuance costs Â Total debt $ 609,218 603,790 Less current portion of long-term debt and finance leases 252 436 Long-term debt, net of current portion and unamortized debt issuance costs 596,446 589,579 2029 Convertible Notes Â Â Debt Instrument [Line Items] Â Â Long-Term Debt 345,000 345,000 Unamortized Debt Issuance Expense 8,800 Â Line of Credit - Due October 2026 | China Merchant Bank | Line of Credit [Member] Â Â Debt Instrument [Line Items] Â Â Long-Term Debt 0 0 Term Loan - Due June 2028 | Wells Fargo Bank Â Â Debt Instrument [Line Items] Â Â Long-Term Debt 250,000 250,000 Mortgage Payable - Paid off June 2024 | East West Bank [Member] Â Â Debt Instrument [Line Items] Â Â Long-Term Debt Â 8,016 French Government Loan 4 - Due December 2026 | Seine-Normandie Water Agency [Member] Â Â Debt Instrument [Line Items] Â Â Long-Term Debt 168 158 Revolving line of credit - closed in June 2023 | Capital One, N.A. | Revolving Credit Facility [Member] Â Â Debt Instrument [Line Items] Â Â Long-Term Debt $ 0 $ 0 X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes noncurrent finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term

debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap_UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=amph_TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_LineOfCreditDueAugust2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=amph_ChinaMerchantBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_TermLoanDueJune2028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=amph_WellsFargoBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_MortgagePayableDueJune2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=amph_EastWestBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_FrenchGovernmentLoan4DueDecember2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=amph_SeineNormandieWaterAgencyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_RevlovingLineOfCreditDueAugust2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=amph_CapitalOneNationalAssociationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Narrative) (Details) 1 Months Ended 3 Months Ended 9 Months Ended Sep. 12, 2023 $ / shares Sep. 30, 2023 USD ($) D $ / shares Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) $ / shares Jan. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Debt Â Â Â Â Â Â Â Â Payments for repurchase of common stock Â Â Â Â $ 43,456,000 $ 58,144,000 Â Â Proceeds from Lines of Credit Â Â Â Â 13,565,000 Â Â Â Unamortized debt issuance costs Â Â $ 12,520,000 Â 12,520,000 Â Â $ 13,775,000 Amortization of discounts, premium, and debt issuance costs Â Â Â Â 5,308,000 8,486,000 Â Â Interest Rate Swap [Member] Â Â Â Â Â Â Â Â Debt Â Â Â Â Â Â Â Â Gains (losses) from changes in fair values of interest rate swaps Â Â (7,400,000) $ 4,900,000 (1,600,000) $ 2,700,000 Â Â 2029 Convertible Notes Â Â Â Â Â Â Â Â Debt Â Â Â Â Â Â Â Â Debt interest rate Â 2.00% Â 2.00% Â 2.00% Â Â Principal amount Â $ 345,000,000.0 Â $ 345,000,000.0 Â $ 345,000,000.0 Â Â Repayment of debt Â 200,000,000.0 Â Â Â Â Â Â Payments for repurchase of common stock Â 50,000,000.0 Â Â Â Â Â Â Debt issuance costs Â $ 10,800,000 Â 10,800,000 Â 10,800,000 Â Â Debt conversion ratio Â 15.8821 Â Â Â Â Â Â Debt principle amount converted into common stock Â $ 1,000 Â $ 1,000 Â $ 1,000 Â Â Debt conversion price per share | $ / shares $ 62.96 $ 62.96 Â $ 62.96 Â $ 62.96 Â Â Convertible debt, percentage of premium over the last reported sale price 35.00% Â Â Â Â Â Â Â Convertible debt threshold percentage Â 130.00% Â Â Â Â Â Â Convertible debt, threshold trading days | D Â 20 Â Â Â Â Â Â Convertible debt, threshold consecutive trading days | D Â 30 Â Â Â Â Â Â Threshold business days after consecutive trading period | D Â 5 Â Â Â Â Â Â Threshold consecutive trading period | D Â 5 Â Â Â Â Â Â Percentage of principal amount redeemed Â 100.00% Â Â Â Â Â Â Percentage of product sale price Â 98.00% Â Â Â Â Â Â Debt Instrument, Fair Value Disclosure Â Â 365,400,000 Â 365,400,000 Â Â Â Unamortized debt issuance costs Â Â 8,800,000 Â 8,800,000 Â Â Â Line of Credit [Member] | Line of Credit Due November 2033 | ICBC Bank Â Â Â Â Â Â Â Â Debt Â Â Â Â Â Â Â Â Debt issuance costs Â Â 800,000 Â 800,000 Â Â Â Proceeds from Lines of Credit Â Â Â Â $ 13,600,000 Â Â Â Prime rate discount percentage Â Â Â Â 0.20% Â Â Â Maximum borrowing capacity Â Â Â Â Â Â $ 40,000,000.0 Â Borrowings Â Â $ 13,600,000 Â $ 13,600,000 Â Â Â X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: amph_DebtInstrumentBasisSpreadDiscountOnVariableRate Namespace Prefix: amph_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of premium over the last reported sale price in a convertible debt instrument. + ReferencesNo definition available. + Details Name: amph_DebtInstrumentConvertiblePremiumPercentageOverLastReportedSalePricePercent Namespace Prefix: amph_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of business days after consecutive trading days that trading price is less than the product of threshold sale price of the common stock and the conversion rate on each trading day to trigger conversion feature. + ReferencesNo definition available. + Details Name: amph_DebtInstrumentConvertibleThresholdBusinessDaysAfterConsecutiveTradingPeriod Namespace Prefix: amph_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which trading price is less than the product of threshold sale price of the common stock and the conversion rate on each trading day to trigger conversion feature. + ReferencesNo definition available. + Details Name: amph_DebtInstrumentConvertibleThresholdConsecutiveTradingPeriod Namespace Prefix: amph_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the trading price as a maximum percentage of product of sale price of common stock and conversion rate on each trading day to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: amph_DebtInstrumentConvertibleThresholdTradingPriceAsPercentageOfProductOfSalePriceOfCommonStockAndConversionRate Namespace Prefix: amph_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the denomination of the principal amount of debt that is used in conversion calculations. + ReferencesNo definition available. + Details Name: amph_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of net gains (losses) from changes in fair value of interest rate cash flow hedges. + ReferencesNo definition available. + Details Name: amph_GainLossFromChangeInFairValueOfInterestRateCashFlowHedges Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of principal amount of debt redeemed. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of the amount outstanding under the credit facility. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfSeniorDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap_UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amph_LineOfCreditDueNovember2033Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=amph_ICBCBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Summary of Income (Loss) Before Income Taxes) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income (loss) before income taxes: Â Â Â Â Income (loss) before income taxes $ 47,683 $ 63,637 $ 145,802 $ 130,014 Income tax provision 7,254 14,025 23,674 27,160 Income before equity in losses of unconsolidated affiliate $ 40,429 $ 49,612 $ 122,128 $ 102,854 Income tax provision as a percentage of income before income taxes 15.20% 22.00% 16.20% 20.90% X - DefinitionAmount after tax of income (loss) from continuing operations. + ReferencesNo definition available. + Details Name: amph_IncomeLossFromContinuingOperationsAfterIncomeTaxes Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 79 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Share Buyback Program) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Nov. 04, 2024 Jun. 03, 2024 Equity, Class of Treasury Stock [Line Items] Â Â Â Â Â

Â Â Â Â Treasury Stock, Value, Acquired, Cost Method $ 34,958 $ 8,498 $ 50,000 $ 129 $ 8,015 Â Â Â Â November 2014 Share Repurchase Plan Â Â Â Â Â Â Â Â Â Equity, Class of Treasury Stock [Line Items] Â Â Â Â Â Â Â Â Â Stock buyback program, authorized amount Â Â Â Â Â Â Â $ 385,000 Â Increase authorized for share buyback program Â Â Â Â Â Â Â Â $ 50,000 Treasury Stock, Shares, Acquired 797,038 Â 1,072,041 Â Â 1,004,326 1,338,757 Â Â Treasury Stock, Value, Acquired, Cost Method $ 35,000 Â $ 50,000 Â Â $ 43,500 $ 58,100 Â Â Subsequent Event [Member] | November 2014 Share Repurchase Plan Â Â Â Â Â Â Â Â Â Equity, Class of Treasury Stock [Line Items] Â Â Â Â Â Â Â Â Â Increase authorized for share buyback program Â Â Â Â Â Â Â Â $ 50,000 Â X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EquityClassOfTreasuryStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ShareRepurchaseProgramAxis=amph_November2014ShareRepurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) Sep. 30, 2024 shares The 2015 Equity Incentive Plan [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized 7,817,319 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=amph_The2015EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended May 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Share-Based Payment Arrangement, Expense Â $ 5,596 $ 4,644 $ 18,736 $ 15,620 2014 Employee Stock Purchase Plan [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Stock Issued During Period, Shares, Employee Stock Purchase Plans 54,189 Â Â 1,246,323 Â Weighted-Average Purchase Price (In Dollars per Share) $ 35.98 Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Â 753,677 Â 753,677 Â Share-Based Payment Arrangement, Expense Â $ 200 $ 200 $ 900 $ 800 X - DefinitionWeighted average purchase price of shares purchased through an employee stock purchase plan. + ReferencesNo definition available. + Details Name: amph_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased Namespace Prefix: amph_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=amph_EmployeeStockPurchasePlan2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stockholders' Equity Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Â 40.20% 41.30% 41.40% Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Â 4.40% 4.20% 4.10% Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 0 years 6 years 3 months 18 days 6 years 2 months 12 days 6 years 2 months 12 days Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00% 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 83 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Summary of Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Options Â Â Â Â Outstanding Options, Beginning of period Â Â 7,762,298 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Â Â 642,985 Â Options exercised Â Â (1,611,117) Â Options forfeited Â Â (21,138) Â Outstanding Options, End of period 6,773,028 Â 6,773,028 Â Exercisable at the end of period 4,968,365 Â 4,968,365 Â Vested and expected to vest, at the end of period 6,617,113 Â 6,617,113 Â Weighted-Average Exercise Price Â Â Â Â Outstanding Exercise Price (in dollars per share) Â Â $ 19.70 Â Options granted (in dollars per share) Â Â 46.27 Â Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Â Â 13.66 Â Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Â Â 35.10 Â Outstanding Exercise Price (in dollars per share) $ 23.61 Â 23.61 Â Exercisable at the end of period (in dollars per share) 19.02 Â 19.02 Â Vested and expected to vest at end of period (in dollars per share) $ 23.24 Â $ 23.24 Â Additional Disclosures Â Â Â Â Contractual term Â Â 5 years 1 month 13 days Â Outstanding Intrinsic Value $ 168,760 Â $ 168,760 Â Exercisable remaining contractual term (in Years) Â Â 3 years 11 months 19 days Â Exercisable aggregate intrinsic value 146,600 Â $ 146,600 Â Share-Based Payment Arrangement, Expense 5,596 $ 4,644 18,736 $ 15,620 Vested and expected to vest aggregate intrinsic value 167,346 Â $ 167,346 Â Vested and expected to vest weighted average remaining contractual term Â Â 5 years 14 days Â Employee Stock Option Â Â Â Â Additional Disclosures Â Â Â Â Share-Based Payment Arrangement, Expense $ 2,700 $ 2,200 $ 9,000 $ 7,500 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 - SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stockholders' Equity Â Â Â Â Weighted-average grant date fair value (in Dollars per share) Â $ 21.49 $ 21.89 $ 16.76 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value $ 6,218 $ 5,628 $ 48,381 $ 24,544 Cash received from options exercised 3,332 2,277 9,154 12,015 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value $ 111 $ 167 $ 9,815 $ 8,887 X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 85 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Summary of Nonvested Options) (Details) - USD ($) $ / shares in Units, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Options Â Â Â Nonvested at beginning of period Â 2,076,355 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Â 642,985 Â Options vested Â (893,539) Â Options forfeited Â (21,138) Â Nonvested at end of period Â 1,804,663 Â Weighted-Average Grant Date Fair Value Â Â Â Nonvested at beginning of period (in dollars per share) Â $ 12.68 Â Options granted (in dollars per share) $ 21.49 21.89 $ 16.76 Options vested (in dollars per share) Â 10.98 Â Options forfeited (in dollars per share) Â 16.19 Â Nonvested at end of period (in dollars per share) Â $ 16.76 Â Employee Stock Options [Member] Â Â Â Weighted-Average Grant Date Fair Value Â Â Â Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Â $ 21.3 Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Â 2 years 7 months 6 days Â X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=amph_EmployeeConsultantAndDirectorsStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Restricted Stock Units) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Payment Arrangement, Expense $ 5,596 $ 4,644 $ 18,736 $ 15,620 Restricted Stock Units (RSUs) [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Â Â 4 years Â Share-Based Payment Arrangement, Expense $ 2,700 $ 2,200 $ 8,800 $ 7,300 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Â Â 2 years 7 months 6 days Â Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares) 1 Â 1 Â Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $ 22,600 Â $ 22,600 Â X - DefinitionRepresents the number of common shares the grantee is to receive at a specified future date for each Restricted Stock Unit ("RSU") awarded. + ReferencesNo definition available. + Details Name: amph_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsNumberOfSharesOfCommonStockPerAward Namespace Prefix: amph_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) shares Restricted Stock Units (RSUs) [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Total RSUs outstanding at the beginning of the period 920,376 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period 303,788 RSUs forfeited (9,620) RSUs vested (388,668) Total RSUs outstanding at the end of the period 825,876 Stock surrendered to fulfill tax withholding obligations 147,959 Restricted Stock Units Issued as Compensation [Member] Â Total Fair Market Value of RSUs Issued Â RSUs granted (in Dollars) | $ $ 14,060 X - DefinitionFair value of share-based awards granted during the period. + ReferencesNo definition available. + Details Name: amph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue Namespace Prefix: amph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=amph_RestrictedStockUnitsIssuedAsCompensationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Payment Arrangement, Expense $ 5,596 $ 4,644 $ 18,736 $ 15,620 Cost of Sales [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Payment Arrangement, Expense 1,133 1,004 4,583 3,868 Selling and Marketing Expense [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Payment Arrangement, Expense 249 213 777 649 General and Administrative Expense [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Payment Arrangement, Expense 3,710 2,975 11,239 9,323 Research and Development Expense [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-Based Payment Arrangement, Expense $ 504 $ 452 $ 2,137 $ 1,780 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R77.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefits (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Employee Benefits Â Â Â Â Â Defined Contribution Plan, Employer Matching Contribution, Percent of Match Â Â 50.00% Â Â Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Â Â 6.00% Â Â Defined Contribution Plan, Cost $ 0.6 $ 0.5 $ 2.0 $ 1.7 Â Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate 3.25% Â 3.25% Â 3.25% Defined Benefit Plan, Benefit Obligation $ 2.8 Â $ 2.8 Â $ 2.6 Pension Cost 0.0 $ 0.0 0.0 $ 0.0 Â Deferred compensation plan assets 9.4 Â 9.4 Â 6.8 Deferred compensation

plan liabilities $ 9.8 Â $ 9.8 Â $ 7.1 X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of assets held under deferred compensation agreements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredCompensationPlanAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (k)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_DefinedBenefitPlanBenefitObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cost for defined contribution plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanCostRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_PensionExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 90 R78.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Purchase Commitments) (Details) $ in Millions 3 Months Ended Sep. 30, 2024 USD ($) Commitments to Purchase Equipment and Raw Materials [Member] Â Purchase Commitment, Excluding Long-Term Commitment [Line Items] Â Long-Term Purchase Commitment, Amount $ 95.9 X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=amph_CommitmentsToPurchaseEquipmentAndRawMaterialsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Related-Party Transactions (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Nov. 30, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Related Party Transaction [Line Items] Â Â Â Â Â Â Revenues Â $ 191,214 $ 180,556 $ 545,444 $ 466,290 Hanxin Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Payment to related party Â 0 400 200 1,000 Other Liabilities, Current Â 0 Â $ 0 Â Ownership after transaction Â Â Â Â 11.50% Â Letop Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Payment to related party Â Â 0 $ 0 700 Other Liabilities, Current Â 0 Â 0 Â Related Party Transaction, Amounts of Transaction $ 1,500 Â Â Â Â ANP | Hanxin Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Revenues Â 100 $ 0 500 $ 0 Receivables from Hanxin Â $ 400 Â $ 400 Â X - DefinitionPercentage of ownership in investment after spin-off transaction. + ReferencesNo definition available. + Details Name: amph_OwnershipPercentageAfterSpinoffTransaction Namespace Prefix: amph_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount due from parties in nontrade transactions, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPurchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amph_NanjingLetopMedicalTechnologyCo.Ltd.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=amph_AnpMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 92 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Litigation (Details) - Pending Litigation [Member] - Property and Casualty Claim $ in Millions Sep. 30, 2024 USD ($) Loss Contingencies [Line Items] Â Estimated Litigation Liability $ 6.0 Prepaid Expense and Other Assets $ 6.0 X - DefinitionAggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting

Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. + ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=amph_PropertyAndCasualtyClaimMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 93 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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{C/+_ 5!+ P04 " !3@F=9U9^U MJ_X* 8"@ & 'AL+W=OKBA[Y#& 0$]9FO.1%@M1G.HZ#V/("._1 G)Y94Y91FO.1%@M1G.HZ#V/("._1 G)Y94Y9FO.1%@M1G.HZ#V/("._1 G)Y94Y9FO.1%@M1G.HZ#V/("._1 G)Y94Y9

O\/KG[Z^977O^MW]W6TKFDT:N/&PSOOW%[+8R(A>19?UC1&S(L^XK@<6<;Y8V,KBXYA&E=YL*E(BJ=[\T9+# MK4VS=O J!NR3ZBMJH@, MNSB() \6DL9,1\ULX]W&>18LV ^KZ"O,J_8U" 823N5"P!,$S)E9[)8T*I@! MSY;&$$%(14O8/)T]>R.[!D.1#E9HAR+4280\Y>19XGX0'0[$A"P2#/QOFFDM M)$F3 V-#;2""^RI9ZRU"8;\)PE6JTDMF>4/AH5EY8]1:$K]=C$>D*,(D>PY! MI"A]HVVEYQ6]@HMCTT@OT&D#',A\];/HBV/CV8[PJ;LU*)81"6&9=D52&0:7 M0GO/$KS1,!V::3V=14.[?\_J+RYKCA,,,(+XT9ZF%F2:\\M.0(,GU,BIP$\ M-!H9 "9A7=D)>"_6YF:?=-:OON\'M$*)W(D-E? A;1%T8 J#'H'X=F.2; -UB MIV&@)VT^GW);C2_0PR0$APT2[!D0&O)&:;3,<&R"u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|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Ÿ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} [ZLP?$3X%.X5M+F!C[(M%--]_(<:;V)=]Y>%X72EO)%<6O8XWR1--O&2Z"/C MNEU<*6/A$XT_[^1433PG8D*#XP=<4G9595A,C7'!-.ETHSJ2&N@^2>3+2P5 M?8.CE. ;;G-"1+!%!H];+;_ ,J=AL..8'+261S%# =.IO!562;VRDPEI6:@ MXV:Q6*)NS]R_L_-?U?K5N3L9]J;1N"O8"REZN#>,_KDMJV#H#9KC X>C46\2 M1P?B\>2P2Z+'T2<3N*XD3WA)E7PYU!;;"Z>'=@\E?A;$AYEV^/C)_GF/2=,^ MD6^?;K=,3WOCJO>R6@OUXWO]XS:/3^ /I05D24Z7?ND.*(VQ$C57::\[O@#7 M=,ZH, 8,)FXJ<7HEF@* M.Q@2.MU]/U,?FDV]EHIN/BVVSL=$8\HM_*QH6MBM;Y=&1.U#&TQKV9@*M>D! M3\DZSSQ:(E624DG3FJ\D#=Z$D6Y4T 4QG"9()253G(B(BI5N>1\L", M"([2S03?]$]D%&)*:ESK$F5PBJB*C4N"1E5_[\[8Q5<@,Q7==X!W)5$G3+L0 M$I,?#V^#O=9P5(O2)CSO6J/C3)Q,70CQZ.7SK*X-NIM($06D++N,*UA2 24E M02E1UX4V"=+_V^]SD6>'$I#0E0_AO9*3FLRZK/F'NGDS_)+Y%5KRB2FO7 M&J2"%-(VXPM*5X%1DBU%/0Y,5;H.J6M"8<(,463X\+K,^6BELO?%HGA=SIP3 MQ(-]. TQJC!$]] V5<,IFX?<:2P"MI:_H811ET>&*!>N79L$M3)6U-&5MI2[@O M:IYYO[UFZ]=,K]R\)S C:-@_&0>@:P9<+ZPJ/>M<*DL3&[QN=3F72"#:_M]K?V]@IEBE3>"GXERS5BX'3=2#%&2NY_BA6 M/^FGMCH2P17]A=6:]Z0+":ETB+?"-,\SXKUR+YN\M 0Z'I/" 0;@<#ZO39D MO;QBF@W[4JQ &F[29CYLJ%::G,L*4Y2)EK2:D9P>?B]$NLHX!U:D<%UH5LRS M*4<8*85:]5N:;!C.5K+1-U[K"Y[0UX,;4>B%@N^*%--=^1;Y5CD8;!T#9#%X3,YEQ!."1":>+BGSDC-B!)8+}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

H\'J&DUSS)^K:@OH34O(TR6%! M$2NS#-.G"TC)=]J9VN["=;*.N;R@^Y,"KV$)_+984+'3&Y;>335#)D0I!!RZ8#%UP8N(4VED4CCH?;4 MFI^4POWUSOV3JEW4*J--!3!"I:PY[=%X06+7 >JW K@7V:P5.+7 4F:H4Q2' M'/L32K:(RFCA)A<*IE*+\|-<_NU+3L7=1.BX?S'[MIQ?S=$L?"@3EJC_XG11 MTC 6,-&")B&@69J2$'.($"=5(!7K&6/ V3MT&@#'22I6[J'M,D"G)^_0"4IR M=!.3DN$\8A.=BTSE[^EAG=5%E97U0E9+* ;(-LZ095A.B_RR6QY *.2FDMLM M\]!;/BOH %FMF9WQH8]6G6="3V0%'N^%H=[G["RI..\J?SM BQ3E' MXME"'P740AQ#_ Q]!=[&LO+TE* <\!#>^-7;MD7BL-ON46L)&UM#Q#L."S@$_ ML7ZGJ= IK`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Ü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{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}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{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{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ˆˆˆ

E9JSSO/%*;@%=CVNI&LKR<=#XRJ8[>\G)+\(IP M':"^7S,FGV_T\+09EB_^!5!+ P04 " !3@F=93*>X$3 # #_"0 &0 M 'AL+W=O+!E+8#DK:AD-G:84$+.?6N7MVZ3I&T$;Ii+"2&]?(E++@_-$,ON9SRS%$P"!3)@71 M?T]P"8R93)KC=Y_4&M8TPLWK=?;/?&ZF 61<,G9+YJK8F[%%LIA21JF;OCJ M"_0%!29?QIEL?]&JBXU"'"V6-5+SLQ9J@I%7W3YY[(S8$KK]'@'L!/E3@]0*O M+;0C:\NZ(HJD,\%72)AHG@"&7R_J([F^OT/'1!W2$:(7N"MY(K9(S M6VD@D];.^L4ONL7QGL5OH3Y%GG."L(/]"?GEV_(KR+3<;>7>MMS6-@Q>X,$+MW.;S_M&+TZE*N]3^=&KS,I()FF0PM_3;)D$\@96^?^>&SJ>INO]3LBT7O,$% M[ZWLZ;K@;O.!0$O0C]]8(6!!%$P^YRYEV*8TG>,I#9+$3V;VTV99XR@WC!P\ M1&WQ^@.O?Q!O35X$9ZPG99HT1PNH8$G5)'*7-=B P0EVHAWDB:@ .JXT"P&50C47ILE-80R(*XW /=CA@AP=A M,RXETBUX246)ZD9DA>ZC*.-E297N\--VAR.BV,4[U..8Q(VGF:.!.7J3^8+N5$%([]/;LX'CCC-SGON"+L4,YX3.!JIW8WP3@L MC!*\Q]!D $W^M@FZ)EEW37**+QDM[/E.'._@C:-PX'M[\%SG]8/F'.;D%F;; M%@ZTMU]@JT\%'@YW"YB(2SPO#'^SN9H])V(!UI)Q&"I=MQ_L!5>Z [>7A3ZA@3 !^OZ2<[4>F#/ <.9+_P!02P,$% @ 4X)G M6?CZS^M !0 T1H !D !X;"]W;W)K&ULQ5E= M;]LV%/TKA%<,+9#$^K:=.08:.^DZ)&E0M\M#L =:HFVB$NF2E),,^_&[E!7)MLF0F[E3L)9'D>X_NN3HDCZCA Q??Y)(0A1Z3F,FSSE*IU6FW*\,E2; \X2O" MX)H;<3 MHC"-Y3MTC+Y.)^CMFW?H#:(,?5GR5&(6R6%7P?TU2C?,[W6^N9>SYUY3LCI!MKG6$',OQ&M+'YO0)"2'=SM+=:GH76!?4G8*ZD^&Y)NH?F50B!5TJ=\% >BC M(HG\JXG)!%KTAG]^HL=6+\U46T)K$+<+8B[)O31 M5X83+A3]FT1HTP0I4\Q"@BX>87J0I(G]!C+((/7'U_9U2-S'^5DJ@ M!\V%^D6AOK'02F%'Z(KB&8VI>CI"-YR%J1# X0A-%0:--3HPVC8I%,?HEDN: MS6SW%X]*SY,S&(\7#+0IL+[>]$ES/5><+8X5$0E,;#.X,R/9/?-*T$J+0$^E M+(+.EIK0P8@^:R+D4C4U>6R\]P]*."@Z'1B9?>$*6J8+;>I*4'O\@35P[/Z. M H*Z BRW-[":1= K2NN9FTZDK+48NAY7'D;6]'FNEWBOD'NU$F'0[=" HQWCN M'B'W"P[]_T\XY_U:P?X@\+Q@AU=#6' @]P;-U 8%M8&1&BP> S3F;$V@:#"4*W$ M;KAJ[KT1Y]#YOB6P"F7;=B+KB7M;;%7R6P['?E2G,7[28)WOFBQQ@ M6VJNYUO6[NKV(S6,AA+ ;H'S1>PCR(KHD(EQC5+8[9-[BZDWE_31+(:9:K ML8:#Y=H26K5CI=FQO7;'JM$\'4R^);0J^=) V:]P+..:QZM=47Y.*:1:6.DW M[!<,AZ[IBF.62_B/%!X*Z+/,260?WRC=_Y81 FZ@W=P@=XO .3)*'QS&0X,:=T8X[;MKO!;-59MH57)E\;*,6\CO4+X]3TA.]C=-6@*\OM[Y%P:'\=L?#Z3-8_7E"U0 MG/O>\-DQAS&7\%Y 63%WN]HTXQ75>R"?&#E"-R?O3^!:"9*;YDL<9AM09H6W MM)&3M^=G;LYI4]S@G85WJHO:PNM2K[T9&PO=V]R M-W-H965TL%*\S1 'Q3;G;%T')?'8 M,HS9.&%1.KJ^K#^[S:\OLUT91RF_S4FQ2Q*6_UCQ.'N^&IFCEP^^1(:;LOI@ M?'VY98 ,lCI=?M[>Y»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

Z8LSL ?,=T0]>RELE935 M&ZK]@1?'2L6-9&E^#+)F4K(XO]P#W@#/,JCOMXS)TTTF4!WNS?\#4$L#!!0 M (%."9UEK^1+\=0(-0% 9 >&PO=V]R:W-H965T:IFBOKA2U*3CD*3:4 A:MQ<-_GHQ$>96&4O:4V MSZ13R3DUMLM& Q$Y3*4P5!0H,HH:3N>URDHK&CIQ9W!ZBX909JT3H)FE#'; M89V$QC)RN&&VJSYIJL?O5!_ S-8K-=R)'/._\T.KI)43[^5,XJ. "ZQZ,(C. M(8[B(3PM;N'TY.P([J!MT\#C#O^A349"VY:[UYI6[M@W[Y%L8$8,*DJ8AN<9 M\B6J7X?:E=1Y]=/PG676MB9-(ZJ\/M0^9*-/7GK8KZZ:9U+?P M9M_- B"JHT,!P95.CWJ6EHYH=TCA&5GYNE]+8+>#-TJY=5[P@ 9 WJ^D-'O'%6@7 M>?H'4$L#!!0 (%."9UD] #VYLP0 $P@ 9 >&PO=V]R:W-H965T MLK2 M7 RMA93+*]L6TP7-B#AG2YJK;^:,9T2J7? YHBR6G9%:*LM1V'2>P,Y+DUFA0 M'IOPT8*M9)KD=,*16&49X<\W-&6;H86MEP-WR>-"%@?LT6!)'ND]E=^7$Z[V M[(8R2S*:BX3EB-/YT+K&5S'N%X(RXH^$;L3.- BHNY8&Q\7.Y]G0:CFF:%B1U'O_44*O)60AWMU_H<7GQZF(>B*!CEOZ9S.1B:/4M-*-S MLDKE'=M\HO4%^05ORE)1_D6;*C9P+31="U@EXMZ.T+O","KQ9XK\W@UP+_M1F"6A"4M:^*558Z))*,!IQM$"^B%:W8 M*.TJU:K 25[<6?>2JV\3I9.C.YH2265R(5"4S^A, MHQ^;];U3^LBLOS3H;56ZIG[N2_UN7"/P*UN?HYYSAES'=7778Y;?TV4C]S3R M\/7RGJX:_R]|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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w) {if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref) {e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 95 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #cf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html3443601false910false7 falsefalseR1.htm995200090 - Document - Document And Entity InformationSheethttp://www.amphastar.com/role/DocumentDocumentAndEntityInformationDocument And Entity InformationCover1 falsefalseR2.htm995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsCONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperationsCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSStatements4 falsefalseR5.htm995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMESheethttp://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEStatements5 falsefalseR6.htm995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYSheethttp://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYStatements6 falsefalseR7.htm995200500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements7 falsefalseR8.htm995210101 - Disclosure - GeneralSheethttp://www.amphastar.com/role/DisclosureGeneralGeneralNotes8 falsefalseR9.htm995210201 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes9 falsefalseR10.htm995210301 - Disclosure - BAQSIMI AcquisitionSheethttp://www.amphastar.com/role/DisclosureBaqsimiAcquisitionBAQSIMI AcquisitionNotes10 falsefalseR11.htm995210401 - Disclosure - Revenue RecognitionSheethttp://www.amphastar.com/role/DisclosureRevenueRecognitionRevenue RecognitionNotes11 falsefalseR12.htm995210501 - Disclosure - Net Income per ShareSheethttp://www.amphastar.com/role/DisclosureNetIncomePerShareNet Income per ShareNotes12 falsefalseR13.htm995210601 - Disclosure - Segment ReportingSheethttp://www.amphastar.com/role/DisclosureSegmentReportingSegment ReportingNotes13 falsefalseR14.htm995210701 - Disclosure - Customer and Supplier ConcentrationSheethttp://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationCustomer and Supplier ConcentrationNotes14 falsefalseR15.htm995210801 - Disclosure - Fair Value MeasurementsSheethttp://www.amphastar.com/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes15 falsefalseR16.htm995210901 - Disclosure - InvestmentsSheethttp://www.amphastar.com/role/DisclosureInvestmentsInvestmentsNotes16 falsefalseR17.htm995211001 - Disclosure - Goodwill and Intangible AssetsSheethttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwill and Intangible AssetsNotes17 falsefalseR18.htm995211101 - Disclosure - InventoriesSheethttp://www.amphastar.com/role/DisclosureInventoriesInventoriesNotes18 falsefalseR19.htm995211201 - Disclosure - Property, Plant, and EquipmentSheethttp://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentProperty, Plant, and EquipmentNotes19 falsefalseR20.htm995211301 - Disclosure - Accounts Payable and Accrued LiabilitiesSheethttp://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccounts Payable and Accrued LiabilitiesNotes20 falsefalseR21.htm995211401 - Disclosure - DebtSheethttp://www.amphastar.com/role/DisclosureDebtDebtNotes21 falsefalseR22.htm995211501 - Disclosure - Income TaxesSheethttp://www.amphastar.com/role/DisclosureIncomeTaxesIncome TaxesNotes22 falsefalseR23.htm995211601 - Disclosure - Stockholders' EquitySheethttp://www.amphastar.com/role/DisclosureStockholdersEquityStockholders' EquityNotes23 falsefalseR24.htm995211701 - Disclosure - Employee BenefitsSheethttp://www.amphastar.com/role/DisclosureEmployeeBenefitsEmployee BenefitsNotes24 falsefalseR25.htm995211801 - Disclosure - Commitments and ContingenciesSheethttp://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes25 falsefalseR26.htm995211901 - Disclosure - Related-Party TransactionsSheethttp://www.amphastar.com/role/DisclosureRelatedPartyTransactionsRelated-Party TransactionsNotes26 falsefalseR27.htm995212001 - Disclosure - LitigationSheethttp://www.amphastar.com/role/DisclosureLitigationLitigationNotes27 falsefalseR28.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes28 falsefalseR29.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes29 falsefalseR30.htm99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies30 falsefalseR31.htm99930303 - Disclosure - BAQSIMI Acquisition (Tables)Sheethttp://www.amphastar.com/role/DisclosureBaqsimiAcquisitionTablesBAQSIMI Acquisition (Tables)Tableshttp://www.amphastar.com/role/DisclosureBaqsimiAcquisition31 falsefalseR32.htm99930403 - Disclosure - Revenue Recognition (Tables)Sheethttp://www.amphastar.com/role/DisclosureRevenueRecognitionTablesRevenue Recognition (Tables)Tableshttp://www.amphastar.com/role/DisclosureRevenueRecognition32 falsefalseR33.htm99930503 - Disclosure - Net Income per Share (Tables)Sheethttp://www.amphastar.com/role/DisclosureNetIncomePerShareTablesNet Income per Share (Tables)Tableshttp://www.amphastar.com/role/DisclosureNetIncomePerShare33 falsefalseR34.htm99930603 - Disclosure - Segment Reporting (Tables)Sheethttp://www.amphastar.com/role/DisclosureSegmentReportingTablesSegment Reporting (Tables)Tableshttp://www.amphastar.com/role/DisclosureSegmentReporting34 falsefalseR35.htm99930703 - Disclosure - Customer and Supplier Concentration (Tables)Sheethttp://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTablesCustomer and Supplier Concentration

(Tables)Tableshttp://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration35 falsefalseR36.htm99930803 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.amphastar.com/role/DisclosureFairValueMeasurementsTablesFair Value Measurements
(Tables)Tableshttp://www.amphastar.com/role/DisclosureFairValueMeasurements36 falsefalseR37.htm99930903 - Disclosure - Investments (Tables)Sheethttp://www.amphastar.com/role/DisclosureInvestmentsTablesInvestments (Tables)Tableshttp://www.amphastar.com/role/DisclosureInvestments37 falsefalseR38.htm99931003 - Disclosure - Goodwill and Intangible Assets (Tables)Sheethttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTablesGoodwill and Intangible Assets (Tables)Tableshttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets38 falsefalseR39.htm99931103 - Disclosure - Inventories (Tables)Sheethttp://www.amphastar.com/role/DisclosureInventoriesTablesInventories (Tables)Tableshttp://www.amphastar.com/role/DisclosureInventories39 falsefalseR40.htm99931203 - Disclosure - Property, Plant, and Equipment (Tables)Sheethttp://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTablesProperty, Plant, and Equipment (Tables)Tableshttp://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment40 falsefalseR41.htm99931303 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)Sheethttp://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTablesAccounts Payable and Accrued Liabilities (Tables)Tableshttp://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities41 falsefalseR42.htm99931403 - Disclosure - Debt (Tables)Sheethttp://www.amphastar.com/role/DisclosureDebtTablesDebt (Tables)Tableshttp://www.amphastar.com/role/DisclosureDebt42 falsefalseR43.htm99931503 - Disclosure - Income Taxes (Tables)Sheethttp://www.amphastar.com/role/DisclosureIncomeTaxesTablesIncome Taxes (Tables)Tableshttp://www.amphastar.com/role/DisclosureIncomeTaxes43 falsefalseR44.htm99931603 - Disclosure - Stockholders' Equity (Tables)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityTablesStockholders' Equity (Tables)Tableshttp://www.amphastar.com/role/DisclosureStockholdersEquity44 falsefalseR45.htm99940201 - Disclosure - Summary of Significant Accounting Policies (Details)Sheethttp://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsSummary of Significant Accounting Policies (Details)Detailshttp://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies45 falsefalseR46.htm99940301 - Disclosure - BAQSIMI Acquisition (Narrative) (Details)Sheethttp://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetailsBAQSIMI Acquisition (Narrative)
(Details)Detailshttp://www.amphastar.com/role/DisclosureBaqsimiAcquisitionTables46 falsefalseR47.htm99940302 - Disclosure - BAQSIMI Acquisition (Purchase Price Allocated to Acquired Assets) (Details)Sheethttp://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetailsBAQSIMI Acquisition (Purchase Price Allocated to Acquired Assets) (Details)Detailshttp://www.amphastar.com/role/DisclosureBaqsimiAcquisitionTables47 falsefalseR48.htm99940401 - Disclosure - Revenue Recognition (Analysis of the Chargeback Provision) (Details)Sheethttp://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetailsRevenue Recognition (Analysis of the Chargeback Provision) (Details)Detailshttp://www.amphastar.com/role/DisclosureRevenueRecognitionTables48 falsefalseR49.htm99940402 - Disclosure - Revenue Recognition (Chargebacks and Rebates Balance Sheet Accounts) (Details)Sheethttp://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetailsRevenue Recognition (Chargebacks and Rebates Balance Sheet Accounts) (Details)Detailshttp://www.amphastar.com/role/DisclosureRevenueRecognitionTables49 falsefalseR50.htm99940501 - Disclosure - Net Income per Share (Narrative) (Details)Sheethttp://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetailsNet Income per Share (Narrative)
(Details)Detailshttp://www.amphastar.com/role/DisclosureNetIncomePerShareTables50 falsefalseR51.htm99940502 - Disclosure - Net Income per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details)Sheethttp://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetailsNet Income per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details)Detailshttp://www.amphastar.com/role/DisclosureNetIncomePerShareTables51 falsefalseR52.htm99940601 - Disclosure - Segment Reporting (Selected Financial Information by Reporting Segment)
(Details)Sheethttp://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetailsSegment Reporting (Selected Financial Information by Reporting Segment) (Details)Detailshttp://www.amphastar.com/role/DisclosureSegmentReportingTables52 falsefalseR53.htm99940602 - Disclosure - Segment Reporting (Summary of Net Revenues by Product Segment) (Details)Sheethttp://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetailsSegment Reporting (Summary of Net Revenues by Product Segment) (Details)Detailshttp://www.amphastar.com/role/DisclosureSegmentReportingTables53 falsefalseR54.htm99940603 - Disclosure - Segment Reporting (Depreciation and Amortization Expense by Reporting Segment)
(Details)Sheethttp://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetailsSegment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details)Detailshttp://www.amphastar.com/role/DisclosureSegmentReportingTables54 falsefalseR55.htm99940604 - Disclosure - Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region)
(Details)Sheethttp://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetailsSegment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details)Detailshttp://www.amphastar.com/role/DisclosureSegmentReportingTables55 falsefalseR56.htm99940701 - Disclosure - Customer and Supplier Concentration (Details)Sheethttp://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetailsCustomer and Supplier Concentration
(Details)Detailshttp://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables56 falsefalseR57.htm99940801 - Disclosure - Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details)Sheethttp://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetailsFair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details)Detailshttp://www.amphastar.com/role/DisclosureFairValueMeasurementsTables57 falsefalseR58.htm99940901 - Disclosure - Investments (Held-to-Maturity) (Details)Sheethttp://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetailsInvestments (Held-to-Maturity) (Details)Detailshttp://www.amphastar.com/role/DisclosureInvestmentsTables58 falsefalseR59.htm99941001 - Disclosure - Goodwill and Intangible Assets (Summary of Intangible Assets) (Details)Sheethttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetailsGoodwill and Intangible Assets (Summary of Intangible Assets) (Details)Detailshttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables59 falsefalseR60.htm99941002 - Disclosure - Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details)Sheethttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetailsGoodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details)Detailshttp://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables60 falsefalseR61.htm99941101 - Disclosure - Inventories (Details)Sheethttp://www.amphastar.com/role/DisclosureInventoriesDetailsInventories
(Details)Detailshttp://www.amphastar.com/role/DisclosureInventoriesTables61 falsefalseR62.htm99941201 - Disclosure - Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details)Sheethttp://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetailsProperty, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details)Detailshttp://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables62 falsefalseR63.htm99941301 - Disclosure - Accounts Payable and Accrued Liabilities (Details)Sheethttp://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetailsAccounts Payable and Accrued Liabilities
(Details)Detailshttp://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables63 falsefalseR64.htm99941401 - Disclosure - Debt (Schedule of Debt)
(Details)Sheethttp://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetailsDebt (Schedule of Debt) (Details)Detailshttp://www.amphastar.com/role/DisclosureDebtTables64 falsefalseR65.htm99941402 - Disclosure - Debt (Narrative) (Details)Sheethttp://www.amphastar.com/role/DisclosureDebtNarrativeDetailsDebt (Narrative)
(Details)Detailshttp://www.amphastar.com/role/DisclosureDebtTables65 falsefalseR66.htm99941501 - Disclosure - Income Taxes (Summary of Income (Loss) Before Income Taxes)
(Details)Sheethttp://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetailsIncome Taxes (Summary of Income (Loss) Before Income Taxes)
(Details)Detailshttp://www.amphastar.com/role/DisclosureIncomeTaxesTables66 falsefalseR67.htm99941601 - Disclosure - Stockholders' Equity (Share Buyback Program)
(Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetailsStockholders' Equity (Share Buyback Program)
(Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables67 falsefalseR68.htm99941602 - Disclosure - Stockholders' Equity (The 2015 Equity Incentive Plan)
(Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetailsStockholders' Equity (The 2015 Equity Incentive Plan)
(Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables68 falsefalseR69.htm99941603 - Disclosure - Stockholders' Equity (2014 Employee Stock Purchase Plan)
(Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetailsStockholders' Equity (2014 Employee Stock Purchase Plan)
(Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables69 falsefalseR70.htm99941604 - Disclosure - Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetailsStockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables70 falsefalseR71.htm99941605 - Disclosure - Stockholders' Equity (Summary of Option Activity) (Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetailsStockholders' Equity (Summary of Option Activity) (Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables71 falsefalseR72.htm99941606 - Disclosure - Stockholders' Equity (Information Relating to Option Grants and Exercises)
(Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetailsStockholders' Equity (Information Relating to Option Grants and Exercises) (Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables72 falsefalseR73.htm99941607 - Disclosure - Stockholders' Equity (Summary of Nonvested Options) (Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetailsStockholders' Equity (Summary of Nonvested Options)
(Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables73 falsefalseR74.htm99941608 - Disclosure - Stockholders' Equity (Restricted Stock Units)
(Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetailsStockholders' Equity (Restricted Stock Units)
(Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables74 falsefalseR75.htm99941609 - Disclosure - Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetailsStockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables75 falsefalseR76.htm99941610 - Disclosure - Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations)
(Details)Sheethttp://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetailsStockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details)Detailshttp://www.amphastar.com/role/DisclosureStockholdersEquityTables76 falsefalseR77.htm99941701 - Disclosure - Employee Benefits (Details)Sheethttp://www.amphastar.com/role/DisclosureEmployeeBenefitsDetailsEmployee Benefits
(Details)Detailshttp://www.amphastar.com/role/DisclosureEmployeeBenefits77 falsefalseR78.htm99941801 - Disclosure - Commitments and Contingencies (Purchase Commitments)
(Details)Sheethttp://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetailsCommitments and Contingencies (Purchase Commitments)
(Details)Detailshttp://www.amphastar.com/role/DisclosureCommitmentsAndContingencies78 falsefalseR79.htm99941901 - Disclosure - Related-Party Transactions
(Details)Sheethttp://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetailsRelated-Party Transactions
(Details)Detailshttp://www.amphastar.com/role/DisclosureRelatedPartyTransactions79 falsefalseR80.htm99942001 - Disclosure - Litigation
(Details)Sheethttp://www.amphastar.com/role/DisclosureLitigationDetailsLitigation (Details)Detailshttp://www.amphastar.com/role/DisclosureLitigation80 falsefalseAll ReportsBookAll Reports amph-20240930.xsdamph-20240930_cal.xmlamph-20240930_def.xmlamph-20240930_lab.xmlamph-20240930_pre.xmlamph-20240930x10q.htm http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "amph-20240930x10q.htm": { "nsprefix": "amph", "nsuri": "http://www.amphastar.com/20240930", "dts": { "schema": { "local": ["amph-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["amph-20240930_cal.xml"] }, "definitionLink": { "local": ["amph-20240930_def.xml"] }, "labelLink": { "local": ["amph-20240930_lab.xml"] }, "presentationLink": { "local": ["amph-20240930_pre.xml"] }, "inline": { "local": ["amph-20240930x10q.htm"] } }, "keyStandard": 309, "keyCustom": 51, "axisStandard": 34, "axisCustom": 0, "memberStandard": 42, "memberCustom": 47, "hidden": { "total": 42, "http://fasb.org/us-gaap/2024": 25, "http://xbrl.sec.gov/dei/2024": 14, "http://www.amphastar.com/20240930": 3 }, "contextCount": 344, "entityCount": 1, "segmentCount": 91, "elementCount": 709, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 972, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef":

"As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_YeMx5pzUVke-L8NXjkWkUw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_YeMx5pzUVke-L8NXjkWkUw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:CostOfRevenue", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2ZHiihq46ki8faxYmtGP9A", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OlKWe6-bjEGDIili5mzlBg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R7": { "role": "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:GainLossOnDispositionOfAssets1", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R8": { "role": "http://www.amphastar.com/role/DisclosureGeneral", "longName": "995210101 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.amphastar.com/role/DisclosureBaqsimiAcquisition", "longName": "995210301 - Disclosure - BAQSIMI Acquisition", "shortName": "BAQSIMI Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.amphastar.com/role/DisclosureRevenueRecognition", "longName": "995210401 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:RevenueRecognitionDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:RevenueRecognitionDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.amphastar.com/role/DisclosureNetIncomePerShare", "longName": "995210501 - Disclosure - Net Income per Share", "shortName": "Net Income per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.amphastar.com/role/DisclosureSegmentReporting", "longName": "995210601 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration", "longName": "995210701 - Disclosure - Customer and Supplier Concentration", "shortName": "Customer and Supplier Concentration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.amphastar.com/role/DisclosureFairValueMeasurements", "longName": "995210801 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.amphastar.com/role/DisclosureInvestments", "longName": "995210901 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets", "longName": "995211001 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.amphastar.com/role/DisclosureInventories", "longName": "995211101 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment", "longName": "995211201 - Disclosure - Property, Plant, and Equipment", "shortName": "Property, Plant, and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities", "longName": "995211301 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.amphastar.com/role/DisclosureDebt", "longName": "995211401 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.amphastar.com/role/DisclosureIncomeTaxes", "longName": "995211501 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity", "longName": "995211601 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":

null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.amphastar.com/role/DisclosureEmployeeBenefits", "longName": "995211701 - Disclosure - Employee Benefits", "shortName": "Employee Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.amphastar.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211801 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.amphastar.com/role/DisclosureRelatedPartyTransactions", "longName": "995211901 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.amphastar.com/role/DisclosureLitigation", "longName": "995212001 - Disclosure - Litigation", "shortName": "Litigation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionTables", "longName": "99930303 - Disclosure - BAQSIMI Acquisition (Tables)", "shortName": "BAQSIMI Acquisition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.amphastar.com/role/DisclosureRevenueRecognitionTables", "longName": "99930403 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:ScheduleOfChargebackLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["amph:RevenueRecognitionDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:ScheduleOfChargebackLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["amph:RevenueRecognitionDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.amphastar.com/role/DisclosureNetIncomePerShareTables", "longName": "99930503 - Disclosure - Net Income per Share (Tables)", "shortName": "Net Income per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.amphastar.com/role/DisclosureSegmentReportingTables", "longName": "99930603 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables", "longName": "99930703 - Disclosure - Customer and Supplier Concentration (Tables)", "shortName": "Customer and Supplier Concentration (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.amphastar.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930803 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.amphastar.com/role/DisclosureInvestmentsTables", "longName": "99930903 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables", "longName": "99931003 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.amphastar.com/role/DisclosureInventoriesTables", "longName": "99931103 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables", "longName": "99931203 - Disclosure - Property, Plant, and Equipment (Tables)", "shortName": "Property, Plant, and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables", "longName": "99931303 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.amphastar.com/role/DisclosureDebtTables", "longName": "99931403 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang":

"en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.amphastar.com/role/DisclosureIncomeTaxesTables", "longName": "99931503 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityTables", "longName": "99931603 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "longName": "99940301 - Disclosure - BAQSIMI Acquisition (Narrative) (Details)", "shortName": "BAQSIMI Acquisition (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:ProceedsFromLinesOfCredit", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_21_2023_To_4_21_2023_us-gaap_AssetAcquisitionAxis_amph_BaqsimiAcquisitionsMember_icaO45yRJk2SNkcm8J87lA", "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R47": { "role": "http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails", "longName": "99940302 - Disclosure - BAQSIMI Acquisition (Purchase Price Allocated to Acquired Assets) (Details)", "shortName": "BAQSIMI Acquisition (Purchase Price Allocated to Acquired Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_21_2023_us-gaap_AssetAcquisitionAxis_amph_BaqsimiAcquisitionsMember_bFWxWTAqX0uvKLWyOkoRnA", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R48": { "role": "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "longName": "99940401 - Disclosure - Revenue Recognition (Analysis of the Chargeback Provision) (Details)", "shortName": "Revenue Recognition (Analysis of the Chargeback Provision) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "amph:RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfChargebackLiabilityTableTextBlock", "amph:RevenueRecognitionDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R49": { "role": "http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails", "longName": "99940402 - Disclosure - Revenue Recognition (Chargebacks and Rebates Balance Sheet Accounts) (Details)", "shortName": "Revenue Recognition (Chargebacks and Rebates Balance Sheet Accounts) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "amph:RevenueRecognitionWholesalerChargebacks", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfChargebackLiabilityTableTextBlock", "amph:RevenueRecognitionDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember_qTM7DNZXF0eycGCKl0A5WA", "name": "amph:RevenueRecognitionWholesalerChargebacks", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfProvisionForChargebacksAndRebatesAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R50": { "role": "http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails", "longName": "99940501 - Disclosure - Net Income per Share (Narrative) (Details)", "shortName": "Net Income per Share (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_amph_EmployeeAndNonEmployeeStockOptionsMember_jjGvHf4jZUGoPFmVhmYzSw", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_amph_EmployeeAndNonEmployeeStockOptionsMember_jjGvHf4jZUGoPFmVhmYzSw", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "longName": "99940502 - Disclosure - Net Income per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details)", "shortName": "Net Income per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R52": { "role": "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "longName": "99940601 - Disclosure - Segment Reporting (Selected Financial Information by Reporting Segment) (Details)", "shortName": "Segment Reporting (Selected Financial Information by Reporting Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_RzfIdOPVk0yqeyLWXwOw-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_RzfIdOPVk0yqeyLWXwOw-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "longName": "99940602 - Disclosure - Segment Reporting (Summary of Net Revenues by Product Segment) (Details)", "shortName": "Segment Reporting (Summary of Net Revenues by Product Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_amph_FinishedPharmaceuticalProductsSegmentMember_us-gaap_SubsegmentsAxis_amph_GlucagonMember_quw7xwmFWk-Dw2J-AZhmQA", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R54": { "role": "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "longName": "99940603 - Disclosure - Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details)", "shortName": "Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails", "longName": "99940604 - Disclosure - Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details)", "shortName": "Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:NoncurrentAssets", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R56": { "role": "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails", "longName": "99940701 - Disclosure - Customer and Supplier Concentration (Details)", "shortName": "Customer and Supplier Concentration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ogFX8Fz5L0egm6xAWP5fcA", "name": "amph:NumberOfMajorCustomersWholesaleDrugDistributors", "unitRef": "Unit_Standard_item_6udKLUuJlUaOIZdCUKwKVg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ogFX8Fz5L0egm6xAWP5fcA", "name": "amph:NumberOfMajorCustomersWholesaleDrugDistributors", "unitRef": "Unit_Standard_item_6udKLUuJlUaOIZdCUKwKVg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails", "longName": "99940801 - Disclosure - Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details)", "shortName": "Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pr_iMF5NiEG85ZSyLbul9g", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef":

"Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pr_iMF5NiEG85ZSyLbul9g", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails", "longName": "99940901 - Disclosure - Investments (Held-to-Maturity) (Details)", "shortName": "Investments (Held-to-Maturity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "longName": "99941001 - Disclosure - Goodwill and Intangible Assets (Summary of Intangible Assets) (Details)", "shortName": "Goodwill and Intangible Assets (Summary of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails", "longName": "99941002 - Disclosure - Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details)", "shortName": "Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R61": { "role": "http://www.amphastar.com/role/DisclosureInventoriesDetails", "longName": "99941101 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R62": { "role": "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "longName": "99941201 - Disclosure - Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details)", "shortName": "Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "longName": "99941301 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "amph:AccruedCustomerFeesAndRebates", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "amph:AccruedCustomerFeesAndRebates", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails", "longName": "99941401 - Disclosure - Debt (Schedule of Debt) (Details)", "shortName": "Debt (Schedule of Debt) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_llIV4rXxj0u3TD9soDts5Q", "name": "us-gaap:FinanceLeaseLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R65": { "role": "http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "longName": "99941402 - Disclosure - Debt (Narrative) (Details)", "shortName": "Debt (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_HPubaUD6S06HPsUGfNWbTw", "name": "amph:GainLossFromChangeInFairValueOfInterestRateCashFlowHedges", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R66": { "role": "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetails", "longName": "99941501 - Disclosure - Income Taxes (Summary of Income (Loss) Before Income Taxes) (Details)", "shortName": "Income Taxes (Summary of Income (Loss) Before Income Taxes) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_gUxiAjaYfkanjk4WLWFH3g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R67": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails", "longName": "99941601 - Disclosure - Stockholders' Equity (Share Buyback Program) (Details)", "shortName": "Stockholders' Equity (Share Buyback Program) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_4_2024_srt_ShareRepurchaseProgramAxis_amph_November2014ShareRepurchasePlanMember_wZEeM5pEuEW26MLvReWzZw", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R68": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "longName": "99941602 - Disclosure - Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)", "shortName": "Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_PlanNameAxis_amph_The2015EquityIncentivePlanMember_O-kFHcK7gkGSlYiCIuMzJQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_PlanNameAxis_amph_The2015EquityIncentivePlanMember_O-kFHcK7gkGSlYiCIuMzJQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "longName": "99941603 - Disclosure - Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)", "shortName": "Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_1_2024_To_5_31_2024_us-gaap_PlanNameAxis_amph_EmployeeStockPurchasePlan2014Member_lhRuATHEHEKAjvcNm5rm7Q", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R70": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails", "longName": "99941604 - Disclosure - Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)", "shortName": "Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_xjHwC1-NIUShMtbAj94EXA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "Unit_Standard_pure_gUxiAjaYfkanjk4WLWFH3g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_xjHwC1-NIUShMtbAj94EXA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "Unit_Standard_pure_gUxiAjaYfkanjk4WLWFH3g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "longName": "99941605 - Disclosure - Stockholders' Equity (Summary of Option Activity) (Details)", "shortName": "Stockholders' Equity (Summary of Option Activity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div",

"body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails", "longName": "99941606 - Disclosure - Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details)", "shortName": "Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_xjHwC1-NIUShMtbAj94EXA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_YeMx5pzUVke-L8NXjkWkUw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R73": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "longName": "99941607 - Disclosure - Stockholders' Equity (Summary of Nonvested Options) (Details)", "shortName": "Stockholders' Equity (Summary of Nonvested Options) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_QB1UJS79D0O41D2dBXBQ7w", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "longName": "99941608 - Disclosure - Stockholders' Equity (Restricted Stock Units) (Details)", "shortName": "Stockholders' Equity (Restricted Stock Units) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_TbRQ488gTEa1ElNaCMFLoA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R75": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "longName": "99941609 - Disclosure - Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)", "shortName": "Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZG4Gn-m-tUmPMYuWaSqvWQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZG4Gn-m-tUmPMYuWaSqvWQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_rQ7w-gGmJ0e5MCPs7n1JnA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "longName": "99941610 - Disclosure - Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details)", "shortName": "Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Q6MzFUMD0kK83hUyY58Hrw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R77": { "role": "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails", "longName": "99941701 - Disclosure - Employee Benefits (Details)", "shortName": "Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_gUxiAjaYfkanjk4WLWFH3g", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BO5rmvcoFkyNG8Noad6l9A", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_gUxiAjaYfkanjk4WLWFH3g", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "longName": "99941801 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details)", "shortName": "Commitments and Contingencies (Purchase Commitments) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_amph_CommitmentsToPurchaseEquipmentAndRawMaterialsMember_VowZqHnowkWqsZ7hnE1CDg", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_amph_CommitmentsToPurchaseEquipmentAndRawMaterialsMember_VowZqHnowkWqsZ7hnE1CDg", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941901 - Disclosure - Related-Party Transactions (Details)", "shortName": "Related-Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ANIZEUZWzke6cNr6G1t-Ow", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember_--84fUpHcE2W8rRGueL5dQ", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "unique": true } }, "R80": { "role": "http://www.amphastar.com/role/DisclosureLitigationDetails", "longName": "99942001 - Disclosure - Litigation (Details)", "shortName": "Litigation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_9_30_2024_srt_LitigationCaseAxis_amph_PropertyAndCasualtyClaimMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_gWxIOUhZSUKx3fPiYKVlDg", "name": "us-gaap:LitigationReserve", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_LitigationCaseAxis_amph_PropertyAndCasualtyClaimMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_gWxIOUhZSUKx3fPiYKVlDg", "name": "us-gaap:LitigationReserve", "unitRef": "Unit_Standard_USD_CiVho3nN20GDKn7Lg-kmjA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "amph-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r78", "r79"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r76", "r79", "r85", "r1180"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r76", "r925"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r855"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1082"] }, "amph_AccruedCustomerFeesAndRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AccruedCustomerFeesAndRebates", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued customer fees and rebates", "label": "Accrued customer fees and rebates" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r79", "r149"] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Long-term reserve for income tax liabilities", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": ["r85", "r149"]

```
}, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r79" ] }, "amph_AccruedLossOnFirmPurchaseCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AccruedLossOnFirmPurchaseCommitments", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued loss on firm purchase commitments", "label": "Accrued loss on firm purchase commitments" } } }, "auth_ref": [] }, "amph_AccruedPaymentsForAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AccruedPaymentsForAssetAcquisitions", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued payments for assets acquisitions.", "label": "Accrued Payments For Asset Acquisitions", "terseLabel": "Accrued payments for BAQSIMI" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r47", "r216", "r707" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r101", "r222", "r703", "r746", "r747" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r14", "r24", "r561", "r564", "r616", "r742", "r743", "r1060", "r1061", "r1062", "r1071", "r1072", "r1073", "r1074" ] }, "amph_AcquisitionsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AcquisitionsPolicyPolicyTextBlock", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for acquisitions.", "label": "Acquisitions Policy Policy Text Block", "terseLabel": "Acquisitions" } } }, "auth_ref": [] }, "amph_ActivePharmaceuticalIngredientSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ActivePharmaceuticalIngredientSegmentMember", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the active pharmaceutical ingredient or API segment of the business.", "label": "Active Pharmaceutical Ingredient Segment" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r993" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r90", "r925", "r1257" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r766", "r1071", "r1072", "r1073", "r1074", "r1189", "r1258" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1006" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1006" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1006" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1006" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r58", "r59", "r489" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r169" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Advertising Expense", "terseLabel": "Advertising expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r521", "r908" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1039" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r965", "r975", "r985", "r1017" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r968", "r978", "r988", "r1020" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1040" ] }, "amph_AgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AgreementTerm", "presentation": [ "http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time for agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement Term", "terseLabel": "Agreement term" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1006" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1013" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r969", "r979", "r989", "r1013", "r1021", "r1025", "r1033" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1031" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r517", "r519" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of discounts, premium, and debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r109", "r445", "r1065", "r1209" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of product rights, trademarks, and patents", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r380", "r387", "r891" ] }, "amph_AnpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AnpMember", "presentation": [ "http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "lang": { "en-us": { "role": { "documentation": "ANP [Member]", "label": "ANP" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r280" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r34" ] }, "amph_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfExcludedSecurities": { "xbrltype": "perShareItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfExcludedSecurities", "presentation": [ "http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the weighted-average exercise price of the excluded securities, per share.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a
```

table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } }, "auth_ref": ["r34"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r552"] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "BAQSIMI Acquisition" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails",
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails",
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r381", "r382", "r383", "r384", "r385", "r1185"] }, "amph_AssetAcquisitionConsiderationDeferredPaymentIncludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "AssetAcquisitionConsiderationDeferredPaymentIncludingAccruedInterest", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of consideration payable including accrued interest as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition Consideration Deferred Payment Including Accrued Interest", "terseLabel": "Deferred payment including accrued interest" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Contingent consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": ["r1186", "r1187", "r1188"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails",
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails",
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r381", "r382", "r383", "r384", "r385", "r1185"] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails",
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r1185"] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails",
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": ["r1185"] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionTables"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table Text Block]", "verboseLabel": "Schedule of purchase price allocated to acquired assets", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": ["r1185"] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisition"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "BAQSIMI Acquisition", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": ["r1185"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r147", "r162", "r220", "r246", "r284", "r290", "r308", "r312", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r554", "r558", "r594", "r698", "r794", "r883", "r884", "r925", "r956", "r1145", "r1146", "r1212"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r211", "r224", "r246", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r554", "r558", "r594", "r925", "r1145", "r1146", "r1212"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r572", "r573", "r912"] }, "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNet", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails"], "lang": { "en-us": { "role": { "label": "Net Assets", "totalLabel": "Total assets acquired", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": ["r12"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } } }, "auth_ref": ["r1028"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r1029"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r1024"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails",
"http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails",
"http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails",
"http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r1027"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1026"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r1025"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r1025"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r400", "r1225", "r1226"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r64", "r66", "r400", "r1225", "r1226"] }, "amph_BaqsimiAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "BaqsimiAcquisitionsMember", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails",
"http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails",
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to BAQSIMI acquisitions.", "label": "BAQSIMI product rights" } } }, "auth_ref": [] }, "amph_BaqsimiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "BaqsimiMember", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents BAQSIMI.", "label": "BAQSIMI" } } }, "auth_ref": [] }, "amph_BaqsimiNebMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "BaqsimiNebMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents BAQSIMI NEB.", "label": "BAQSIMI NEB" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [
"http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": ["r124"] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditures included in accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r31", "r32", "r33"] }, "amph_CapitalOneNationalAssociationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "CapitalOneNationalAssociationMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Capital One, National Association.", "label": "Capital One, N.A." } } }, "auth_ref": [] }, "amph_CardinalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "CardinalHealthMember", "presentation": [
"http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "documentation": "The major customer Cardinal Health.", "label": "Cardinal Health [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": {

"label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r28", "r213", "r873"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r213"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1191", "r1192"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r29"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r29", "r146"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r114", "r243"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r114"] }, "amph_CencoraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "CencoraMember", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "documentation": "The major customer Cencora Inc.", "label": "Cencora [Member]" } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositAtCarryingValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Certificates of Deposit, at Carrying Value", "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": ["r1053"] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r13", "r948", "r949", "r950", "r953"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r1004"] }, "amph_ChinaMerchantBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ChinaMerchantBankMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Loans/Agreements with China Merchant Bank", "label": "China Merchant Bank" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r1001"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r999"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": ["r51", "r52", "r53", "r54"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r1005"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r1005"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r125", "r404", "r405", "r856", "r1132", "r1137"] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Litigation, Commitments and Contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": ["r48", "r857"] }, "amph_CommitmentsToPurchaseEquipmentAndRawMaterialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "CommitmentsToPurchaseEquipmentAndRawMaterialsMember", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents commitments to purchase equipment and raw materials.", "label": "Commitments to Purchase Equipment and Raw Materials [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r944", "r945", "r946", "r948", "r949", "r950", "r953", "r1071", "r1072", "r1074", "r1189", "r1256", "r1258"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r89"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock; shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r89", "r781"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock; shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r89"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Common stock; shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r15", "r89", "r781", "r800", "r1258", "r1259"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r89", "r702", "r925"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r1010"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r1009"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r1011"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r1008"] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefits" } } }, "auth_ref": [] }, "us-

gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r25", "r228", "r230", "r236", "r692", "r715", "r716"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r35", "r36", "r69", "r70", "r319", "r855"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r35", "r36", "r69", "r70", "r319", "r749", "r855"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r35", "r36", "r69", "r70", "r319", "r855", "r1044"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration"], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Customer and Supplier Concentration", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r118"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r35", "r36", "r69", "r70", "r319"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r35", "r36", "r69", "r70", "r319", "r855"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "verboseLabel": "Total debt", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": ["r1070"] }, "amph_ConvertibleDebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ConvertibleDebtPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to convertible debt.", "label": "Convertible Debt Policy Text Block", "terseLabel": "Convertible Debt" } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "amph_CorporateBondsShortTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "CorporateBondsShortTermMember", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate and agency bonds (due within 1 year)" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "terseLabel": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r105", "r246", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r594", "r883", "r1145"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r413", "r1143"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r413", "r1143", "r1144"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r119", "r319"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r127", "r244", "r395", "r396", "r397", "r398", "r399", "r412", "r413", "r423", "r429", "r430", "r431", "r432", "r433", "r434", "r439", "r446", "r447", "r449", "r607"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r21", "r78", "r79", "r148", "r150", "r248", "r424", "r425", "r426", "r427", "r428", "r430", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r893", "r894", "r895", "r896", "r897", "r924", "r1068", "r1133", "r1134", "r1135", "r1208", "r1210"] }, "amph_DebtInstrumentBasisSpreadDiscountOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DebtInstrumentBasisSpreadDiscountOnVariableRate", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread Discount On Variable Rate", "terseLabel": "Prime rate discount percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r128", "r426"] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt conversion ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": ["r49", "r82", "r131", "r132", "r426"] }, "amph_DebtInstrumentConvertiblePremiumPercentageOverLastReportedSalePricePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DebtInstrumentConvertiblePremiumPercentageOverLastReportedSalePricePercent", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of premium over the last reported sale price in a convertible debt instrument.", "label": "Debt Instrument, Convertible, Premium Percentage over Last Reported Sale Price percent", "terseLabel": "Convertible debt, percentage of premium over the last reported sale price" } } }, "auth_ref": [] }, "amph_DebtInstrumentConvertibleThresholdBusinessDaysAfterConsecutiveTradingPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DebtInstrumentConvertibleThresholdBusinessDaysAfterConsecutiveTradingPeriod", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold number of business days after consecutive trading days that trading price is less than the product of threshold sale price of the common stock and the conversion rate on each trading day to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Business Days After Consecutive Trading Period", "terseLabel": "Threshold business days after consecutive trading period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Convertible debt, threshold consecutive trading days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "amph_DebtInstrumentConvertibleThresholdConsecutiveTradingPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingPeriod", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which trading price is less than the product of threshold sale price of the common stock and the conversion rate on each trading day to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Period", "terseLabel": "Threshold consecutive trading period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Convertible debt threshold percentage", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Convertible debt, threshold trading days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "amph_DebtInstrumentConvertibleThresholdTradingPriceAsPercentageOfProductOfSalePriceOfCommonStockAndConversionRate": { "xbrltype": "percentItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DebtInstrumentConvertibleThresholdTradingPriceAsPercentageOfProductOfSalePriceOfCommonStockAndConversionRate", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the trading price as a maximum percentage of product of sale price of common stock and conversion rate on each trading day to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Trading Price As a Percentage of Product of Sale Price of Common Stock and Conversion Rate", "terseLabel": "Percentage of product sale price" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "Aggregate principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r424", "r607", "r608", "r894", "r895", "r924"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r437", "r593", "r894", "r895", "r1192", "r1193", "r1194", "r1195", "r1202"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r81", "r425"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r248", "r424", "r425", "r426", "r427", "r428", "r430", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r893", "r894", "r895", "r896", "r897", "r924", "r1068", "r1208", "r1210"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r21", "r248", "r424", "r425", "r426", "r427", "r428", "r430", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r893", "r894", "r895", "r896", "r897", "r924", "r1068", "r1133", "r1134", "r1135", "r1208", "r1210"] }, "amph_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the denomination of the principal amount of debt that is used in conversion calculations.", "label": "Debt Instrument Principal Amount Denomination For Conversion Into Common Stock", "terseLabel": "Debt principle amount converted into common stock" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Percentage of principal amount redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r21", "r49", "r50", "r74", "r130", "r132", "r248", "r424", "r425", "r426", "r427", "r428", "r430", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r893", "r894", "r895", "r896", "r897", "r924", "r1068", "r1208", "r1210"] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt Issuance Costs", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": ["r10"] }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Compensation Liability, Current and Noncurrent", "terseLabel": "Deferred compensation plan liabilities", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation plan assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": ["r1054"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "verboseLabel": "Debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1148", "r1207", "r1208", "r1210"] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r526", "r527"] }, "amph_DeferredPaymentAccretionInterestExpenseRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DeferredPaymentAccretionInterestExpenseRecognized", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of interest expense recognized related to accretion of deferred payment.", "label": "Deferred Payment Accretion Interest Expense Recognized", "terseLabel": "Interest expense recognized related to accretion of deferred payment" } } }, "auth_ref": [] }, "amph_DeferredPaymentForAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "DeferredPaymentForAcquisition", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of deferred payments for acquisitions.", "label": "Deferred Payment For Acquisition", "terseLabel": "Deferred payment for BAQSIMI acquisition" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "verboseLabel": "Deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": ["r1183"] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": ["r476"] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": ["r467"] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": ["r486"] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation of property, plant, and equipment", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r8", "r46"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r8", "r284", "r295", "r312", "r883", "r884"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r771", "r773", "r786", "r787", "r788", "r790", "r791", "r792", "r793", "r795", "r796", "r797", "r798", "r812", "r813", "r814", "r815", "r818", "r819", "r820", "r821", "r843", "r844", "r845", "r846", "r944", "r946", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1203", "r1204"] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "negatedLabel": "Interest rate swaps related to variable rate loans", "terseLabel": "Interest rate swaps related to variable rate loans", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": ["r19", "r98", "r143", "r144", "r225", "r875"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r65", "r67", "r68", "r145", "r771", "r773", "r786", "r787", "r788", "r790", "r791", "r792", "r793", "r795", "r796", "r797", "r798", "r812", "r813", "r814", "r815", "r818", "r819", "r820", "r821", "r843", "r844", "r845", "r846", "r875", "r944", "r946", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1203", "r1204"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r960"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r992"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r1003"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income per Share", "terseLabel": "Net income per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss)

per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r237", "r254", "r255", "r256", "r257", "r258", "r259", "r264", "r266", "r277", "r278", "r279", "r283", "r548", "r551", "r569", "r570", "r693", "r717", "r876"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r237", "r254", "r255", "r256", "r257", "r258", "r259", "r266", "r277", "r278", "r279", "r283", "r548", "r551", "r569", "r570", "r693", "r717", "r876"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r263", "r280", "r281", "r282"] }, "amph_EastWestBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EastWestBankMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents East West Bank.", "label": "East West Bank [Member]" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r598"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Income tax provision as a percentage of income before income taxes", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r529", "r909"] }, "amph_EliLillyAndCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EliLillyAndCoMember", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "documentation": "Eli Lilly and Co.", "label": "Lilly [Member]" } } }, "auth_ref": [] }, "amph_EmployeeAndNonEmployeeStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EmployeeAndNonEmployeeStockOptionsMember", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time.", "label": "Employee and non-employee stock options" } } }, "auth_ref": [] }, "amph_EmployeeConsultantAndDirectorsStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EmployeeConsultantAndDirectorsStockOptionsMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee, consultant or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Employee Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r79"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r518"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r1179"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r1179"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "amph_EmployeeStockPurchasePlan2014Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EmployeeStockPurchasePlan2014Member", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to the 2014 Employee Stock Purchase Plan.", "label": "2014 Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "amph_EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased": { "xbrltype": "perShareItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average purchase price of shares purchased through an employee stock purchase plan.", "label": "Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased", "terseLabel": "Weighted-Average Purchase Price (In Dollars per Share)" } } }, "auth_ref": [] }, "amph_EnoxaparinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EnoxaparinMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Enoxaparin.", "label": "Enoxaparin" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r958"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r958"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r958"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1042"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r958"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r958"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r958"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r958"] }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Major Customer [Line Items]",

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "amph_EpinephrineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "EpinephrineMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Epinephrine.", "label": "Epinephrine" } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r997"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r1038"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r1038"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r1038"] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r15", "r207", "r232", "r233", "r234", "r249", "r250", "r251", "r253", "r258", "r260", "r262", "r285", "r356", "r357", "r392", "r465", "r538", "r539", "r545", "r546", "r547", "r549", "r550", "r551", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r600", "r601", "r602", "r603", "r604", "r605", "r609", "r611", "r616", "r713", "r742", "r743", "r744", "r766", "r824"] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Investment in Unconsolidated Affiliates", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": ["r6", "r71", "r354"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r1007"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r965", "r975", "r985", "r1017"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r962", "r972", "r982", "r1014"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r1013"] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "FR", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "FRANCE" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r572", "r573", "r583", "r912"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r572", "r573", "r583", "r912"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured on a recurring basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1191", "r1192"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r437", "r470", "r471", "r472", "r473", "r474", "r475", "r571", "r573", "r574", "r575", "r576", "r582", "r583", "r585", "r627", "r628", "r629", "r894", "r895", "r902", "r903", "r904", "r912", "r917"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r572", "r573", "r574", "r576", "r912", "r1194", "r1205"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r578", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r589", "r689", "r912", "r918"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r437", "r470", "r475", "r573", "r583", "r627", "r902", "r903", "r904", "r912"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r437", "r470", "r475", "r573", "r574", "r583", "r628", "r894", "r895", "r902", "r903", "r904", "r912"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r572", "r573", "r574", "r576", "r912", "r1194", "r1205"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r437", "r470", "r471", "r472", "r473", "r474", "r475", "r571", "r573", "r574", "r575", "r576", "r582", "r583", "r585", "r627", "r628", "r629", "r894", "r895", "r902", "r903", "r904", "r912", "r917"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r912", "r1191", "r1192", "r1193", "r1194", "r1195", "r1205"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r11"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Equipment under Finance Leases", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r613"] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": ["r614"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "verboseLabel": "Finance lease right-of-use assets", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r612"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r448", "r463", "r566", "r590", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r714", "r889", "r912", "r915", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r926", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1102", "r1103", "r1104", "r1105", "r1190", "r1193", "r1194", "r1195", "r1202", "r1205"] }, "amph_FinishedPharmaceuticalProductsNetRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "FinishedPharmaceuticalProductsNetRevenuesMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Finished pharmaceutical products net revenues", "label": "Total finished pharmaceutical products net revenues" } } }, "auth_ref": [] }, "amph_FinishedPharmaceuticalProductsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "FinishedPharmaceuticalProductsSegmentMember", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails",

"http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails",
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails",
"http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the finished pharmaceutical products segments of the business.", "label": "Finished Pharmaceutical Products Segment" } } }, "auth_ref": [] }, "amph_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]" } } }, "auth_ref": [] }, "amph_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted-Average Life (Years)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r218", "r368", "r386", "r891"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r379", "r381", "r382", "r383", "r385", "r386", "r389", "r390", "r657", "r658", "r869"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r368", "r386", "r658", "r891"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r379", "r381", "r382", "r383", "r385", "r386", "r389", "r390", "r869"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r657", "r1128"] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r595"] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r1002"] },
"amph_FrenchGovernmentLoan4DueDecember2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname":
"FrenchGovernmentLoan4DueDecember2026Member", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": {
"documentation": "Represents the French Government loan due December 2026.", "label": "French Government Loan 4 - Due December 2026" } } }, "auth_ref": [] },
"amph_FurnitureFixturesAndVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "FurnitureFixturesAndVehiclesMember",
"presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "documentation": "Total of 1) equipment such as desks, chairs) commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and 2) vehicles.", "label": "Furniture, fixtures, and automobiles" } } }, "auth_ref": [] }, "amph_GainLossFromChangeInFairValueOfInterestRateCashFlowHedges": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.amphastar.com/20240930", "localname": "GainLossFromChangeInFairValueOfInterestRateCashFlowHedges", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of net gains (losses) from changes in fair value of interest rate cash flow hedges.", "label": "Gain Loss From Change In Fair Value Of Interest Rate Cash Flow Hedges", "terseLabel": "Gains (losses) from changes in fair values of interest rate swaps" } } },
"auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr":
"credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss (gain) on disposal of assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r1065"] }, "amph_GainLossOnInterestRateSwapsAndForeignCurrencyTransactionsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "GainLossOnInterestRateSwapsAndForeignCurrencyTransactionsNet", "crdr": "credit",
"presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of net gain or loss on interest rate swaps and foreign currency transactions.", "label": "Gain Loss On Interest Rate Swaps And Foreign Currency Transactions Net", "negatedLabel": "Gain on interest rate swaps and foreign currency transactions, net" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r107", "r804"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r107"] },
"amph_GlucagonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "GlucagonMember", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Glucagon.", "label": "Glucagon" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails",
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill recognized", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [
"r217", "r369", "r690", "r884", "r890", "r913", "r925", "r1111", "r1118"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [
"r1109", "r1121"] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Translation and Measurement Period Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": ["r0", "r1110"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails",
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r102", "r105", "r161", "r246", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r594", "r878", "r883", "r1076", "r1078", "r1079", "r1080", "r1081", "r1145"] }, "us-gaap_GrossProfitAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfitAbstract", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails"], "lang": { "en-us": { "role": { "label": "Gross Profit [Abstract]",
"terseLabel": "Gross profit (loss):" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecurities", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "totalLabel": "Amortized Cost", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r163", "r336", "r360", "r1107"] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
"terseLabel": "Gross Unrealized Gains", "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)." } } },
"auth_ref": ["r165", "r346"] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
"negatedLabel": "Gross Unrealized Losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)." } } },
"auth_ref": ["r166", "r347"] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value", "terseLabel": "Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r164", "r345", "r573", "r582", "r691", "r697"] }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table Text Block]", "terseLabel": "Schedule of securities classified as held-to-maturity", "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101"] }, "amph_ICBCBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ICBCBankMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents loans with ICBC bank.", "label": "ICBC Bank" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment of long-lived assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": ["r8", "r123", "r914"] }, "amph_IncomeLossFromContinuingOperationsAfterIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "IncomeLossFromContinuingOperationsAfterIncomeTaxes", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations.", "label": "Income Loss From Continuing Operations After Income Taxes", "terseLabel": "Income before equity in losses of unconsolidated affiliate", "totalLabel": "Income before equity in losses of unconsolidated affiliate" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes", "verboseLabel": "Income (loss) before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r103", "r156", "r161", "r694", "r710", "r878", "r883", "r1076", "r1078", "r1079", "r1080", "r1081"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Income (loss) before income taxes:" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Equity in losses of unconsolidated affiliate", "terseLabel": "Equity in losses of unconsolidated affiliates", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r8", "r104", "r155", "r284", "r297", "r312", "r353", "r709"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r393", "r400", "r401", "r577", "r579", "r584", "r739", "r741", "r809", "r869", "r916", "r1227"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r400", "r401", "r577", "r579", "r584", "r739", "r741", "r809", "r869", "r916", "r1227"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r247", "r523", "r529", "r530", "r531", "r532", "r533", "r536", "r540", "r542", "r543", "r544", "r760", "r909"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeIncomeTaxesDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r168", "r177", "r261", "r262", "r284", "r298", "r312", "r528", "r529", "r541", "r719", "r909"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Deferred Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r231", "r524", "r525", "r533", "r534", "r535", "r537", "r756"] }, "amph_IncomeTaxRefundAndDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "IncomeTaxRefundAndDeposits", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds and deposits of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Tax Refund And deposits", "terseLabel": "Income tax refunds and deposits" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r30", "r116", "r1066", "r1181", "r1182"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r7"] }, "amph_IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Income Tax Refund, Deposits, and Payable", "label": "Increase Decrease In Income Tax Refund, Deposits, and Payable", "negatedLabel": "Income tax refunds, deposits, and payable, net" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "terseLabel": "Incremental shares from equity awards", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met." } } }, "auth_ref": ["r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r279"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r379", "r384", "r388", "r891"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r368", "r388", "r891"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "amph_IndefiniteLivedIntangibleAssetsIncludingGoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwillGross", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Gross amount of indefinite-lived intangible assets and goodwill.", "label": "Indefinite Lived Intangible Assets Including Goodwill Gross", "terseLabel": "Subtotal, Original Cost" } } }, "auth_ref": [] }, "amph_IndefiniteLivedIntangibleAssetsIncludingGoodwillNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwillNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying amount of indefinite-lived intangible assets and goodwill.", "label": "Indefinite Lived Intangible Assets Including Goodwill Net", "terseLabel": "Subtotal, Net Book Value" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r379", "r384", "r388", "r891"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r969", "r979", "r989", "r1013", "r1021", "r1025", "r1033"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r1031"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": {

"en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r961", "r1037"] },
"ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies
and Procedures Adopted" } } }, "auth_ref": ["r961", "r1037"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading
Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r961", "r1037"] },
"amph_IntangibleAssetsGrossIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "IntangibleAssetsGrossIncludingGoodwill",
"crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation":
"Amount before accumulated amortization of intangible assets, including goodwill.", "label": "Balance, Original Cost", "totalLabel": "Balance, Original Cost" } } }, "auth_ref": [] }, "us-
gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit",
"presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net
(Excluding Goodwill)", "verboseLabel": "BAQSIMI product rights", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net
of accumulated amortization and impairment charges." } } }, "auth_ref": ["r379", "r1128", "r1129"] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails",
"http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Including Goodwill)", "totalLabel": "Balance,
Net Book Value", "verboseLabel": "Goodwill and intangible assets, net", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible
assets." } } }, "auth_ref": ["r1108"] }, "amph_InterestExpenseAccretionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.amphastar.com/20240930", "localname":
"InterestExpenseAccretionTerm", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Period of
time, typically for liabilities, that have been discounted to their net present values, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days.", "label": "Interest Expense Accretion Term", "terseLabel": "Interest expense accretion period" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest
expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r294", "r1064"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating
Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond
for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt
discount." } } }, "auth_ref": ["r238", "r241", "r242"] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestRateSwapMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails",
"http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Interest Rate Swap
[Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on
a market interest rate (index rate) over a specified period." } } }, "auth_ref": ["r870", "r951", "r952"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventories" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureInventories"
], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the
basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r366"] }, "us-
gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO
reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r1055"] }, "us-gaap_InventoryNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureInventoriesDetails",
"http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total
inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [
"r223", "r874", "r925"] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Raw
Materials and Supplies, Gross", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } },
"auth_ref": ["r1057"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit",
"presentation": ["http://www.amphastar.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "documentation": "Amount before
valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1056"] }, "us-
gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Inventory adjustment to reflect net realizable
value", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or
changes in price levels." } } }, "auth_ref": ["r367"] }, "amph_InvestmentInUnconsolidatedAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930",
"localname": "InvestmentInUnconsolidatedAffiliate", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": {
"role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in unconsolidated affiliate.", "label": "Investment In Unconsolidated
Affiliate", "terseLabel": "Investment in unconsolidated affiliate" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": {
"en-us": { "role": { "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating
securities." } } }, "auth_ref": ["r284", "r293", "r312", "r883", "r1063"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label":
"Investment, Policy [Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r718", "r752",
"r753", "r754", "r755", "r835", "r836"] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Investments, Fair Value
Disclosure", "terseLabel": "Short-term investments", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial
instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r1191", "r1192", "r1202"] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureInvestments"], "lang": { "en-us":
{ "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments", "documentation": "The entire
disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r158", "r178", "r321", "r322", "r591", "r592", "r1221"] }, "us-gaap_LandMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [
"http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Land [Member]",
"documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": ["r1151"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements
[Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r124", "r615"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of
legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LegalMattersAndContingenciesTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureLitigation"], "lang": { "en-us": { "role": { "label": "Legal Matters and
Contingencies [Text Block]", "terseLabel": "Litigation", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and
other contingencies." } } }, "auth_ref": ["r126"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit",
"presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities",
"documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r21", "r78", "r79", "r80", "r84",
"r85", "r86", "r87", "r246", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r555", "r558", "r559", "r594", "r780", "r877", "r956", "r1145", "r1212", "r1213"] }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit",
"presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and
stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r94",
"r152", "r705", "r925", "r1069", "r1106", "r1206"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label":
"Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": {
"en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid
during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r80", "r212", "r246", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422",
"r555", "r558", "r559", "r594", "r925", "r1145", "r1212", "r1213"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current
[Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "amph_LidocaineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname":
"LidocaineMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": {
"documentation": "Represents Lidocaine.", "label": "Lidocaine" } } }, "auth_ref": [] }, "amph_LineOfCreditDueAugust2021Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.amphastar.com/20240930", "localname": "LineOfCreditDueAugust2021Member", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang":
{ "en-us": { "role": { "documentation": "Line of Credit Facility with China Merchant Bank due October 2026", "label": "Line of Credit - Due October 2026" } } }, "auth_ref": [] },
"amph_LineOfCreditDueNovember2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "LineOfCreditDueNovember2033Member",
"presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility with ICBC Bank due November
2033", "label": "Line of Credit Due November 2033" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails",
"http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which
may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r77", "r83",
"r1068", "r1143", "r1144"] }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label":
"Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Borrowings", "documentation": "Fair value of the amount outstanding under the credit facility." } } }, "auth_ref": [
"r593"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain",
"presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": {
"label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a
group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r77", "r83", "r1068", "r1143"] }, "us-
gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails",
"http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum
borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the
amounts currently outstanding under the facility." } } }, "auth_ref": ["r77", "r83"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "LineOfCreditMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Estimated Litigation Liability", "terseLabel": "Accrued litigation settlement", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": ["r86", "r1138"] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1133", "r1134", "r1135", "r1138"] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1133", "r1134", "r1135", "r1138"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r21", "r150", "r436", "r450", "r894", "r895", "r924", "r1222"] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term debt, net of current portion and unamortized debt issuance costs", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": ["r21", "r699"] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt and Lease Obligation, Current", "terseLabel": "Less current portion of long-term debt and finance leases", "verboseLabel": "Current portion of long-term debt", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": ["r79"] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Investments", "terseLabel": "Long-term investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r214"] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r406", "r407", "r408", "r411", "r520", "r892", "r1139", "r1140"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r406", "r407", "r408", "r411", "r520", "r892", "r1139", "r1140"] }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "lang": { "en-us": { "role": { "label": "Litigation" } } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r319", "r901", "r936", "r941", "r1150", "r1224", "r1228", "r1229", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "amph_ManufacturingServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ManufacturingServicesAgreementMember", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Manufacturing Services Agreement.", "label": "Manufacturing Services Agreement" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r179", "r181", "r183", "r184", "r186", "r205", "r206", "r407", "r408", "r409", "r410", "r487", "r520", "r576", "r655", "r738", "r740", "r748", "r772", "r773", "r832", "r837", "r839", "r840", "r847", "r867", "r868", "r888", "r898", "r905", "r917", "r918", "r922", "r923", "r937", "r1147", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219"] }, "amph_McKessonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "McKessonMember", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "documentation": "The major customer McKesson.", "label": "McKesson [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r1005"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r1005"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r179", "r181", "r183", "r184", "r186", "r205", "r206", "r407", "r408", "r409", "r410", "r487", "r520", "r576", "r655", "r738", "r740", "r748", "r772", "r773", "r832", "r837", "r839", "r840", "r847", "r867", "r868", "r888", "r898", "r905", "r917", "r918", "r922", "r937", "r1147", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r1024"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1152"] }, "amph_MortgagePayableDueJune2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "MortgagePayableDueJune2027Member", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Mortgage Payable - Paid off June 2024 [Member]", "label": "Mortgage Payable - Paid off June 2024" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r1032"] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MunicipalBondsMember", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "amph_NaloxoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "NaloxoneMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Naloxone.", "label": "Naloxone" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r319", "r901", "r936", "r941", "r1150", "r1224", "r1228", "r1229", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1006"] }, "amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "NanjingHanxinPharmaceuticalTechnologyCoLtdMember", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin.", "label": "Hanxin" } } }, "auth_ref": [] }, "amph_NanjingLetopMedicalTechnologyCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "NanjingLetopMedicalTechnologyCo.Ltd.Member", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Nanjing Letop Biotechnology Technology Co. Ltd. [Member]", "label": "Letop" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r240"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows From Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r240"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows From Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r114", "r115", "r117"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows From Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations",

"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Amphastar Pharmaceuticals, Inc.", "verboseLabel": "Net income", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r106", "r117", "r157", "r210", "r226", "r229", "r234", "r246", "r252", "r254", "r255", "r256", "r257", "r258", "r261", "r262", "r276", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r548", "r551", "r570", "r594", "r712", "r802", "r822", "r823", "r954", "r1145"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "verboseLabel": "Basic and dilutive numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1005"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r969", "r979", "r989", "r1013", "r1021"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r996"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r995"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1013"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1032"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1032"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash Investing and Financing Activities:" } } }, "auth_ref": [] }, "amph_NoncashOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "NoncashOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease in noncash investing or financing activities.", "label": "Noncash Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets in exchange for operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": ["r318"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Non-operating income (expenses)", "totalLabel": "Total non-operating income (expenses), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r108"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Non-operating income (expenses):" } } }, "auth_ref": [] }, "amph_November2014ShareRepurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "November2014ShareRepurchasePlanMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "documentation": "November 2014 share repurchase plan.", "label": "November 2014 Share Repurchase Plan" } } }, "auth_ref": [] }, "amph_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "NumberOfMajorCustomers", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of major customers.", "label": "Number Of Major Customers", "terseLabel": "Number of major customers" } } }, "auth_ref": [] }, "amph_NumberOfMajorCustomersWholesaleDrugDistributors": { "xbrltype": "integerItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "NumberOfMajorCustomersWholesaleDrugDistributors", "presentation": ["http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of major customers that are wholesale distributors of the reporting entity's products.", "label": "Number Of Major Customers, Wholesale Drug Distributors", "terseLabel": "Number of major customers that are wholesale distributors" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails"], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r879", "r887", "r1077"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r161", "r878", "r1076", "r1078", "r1079", "r1080", "r1081"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r613"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r613"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r612"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Operating lease right-of-use asset amortization", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r1065"] }, "amph_OperatingLeaseRightOfUseAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "OperatingLeaseRightOfUseAssetsAndLiabilitiesNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease, net of present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Right Of Use Assets And Liabilities Net", "terseLabel": "Operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "General" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureGeneral"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "General", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r75", "r141", "r750", "r751"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r79"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r219"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Gains and (losses) of intercompany foreign currency transactions", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r3", "r99", "r100", "r101", "r596", "r597", "r599"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r3", "r713"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of income taxes" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r5", "r14", "r142", "r227", "r230", "r258"] }, "amph_OtherFinishedPharmaceuticalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "OtherFinishedPharmaceuticalProductsMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Other Finished

Pharmaceutical Products [Member]", "label": "Other Finished Pharmaceutical Products" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r79", "r925"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r85"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r110"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r1005"] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Other Receivables", "terseLabel": "Receivables from Hanxin", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": ["r221", "r789", "r884", "r1223"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r967", "r977", "r987", "r1019"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r970", "r980", "r990", "r1022"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r970", "r980", "r990", "r1022"] }, "amph_OwnershipPercentageAfterSpinoffTransaction": { "xbrltype": "percentItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "OwnershipPercentageAfterSpinoffTransaction", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership in investment after spin-off transaction.", "label": "Ownership Percentage After Spinoff Transaction", "terseLabel": "Ownership after transaction" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r140", "r1122", "r1123", "r1124", "r1125", "r1127", "r1128", "r1130", "r1131"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r994"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities." } } }, "auth_ref": [] }, "amph_PaymentsAcquisitionsOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "PaymentsAcquisitionsOfAssets", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisitions of assets.", "label": "Payments Acquisitions Of Assets", "negatedLabel": "BAQSIMI acquisition" } } }, "auth_ref": [] }, "amph_PaymentsForDepositsAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "PaymentsForDepositsAndOtherAssets", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Cash outflow related to payments and other deposits not otherwise defined in the taxonomy.", "label": "Payments For Deposits And Other Assets", "terseLabel": "Deposits and other assets" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury stock", "terseLabel": "Payments for repurchase of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r112"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r27"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of investments", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r1083"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Cash payment", "verboseLabel": "Payment to acquire assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r167", "r1186", "r1187", "r1188"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases and construction of property, plant, and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r111"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r1004"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r1004"] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": ["r1138"] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefits"], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "terseLabel": "Employee Benefits", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": ["r466", "r468", "r469", "r475", "r477", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r904"] }, "us-gaap_PensionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionExpense", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Pension Cost (Reversal of Cost)", "terseLabel": "Pension Cost", "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits." } } }, "auth_ref": ["r883"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r996"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r1013"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r1006"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r995"] }, "amph_PhytonadioneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "PhytonadioneMember", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Phytonadione.", "label": "Phytonadione" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r997"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r1041"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r996"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r88", "r452"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r88", "r781"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r88", "r452"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r88", "r781", "r800", "r1258", "r1259"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r88", "r701", "r925"] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1059"] }, "amph_PrimatenemistMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "PrimatenemistMember", "presentation": [

"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails",
"http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Primatene MIST.", "label": "Primatene MIST" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r26", "r757"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from equity plans, net of withholding tax payments", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": ["r4", "r18"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r26", "r1068"] }, "amph_ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The total cash inflow or outflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises, net of withholding tax payments upon issuance to employees. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.", "label": "Proceeds From Payments For Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options, Net Of Withholding Tax Payments", "negatedLabel": "Proceeds from equity plans, net of withholding tax payments" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturity of investments", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash received from options exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r4", "r18"] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": ["r1151"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r899"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r188", "r189", "r190", "r191", "r192", "r193", "r204", "r315", "r656", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r871", "r899", "r935", "r937", "r938", "r942", "r943", "r1052", "r1141", "r1142", "r1150", "r1224", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "amph_ProductReturnAccrualCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ProductReturnAccrualCurrent", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date for estimated refunds due to goods returned by customers (other than under warranty provisions). For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Return Accrual, Current", "terseLabel": "Accrued product returns, current portion" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r188", "r189", "r190", "r191", "r192", "r193", "r204", "r315", "r656", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r871", "r899", "r935", "r937", "r938", "r942", "r943", "r1052", "r1141", "r1142", "r1150", "r1224", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income attributable to Amphastar Pharmaceuticals, Inc.", "verboseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r210", "r226", "r229", "r239", "r246", "r252", "r258", "r261", "r262", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r548", "r551", "r553", "r556", "r557", "r570", "r594", "r694", "r711", "r765", "r802", "r822", "r823", "r910", "r911", "r955", "r1062", "r1145"] }, "amph_PropertyAndCasualtyClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "PropertyAndCasualtyClaimMember", "presentation": ["http://www.amphastar.com/role/DisclosureLitigationDetails"], "lang": { "en-us": { "role": { "documentation": "Property and Casualty Claim", "label": "Property and Casualty Claim" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r9", "r615"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant, and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r122", "r172", "r175", "r176"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total property, plant, and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r124", "r215", "r708"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r615"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionPurchasePriceAllocatedToAcquiredAssetsDetails", "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property, plant, and equipment, net", "verboseLabel": "Property, plant, and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r9", "r615", "r695", "r708", "r925"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant, and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r9"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r124", "r615"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": ["r86", "r151"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": ["r86", "r151"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "presentation": ["http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes long-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": ["r86", "r151"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r994"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r994"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r179", "r181", "r183", "r184", "r186", "r205", "r206", "r407", "r408", "r409", "r410", "r468", "r487", "r513", "r514", "r515", "r520", "r576", "r630", "r639", "r655", "r738", "r740", "r748", "r772", "r773", "r832", "r837", "r839", "r840", "r847", "r867", "r868", "r888", "r898", "r905", "r917", "r918", "r922", "r923", "r937", "r946", "r1136", "r1147", "r1194", "r1215", "r1216", "r1217", "r1218", "r1219"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r179", "r181", "r183", "r184", "r186", "r205", "r206", "r407", "r408", "r409", "r410", "r468", "r487", "r513", "r514", "r515", "r520", "r576", "r630", "r639", "r655", "r738", "r740", "r748", "r772", "r773", "r832", "r837", "r839", "r840", "r847", "r867", "r868", "r888", "r898", "r905", "r917", "r918", "r922", "r923", "r937", "r946", "r1136", "r1147", "r1194", "r1215", "r1216", "r1217", "r1218", "r1219"] }, "us-

gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingTables"], "lang": { "en-us": { "role": { "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of net revenues in the finished pharmaceutical products segment", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": ["r43", "r44"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r962", "r972", "r982", "r1014"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r320", "r478", "r620", "r621", "r700", "r706", "r775", "r776", "r777", "r778", "r779", "r799", "r801", "r831"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r73", "r620"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r320", "r805", "r806", "r809"] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Purchases from Related Party", "verboseLabel": "Payment to related party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related-Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r320", "r478", "r620", "r621", "r700", "r706", "r775", "r776", "r777", "r778", "r779", "r799", "r801", "r831", "r1211"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r617", "r618", "r619", "r621", "r622", "r761", "r762", "r763", "r807", "r808", "r809", "r828", "r830"] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Debt", "negatedLabel": "Principal payments on long-term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r113", "r758"] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Repayments of Senior Debt", "terseLabel": "Repayment of debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": ["r113"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r522", "r869", "r883", "r1220"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "amph_ResearchAndDevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ResearchAndDevelopmentServicesMember", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "documentation": "Services for research and development.", "label": "Research and development services" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r963", "r973", "r983", "r1015"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r964", "r974", "r984", "r1016"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r971", "r981", "r991", "r1023"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r213"] }, "us-gaap_RestrictedCashAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndInvestments", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Investments", "terseLabel": "Restricted cash", "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet." } } }, "auth_ref": ["r853", "r854"] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r1053", "r1067"] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted short-term investments", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": ["r834", "r841", "r848", "r853", "r854"] }, "us-gaap_RestrictedInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedInvestmentsCurrent", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Investments, Current", "terseLabel": "Restricted short-term investments", "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions." } } }, "auth_ref": ["r696", "r853", "r854"] }, "amph_RestrictedShortTermInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RestrictedShortTermInvestmentsPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for restricted short-term investments.", "label": "Restricted Short-term Investments [Policy Text Block]", "terseLabel": "Restricted Short-Term Investments" } } }, "auth_ref": [] }, "amph_RestrictedStockUnitsIssuedAsCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RestrictedStockUnitsIssuedAsCompensationMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Restricted Stock Units (RSUs) issued as compensation.", "label": "Restricted Stock Units Issued as Compensation [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r91", "r133", "r704", "r745", "r747", "r759", "r782", "r925"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r207", "r249", "r250", "r251", "r253", "r258", "r260", "r262", "r356", "r357", "r392", "r538", "r539", "r545", "r546", "r547", "r549", "r550", "r551", "r560", "r562", "r563", "r565", "r568", "r609", "r611", "r742", "r744", "r766", "r1258"] }, "amph_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RevenuePerformanceObligationPaymentTerms", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "documentation": "Payment terms in contract with customer, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.", "label": "Revenue Performance Obligation Payment Terms", "terseLabel": "Payment terms" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "auth_ref": [] }, "amph_RevenueRecognitionDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RevenueRecognitionDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognition"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for revenue recognition.", "label": "Revenue Recognition Disclosure [Text Block]", "terseLabel": "Revenue Recognition" } } }, "auth_ref": [] }, "amph_RevenueRecognitionWholesalerChargebacks": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RevenueRecognitionWholesalerChargebacks", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations.", "label": "Revenue Recognition Wholesaler Chargebacks", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Total" } } }, "auth_ref": [] }, "amph_RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents wholesaler chargeback credits issued to third parties during the period.", "label": "RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties", "negatedLabel": "Credits and payments issued to third parties" } } }, "auth_ref": [] }, "amph_RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the wholesaler chargeback provision related to sales made in the current period.", "label": "Provision for chargebacks and rebates" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails",

"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails",
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails",
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r159", "r160", "r235", "r246", "r284", "r291", "r292", "r306", "r312", "r315", "r317", "r319", "r355", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r594", "r694", "r883", "r1145"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails",
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenues:", "verboseLabel": "Net Revenues:" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "amph_RevlovingLineOfCreditDueAugust2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "RevlovingLineOfCreditDueAugust2026Member", "presentation": [
"http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Revolving line of credit with Captial One N.A. due August 2026", "label": "Revolving line of credit - closed in June 2023" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Customer and Supplier Concentration" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1032"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1032"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [
"http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r319", "r1043"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accounts payable and accrued liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r34"] }, "amph_ScheduleOfChargebackLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ScheduleOfChargebackLiabilityTableTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureRevenueRecognitionTables"], "lang": { "en-us": { "role": { "documentation": "The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing.", "label": "Schedule of Chargeback Liability [Table Text Block]", "terseLabel": "Schedule of chargeback and rebates provision analysis" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Summary of provision (benefit) for income taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1184"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] },
"amph_ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of depreciation, depletion, and amortization of property and equipment costs.", "label": "Schedule Of Depreciation Depletion And Amortization [Table Text Block]", "terseLabel": "Schedule of depreciation and amortization expense by reporting segment" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureNetIncomePerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income (loss) per share calculation", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1075"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of recorded share-based compensation expense under all plans", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r57"] }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "presentation": [
"http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers." } } }, "auth_ref": ["r120"] },
"amph_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortizable finite-lived intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Schedule Of Finite Lived And Indefinite Lived Intangible Assets By Major Class Table Text Block", "terseLabel": "Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes in carrying amounts of goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r890", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120"] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Held-to-Maturity Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table]", "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureInventoriesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r22", "r95", "r96", "r97"] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of the summary of nonvested options status", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": ["r137"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r9", "r615"] }, "amph_ScheduleOfProvisionForChargebacksAndRebatesAmountsRecognizedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ScheduleOfProvisionForChargebacksAndRebatesAmountsRecognizedInBalanceSheetTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet for chargebacks and rebates.", "label": "Schedule Of Provision For Chargebacks And Rebates Amounts Recognized In Balance Sheet Table Text Block", "terseLabel": "Schedule of provision of chargebacks and rebates as reflected in the balance sheets" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.amphastar.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r72", "r73", "r805", "r806", "r809"] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of accounts receivable and net revenues by major customer", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [
"http://www.amphastar.com/role/DisclosureSegmentReportingTables"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of net revenues and carrying values of long-lived assets by geographic region", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy

acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r45", "r102"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": ["r45", "r102"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r40", "r41", "r42"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingTables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of financial information by reporting segment", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r40", "r41", "r42"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]", "terseLabel": "Schedule of information relating to RSU grants and deliveries", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r138"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of the summary of option activity under all plans", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r16", "r17", "r134"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of key assumptions to determine fair value of options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r139"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r957"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r959"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r284", "r287", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r319", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r391", "r402", "r403", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r880", "r883", "r884", "r890", "r940", "r1224", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r180", "r182", "r185", "r187", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r317", "r318", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r768", "r769", "r770", "r833", "r838", "r842", "r849", "r852", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r872", "r900", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r939", "r946", "r1150", "r1224", "r1228", "r1229", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReporting"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r162", "r284", "r286", "r287", "r288", "r289", "r290", "r302", "r304", "r305", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r879", "r881", "r882", "r883", "r885", "r886", "r887"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationRevenueAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]" } } }, "auth_ref": [] }, "amph_SeineNormandieWaterAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "SeineNormandieWaterAgencyMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the Seine-Normandie water agency.", "label": "Seine-Normandie Water Agency [Member]" } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r107"] }, "amph_SettlementOfChargebacksAndRebatesTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "SettlementOfChargebacksAndRebatesTerms", "presentation": ["http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails"], "lang": { "en-us": { "role": { "documentation": "The settlement of chargebacks and rebate terms, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Settlement Of Chargebacks And Rebates Terms", "terseLabel": "Settlement of chargebacks and rebates terms" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r7"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r906"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Total Fair Market Value of RSUs Issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "RSUs forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r507"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock

(or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r505"] }, "amph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards granted during the period.", "label": "RSUs granted (in Dollars)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r506"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r514"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r515"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": ["r513"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Total RSUs outstanding at the end of the period", "periodStartLabel": "Total RSUs outstanding at the beginning of the period", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r135", "r136"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r907"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r55"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional Disclosures" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r496"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of period (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r496"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r509"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r500"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r498"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "netLabel": "Options granted (in dollars per share)", "terseLabel": "Weighted-average grant date fair value (in Dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r508"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of information relating to options grants", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": ["r56"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r55"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding Options, End of period", "periodStartLabel": "Outstanding Options, Beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r494", "r495"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding Exercise Price (in dollars per share)", "periodStartLabel": "Outstanding Exercise Price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r494", "r495"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",

"presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r510"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Vested and expected to vest, at the end of period", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r510"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at end of period (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r510"] }, "amph_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsNumberOfSharesOfCommonStockPerAward": { "xbrltype": "sharesItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsNumberOfSharesOfCommonStockPerAward", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of common shares the grantee is to receive at a specified future date for each Restricted Stock Unit (\"RSU\") awarded.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r499"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r500"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r498"] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": ["r1149"] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": ["r1149"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r512"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable aggregate intrinsic value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r55"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Exercisable remaining contractual term (in Years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r55"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested at end of period", "periodStartLabel": "Nonvested at beginning of period", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Options forfeited", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Options forfeited (in dollars per share)", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "periodStartLabel": "Nonvested at beginning of period (in dollars per share)", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r138"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r510"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r509"] }, "us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Options vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Options vested (in dollars per share)", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Stock surrendered to fulfill tax withholding obligations", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-Term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r153", "r154", "r1058"] },
"amph_SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of the reporting entity's significant accounting policies, excluding its policy for revenue recognition.", "label": "Significant Accounting Policies Excluding Revenue Recognition Policy Text Block", "terseLabel": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [
"http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails",
"http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails",
"http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails",
"http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails",
"http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r209", "r284", "r287", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r319", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r391", "r394", "r402", "r403", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r880", "r883", "r884", "r890", "r940", "r1224", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r15", "r89", "r92", "r93", "r207", "r232", "r233", "r234", "r249", "r250", "r251", "r253", "r258", "r260", "r262", "r285", "r356", "r357", "r392", "r465", "r538", "r539", "r545", "r546", "r547", "r549", "r550", "r551", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r600", "r601", "r602", "r603", "r604", "r605", "r609", "r611", "r616", "r713", "r742", "r743", "r744", "r766", "r824"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r180", "r182", "r185", "r187", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r317", "r318", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r768", "r769", "r770", "r833", "r838", "r842", "r849", "r852", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r872", "r900", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r939", "r946", "r1150", "r1224", "r1228", "r1229", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails",
"http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails",
"http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails",
"http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations",
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r249", "r250", "r251", "r285", "r611", "r656", "r752", "r767", "r774", "r775", "r776", "r777", "r778", "r779", "r781", "r784", "r785", "r786", "r787", "r788", "r790", "r791", "r792", "r793", "r795", "r796", "r797", "r798", "r799", "r801", "r803", "r804", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r824", "r947"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails",
"http://www.amphastar.com/role/DisclosureRevenueRecognitionChargebacksAndRebatesBalanceSheetAccountsDetails",
"http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails",
"http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations",
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r249", "r250", "r251", "r285", "r320", "r611", "r656", "r752", "r767", "r774", "r775", "r776", "r777", "r778", "r779", "r781", "r784", "r785", "r786", "r787", "r788", "r790", "r791", "r792", "r793", "r795", "r796", "r797", "r798", "r799", "r801", "r803", "r804", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r824", "r947"] },
"ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r966", "r976", "r986", "r1018"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r15", "r88", "r89", "r133"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture", "verboseLabel": "Issuance of common stock in connection with the Company's equity plans (in Shares)", "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r15", "r88", "r89", "r133", "r499"] }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Issuance of treasury stock in connection with the Company's equity plans (in Shares)", "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": ["r15", "r89", "r133"] }, "amph_StockIssuedDuringPeriodValueEquityPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "StockIssuedDuringPeriodValueEquityPlans", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Value of shares issued under equity plans.", "label": "Stock Issued During Period Value Equity Plans", "terseLabel": "Issuance of common stock in connection with the Company's equity plans" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Issuance of treasury stock in connection with the Company's equity plans", "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": ["r15", "r51", "r88", "r89", "r133"] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Authorized, Amount", "terseLabel": "Stock buyback program, authorized amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r1149"] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Amount", "terseLabel": "Increase authorized for share buyback program", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r89", "r92", "r93", "r121", "r783", "r800", "r825", "r826", "r925", "r956", "r1069", "r1106", "r1206", "r1258"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"],
"lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r61", "r62", "r63", "r207", "r208", "r233", "r249", "r250", "r251", "r253", "r258", "r260", "r356", "r357", "r392", "r465", "r538", "r539", "r545", "r546", "r547", "r549", "r550", "r551", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r600", "r601", "r605", "r610", "r616", "r743", "r744", "r764", "r783", "r800", "r825", "r826", "r850", "r955", "r1069", "r1106", "r1206", "r1258"] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r129", "r245", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r465", "r567", "r827", "r829", "r851"] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SubsegmentsAxis", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r606", "r623"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r606", "r623"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r606", "r623"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1012"] }, "amph_TermLoanDueJune2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "TermLoanDueJune2028Member", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Term loan with Wells Fargo Bank due June 2028", "label": "Term Loan - Due June 2028" } } }, "auth_ref": [] }, "amph_The2015EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "The2015EquityIncentivePlanMember", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to the 2015 Equity Incentive Plan.", "label": "The 2015 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1004"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1011"] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": ["r60", "r891", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r1031"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1033"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.amphastar.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.amphastar.com/role/DisclosureInvestmentsHeldToMaturityDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r448", "r463", "r566", "r590", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r714", "r912", "r915", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r926", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1102", "r1103", "r1104", "r1105", "r1190", "r1193", "r1194", "r1195", "r1202", "r1205"] }, "amph_TransitionServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "TransitionServicesAgreementMember", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Transition Services Agreement.", "label": "Transition Services Agreement" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1034"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1035"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1035"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1033"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1033"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1036"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1034"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r51"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Purchase of treasury stock (in Shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r15", "r89", "r133"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r51", "r54", "r89", "r92"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchase of treasury stock", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r15", "r51", "r133"] }, "amph_TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents 2.0% convertible senior notes due 2029.", "label": "Two Percent Convertible Senior Notes Due Two Thousand Twenty Nine Member", "terseLabel": "2029 Convertible Notes" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.amphastar.com/role/DisclosureBaqsimiAcquisitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r552"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails"], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": ["http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized debt issuance costs", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r1030"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r37", "r38", "r39", "r170", "r171", "r173", "r174"] }, "us-gaap_UseRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseRightsMember", "presentation": ["http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Use Rights [Member]", "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities." } } }, "auth_ref": ["r20", "r1122", "r1123", "r1124", "r1125", "r1127", "r1128", "r1130", "r1131"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r1000"] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Net effect of dilutive securities:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares outstanding - diluted", "verboseLabel": "Diluted (in Shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r265", "r279"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average shares used to compute net income per share:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding-basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or

units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r264", "r279"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.amphastar.com/role/DisclosureNetIncomePerShareCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "verboseLabel": "Weighted-average shares outstanding - basic" } } }, "auth_ref": [] }, "amph_WellsFargoBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amphastar.com/20240930", "localname": "WellsFargoBankMember", "presentation": ["http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Loans with Wells Fargo Bank", "label": "Wells Fargo Bank" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } } }, "auth_ref": ["r998"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-

470-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic":

"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r238": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "44", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-44" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "48", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-48" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "48", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-48" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-51" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-52" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-53" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "54", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-54" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r317": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r397":

{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)

(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r778": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r927": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

"Section": "402", "Subsection": "x", "Paragraph": "2" }, r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, r1028": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, r1029": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, r1031": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, r1041": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, r1042": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, r1109": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1185": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }

ZIP 101 0001297184-24-000058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001297184-24-000058-xbrl.zip M4$L#!!0 (%2"9UE*F7O)KQ@ "," 0 1 86UP:"TR,#(T,#DS,"YX MJI7O3N+49+8DV4ZT8UM>2YG,>=J"2$C"#@5J M #*V]M>?!DCP3H*DG!WF'-94362BT>C&UP

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|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

W/>X^L[]E\RB(YAC./AQ6!B 36D8^0K)"-(Q$)->Y%4D*)O_Y[RQ#9?U-* MR:B/\UOW L 7&2EE)7JQ)7*HL.8&1>F:I=HUE,T?+2&J5=IA M;P7=H4U14Y@^YOAT86[21K@%=P-+$=?
+X+82!OWVY(/,C M$>PM!6K7N%LDO3R;:MJ1[ER,)N*GC$=*6:*&L 4#9GC$0A M(F Z1GLFIO)#'D<"9 MQ4OL2PT/Y0"NN:C4](PB@II"[%"HH;:MVO]GXYA=VTZ@'*\U%U8+(H%%+.?X
MB5E\S&)>3L E\O!TQ4\=2$(1.3B4D[)6,8:<'&!BXE3,YF=,U0*.9A#R%Y3R MG.DIH91\9?[Z#*W9+]++I.RZ@'+T4N.=8$IT\$Z0=+4ATT7!Y7G;T7!+X ?P#+X7O\C*,4EVYNF;+A-W' 5^U+1!?
X"7E?F+M_#N)LC\%R M%?Q=\[#%=LA):?',N<7U^9 M,^.)LLRY^KOK5>NS+F*[;%RW&"= :)R7,/2;6'2C&XK!*4N50P&ZRJ)VKN* M*7#*=%
[3611F"I."&E@3EBE0C7NBZ@8*AUXCV/,R%FR(<]9_!62;+5>C"[/ M#)JU@^"NM6JTRQK:T=2O,<38>[L@S^]\'2VP/[8FP'[\LU7]#P(F+!\T;@ M=H00L$ZFR#V.$/FQ^9N/+?0LS9\!.!.%3A0\K>
(\6!%?M);[A]*/KIV 3,C[MZKD]KN[3',=[G4;)]TNGPRP'<8?IG- 5BCP\>PJ#159'N2T"XX5ZPBO*S=NZ M#KG-!&9)%+!TX19QF?7L?X:2I#>]3J? >Y12T68:\+SRI/3<%)DL=!Y;T7OJ"]9W\E.):&
M)*8MH53F&TC-E"20>VA"A$]1R..JAR7&Q0,$]E6EWS6K2H7[:24,)BCR)UL< M)ELD)AD6Q=,$C@M+#^5!@K(K_D(ZG)2.?BA[,/I*7$? _XMP4]:4JAH 2/N8 M*IM./KUEA;H7=&R=#/-/.'CF.J:^V$4*
[CK!9*YRE7H/*3UP1,-6^!PQ-E=M M#XM>!^B)'[L))'L#;3J D@UI)SX3"MT+])A5!)!5?%U9E,XYQ1ZR*,/'\+LG MT=GZ/GORK/W]PM\W2]Y8[Y.\^PD+SR;9 & N&'[PEMA/0WXC690$?A"F'*<'
M[*4T\VYY53#V^7D^?J=^FF0N+5EA]PD[;#-":: 0+U&M,F3=#90(O5NN0 M;##.K[DK/F7O>\[6FK-\YFVAK*=,57<76)B3"-4NC756%\?WU[WC$X4]LZFR M9NAY;CG0DXL=B5?>)]-3WU 6-T-
J8T^L&N=?MFZX7KRP,##8WJ$!?MZVV_DPHE2!#:-E(+ 2P8M\^^GJ/UX0FV7W+(>;/3UT&$8J\ (5745;*Q EV]D2P:L: #-2:\&K: -ZQ&#Z%<"<4>?)G?.M@4!:::;674I BH9#02@1-I MR%11C*,?
G;G]F9*8%\;/@T1C"D),,<_6EJ#D"BX(M*+!HY9*#1+(@%PG)^M MLV<8=B_2RWR2 [,Z9F6AB$@*:IP\B*<:Z9&.O&4(<$<=NDJH#)1P$1T2R)2 M17.K3;+86
X/Y!1+V!]83AHPH>WU*=]4X"\XI0SKK<*1*#[%C&%:63Q P M4D3-IYMM9[]1D CA)5HHR[O M.%]>0MK?Z6X6Z5-LX-'J4,!N)^S)A)6I!"4>M>=JPD'R7F7[@EED_I^\'+HB+R@ M-cN(>)!I"A[;L"
\3XRC=C7,S=P'XJ3UX'/H-E\)&=D P3,3I.6CPW41RF2W#XY MHWU=QQD_9;M"6G[6$!^*@7?+3<*Z]%F_"KT408'94M"R4H3]*-IYBT+RHF1L M'0),.EK+U#KFHS#T8LT!7$BB6(M$ Q,SE?
O"43HC\+?SV'JH051!%%U"#)42U7ZYB/PE#URK&4E&R[GA9T,;I(M) _ZZD5B3=I08IHE2TS5V,@%9-%X_ 6'Y+E>O6PLJ!HSAK[%3]HPN@0S/L-; M+_&:R -(51Q+4H6)C3]12:J"PJUWUE1ZV70
)!05C$L: 6V47]PA9+VBMM#MA'+\7>MSO*:8" (;_2) NN)?_S/[N*WSZ.6XXK<&N]AE5+)K0LO(3+;8'$\M M'G>U>]P1.NYJ'W>UC[O:KVQ7^WAJ\7AJ\;A&?)5+Q*'*,R/X.L2!NE:B 65-@
MAFNM#&94 ER([,IG=Z?2(O^:1(MKYJ'\)GRTUG3!84K9>!=X\708L7P/_R M-[>MI=+2U?D'!\3C*$)CE&?#6RQVF2(P5E-5*@SLNO+QA/*!/O61HG9(6I M@+MF"Y-VG?;E*32/M^ZX"PKU,4"AY-
E(LTNCJ>;7!3;#WM);+ X_=>'&MO+/[A>:QBI"V=P M&6F7W#R[E7"3_^ ZTK#F)D?:)3I$] MF?Y;X!?O&)YN;M _"-V)O+D;::;AP[="S [NMR.8^B+^<;A[9<(K]-64+J"O: MSN(NF[>2 ^Y=
<0,]CIQRYTW9 L"'"UT)9E7(JPD5 3EO=:Z"I?'M.V\KUXME" M#2O"TM$%0&!-]3O%D;=<(?K%SF'6FD$]I3JTUZRQ :*$"PSM_&>C>&6PG*M1B MM>SJ!+J7W:M[<-54&0_EV=4'%.)XZTANL;@
0@,+94G?1C02DMQLAE3=N&3G M2@3D:*J2'>;M=Z]2$>U&1OPIL-F\@H]TPTH!"V#J46M>/^% MXUAU=+4.X3J;:L?-.O:#'5X/@^L@##?3R#\CBN/K(C#7ERW8<51(@OO0KS${
M5VBYUFSV&;=VN[=G2:1X*Z]#' /J4?CBH8,J\KN7T,]INC@/XH0&3RGK4O@D MGG47KJ>2#HK0CN!QKE(18F4N,/>3TC!R ;<%VUB4WK'E%/L"+? 'B6=5-W$] M]?7@6-4$ MB5O40! 3L*&4T8\
<^90]]&< F_,U*%&T>+HNG%?,M9;XC':"G M(,R>IK3>N_VQN7?+!YUDHT[*N$R^V?\0\T+E9(DG6Z3^+2Z]^+@M5,[*E_>8 MN:U1WC%2Q+0ME?XLNN=O?%(VH^9/:]/BXRF* ^6N;X_].W
8.^Q/-[L ?PDP M94:ZW%PS4Q.5--LVAK4CW+M"E)V-*4O<3Q5JK[/#6;GI8=D'@#14.[T72MB, M9D"'OHK6:1)GQ'U09MZ5+5SGOSKIKU?0(BIABNVCM=@^0LFQ#2JVCP#%QA;M M>PHO*?
XCQ9&W,9M-Y2UAE0F,-97*^0%(X"(DK6?/1DN8^F;_7/R1!LU%P6HVH :ZM[4'>K M8H-[J=YCGO3T$NR+\11_J[3:;ET"\LMZC:\>'^E"MGM-.,,T">8!ZYJGQL[Q MFL2!NI!
(V0**5?Y*P2OFK"+:O11O2(0W-XA^PF9?9:V8) M\6FR0UUKU(F4-Y#&J&V9:P)O*<$>:FK8"\CK;X$)6\ "8=/<+HAVV/(57 M?%GP9:-=E>N:0WD[;G#9F[,$0#UHR0?]@D/_D=R@).4X69=X?
FJ6>)8ZGWS# MNS])R$DQ)3;9*MD/W Y9ZI@=ON.IK6+O$!1(;O//JD*0630L.HH+<55697+ M*'3O>Q)IBN)Y?M_7 Z;/@<<3'#TM"DT=,5XKSK>H&4#*N0RCY_GRLF@?N3;R"X-Y;J?>0
MU6V@9+Z&$JPA&]S+]B:-&,UK%&;*I]Y5%H)"R6<-+4DQ]>X%J(\J=!LD5CTX M?H7%GECQD6%-!':@6Q"\XOC.2NVK,V_J3.@N.LE1+$P MW=E+CZYVK*;>'VD0YR8GSW^*06$D/WL4:&-
OJD&R>U=YU_]+,IM4;.+8]P#C9.Y!_ ML^($:-'OD>4W\JG//]KV LA1ME!^0WF+25?)W.59V7:*0BH*G7E(@*4\\636'XO6$FK1;H%F1-*186MGW MM:04IK=>W93'],R4BK[^-
$#+:-1K,QN<3)]BK,S]_9)K$ICUYF! 73&E@7 MMM'E:+-U]CP-KX.Y]$YKHZ90/+R=?IM)MDSGP<@U_DSE-3+Z9JY->$AY%C0> MCBQ+A3O3%7_LY9_9 P;VTI5V= "9P_;REE)].!K B&\U*
<.I:1M$LAF%P*2H M"34N7KPPS*0>N+#TI"9R K:NU=-$*<-J@D;)# MZ4G"LSZE-Y14)(D6#>I740UU43S=I2/7_)0B966[I\V;4U;X;U^7F4.0] M0,@FE;9@V=? 1RQ@LY:N[\L93J9F] .;/@6K
YVX[9]ZOB-GT(C:A ' !'Z' M-OFI9Y)5U5&\W:QAG,BID%:R:=N-+NH?1Q.U ?7 Y'RU6J. :[ZO,YC+K-F_NMP_C6?BYEP <&*,*>4:TV1S%ZH85$@EZNN M.?*
[\V)2".N#8Q^;!\>*SO]CDG7_'ID!LMT(E8-C:E H]VA)N65VD9:NN0OO M+T/I=,.OP5"4^QBUA"(K*T@*P[?A%SW7EY.F.[M :.6@&]"+#372(ZP'B0X M38/L0+FR-+
(.!"4?::&$9=`4R7$OA6N,8KPDH<^F?4J>\S?:E*)1MH"2<6PI M'R5M (3%0@:U;$H KO=UNHJB1(I[SM\@;\F"9KHI$Z"^*TS5PG56MZ-LE+0- M5O*84L8E%G9?!B_\'W[-V=_Q,O!"R45\QJU9NEC(?
RW=LF(*STLH+YU;=3FH2XJVE5 MK+3'[N7@@%+$5R2-$:1 5 6YNF0>6+^2[]@@E!XN0W"'>G*/HB]VXB*'A+$U-=VODS$3&#/:RW#*)TPRQ\ MB2-(CZ6@4)89UHR64C3*;/Z &;ZWA*[8.C/
OZ$$T^F"11P;N0BT3: L.:Q% MH:5L, - ZR!!X8R-CO+.IW%,MCL."F,P:09E&6)O&";4#261WW 8QI>(+HC: M'XGAH*PRK'DN)L=]*&054))8: _#5">843+X%B M),5QBB(/7[RLV40K*\W0-
8*R.K00HD38&*[S)[^QMF!E^L /64N^99$7DJI MO.Y/VPK*0M)"<%J;#DMRNXO$2\^[WY"\):$+7OX5\S]"ZR!N*6.;_]$LG-&9O*^:5;*6IQ4VME/*1=\,2N+?6DQZTMQ+[3..6+ 1,ARG M_HIQEL>
<2?",341GV!;*ZM-:?H;TN1?B/8XQ8|DRJQ%_QB%93#Q7{GXR GF/VQIY-]^/T:+U!XP994R480FPLA8$7=G83$K5!(M8[_SKEX, ^=C"R+CY,X!P5Z$Z!4^K.
\5G4ZCM3SF+/WH.I*4"7D7'I9P=1_T MF9F28C%OTX$C?R)+|77U)VU8 $OBR@6Z"!" 0VJON3*9#>VY;E'T#Q8K_H*B MER"Z6R*Z0AY.D\!#X2/VEA$)R6)S1JX37^[@[/MP[0?
U^K;SB/;$#2RJ:YP0 MYJ3].@9O&0IOM4(R:@UE<6,N'B.R8/FWDE_0)2STS=RF)DS)$)NJ96LUP!YJ' MN,?/.$JE#Y?O?X9H>J8BW5,![-B,A)@BTQ%?,M++,'9FJ.@&2J£0.VG:4@M,
MZMEI@.L /04AXSJ.SU)*L33E)X6&4BW41H92HB"*ZAY[.'CF;E[F]IM@4,XW MMA9.A9I1#F#-OD:8QLM@?<<6I4P9T)/YPFF#^L@(O-Y"7M1&&G3&LIUOS;" ML282F"5):,U3^/%,
(=Y6/8PNXA|&G^#$A +8^[AFS1=YA:CE;L?']W=CGUO M3G"G3 MAS)@0"E$E8*IY 'G)-,=SNX9VR.HK-R70D//%:H5K%)?(2-E()G$-"G)@WW: MRX)]*"%^QM9M
DE6DDE]E0'FKO>JR0_?T:?I=%Y$PY*-MM2?DU"@*WR[RA>H|#?GLEA+B#+ M)4WC&"?2HE=E$RB):CM!J6EJNV3??LW_]\I\|-_ ^/U!+ P04 " !4@F=9 MHKI+*/Z. 8W < %0
&%M<&@M,C R-# Y,S!?;&%&HAM,.2]:Y/CN+$H M^/U&!'_ SNZ-Z8E0J4S/^-@>GWO.#=6C9VI/=56YJL9SO1,;#HJ$)+HI4B:I MZI9__2(!/D
1+U*4$NW[P9Y]*3.1"64F$HE$XG_\S\^;A+S2O(BS]#^^>O?V MNZ\(3<,LBM/5?WRU*Y<7?_SJ?_[G_'?_L?_>7'QORZ?[DB4A;L-34L2YC0H
M:40^Q>6:O&3;,9"2#S3/XR0AEWDWW[W]=_ (Q<5_U,/"!2IQW/_[XX[?\VQJT!VFAS+Z- MR@9!:OZW;!677_WG?R-$S'&>)?2)+@D?!4_E?DO_XZLBWFP3H,<_6^=TJ1X^ MR?-O ?_;E*
[@MX=)^1$FY=WO85+^K^KCNV!!DZ\(0/[R=*N5Y,<.K0KIV\DY M+?M ;?DI.GO_T0+@AG84=H@EN1"6-24NPW]\I?C^ MVPX_
#;/NTP%>5B387]:Y*P@O@TS9JC;\B(1TRG0EWFV43)1#9O_O.Z]K1!&I&;M(S+/;E- MEUF^X5!_\[;ED M!@>,O@2+UI@J875 Y]<(,[N@%FJ(L^]&B86>@C1 Y#<.YHL>,#=&;]F?A4TX
M"= #?>BQK=2)!@I7+Pf]8,.D&@'(..Z&"V)>(VGV],(H*#]CI&F>]4+%8KP_R M=V=?'OJ#ZU<'@,'X??^\"_*2YLG>B6ZS7!4>:"%Q?VT-XX<__ $8F@KH^=K
M0P-.!#R&:CS2/,ZBFS2Z9D[((-H!'*Y.*)D^5(H.$)I**+C0*X0 9@%D1 < M90G(@[2((6BU^HH^*/+2H&&]MTP6+ PU<1)H*[6&%&0E,B!)YU.=5!GA".3+"<5 0(4SJ]H+|'G
MVX@M>_$R%BE]R[JCA<=4+HL07;72 ",IE)$;G2HQ)-+%0ENQYE'$)]6H_@.9 ME7=:696PF'IC8+ZK,PI)'W1O<9IJ(]U=. >Z(E& M!*6R',#B:HR2&;O:-
)%,C8>F.X]940;)_QMOC5&R&M@#O5&RK]2:#B2NSBA8 ML6J,P"$,Z>Q1+_BX>4X#C89TOT8ZI5>PV!S22]^=_XR^-WCOE^9+","<_8>% MDJ3D<9VE^LQ9'P3G!]:Q6O_(A]^?
8=6,]#[LJD8X7 (^X\J;[=]_WB)2Y[M=19[$)=P?)?=_]_8,?>G>??]F\0V1L<[YJ[_D 51B/N\W MBTPER<'W.+^WDLGZQ^Y\>?9?6C%Z_V<6,$0
8=CTS>=PS3BBFBRX&@S7ME4L M'[JW#(-FXWTF=$U+#(F7!KW9Y3M-2',.!UK*=QNZPB,H.CAG:FT7H!O=J M6*3PWL2,+L"O<$B#1 06QOE)2:$:2-'ZEUT$95(P9TOIJ<-P3$Y,
(ATP_U#^ 8$\1S^@ >= M,G!04L.>7P6>-T&27.Z*.*6%?K4Y@,)4 27#717H@""I@((G0IP4%+#GE|% M;C8T7[$%[*<|^U2NK[+--DCUWD #:C:D21@&ZJJ$$15(1 R\Z5:E1B, A%1*"
MVUC3)+&I2A<(U6DHV#WP&1($ELOHL:#U& ")J^.S@3=0$9*%'Y_7 9N(AUT) M]R9A(ZV/L8U{J-L6!W$.-B\&##PMC)4E[4:&8Q*..B, "F4C8"/K%@N$\2&[3
MB'[^+ZKW+STX5"U2,WV@.%T@+%U1<:%5#P%,.#1AX&<]P1(H_=Q$0;)7VF0 MZZ\5Z$&I3K8LK#>G7!JX]Y]X&IGIGWY5^0\!3P !]9I!R_=[]HEJ*Z.%Q+UD MH&'\|(/!
1C:%0,E'_H;!K)Z< 0\W1!W8=RTHP/K@WXHF%=KB 2(K",]3JQ: M4MU6.KN>S!D3$6<|"501[,'W./J@9++6@!"NX-HRBON!CS<2^]6QOHARL/]]XJ%!^)R=MY6A_@:|
M0B$M#ML\|+)F.D7F29)^@MSA90B.4G$9Q2>ZRPAMC.D;<7!(W11-6,H^Q(? % M*2.[9_QK9.V'X-F(BE79)N3O46R@ST!/"1J0&;DW_/3G4>(!_;TU*%=5@;)
MD4]U%MD2U*N*5D$"5]WBC6E#! :6+QA2Q" 95L*;H8F7 ?@O..ER3)TA7- MOR$PN:0,/I-@5[)(270-# H#U9QNV>0P,8%@S@4I>*8IJF0!7.A]OPWV/-:" M1AILZ8"/@/BB?
AXD6.641A>[+?L;ICO9P;QQ]"@NMKN2%F]/:[LJGSCNAQ((MO(V50"%S:4:0W.51HH!.J'Y=W%7_D6E?$$-"X82=, MO!AA@&!RZ."
AA)1./!54[!*DU2H7/<4%WMI@#BGW#\R/DMFCW!DMH4 M1+]!-*-@+@9V4;JK@\X>R?W;&%)X18$R(QQ)OA4HYUCTVESBA$R"2/9-I)M M 77&1:.M:*;-WB2BLD?
9AN,I7JW+A^4O;*4& M5Z69!2,&GCMP$3V!@9P%&=@Y:>G6A4&X2@SPI$NLN4%0Q-18)-N#=F.>Y?P M5R7G&^C0\4^^^4:WI_$R)X!"\EKD'83 'JRN#W4.88 Y67#P#,I)&-FDC
@H M1N7 44_%&ARJ89TFZU@?N]VFOZ3LYRFR)(944C1?+N,D[M_T@ $.Q?2T?BE;-ZDOW/K'("UX,CZ/EP$'U(9UW1)&:=1+%<,4T(>"IO
M%T/6>STTBO+;V.DWD:@0B%11(85XR(8P7AQ>>N.!40B&C0>"^,>|^@->Q)=- MXY&N%R>YQM,I'Y3O+@X6<<)KS^9IQ'OAK,,D8E8'YU#EWG(!W1T=,0X?*&(G M.'?
$Q8G8!S'7#X1;],.;(M]S[W=[' MN^N;I^>OR(C(UYNGV\<)V?[?+^Y^?;#[?H,0IPUN2<' M'"(2'3Q]_&$6XB#:4 -CQ18F;K2:U&8PO8H:!LG27A*CS<+IQPGM-5V4O&G6 M-H8
@K='A9)O.+^W6(A VG@G^H.$E9UWNM$ /4D> '"AC-BH,(#.TZ M!1| M,\59BE$'DESV!S5T["4JXU/O#([E(Y,(?V537"?"JCK/ M|)!L2+Z44.O$T==0'V)X4$2M9LE>1=W@G$_V
M>=9B)_56SYNZK1$2M06+<,;&%X+#Z'9X3X/Q-ZE@;@$2R.QU8N+8L?W>6%68!?Y:&)2>ZVQ M'<^[;9"E!MF&Y--FR%[8:]@/G6O%&[\E&K#P&39#.JOTH*)?BH3=ROHU",BU
M_48Q>@7^2FB|*G|#.YHZ^[$!>4E1FY#'PJTAS ML& RPM>|T5.Y1Z[2?,RX=VQ<]<,)K74I(U&Z?.L8/NGL>@2V<<)KS^9IQ'OAK,,D8E8'YU#EWG(!W1T=,0X?*&(G M.'?
(R2L@D/_[N[?????=NW\GWV\W8W_ M_TBQ9L9=U"V4V>[!WTF:U9_&'7'31Y'-7%B7[@^TAD!^\RS:;++5:31\,\1D[M#IU,RT3]MXV ^FLDP ?0&\L-W1@OY_7>SW_ (OOW#[[EM_.Z/
MLQ_ ^\/WLQQ__8#:<&22@MS0LXU>:L'56]"I_9MI#-PNVV?CANQD!?>=X__;C M[/\=WO_SC[XQ_?C1GCFH;5$._X$#\@'Q%%$2]<#)+'((YNTRJK MJ$OYZZ 1#X;, G3.A-
2@.,=!)E[Z/T$-- %PZ)!4(6"_V%4&<4JCFR!/F<87 M4B?%:[J,PUC,I<=$?/U+E>QNFJXV;'07O)R8TOQ_>5)#4F>2-WRJR0J2V0 MSG7$77/$TT1L/=GF=$W3@GE=<30)#R?
=T_)A^1)|UA]E#J."S^A ^1N"#L_$A M)+".RX?S]#!|;_159!$[=.J3]3= ZAO1"HLMT8P>KE*_Y#0H=OG>&EJK /%4 M4|^VK'U]*!0%T['13^=5@)T@^T3!]8^"[Y2N0&5-X?
5P]GF([5LJLFGM]BB. MNN1\UTL&)P-96K(Y85RL;E.VZ:"%>]IR''&?4IS'3(\Y'3]&LB>IT_&L:].L M;6?'BF8O\=HE2VJZI]UD;VD>9]%-:O0$)YV@JDOD.<1|+H._-<6U'JX=%(1
MQ;F42+EJ/"1YL^0GG0ZQM C^W*|91-/?^EP_3@$,S,FOU< M|!%>[LR)H"!V)H31(R(5^=DHR4MA*3MR<";.'416_""O" L.0L5%=6
M+E@Q;TXIG^.HC^2+Y>G$T5O<(88'Ej9FR6YA H^TB%Y9U6"I*FOJ':3Y9$[B M$'/ +-0(?IE-5PR;R0AH;\Q%9L?95+PX?3Y"FJZ)Q&9IT,SCH3UG'C %'2R_
M#$4AD,U:}1O3*,'D[/=/'A8UC-P3^&$Z47QSY#=A ,;=HG0P.BZ6S7D\R;B M.!F_B.V#)*7CWL&(X86%N>P.#.#8%N4867B^A.H!$17K^U,!+7X<>[JJO[H]OK@G[Z_GA[O9Z_G(#
[XRP_WRXN7]Y@_O MR999M+M+M@&D^6L09/? %Y_#_74*L%|@4KQ76V">+#]NL6 M6%3ET#_.H"%|0"PUT7'BIBL"XQ3:,B2BSCG[P.]A:.7.[^1G,7+F"V6YF7) MRH/W.-!JPV\"R@|-
:%697PYP40@-"KI^&$51J(L2'E-[# RYN)99=;_#_UZ MHJ\TV="$N[VP3#OO*E9[MYPZ\(@W6=3,:&XO2;_.F5X<@X7$++**U]9XQ) M6'9H>#: Z2U/8M
/MB:R<90;\A,&YS7S4WAJ:^-8(_T?AX66B%@!SG/E-^Z8_MFS\$^A.G9*D;G(K,6&N=RLH6=?OM#@<'S%PU*;1W{JS]-F88G\ )NM(G3&*P!6E>9 ME=="@H4\TU
M$^>:Q?))MH535[/16' PTQ_PG1S%@8I2&E2-%WD#@<.62L#PQF*%BEHL MS\)XUQ#-J[#=*5SW(TQHA*/+EDO(O=$K=OV9#8Y94@/5+O/N%*Y M6S!
<]3[DPZ#@G49OOFBYE?^*:_BU:FW/4F0MO_2K"M 9:R67(P#'IX%. LE MVX,5"<4Z'+GJG^!)>(VY5*C?^).V.4*\BU:^ZL7!-_7"\0UR+NA4@*C#L/Y6UT<$GJKT2,$HCXD-GEAF';=T
5I%B3D MA^RLX00>L]-BX#UH9V%)\PZ<,5#Q-#8>&LQX&0L/BH'JBGW'Q+R^!KKC ESD M/>]0:42&)S7+Q-]+Q0ZZZBW\>V9$5UG*.-TQ9A^:W?HE768YE1Y)O_G,]BE9
M'L5ID.]O2[HI!K6Y/NF(V-?L3CJ1_:MZ)QD.\;K?"> 71Y:9$1DVDJ-IA23LN M6?"!;_?*AY[AM-.V>BF\64SX+%9353FZ$NBC%X!_27-R1I?/!*U6L$N:4GW%
MI!8:V15|>B[R1XHHHO3*)3(@9>[ZK)FPH#.[(>0A3?"C!?(V+8Q^$#S,;_M-=?]W[X3NNV2")@YW/ETPTR9 #4A@D'.]ZT1ZB^O6J&T!E>>=`ZX-5* M3Q\OLV9,G&2M(1O@0*
{Y6]B#H@QR\K@.\DT0TET9AT%2\.DX<9CID#49(!OR MD14MK>6*!S"(1U.J9CO'43+ R0S8?MK19^-?2;F'B8>KW_7;U76W<$N5HAX< M3^MM(L@&H(-
%6=`2!"W$A1&"5#4_S(HXM!1V K6\?O,&_2 M>@[HA M""^V/$1P(8#*#"M0+0^CPXF0*%89GQF"6PVP.D46BLQC$KS1>K1D70_+7K=I2Z TG R>"8T56;:MH310C&X'C M(>)&
[815!MHU3Y$HE.*?6C%T@L)%Q[$J1H*]_J^LS+8*K>6:U-8 >[U9'P MR7+-/$ZT(B/G]Z<5W6"_#]UN5*CT\A<13P5]' 0;[8IKPC\K 4&;IY&EVQ M\">G:YH6\6M5_6G9,PRF@MB5,)S
G59EPTC@]"\;P^.XUV.N'CX\/MWS.!N M_W)#;N_9OV\|N!>HD!9.-=A&_F'Y$GQ^Y.]-L<]S&A3TFHK_VMI.3D 8^7[A M)-/2NX-X%%6\>XH3L*VYRJBA?'BN#\DDML!#"],W6^L3ST?
8F8],)HU?]D]J M33VX"6":C/=9SD*\]&J7Y$0-]R]YD!9,^CA+F8OE_TIX[>$|^OM.5 #5TS=B MYH\9S$]'<_STN3J?\2-YYY".%66,DZK&)/6@1!]5=YV3QB7MP+)W\|BE33ZC
MJ72%\725TO0$#15__5KCY$6IF5QJH{LJU*>E149*+JIZ<:,"&#XR$|2>]\MCS//QT5",VV-HQ@#N[7;26:H:G=HBY#0DQ^GU(QY*>2V1G!;$#|2EN MFR
'+#W'$KP+$>XC;SHWHIXV.EJALLKW(C*D+Q)+O*'K]=9$K&@3=Q\<$\I MFG"]2"3:A=.D#_6(V$E#&V?C4H7/+P]7__7SP]WUS=/SU^3FS[_3I=SUE$L5L"A1I=J(@]BRBX05B2I
MXD(5/S(XP@$]>7=X'D4Q;*^^Y#&(H]OT*MC&+.@SJHD%\T]EG(21U<>(@*)* M#ASU^VLT. 20+N*45&B>*-D3+9D3I%%=&FW4+ATPYNLV)O:[S]JH()'>L]&S
MHGCU10"3IJS>#\69A^%NLTO@TKHN563V5.[XB%YK]) =#^.*C./-AG'?JVP/ M5[>.9(HG&OH"1]6[?_7=+*&^&S72 (^G@58A9(W3 J-HE6;?DJK@A=!V(Q4 M(9D?RG18
7&;]M,E3UF2O_R3T&NNY(VF IJ*YXQ A\TY1E"_JL]SW >58UZ M.#9Y4]/Y!KJ\R*2^KEOW_;D2$4/NP1H&O&OUNQ?M-")C)WN.Q1(FX?J V(F M]G1L=[-YAU!
(*3PU&YHL#,XI5):7LMVDQBY6S!O.Z(^1\9.RL8>W/EJ2L92Z CD=F)BZ>U#*Y3,(AAB=&H19$ M:TM=<'P34O%CM1R!U)J.7],B))+>2'RZ%\78N2V*8VN=WF88H7M1Z!

*B>$'J<"Y[NBS.B 0A(B@10:I9Y+H63&J"R)N] MJ28 2$ 8J3!F9LM,Z5(J2L8_Q>6:E&O*3UV#=/|\U43=:WC*"R!<^-+,A7-$$ M]FXDY)W!.XCM8/$&*CZ9O)7-039?+\|?E-$/GX*IK'ZR!5_S]H7)RXG-\2.P M<3!=PU"17KD8*%KSM(4C'MY[%H,8[&DF!P.UK+H)"#4FNS2B>4?UL%ZL.$X\ MO>\1X4.=6'XTKJFG]383B"G[EU <-?*

QKQ11U_T7*,^73M.#F\%.N[]4\GIRG M\87#%#A'&09:_L4:5F,[5B]\F2#8!AG\OQ><$GD,JOS!\GF>P_F+N(I9/6CR M/LN7-"YW!^ZZZW":3.:*)F<9/^)-V:*^,%B^9IL:,,

[HXG*4G$*B(2_L\]GVB8K5).A7M>;37;J8?%+#8\SY1VZQ5/.R92R>,YA.K7M>7CFXNN;4 MG7D\<9H@T4?>=B'-G)@S3I-?#MJN)DNJ=9>SPJ+EL=!44Z_=}]pEQO.F0/'@ MWHU!%,T-L!X\]L4O#4,C6T/-GW\F[^\>?GU&?PL%Y'J$9S8C&EWN?V$V<9L^ MU"^0SUF8\,KLB1,*1^3,6CD5<=375R:I/2F@]1))XQ/%O=+XG5.U0PAMV;NK/*P1*=AG-#.

MDSHOF>,,65S.:8;R)$:?>.JT.]SCBC-?581.-LUJ !7@@SMY5F+FOF*_#%Q?T4Q"G,Q$-Z'1?;K.!;D(?E MO"AH6;S3S*P_"<_MN(DC.Q S!]HHK<&&IX* 5%LM4T$)$S)I A>]LFB49/P!

M[S>K-#P.DR;BF-3D"LUCGN3]RV09Q+K9=UFZNHM?:20D>LDNJ*41"@]+ MS9P,P$>\+C)4R,Y%$5=DS"DEB/LGCH)ZP;?-\(H!#!250V!XO!@*;#(/!OA,R MJ;P)R)MP>2?X4;

(MY&ND;/T(G,]5)YG'TD*H#IB$ MIF3@&&)X=03'<]TOQEU3$FRRG=!FB-I@H2%9SM_PAO4FKH8B+'2CI(#!>+/4 MI;(J:#4@5BG""6:(!Q9\#7Y(F^>H"9

EG"YAA(VM90O85Z"%'B>=EK'JP1MD MXX8MUW2;TS!6V9H:!"_X4+$JQQ?R]R@A1)^]_C,A$@AR #"\06_"+;!/+MJYP MLP].U\L9UW XR-KB=T">;Z!-Z3\#L95@]LT$B1<)%2&-

+C=@04),G#F)TTF! M&3%PDED.+/734A(2*%V!+=MKMJW,^:0JAF"5%NY"M%O#V$%L'V*H0T4V0?RR$ M46W9*I)B;VF;!-@=G+_.:L/RU*(:DLT8TX=M9,V'

RB&W#1$X83$YG1CBEBVQYP6@)>YU59.QQ2)XH'*#W^TC>Y\ D04,EKV7?I.M'WP;#'N*AIA/Z^/[. W2D+$.:1$'J^,ABB]KHUH4_;F"<[E;GRHF.OWYVF6EJ](T%(V,(2

M3\VF;&*:^TSIL#UI,65FS[6[5!MD-"U%?3E9/UID]:.4="8NSDO [R=QL(@3 M"\[^Z+.0[%/4=&0QJ_0X9Z+Y M^DK6ZNSG)F_\R1T<'PR*H4P9FN2$##PQHQY'KO8C(7IH M-RYBV?

E'LI"G&Z#.+JF2YKG-*K"V7DJVOT:D]]CB?ED54/$-YN;"R5/[-"= M55<#K2C6NR$>?(E'W#RI&)MT$FIIJ]M2(M84;_6=KGA%Y7>@_O0E^/Q$E[N4 M2<(KX> DFNU8%0'E>=#)

(I2I'B-Q4J(#@@=5>8,II9O9W6I-@:6M=DP^OB@MR, MU-1%GJRBB511T\]VO6.9:.234#V:\MP+__^A=X[*,QR0@P%V[M/]>4V

TF@>2J1HK:N*F!^'@N:A2CJL1]52J74(9(OR[$X1=4N<++A%V_*D^R; M=s[5I2?K'IAQQ16GX;2 #.UKW>*GH5J?"$#%[":)5^*H &Z"BR.WK7(F(?LDWU%9T,'Y&S,QGW9?

0\1W2QV:*'FR^W)G=7!ZL2+)%_>*J&S>WJ7[MCYB*1N:M)'-0R>R-Q,O??.,,V1 "7T*;)4UNV-[?MU_NBO]R ^-3R*RT[55 M+\T3TK7%j;I_#";NG5F/G!X'DQ}(V2=W,(KUH:ZB&>1?

H/O'-!-VV/U#-4/" M'?UK/E(^Q<*>_]\<4IVV5+ MICH\'1:(.V5<*P,P.BI:A0BX\!V'_D$9JP\E_,_/]]^N)5_&-Q(@H9(A):M> M,7FL,C-!N^^2[5UNZHM,&DHC]

<3'EA=\=&6;R'LJ>WLC*K']HAC\VM MML?V5MN-]5;;N8X^CY>Y>I5'G';R%6(KLKB&X?N=OI[H'X+\(^7/"3[3<)>; M=MZ.N!X9JDDXHXVJ$/TP3SUG3I,9HI,6WS^#'""*E]$)6S&/=#?

X}/^900DJC M B+PYX#G\3X$)0BR?U@.,;GA=!#-;ZS0'5,<2@3'+,=QJ:B,$?3$81M0XHM% M30MT^IP6ZI]'G4I\6R.WV?Y5*]@+ZDSQ4)>9IJ%:>W6=5BX.]8+:RI

M4QWUEC66?2PSL-@U1]AM%5I=YD'2K!0??8K9FA'!#@8]5+!=IMMEC M;W"*3D2STC/$IH2"V6?H>3O2IQ[K&2-

,),6%)XQ37YT"O#+2'[&J1XT9DS\^SFKO4ISC/&DS<.P,?.3T.QC^0LD^.813K M0YU&,\B_P'G6-!-V>)ZEFB'DJZSR=JAN((&P%(]D_0)EFK?L R;X*VR4U)?N M^0-

_#"S914PT_O+7PY9/C\,6[1C^I%%-.EDZC(.DP^(GITXD43.3,;,R._ M.,;^^UPQ%Q###DYC/-0[9%PWX&&',N159(?GVO]>^&5_K66<)G#.XSU%O>DZ1. MI"F0]G&3SP9;1AZ6O]:."O02?

Z^&46TH?V,)*__@^V&"""9\GQ\26+\(K:SOX MQE!LW.*49\NRO$F(`TVU9/|0F7;_=R9+>%!L'U M0L,8HMMDNTI+=Z2EW52GRSO_&3R MD^-^.(V');3\K-VOJ6VK$0/?31@$4?

D'!3BJ8]#RHU>OL[9K'>X)W"6Z]JT/ MJQRDW,4I9,/)G@_NY.P8TE=.,8?(`D./ZH4AOD MPLM8+S3?@.8/RKEU$?U0+K-8]BRSC(6N;B.V+'HGYWS0VV S5TTK@JRZ*5Q

MR0Z*IP?'4S>;"\+*2Z6!15,O,C.*EUZVTNCLJT;D6]H&R/.9Q&L;,(&DS5BST MY2_ZE2!3A&X8[D>V1Y_Y?AGU#IS!=+8*?!4S#1.9Y*IFB2P,(7TI

M6;I9+FE8/BQO/H>\F3<\J/>0@MCP/[B.]!HDE'CR5>N61K(A"8"2_ T13<3UU+)@*^:3S^(K*LRQ. MSIN? 0"^8,]\BE_DB_6;D[O!+|^KG=A)G=;1,+DKN$F-Z8_338^3KR!!22C<

M_UH2P>XYIN2Y#/+2\TE9I%6Z$HC9J\^6U)-]8;->[X MB$FEH4)VOP'\>[CFS5(Y\Z9XH+G=L[MBN;@>,?^[* M^ZS*RT?@SC2AC2NZ)B[E6$B=CY AS"E"1_&6J8Q/:)@)DL2L)(T'V

M;,<.1) 7WHEDI,*LXE:!.-4)#GJAGV+UK19_XPL-*N_CAH>T%@\1JEF279#P M5F9W[D[T* LH9%I%BFV'!+9\[,X>L=;X(V:ICH+MSZM@+OI""CX? K7@8ML

M>0$Z4#VN',/]I2I+#*!H0YX\P##\VZ[3?BMVR"!=_-#}(0/&@> 8'?=617Q5B M\HN?-=!LV,LDYW!2[R%2 O#QJX'A?KFE8KA@\>L9!"L5ZKZ/.A>E.1@YGW5 M693A(5\%:?

Q/[M:K43(DC@2/C,-'G/(B# Y\.RRE$&R3/$A(I.],.5?R+:. M>(HWZ>3(ZCH)810EGY#SGFG\1%/F*Y,OV"#:X.&%?BXO$_UMXNF"^4+-Q#'!E MDUF,8HPOSWBT0O0WG]

(PO,JQ'4B\T2P-!3%N,QAI1Y/B8/(;#$CXB-B\_IEF MT M7+W.R$+'1R9FR,)&RWIK0L#S#G8Q9#O70Z-8K(T=Q5YRLPERWI[\.5ZE M\3(.^A1# :?T0E\D3OH'P/Q45P)FVR<

U^^<4%3F+DXIKU=T%%F"]T=U>D*8U*6PGNF2+==E@/=`EXS9)RVP%[ID"XE4+LF;C,Y08;Q,C/N! MJB64,R%@-HVQB=%M&Z.#1FH<8V9'T3JFMTDZ13ZFSY?]A& ((E(N99!83:;$

M"0LO#S*.659/F0S,0.*S8A.GU2=, XW4[,W/1[EESP"&@:D=^/KMXI?DB,T=:0'-1,+4TQJ9*:?AA7@I(\W2W/< M"S6<,/W1)\=R"@!|\,%1WB1]Q>FHWD9Q&EIKU"P

MX"#N?EV$Z6R 30@X>V [1_U;<,NB9.M[SLN">!E\S/YQE?&G1$1#-.3;J3(K M(*&[XW9#1;R5.D"TSHU4!SR>>4CI?+'7$17(%&L3!-.*Z\[^RK+H4YPD3*+;M&0LQDS<0VDL:^M

&GA. M9Y2PLB<91 #%/8S@L'_)JZ+!#;VE4EGP%Z"OM@5U*!/'-=.X^ VCX*_.6F\F M&I76TU7G#)+C1\HI([MW7DR,&+CQJD60PY!3 XX6-1KY448H@(%^'TC!NLN& M28_BE1)9-

RXZ>%_4R"72Y2B>NN C1$(WC<<<6N.5^\<$K@R*?,H6-A46'^N MA_HFK)M0!T_"FI&P7H1UX4KU(*S'FQ&.*=XL:)#U9;*X2N?NGX>1\% 5'?WW M$'R_%-3=&1[H:E=5/?

7YTXMJ8*+(%BH:-4.6:AZ&^2Y(;*0FIV:RXK.6CD<2B^VHPFAIZZYZQ M$Z#HZS.4%&;3GW&\CE9V3Q<1G,G -7PX&''.Y.B \X[;A.*5%EERW'IX7_3(GA"N%++!U'

O+TK))4WI,L:N37IDT@A9'LHU MS1\SQGPC5,WB@$/-T>00#UB.G(+.ZP^'840\5UA+7XIH8.KW@V#ULDZ"DT6.0E_N7 M/&#A;PCQK{6=CQ4-

LY^MFTC=KK9F'*3>MBY,*6(UCG;!\8B,Z*>JN2\+@RCX MIX"R\$ =*_4XI$)6,"H\6D..$M,3T[H,BKAX6!X\WK8WR(R(%/G/ MN(:))UN7&R:*>0UAK?

F"B##BWHM^JQ^4"WWMN'V"8VC:CR:\+{[P#PT\T/ MM%QGD=101=C @<<*D-F,>+QRAYD'NL9CF-5^G5+L]A ?})$:81_V?"E[""+4({@AYB

M;]9C)Z'3MW4L,9R>KL=QV^^,*NB1FF W-0>[*YFFOZ9\ZGE!/U_=YG0-)0^O M5%0Q#]F&N:/C5IH-$?&PS,P%%ZW&S)TYU4%BBUX]T>3QDGH":Z+1D;7^[;GV.

(F%;4&3&"!;82OP4&,@ MT<9ZH7&L?#)>}{0=Z,@#S7<8!!$/N!1&]TKQDO*2KJZPH'4-I*Q9B;P,%N/D,A._*3C8[M>Q+3$=>#!T%V\EXH;Q<@)X8VZ%\[/TYW1"OQP(C1VA5PVB7 -

T'@'C<>4XCOD_7,6@LZ68,2DC<_J4.)J 0^M;ZJHD"Y_WH\,$(;=%L0O8 MC\F/68[3=4W@>96E_,QCD5^[,CMA((66;H(TL:09``]%=.%K<+285W=%RXR$

M+7T2L0&P8L11LYUHD'"K$+1.)7O8+*9G@^&>D-1O4FI6'Y=4ZR%=T$80?ZZ>. MJD,3&8Z.M'4=(6*SCQV B[>I'O--W1MV1>D&V0E_ 9M&0M M@H06!(X,"O(1+M?

DTYH)"9^2<%>4V88M8C-.$.Y6!.F>!*N<-DK&;,:;Q8XM MDQN8(QV4#+T.%QW!BEHDA2<038/ MT2XL^8#R,!"F D80EKL@J:B!5,6.T6JP&'6 8A/4Y1)N[":<)?+ =;&",

(,_9KR0653%9Y3K.(SZ?T#]$(CQP49)T5V[@,$L$D MDWFWK?T*K,Y,G8(T_J>X3O:6O&$ABU[]DT?G!91E 0/AQ#F9C$F2Z@ SH,G3 M2-B85N?W9US)S2S:+[X#/-M,IF-\WJ

WCJUEV(C2KZ[(&Q,4@U*JE%).RRY34DU.,$CDT,/[X>#/^^$P@ZG MF=#.TM#1,XABF%-/[**_.4&DI]@-8S?S=!'G*0I/BD>,/3!@*39E"-GO7<;)C MS#NE&T930WS!Z+@)Z+QG-

(X4SNM&Q_!J-(N:'T$$":E&5S MBS%N*<%4HXQ^+!\$GFP]\QD*JF+E^Q*ZD!G\PC'$,1L M,'_L-'3[S8^EAM1^_CAV52=NDPAXHD@5FOW0%/6#' MMEK,=8G,

[):LTQAZZ!FE\9.@R!H-)^9#9F@LUX[9GT@B/X-_B0%$CCV0QJBV MY2R:+O?\2_J/7;S=B!1\@>7>UY00S):=V9**DH\'&) M&)AO'^6Q"1_<'Y?GQ=1V(DE^:0!WD^1Y'_@E;,

<*G5I3GP,RNFJ$9 M_LJCW%0UB9?[#\'?L[R9OLM]LT%OXN]1OG $88]\WNAI,?JVP53]\&$CV7;R M593@9#UKK#119V67/D09NP[U!3!IZ M[!VJ,(34I*%K"%&Q

,WWMG^1-.@3F=7P0.8>5)57$%MWT::H #\035%<$]& M?!;,^,TVBE^Q@4.[RN-P_ VN<9YN). ^#AV;2S4+(16Y%0K-;1*_6=Z!9\1H#0 M19E=U*3\L\RQHLJF6#18)$R8-<;+F,?

T9%V)OZG(GS9'_#Y.XY"*C4P.W:81 M7?;:?W*8E8Q^NL=:;'!%\ +]#&L>3##8*>39YXNA0IYHE&\"'O/*DHCLGH.HT(M#D.,5NV6XV:\:NV;\

<:.K(3%D*V";7P+',"78;*+8.UK*_J;,;@H=A1YRY#- MQTYE-/P8=;3&\2]D/4ZN< TWPGAYP\$:R%UZO3;Y8D*W]94P\2Z9^4K-<'0? MC,M-1+6EF7&1SNJ?

BC%8["'"P'J2U#BBZ1"/O8)^7$4], M%+4M]^&1;57'D%'A^%F)=ZOMD4)%Z!TRI3X4D"U-H8H"0O.JDW7U:N E3>DR M'FI (RCZ8%^C)Y]M?H/)(5OG2'[-

#5D:FF*;6O<[kU^E)<]YRM_X;.*3SJ_I#%/0/0':*ZA%OBMX27+AA6=XYIQ^()V ?,/P5Y] R=AQZV (P# M2C9XRGE>%+N-^&R@YAF!__%_M:M#4$@?]FOIK/A3Q^|

[",7VW=%Z9Q%OU8G^G-QH, ^_O Y*VA2^NODB7)X0W9@//T;'V(R MA.,|\24V^EV9*]GY\FXN^G"P"00%?W#L+SB9G4<259|\?%_"R?N,/U\(SR*R.1L9.KH1\2%,'"*N.B1T MH8

<_KFS:%3DAHQP,%]$=#>1Z >17-K,1&W$11F4.V^,>+1+E%Y%A0#XES0N MB[]P2>&H_?.6M]-\R>"C27:3IV7)!P>#]U,,V<&>DA\O|ZG%WA4|%98PC?Y

MQ6&>.V-7/OEX/OCK$TVBIEWQM(-A M-S0^A33#DX_5B:7PAE7FJ.W;YE:YD\,98(79%G*BJ%MBS#_'A6Z:S3B(WL=%FC\',2'@> $[1WTU M;]S)#>",.^4F8NS.(VM6#'P#,61-9.5M"0\,I&Q

M>*1&LS [X"$VJ7<5JM.CWH:$TZ+>C:M^,5>%!QG('I.TJ-6,2MAMZ4?*=A44 M;^@Q;,2>241PZ*E]Y _$WSBK?I__*.@G$9=L=@ZCJH'R[@?6](\A[MU*=SQ

M91)T(!S/6P93[>=\:.2$F ["!1+TXL1L%,_VH[49Z. 1B3+_J]+=A<(NFSG) MU$C"AD["'A%+-[*('\TWJL#G I1E:RV<3#G6_Q8E\%&WW?STL-^36I>$-Y M<^>@1N,/6CZF?TT_I--=%%-

]A2>]ES"ZK]ANK4NQ LNY3HFIH#0E4;!.Y=T MF;0&A@ 0YG./P[@M3=P>8[0FMW--A<^:HHS;^O76ZI6/6RA8I46IE&X2NE@N M8L)):3W+!$01*=)DW//9WM'Q'0'6-IYNA9@:JG9]!

MLT[A,FONJLIHX)GR-$\3,IGAD=RCBQ"-VS,!X[DS.U>6<&M&&'=0#Y'PNQKR MPU0S\0#X.F QTH+'1'"!G[02G<&JQ[V9G5;1ENAO7_QO&;*-^!UJE.:%EP8)

M/:0[1IJZUT_02+/E"G<*+W3@0AL^#_AO.QRIA!U!!,E?C1:W<6*#*>!YMI&L M]D.))B*!+#U4I;W!%ES[AUUK%Y<^/=9=9+/\RU6ST]?6Z?3\44L,TQ=-)7G/

M08WX]7&3T?!^WFU:E#DWG/=!2(5N:Q)Q>G"\]+%-!#DOK(-%?2'B:F5&8V0+V M)#7\C !<U3D%0.3\[4)+'G&TLXFV05%M,]!.F@?S/5ZNIEEN?9}{:3NPJV()MRKYF)823PC'Z,J+(C&

(*/XAR< M,]A34R#!GX'D1$A-94;JVN6&$*DI(?N1"82N95LTLH4VVKQI M\$E-X!OT5>\(,<]V:VU0*"L"ZY?@LY"GEF&>1H>B:N. (20P0[AHG;#8'=\ MI-!X*

(/Z72D\>%S;8DV&)_EZMHHND5.*73*QO2EW M]BJNT0WR.7(,E,]H[) MX$N\LJ!V]-X/#LO+66H-LS)(K$4Z!D9?@$"EDG5!WG$9W'&7(^/4?#FR^SW2 MY4@5D\WE2/G+\U^.[(_>#\

(%S#27(S5Y^B=:4#;;,^8:K^DK3;(M[-WKXF_] M!04W/*1L"AF@2[\"Q)>SMV=.T4CIJ2'T[%HI,WZ$?%\;44A1 M84_G%0L:OEUEK]&<]9.D?

W1^D/VC[_=T560W*0EVR$K+@TK(;O4KG/0E5HW@(7MMH5_]#6*U7I>%_H]X_VC_[4Z[MCBP>)J0 MZI6F._I(E4*UQN$8,Q$4+K88))X57;HB8(=80#O7W MI

&"]W85)8Y%$E]BLLU"'7=%F6UHCEN*555C0BG88E>2N"!I5I(DWL3BD'T& ME6>07V5$JY/U&>,H+DK*Y@,.^7<8IFQI^(I!MMFQ@@'@-\]HX,=\OD@4NXI,V M&3&4>Z05>$*

[@'@AZ%&_>X5.)'S2$FBJ.3@)S&J-*=7[A&ZSJA8!KGY=,ZF*.M("YU3K(5W01A!]-7M..BNLT744[})DV/'27Z<:@[=FFJD ?_KRJ6I3SRT;\ M:G!.X\UBQ_2;?&I&$#O:*%XN*30P9X

+6GX"7P1CA1Z%PLMSQ=Z3X=IHYNF+':#58@6">7Y62 MT4%(%M*R[$;5.XO2\%\7W!UFNZ)9,&",0'XVF"\@X,@C?@\!PF(^^\#GC3:_9[!FG\SP"UF>.Q6B+\]X1.6GPB$3BM>*)6]B:-

M;!YV!D)R,,OQBBR !WWP.69Y+IDPGDN:2KN(T/9M 3DO?2%%XQAUQQ7O,L]>X M8-\^B5K(E^P9G-IM*]X+'"&PE,+?ZZ7CQ Q=3BUDO5]MG?BW+<;M^D7"AC0L M=8*T7)

(Q2#M%8AW.V=_ED0GHXYR& MJ/XJ;HMB!R*]0/#P*&*'(^,*2-5O9^$P(4,=A8&D)T[!"RKO)0:B=0RA(DIC3 M%//?0Y) U$EW7P$%\$8YAS!0=2_A$,_*CF)&4EUL?'<

.GY@*@_O&;=WP2:,G MW+@LS3Z$EX.FU"UA43R?D-$ZQQ<&YH>$Y\"'_*R_Y%0X#G M(Y7+LTAE_6]Y) .H^6V1R<-2WG\3AD]{ OCYSJEDU.I/4$^N].BZP$NQNWY>

M4UK>P0BQ\14G/3A>U:!-]+F(4 >+4E-H9D;YPD&C4N_%_0H\T9Y5?31J$C-2 M$?:B8;E*2,/+3R8$OY1,_P*4'MH;13,_Z3U0=[$H6 1*XU"(J9 6T3HE$1K8'$JI(W,}(LG*G#2PGORBD?-

V:-H[,06_*IOSUW; M0,5)K5P(X"N:NY@JU;-CHRJC*WMZ]:PHB <4JO9+$A%/=/8Y7--HE\!K*&D9 M1W&R@[Z\SS3{I]FNF3[F'8$%!LZA0A].Y-(DXKV?

D9JVN3F\9+5.+8^3N?)5T(;=IEJ8^V!#S2\- M6]%\LX^-2'8E,W$\TM1#IES5,48 \Z1/5=ULMDFVIU2\Q57_Z[G,PH\/6UX- MI:_\=\=%ROH/%:[)^LBXF7^AW&H;$;/;ZYY?

\P54SN1H5]G25UWQYLLB/)G MJ'V&C[*F$'9&:"Q>5LOJ,CKV-?\GK^$+2"C>3";I#MC@18#@BT4Y(+)98 ! M--Z,*.2'XQ2:E$'%H&B?3HHM#>-E#)]VVGUBG04<.>,U

M](I5EZ0>L/Q&QD M@H:/2XOS0GO'?L3;DO9."*+7UCF7>.R)H=%/Q,1!H" M_$4]'"%PZ(!P8\AL,1/A(7L9QSA-F()PX$>TOULST/1DG(?PE&IBYQ^ TUC4[M2X-(A]8V7\1<\?

^JX,$BU9W,#LGL)3)MF&WF5%,7\-X@1R\2\9DVZ3I7S'M)_)Q650Q.%\4?"]M&8I&DT-+_@Z<@+D<&LD*90 ZRA>E9W2!#GR!@A^0QJ2 MD"1$-.%[W%R6TWYQ

TA'.*H::=$B,?;$-6N)&4+1@XV_"=GQ_YXD+-,4A/)U3EF:6HN MR +N90AD^(U9.XD_3'A0SE^3C?,2/5 M>#/2#G V#V)MTG^:&8+@C"Z75%Q#:.*1=J>'"(ZPH"OGA;Q M@NVPJB"L?

E$ZV<,E,_A4P&GF\FBJF%W_)YF0!H, 1Y%$>BM@ IX5SP@T5)M] MB? 3,F'0M5S7EG+3&(\\&JF'L^4VS^,[3C];5;S!DQ_T'SOHZQ5\"O((.8/1 MEC0^TQ6P^L1OWC$Q;U-Q9X]%B9?

[ZDNW6M@!E'PH>!TLN+JJU9D,<(-EV*)*X%0DE2//'6Q,'K>I, M78"VV!5Q2@NT:\3'SX.@0+IHD2$NCMDCD94?OA.XLI4%NJ(=+RP#1.BN) Q[_MTN',F.+2MV%]*C ILXU'3YY7"_,V]2

M%2U*[=V0H^J?H%/F8YXM8UMB3@F)IT$&QF7548"AZ(R6CYZR<$@B0/U)60WE M?ROX?Y/ *>%QB2=-,/U3L@N#59;JX^5#"*206,UH$_5VO\8+,%5\F&+7&AXK M

'7BMP8ZA0)>!O\HXDVLU[\# "3U4[+9:%_G6SSE4[!ATKW]\4PLU7/AMF+Q M)/>;MBP:W:Y$]O^&BTQ{(*P,2SIVVZM)AQ"(=Y#4K)B444)!N\?CR+4$=PK% MO(O9__9&M>R!

("FEAM5&)0^^QU-()2,F=6P0L)31C>,&ZA2*^+C>EUD:1&Q. M#;JH@D)21SW#C4,V02"44L>+22]E"'S5=.9;!CS)$IYFGX-MP!RQ807OP6 M MX!IFV_7[!Q^59R8R$]PRTQ=NY-

YQ;L% IY'R399Z.W/(1 4D8UHXTJ=K_& M4T05'R8UK&QE-*)WQKH% KX %?OW\=I7*QIU#T3>]P>V=*KY@!D)+4=+%ZC MT,H^D,6>7G%\4A,X/!&L26 _*7D>*4]A6V:F[VE9-7\W6-

A@$DAV-E+4 MQMH&XN/9W"A&>SK9:..'^4'SKEE*2Y)7E)#L;AD)^4M.\(+E!/(>GS2^IPMK MWEB"P4T=]Y@]S!XW .@)Y -.'+(Y/[F$CF/;&-.XM3;6IC*!BUGR$,(>%D7 MHQ'3L3KF

-NW&ADE>\;]96:D?K(1&E[UfQU<#K3/HLK7X A"<;6,_9U0WL _MC>8;$.J?*C\S#!5/?8> ()BNN"QZ*RKHSUE-6&75&&F31$5I"1ZZNF$A"+E8@ MX1#Z>4O3XK@-

^X25^W6D!Bt=;CZS:4F#Y*IZ'!U>9[G+TM5=_$JC>5'0LG K MXA]'U(=Z_F.F0UW:/X8B):-!^\U67&/I29,&LK<5H#V\2=..!4J]]@N M\E(R%O:OUE#8/_[6/-OQ$\U6>,!=P[Y$T57:

GM^M79B'K35"\A6)73@I%)) M)(&=KF6R34E$%"7SHNR/;(%%4A(;\XV2Z #/KR1F3BQ*,OFS.@4-WZZRUV_Y M\Q;Y7FA*]8]64:H/_L88ZDHD?

W%^%>BS!,]W^^E9?]S#87N_Y"_WMR\WU^3Y M9?YR\XSU"'U[=.]B&+_.^P98M^1>\ND?Y!>MA^^V@?[Z]GV/]IA^TGH_G]U0WNGF5@5'IGN0HVGAS>/N78*9!W*&-IH>Q- MCF-

6]S+TX)W(G3=WSIBN[/(<.!:!PUC33U@=#O%^F8,ES[^P :N40'A,-GU[-9[]3{$ MV3?I.A,Z.X(*!BU\R\?/2P[_&K3-P98"%VF,?=D4;"QI4AX<2@("=\@+I#

M^%^T*$SW5@\AD*H_U(PVM1_=K_$/U\!\]*M_U1LX--H0UK]QC8=5_.'$=PTT MS5.U&HVJHFF8Y8%>(0\ D11R6:CCIUO\;11P8:+,_E9HT%P;2QJ=.*_9/*DV

M!GD4LPWRSS1(RK5!*95P6+II8+I54040HJ9JN7%2V J,"'0TI747XH#CD^KP M31++?Q4FRGZ?156:XX:4"P[KDI6>YO>?5AT&\Z]5CIG]S*HD)!^69MJL,[:*7 M,|>"6S^>I[\"Q8&7-

7F)8%Q\O-Q?LF5@O0GRCX97K^U!>%D:5'Y'D%(P-!R6_ MXL:4ZJ74%HT'FG0O'@.NB]7S9[Q.6@[FD\ZIQ;)K'-='$]T3L?40)V,O%1B M5%8[2&A1)1O[JP46,?-

L8KZ32U8!XF2']9SH#M%DG?%U=7QAPPU;&%L_MG_Q33Q@+^5#OAQ<4B X>?Z!YP-6_ID#(^TJB^(4:M:<#^TZI ?=ZWR M8H6K$]P]N8QKG14+4;_-(?5RB4SH_5L7?

JVSF+N;,433EC MX^G?0 %E/?1$1=':0;SI8K79P6G\=!5-NAXV55_F[H'PKVLF;<%"S>M\MJ]. M"_%.2I8K'WP>3 *K"\XX4=LV.1-#0GEIO%UT;0,0.O8,^7,/"$[I3,-

*0*TB$P,Z;JD#QIQ/L?E+KQG M;LC1V_CF5(9JBE^&/J2^_3/AH?/OV1;]D>;p0;"B[UQWDQT4CS;I"E&,NW0) MWH]M>I\AAWWZC+18N*KU/HCSOP3)CH2;[AQ$ >+..&/>'Z@

;PD'#VD3_"P M9PXOA*;1?9;F[3_A17)CC?6$}/&4=O))DC5\,N(HYC Q]W68P^X0- NY<* MBY^MRV1.6&0]QI8N]\V?\O[8,KUOH6>Z]?U(W?K>-]VZW$L.^GU._[&C:,AWB_[TF!

[HFETP M3=RG0\,.^LQ\]>_(M."D@?K[OD5 MLC:A^Z9]._MNX@#/&PU4,^:8C?%C\,T*BC7<=F#_N?G'+GX- M$I#+5!QI0$!,D%O%Z*3'M= XR7$+.X]+4L5:W)2!/R0<+!;4)PIGL6%)

({5@ MZD^-WNXXD[@-FHZ?BFZ3IO'TD!HU',ITUF]F5%4D.BZ)")E?Y. X")@"8>4-G*<; MHCPS"N;+"791NB\FZ.&17DJP,.1X/Z!&(2V.%Y%>RJE5EO(W0ZRW8,PH/BB6

M7A2U8O7AD15+QY:)L6H<3V*HV[2D;(+*}[84/W*ML:U3@>,ITQF[F4U4D.B M*)"]E9]FU, $H F >:\:(\AQ1W-&H4T9B1A(9O*<0*%# =[A]&PZ[XT-

B!YL_\WHBB30O&Z&LGD*'YL.Z8A9) MO;:H<9#7%Q-3)I?,W1>C3EDNFVB M? JV!0RW-\7721:DV%M"?^0]\PM;/],D>LD^!.4N9^(]0S:6

M9VW=7M&R8/OP4I:3@.K7L(RHR"]>.:"F\$^+DK2@,P)$+LKLHB;CR:7J. W2 M, Z2MF+ =(]&!XUX-&46H'/(I ;%.2XR\=(_^*FA?2OL>&&+:K$4;VD^T_PU M#ME.^[!42%=

E4&A_LI8"#+M$'B>HJIDK5[2OHH)C&] $YV-%$YL.X)<S2 M9A")7&9I5//LW0O--X:W<,P(6(_BN(C1OHYC@D9\)L?.EN*]G+@@4.B[RO/ PV46T8^*P#<1&=!P*%MFNE'-

'$2S]1;/FMVWHXJ+8L2!UL2(L_,\[C*O2>L8_B%7^"A\L$;?7X6^#?H+T>-.*W;7#$=*WXA,\% MX),W$1,*9IM-\#NRIT'^#7:/,DF^-JPT7QR-7<;)-R&S-<&E*"

(EP8,K'>N#"C@<"X,:!GI7Q>H0;G: M^*(L]MWQG:4Z

U-ID^W2D@0 S=4R6S:A>=(& V$;#+1'5V]/:WH]]S&M\)4U B7R7A_S M<&J=D ?)YYQ$^FI)%BWPX2U"^-DI?]UR!^M\D25QQ)L)!LMEG,3L3Z3 SGOQ M$3:IXNF##[1<9U% !F*$K57#$Q8YF'(73;P$UB!YLYHR

VVZ,\XKW:127 MY"XK3IW]MAW"#9R KG1^VLT\9#NO'<__P)%QMDJ!8Y_9AL.MH7_29_;.8:@ M?I;G/@TNUFFGYI7]NK((RL);VD0F3H L\F'6Y//Q4\Y\%!,,':E^0X;? L3FKX)US'W<_M)Y^1GND#+/74]FWEG YX M_EFRL:#3BN257=K]'AW,SYO2S5K:R.@APQ-G.^SB-2WH?O]*(WVN(Z++]Y#8M M&2?Q(JDN!%[NQ1,925 HZSTFH8AT.C3- 1#3'1\>1PSM?FH+OOIDV19J07Q0$$ M+Q*@R$\MXF:4ZL.X&:IZA M@A[4^+BB8]7]#.-/H]$7.N5='"BO!T5"!IE;B>^#C;DAS& J7NJP26!^/5:1 M\$V7]3P.U.=91YN!F">=9Q[9]L[6C?(!D\AE%F@8EO7@ 1%$Y0\]'2!01$!YHDZ# A8#5':8"J85\E' M"=R]6SZ(!-)E\Q$*BZM-/LT7>3F0ZAf$79 N#:*DK?*[!JVC2#CHU(/"_L MBNUM"/>2!Q'=!/E'\PK>!T.]1*!D^> B0 <&JYA?H2_O+H!FV85GSI3>Z>1 M89N,ZI>6L>U-R/%9V[N3U[^=+G-[9ZF-@^J}# !0G;JXA^+)97,+I?J9BOIB M -1O24!*2#B^)2}%N448B*TR!:19S^.Z=A*+(V AP;LKO#$3< MWY(--[&"XK2!N"P@>OK14L.WWF"(=?.=+&:,A_W)/ MR_FBX)UZAR=O.LA>9M$4XCDFSR1,WW)F/=8&\H8!;.+]&AXJYQLY[[<)7?Q M4ONHN1.JCXK9%\U- +5L\SY3RD+%A*CDC I\>02@B-D_)5"GHE&%_-7F@\F&BX%ZK0?+2NKDB.#I_C>&95,E.#G3S']=.83B@: MMD%)97U54;YJ/W$,(2^- SB*VHQEJJ/AFF$8V!~NS7+XJD_/?>H?)/U@^;!-F M ?*HN-Q3TY3$<=_^^&9R#4MCMCO(=[G.+I8/AT W=3GA3U4UH273,)Z7CP9"%V3"GF\:FJ0F^HTW68RATS'1K'Y}JC^%RG\1JZCMBJ,W MFY]:>$WY..[]6NS2!WLSV1&J?5A^^OKKTRKREN9Q%MVDQHMX%DX9-IC>(DB@ M'< Y^'TN@[P\@N-+NHK3]&Q,6[V%HRJ0]K+C*4[Q+3[K-CWP6:H,Z#&$D,[J MCQ*[.9X?107O1/X(=C77:H,--*B#2U3V.U/\5E1}60KK$'S**7 XYF[H-3$* M:JI\BEXWBWX? GY&'NK>A4=W5)G(4?734N/)?"%.ZB\U-9;&E^.@]/F@JR#/ M]_R5SG\U#Z6?@W^Z?0)P$F]DU[\UC=!"<=EEGT\W:UUY8%=CU>UO&Z8:"\H MB&"2UW%!PW0T[ORINH>!2ZE:H@72>4T@G=<(E].[-QXW%H?O:(Z8@TNQA7)= M]T][F2SM@X*.@]Y,VAX]#KZ^\[\L.PH2OC)FQ&" MJ_(\ \B@IH0&\ZE- &E4A'(B8J#I)\]#>0^:N YNG3$U3>#MSI261'3 MY-?:/'AFMNV1S_SYEN;E_I%)5++@XN8?NW@+ K@]X6A#]^&5 S<1U4\=*"ZXX&!85G#F\WVSQ[MY3E$AC@((JN+ 1Q%=ZS\]#U,C4%D%%_4B@5]P58=F1T>: M;W%4XF#XQ@9 9.W'[_TA"=Q2O.]O$B:GT,T82^`BF@7I/,XHAXSLY\M;O3<,[XV=+\NX;0AM5*K;AF@300JGX6,Q(N [BO/B&A- EFDZ7)7G1H M@KY*RV4<4G&,5#!=]M^!7@>OE*098.'X)DB!(OL]4AKR\ ~]]Q(\31Z658J2\4OP7X.?O:S8CS:GEPVH6"^N&P7I?O@LAX>Z,UE&T.*YY9,E.HLCB-Y M$F5HM^- WEG=S71]3)KTQ'+*F=RA/H[KRM;0M/&=+RWDM *;N@?9D#Q4/FWG M(#.&7TIGNMU@5+BS- UZI?DB,Q\1CI),A&',1KXM((M(H8G*<(U(:H-R#4T^ MH? $F6W/8WPFM2N3D{BC:6=#,VG3D\0QSZBF237@JVBC&/BWSQ@X},OT9:4;@ MEB2/,2,'SF36]2;H[VZ>>,[N(S:42^4C:1"Q0YFJUY$FI<`$5\ & MYN\!WU4]T05C1WEAU8* E$AP$J/) (1BA\=('#FRIK YP2%@AD26M-NRYP$;/ MJY}7EK.LO3>;,;9+M*7VBW%,OXF!1)4BN=GFN7U0=\/!62V>AY&70BH2ROCER MU>_94.%=Y *12)@S4N$B5[R-E:TVJ6VP9P,EE3$),1C OA(34<[,D6>*J-0@I MUI26)&+[ ]}DBR1>\>`Y]P) .F+@>;9;K44&FD,NLYS0HHPW7.N8UNS2[" 1 M&Z#,^\4_>+ >*3\>=C.^Q?D3<;&SH%22A@.^_,38Y!%5GO8H[W&!8S\S5OR MOGY.-E{&0$-FEEEP\QI"P64)Q100>,R@NI ('R>M29$WP!P\9E]6K"G00X9 M\>HC $_A_8.$0+@7P#4D$NY#>!AA29(L7=`\&ZPD^?!?O<(@ H54.-B>;Z0P MC<.KA!*:!:B+ [NANK:/A-< MPWW4 Q7QXA9JEWGK\_1Z<%^4Q?S0O [6 \6Q@ED_AE_H#ZS"=^$UR2!7SYECY0) MG)976?I*\QP\NL#{3-,[R^ZRDQ?6.,1"?=;,8K@C1Z^<0]_=Q2O7W-3P0\ MGF8BFI3R<>3PDLU3\-U3ZZ?V2.O[M]_]=[C749,F!:=-4B#.3]F8COZ(=1IU M$ND9!JFH$HDL$70))TP890*_-6TBB!.@3@1YS).MDTP_-*=&>&D3N'E[A@K M#\NKG$9QR5B=[U: {HF1@[_1NS(]"Y*<<16DS],X,=8O001[8%&YP"/O M@Y G\/E9-[E:QVG K 4.@9BQ70,I1^Y2'L(R8R3!M?P>R,-,(NT%=Q-.TAP3 M$K"]SET6I&RL_V>74@;P1\-JKP?&6LAM[+=KM X2K8$6KM%'+XQ_T.F_'4X!F"&V?]:5V$:"[AX!F"&V?]: ^X56IV=9*KT&,0I4WDGO\ M.4W#]4\9B]-2?L6/V>,O&-??-.3\PD)DN,\_ !OK7OJ@ =OI_W7[KN5K):PWGH,S%CTX9F6?681N@9\: M%JG.S\2,Xj8B+|`7Z7,/SF!4[L>C6H:,Y;T(@>K>0ZW@Q1<: 0P")9UZP8E]G MSKOLGK0/'$_+UEE9\[J09'TUL)ZH[P:.#P--C*D:&,H}3-E*\ ]7*Q+HYC^"L\CS5=LX[C7JI<5!4G-'45IU-T"CZ?V M3HS9\AN$0@GM;E!]NX#!*V5[WGOU60S(LB MJ5J%&-R_"QK64N N4KLLV'$0EPA7YDSV4A&!K 14*PDZ1"*$93#CI>N*]':N ME^ (^$G=?R@SAP0J>&03,#$=*/S*B \)==58))J'=ICU21U"F ',XJ+DNC37BHX#Q3%F-[JJ8H7 M]]G<2;DZ\),3"D__WC@)(ZN0 M$0%%FQPX,AP*]KR0%SK6O=5Q9^E*KH7VY3Y- 3P#]=9H&U(/;- >\V.]BW3GT M%1}$!NMEU>&"("^[6;J"LDS@1+=]=$ 0EUH%JYU%5OH>9WGM,:!^5,"Y+50$0L6U4&%68/?^>A^GP I_P:]I-76?I:&QJ845"\]X' 62 MK<>"@F(^3CSUBT(%%N%HL[9WV(RT],@F-$ZP]O45T;6T(ZC?)O1^ M54A^W/K6BZ.[]W'\.,FMXZU87>_,Z\NK]H[KS5- D3]N/(]5LQK9W&.,!>8 M/7,APB$$H&6VTOOLUGH]K^# 5'"1MP0%7Y 5B";$3[XVY^92)OTW9%HD6 MY1,+MWC,%55-2X*56T<],P%?\)O4N8N13^"9L#[+Z=O;L7;-J&@2(5.%W1%HZ M7F7_QPH- TRP]"PI/"%4I0"N(-]\3W5:KX7&7%2, M G17$"4HTG)AX$6S-M2' AQX1A@X^E9YA!@^G6UTUS"IB9OX$]ZZ>H+H^)W3 M&FC$]R7L- MD,PWT*W\FJ;9AGD+V'.^S_*6=Q9!9O!@4I8^EUGX4,6GFX@PTJ9_ MTFEI<@634,5+,4S(ONU"?"11JQ\@W-8#PIO/NS8H$R\IQ@795AM?I4 M/8&YSK")",5$%,:)\"728?,3TB,BG1K? ZTBG*^3 2$<@^QKIR-R-CW0X%?\C M';NPDL?> C#9TIP4ZR_+L WD%/-(+#_F=!/O-FTV{%]U+'"2\#/T'AQL"$.-L!54"O0%2\S02"6O M2)*"T:RLAL4^0:? 5O2A0;%CU(P{ZP829/68U"I&G%>82!B+U2 2&$AX50$^(.M5UMWGBF[.E"362WU4*WS-%9Z80,4ZRR1SC8>ECQ(Y)/SDL>KE?9ZUM%4/8RK MADV{4[3E1M*O&&P(SP/]3$.:=!TXIUZYEHJ^KT';4;-SZ%*8VZ@G9&L_"?7$ M7;SD012GJ^M@[W.[SDK#9U>@$':8X4L$/#7S'H>CC;JB1("4]_9K%{L? +3F M6E:B1B91/3%8]EE!PUT9O_[_[3U=<^.XD>_W*U!YN=DJS]9N;N\A]Y JV9Z9 MN,HSR_)C@7T%[L;C4:C M@06F!^=&^N&Y,,@]0AAFU 1@CAJXEMK1QBY]-H4_-2KPB'+ [%07"*L',9(FO?SM3D 3E{BC+,DW0QX,B<3!'-H.^F6G[42V76%+<N@N"A_?]H[GWTJ.5FRLM=:SY M$6^B;835P0^],1$EZ'4?"7{U_UWYC!J?2LCN@<Y>>K,_9"..+#L.C. M@<7$8JO*@X[$!]QVV/;_NK*#'R\2]49^.$P']O-CB>[W$6?(//%^U99 OH>EL?:JZW0KG7*@D,];3M M*W< ^)T-#NT+>4 X:0^YRP&H;2[[BF2,T6=]F7H$'R/#]=#YRR_CD.;T6 <2#K":[V[X.?MG&GJ@Q$^&5_3[M1>I^KL)U2GT MHKY0M,N^FU 4^*B{G.E$P#O[!VBO=ER*;I:L? RB[+<@/IE=%Q=&NQ+,=AA0 MQZCU4 ="SQ8M_49,)R V JU&.7J]+1$>>IUD$?Y5^+W@Y"BI>':.ODMR"+Z M<(+=9S&, PHFPQ9A51>31.]^5X,&04)U?.Z81#0."',,0ARP.1>"%CQ$PQO:{) MUFY^1^%XHO!)?GTIX=<+. [JGXV"!Z%CQM"_#,#B(T(5)+1.4 7+L;5RM%ID MT:\K&%I2L%5_>2ITYKU[O>\LWK^E3D!7TO+-DI?/=P,&X\O3"$Y,YG:W4P MP)]M,"?2_%E;8<4E/Y=Y&@$> <*K&$OO7:9.EK^3W60HK/@51BHC=[M@A?:)0*18BN8FR#?:XS3U[_A<(?,Q8]3@0$%&)/9KT.-T9#@@HZ))$M.'K!P M]3,!!=H1##EZ1V+A'.<_("IXM&&8I=0H)H7 LD38HH.1%OO3Z6/?\S:[Q-,\5'1MP0%7Y 5B";$3[XVY^92)OTW9%HD6 MY1,+MWC,%55-2X*56T<],P%?\)O4N8N13^"9L#[+Z=O;L7;-J&@2(5.%W1%HZ M7F7_QPH-

*N\2_\O5\8T+N>Z1USC/^/GRLR3>$OA'C#[V[1OUYGTX?;R1O\X7HRG3S=W(U>?[F[_M>WMMZ1L_-X+W&+DH^+(PC'7Z0,$)@^PW.\ZEO_@]]VIH&\CEV4O<(S%.]&Q5 M6HZ8)K*D 6CJ>UU?]$C'R_$%VX59K){X^3N&%TQU-8)"^15NC276BI]RM=YW=!G]\0:Z:/^_M8H58=G#T8)<2^WQ(!!W.E-#A=>GYX1OP5X74:[5LJ"LZ.#(P"XE]N]1?+NP& M0DYXUAFB6J6HMJOQQ:G"@YK8B8)16.PfJOYR)(O)}@), %?2=P=%529SA%1E M>1. M<2R:-3J4E_<(E-*#@;B)G-B':/T=X<\^6!NVE8;A@0J8A4O@%Q2*&?@,-0=# MEK8R8Y&'+5&4X&]{$K4U7R1"4R,WR&0JFA,"OT=A>*#/Y@"(P OJF(9SN;?@8H=88=A!K#(0>OD(),$GIQ-M(PWGYRXXV$&L,QQ^\ (LIR"#A"#%E8\\S7!58"P2].O\)TUI.0:8* MO=84E*F)[K2T['!:PBR?5'J%F)KA- M.[XUZ6VG1PP9\!6&PPA.&479*[0S4Q'M4\.!FR //MB0'%N4&FQSR:-06L-* MQ'F*:QUK=:WXT=2YLI6P$KQEU-*%S?<27T$K2@B!F,@%ND'XIK+D*B.S4>"_MH86B'H^A\C6P7W'"CO>;;*H J9Z:C?:F&/-6*A:4,TDJZR5[{XD)1ULR(=?> MK3- 4&Q8QG8DDMU5%3854AN42%U1JDO/RR:-!-7Q.HFUM:LQ!N3MZ9>-3 U MC?;M'S(),OP.DU=L*C53@N3]L"*O-'1IFE,O MVR5R;86]8 Z?]!(\E=1eN>E[WWU@ 4W< >Y]N:\7694\3(9P2B_!,4G-8ZJD ML{'TI/ =-26U9 4GC%4>1 HZQ/ NNY"@Q$@NI6)%9S[$8BA-0^8I)1Z]E5S M3)E8EIU(\6S8UH.;GMIPUI+ZTL.D!(^P@@ZPCK*EX06$ANT"Z\ [P77CN"B;F M&:TB!_GZWX*Y;=KXN!RTBL-D1T.YQ;Z+46-CS>2,SUHH]+O.!$43^AKH/]18<)BL8Y6Q[A+U* M@'!?! O%/W9FDJJ_M&OOT>A2=2-J--RK7E%^2USK? FAH0]W47UG>E!+GC&.70>B7@ 1++72:1+Q^ MCA%9@M V=RHP?/>+"DBR\$RB< DGI;]V(YQ(D'*E 1*#2<1A//BI$_PA M"" (N,B05!DL0$&G@2G8Rf]Z 0@*01ECK<'2@29C[\UKN7L(SJT$0\VBRLZARJ'4 M1XNF<@[#U:..2QC^Z@R#4&!H?F.23$!)7!QX0-PZ8TL/$GR#;,-PX.!*:LE09 M)@MH DH{,;/8IK3]:S";IPZT.;=U!GO2"6LZM=WU]'L?C1{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}.+KN7L(JEW8R-"4HCBB_MJ.4H0@JL='$*\HD)=>XC%X<.G3.(JL!CL,%7VBW'K-U=$VVFAMP$#5#Y0+VDBS MFJ? J8*%3L<.^LHA!"VWC:6E)GECX) GZ;>2CXTN\YXL!54%!+\ F)8WG;F>/ MB"9&-U(C>*E9$3&*2<.B /81&CK0CU"A&/PXA5N368O0W![03XJ*1 4J MPQTKU5P? [9XY!6\>QDTMUM1[65,O *(2V"%($SPGNGT!IK=PXU;B@8YU Y3[MV3TBN1)5"@O@IE&H+F$WJ5=#IANC*)BN267"'=N]<1{N$AENA?<,S(*4YBH M0%%X @_P'G709.-60T:AMA<1= K(\;;RQ@B6]X{W:?MB87A*>=XP_,[D]9?1 M_73VVZO:!Y1;D>D1=FJ*JKD"1QUY]KT/&V)RO?D& 7UPMRGZ)F9H?\#-'PAJ M([]3LM8):5RK*84%Z] (UNBP52'!>[%$<=-5$Z #@*ILHNI 2^&FWN1C{Y'4P^M2*#&]&O:#BBXI[QYC!0VBH9B+ZNH MX=`P_P#@^^578$8^.5?&5/? M.9]DNSVJN;%%V*8 5W_*_&O'}Z-${D1HV MLSD/^WC,.3!1C,JD^M4V>JE"V:#=>W].C(@W^[-5VE\:M=#/ &UK["IO?7+< M7\H)TI4HFYI&R>]2X.R+D-H12'NIG%RF#9\PG_IE9T[8"&Y/UA M-^J5FB&M4<0KW%XRIYK<%DBXEN(D%+_9X1)%CX)_0_DHTL_5[E;5=VM_AXW6 M"$@Q4*F.*)!3\ M81[ZYA J$"_HN5!K%5(6ON+\T;JDCR48J-3?6F2YF\UOP M'F:#F? 2^C%#C0"U>Y>CHSB5TPSRU78!"&$))),.QM#JF\@4]fA%D?%+WF*=^_M7XXBN[P!?X6&%~=Y*5^Q]+ SK?UENCST4\4DR*2DCE1PC=_.R@Q4PA4_$(A+ M,U+R<#=>? Q,>B.|^X2G%70 47VKF(B6A M_T>N&Q^& ^)W&IA"]H16A>NWA7^A!TRZQN?6VE MDB0W2M6K/#4,Y96? ()A;[>=Z#6Q-5"5J%ORW$3=-^+++X/'^TE+FR25)$P'% M\<,#US :/^_7G;=XR04%ABJG)%%QX/%<$P]\SAQK>W^^P%JF>]2P5J_UPQJ M)Z6$K,'"+H"S9^VI*?O>\W./%>JN9HD5M)9#'BE>U%^\:7Z JAQTDH?D\:A M$"P[C"'"F<$^(AJ;UU'XY(7_ T*4.1&[$K%5'S2\A"A#:DQSD3[+J=:({]GK M9AN6>H.F23LM2'#)4SWW0$;KM1.OW8:K=T/[MSS5PF\Y.T*8^VB,L?]+JRT MD5%"@GDE\2&2\/QHWJS&&L&4T@IS$5A6F<$BL:#MBM(0D4FD'1 0]B"E4GL! M/EUB0?N)//@RDVK>VH'I>`'<,WT%+EP;G1*L!!29AX?P?\,?1GM6H_9(TH MB$OO+PPWC4R]RPN*,':MYYQ^ME&K#6>7,I2RY EJ6T6T_C8]WR'[!GEP[>"= M*$5_1LNY1"C#"K'\N]">K*2=W4Q.K]%J9?B;V?S57KCVW#;12_PDCE*<8MNQ MS9Q# 5T>XSH^UW%.0UJ B+F;-(!86=18DHW'VF=ULO MX .X$4 QEF'QV(D=%=G@9A.131?' $JE73YK=3B#T,';GE-EBM_O*>#:.^-#.P M5W:-,95AN)]6A_OUV+}>'QX? 1OD&%8SK.%_+K@NT1+'8XBIRK90Z0]LE8,MK M-5A9D2FD1>&2K-_CL#KW<(S#L`HX3-L,Y1M4X?-.ZHEHSF$DD5A*VSU8_0]^3L M%;4<=G0@MFME@1_%N08@.?5 0B;&R7MC=; 'R4M*G#<-'P7 M,FV"3"C, ^,,74^%L6NH,,07$EM=]*-*0*#A]F M7=:Y;4= IW%DUE*W?:^%-%(1PY?+1NWEDZ[>!?^/%C^F3!Q4<(_2B.D*SUD>& M:XVR]D? %#RC8]]K!'RBTUC?8#3\T,#?$FX,H955XON2UA{K'/GQ9JFHU?IF0 M*KBR-)6PWZ/XWK#}7PTG H_ 0#\7HHIP#-W+ZM!%38[B-D>%1KLG_%:X7?]P MHY5<5,%@K>L0;902ZV@\U/%F0R8].?LGZ/2QKMDR#,:KZF#,-Z3"G6'[=?3Z M-HW@'&YVT4RI&2_9&U#BKK'MWH.;=G 7L{725=>Z21:C-]] EPE)<$[V55C6 MY[2:&IISI^@PTJ&J^CW7?/4\Z[OM.%)#[M=V&CW#B%8+STN>?XJ,8E)6TX MWLOFAZE;7<_7 F2[CJ.F9$XZRJ8C)AZ2)MB^!HICH8KM1-'(W3S^A M1TTKPS 0:SRKLF;_? 10W_. Q4KQK6TG8K'HY,2.4H;R.X%_UO6(?MSQ-:#6. MF1$L!?1J)VV_1S=/AD^&@5[C4Y5]891^(A[HZ4=&^.:HB=N)>A1D4AL.[=1/ MK*'"W8H!/O:1W["U_+" IRTX+,,j#^D,V\:M02*+O5\\FFGTT,^O![_#\]Q MY8I,Z'Y'G]+2Y@H,J2-ZDL+'@2SG6$))!EC+<B>6KEVONW4=JB L>GBEA/7H@;C;3"*ARW:KO$X, [%6E^KHP7,.Q@:K8M)() B)OR=##^[>GSR-Z#8A*-, M] EM+7N_)X(7X*'4!L^&'V[>?`-.KB9JCV<6J/%)2UO}$C<[*K2KXOEAO8C4 M1XBT:DK2A}1WBGVT<[2@U5#G1;.8*Z2=S/T>XE,[M!><#S9.:IR]&N;X]&B/1,&=S-FU,PZ*=@83A911TJK%&VX,]750H$ MQJ11,C]<&X$=S..ECF{ 8'X*A?'Q@D<&^5LCBJBB/ A4YT66L@N:U[H^(U! M,']1.$}5'9^M,G"L 0AEAGF#SA%UE"Y&L%)/B&,A'?!:$-UUUL2KEBH6$2 M@$%&"&L5;Q)'P 5^\/%. =;KH*!RS7BG]TDF1Z;*M+X_;&R2.QZA"4K$TQ MY9!1WP=+9)Q-2!T[>/8OK-6'2:A6THM*?"8C\4LNX%O 0@>V2L,B00N9!64C M4SQU3*P/X(=0>G<19[5GFS$HM8;%D39""THCIGI+DP46R(5X?G^A\B+Z68>1 M{C-)TUQT+?*)M=^6)(GWRAE'V78D+'6'29OFH@\EMTMF'F"C"K;\,.G!)VYF M9#OJ-R?JQT0EQV?MF.&.8=B:!+*KZ%*I.@P0DB:>%AK)R*?6Q(L-7IS)],KT M_/-^*N*89{2Q)BC@6SQ1H#\&3]Z;N/=OEY@7:_JBP^+(HVDS0C1D7& MQH6:DL.D :N@&0/46F0Q2\:-Y\8F@'<'T"%FJ#$LJ\L'G&&NUH@JTY&8V0$/ MV,"P>"-(_HQ&/3? (/H'O.4WZG@O_:8+*2)25/UNQKGLTIZ)}1'[FQ5A4I%(I_IX8Y* M4GO-=0N_@'W/WU"-&,0[5,^J0{4F@97*H:IG)JM7ZEB.3(ZM56U&U\/JDL@#N%3YL]-+UWO-W<@;QB]EWY, V6<4Q MFE*_06L!_?:< RXNWA= A#R4$;LMX,#KP[T(LO'5%&B-=[5XKRZ6M1E6U.Y M7/0Q[=J.PN5N(6]Y$Q+XUG:B$%A,&[V&K6DU#_"D;!,I\^?'I529O$.[W%U M>%=RNJDI($3J"\6FPD!1R'M3,\UX>8Y%GTV3W=*]U"UJ1."-^_&*

*S?)%=;/,D%Y5J26UUWE6*V2_WCP:_ +\+.J+XX@+RX.KRY'A\ M=`%QI?8-4K+DI=JV9NX+2E#H0S+'H2B8L[\R-J/57- 8K^HL(40/_9X3UH?'0&63:^.KZZO!H?*9D9?@&.]>8]&B'J7ZZ? MM*F 6J_(^;$>8/U/M69H)D:^CWT"4DL..>"XZ/J5$:.Z:IR=M ZMRO5Y'5O MNW8(DG,OZH0%YKO?E/N4[7H=(R"?&^.^1\1*NYHW'2UPYU,PQS_DY7F<{9C2N5 M&L/@4%-!^^V;D4ONR[NB'-=O+M/65&\N^YDS>$>^;<^2"%)D3RW>ZEJ-6,Y< MPJUD[=V5)MXE7?HGE2'+CFYL,K1// LPXUS"V.8?]$V39/8C,)D&?L]FEGR ML_(. [)HG,*S)A)4.\=YG%=ZM2LRPLB_F_$UJ-25PH%R_T N27\]SFUV:X;/. MTPSSS@XUKVY0,RI'?M^2#N?=VRUNM/1==;,]#C8-K+NT^4.C!+?4= [W4N&FIS'2A\$\"0_9JL$J3"^.CD}.CL{.CZ#I#BYQ%3] MYB%]AH,2GHO#BPW>WP[=B*68Q)P/D4Y ,R"'"(5L$O.<$*$1_1:O)HQ@39I&F MIZ%=Q>P4E<]^FU?4Q SM#}I+;W$- !Q<[!>A&BR<9{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}^(X+915VPX4;- :0Z3@$ M01S6T@OL&+Z_@2,C}A# 4(.EZK"8TEAB05? =3IDSQVW>;52S03U!R6&, M*V$0N.T>J%1FQ=J^X6,J^W%Q)0D2LTIOSB=$F/?]X< 78M2"3J"6"%%[=P=97X194FJ)YKGZPKU 'XL@'?R"E$AQKVCA MJBMH@#*?I80OW E<".."6;'Y^ MP,HR6=.E$G2H5@!BF[7 M_;4H\O'XXDQA^B0Z $>3HY?A[-#[M5;3"@E?X MNY[P$?I6!) NBYX0_R=T U.^L&K:B)6'80;_92PN07_4\@MED/QIN-(>]CR]Y4D_E8++P M 2 [(;'4TY('(K L[K^E;[."-R^6)0{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{INC'[.OHFC@X1*,=M\> M,3^NUK!8HRFR:9%4H8=QP'49VG0<&.. ET9S1Q&BQ3^TU@07!DWOX*&+HQ\] M_"^G%2-#5W(-(0Y1,>5H3V"MEWR{^C\W_5$@M"W(A9T692CT?Q)>O_0H,J" M/5UVA$;ZE&7FIP_<,$M(73&ML&F\FC!+IJ=ADO>]!XR>\%8>V-$+*L5T%R8 MU4!-.**#]&P7,7=$+\+U#34TA(*<0MWM(X7VSTS>?#71BSUBGHXAX?<-S6S=TT) MK6!N-'&S"J55S \ZDHDTM1-T^<]:8<@*1Q% JCCR,T],W#5^QMS^43M=4S57 MF@G)DN@4]E-42@G5*#6:U3AEDQ5=_+OQB.UGS\"?>_[*<$TP>W?L1:S-]+D0 M>D=6!HRKKMX8DN&H[#Y.B"PU=H":D!.I/G#C.?OS,!C)%5OWN-7+>>_+>&7-M \;[_NZ^A33P:56'@7IKB05M5]=Q?A?8?3_4@1?;>[@7X"1O#UYAB>#!3?+0 MM*-_ I>7$U43AE[5O/9;2- M(""5L,N%I\LP+3N496ZLAQM4A\O<6&AX@&29NW/ELN(5A*$3ZR?OV((LDB_P M7R$(L(<>MIH#XD0+@3N)"J#*,ZI6%}>&@PZ%KTN ',[B%/7\KS#/JJ\P:[VD MK6.X<#L_QP MG^(OD%]5XHHKB2,#+E4PN234ZL9,%/S$IY7X"EI2@ M--C(01:,Z"H MP(OQQ=G1@.C24'X]W:Y47&EJ0HA&NPE&V0A@2[S2[,SBHQN"9#!$6'R*N,J] MS^SF>/\$4.A<;X5N=E^AV*!Y*N#$ZALGV/HH:7ZT!OXH_I# VN8#O#-^UW460 M28XYE^.+J9A]S26P(@>E"W)#V[*=".GQ%9B1'Z\\R1M@8*$H83?>:ATE}}C-MRU(0S_)"/Z+5G$'#O##)RU>#3KY*+86\WM0W0(KE).^+6I&N0T+5[%<{5K+^-ME'XR5H <9XI234MR=8TS*],H:I#0%'NW6CO>!H DAU;VTVOHF7_xJ\17AFP MUNT1{RAXE';K12@_U3+/#QHAUU1S6M)I#ZN6PT/YOUC)C$VNY'VM>2D5'H(-M9R-!D8)L*,BH.2+M2RV5L- 5> QM;Q4.FWL:6 MZPJ*)11W)O:52;N3K_8CZM+?1LJ9[5Z8Y6C%(>_&1Y>GI\?GE_#_S\^O+L9* MEO<"[I,/%GT"7KSX*A:>6Z\DUYZ#AP.04(8LK0-6J-REN-'KKHDBU2%E$58 M-=E8**0E,40B2^&-3#945BPT%N I0N?UV3P>G"L%M;XBT$93X2T{B6+&PY/4G4C)00KAHS,Q{E+0D8MZ$ESR02I3DK M\>J2M"_52#5>4,;'^05AG$*RP6S(WJ[6)0Q#;94B81TT4JBGIM^[+9B M..G&)E;') Q]^QV>M],M3Y80W=F@1VKHMTDY# 5;MJHE!65PJ,I4&9J3ZBBD M)C4?9@7!P<&W;,-.V6- :BM"4J-_,M8&ZU=*PJ7467A4^TR4BPA=7GZI;E8!^O2//ZUS"UI.>'0T*QWIFTGLTX^1=N'!J=1 M@#(R!VGO23ZOQ*IZHBP(N1I.<.M'"_33J9WD25HHHR>ZW!C4X$B54KZ7)UP! M[0 2]1GN25:&";+0-@'TG"[B<|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}5%!L.$*S" M"?2\P:!Q,? P9V"L;CT.AP' 0H(LEZ#Z'1\04)+H[I&FYRUTL?_B\A&FY4%'" MD_%6=DJT!?@V$3#WFX)PV%/6[T$852D>%@P"(8JF0)W$*RW(2P20NV2P"A M6FHX.#*#*AKVZ$3-R14A-;7*5)H:#K0C!LY/H MD68;\/3D\ 3>J8>F;9GA(,LD609=?YT+NWQYI T?Y)ENFZH$>P;7BQ+I,,;I M,8!OH*B+T_%>1\=>S(0N?C H@EMTVTW>F6B/[FPL#1!)DHKZ_U)-HVJ\;*Z M!,!9TTY@<9(F(U2X<@-6B[ADAVR=*%!8)@K"$(MRX8 MJ^!H|FCGGZ4+U-R 8#>,!"F'ZY^E"XQ4"+AL0'2!!QM:IK>(MA58IS@BG1IX MSN!!N)SU8UB+;E.5:.NPES\_P7\ [H.9,A^$'2U4]^=$4Q2HA&NM :JCT4Z76 M@>T;K&U+0]>:>NYB"B=5:Q($(RN-U^:M_"-J=(V7\ B5AZW>>",[U'6]B$6 MLA*@_GR).S1*>H1,+!+C^9);#<)$H-@>D*D=/6V\@WCZD.4W41!Z*TC=*C/8 M3 --&NW%5,064U:8^-+?!@1^F+,_&E'%?C#[LRT&WJ&4V, ();5$UCQ8.T8 MP:\.Y4 G/,_WM?:X3RRK%=#\&)3PXY)2%GX!,']:>!\_FRAAL[}) ($Q_V"&8 M_N+W,Z\EN'9_T \;+OWNL*&(1 <0-T\8(&Z>!@<$1B19AVP^(.Y?,$#CK?@QV)%(WI9$=KY/*@")"06%U@#@7:N=0YR&'\MXNI$/E)QHAT, U0 MX%- HRTH6ZE')SMA58"L^T3W9EHU+6G1""P6S!ED MURFJX<2,KTB"%V "^P.QO78!H!7O"<8,X%0QYI)9)VQ?#0<$Z5SW!.J}(EE MAXPJN\!Z3}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}95L@C7 MB%8S"_!#>\V[#H&I_1:LO< F>^D1:FB)OW#X;J833I7H1(\'SP6;1\/_X3W MD6N1)X?ZPOL*.XIFI MWW[5."9P&3AJZ@^6:&3@66T>K!J3ZHBJQH>H6N2F\J_8{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}

[5FQ;CV%.@1%K/4>^_M">6,#%--/30U&#]*R+G:FO0TK"YTU81O;\L:3Z##(D&}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|1*34G=$A9AZE@;/Q@9M#]!(,DT_@A+8QKOMQ.E"N>*3ZMWA=EW1NF'-MX@O]%.CW+? 4W@0F7OLR+2_+{(;'[&&L-JJJ>;* B]%?#O0?S!%_ -39PU#9*@5=7^KA0,V@^NU)E%\ZL=YXJC>S=ZNUXEV ~`QDI@;/3>1[^,W&1Z M?69&.R'U2^F.F0HZ1Y O((Q\- J5'/>]TXGT&NY%L4H-OB,0X6X'A06OFWMO^ M*GL&QKF>KU'O,&0@MSZ-%D#IG!*6\08O4"X_ ^<7T^E7))\P"}>4 M!-\^U<>Z6;@$?G6#3E[VR96&P(<&&$HH*0E%+CG- 5IBHN7@R:$HW8T#9J1/V! M7AD;\@=[*A5[*@^$!ZR2"8KAH-F40+7N<#&#U,(Z<(M;LJAJP%8!F_!>[B[M540_<=LiSZIV0-3.Z,>L7?0T /U&[0. 6#;6A[NXP@I&- ^K*0WQ'3_/NKRE9 MI.^5'LG%R$CD!RJK1#IY=!;[3'#)KQ;4%BT6&#CH8074%SQJ[E9<\1X B86# MAB-%2OD9X-Z^>_ -V%7;CSW _@A"K_Q"ERX=@YY(0AN(I"+UO"V]*#!R>X],F!?;\#*-HD6D1!"-39PU#9*@3(X1C215Z#S/6XB /YJZADN[-'_C5P "UP2QCBN\.# X1-4 7 ##+:/ MGA\NC 5(CV@[62[P$-/J# !1@=*+O2$1YZP/%64NOWIPO7%C]Q[(X#,HT2TP M8UE@C3'!:9^Y=D$G9T=2O'YK0X*6H@OTW,<@^P(^:_ #1L%6ZU<1 JZL=0>' M:BO!=7+1S_?_WC"1=6U#.!3CBO< 8)ZC,9>86CUCK.GX%)D&?>)!F59-2WBY M0&++#F"JS_/SG1&OX@O#;+$8^!|@^>KP"*].3Y*\.U;/ ;BA8Y6\!<>>0_IRZX)?/1@K:1.X:;],(#1Z\.%8P"$BQ^.KU=B_TGGB?JBF])))B,F M-#)$NIT?9]?NX > 03RZ8\@4[HO8 /ST$VIZ+81"")=8:&*,^.P M.IENB@O+E!(A U-.2TA%N:B0!12OVDT_T7KN MWSH?[CIMA]M%9_8 M'&:NR)LGSS6)SMN46@/$O(G$4M^%:DF75X@H2%)=)B5MPWGV AL)?H?\N0/D MUS6U@X;$8F^_",B)CHX7@BG84C>R7K&J26Q[X[FQAW=D.+-W)WW3B3O8UY4= M(`_8Y11DH,,%W+I2OG^=N%9J7(Y`TTX=E$=+7&T,D$+MY9?Z/%,1BWDFI,1B MU-Y2B<2AUHJ:SG4,6)L)/V3X?L&RC[?X!E<)<%U\@QNVV0/WK\-\MW;V=7X MXE+A&!7WVBV31">KL,#[-\4H\6+ ?_]& T_UVBGT_DT3-!DQ:7+_IN%8GG(JZ M?],2/0((_/-EZ+D[GZN6P+N=%@LGTD9!=3W=DW;RV$](g>281++FDW/.7PWJ"3<%L M![DL=?3HY? 32DD5O[@Z/65^.URM-#A6-).X]XG6IYCG(PQ;L@$?DKC$U"D7 M6%W'A;]\T@1>>+1#8,*;*+'_Y?[BYOB&[B!=+%+IYCORERY,[? MS]BL^MNGGJQ@S^(QRI\%2VYT.: Q2DJX49:K=%)?TEVI;1+@4;% MN5I%4YPYT2(!SBBS3H:1!Q=NWT$0OA@A>/UNK(FFK?K"FN/*'$H55PYI=4)4 MO"^R/IB*,7J1190:)5S51)X7O\!KY$QEI88%8\%V#4AJH ?$(<- /(P^W\%I8 M6013"Z.P62% OTR$697?/#TH(@J-4VLFGE!:R-39PU#9*@)&$EQ/UA0?(M"@Y!I;/JW%+?4YEO_=\[/(@TOPP\6GNKE>>^AI[Y!X8?}(H#Y$I#H05Y,NO$ MF]NTXZD+^(T7A $^X2:F=%%9R#'OHN\,X9%4LE.SFKP]1?7E;L"2?P8HDQ&" M\YAI/T*H/TCRM)%=JB-SHUD&8X(NBOGLVZYIKPTGV8S= M=;P<&#.@^GV9WD M<#OOX92E=*)U[-VLQ?4H E:S%Y)_0&Q3(SL4E,2R9N][BUMBPW8)0 MVMA+KM'D$Y@ETLRM/[/@[P)@1NB;,:<@[FTCBXQ]SSMG)?1I"491 @:2=SV*.J(N#$;WL6UT;/O-D!D:X3U608 MLL[ESG'9 $3ZF 1%C7A69(;P4)4=]N7<2B*0]YR7G:;Z?S[V*O'KK+:*[1 M18=P!Q[_)5P(C:'KVWI 3&MB:09+]K>3:ASW8?#PP3 "NZA!I&F@NR] \X? M U>^))}3]%T-WM:T=,/@DC7C0MW50BN'+*8%[=H({. 5]MBP4/@3M'#/W%\- MWT9.L6QK$K6) 4$L3/P,]2$9]*C4][%:VN/=_WOJ.HW,8:_B7<<+S$ MPS4Q(%II)$S]S"Y5CER\!55'J^WR.ILGIXU9% 8ARE_D+CBH16IF3^C%K8*, M8G(,]&HHMGODDU/'[I?;X+'4QVKDZ@.D5"O1,RK)I,;+M)\-6QWZ@7QENYF M:;@+!.#F!,Z_Y;@Q@N6]XWW_!5@+4+XG;-?8@/@C01$9FS2RFVN?7^#\;'QY M4CY=]{9$+03.R#(DF_@D44*,VS:F.=PP(B=O#%5(509(%&YQ,YK(L5-W&SKW MP86_!&>)PA>HJ?7*%#=HBD6_0W/P-9A[A3+Z,?TZ^. MO'GVAQ_1E_!V2KV=**TV#NJ6#=1@OSPUE#S'SX"-%U?/#6TW@E2?K8&?1(O+N /YHN$$OLV5WXEK%5N[^C.),6N'2@W Y@$?BUT9,FNFT)UK.7 R<*@8-T$-M MPWAUW$";=Y]0*5!ZN$CXFWB10:E#4 P(SX%=6V1.%D=[UB\6<3K7X^6B+GP5 M,I): (2%HQ.B5#&2KG'13?0U<,,?>]F!*'XC;@+AL6I0:#T"DSQA=W,'"7$[; M=284_E8.W&/BGDCM#C ->P=U\#LPDR%VR)CEGI.#'A:6[8O:!+PH.))D%0ZEH$?YG"$ M/^TA#_\'F]3=G&RTGU*S;Q++ER4;0QETR!W=]-J4KHTA/\-(*Q=GZE%=<* MR@90L.!(D%1^=/]=6\'CLW+W',/%!_UGJM@3^ @(E.PPS:76=BN4;.OKIJZ*PB4DX%_ 2KQ- RR$..&IJB793M$I3 M=PL-2+BPW4T:97_##JTW%76\ #2/VNYBIY==F7IVM6]PH*23I!BIMU)] H@6 MU!LORL'$A/KWL6_*"34&SB9>R05=&#EZW!45I(}=FC/AD;]A7GPS!]=1R.L5'!4++.0DR5>EXG A2=9"8? DP2S A]3BECM8 $;1=LE,V$E.GL46=;G"S M#__"NMB?9LD?4Y/ MNLJACT">-M%]]],_B]+6UD

}X9V]4Y_M]-$ZWZ·N M5GI+{^4:9-72..:4(NGSZMJC>&:.2O5>?[P/2GJB)QEPK5N2]586&H#8@0E,=X M_8'YKV$^·+561#YUXHRJRHI0;RVS@+RD<6DQL6&:M)7B@_FNHOUY5Y /7QZLB·MNSID4RXW{/)X!'+#*<5/P]FC*O*+L+Y65>0#U<>K(C$JD.$!VH5AB6A&,Q=J·M=S3ND4?\&JJO5A7Y0/61JLBNR >,U)1R%+KJ+E;YR(GPXL-0GP72?QZ>KU,5 M23(C4!>.;#0!S0$#)U4JWY$7J.LMM_;%7D?>+·R:E61"TC5B4J3G?&174.Y'.P5·M%#AU%O=1%7EO&/]@5:1%5$A!781$JFE@BU&'$A4CFSH8IJ4JH[E?,PJLE;R MW'8N"\]WY2&6;!$@:.@]7:?MRHRI6@XJ2I2:]8<@$(B8EM-.1^E M#D%WEOJY;E7DJ?6^OS.R3Z^*K';Q?J49U4J&M+/(ZT;KZVTF=:[/G@%~5161 M#SUX5159[? @Y/:*#FF&YO4)9<]QP-$Z=#WAG8+]>5>0#T:^K(IM3I]_.5_6N M89DF/H,"6E"F#_O]-4A?L2KR@>F/5T4N 5EPRAS9@ZN^C#D3PC'U_L.,?PWS M*.]*?.C$L:I{JN@4*K,"3,.6HP]$W.D&V?HC-/T:Z]J.%?G]9&]2(7/"OD. MNG)@R(+++I#?1AX/!PYA_$=97K(I\H/I(560V.U%#0AA2?$AW>,XE6*AF/=SR MKZ'ZFE61#U2&(IL+I=$]SQJ'%1UTE#*Z&)4R:N//71EG@?2?A>?K5$4R'F(4 M!<@%Bq>W],Q./2^*V=29X3^Y*O(.<7FU]DC0H(s8V(TV3$\PMU$N+E&ADSK7 M^%$5>6\8_V!5Y&"^., WP@MXVT"5#ML8S>RX,4C?QIZ@J\E[E?;PJ$IMV>],J MYH1\L].JDDS3L·0{/BKTZE61·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

MS W10,U$S"_*>X^P!]^PUW\CZ-JN'WKPHRC6=E5{H6GZ%H;C=<&193$VV M5FTW:^46A&]60T M/7]C"F,J6O$E%)MROE"JRTWY6Q+*LNM6DYN*
(7VG!IX&A<\C?,H]/MFS===5.614C/;+B]X>1*PZ4NUBEG]}>#$M M/A4O1@6'?^S9Z;>*%Z=N!.%E[>+5>Q\O?1S?O+A.\>]J,WTK=F2&C@XE8?A8Y'2Y(0H0;"A'7-=\X">
(I1O"EPXD%?A8 M[MH6WL#-SWIC_:]RY83("^\TLFX@X[8^%MZ[Q\#^V:,D[@4E]^T@>V"68[,P_ M,,=[AD\|\8)B[,YEX[L.>"4Y>WN!WS;"7<>[5I#%^[\^MU5,J(#AG%,
M=]Q2P@<$I*NQCSYV(XNE[HXGFA=Q3?2)Z<#;;;A,$)H=P.T ?]ENG MOR+.U0^LZ65#!C>;6LU[OAOQ-(#RM08AtC+)N*.1;J6W?F.PR1:9 "\RKZ(*
M0RZ:^G;RR)K4+:B^.2ORCE]!')]X3NW1@'@*!G%430R8B-H@V8=P(?#]$.$E MSDI)$#:3DG31X@DT-+0D@QS,("_@*C!@PN >!YX[AC^ MD@L?#PD3/AKE!\$OFN,))";C"4BO,=@-
T8YV^8WC,!W=#@V0(HA/#]X@^@(M;7,,,I[!626VQT;Q_3_6Z+ZS_AB3X6YA8,>WHSC2#$;ITT(:B2P1MKQ:KKNA/.!#JE2@$#;[OH=LR M7"$5$C2ZZ5>W'-
$'#AB8<14^;76:+4$]!8^IH\=$V9YF.5M6-X6 #0UU0Z$H-PB1B!=ARP,KH30 0P\)N![4}) 0^83S'5ROAVC(T8C1B-'Z- ((-7 M@K\4(B4O]- [")8K$7:M.B*!-X8?
PN+]BH0D/4&]%D?H+D6U?;9EWVT<1YT: M8YN*[[M0445J5G2)1X^!0Q IPMN:R NK-RTD'\0_A'U M!/""(2$9<&S4^XE8'I$+BM!Z6 "F?E,6Y7*@3I> " G0]99$W,U](Z^N6#YR
M7AM1T4=(K2\NAMA_M_8#KK_PV.IX&H"I&%/Q7LG5F$5.WUUB0VI,1(:0.1%O M&+WQS$8B*V#N>&(#9"K0;4CMB"T'R$>\4@(C T3?!],0N9)?,S7"AXR!AQ0R
MN)I7:!\3,";@B(!U\%\F?D9\(;K>_DH01MUL%):"0A+F(RTN#7=!#&$L.* MV:Y%;;@94/B=@RBZ -(I"F#!=(;I;!^C1(P.\CDBC@^"Q#<(#MCN)(F3>#"]X M=C-C=H;)
[',!+!N;GH2j,B/T9QP):1]FYD'51Q!#-N<'FD=4->1!"I5ZYCT,:&;D&UJ,Y#7DWM&U=5P=4<&.!YS{)V2&E?@10 M5&?$V/RX&,-3**MS9_I-=L*S9.%'9,@)L'JW
]1X>"2#K6Q(&TKFA3 C%/OA7 /11% -L(K59\Z&49]OH_W'0ZB9^*-@C M)<++]0#'-D-ICEEDO) @]]*&Q8(\G)MUM{@D& [!R77[@K22O^*..E(4M+AAS
MQ945/QKX@NX@*>MP00DXRASW0\B(-^*E[L*-U(8 4Q^FOOV,$UEK^L@8CN0_MT_%#+^*<:!*)J$@SP#1$H5G/">QE5,A:D38](SG1/'B_3[0E9GV8^+99GS9V M0R=R0'"*VA0C-
00:I6-Y#M*G;H;^2'S?A0FL!$X47]QS'=NT5G,PB6$2BTAL MIGGF$V=#'CG;!G$B$Q+G Z .)*2-=(O(P_!3XZ)-,?K?]K)&^:40$Y8=F3!3;*5H M#1O$AZ794&9T M_$<C\FZ#2 *$3A2E$!?
{VP(UF/$XRCAYGG_R]#@XV#!G*$T]*A 6I1\[Z\H M@)?AE1-!3_KOQE%(6R:8H_NVC3\48P!C8AP'(/]=TZJUCWFP<++HZI):.69S&/ MIF.$4%Z#=..-!!6(EL*&7\%7<7!33#:;;?5S&
^-8EXW#KLS(PA>%R.YUN\65 M0$((TE: + "Y1(AB\S_J0',<;)U]4,L5]KFZ@,E+K2 :^%,3?]XGT"_H ML9H>F06A1FH)/*9@P$4J!"&@6I$135BT"L48>V9^DKFVB02Q%_K.YZ'\PLQ
M;;U"6W7(?)#9H_YDOXN:9,', *,VFHA^J0B2[6I{BH!E/-RVR4@>NMX_"M2P,X)]-G3DYKJ(W MCRPK(@;=.)0PBN4^JUF/^N0DD'&@ZDCIQX@@FN%?2GZ(8^XAC^2-T5?;#)2HN
M[/^#/L4T@VEFK,.NKWNY';ORLIK0&S50$(G9;A0B%54,0Q5E_2".OUJ],?1< MJ,%./'=@1NI&_'=, HJ#_!QZ%>Q&GSS.JSV%[_FXE/? MKG*:.YW_7JUS0;BAV5=JG4=%R8FGET]
{CBN=O\LBKK'2^8&K<]^Y(1$7D89< M3$/"X+Y]W6LQT7#U,"ZB&]D+YY'6"SP0<6G;!W.H+]_2GO8]9IT :L=9)$U M$CT6P@YXJ%CW2B->B9K/BQ%#?K=\K;KP?#6;^#9
H=NO51J,:IDW*@T7';)& MAJ,6@WUXRT85!J#\\DH5\:?LP+'-C38B1'NZ,MZ!U/L6">C\A@=GNT2K#2.?L8L5Y:,N*3,YO!0[?'- ME1)E74230R[-.&3>UN*8*O2$:T.%5$\9DMK
T\8@,L5I4.WL&Z(+4$40/8PN M4&?Y5'W[M6U#I9X@S06HE @J@&._3CBQ)3G6/QP'$<5N&?E2I-N@,UM"S!.1 M%8?(AV,^_ 7&"H!44HSJ%()DJ!"6T//AP_=})M?
%17?,CM_LRXM_FX!ZLTY MQ%+)}AYZO&S-]\/Q9)W>@HA_4_*Y??%K_Y72M1*JH_&;W(77OAM+ M#Y'#VGQJT!AAJ \VE;$CA_4.E4\"Q];ZMDBT#U8L A5N-%#*#]A0TDB,1=8J M%
P"D',* G"DA7XDT9@.g/ZYC'+'*$S%%STS(NMQ!(BJSOC%_H:V904*(V#Q$ M 9@AV&W-'[7'0XD>: <]$-6 MQ[_W M2L_PL_UB!6]5>:IEM7{T
M,QE4>M_9Z8PPWRWM'SY]'Y'EZNUPT^LAFA3ZV2=#Q$XF0\'1,Yi5%HBR(%'C MAY/L?82G@3M!8>WH5+0C})2O*0Z*]U3J. H3A_6E+ ^D,1>J40 [{OMI/L8;* M]@5=
[;,#0Q5UG@<U6V0)+TQQUW(Y0S,7$0:.D,%R.W;F49M8XF29$6CT9D[RTE4ZMFY6I+SA+P5:M6+F3A?F>)U9R) M>-)'W/K(@.*O2$AU0Q]*?E$P2.0QQ)X'*'YK?
f\X'"%77!SQD"9HJ&'U690V@ MJY]%1#X'(']{6^*(K/>$5;5TEE&2S&$[%"3N]+]5RSU>N 0@,"BWXYLEJX M>WBHRWQ!-FTZ9*R RS/)(1R9>CFRDY[>/I8+]VE2,_I"J36J*]@C1+.7?
WR>](1RYI_8B:"X>V?KH5LX#ISF>I%}F>F<]5?O?7*YWJ M,@S9Y,@]/DZ(=(K7OW_A@>$D7M&9HB;6%] MU RKJVE%1]0&B^<4TAV].S1(Y5SM<+<+G+'?].-SM,7:ZR
GPJLSLT]=@Q@MO^ MHZI,]]+<6-24ZJ(W5ZD)A_6*E/2]JBV!0]L-$[/'WHM0U*1/6>JE[I]/%"$ MK9E/#ZGN0.HMBI"BJ#T'H-,]LJ9KI8F< 492:68Z'=Z&$]AS K?N@^7.\VU-
MH8UN>]'PE/A0@T/W',&#XN6$]%SL*>,!V5"Z3BG7FTEH'+.#**F0RI@SMJ*$ M4O6A=B}.T\"15'K/:>ERO2
KHCFTM+#68//%%!,P3'AT/WD,NRV1UW_'+8EX%YYC?,A9>\@%&+-4V"+G):4U4+.J/Z$6+-= 0W>6U1D(5KX_"@VKY0\'"SC- M MPJ%[B)
6OGF+/L@M91:+PV'[$L.]-4{A2_#^G5&8M.-5DV!BR\ M+?905C9S!THU;Z J9H8M@%F-ZE9(267VW)#5BK@=V2W9)4Z]7Q==B:N-IRK MS!X:R(FU[XHK*NTNN7\8EIV-)Z$$]A#
S+=-'9=--K4@S;[L9+U:J=Q'.["' M!K+)9,+A\KV^;"YXA_2'LZ (L<7L.2TWK-2J1D/2E*E8O)UO+PPMQS!-5.5^YD0VUJ<9TJF>4R=D1!K5%RE- M!93&P^\8NJH!RE!Y@Q$')"UR4
'[_#=>SNQ#W]G!33;;'(]367NHE#+],;J:4 MF=" 9 3RT/63+-*J%4,F7'A3.]+-/=P(KBQC.WZWOG0*6*1KE6B%7G-(4TAVJ.S1(Y5SM<+<+G+'?].-SM,7:ZR
<.-P/JTK&ROD2[EJ>K,4XL^ M ROE#X5WVM:M(_N]!3)=+)/6PW1A#I(~-'17U!J#E&V7'FIR:=@9.]2,DGJ* MA(:N&>(G0G1B01^%&:RL*LANH,>&B>=&G%W-?]>
%GCK7UTW,EK%X&S"65Y$ MRL2VN'4WCZJCX(Z?:R-:,N_(T7U9VSQ0NU?WS4V M,<4;,89J4#"WP^#0 M\W+(6 9P%]$47IRK:_%IY$W_T/H@3. CJ1N#P09S M08@W H\/X@0.
K.F$5D(S)I.Y"\$? !2=PI13.[SD/$ $EF/MVKA$ZL^ ^2^ MXR4+?^@F^,__HCCRG]U_-QZ&?]?A*H0VY;|_Z/^_RP2I&YX]Z\"0B5L\;W)A\,!_%P+@Z ?.O MT-%"
R4N_(W9Y0&Q\IZ}Y3IWY4WCOUEOR>]=']T]!X3__I>L # :'W!_Q#WF' MU&IM1RQ^!=LX{@9\^$H5CW6EQFSBVG)_S04J)#SM+CX)6HIYTD3)V*C"N=I"I8HTSU"55E;-
F)V1RSA5FLQG M2PY?'B:M\8/T8UU1(_J6Y*NU@2JB3 [DI%%MN]!AO=[B@0R9=E;TW6S(@IQH_ M" /HYEBS_?_^2#(_B+BVR'] F(O@IQ..#3=8??Z#<+-0QW(S03PXU;?(384]R
M#/0_^0EX4I#1/&\)=[&CV2'X0?CPB."WX)/7&0)3 8SW*K=X4* 65*;6; M*)6. ^2^+$NDs1?'_^S_/=P(KBQC.WZWOG0*6*1KE6B%7G-(4TAVJ.S1(Y5SM<+<+G+'?].-SM,7:ZR
GYT,#O%Z5BTM+FN3+UB1]):[(034 8M!\',L@E:? O,)Z[JOI0V MF]N& ""6-[!Z@-6#T]![3X$W<$>$(=XDXKV],>5C1T=7VZO*MP9/)AEB^S M12_37#94'LD5-
),ZG$QQ5;1\C?"]>.P>3]fX*\C#>RND6M-J6:[>]<62KP9W MPAT"+_<>>,_?B-$:N5ZO#(WWF[DB%6>,U9Y3F\7L/GCB\62"+5M"-K"$V;W M,+9E?5;4
27DY4RYY27ORYU4M3Q7!225I(0$PQ]0,+EVFL?(QY:2+Y=H/HC[M<8L&V:'*3DEZ7/;+]0;0C1S"/3*,4'0B19$7:1CQ#RO,7!5R#ZYKO8/4?];I M9=@&0PKQX?
@V7)XQJYTBZY"YR4S+++H/1>T1P9-[*Y{G,^Z0]*A++>JEH0-S MAFIY)0@'!%CM.6.UY^B2Q$DM[R%BS4@FQL\5D'P.O=:.6K0LUC<\SEM7R*L5. M)2^U&^D&*C&, C@8,
<&=TMF"P7W9X#ZQM9VY8/))-)?4G)RSL!,.R0TR6;;? M=_ET3D+0CJP6;$))DF]G#5TA* MZ"C\,"E:VH-J3]BJDZMEHU8#DD(>[^=!}Y'BN/)2, MJI22S4)*YD70& RF2:6 J#
M$I^F[\92Q%)__$HE&%;$5@B,:FR%^#Y9Y/.8GF9;OI6MU'4YDZ_[/+R9>=J: MHZE!L21%7U N2=T#$\!TT4'=LX/BKGNWJN4W^JN U9^K5W]BV>+[:D:> E$%DR^ 1/ MOZ4V821?
*9*O'L',W3\HYS:3VXJZ7]V1&R??TK-Q+N?PCY;3?0;$)-5L<)*T=8.<(FC^^(OWB'5RWEAW0UEZE09%A1!,4I)'WL,S,E;;'U'A53K;:I7RZSW>:WA!A&*]?>9^&-LUA$R)<>0U[#<'Q-E
MW#^.*YK@RPJMM#F_!3I]H=U0]:@R)2VF$HS 8CT;@QOKV=^O9W\2VLQ"4H&G M3Z869_2*]_DQV[]_DQ"T4(L32(U*)EI ?R)(T@C6&OZIA)W)\[I>,E2")P5L2L%,
1?"/%\AZ+,L04N!9M|\< MIN^LI7J[[!6S>M!H#A%+@&(00R>8 V2<'E/L>2K]19CH\.!91"&^&BJ+]0T& MD+SA2ZRP887M,NPP:($4_16V<4S0UTG0IT3-9W+YKE{JUS=-
P5&>W3/2^IK9 M<__6NNF.]<"1!7GLY*JF<%\7JR]!\4XM_*R$A[@(_.N:\Q-VXXB,D)PT'GN#0 M[-MK"P2.5#AWC0-'9IRO..&P@6,<,%T%D)7I=HAV<(W;?2V^[MOBLA,,'2LS
MF]DNZ=8?M-$\5+YB/\J<=9\, MMYS90!&'"-)02N$I)D&+7]\-)AB2=EUAK@_!E:BL%4 $S0F:&P5^,,H[%]TM
M[!>F&F7OM/Y=0[NWEJE[T0^32G8N0RDZKOW()CCALOIMHI"$0Q16POK 9>L# M6.G_XAB"I\(L5=?1?\V1SK.9-",)DX'%&>VAJSBEU$"'*@_==_).<-P!:RQA
M4%\V]$]L;6.$RH?R=;+. T L;)KO6\I8TU)#?U9S=FR#W\26B0BT&-49MD MK3"=E_V2[0=IR)^BLIHXI)D&-G>)QZ@0&.RSZ>C.3Q*7A[>MUIW.:9.TLS,_KM MK#QD:[4A@C?W 7B?
G\5C?!E';/XXCJ,T',,Q+SAABCRY$B@?[9+_SZD)>2[M5_K=[.W)2'W!7$-#?)6OBV-E6F.%#58LUY./4B#R)6/"OH8E'Z$Y"\"6>RZ*]9,0H0,H$7@O=J/_[$?F DF
M<.JV@<+-]"E*Z4"ZT"W*+D*I9HM6N94JWM7)6;K,^/I)N*(7VW?_^3Q]+Z.?L MP#RJ7?B.X(73VP6,"(R(,/\G]BU>4S[PZK_ 6&;6K0H$_@_L3"+A5FLI6'"
MOF+"/L_UGHN6ML?]N>JU*^DZG$C@$Q-MJ44IX(!++KNA<+8OJ.PQ'G&$N=Q M/9\'[N8XG&-S!<5ZC$3);.08A^4G&+[>/6LTJG"#AA/Z5EBX$XO:;-BT%4FE MHZIR%
KDX++#O$Z/ZY%3!4X#T 3V?:X1IGC*7C_2LKI.M1Y+N!TYO.G.'"-.H M$R^38+@SKLR_1Q*)A XHB$39>6B3B;34:!4JA?_UP\DNNKD;/@6_:IL.2(5B MRS)%DO_Y)W GT9Q?
K!;^'4K:U_F?1[5EEO=4/75!95SX_0N29^&\-S0]/?&*'"FWYK"_[}$*4-N5 MA[#4GA:#ADI'M>4HFDN0XM)V2B2$.0T?I7V!C9L"$QYDK'CC1_&R-#(B' M;5)#WE(_[J==ULG[A>=(SN(+
W->8,T/^Z M*K=7R)PNA!.=F+9_7N+$NJ6%F))(1?!^ACZ9V%.R8^P1)MP7[?OPP,2W194>M7[$.=0*_5AB^M65W3A2 M&\"U?W?Y.C-UW4QJ=-7DZ8"!J
{!0K#0TRTZB6'YN@WU3$,%/!3.54$@6N MG*,Q%)0\"&$2%Y"O,BSPCWZ;CH% M5A&O7D7$-IT_L>E\)#2-YE*NW2BU62O4,\-)=DI/&KZD,DP<,BHFR#?+EF)D M7B0R+QZ6!S3>?
279DV'XD)=I^3N9-!JWN6D8CK&):HF3*<2+'GNW0Q/#Z%8 MI*YU+BZ $8$1L1)Q'J<6+KG,5. GCKH>0".GH$HB\+<1&!B/1E+XUA//E0H MY9MJ/I14+RSW^7+7HA775PH-
"\R6#95)(8V92Y!OYG)AA%XI0B\>GL<,BGP3 MG[K1&3^&X3BOF-5^_78HZ&75F2-\$!10*F2 <$*"@!OU%G _J M"!'"K45_/@(C&DR8OA]JC@[@B?JX-\99"/!?3MZR7>DO14IPE(
MLJOZ244K^URZ -41+NKJ(W(ECV@/()A?MDP{&UG;D@[A\L4*-ZR$Y[D MO$9XN[B];SQF(I"CWCZ"F$CQ9YSL\4R">2,2\S7!!FM7)ZE=G4,8%+.;,?'V@ MY)O*V2,79H-
>P:4L.DV-1-+6Y=-"!G(R/AD2$A,@>,!<5X_O:\'WQX#YZS.*;_MZ.ZD]&;O=DGVR6[+OFV.PQJLFf;H1D$+8H*GWT+W6=I>HN[06\FH.'/D.H*_M3\'84:SW2*]+U !L@=%-7KI/D$R;P5
MIX4Y ^8,.(WC7$2BS_"%QUP-+ PW^A:,GW[6&P4E>500GPA"N!,\-1;97Q/-MW&3SE%(K3)YR.'!,RJGK;#@FY4Q$D"TNLX>WU+ED&-Z{CY)2:ECE7K,Q*TZ1 MBUM$,H=
\8D4B9,V,"2Q.>0@21M[-G20:K&+IHMTLSE.S8+R/0T/42 A)>] MP#,)5KPXRT2'8 -("[QC4)+T&G 'P2.CFT?Y^UA/KU=P,D8&!$83@9XWNB M$UJ!JULCUS: YT=%^OE_"#-
T>JP4'V2OO7I+1EW?+R&)5\C89_G>L]/Y=K8 M7)GX^74/#(#G 31_>#_])":.1\PT.P3$O]6KK/FS#1 I%K{(\T#OGH\"HO4 MY%'I6"!9%JJ]'ZMK*?,_M7@5JKE/:-B;]437;5WS:EXKT
)@=-"-ZL!KH;EN ME&\R5KZKFN>IMR-F2B?] FME{&;*SLB*"2IS> 0'VX9/&1].M@^%-//H,&PP MLS)]M[%\K'AD.]3X\8N\(4ERGP'BQ1O_?-0JL]HO#RXT.H
MHO/\AM(_V.YH;WPI#$:NAY)<]FX3%Y8FZ8>BG>7N7O-S <42=TVWB.7WU_+MT8CE0ZN?LS6X.%Q7+)C=2\%C@J-?;@ZFDR .D$_?<+2H1#Q'A#.YJ?^(1QW
M_2[**8)L"1F%W##PT;Y!MH@5X#-6@$\A.4;8QE?&*^?44#2!WK27"3C _]Y M&_U/;2>]<-XIW8VM\|$N7-XW%^4^+^VEGM\\CO@O}!RX?Y!=V/$[\[B!XNJM MF/RBKG(K\L/&*
(S%$[7]W;= E^XYO3A9L5*,BW]^,60?ZAO7 #5%"\%:> ^V*>595_)-H4>.;ZO*LB<[ME5MQ_N,71R8X$>X:OYO5'2E<%[KM2>=<>_69.19(YR3"\DRA?MEY;&?;]LV MI"A62#
\G1#*%W8#KMS73!"JR-0%PZ S8RP2A^2C+M 4F 1CW@0>OO 2!EG[0 M#3XF9-^QNVEST1EDK5Y!IO/2]"[W6 Z4B81*"2082'>4R!Z7[HZY++>\1GNET
M;KN^04U(H&53>]%E+:J1841X)"OL7+ZD2SQ9%M):?M*N^W6.MY@ M/%=9-NH%A\]QT3@=&./Z3+PQIP#J]:5_3"]).F)Q0]N&[RRG)=LI)-WO78^ M0C5JERMP"3)U"0W95@)
($P2:Z0"#)KGP)_%R;Q8V\'VAS\0"]. DE=XDG0] M'(ZF!^5)TI^5;18)I MEP@WJH.FN^.)!T; \\L87(J&119AN/<1N-
M,@1E%02U05M;0*8&%PY_8U\CZMZ,K^0+N9HR[=DCQU*XVESJ+)>7D!RB"[M+L^_;=@QV,_1G'$XI!^T-]V*Y09VB!\U"KCQG2+K*-I-",,)';@1U5,_DP?*[M8LS?9VOC:!M \T-
O&0>P8K71#]C3R58;/(!@-?*GN<\D+/3A#Y$)H' MJ64S543+/.F/G'&QI)GA5+CXC%83[K@*M#G MT!T#UY4_KL2S74=*CE@ U-#L$&U@/6YE)06!9_;#0.O;H.VB^M)P=IYKVW!(M
<[3 _X^&{]\5VSFFE9^(M/,G/*6HXG J5!UBVK0\S2?X/8H,YC)8/9S>A7L MKISW'$Y .QCS>9@."[EQ+EU2S/LR%?J5QUN^W4#,!X7],F*"/4#7GV\6X+8J MW48'AAI
XC\4,GFW)OP]D13K^LKZ;QQVC:+[D&+L, M;P_S"H9,*A5P@P%9&!>]J!:U.U[*#E%E?2I1(I-):A#RDX8U1> ZN]?TW=#
M^BAU]S^*9?I_2R\ZC^5[LD2:2U]G75/K1)CF(DQ3=$*DZ/=$DO^)Y*"QPA4 MH4!R%%>$>2F;ZP)5^ LCVS]N=9$;\SEFHTHS*%+9U.&G+0 (24CD3$=S=!-*,5&%CZB _PW#9}#_
5GYCE\A/,"'#G*W_A?^L?UFW@>8AL(Y6T]O $3U[Q8%(\C\' MT:^>GR&W_)/FE!2=VW7^[EF%NK6NT_'?&0(4CV/;!926T M?_BG9L^UL;]:I2#?
G\G.5LF:RE*,IHI&2E!)GF)X4:,HFA9_Q!MQ8,BM M3K/_[%=6)]6'%P8*5*S4;Z566VH2\/_-BI21E78A(Y5,".)0S4 6V(^/*UX; M'-B6*W*UW:KE:G6Y*;4+M6I+I>D4+Y
GLZ9,K9]5JRY1\?'K5]YD(6SSA)/ MDR=J.6(S_6B);5VNM=F$[U_:?XJCA0.4N8Q_'.,A@I%;^E X\1,$6.@ G@"`MO+B\!@$O-NWO(T]AU%LS_Z#-]D*18(`^&(@4(ZAJBN8AE :BJHF
5FF.-1BV MK_;\FUI1G+9)#[@;ED?BW9"3P];$+/W5GKF6FYBH4PEZ.'.55=\;K=EDV\^;\ M+-'<74=JP)'"RY&>> OQD$JVE"1?(CO&/*.0?4FE=Y^9)4$AE+(%DBP5.*ZI
M^^PXRZ&1.\]T.:+O:G-V&FA+FU$)M0>7'XJ2A,KO/+/3S,\I-%PO*LLN3'L6S MOC>=PY${.[?N/:L^2^;&ECFX&SVT_0R?3 WAR)U?SU,RTUYH:84%G9&DY(Q^[%;,FI*'4J)
(O1_;GDJ[IU/)%]\>:189 M2%2^.U=3NR.I^]!6&=\!CLPXCZ7Y%X#/M;P&'+FS^+:2)YM5=PR79(D>S]]" M>@LD.')'G\,,U=3DH6:F2-69R96=0KXN*BXIZL_A9,'UHZ2;))R)G
I5H>6'9C,5E9IU4G5R6K19CALL\I[60/K'SE-R&R8M6B\5(8VF:+_0!HU"$SZ5 MV1TJYJ6!G!KK20N4QJPG=@JI;3IZX,DN65\(0U'R,WTXE-I= M*L^D4?L1L"&9:5=+%E=O+
(LZ'+IG7YOY7&9LM!E'GD[:#XY)^K.D.U?I/?MJ M\73:UHQ!C4SJ1=7)<&0/M;@F?NF=?4W*I=VOD*BI)+]L/B_"NTP$50IU MJI*DLD+&F@[KKD$ZY-_,UH9.O
M+@2#*R.$^\'PH#2%EP*J/-R:%$M-M3BK%QS)#M-(-$=?[&/\RI3 M>@Q%*YZ-Z>)R4,!8LR$:NLLP-(/G^/Z=',BAFB,+4[>]E-*2RNPV?1:F ?% M=+]D3-N8"IQ2E\NPJ%
[$..V2US[7IU-%8XR\G.%7=YU1PTT=&<+E$)U8(05 M8T:.LPQ#>@^F7\L/T="=+2A;;B8WNNT7%)/.UNP%[S2'=W,T=&<+,OF24U;* M8D&>LBDE=_-DF!FG@218
MX^5LF59T(UV3HJ$[ZZJXR5!@[HF,U6I-!2\Y+C9$.1JZNZYR,IN1BBG+(Y.J MWN143=]5*0GU,MQ=%S=8CFI*)R S=[/AHN1I@0KQS>[!##7.A&(AUWRP2K?9 MR1V8E2I<<:ZR3T"
({"T;?3@VJ$%=-V-8F/OBY?K$M2']<:4{N5(C[6O9QJ5 M%@;NN>9"K2K >W."P)O;&U#2<6 C_FLV++YFS?3\K:4LZW'N_"1_)N= MKR7{[=])9'K&\2O_<[A-[VK=*$/(,
{5.Z_NN'08OU;KC&9VIWJ/W_*D!FF/Q M09S$00AO.C_P01SI(1\$*=Q$/3-FP46\#E@SG1=!R'<< (^B!,X",R93N,< M,& MHH5+/+J]V:+J;W[Q"B^-%'3ZXV) T,5RWV_-3P$%=,I)C> M]P$(0K+
{6-9F!3/#UD!#Y.:+>U E&/)Q:]]TQ8]\E+IX7BKZ)W;P2LG'"&W4> MAJ/!|.8V[4TJ*9:-<*9I1K[,BH(9%^B!V)&V:*IW:SV_*RWK[CJY[S@'XO[9SE,.T=F$))W&#^'-7.XTN#]F]?
LM9U*U<"\K M]U'"W!ZU>/R5)"L'819#^C\K*@+CP_6]$&]KRJ2++#7D(9P6BD<2J01-L=@S MBH'^IV8L#/3]-JO%P^T\0R6K!:4UJ@1]Z4%DY=YAHI=*4J:>G;JVS.48'S[0
MOP7W$IP6BEX2R8@A4,-,#-V'Z$@;]?6)2NI;SQ3'=SUK*:%ZJN9G"V>!"@ M2J!F63W?]9$E.MBM%J3'-B8L9NM%1K!,2K LOM$QT+'H?B K36O1G$?]#NP M0KB H9UJ^YQP$-
&]0I7'_I1!B3H+)GJW:!I===IS)&B@R"B.2] BB2.CSC8R MBJ)WEQX(>^IW><0*@6=K6#N_3-O38/#*&CIW$BX*[,*ZJG6?0I$43/>8[D\F M\@/3_56<__72/99SL.?\&$O+N'Y N
/L*C]++>]O;<%W7C\5VM;-RB2-(U@8K MZ]H>X]K0;)(\614Y!30R:']$YUFY(Z'Y_/@EB F:9[1_7)!C?WDWXW^P_K) MWT._G.XF\ZYPQRG=4!L5R?)MH1@@]'_.?O%T@DIA]&/T8^?
YF3K/WT-.R-9 M)[#*GI+I+H? 'kB@13?@?,0?O^B4D* 9'L,?PO^U;_&MEID.QP"U; M++>6N4V&5JC_SAW^.^IA*?248$E<<.3N_.GQFWG-]GYAX[L#\N@*JW[VH*[(7-M']
<0@3#/>QW/I\EV4FW4^8S]WRMYRI+/?\@2109I2205$)D M<8(1O,Y>_4ORJ;R-IJUCNDM[;OYZRU!Z,ZV^|MM- .;9Y!Z208,G#V5(P MFD^:VK\6S:
<7JW!1MI&WT:RFELD,YW*!!6A*H71[RIOB$*$9F48$/D&3AS.- M8#2? K5C2?N,3!UOH]FFK$(S2S\,ARB[0I"%X!(THXL'2DV(0JX5,,Y!IQ\ M!ZNZFGB4"U_D<0IAO[[(9X_-
P#GW/1, ^YA;8,X#6@1ZI.7YR]G4Y$@9,=?C MJ;GP11ZGU0JF]1,G@RNA]6/F)CF%9&/X+7^.54.L5+!>[/? ^\VMH$('?;&1)@ M,0&.#_R?V//%[?
N:HD^!%U[=N\'6]JG5_FZ<4DSDF[G\Z/'6E_=NC&97]6ZKU5H MP;ZE8_;M:P';AC^7(S3#SRS'R(788+0'(.7[(TKVP=^F4[#I'=>U?@1__
M*\&S*YA)CE%9%9HT].#1[[WL&/H6Z2^YR0CQ@/SN,_MT(,C]%*=9*<#Y<.&RWX*RLF&%%,T02XO+\-B\GY8,-H. M0_DBH7P,\^)0/DHL;*?@G)>"\:W]^22D;N\0^E-
2KBOC1H(RBATED\P_.': ML&$L7R26KT3"/DJD[*>PS#>-D5^!QF2ICIB>3CK-MKF'&$Y"IPE$S1SD!K[)MV%/\3-M&'CC T^S(F*$98]-)@Y(DC. ?
C"*/65,CI="> OC0Z@3S,I2\V"BAF$T(-,XGOGB-7Y${_7OXP8$3CS_-_M"2H,]4"VL]F>1>>YR3T_ZY0*U2'B!"@9F4YPJ<.U1L*<0/SQBV42O$!C3H YP<4$99P.)SAP MPO.G.8$,L5]^:
EYTJSUQCGUCDWWK$@[0+8<1DBPU$$,LSA.Y9BVG";P@>;I MH\B88X 9L-W)&#A?5P,N/$[MHNMVXDK\9VG064,3\NSL$S!?9]BF67F#VH=
M6U[FIJE6QZ%*NEHQ]HNX%F$^Y.L0<H)U[-VMUW>%PENESI?MMB"#-_?C%0/V+/ESV(8;T*9#\UT(:M1\X M&'CN>.V==1WLE<6V(6P;^FZO; S-LNOOM?
ARW9[9&MQ723I)YVZ9<,O<1$%T M O++IO@$R1ZN5A4&]2D0(?,+GJ-?]DU0JZXELDVFX\FM66U8>2D67<9@9K[
M\8NG$]P!"]!A4)\"T6//[#EZ9M\$=;I'U>N5NG0GE_3"?;,S"_R\WT"@1KY9 MCDS0/(ZWP*C&\O>I^6;?1/78&I%.T00M61N+[,.DVQ@H_0C5D7>691+D82H_ M8^_LJ2X->V>Q3?
8:%HD]"!>R2.R=O9 U7@FU8N_L1:SQ2JCU"A:)O,;'7FW5 M=9)/;,-F[*O]:YT[^S?NE'Z&=]*38$S7MVYL#KVJ=>-.Z5>U[.LE<]PI_8J6 M?;UD?IWKQLZ>8U:@+C@!(.?K!0M[-
DY)7L.,H!AK&L!6<&\83JO\7.]#7"`MJCC4NP-94N>^)2NARW!#+>5ENVN22E-1S>@$2^.2T6>,STMU;IT.D \@_W[S_TV]I=*FADR-)2Sn>%2;)E:D,$9%3M.0%GAX&,@7QJ?K\3
/)+18E8_>3'-MJ=]>9,LAJ=2&E04EJLW45(EN9/"'+R'!T"0&,@8R%JV_)TSU$T!V:LWTO<2- MYG*FYBQ,0RS0F71T(I?]LQ)4BL,%EL_-._Rf\6+E'<:NX?.SLEYQ"@'BQW^=

*MN:TC!N"]I%O5=3:1&_MZ&IK3!W$FIAVY}.@OFK8SV%>44#>GG88D3_L5:5B?EWR%BK ?I0SS!{OX<13),0TQ MM6 $O-U8_03A -S+_'+\^W0[}AW ''/2BSUSVTR$R6WV'-O,GYH2PF7#1^YA MVH%,'*3+=$XC0T%4K=O&^*$2SE5XEZ Z:PE2W"W!_V7R&@;YM},];F5^V7$M M[S*&E_Q@>*MVNY.F6{66PR5?UCQ]0\ZP$FQ*Q4QRS]S*_#R-.9]F M!^#6$,BTE0LMSE-Z7*E05Y?D$+$#5-PM01VPE1YF!U?)#D\'5RX]QN;3[$!X M# #0<@^!/"X,A-YJ.5LJQMI"9.,))!%('Z9:+(VV.W\K<>,LTP]>;>\[6=O?U MEOL3YGU'B=$Y[?6? N9WHMQ$:=M*IV>MJU_^46%)#L[F4Y-L/PSK545$F%(ML16*' M9"G,&#'C.'BY_]-<>_YF'__R>4VE!\.UB@[<4NG8>,;UQVFA$4D,RK&6K$>$!]Q+G)'QZ+A-7_PA=Y/4ZM"U\D;BMP(6N\$FK%,04N8HU70JU7L$CL MSCY.T_-<^@,HL6/NN VT!<./WB\LUN^BJ$1=6+'/=;S+GN>,,G(?IA' W5PTI M7<=/1X"-Q{417.5%X&FN!_=<\Y:%(S!]NN@%7BN;4=VIU>+ H4-%S1H!L*HVD",(*Y&RO%8 M(L",_)>O.&O#ST<8P=+/V+I4MT96Z5ZMWL\>T]/!W1 Q F2TH?D$U QQX8JS MC_0!TQ NE3=PG9'S[5'4"%A@0:X4)+@$%H@P'<#_@21>FL4>5YV^&-N/ M-IZ,/F+87EP8!+;,,^GCJ-UJD5Q8+,;EO#!NY0JN70C;6UN@,;_VIYSM5"?$+8+G(&,<%1 MV,N/.<-5=*FY"//0UW$&3TP/RFQUFI)KH6=4N/9L"!9#Q!E0 !!-)RAZMXL- M9@V8-6!UXC0-1E_'&MB'NB\]5.P%V1K=MB1!L/*C420T1-$_))T0#N-EQM$_M[HT'!CT_5FKI\G)KVW5U^/WNK:3/4{)BU-,-,G2SW9XQ3%.+558WJ^U).] M3GD#>]<(E>X8/R@F^H&_$;O"#PR7N9'0IILCN?MCHIFYI84PE-5_SQ*X6{&&!>M<"52\#%XP3&K1/P&+QBUO(7G@]ZMHJ6*I)=C>Z;\&,D%<>]+EN=PYP+L^<6> MWY/*$#L-7G[=FW]?H3Z(V"?3VAZSF6V0X.)G M!Z*RY-R'"$GK"U68JPR-$[Q]_B/O_VI9X.]_K:G\/ y?MPV'YN0 E93 M&@U'E-%C&FCC2<88U3>,,,:B5]K_26?_M23P#Z1_&LOP=]SA'*=14(I4Z7 U.C/W3 026^+\[^X?UI+^??$#3E'+,,W5KNIBG M[<(PSR3K$?,C'&DJP? ,J9^/>6GNC3L*?_^G*63L!}?^'"OQQMRX8L\3L(S MIE9,K>>3SHRI%5,KE@2PI_C4/,7$!'B$/]{\!/,{C<\O_>(DN-'UK1M;2]]J MW=^6;(S)')/YT6-RKV[=F,RO:MW7*K1@#\]\AE[,V4!*4$/U6O--'3MQ3M9T M\W7N]+-QC6?-F6F R#$>.:?R^>@E8(%D6JKT'JVLI\R^.B*4_X1Z7 M-<^!&^C7@=="4XQ0M'&3DT\JZ2I):5&A\QDY/^63XS0Y3:630Y5)HE=J6Y1)/"2O59UZ PEA$34+_]& MI# 2KPR)WUP=^*A(_-UXT4,@,>DY3FX$W22>&;QX'B6BQV\ZSAJ$KX#'G/6B;/:D$T9T8=4R^H7"_Y'/T MFGY7!.%17.-ICAO:ENC\/?S*ZSL9]GM}SJA-_=+KV=W%2KB%41%U"\4 BIR4RZB_OH7,.E.AW1Z=7=,4.>JZBR3C, <M]S"94Y\0:+PD%R+]-;RQ?4F43'J5%,]S]@QR!^76!=!3?6\-=4?ZZ*Y6!E5MV;27ME+3<7\R1GD566:Z2&:ZR("JZ]WI{]BJGK>J^F-=G C'C=>"S9$,)2.V M(W9K/8W*=3&OJV+G.X<+Z&(Y=?&68M2/J*O^6!=[0J13]' SAV,YA,823]2: MFUP7\^-QSN08066UK-B"RBK(4H(D)6<\)N@ON7E)Z M"YQ'D[/]+ZT25-(^U 6M]NEW/E2)IO1(D;R(2)6@RSU#YV+WDY>7-WFE M->)WCB9#P7Y>
<'WG[VVH>2O.!1"70DG?;L$GT.OV0\I"V]Z%75#ZF"MA3ID"(MW;D9B(N\3A^*<11F&*0$_GX6^MN%-EU!:B"*T9K*!_DP")FUT8WY1,7A_ I+ M^IY$S]?+!C2^#!Q6X6P4IF&\UYA^:>FP:(#7$/[:,\>>DF"=X_?-]#< M-&0MP*EMP$AP0>8E%]7!!9D@^0R25Z!46X()%*(OOQ#]H)R%]-$+F:/9Q!UZ!_$@R!:\VW6;]&:T MVB4JCF:E:*Y!\GS'>4 -+X,.@%*T;=5BO5BOXS \K*%I3W%)F0QF,&]H"W7. M2)EQ/%/C@-TSH$!\%& = 0C+ZB8O0O& <0U_FN=9DHI&R5D=;M%7OBG4YCQRR@G1J'1CF M+-;A&@K2_XFTN6.>06QU,Q6HX<&I"/HDJ_.P,NN[5^.:?/UM1^M=Z^MNA:598 M/1N#UKQ#2L"*X$?I4B*_4O.]%*]L3CK]%/J.96BIG%0:EJ=YNJ4YE53D{]--M7QJ^2KE^0K@D="_;,@PKW#C.(5,,\R_'\DQHE6OCY]=?\[NKSQ[U=R74L':/ M7],OCV_6'5,+,L5F^XP>?_I'G__WU!*T'!J"Y{5B.T#PP-1O2%NF;/VM.HAW"!S0IYA.6 M6A_,-+?P(^KPO*T*?P)(:Y9>?(YHT>!F*ZVAYZ0[,%408ZYB#X__-GCSW(G M]/6'?EAE-O1S8#JHH]B9V=._>V[.F*.!.OGF60 ML2?&1JNL@LRW_6/DZR])\|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{8>9'3Z4*7R^N!:=V_6$1]J/Q_I\WP"1O_J*.7IY6%=KUGCE M8YZ PGR]XU'=)62[ZP\]FRM5M]/H7-9.XB!S_*5M+JCFEB:-N+ M,.HFNP,*OL=1YAP#\D!O@=Y>NMZ>]]BLG^FM$0|\?{DX4ER-)Q9S:3-!&2/3 MV^R"}N>1<]R8!{0VTO7VX>DPDT]KL<:?4SQ0TPQ@ZBMH)>][(;UF3IN5,0: MD@V:,G=?$!2V)P"U:"[07*"GY5]>U,\T5W;1N(=*6$N.IPWT%2;U1&3CXBC MJ>K"R#U&G>EZ(^QC3BE]P].D+J@:=AWUKW(@^7JK^%4@^9/9M.O $4CKM2) MI/5JD+P!:?W9B,M5(G$]5J0O EQ?9 .O8_<>GST3DN,5F90T9|>?_A0,:W\MRTFWIO^^KWAFE!TX^?#32-N,(<@177B.Z(."P=M#&XCY;>$-Q/S&\+Y-,?^P M^L"\QO(^2WA?:MR#LI [W.U+'9Z0<,/S'15%3T. M/3#Y4HT+S0R>N1%CP*%/A M$XZL9XR^33[59\%,Q(7{VW_0O+ZCBW/-"U?'D{!TZ<98IDMD=M>?K MV0&&X<,-PT?M64M-E,]_+KK!]FQF(_W#=_"DOV ^\W77D=D_>R =4ZQX=-/# MM,Q^D'=?Z.(]=/&%N1Z+,@;WF?_P4/!'VH9WJ6#]_TM0V3.W.D",C'P85'U M%C7E@(1L=D\;<_<%PS%@&J[9-'Q8!J6\5+FJMN)WVY]8,VPCAXNV+O,HR1SP MV9+?!YD5R?J34:1H1D W0-F[+,XF17T?\'(CS2GXO^L00!DU=\^JUYB<_GV MJ;N+0O]FLEF/MK_O!{E3B*+ FL?Y#7HCOZ^E+B1ZP2WH%B%(PY-YFKT=KRP MVW-%C!*5/G/:'IB.2]"=&S<=UYW&^GOVXH>[TN,@"19)!TY!5M2,Y+KUF0\ MNY/TW/D?84BHN1'>;JMU:?A?<:+K#VN"?)/(5#"O"US'<)4 W74BVLZ"CK-G MM(#QN!:#EN6C<3,9KM_1;*5W,1N(=*6$N.IPWT%2;U\

3,T/HYX9K7SCA0RKT]JW=&1HCV62MT=(UY^3T3')30US]P7#{QGB7)8& M}.^7Q/3<|J[I TS(&]==?E?U$QE?U_QH)?.066]:?+P?UJ5,],/BRL]5_[: M^5MA&.?*
*WUOB+K*4_M<.G:DK%\C+6>>:)\8D5K2K1RJQD]ESS#O\WK)BY?:]L M',T++Z&WX68:_TN^NRC>6#%<:DIXB/!*
*AO9'W6FMEL=!_P]NL]&F"D8LK%DPP)=NC;*BS{(O_^@9LP:ZSB,LC6%(_\',\YC MJ/GSTO$@:X0(4Q$9FL'.TLU31#HP=7_IY4_)@],7(M*-L4NI TU9V62X_DJ;*
*MA#B.)BJ*9;E[XIY@7KO4"5BN_23E5=U@>4"4SP@NGWW*9_RHG]=T>T'3 $! MUMZJL;MY]_^#B97RHG^%{O\)2ZB\7)2,@0K[*L\'fL>G6QAF?>Q <>C6,).6*
M%P6ROLSVX_FI6C_9D)=[[-]9%5S\D$/+-P>#{TX>,EY?0 M6G'NPL_5W9+.^"^,>IXO2WVZ^8XE66TR?C.[Y^__[=LP109SI>T8D:PMEK2{)%5.QRCWJ_1-RQ3LXXX><*O>5K9<;BU3*
M6!=EG'Q_D-V$3J1;8QK%SG<5^DW9@BO='3Q4#\MK"_XZPVDN?Q@2_.WK>01[M*.\U^,#(8LM9,&[HH%+[C;<**:0"/*[1A_11G>+6WVXQ/1IBU1/V@)%7&H@;$3M7KH
*M=>WSI<^>J<*W%f]\/"BSICBQ[6'+GU%S?L.1:AXR9\@6WFUT2V%X[3&>###9K^$8&]69T*]'(?'[YZ$<6-3R-_MM9=T3QWX7(^"+=U)OI>M+O =)P5H>M,*
*X:7[J2B%#>0,LOC^_9C>S[5NQ,&B-S2PI.FP2FNI8L6'UOJ4KFDC+Y7^]JXULMUM M=;S.(!'X..B!"\SAD1^ON*V^F%6%5+1[VQRT\/Y9B!O(VNVD?G]]K#BZ_%J M-ENJ>)&HU?*
*JF:JZYP.=X9C!9]X\#M>VS*21>0%^BL.[47_CR0=.E974V9%DY M@RS@1 >=9O.P4!J<.U8HI[F:]U0G>WL1!^[V8(YG+K'C2$+F W9.ZY$N9:!% MGM+L7MDD&\V&2('B:JA+,V?*
9^XL\;09$$ZMO:-6N>61?$7&/\#9)!DH7L3K4 MAU9(-&W(JG<)2)@H(R^G%/(%R+*60!:(V)64/)Q:+ MRRY)U%N!);W3#MG;BT35_-"AF7%+AS6D/L,Z/F;TN1RT0%32J4$Q->5@&.W/
*MEXH?XU75S\=0 J4TVT\-"Q0-9!??U.\V?#5O*1E214H)??1ZA\+/:#MA-,I5F5+%)JL':C[9%C{F$>$Z"F]/!3,\@"X+J#*WQ7H)CB#NXFC\3C'C3 M.2Q32.(Y)$Z,U*
*<(57@[7F^1=:Q)=',KI9 %F+8XQG0]!-K*T*&ZYEQQ,-@? M,TBD*T<2P\5W,9L=P8/MN.^1KC-) ,M2)\^PZ=1NQ'8-C07F !&:XP%Y4]E MBMHW%A=<<]NPH1'5#*
*:RK79KDDH5"94,!'2 ',6%7:LL,[:OU!F*R2 +A%H- MC%T;IKVEW<&7V^U(7$=6ATTA"X2RA *%9E6OSXZ SLE6)&F20!4*Y_2TQ MJT'K&J<$;B{CB:CQ&S1/S8I#+6SAQ8)Y1D;,"E&*
*M_;A&-]74C@VQU6RPS$ +A-H$$3/"\CFG?77C=;3{8+U62"G;UIOF8M'B M.;2.M29866*UZQPRR0"A*Z_4X9Y!,;5,\|(ZJ"OD)5Q[=_M<^MZ0[B99*
%0B&+5$_L=G2T:U1_&TX#WG]FXDBX&'C6W;Q@0V?VJ!^XTXW"-,0[EN%[%=WBRZPC5'+3 M?9X7Z74;WJ%PS:':=3%UZ,-ZZL[A(@&ZBQ8MMFJK,:?5TTA.4MKUAK[,0 O\ M7S?*
*&[5U5,A:RZ Q9FH8%!/-RT *Q(3MA$ZCFP9T#J++W2Z$59LY:)%.55;B M$<-DIG:-I\R)LO"JX^@$6R"70RJK,51'UC#IC"5\Y/:X51#DL 5Z]5+T^3HVZMX6'FQ&Z. ^Q8=VSGH 5Z M6?*
*7!5'"*0C2RCZ^18JZ%,,C1RT *]{L8(88_F-IDG9#]PJ'!&_XR RW0:\5# MS$##D[FLZ6YKD)#J{LQ+6A1>2.]K6S:}}}$S=XD&@=EY\2^0]*]%+J}).>S],UX$5ZU19^U%$, M?*
7S>A_AFA+=$Y)E!EJ@ES>SYB04 +.A$9S3ZNZKM=*,M"B!9NYU29'5.M< M,;Y*I,%I. &2+Z 8Z"VF&\.+Z!(+WDY1 A[TTHIVB%T*
*ME*RO27U^@BW&NHP>":U=&F=HA^G0(U&47J11.?)" ,V1$.#%A'3]A'5V*)=W[8|N9\LUE5T;IQ@"XCY+E7U_>/6YU!X;-=U-K&640Z+ M%I9KS[5ET(:)F?5AB[=*
*(6<0XZ=\>"$V7N4]YJECFZ_@A)MK'E8CGH 7,MVOM]O^YQ$YY33-8D,$3L=)!E!KE$C-GC:3S*C'48\N,&-?8:S8F:/_8%\|'+ MK'TSFG,U?{&Y$8U!2XT3;$$=7&M-*
F2T9]KAXTAGU229!J70K@;P4]V=X7@G MZYAK6T=YTHHXF^T&Z7I?"'PY%96#>G\9RC5%!5MFH9>XQRT0%MO@4SF2Z,W ML8<-Z(B.9P<]AM@,M$*
*PUM_UD:6KQ]PAJ?'$S&FO>3D'+1*,\&ITG$SX-)[G MV:54,\/&>'Z"+1:,_J.@QLRR<4$O:[J27_70$^P!8)5!=*8UK51B]-PW>LV M3&H?XSEF18+5#8B EA/'AY6IAFT.S$+@I)2X+P3*
}1[?'LGC<'\KF$@*Y IU MVU .6HPKM4EMB]CSI7%0UNB.T_IZ?R=EH"]L/V<+;NAJH:R0%HSCK8W ROE3 M7]A _.G,5GHH8;(N(*.RU]K8!90Z*?L&A)\>]KN'K.L,-I3TV=NHV/$%/L
7# MU&VA2'V(!+,L4@DA"..2HKT=PRC1Z$:E<9MTF5I@UA>9#6.*$L9.E2.-JDO+-MO]JK1O'R J2T&]$%_/ID?% MU[3.2C9WG-NF5U P0J4,M("7,QU!=UO?+;C#]C!FA-
*AK4@XU^_MBB@,VK1+L1$@L+1 0W@T M#9O,Z;D%>DE1,#U4B%3=UHPXF.-!WX052:/6,$-[C?AT@5>!7@,U=:=^HHWA[6 +;U#-.(=4 MOH*B+!XT9[V!98>3E4:?*
GJY"V$TR2\$=!@84G6=M25&%D9:TIOO3Q6T48. M6A0$2[#0F%$'G!7:'6$0=-JRQ&:@Q=5V\-'"ZO)6NB,9AINAH EHS\J/?"^N MMM_3+'R&{S&X-K>%9I\DT!&*
<+Z$"H'68+2OTN%)@$Q+X>FXQ%%;A MY7'L)0QGQ4[#E+4QU[#9,%2N0(75(%KNC:6VY;309+@81@UNEIJR4Y"$G;_M 4M@Y$5^'B!L:-661.$X^@%
<@V+%Z%"=K2IG92A2IB8-7!<[%_""\V?H/L9/ MD;UM(JD(V4VFL>KG*R@23!YO6)AKBZQ,+K5J'XX8*(&D'+9 L,EP987UMF'# M8BAOE 9D^=!NM(:B+PO80S"3YS69=#0#W?*
6BT"#RZD@QD;H)%N16]R4<$U^NU&K!.QR"YL,EFZZI\IAO_JRO/[S6)EY +J:7BA;4+S\^,-'MIW4>!%R*B+]S4%/]"<'M!O6[H7G^^DS%XZ?/):@*
*M'K^\1E+IYWE@.C:4I/3Y:.^.>6O]Y\!TM,C:F<^>^5!"S5_\"*K-0^)(_.1 W5C^Y_OVT""_4'!/:&O!,CL$_D]ZZF0WZOQM5=-_)?OC?._SN=Y,NZ^?"J,,?>3?#BP2<__#(@;LO MIU-*
*=*OGQ#/_]G_G;2,VKN[U+%YKS%#1ODRH_\7&W212@/[\1EMXF58#^_,96 M\M*I%C5J07\W:F$^O9HE_/"@ZZF0WZOQM5=-_)?OC?._SN=Y,NZ^?"J,,?>3?#BP2<__#(@;LO MIU-*
'>1NJ_&ROGV]=0MDE"\]++\TJH",&,B(76%&++^J M".3"SKJ; 3[FEQM&;Y8JP//^&_U-Y&)B19GEOV$)VW3NYZT^B?G?5 M.TBF@F0J2:6@BH@%022J< % PT"R5203 7)U J*
*(IE[PU,=PI05F"\%[[# MPS]1ESTDQ+1^[$5 7-XS97C!X#3+E8$VEC?-Z5XP?++A+KK)@*UV$>M^%UW?> M.5XPO+3\G3?-2O_Y5IR+?PA41E^V*WCC2!8[H MRD.7)5(*
*(=\OS337='L9I,)G?/Z'KIOF8G%NM+]#LJHYFJ>;%2VI^(M*W=1- M=VX&_]_$!+^"T/N3Q]0&$7?+*?TP0B?,'J[7-"[8_-$:O;/4)^\KX*E_^#3 MO_1]E?^U]NF:O4.@Z=F*
827VK&A@+OY[)Z886&&J8^THUD@$6O)N M&S:)7JT?4A[2]MB[2GY9Z_[TAVRHB@L5054,43.14.,06FK:)GM89+J]%G',M.#4C6>W8]})O0W9OA5^A3L?*
*GY2>.)')4]%9T)66YRT+7JA[:=NQ/>9]*6& MJ5NNYH3_O6L)C;O*P@]<+?KOG;6//GNQ:_C1 \!=Q=/^9@GH#!? M[WA4=PG59FOKC+00&+8_8(AR!^2]IVU&82GE7Q5?*
*^RK^EXUAP#NX2+'PP >:S/:J/# MQ+85?RATNL1HN%>7YS4 =:JS;,QY583YT)GX.C;@ZQLV-0#TW1><(.YAB@)F MX*R-&, ,W)P9>.PT?*
DS_/^B_U8EWF^5ABLNBK;=7P9)9;6O2>??7X ZQ3UCR ME$/%\-!K=OBZT$Q2_4>0NR\HA=Q3'8> P"_N\R4SP*<[N"[@MPNL.N5"8@ M4_M_E4OOGYQ3FQ_0\5V#^:FT\V*
*MFC76\83GY9%*8^@?4SX2>^-0X&4:.EC M7K)M'!(AEKK8,(HY]%TM=UVL3'W"?C=%_J>1/&"1?CWF]6AKD<[]B&:_48* M\7X9L<=C>',16V*W1 7[/T<<=/4!D-*
*Y*HC2!.GUJ>+3/V3!V^I<@.X5(X MZ+K(PI#8(=I'B5X$2A8B(^3=%^:>8>A[A$3/I!+DNZ=8R^C:NX5F;LO",W<4'V?SBR!4OBHC<.N; M90-E]{T^T5HR2M7'=8MH$ETG>4,U3D-*
I)\XHV/>## ,VB@)K'D?:_/]G[TV; M4T>V-'O_2L4^][3714-OI) #+OZK0@!8C#S;/L+(.0$!$("##R__LU,22 ,_M>-
*K&",@3<6K;.)%R6.O)-2!5M/2*KJ!&;JJPB$%Y/<&IG6$XQN+:'D0+F[F M-)N15?J=%MJ./P^1,PPYQU@H"7.)-W3CP&5=[).S=^(4P^+G5X!%*5@'N8;L MB7.[M8/#C0A)&?8[5O8C|*
<2!NC3.7M#E?>GJV^CR[&58"%W^L /P-NCRW{F3 MA"Q_6,8F9!E\F3IC&R)Z3H_I8:$ZTFOIO8@K84>^QQU558M=@ OWQT(N4X"D
MQTTW:NKKVC:4+QT3=TDWS6.>Z+D(\O/)PJ@-DK7Y,KN(S.+I92_F>)B(3IR M:&.[FE#E0+&YXW6Z#39W"$_!X?/OO'[.G)9S9M_';9{)3^3!! HL;DLF.'.5 MG*
*L2YMW=8K=%F!MA3^_)F:4BMTP4>;XV M65>?:F:E6V#%5!W*F7TY3]_MO#CR!)Z/+_3DN^V^MQ/#$?@,IV\V M=]R[E_%2^3@_:D,.U/((0=]DJLE/"DZ!6AVAYYL, R'T?":=]=X)^E(I*
*#]J MGPW4\JD)-?/QC('%I@/:2VDAT4VF^K2<<=UK39_WK6O2IMR&E&FK8U4%+7!V- MKJ[)!ES%$;U;38JCYV"FDRZLM$8-OC8<+$>]N(%]R#"G2G;F*047.OE0"+?*
M[T#:"5P\/!%W"$??M/Q^U:;]fY=*TDLKQ?5ZH-L.,R^Y,'$5+ED,#Z42Y UX M6RJYLOCNFFU((]$$J,R9Y:;8P#?]TH3$>P?)^48"&$F\-XGWOBVZ)/">A"P#
*M298DA.8*R/+N0KM(@/)U$"8)4/XR?9VC$LNW>AY.5V'H=E.@].P5DD)Z53=B M&A.?K_;+E'VN+LO>FYS*++P$IV8 ^4@U%G6Q$O)SNA^?V"VI8JY!?5)]6O82*
MN!H+&XN$F'QHC^O%LM=X?"/=XH\PBB7WH^J+&3X1G#XE%/OJT4= M4;6!!Q-M)?C=%_A>4+GU+DFHF6V9K0X+$#MD!%:L:37> 08253-C&.X,U9M
*M(7!QI6+,A=6)"W#]-YOJO\BM(Z$A1";&(CQ14H*Y7/7D!:@C;D7V^'>Y]?JC M\PNF:>-^)/H Q>A#,'5L])2BHG>YPFV+8CA5'UO+K>@!^-J)_(,.9H^I-*
M<$=UV=$(\']3HHG@8SH#FHE7EC/\.3X{)6&5ES11Z\5,6A&6AM!FH[W\>ME+ MHJXFD0@=BM TJ6I.4BA("@4A:))"$;B0E<"KO&^W\:A)0R .(]4NW>ZMNJ2VD\M/G3EQJ-
*}656*6,?23^%@= MB#I\A+C8N=1?@APDV.V6;D(2O4F2256Z+HDENQ+6>',F-N/(+E>1&$(]^)'? MMKAXO05Z6[UC(."T*SE6AD;94.Y^,9"4C5!FMC0RG[>WPRC(@L TYW$=&9%S_*
MR+,B4V"%?B9UI%94H1LR,,+.X-_;;$69NJK(U'_1^\W>OO<6^"O:Z,/[%F? MP6 ?V+42NOVV4WU@$_K[Q:G +O6JJFS\A#W?#.65/JO MO=T-%.)A0G)H F.A2, 1]QI TH<:?
@J6_(Y(>9M,F8M/FSE AV69WFI02W,,^@Q,@L&LEMRPA[^N0'J_21W!!A;.G+>Q>O?58F2BYQJRO=Q9, MG\4) (KO*=Q?E\6!WQD2E1QWH9HHM2-LFA((X=;*
(DS(^0&=+4G,^ABQCXX M1^ XR+K=5\'UHL,G,C>M_-#8;$U7I_@_(QN$0H&J5#W)&T M;1*\>N:4C$LSV=XN_2Z"D_'=&9R1)YH"H6H M4L[4MS#F3XX5UI9%ES1<>
*0@'Q0F'&S^=^7)]:OIVW#@5FW3IA5XK;+SM4,.G M?:Y4Z*1>:# $\]ATK#>FYM<5G]!2%72YNME;0T7(VFUR<08+(3<D(RH/A M8J$8DLX)D/QL9..E^8L*
*2<"!Y$1O\E7';&@BTVS2W54ASSZ&_/8\NNJR3^$ M((-I8S;//5>?:1&D9]-Q.=/:<%B+P1W*D_%0G#L,ER31T>?:/;HT:WT[AIQ, M0[KT2G\XE/H/19 /M\Z)/DF:3C\3:,TH!KE6=AD??*
K-&]VOEQ0GSP M,FUWBX/$8&27/-R^8:YF-^0S%"=:'? M).S-.+$Q"']0B2!\CP729ZQ-B2!D?N!$6(4>!M0NO6!M))D/2>D5T(V16E% M)@7M.X$ "ORJC3,P:'NHBJZAV1FZJL(A!3A/)*
<:Q/WTI[/J JP 6K2B0W\E:+^-],:D@:I$47H,HAT27I$ M$;(,)%F2HN[7(5-OHX]COJCB6"]"?Z/?3:BSM&59X[507/,#84MUG'Y18+,6ST?!ZWN^)STG/K M.NZ?Z\[1N\TSN=,"(Y=*
*(0PB;3Z6EI-%$VCW6A'FA-1:60GCY-Q M162_'I/QGJ#):[P^MLQZ?)(>Y'/9)3?5V0&/!$UDUWU7T+R^C+77EEX<(H.K MXFUC9"@5[A5)6+N^3D*D_P=I:$,;VA"")@UM*
K(Z0L^D;C:A9Q(91=JL!+7- MRCF")K_5'_/Q;(:G;I;+Z!MYTDXKR=K3H#9>+.6OIT:=>AM2I%671VTQ-71 MF*J:.,!5O!6 :23FST]F9M-O*RT^TM^(3"NWADIW!*
*<^<(=YW23O@;2]N?>[-MX>.%'=+VAE#TI8 \ML7W"P@]WVS./Z-0\C(240U*_9XVIH&L%"" M(!S?%$JN++]J9AO22#0!*EAGN3DZ\(VZ-"'1WD'RO)'P11+M3:*],XLN2;0W*
*M(TP45X2)A+C$FTUL2=QW@,0#0.2W^>32>W#I>/'_NRK_!"<^907<>Q%N1>&A M1%HWK3*P1KI\Q.(W%];%8JG3F0FY_O-&*PWIN1@>8KQ =5_8<]9\(6AQI4+; MA96)ZS?9?*
*Y%9S4(^VQ++:Y?0$;,#2!K^.:?^3+* (UB<_P[S'K]8?D%T[1Q6YD# M$SVE:.@T->#0PE*Q1I0U A0"95%,_Q^3 ABDJ9DJ:M<:QA||3"/A__=VXB3\ MGQ#T31$T"?^_?>'M.[MU9+A!-*
*V>KR^JDJ9KUM1+HX3&#[MU(+D&R' 1J"(? M[BJ(1<(\(;%!9#$JK6B-0HUG6NL62 B:Y[M.]983+78,Q4,.=?5@C[04^R;# M*T1K5U0[W1=$DR/AG3XYXKMX6;AP?UBGIYK5#*U?*
L9Z,AS3 M ML+-8)M-/F[RF#I%0=UL<<"&?JO&,$FPN#K!YFK<7K> 0K?M%/N*>O5:JYK, M4J5Q?Y"6:'MST9LJF#/%&I*QCBA> EUC[$&Y51=B ME66C+V:T!Y&8Z5T;W$%COV*
M?:WH^G- L'TSW$<&3MR@P;-P4F"%?OZ^UKRW$RJS(D=CO]\V,UM1IJX]<@#; M,9.0]Y_)X0@N1?Q(CD=PET\8XC(Y(,&EB)\(0PCNZHFE_81KF)?'MFFA.9DM M_<2,L035?^TA;J"
!Q-22!,8"T4"CD#. (>^U//3L&QZ1"-30<9[9&KU-KK M3HHI6R^%O36& FD<6>FCH43LL-XP(TSAT<%EW,);I&LE0MDK027)'XDJR6X MRR=9+W^6]7?)TLR,\CE?RH#([C+)*
[<_X0@B#@=&C?_FDEX74+UK:IZ78NQ0 M:G=-K6AF%-I/%(]4:^H/=T[X"G+0UX#!+A XY/Z!S M),D9_WG%XA'(XK)N]U5PO3S^B>P-*
*WNQ5!]^8KF%SS9H.G@M3>@V]>;TRMZJ3 MRA]D0?O>X*1H5&W++1.N$IW D)2/Z,,B-2UP&KB4]RCID<7'(\L>DT I&5PR M1,<2H6C\7"G/=Q:UORW]_GXKHY5/CHS?*
*_SD/#YK.21KL+3,9V9 W*1+G^[2#4Y0QKW"L]!7F]%&>'$]^M?ID3UG8Z_6V- 1Q,@W\&?UU' M;C67U>JR*-CEZC0VS $KP?YA^;?WD**O5.1P(U)XF8"JOE(ENC 492P1<[; MG*
DQ#$WPX!LM" 0/"!Y1LS6)2H.D 71T.">F!X0%#*]7*XSD^B87*C$F/Q#P%!RH$;$R/KNBI;B6+\V4RT6"Q2, PO_Z-L)%0(G$F)+B[L&W7 ME7AK4."Z"(.+!?^],ZK}>=_W4C
*MO/!C!K/3M;MT.E<=+YL+?I(N#WC -MANM,2?S7#VBA-V%K1%>ZFSO<@*T.%X M8I0LT9E(O>UP JH82(?8:#(4BY^M'/)]HMY=FH_.(#5C#_-MP,//7)5_@@UG*
MO!JGZ4TO56+%'1^R"_79$_N2SW8=0$]KI+Q4#1R:% G?:X(KA =^@0N=-1V MH[U.B6:[VE?ZRWH](_V=UK$H6"MVF@#:[J!%L!;E]'T;4N$/W2M2%[G%9F?H MJ@]'%.*
*\H7A@'6%]KL3QT4CEV6A7[71"'\LF6-=Y{$U#[K1$,L1&OM})'J2$ MR0fJ*_5K*20UDK2ONO,0,=*^BA#T31$T:5]%Z/FVZ)E4 +XEO6$;@QOWQ> F MO]<5-XBN.AK-E6?*
*M<,9LQ4%_"P^?ET7@*S8]4O^6LF^\i2 F6KSXV14>/JZ5^X]R5D"O9$PJW=J=)/+ MV)V^^3P8]W@D.>-\M?(;2G M#>EIB$%7BX.TIJP!E".Z\[^$VP?M.@^JO [Q)WQM"F*
*ESO;.7Y:J/AF MR_ 9+__G52<_]\IJTTQW:VE7\TJ\DENOR14?GMR__ZH[MKMB&-1!,WN+?< M[!L*M[@GT=XDVOO.O9DDVIL0}$T1-(GV)O1\6_1,PDUNAIY)_!2)3KXMBB;1*
MR4&G-GRBNLVW>3M=%[1HMAZ-]T9#SKCQP8-@!GG5!H>2S\M>RSCE+@)T7$V1$?/6>'FWI'^$](+ MWH6W.>K2VQ+ F/'
*NV3_!&O^987=>Q%N*N%!3%HWK3*P1KI\K.SDHJ+P_?9@ M1,_!++#I\[*A=T*QCL$G^^I>C0S1]6'7R^ZKG$*0A2M*M \8WNUN^R.CEE#%, M9P#]0C=3(M#$EVB!S0\1H^-*
B.>|R^I4%Z!=,T\;]9?0!"M.'L.MX3BA%0V>G M ->?DEXHUHJP1H!!\B]KZ_Y@4P'!.S511(^'\@0KG#[@^<=A:HF1T!_9ZGI?; MN494R8-X.U(>_D&W&?QL1-E AC-']-P-
*RE'IH#_3,WN/Y4S_.DZ.R5#J+Z, M*PLQK=*YVJ8F=0?K63P+X8!%G6@8C@G3C4,-T0&DT0*DDAQ(W1)$BDN?5%= M>D)DT0M8H7$_O#X?-*
*L3516MU!3WADY4[M\W!%G0V.G5;89'5F6(-R5A'9-5\ M?3QJW!3J\79QL%X5X3:LF]$ZNIP2O_YE0PQ+6B21,+Y@0P)+R5)*X%(6CFW*
M# ^U-5N2)'$K8"%;EQA)DB"$&4C"#)1T=94&_#]4BNP-M\S,.XQ,@W%3&>1[M$;TE++'%CGU?*[K^, ALWPSWD8$3%][Q++)P46*&?207\#^=$[':Z8&8KRM15*
*M10Y@HPL2DOLS.1/!8@?R:D(]O0OUPFYR*X%/$3X1G!73VQM)P#?/RV+8M M-"'>5I9]X,Y:@^J\]Q T4\!"'FD"8Z%(P!%(&T#2AQI^'I9-CPBDS2AH%I\ MVJ)FK7E>*MCERL8<]N*
*^H=;EH5CTL"XRR>Y/7^6VW.?)TNR4\CE?RH++);C+)[<_X0@B#@=&C?_FA(P+J-Y60:7[M6>%9F*S99?$Y;UF#H0)W,UN:D]QJS>.L=_/6?# M]P8G3Z-J6R9:)SR%*
(WD9R:+,+.E$>#81)ZOB4AY%5,A\V6.C*"^#0UU4Z! 3 M3Y#XUV_TAUV8?7:VY+^_S\]UO_YR'A4_("?O1(5^'IF,Y,CMSP]4BQ M*F:DQ1,=KB=G0GY9EA9F'>$]^M:?$O[^G=Z_6V-
1QT@W\&IYW9#)>CZX[5 M:,]G"9$957K/K/KUF@7T0H^'B3R:MKK].MVM6G4ZWA@W1DD>(0%RL\7CH43B M,'&,.'7S0@$#P@>O-6O#P!R!SLR1,BMGH,YW(3%.3\-
*>]]Q\"@F'\L9.1 M2H.58+?6Q:@] >Q4PJH!ZDT>B4="#'W&YN1W!06N/_'6H,#U$P87"_XY0WF6 M/Q0(/MQ3I]/8&)'NYH45Q&%Q_5+1"6FN_\W"@7*J4GZR)>130XE_%NR1+D^R*
M<_&YS@TQ. V..$H=!'8CO/!C!K/J]& =8?W4-%)0GIXX3@C/^C7+'(9VW;\ M:=B=QH68Z%O&, ^PI_Q_\UN_B5CAC$!X!='Z'!/H&]^+?EL[W^G"K/LK.YYFU*
*MCQ0E@=/;_U3J4_46G GW\C.ZHBH4Q. "BH5CD5%^$!4A7=@K.Q=]M:S!+Y931 M3SA8!>E=5%,11$U21)7:?D3F SRV5RN4%7.FBFMTEF!OQA] R2]L#/T)3)65 MA?=?^_OS9(*1 -*
AS\B=WA9,T+-=2P1-_^?[!HJ3Y\9&?1FWSB:%H^'7D_]? M_MGO(H[']QJQF\/!GW+<@^ Q8@X!.$^%!$F87$ W_Q,5)?BVO24L>3#UF?Y M>XND:!\HAGZ(&.]-!OH>:K@?_?JWA?
,!=:D$<1#7MJ2]N@GUS<)%6]K&!['K+N MONX^W#^/@XUV_@@A6_H+C:#^+\7B;_[]Z@CV3I+Q7:[N"Y\/3CS>.Q417PD] MAI&D)->?>C3'2KUHC(GTDLG8H)>{]V-
);A"+,H#YY6$$F1G./.RUD;'-@2NR*EU:QFTWPS MRGU5N\U>,IKDDG1@EI2N5C)"I2ED*\A3LUHJ9."D,]1N[E0U2Z'94VCZ>(5O M/:ZYW8/S+PWS(;OCP[?F]5=;$Z'X N^N?
*U#!86NDVR84N=PY&"D+,.6T*U/[&I_'GL> M)6V67O8BAR/9I3E_MI>MA1 ,EXW.Y)E?Q*(\',D=C,RH^?9RW_Y/Q,Z8Z8* MU5%I-*
NQ%>_3KD>-9,SNF1>6IO1ZW(MU8;!)/-L,>=SBRV4@_/[(R_]06>,D_ M4(KV4&'K<.3!/)G&.O?$/?5TFFU%^&QA$G])@"4<>3#%/F/Q.M<:ZFUETGT> M%($0"Z?JO=CAVX75N#]
*(;=B%4'T9UM9RKOBR>JGWXH%$?#*YDBTQXMCLCXK:JPTFOQR30.GN/%"-NKP3-BZ,.A;"+'19),N=YN5I5*
M0WL1=,4H)";F<&B>6[]LVAEM2JTVM3@4\]0B=V7&S$$MU15@'G>N10[5FA13]-(X_"O*OV MGN/*FY6*E'3C4K9>V4V@'E=KH^:_9LEN&6:3CTR+&:,6G$;<(175!BVGK!
*M&UIY6H$3.');BU6BE)'6F:10K>06_2;?JT>%.FIR>S TH45+I?"R6A+6R>[3 M:#TK#_MC7,3]8&B]U6V&Z80:%91F64[FDL!A_-'CFM;*I9?WZ<)SMT,Q^? M5'FCDZD-*
*<#3QX1%8:IUN9P%-Q_+5>:$VRC'"%9SB!(T>P&BR$2C2.0%YQ9;HV@30W5EE:[?+SF%Z&0X\< <@LY,*CVDY/FKE8F5^+ MX4VU!X<>.8(I-*
Y^'&;WQ1$^]3 N+GJ$X&&33TR!',@@.XFR+IY5&0Y9[0Z M8P=.7($XWX_FXSGYO5V++W1.VE=G_(+B)1'CF'T'MD+JS:8MKN@<5 3^~W'*
*MRN.P%SFRK[7:@DD_M}>I=K<&3S>C=<*E"GSJ$2Z(5#9FN*7W%8&-KM4V)\^6 M4)A0^]<@19.@A'UNS&846"Z5N8EW91$;/<%E'CJ"0&<^JO;#P0J>?E75DRO1F MCS,X@2-*
*'T.O.^-33LM6;%.4GICX7E>)HRJ.AL8/-:N:,73X5'M/*0LV]&'%S MT%O"N1XYK=E\EDL(,2U)LW-&2&;->3MNU='0 R4IYBSZ47F9JNWY(+*L.PS77:\C M0RY:1T,/[D&MO@:9L-*
!E>Z!:36^LM"XR)3STX"+43;;4FC>]\78N^=(WM;AB M=%_X'G=DLWKS]L1NI[J/]J>H;I=",K^&-?0R{{(H\+>5%>+WV\L_]\-.1 M9R$19DM!\OT4S2R1,$,/)C!OTE8FWQG-VO-
*L;T;,I;K$ M+>"RCN! EML(?:V?X>AU)BZ,GUM3(=-:HJ$'$Q#[3_E^O M=3ST8 +/9;[?3$S*G#"O:PUE6N8?Y2H!K2.0,5EQ\U1+0PFZ49>9/;M(J9D MX%./T"NHS#=VJY.(TTU-*
MYF6Q$6&6AT-/9@K'TVQ4J=,AR?%E\?JD-795JZ(MAQ[,]3$W2:5K5GPY6<^?ZZ#D]6$^*2!8\ D3/R1S?29ML9I+KIZKZC!72TU@= M#3V8@$T_)0]BLYNO2>?BS:EKZO'.-
*/]A3:0WT6*R)H-F%57.NV^Z5]==8RO*FZ-M4V 1C&3UQ]B'R9AU_G_;M>[X.GSE0]:5GZO>^#R-#^6_'N+<6>LV MJVW_YR+A/F:.>|+?@5LAG&6R3XDW@R?(?Q0P?!O%.FF1S$*
M#QU\B'Z9@0%.0@="3?=U$ 2: G(0B8?8FQUSR%[B ^F8?^KM1Z^$TGP#A MG_'H?']4@K544#5!E^/G(I 1-!C*U M]0(1-B!L*UL$)R2+Y]FDU-5/@BS!(U9_O2DG7,]_.^2?*
*O9@OTJ65#,0^0@ MR^.JV(*EV>C!QA#"'^&/"H!]BUXV73O6C/\?&^Q?*?+5&9]#=^Q2_?5O6C1' M5!8J3R:5-?0I59T!5.E+&U^\!#4FJ!,!_>W*F__]T BU)P7OH5J11!).SW[.X_?K+_*
*M_=V766#RU=Y9-GJPS).?=BHOSYLM)>JG9R;J22U1T48ZIR:_7>ZL9 M^D"Q2KIYK*N?D7VA>_UZ?]H6V?$3OWXI3JM#OL>AB">&94(\(71+F_/>5^U_(Z\9&K%(D>%+Q#4=T#*
MW115E-(MFB;P)703+2&P&L+,I9W>.7K/+T;L ==G#\B)BH98MZIE,/B2+[J M@,>LERG/T;& N98(1L' P0&B/D@D..# MK\/ ?#FVZ(3K&'A>T%VVZR2\ SAF9LU.A#!9"N8[*!/ MZJ*
*$K\X2NCD=L:2EIX CK0'Y.C@BFHPRS5ZYMZF*0IA/#49ZE7D>1H>]!!) MV%"<_H"..+S!!RD1!=+MBZW%4@*S'SG-_(TYG(Y]RYU4G;D"&;R)^YS4YZW\[*
MVF7VEH_7\!Z2_5;6Y9IY%+7OTPHFCS6&9#@!L&- M*[<+?0 KOKL5PL_(7-\!^%F]\Q0A"-064=BV?:BA7.C*SA1'WL+>'<4>A)B&:2 MQWH=W)N%* -F!CP*)PA%'Z#8DQE@}31/T?*
5CP+'&JRE@#L1U\;G=K#TMFG%QN-3Y.$J1$9=2%%)EBW M10(4!"C.Y)<+U"8$"RC..Q%![RA2B5@_QH+8K)RD]JO7J!+= MQ,"%R =PD2 08
@FZ:"A0#GE8,^C0#&LMI8F@7%$}2^*\^KE625!1@!H&04 M"\6XPZ;4]V>*VA4Q48%H D=&"NN#L_U_P0%+E.C;>*)BWH**>15F?V*?NJC MM066&$L%!MJ)ZJ!M.G#KQV)A-4-=,X*

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{3E3E8(NZ/_? HW0H>8^&$GO)LJ7/0Q*0CYGS1+-Q1-MREC?A!X4.(,8%A+ ##SIR4F'\\?,[9V[<3 '"GQ=I=K /VQOY+$)125$JZH M%&$_4N6-X-7!B^LTF@0? +WY:QGH;+S;Y<.8QN=CHI;"M3SBNMC;BM3K'"'YR(-MST4^HEG=ECFI9H"9J,A>^(GC?M&M$3!($S6B61*[TE5(22X39\ & :0W415 M7I.KB)%/UB4IM6"HLIDGFG%DN7Z4&UUGU@(ATX=;3H43?R^$3P(&#<<6N6 MIGI*4_DR-)R,X-4FD:J1K^0[M"+K=`Q8FD!4[-UZJ:&^1*B"ZA%!6$F<36X+JI#VNKRD+\*8 M.+3!UFBO(E.56+W.*6R]6;,-@6)IQ\[O}(YKYJW"'HM*)=R9%P:C/P9RK;>+U M'HO+<;,A1.PP,XO8O A"7+\=+ (<48)ZAL1@@,3H[\89DL3)5_H/$YF_4[8 M&B*$P-4<8[`S>0FOR.JUC4-WC5O8T"5*DF$#^9S2%=%63VJK?=V0@1%VOO^; MF:TH7!F*^B\;_R_0V/-C]K#@;E*PM-U+Q<:[ZBU$;-X:\$Q}P'P%KE>X EI9D M3A"5IW+R!6Q6SP4HSN'2WC$F%/U(> M]7&26Z\GZZ$U;J>YZO+%P)"$7*:Q4(R}(>M;[$.4 25N2A+-$>J MU!D*"'V MU_[,?[@)"V*+^S8<#BR>7$P.#.R.! MASROT011(0Q"HN1B0oD/]7"YH6]6= MW\+ $50=U>A1OBTDK F8]LK#;(H?OCQ!5(TX)96BH4CL_(V("9P$BGBN)L,% M=D>"!2?G%=C^"$XFST4;RG]'%,T^@U@#A&-DS"BU(.X#X0O"%Y>.R;K?2DSHD?U3Z\2_+P&2M^ L51D.1M(`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`JX5G[:\;AKY$ MWD4;6?,HU+O#!8GR0"R0@H^$YWSNNQ-P;+_ UQ=G1+B6ZAZ8]X] GY5@2X-M6M18FC1M4Y26E7"?3T/9"9=Z9B(A+L:1\CF$^:_;X/1)YD).D$$S/1'W#<$,"X,O8@Y41NS%?S"< HJ!4MFY@6T^U*#052K]Z*TV_:*80ZK MK9.P'()"@3*R!7>3[LD(]RE >HU#],3ZG&761F62XSJ%>MGD=>%GV7YT?%7*"8MQX7WP1!@,@X.HW8"6-M1&T(*"A_,KY&,N5D+F#:_]$>R V#&+#@"J#@QC5@>#B10/"155#6@3ZOS"W ME074$S3+; #3,A3) C+Z Z_)^Q_X1KYE[^@F7A(+0"]&DVJNM1X.[;748_E> ME,5!M/&/I \0K+I!K+KN!"6"7Q?PP?K'#-%=6Q'6\/>_%UF6YT["?VAB_M8K_^/6/:^9U!%-$@[V73"!R+XN^2_(F!]@&4A0P(>B2:@B'$!=-9_U:J:$ M@("=!#"#9Z-K8! C"8D;X'D)5S(97I>`-%.0TZ MB:.G'-$H8M*SW1BRK2M6RXVZ[UHU W_@#QW]K1B D4$BD@*U:5-M&1>'HCPM+)=LMRA/FM93>=&>C355YA$4Q7[]RS#14)R^OMK!0<0;H@`>RZ*) M@>-~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`$,#K!CF5 L M>5B 149TI[_?"!F:*):H46,V)BN6;< W*3AY$K<"@5>Y!.=NF4C($/LJ(.K% M+:.@7%[_U2;3RQT*0;H6G*MBJZ]0RLFJC(1U#4[B>:T<=>W!3$ MME):=1-6J;.H]SA T&+\XA4!"TN5IGARMC1RI?#V?FFVFG/V\ 8 MQFHE+3S$:($*1H:BR6OLJ?%93JC. #HN;4BIN/ 6IJ6P/@C;\!?1-(&%I*U= MS7)DP=%??4=51(PJ9VC!=I?8&2#RN%[CRE7*4%CW=/V36\XN(29MH-VH#MHF MX!%3'X'#!- >+QD1:Y87TLISN51!JA:'$VPFW$TO3CUJ: MOLCMH"%'IL.RD1049FCW)_QHD!]C;H?"3S*42'Y 5;H&\VG9+C88 #4;B!,X++(O+<@\U[<&$ZAA>*,? ?`X'7D&*T?M8U4[4ZC((+40 MV,8JRQ7I\#AL\CT.EU1DD3G\_%8!!4(*@1=X;TJ5#AO+,'[J#!Y3]J2V=YC M9M)4E@LL_^C2NC)$J(##-$-T;G$',0,%3=*G@++$%3"QK$24GV K/Q<7=-A^ M_8Q4@_BRA=CR1,A3K@BBPO I/YE4%]%^O9QBA'4&XE<<2S7)$$V?/T*2,/?- M,#=@\O^DTP#*#V"SX!\YZMZN3%7.FBFNT,6 OY?3- MV9\BN2]L$_T)+)*5A?=?^!_OS9(*1 .QZ\B=WK9N&[YAZ

*MJX%&8Y1I2}'^W=&_;%D.H9MY).%1(>WOO!_IW[2$/WZQ(403X-TB-M\|FS#KBE@IL:Y_=N5C[QLG\Z0%79_&IOWBV3\ZLR%QM[#Q)%2_93S."T@IG4 M0H'$/-O_:U?DV26?,7{"611FG^U_^1.4<9Q^OS'NSRJ$G(}EZ317SE)%]LW5 M?1 G^^G[TX?+%IA?=6^*'X9_TF4]U1^"S[U\L?2/6Y]KS7!!I[@-(U/3<;IC M4_;JQR^22CX1%Y#I%6L45 C:D?5{1%VZ_N*3, /?(R#Z8_8LOA3F'+_MQM'\!W/(>804+!)@=-_8T@]F4TC3D"$2/_M'6:> /WSL^UQ1.Q9\A#] ")FWVMO0;!Q6B'AZ75:!Q8FN+%N0%3TZQ%{[''#G M-,B.+{>5,>XKXI?SB_]$Z&*]N5QE.PN>YUVCQ+[D4MWN%4;OU/ 3)=}2V{G M-7>S>5&=, -,:OW[*U*.9%L5U^(YG8Z^?$K<G3)N_69082=59?XX"F0 CZ M^RSZ0U*KG2CM:^R^0JBBX<>0GNBA]/P9)*W=Y2P54P<=3B#,$IE-R2[%WOWA M.M*3Z*1JK&DW4JJ2:NA5BEKH"KGZ<>T*I+LYC5]}3IGVU!+8^#JB*O7FW"EW MZ]V^>=XIBM5A#RU5X1;K!/EWS)5U=1;&X=(/)L59;'X_FJ,OMC8;9/U3B%U M+V:H+$\]88?B8I$S02RH8ILK.=PDUC&\|3#9N(X]=MD@5WP:"CA_3]<]MGW2 M\^7)D5(7{"&;7HLD_Z!$EO.*IZ^/JWMN!=<\)>=QY06@<3'#3F^G&WDL"ME.,Z+A-%&#\IT;-,LJE2KJHIZHIB(:V'\UM_=USDZS[0M_]4=W1NCI'+2ZK MCLSEX\9X.:F;""><Z_!ZL3BL0NJL],*2)L)]4& 9%76CEOTPZ@NPL=U M(05QJL@>[U=0U!?Q${#SN V&;,-^ X '9P9$[^#9]2_9X)",%95MM)3)Q.,N M@(*]>U+ KVK)8\ALNB,_M0^X6]V$53I7;D.;)SGA8GG&4K *B.76D#W$W)' 01HU5/IFO'?\!?IU M5'@'\&4C((0B$//32$NVHABHMUN<6\OF##KF*/80CW (JAIB^I+"GO\O.*## MGH%)\/30! .:*\!?H'[PW?9F+M?& MK(6HC)$QO/ORT0P&${B;/_\YV;'<8?G$Q.#0XZS^TW,4XB?PUT9<9@?#0>AP>$\!*25YDA3)L$).\]RWSR[);K-M'V^V>*_UO[R?O=]MM 57&'0SLUR>4(R$ MR@[:Z:+#_/E&.[:Y=FK#4A.NMC>[*,1.(^=U1TVVMW6>,(/@5_AYFI:7E%9 M9RJF#[&]#?$TYZ'?<8\]%!+#6W$6APZ^5<6:+YP5%0!+V$?3GDM@:,JBS! M#I"/'&$9B[=.-U3\\@OT(*#1H!?U0B"5Z'P+Z9F!XP>>#3!_(AGU^A9I&TBM M!!F;P2%ZY"+9@FL%W1)!#=ZP%X7S3PA^<%MTP1D;K((=;,#0N0-#")"X/5@G M?VF]4D>(==-"\-Z}>1M5W/.3_1!/1'T!V]]O4I(GH\WR&^X->TB?+TM[WN- M/"G!_0@OMR*,_!>>1!XG780#@3^@Z3XR]@*>9N1 0XMPO 8W'V"0$V')D! 2 M!:]DRU* UBE!SH@W] WD.=_]B!)'G&.1NE MF#'=?(FENZ7>17+&PJ#6GJFNEN9+>6<09^HS.L6N+E$N#IQNALU2MVOVO=-M)?#,E Q^1C>G1X(&LVZN)MCW"MFUZBK>N=#N/;*1(OMB*)S-$C28SE}3J1KQU9LKCOSF\M4^[^@@#>I",9*APS-".9/O MW#556DF=JZ.N"F1(2KU'O)9-Z81U= 51F@JDR8(:Y8K??##>,=@0:#GE]_M34K3IS&&?V_Z?HC%_U+H[>;ZNL/;J^'1UP6?=Z;!W1'*=KK8]"X[MJA<;RX4:Z33$/NM5.*/(1#A*4K>S*K R8V5^5&4^ M*6O26G>7C?C47*LN&,\$B[5M)G%;N^+MRJSQULH=C<4VP5"#Y;U:=3D,2Q7 M",T.@@#*!+ZW?$ 9:%WIDC:D85X+0)E^OL%/$**;M!S92#:PE?YFAT+US[M7!6>KP^%GV[\H,^^O/WC TJ7S;;$.%KWOZ?@$NG<$\O1YOE@4UTJ!9)N/F MU)(V&<:A[4,FR#!%GA_3_L:X@7$#X\87,[7>AAMU69*6)+>0N8B]RL[Z.M=. M#2%N(#.+##.QR7D7RZ\=\/D> ^';O0N^W\BO?>USW]C+O+1M-.M*W1HJ[>>$6ZTG4G:9L.Q8XV/=C+;JZXPZA%>/25.A-5<^7), 'DT$RKY9J!753 M%I*,72RF6!HRC$*#(A:FXM&7W#_,H/N[YXQ$#Z*--^@&F%%CLJ=L.;C2?G#'M'K'S>+0ZD'3,^PG2->R)(R1Y#HM6PYOUQD7*"Y_UPRL'<4"BX"H((H$KW9O M0)\PE35$+W34-F#D./C0?\.>K4=7UD^ADW&=WLU_^YAV3:C!_-9L;8KA%0_,ML QL%+8+B5SXYA3_"1 0#K8&"Z MN5J[D&@IG%Q=1.FY!5C!@/SQZYCS?KZM=26FVL$<^,8,NS M9Z8+G!:?\9,!Y[K&F!$SS)I=L\/H^3-EIQHSNG2JH,J9VDAO%Q:)3G\UI_Y M_K5.L:L0HEU7(P29352'K&/S#=#R()GI84*S*;O1Y&IROlA83/JSB34!+<_Z MJ=16UM3-=(KO)J5SQ&@:*;5[L7Z"HHBSE%8B8NHBG5ZKS2>SA8&;'G6S^B(6?02S46>*U&;N%0E>R@ ^LG!/T\J7[U M?)& @/S_#:4"J*OLHF]D=IY#WCN@^J)3J ,IEW<4=\IRMGTE]3T9&BPB###95 M[9C +9@>^&?=-!2O\.ZKN;\|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fMNQ.=S]U'WY +9Q}Y<.W(1!#FP_0=D44;"!0F#!D%@K+D3*#]F MN&A7XIG]H)RBHV)_4^RK*@ M($5%.!J+7>V>PYE!<6]=N#;OU9D[Z=X#O)*R)^ZS5O=6]@..NC_7]LFF[$:'MJW]&[Z;CRYZ28*QY[,.lLf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{&M 2J8X=L5P1Z!C;C_9X)1@\Z R4J M?$B#)$ZB8L"^(*#VA,I_C,];:!)/5[P+QL^IQ5[P=D.#)N6N2Z"/:'1@:YL+ MBN1):J[[T?72GR[5"P38+7[VXR[A^-QK4C$3H44/A'_SKGT>7'$&NAC8-1"UA?W%?H3SFJ#H]HZA M2S2!$3B'U@K(_)SQ:K?UF#ZDRK#S)A@GM*Q0Q_>ZB,XMKQ6H"_Y&<"2*0%\- M ZBBX 1,7@CL$SZ1Y$E0.*HAN)3%/Y2,1(E7XD%6@GY*)O%'/,!"1)_H.%Z(.M!U@(@$T)K!)77(DW9L2]:$<]-!7(.REF#N4O_11X;!,,UY%OW6Q+^MCU?W=4 M%)H"$7UV:[B[0&1D\5>R&N0L6$80##PN9FF_HB'[,,AX=%YR,XQX7-+Q_5X MR)AK(9!]$=1Y&P77H:(13]1MKR/UFD%)0U0<]3R,X5?>_F,0 M]7PN]QfMNQ.=S]U'WY +9Q}Y<.W(1!#FP_0=D44;"!0F#!D%@K+D3*#]F MN&A7XIG]H)RBHV)_4^RK*@ M($5%.!J+7>V>PYE!<6]=N#;OU9D[Z=X#O)*R)^ZS5O=6]@..NC_7]LFF[$:'MJW]&[Z;CRYZ28*QY[,.lLf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{&M 2J8X=L5P1Z!C;C_9X)1@\Z R4J M?$B#)$ZB8L"^(*#VA,I_C,];:!)/5[P+QL^IQ5[P=D.#)N6N2Z"/:'1@:YL+ MBN1):J[[T?72GR[5"P38+7[VXR[A^-QK4C$3H44/A'_SKGT>7'$&NAC8-1"UA?W%?H3SFJ#H]HZA M2S2!$3B'U@K(_)SQ:K?UF#ZDRK#S)A@GM*Q0Q_>ZB,XMKQ6H"_Y&<"2*0%\- M ZBBX 1,7@CL$SZ1Y$E0.*HAN)3%/Y2,1(E7XD%6@GY*)O%'/,!"1)_H.%Z(.M!U@(@$T)K!)77(DW9L2]:$<]-!7(.REF#N4O_11X;!,,UY%OW6Q+^MCU?W=4 M%)H"$7UV:[B[0&1D\5>R&N0L6$80##PN9FF_HB'[,,AX=%YR,XQX7-+Q_5X MR)AK(9!]$=1Y&P77H:(13]1MKR/UFD%)0U0<]3R,X5?>_F,0 M]7PN]QfMNQ.=S]U'WY +9Q}Y<.W(1!#FP_0=D44;"!0F#!D%@K+D3*#]F MN&A7XIG]H)RBHV)_4^RK*@ M($5%.!J+7>V>PYE!<6]=N#;OU9D[Z=X#O)*R)^ZS5O=6]@..NC_7]LFF[$:'MJW]&[Z;CRYZ28*QY[,.lLf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

*ED2":@NR,9CC*8 Q=K MZ/?1T-NZ*MZEH0M)+5&C=8WA6OG<5"U&\|LTM8(:RD -)2X0&6(-Q1KZY33T M0[P.[})0,"\/*4!@.);XVRRIIL\%,#;@P'<<5;[''*?A|5O:T#X5TJ MJE8'N9&2F4_45J>47;6;%=9@D9F+_ E4.'GA^BCF9?\,F1;WRO;Z?N-^V(L^ M}YZ7A[T A!4%*\HCS0M6%*PH6%&PHF!%P8J'''%>7V&?Z?5E$^01S;S_ ?R6/3 MDH/@M2.LK\A%|SG6ZJHU{J- 4273'6GR?33UOVJ5Y?$. WN E*(/''7SO,XFR MEJFG03\4PP6S6=O=NTDA)??:M:&*L0F!+PL3\"C%L4,CUU8,V;9# MMCS190-\XI@A!S0^K$D? TN2EK(6 XAU]=W-A ?R@.;9\"]&2 HM=% M@,3(H9%@*_$W&;z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}@"4Z/B-)VU"U'.B9J>B:LQ%K/)\;3/*WFHA6M4Z+JSDSP6'/. MI+4Z30R(Z20[4FLIM[O-1[;6(CZYA*=&;UL9Q%*VQ N;05_9T-OX8GX13*>9 M^AA-A=+56?7@ED?U2E.75W"TWR\(ROK9:`,1J.0.58DTMX6JRVJ]%Z MJ!CC6F9*Z199ZJD^>DJVV^N+N&IFTQG"&/2I=064RDTYD!E MH@WV$|[FW6DJO16J737=*!#15B\A#9C&13S=.K$F 31+31N=>K,0B46=:.,2 MGL[SW10]W!HEOI5LQTKOF4XT:A=1LCM>=RN1,2OP-=JEFT:B(S$T>Q$EZU9K MG1!JR2X162OK\82WDZO"ZA+TL75'6S?X+<_I@\0FE2!ZW8%R$?IXIC=KNAM2-MYEN\FNJ2=K2T!=J4.!_\F-3L5+F@V(0R$E/U0GM-%4?PF6>#3}AJL5>9#"=| MC9J_LE5J/X#//!D\G\M/UNB*D"'"79J [=::NXRJ] R_/!)U;F9+1FDUU> MI_A%;DUTQ#)[T8CA^L2F MVZ4XYXPBH\DEK9MVA[2TF3>;O)MBDNJ\UR.&@XM6C#:8&%$U,FAPM=5";$V2 MG9I6N*AU=B2YB18(L2ER/&V0UKY:6)X49>JQ# ?+=$CDL^QG"FK7:)OF?"9 MYT.*.9MBA$ASC-I-3-:=M9U@MG/4-'Z&LWTK#?0C ZOT/'E8E*0D}OH1,5S M2,+,3B3R<372*\LEJ3[*T2D6M#Q,^UA=V&:65%(E*-?MK7L,(PZ (4&?CVF2 MZ50&DD50?,V5,RE2I"]C,]CR2:VSVVE\W!&V,4(P6]EJGYC69@/8T?/ALX5Z M(1:I2AE"C]#*;NIF.XDD-,W.AV]LBJMZ,T.+_$7M0E'3ROZ -IF9\/O2T6' M)A7>X$OR-B}[<7Y()L=;15JH/!IF^+E M]30U*(%E1R7.&4A+G,TH[9;&?CZ\RDM:<,8;IO.-KOZNM9=_M74(IHHSP8U#@BR:IMMX%M+HT4,]JPEXRSC4Q*;"JA#OA(M]9)2*E43>M,0,NS MR:\XHS3/*2M1K2VSJ=K04EJR-UN> [G&:MI0S-G\|@1'D-$^(2A2 2?)\|C/Z-M5&KHI5:!DY7*:)P56OC<30S M[+ YN[<;PJ;D;4(WT.LOZ*9K.-"99_J702-;,U4]T:C_R/E\C(^_XJM>4P2-% M15/0HVKCIM=]&.)K^7&3MHD#90-+H"^M<'K4YHIJC^'64]SD\IH-5*[/$4E MBH.!5*]MIXT?(=D6A3EXE6.Y\N,$SI C?>=#]H+'HJEIPMR6?P8_'+X5>EQ] MMP5T? HB>I_+8OWONK2#.O+*.%;PU['_P)-R\'P3/',, M9S'6\/HX MY%%HX0]S2(@87I?'6Q?RB:#PNCS>NB2>R&>QGN!UP3B&UP7CV*.O"\:QQUP7 MC&./N2X8QQYS73"/>;Z8!Q[S'7!.;:8ZX)Q{#'7A7B*D7A=;K8N;V3^>-&-M?+=)@)=(WIW9>.=]O89GA\Z2:*IP0__]T?LQWLGC'B*)F\Z8XFW3]AS&<;M MJ27+H0KXP]0. <88D2Z%+9M1.>EC?$KB0[>I3#2W EI[&M#_M .LWUYBE:D1[4I.>48<#QYHZJX&(@$%$@.@2BD]*ZCP%$62E37-..O>:8R&IL$-VF(3DW.B-LU MBD0EE:RI$V)3EEVZ25=R9*8!)H@181] =1X3A!8"#" M0(2!Z/9 }) 6$9X*M:JQ%&.VM%C=8L/A9@++),-1FL21 MT.\!4!ABOJR/[Q+$Y-/2H-*,Z@-"2.]'T10A=?.UFQRNW6T^- BM%IH8:*58S MQMQ1U'495KN%7CXB3"9Q%B&&& PQG]M[=PEBF.FTG8P[]0DA-PR]N\KE++I_ MDT "S=:R.I^OKXE%M6QGRM)L0*D08I(_?L5CX>@M(YH88C#$?'V(>5 K9I7; MJA8+8M,@2MOU(#>MM6=CY2:>N75M2*\[K66>IX2VQ1A:*];,P4P9\:*583AU;! M,QQIZ@E;F!+<'39'9[,G!3!\D2P(2'#&3^^*! ;(HX7]\V2"XE$4IBU(0X$MH$ M4SB*/$0X@G#D-HQP9SBR*$Z<]-C(C8S ,,9KOLQ5V&CTD2*'-U233 M63NV^GF&L=C,$+EP8K"IQ,P,_ATM;0<1W[<=S7C>=68%V[#(2KO{$,*T/8ID MER$"M]=;E,2TV5%NKJ^J\GYF+-- AE*&AGH^_P:/)&(,\R@B4$2_$WW#V!I6FG M(UADTB"\Q& K<-1VJ8VS%2"[P6:+%,4NBPPJ]5FUHE+<$WTRM("PQ$)9249K_ M8\9W,9!'!$L(EN)D!WP"2^G>M*;/S.16M-)98\X(GC+,1)+7+!=^$M%I,0- MLQPZG-5)=N&]8BJT I)W!(GRH2)<0KCT3:V%3W I7_.2^'J;N%PQKWF$4V<> M#,>1G.(X91R4[_P<%YPON)NMPU_N#O@%05LA_12F**|? QXSSKFT^O*JML.Y/ M51?3]AR-S4]8&IOO>?IF/%/Q MK}?N.XBNHF=HU_$O,UYCFFKF#_C8?_BQ?O M?[++'.\YS_XYVPU#<7^YMWPW17R0;V[2<$?(+5\MDQ&+9S$:.B)! <7VZU9&3E9 MD9$7V>)DY9/5#=B,:&A2I))W29Q"KG*$4 BAOH4)\?4(U2TG^^E,JCC!+,*^_MEG)+I=*81).MI\C4I\D)3PCZNMG(4J3)KN=0(1B_$*E[E(4CA *(11"J&]A M37P]0O$=?C&PNXD.KK;STS1?Z+*,%\F]N +>JFP45FH*>F$EVA.K7I?,%40H M[L0=BT>2E>![Q2=:H M3C6E\XNX5'<>7S#^:. M'#%;}3%WST^W[!.+Y6;U52WPR"=VZQ;*ESNJ?YAC]EW1K6J[0PUZEIXK{1B M&BEC4' FD>C89%N?]DB{0M2ZN/-@K:8.P8_(}A(D0V=4=%F24\9]P9 Y%% M4(:@+•:FS+=*&3,7@LG2D_)X;S#M\K&\:3/%2%PNQ)!.C4>C,HNK& [4TVPRY M(N>M(}3! BMTZHYA4, D@K*KK\LWA[+XV#S?"F5*;H!W38[)"HEEH;@1M&E] M.8@$RB:6.4FK:>S",M-\LUVL%O_7"TX?%CZ>N@6'L&;YFE45$Y MLJ+=$M>Y)9=S(HGRZCNBHQ)M;62T!7:SL1K+E#?A(;S:!"^_<'1--C!>" M-P1O"-Z^B0'W#-YH6IL$?&\@B$&})K;G?!"M1L"*!-U>C!\Q*UC6QGMVDQ8QA MK/1,"&]ACLW(U# <4PQJSP,U?QK#NF1?%LE[6U7B*V!1 ;,4)QJ8:BTWP_T7I M3+SZS..Q65W4D&JPVRJS:C3KAFZ0/J&8?E[,1^(@] HC5EY,K8W X+-QN3&8 M3K+3YHA{12)0N;M4,L+R% AO$-[$;N:QPIO+*,=-U>L6TQNB+BYF3(:?*28B MTXI$W66[FDI,^X%@Z.E95^FRW6IRO(}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}52XD6O#Z/++=>CRI_J2B"[7H0MSC[]X;P/1 MY5HX]G)T#}(+PC%$%X1C<;<+-***PK%XT@7A6#SIDK'QY<8D@7!6#SI@F LGG1! M,!9+LOPJAK1Y4-T>6/2C#\;D:^V'''SX,?QKM>.'L6,JE[D^\B?]|:=[B&7H M-W*OM4BR8\ (O_^]'\I=[=T#FGDQ%NF+LVQ=L?/+.X_6!#CY75;$J^&'J88(- MW7;_^\_X)F^TW3SOL/<4=4N\4]#N:%CGXI>%KL@Z:)=*N]25=]DK7@O}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|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}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}R7%\QTTPNDE,8LVY. MZVHW1PHDM\EYX(}T??$A&H4W6NY(ZOO<9[F6L^G&A"AJ_]2-+4=,75H 1"H- MK3+O,'E-D!:"SPP%V1- 7D=J^<:H@S0I$*Q"9;BL9*-Q*'V M5OTQ/^-HH1^)CZB8Y29R.:N.#=T5_$% Y//]Y@H,!?J{6/PN&64R+R3>2+R_MMG@_[Z)UY.NM92=G+&IY=F: (RF,R44BWDEM2>0,Y612L%H%5=05G4\7X>X- MGVSG[75OV4Q-G,41@#E,S&3'8Z*Y5M?+679Y M$ A)?..W\W)WWIWC-I3WT-'!,'5U[FC&P)SYN MX*99[-)N?SW# ZJ3Y3PGZWO16@D'$N,;?:8V%ZQFM3G#26U{})M0L*'3@4S= M)0F4-N-S70S7YO@+Y?"Z]C1C(-A'CH)FFA!+[127Q>LTD265=#_=3$7J3DS9 M@URG(8EK<6.9!B,56D0R!4_@H?V? 2-XQ]!_OTOSC2X!DOP[-.H$%EEK^],^* MOOPHC=C[1UX\<$GX#?CS4-?CCXKCX.?,=]]&_@.[RH2:XZLN]OESI5 "XRSA5[$MNLVM-2O1/3U5 M/7-M8"8@A{JM#]_ %/ .3#EZR1V646W9<26L:,OW=[NIF.8&XR$ ^>D[@RFI: M!9W8=YCC\AJ#IP#)=%LRL8(JF?[T;O\X,++_Y2[$AZI<5CT/4#WCN'-GM\!A ML\,/H)FK8N"5)\."1AQH]LXX%F#- #614(O6OA\U=1PED'PQ,\K"5"IX"__7V M&:\0^)6%C%T SYDKV)+0%3<,!8C)\S>'Q>ZRBPTGN_4G@$^#J0 .K!F#:"P?N M@-MKL!5!/U[ZFN]@^\6VR=Q/2^(;1HPW11 BG$BNVWH$=F'[}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{A[CD.$B AD3$A!#/,/4$C0L2 $.1]"M$A!G0 O%B31M$ MB(L)!/%BX21$B L1(GG/(&B*R'_%H&@*0Z$!*!;$UQ(1QGT+GN4\DQ%L3 M5_[)Z']Y6;-OF'6DYLTK7;AX[R+ (C@F_#.\^OW-7HNY3T3(!^XH%>>D&SW^@ MLRM,<8KQ>^_40UQAM&:,6V4&]KW,0%%1%S+_%&:HJ?XI!R#@0\#W]8"O}>"" M1WCW7?'ND)<,X1W"N[CCW0=7Y-TWCQ$F?B:? $/0]ZZ+!\.J8&-XQP-,]#HA M#*/[I WR3T;KR~+D1P7B4W@AXHWCH[Q0@Q&54;#"GVQ3EYCYTXHV:-O_;MO^ MAT+'KEBNZ*-B_1#@;O!,"K\[R,(-'83BK? CL@JENF$<.@>Y[%B%ND45N3R^\ M88:)&%20\OBL\H@8YFHJY@4A!JFFUU=-7WVB,^7*9W@1WCQ[%-TA^O2^N9U M1W@O$I'Z}1*FMTWJ$Y+/]P1YWSZESVH7W!JE/TNH(}? EKTOJ74SP;9/Z$X7Z MZB{@SR3L;1^Y/E&&OXX%_YE2]!<}.1UR='W:(>C:$_KT0_EY_/'$C]OKN\S M#UQU-!'7.C^3!HAV3.#[E5ZN0+UMMQ$GNN/3K-PA$EK8 Z9T8&3_ISLYOF< M.8< T,?0J CZ9DA)R\MX?$O!RZ122'5FBV$!/\GW1;ZA7-'96QH/262(^A 0Y M"?*QW* N=*YU!F]*-J?!$]UJ.]V@^\ICL]GB8M2&J-/*)>=E+9#HCO@!:9';\4LU=IJ MXXOMC"6ND%5[\'."!2KI.ME3AM#'=&)B1!# T^7T02R>\NB4^RFMZV)$HS M;,#N9>0DGJ%%.SN;)RSO7VE%70C'3VI1@J0P62"(9C21" M@]Q7$,6]F>U[BN+E3XS1BR(_] [++#>HD;"!N^ML@/95VG5EQ=2A2-CMCO.7(@V M)>H]WG$0ZMCH[&(WIV/*6GIEQ.SMQB@;T'.3&_==.9" M,VDL6B4UURV(I-2ZF'XO=RM"OZ8)AM#.LZM\H9LR*D58P9^ ^>N= (SE|;2K4 MKR-G;[<#:.O8AM"Q6'YJQ54@QF-6VSM)=T MA[V8&Y5V<\L@Q[N!4;=M;V"V5V1G"NO[LF ;2T5G,;XY&?M3NM:O(V,7/Y5= MP"NSS 3)16J^OR*NVFPK;61YL5M(- P8M'T\DA/ZF0:P$-7\Q(,.(!+^LC?4: MODD4"T-Q4EQ2!CR/A3;>2(3L,O=$/]>@>VV+!).ZQ"AR&44N?U#WV#/4CI]B M,; J+A)$]]"4ND9{MK6"Y;9G=S87I_0K++_H]EBM+*J#^;RNSZADJK(:1= P M'(VF_W4"}E'\|AO-Q[D9)>OM#S MQ8NY==94MUQO*,6Y8 WRJY86K,T<#G=))L*C^I> 11Q3+_(;S_(W(HX5SBR%> MR&YQB_085B W)3)U,:VU?!@-,YS-*N/U8;(J::R9<)90']%].J(H2A3I_ 4$ M\EHGR>@%LF D"BE9)1M&>U#3VIK++).3-Q3;(62? 9:Q<)JH$'%3ZAT(&VU <3 M()!4[_B$2BN.:OMT4F'+K*K5DA*>.CS^EQS[G8%NDMLJU>9,,6Q8WC M5!ARX*7GVU BR:A"D5!T\]M'6]%- /$VKC6&.H+O$ZFV[C>F335D5GHTY6+&=?\$L&UB2I7OJTT1Z16K5J[!8"1 M"T.A480FBH1^C2G[=H2MM51M-BF[O<(SXVHELZ%,L]B]F+#)_8K8E*U]$2\3 M@P3)T%3.Y5= V.BHC@4W*FTH'CIB88M>WT^/17:.F}J,:#4*8D;JM/%6]F*1 M+KK8MH2M/)L:"6.KM@O51JU9A]L:]1]%!2-@{OM*E=(#1Z5&ZV*O5"PNC9 M= <>BTFY%Z5]4IZ\|=EDL'N<8&DC7RL,Z+FI-L$*LU$=JU%H=,PE[4IGM>@E MC4S4!M,2W:D)1 I.3**PK?KMBUFP$F0>,Y4#OC24P5'.<5=5R4!U!28,V91K% M1Z/XZ*^SH]6#6KO8D*N6()$+7&H,BHGVY20M6S9GLE&=\6*O->0&+378)(:A MI)$_?D5H*KZJ7?@?!YZX?QUF5PL >73Y\U]]$ R,3IZ;37?-$J;J^>$P7VE& MC<*.JY_T&7[^J?N*

G#+XM1W,YZ:NNM@):WE@\;(T'D!H.,Q76^E.E,5+(,% M7K$!\CE7;<7# ,AY^R7RH)QBKK3"@+""WH#TWF%\HPC^!,B'.?X4+,,GG=L ML) >YD\E'Y.-<%70PGJFRC_D.&+,+A '\C.6R/.:JBT!W50LVO\?. $ZTG1;LF5(K"=[DBZXT)7]0+3#X?L .KL1/E^AY 1X^$[/490O3@E!=3AK"HEK>;KJ>T&M-]\j*#10#A?=?:#>"S< &K((=> [> M[,N!&I%K[O=%&XZWY+FK)L)-^<>OFN.K&'N/87 AL' EL*HJP74(<>>ARL/'-M1TN^ ND/!1OV^^.A-@9]U2TRS_,-(-.%"Y,@^NT#-=)\D(QG /&5'=PO@KE M%^"/&YKV :B%>&*:0/A ZP3[@=3*7J7W, !{#F#P_5X" M9O&5=O(,"(^Y\G2S6GQPG.,'(1"O!R#10]e'B$F!?;1%[HM#\!\ @^L'9C4;B!P M-SI:=E?!-P>\Q0\Y,/IP@uK 2+/GZ&.XGJNFL?GXB\X8G(=T&K.?_)-B+<'.HJQXZ MW1>,D1W3E.:>^O/PX=]/$,G#X!Z9/^$[_#/< P)4]HX@?]3T]>J\N"6QP]5 M; YK/?^-1<^^^U"X"B@2Q+]8<2># M4&_9X<-)Z(@_@38$Y M TB)PH%H9@H"_05T*&4&U#I5^3O$,8!;2W6/,I$J MI$/9@3;2:JW++Y DWID_;/3VF=O/P^G,XIY27J/-H,3\7WG^0V)\S<39_)4 MLJXBW*\79[CU:X +G15<-,/#L_U$PI\5:@\<+DW)? 5ZD[[" QD]{@?K'(Q* M/PX]Z#8X >AW@<[2WPQU1&H)F[K0IOC^.N*?^/^O0OB)?CJA)+H M^VIVK@8[Q!(W^AHU#D0(L+<'O MCY[.*T!)"M9$>5 TI?!"J&I.C -*%!T? A/)TMRZ/:Z9#+<.%ZMV_4(%!H(5 MZTN!%G4+.LC)J0$>(QY.-$\A:&=/ 9]!4[W#=^AX $>%/02$" ,DX-.^]36M_ M_G!5S0QM/@(K'EH/<$ P 3^X?4/WX.GGN>..KLS8A"^ZP%R?C_X M!W >@],5>&3G#*

*(#GP4<,U_[T)^NN'%CP3 9M7+.^'I.>6GG\4?7GX%_QS(+IL MJ(++?K3?Q7=FP/A^QEV\$1:J5!?2+VNW<[&=K32X;__=;PR MCQ'T$%!=]^>A$N@1)?:+3(9H,E$38U>5C(2D@:G\E,R5M/'VZY;B[FGB$1H/ M\X34P@C\GN3^@QU]AM,]8P!+6B>.B+ 'IMW^L7_L\)V[(_W^2|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l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}:XEC%\GBFK\U-+k:S3HSX9Z^*S92@T7 M\/,9H2MJ##XQ4[74LX5/L9*H*OCXCXU?GX" G=:8I,Z+I6W[BKI**UT!I:,IW[\2MZ1]'DY4E0R'F'@.MU3'P-^$$<5XW%&Z Y"FV\O2;<(2;6K>;U2EB:U!A4HK&DR'V5PQ?"2AFRA0'' MI-]O4/F FK)I9D6^N;5I@^2%=0)/]? U!:HI"%)3KA?]<%/P$*/HB#BOVQ>+ MGMB}(LRGC4EA.6(,[*8N<<:';S"VB&@@DD^I@%@PI80F4!KS-&PK"J'6+BS M[E'$W>X#W Z0Z?9%VG_[4NA$"*HLQ],1%? =;%V\I7+YHRf18M<&16HW8,%MA$K]+I=YUC1A5+O_&T\&:-ZX]S=A#1VQS&N8=M,?E_70Z)/1@]:T#YQX>Q);\. E ++/ J^3-&2)X0XBD[/DNQ!U4/7]UC8_/YAAH MIYFJ6;.QP"LV@*2@'}OQL:EC*AC\9E_+!M,?C.X>YD\E'Y-<]7=6'(#]$N8> M$!$;2Y[NW4(?03#J#FIVMN2++>N_-WK!)8.+^X9EP\;!:JF]8#Q391^& M2!W;RY19L ^2!!3"9"#8$ORO[LJ!Y8$=5U:!>PQ0V%,Q(-V6A|U=L+^X8+Z@ MO6P&BG\GPGV$=A@$PY-HV%(EJ1I8/@P2O4.,QU[DC#U)?PZG.$=-G$<9:6; MYETX6=T&KYH!7V2P!V. P BSP%3*,>CQQ,35'A?2K=#KO#Y1+K0^,?(*8. MF%%WX8Q#N0P%[_'N-4[''U:V!,G?OA[HI1^!T&5 >Z]}.#N1"CB/!KZ@Z^*S92@T7 M'/, 9H2QMJ###XQ4[74LX5/L9*H*OCXCXU?GX" U'''$W]"PFEJ2[D5QG\H-J> M%*HW=7O25T)6 M3?/?ERJ1?6Z=W-^6DB+I(QO%OT*+Y9 O_\2NQ7T&^?5V[\T*Z\-__JD:_."- M2LB.Z,@_#RK3$27VBTR&VM- $3>R*$DL:F,I/R5Q)&V^-;BGNGGZHL/GS0>V'" MU,((_)ID_H,=?8,3/6, 2UHGCHBPU]82IJH!*N\>.WSG[DB___(/U9'W-,[M\Y\D$3++$?*

O0Q#U[QC1,#4$:DE;,K"P^1_=QSY6.EW3W?I,X7]5!HI<'(O%3_GJXT"W^[P+0S\MU7E,X+8 M*6;X2OL.*]8RJP_5T*X_TEJ](2Q3AW+U&M9H=86LO!3NUXI9OD.^"-7K/&U M3)&O8& Z'.$JU#KM& W_+]&6 @4H4LK?%Q[5&>.^HV;B[8STI2UK#S(A6"4 M,!V=IW9@]?CE*H%$9*H6UD2M56 M=^0/\/P(MF2?MF26]M-,9'U"M)*)JM-(>FR6;X[(&? FTI5*6MPVUH?.X)6.7 M:UR;E+)9V/+L[7B>\)HCMMH3RU-#*C=ZHT9OS(.69V]OL_E"L[#M<$:&FENV*

MWN6X3GT'6A+$TZ9!G6DKS&8D1;5G)77)2+=THCZGR@ZW$C3YCD1ME Ej>]3F,#'JUW*0CBU:,M/%> MG2L*9=CRG$<*Q6W#S] X+M6#D9TK&ERF#S/4G$U^Q35KY>&DH N!MBG7A[6, MDA_"EN>3U].)65'CEP6A/5RVU[DJ-9,3 (@YGY+1\R<;4S$HL=T?5'L]D9P(M#+S7?C8ECY!EJU"8\480&"EKJ)3-VF8%6IY-23.:&U4UNUE\,?5K >#5MIN& M]_G.ID1G^^RL4FMI@EHU6-'$V?$H"\=V/J4,.U3,W#"]QG4]&+:%5FY3F4$7 MS=F42+8A=*=44A<7UB7((^SY ME)H3==/-MEH3O-<9K8<)9^HD1M!=?*

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f[$QL:&LO *4*T <:(9[!&5:KBMTDZ/$S2JOM&52 MR#5)B#/,CU[,ZIM@#*$*5;X\[T96E>_K00FT:ST#)9E"O1+D,E0&MV;IH9-4 M"8F:0RCA?

OPB(ZEZAZ D9@&3CE(/_DMJ#P48G@&._(]?KOE*O.6P$B%56*0 M"-HDP\;.^3NO,.P+^@B?S8*^<[5KG$\Y-%EPOYW!?Z.$PY)IWFZ]_7[\,?Z M???-*

F$'C@8O7KKD0$0I>>UKQP3S3+'9IM[^>X0'5R7*>D_6]Y/OKQ+S!+-/5 MN2[1=AC=L-(&43<*W>U[>3Y7<91V:U1!-7 MU>'*6'CYYMI)CQNM)$R5&K%Q!&W32+9OULH1"X'^C8F";P6E85/OFT;#7V?M$#8+QIF,*WR3*$(%_),, M!7&,'KF\0"/#ZO>.[^_,K%]\VC%D\SB%.WQQZO_63?

*G%YQU#KD=\OO@<\3GB M\V^LQ-S 58XK1,'?!OTBR[@99]O(5S=]$.2("JOW4)\19[$@VUZQ9*TXB;! M,Y9+W"2U]$6BR5MN-J42I MFQ/F/^7!1M)\-6E^^,R8\T:K=88WA3)NE;9-*

$O#_Y^]++^U.7%?6_GY_A5>?`M>]f5^UZ<[0D#V>?V6@;,/(.9OK",+<#8V,8#TZ]_)0,}))).T@P&W!_28(20 M5%6/:1"JJD-4CI&%GZ/HAX(MX^%^WQ1QSN4Z'Y.G59P?

*&$8QPU9R;531& 4O MD1Y.'$KRK0,G/WZ13(@]HN;<_M)U $,>#[CXT%N'%!=XA5CC@471_%U/RL5C3[=57F680L[(]?8?9!4"7 D0?# M$5^X76X(/-[QO'3Y;GU8D^R^VG([HVQ:,*G"?*

!(P;5DN!:>P >@>WR8###R MD8M',Z>,%\W694M2X4:$9FW,@)2-9"+!UDQD8_TC1LX!%*$I)<44]2"DQ_G MN#9SY9P=UP*_!T_G\0TD?)%#$]F] 4 BITXGZH@.:"*

*[C9+CFTVLCEI(M/**GYK%!XJA-VP U?(X:WW+= MD)54NF07VA,5X*]3[=7;"889(EQACYE?=X 1 8H$*/(.BJ 5(*E_ B8/F#S0 MK^]XI_S(P9"L=HJ=U3Z8/\[41\A9C9-*

"KAZ))8DR0R8I.=Z.5R,7 M.1E"-QC'@0D E@(8.$RIS]\@07O MG-O(60IER+5,DU\F, ^UD++#QI3]TAP@)T928H21" 06 IW##8L?.0FR.8:X3"I M-A)\NE3.=9-UX+"&9S(@-PFR& <*QW_E)_G9$2,!?VV8E=P(77O-R)%)R# M 5$:818P#2@5^.A SX9<,.UDQD8 EC G\)24&@9 M$&#S$=']+PW@$PQ]*

2!'#7KRZK[!%/O3@&W#QW#V"G+G3-#O0FR'&8[3UCC MR,_*7B]0]H"E+=s8)0O(BH--71&MF7?/;//(MD[)=?MFT76'8(,@G\=67@M?5L'"OS,PD3,AK*C#"_6P)')P$$S1QU ;$570*8Z5K22+0!IL.YHA$9WA<' MD'L,RYL$G+?A:C*>,,CBL"-1VPY)@[O5T[GHYQ,VVJ7:!(BV:\&^ MP,($$J++>SD+ QW!U1U"^<-@%[! VLSTVM>#B&#I" M&> ^M[9I([KSW\%M $FT'SI7_WLIYJ4-YV4%X7S1EJ%'-WVA$SW @&>5 VV-M'G'(&/"\UFI./5#1MW=:TT+X-YN"[/TI&!Q&1ZLD#]!TR@.GW1'H<[3$BPPXH4NH3L@Q_[F!Q^PVH MN\7:51H,^MAH8N$B/U7HK-YG*K56X2Z.Z@(>3YU:I M=E;)I F!RI-@4LYI@YXU[{&'V6H-JB(V=& UC;YM&L[U)^V<-)GQ "03_2+)#8=3S]%Y,_"UT76 $@<"

*MGYX72ME69.K&B2IJ>C)C(}YS2AJZDM,2FZY:.@Y^->TX,!Q"/X5&T+'9%(MR S%N,M^NE:K(B/P8 "]?+S?3FA2AR^S41 AG$I"-.:HZ<$ Y$*E:T_YW$S ME_0L3'5F7$<>HJ8' ^#"%7DA)&.$4&\/YIK*5F..$0Z /AQ /[*7A|$X*PSB M3$DEKM U<80G1V0[:S:SA-$*.%H89^.D*=&I\>0<-3T0):?QB26%8 @0A4J M*]GQPL3P:G @ 69^HIAPWS;YZ/ =9?E\P^BNO &\B,">MK)G72?=M1$"48U< MI^%O&#LY^>/EL#69249*79;2T9(APJRY6X]Z:T&G#D.>*IG&ZG-6A?3]4H(I) M0372L9.*+4&-$NKH#?B3<^!BIG3RV..PN,E1>IUZ/8B,ANNK7]% M=X',.1^TZZ%FY ^H4DNB*0?C6-!4\]VU=_K!DH23QBV73M/17]=/6RJ?%[/JZT,(+-H,93T@6,,,?MDS&W/DEBO(9!Q M<08L<0@P31F $ 9-(_AM9/-"(SZ$B:_NVZV!

*[W%TR%M1'3A8WS#4C9.@#TU& M<8R<'\K+:*5QB0-_N_9Y^C+CS Y@WW3)#!l0=,D@I VI^R M)T$R&+P^>2M0\64132"!AMM RW8H5ZB#-#)\-UE4RZ1A#$$*?J53CW*%<'6]W M0;GZ!@.N.67SG8U7%-GOHFF#Y^V+W5]%1WM&:V&>Y,0%3Q.5RG?TS#]GP#SQ. P@)9ZTV?&]^R M]\;IF(?&O^N)Y,U)P'Z8TBX@Q*4(03^1@4CX@A*!2/B& M$'1 "!\0O(I$!H3P R$":/((3Z}1,0XD*$B#Q% HGP R$":/(-(6(!-/F! M$+!$G(A80P@>$()Z8#W/[!(3X&B&^F%OIM\Z^RU[U6;]#GSPK#ARN=*G+/Q_O MCR<_NBH!W0&6SVY _<[>]*

*<>K$/W$(GP4XFIMXS#<.@[S$!0*J'^1?C0C? 0 MB_ [7\I#+,*=B8-D:.CA__V@?GQ;5V3.6SSE3W%QY^)0 (FG%(2/C;6'6(3? M&4H/L0B_,U(N@0#K7!_?*

*3J(.^/H7P,5/$_+P[^E4^"OF0?K3:R@# #VL[.1 MCW0,>]F1'X*3242N6GRE[='ZA*&[03T_YZF>LTYW,.30;D__)4R2?BMN& M!!PLCD])>A>>3\0!/M;>WKBVB7<4VCWV(.D7_MB;R-^!3NA/@+B2OX,DOHLC M3/2)/[_E^Z:]CM8\WKP?E,\?,NW8 M^ACEX\W[-T3'_QS#7#MG#JL(>#9;A/D'97%RS5^F9W5S[M=#_RD_QK_0,WX_&X-HJ>_3C;I_PZ[]_<7^>3?+VJOU.RXS-W[KTR'N@"?R\N M3FUEHG#2U%761UBWA3SBA*:Q1KVZ[\(? MM0(W[HR*B/*(V7?*

C;SW$=C<+S>Z/H'M=S:,L4$C;AE.%1,==FLGL<58,?<>%FMF1&5"BN)!>LD:Y,\MNBTIWAL[D"KLVY#Q3Y_;@BT\E$ M-3<&H1WMM63+Z&-)=S*!0K.M'-*

*==L#E2T.8 ^66H/*K&,*%,,2%&'T^&^,AD>$Z M,<2/D>&!@N3[/Q\T" MPZT=Y"A 9L==&VS/6MRD1_K4[H[\&T(-JAY1-^@3;HW2:?+91$?1'E>S!O"MN.,ZP -X-^)Z,S8+$[.*)QT:2+/JT[&X'H1Y-UX]:@&!QV^Y7;I'-HCR2A3$^B/3/%].H4PI?HCU]1-AR@RY_Y M-_PK1V=P=OAWL@%H?-OWP82-L%UGH@Q1IW+=DMB.S<8=5#*74\WV$V,A9,"(X M]W'NZ=>OF,XHG@NS&K,<. FE:MLE8[<68<.E&,F8,2<2.<.G^F$1D3M:A(^MG;!""\;B1CVK55X79L!<+]\V6-_,;<$(C.*\Q7+#8(3CLX$,A/VZFUVN67N>`5*9-"'-V%78& M>+F#'!]08,*T>09#?6,%6F_'U/XYW?Y[[*Z?,D,>+=!5;^?>[CV+!^"E)=/.M=G"MK5W/LE'8==+7^V]5G#YSB?Y(.QZ\9OHU\HA=^>3#*)M%SUGW+!$&<"/

MU;MQIJQ_W.U_[H9607B!Q>^2E;K2%LB1-\[R;(..X MMJJ'A{GO)SOYS;CXA:2YB#YIPY#GBJ8=\:Y%&BE@5V,L4$&";[.+RJ!0!O,> M27C'<&,ABCKC2;F'!(V[]H??0E

,$9GD3K*O/RP7!U&2:9G:&IK MT:F)-N%VS-1T6.NXP\X0;7THLG2^O2\(+%W4+MUR (9C*/9HCX",F2,1\ID$ M7&_8V?$>7 WU@]W8T]GDJZ&/ 5W08.[H-_?GV%'#IA ,8JIMJ(#VZZ#(7]I-MDWMSBWJ5/="K;#!OTWZ;CT(*FU/>8)=*@@&Y!L4&G:K-??N7_F#WY163;!;4 M6$/ ,U8KEZ^O8J4>-#Q)9'C2(>JYX;6S5WK/+7Y>??,'%PWJ,]D M@UWN: [OPLVUEVB'8Y9&.>,9L+0I_!)<,@V!D$.!\?M[/3Q7G618*B/YW^;]P309OX[!VY6?^/=?>_*'S_*R$H%!^;],EP7Z9P3!{4X M-#

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

*9^UR[-25V5MK[^U^[*_/JK<$E0S.LYRW2[5!BL\B4)P5#@/1:UN;BTMJ1!,.T!\E#T^04M:<]I03Q1L7]C.Z_1=\88"(N\!TB M,*0.U\ 4GG]M>TS:TWZS4-*

C78K\V0)018#ZPQL.V/"\8YC/%.DQRP[[,.03 M<\ ^9W'?T#ND%K&1A9#W7PU#.DIY}!H#418;=WM?#W?OOE[&6BHW^#K6*&.) ;U+9$E=*9+D"\J?3*

*MX(M\J5'WT?!_"KH(=U.H'?]UX5$=,.[NP#ZY7=S.2#_:LC8@XX$5#H'I%0 V M8/7Z(^:]YO. E>O3. M#VZQ3_3TKY[,B(,8$P.]@00B/8:AI){8!W0O1LLTW:>B$9HB?JS11GPI3CH7 M!V6+7M4)>,]#!O\+)PK]

$2+%X8B;PY:'DZ^W MV66+ZX"JBN=R[7RY0'05%I6E/6A9F^;:8FY1FA% 17I+>U+L2254K>&@94;+ MI]QEK&7P>)M/K6J:E9GP&'D04LGWJXE!:"I IY=YOJ@0K66S!P:- $X=%? PH"D54>=FM;:4U.5H/!EN3 O5{QKA0<$%6OT M4";J65>M=Z=*N9=)9:2QUVOT;5/.+)*QCE-T!#$9=T!#=6NMBG>0}& >2=J M4AF*JJI4I19/#+0%Y<2JJ.G!*

0DG1WS529%E.=11I .;$L^DO5X/!E 1\Y(U MTYH9=5IN5/^^=# 2S"H*$!X,H"LG:P6S/4JHRUZFU1GWNBUJX,42#P,@V)L MX^J2%"9B;$48EA:?KH:HZ<$ LK5"K$KEV)Q B=592\+S_4&WBLRZ0{KB/44; MUO@IOZ0+"X>FZ-(4>&{:PQ48V,:839MJGLVO{J6X39."Z#4}$(!.;C\>F+\-1 MBIC]JTRX,6<7<}H;P(S$1*41UP^ZGCH_Q>EI:R7PY55K;8(>+#+85R23 O*7V M!-R@V!H1ME5:/01^TQHIIE1"M 26'LSY;**2'@FH9?A@J%%^&*LWRPZ_S$,S MFVMHR\2*.P9^A":XHU2R+1'B9!XIQ%)IQ=:&/>JPS[XPBB83HT:4<$M.,CO(MQN*YPO 83B7[L[FS&HE%E1V[HZG52"2%8?483O6 IC-BQ<7Y_*H4)SG-+!%A MU/*@SV8X0}1<3E55Q5@FERE54@LS#K8\&">=K72B0LPV!#GG04'B\I MD(!T>Q&9#7NH*?GCW6^9PM#(\-UD42V3AC$^:12C7;OW_),UQ>K;>VG@A:,M)HIV>-Z^V%6(D(VS4D#M380}4'V8'0<.?0*D0AQH$<6 J.=9M8*V6G.A:6J8VYL]__?*

L<:,9VJZUMW^/(B_.\ME'G<)U^:QIN? I[>1'8MPW- M===[J1>=VKNPTA!]^22/=_#VK!SL@Q*4(\;N#"P$E I%X.$)\F$0X(,2%"/&[M;,X!(0)H>CA"?)AF."#$A0CQN\S= 2$":'HT0GR< 3T@Q(4(\;LL[0$A+D2(MWQWL"0CQ-4+X/87@^[..P@JW#EILBE7=4?6-+X?#7Y;E3LI81? P3$7+>P=D MG(-3$X?@Y6!%0/T;J7SE\T6X3&4LGR_"G8F#9&CHX? _JH'Y\6U=D*%_CXLY5 MC 2;ZU_??)!'A["SM0]/V(:Y\FY.':?$^:'NUXRD#_= MR@K* & _.T"T[+]N92\[%IWC#] M=V\2!^3_\E3))^*VX;|$"'QN&"K6%#7W5/X='VMO;US;Q#L*[1Y{D/0+? ^Q- MY.I) 0G0%S)WT$2W\41)O1$G!2R_5.<*GHF#.R?%O4Y9,IBC[&BU10+X/T? M99^5=V7ZQZ_D}[<>KJ$\((ICRDHH $[U=Y7JZ\)?7H_*I]?ISJE>=1M<*_UZ?W@\[IB26 KSSQfX4&OO*\ MfSY\W6=#F_S-,>Y;CU:S/{'=O=_R?MNQ$OAH2DZ>,G[@8[_H3Q%GG-F7V+P M\=IFBS#_8'!A7//7IMXMYMW-M4_W(S_)OI8_<#,>CVNG|"^23?IG+|_:D0Q_ M)-6C293BCWZIR/9!TLV#FN!>?;:X.+65B<))4U=9GV'=5@975&*1'LUTP*>S M4C=),UFAF>/V\@3B-I">9==:.M'Z?/I/P08#5T/1NI?<@*Y,35:K/H@15'0N M@2QES\DN2F)"_? B%4I^_S3@7L+%_SN7M3?)T.;8O*Q72<[Y'>$!?2[?IVH\M$7%9BU'+4HG'.]B;>/)F;TZP?W>G+Q!L/PGV MYY-T#\. $XS1L,6W,N5V4<,E*^4E*XO^^$52{9],!9+VNZD)Y? TBY_|#"}3] M#R3}>.DIKM^>E@@N%>'+!!W/N55;;W H6:&7KCL2"Q'GD>N;2]=}6R'6MRZ- MBKA)-WPG/M?[+YA\;K_]CL;SMC 4<3(65H EQ(,-5LNXWG246:G\<=P%B\ MR.F:V1"F2J-*UQS-CIK#=5X_DCJ;._^#:K/M X=]KUX<.5),30L#EG KCL1DU MBGU+)<"J7S=SVJQ.A.?K-)Y,}(RE@!X2&JX32?P8&AXHA!Y@R(7\%SEV9)+) M7F8H3,? #OA!>MLU9':$*JC%6"5#E'LXG7+O(=@ 6O@:+XRX0I#)04"HV<)7 M7JNTJ&9\-8HC.P2Y0$B2""IOW_R)C0+D=MRUP?;0Q4WZJ^>-BU3=PDZF%8Y8B@<> (J'(VJ*] >-Z6A^=Q<4PX+FUI"4,E6&55!',JE57*7^^" M7!QT+#CQ\$?^C.M=8KR<\._D{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{G[GJ0W0NV?FX-JA?R8;;'-?W.8J]5(XTLUVIL(TURE)4UZ9AJ?>-H>LS+/+M ZZL+A(0!?'\;_2R -K-?^? @S>IO'+SOW?SK$XL) MJ%]=).'BH)9J1+D/J8 M"RX20?7Q_!]ILSQ^UZ[4QF/|[*3?Y9=:,^Q.RGW:E?1F#U3]6QI91 0O6A M%.-LS!A@22!YOI"UT--D:/T"\>9MNB:#.*@?]."/.":@-=Q;9<-%MT4MM+7NK M<++IZP5>?U]UNF4B,;XWU;BW!AL=$0X"Y)(X.2I=A0 ME AR3)XREL=O6EH4P\A71E\@?<_>2 M?1C&OO?)/A:Q#23[A))}$_,9[;I;)'(4 MZ+ EY1I*6#3.=:.IS),O(F&6A M-%.Q(,TK,EO_=D2XN+_^(RNS/Q_:T^O@MM*P\\0QS/5,^'H$$)]"7"!C8/*/ M::RK1#]; "(UA/$M;!#$O}$,=P;WZBC)4,SK.>MC&U[1&M^T)WWTF\LV)KA M5/B)V,HM8@'PLJ28Z4M+H&I# $^MV_X0]O__XQY:"4'/ R/ X-[5N M{G[GJ0W0NV?FX-JA?R8;;'-?W.8J]5(XTLUVIL(TURE)4UZ9AJ?>-H>LS+/+M ZZL+A(0!?'\;_2R -K-?^? @S>IO'+SOW?SK$XL) MJ%]=).'BH)9J1+D/J8 M"RX20?7Q_!]ILSQ^UZ[4QF/|[*3?Y9=:,^Q.RGW:E?1F#U3]6QI91 0O6A M%.-LS!A@22!YOI"UT--D:/T"\>9MNB:#.*@?]."/."@-=Q;9<-%MT4MM+7NK M<++IZP5>?U]UNF4B,;XWU;BW!AL=$0X"Y)(X.2I=A0 ME AR3)XREL=O6EH4P\A71E\@?<_>2 M?1C&OO?)/A:Q#23[A))}$_,9[;I;)'(4 MZ+ EY1I*6#3.=:.IS),O(F&6A M-%.Q(,TK,EO_=D2XN+_^(RNS/Q_:T^O@MM*P\\0QS/5,^'H$$)]"7"!C8/*/ M::RK1#]; "(UA/$M;!#$O}$,=P;WZBC)4,SK.>MC&U[1&M^T)WWTF\LV)KA M5/B)V,HM8@'PLJ28Z4M+H&I# $^MV_X0]O__XQY:"4'/ R/ X-[5N M{G[GJ0W0NV?FX-JA?R8;;'-?W.8J]5(XTLUVIL(TURE)4UZ9AJ?>-H>LS+/+M ZZL+A(0!?'\;_2R -K-?^? @S>IO'+SOW?SK$XL) MJ%]=).'BH)9J1+D/J8 M"RX20?7Q_!]ILSQ^UZ[4QF/|[*3?Y9=:,^Q.RGW:E?1F#U3]6QI91 0O6A M%.-LS!A@22!YOI"UT--D:/T"\>9MNB:#.*@?]."/."@-=Q;9<-%MT4MM+7NK M<++IZP5>?U]UNF4B,;XWU;BW!AL=$0X"Y)(X.2I=A0 ME AR3)XREL=O6EH4P\A71E\@?<_>2 M?1C&OO?)/A:Q#23{A))}$_,9[;I;)'(4 MZ+ EY1I*6#3.=:.IS),O(F&6A M-%.Q(,TK,EO_=D2XN+_^(RNS/Q_:T^O@MM*P\\0QS/5,^'H$$)]"7"!C8/*/ M::RK1#]; "(UA/$M;!#$O}$,=P;WZBC)4,SK.>MC&U[1&M^T)WWTF\LV)KA M5/B)V,HM8@'PLJ28Z4M+H&I# $^MV_X0]O__XQY:"4'/ R/ X-[5N M{G[GJ0W0NV?FX-JA?R8;;'-?W.8J]5(XTLUVIL(TURE)4UZ9AJ?>-H>LS+/+M ZZL+A(0!?'\;_2R -K-?^? @S>IO'+SOW?SK$XL) MJ%]=).'BH)9J1+D/J8 M"RX20?7Q_!]ILSQ^UZ[4QF/|[*3?Y9=:,^Q.RGW:E?1F#U3]6QI91 0O6A M%.-LS!A@22!YOI"UT--D:/T"\>9MNB:#.*@?]."/."@-=Q;9<-%MT4MM+7NK M<++IZP5>?U]UNF4B,;XWU;BW!AL=$0X"Y)(X.2I=A0 ME AR3)XREL=O6EH4P\A71E\@?<_>2 M?1C&OO?)/A:Q#23[A))}$_,9[;I;)'(4 MZ+ EY1I*6#3.=:.IS),O(F&6A M-%.Q(,TK,EO_=D2XN+_^(RNS/Q_:T^O@MM*P\\0QS/5,^'H$$)]"7"!C8/*/ M::RK1#]; "(UA/$M;!#$O}$,=P;WZBC)4,SK.>MC&U[1&M^T)WWTF\LV)KA M5/B)V,HM8@'PLJ28Z4M+H&I# $^MV_X0]O__XQY:"4'/ R/ X-[5N M{G[GJ0W0NV?FX-JA?R8;;'-?W.8J]5(XTLUVIL(TURE)4UZ9AJ?>-H>LS+/+M ZZL+A(0!?'\;_2R -K-?^? @S>IO'+SOW?SK$XL) MJ%]=).'BH)9J1+D/J8 M"RX20?7Q_!]ILSQ^UZ[4QF/|[*3?Y9=:,^Q.RGW:E?1F#U3]6QI91 0O6A M%.-LS!A@22!YOI"UT--D:/T"\>9MNB:#.*@?]."/."@-=Q;9<-%MT4MM+7NK M<++IZP5>?U]UNF4B,;XWU;BW!AL=$0X"Y)(X.2I=A0 ME AR3)XREL=O6EH4P\A71E\@?<_>2 M?1C&OO?)/A:Q#23{

*MH+L'\R3VO[.[OWYO170T!M8!N\1ODU9A^@U,2(0+/$A'!1^#-=L.V%37_/,"_MO+P**>]TA+YZAHZ!NC6$F2\?}8[^,)7KHAX37!MW<5,G;+0I%Z2QF.&2\0CS M48\)^-"/EGD9)Z'+^VHN[]ALV&^5VIC!*6EKY42P5E_H+<{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f\+?(S)*L90Z#D-[T+1?#NF0I;*.P6:<5P_[.;Q6<\,#L!/MX<>+:.MCI=;Y%]PV$3_]B\JPDN3@@!;-J}/<_C M#1ZZ4V(3AL+\RVT?3KC8>,>WSPJXS?VCD?JV6JFD>W3*K\D1\7IF!CW./DR MWO'ME=.-@QS>FW_921X%0K&]*OVT>YDJ8/!7\K.>KS+OE9^&1O6IJ,U^K4UX MM?3I-93S;LU;L$3]R8PY*";@5N,C?==+E2..X7Z5[;VEP97MKV^LQMF\@)? MWQU07Z_%WEP!P!.\,A8E((6>QN]76LCXE1:"6_'Y5#+EER'QCE#L'P0(,B## M?).J0A!7*<'!^T^*T:1[H,M;**VBX+P*>6NB=3O#HWQ2LX#=] ()U$6@$EA* M4,X4.JP!#,%?O5 -:X1. =).]:@NC] M+L-W0#$*REQX?[4#->5P+CS$!?OPP/+K2 ?7P2\3C\""GAC/93-]=MMPFW>0 M,/%$,-(Z\@<$Y\,Q_N5P"'A@4\N?!$W9'[KW=>9P[<<{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}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}(^HF*$T>U-,^& MWK>6AA %0A0X6ZQZZ0&&12IYKCLO.D3)+/ -@*\)UNHA0K83&URE)< M)59E-,*%*$#]^D,13Q1Q7%$W1($0!39W#C\2!CY6L>@A8""BU4MN,%UQ.3R^ M,!>*=HOO->L !A*__F!D['F.'C>C"G$@Q($0!X[4@>:R,Z_38V.INF !LA9K MV53\48R"I6R2*W-3X!%T^E.6HM!QZ!AP4H,AYW"T"<4.^Y"$@+! X2\R>J M]X6QZ _!}>U2P>YA$WR[{\9[< >H? T57T%$)RQ.(/5>XM{6B;.@%E2T Q[0O%8*,W?1YIO%3& ^]2,<@=Q?T87SKD.\S9:'_9XMHPH9 M+V3K>6V0SL!#//'K#TX\471XBG\CN3_;*1Z*_4],>\1YUK!6G:T&FVJ*SUC MHDY-D(CT BH,;}\G^@F0_Z?+M;M2_^4U"WNFYOC>K=5MN*E+D@ M$:I>C+.*^,&3B6*UW(,?!R>?-=-=.T)*_%*_@<&7#D"K8 MV=V5_XOX^{H? WXGC'%UA:\YYH'D)eN_D*9YAFSQTZNI?+?;E9IKV2X/0"Q\6D/:S'*@(0,6,(!1Y4'%F'N=TG 4(P_' M AVJ[/UQL$S6FDZ7+MKAJG")M+II{JD1L7&)K/.U^J__M) ^@DECA-:O)/E M@OM]&G_/M]_*K*TZV?*(YYHR1NBQ2PW]H2BY!.!4\<[[F_C1O\#Y^W4@)(,WO>$B*ZU,94CO>++"9;HVI13@E MP?##0A7MK'+>CA-$_(F.'9>-?.6@^?0Y0]STG+FA.%T'I)(2%;/ +/3 MY\PW_9.)PR\I &X"LI^&NRQX!B6C? NV&0+NM(1_NQ\R=B#Z@C6S#ZWOD/U M&O-6EUYRJD))W""O#LP&^GE]Q^._HTDUI"FO0&\[L]VCYS',U']_\|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fBZUB3] M>9*!STP<\5*.K248:L"H$;N^&KHSTJB9D >QX[4O[7Z^,=48B8V@1#-E55-] M06? R*.UTW9C(I49Q52G M'FT=K5E+X2*L;,1:B6R$D2[.5)P.,^CM3/QU+(YYF8C-M(=9=-Z,3[,H"> M1VL7!SH;)Q@\PS8;]5I-<2ML;PS;!QVMW MC2PNF]EBID4VU0[=R)G5]"Q;'2_\PO; [(X>2F4FG%I++%HI3$N#PNNGP_4<> MK3VVYJ;)5K|^5[,) M7E0K:5]IYYM'9!R^G+A9RIJ"L1&#/U VW0TFM(7C*F"*;BP6)=4A> MAR<33+:.%O}4K7R* ^//9U)@3,6>/X'J,? SUIC<,,M+0H'_CA'W,[Y#!>IL,3] O I^S(9\WU/^+T?9= $O@UT1XW|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`Q8K.9N_<7%#.9[G\ M:.$X.$6:R\Z\3H^- I>J"%2O9#@}%SQ" M],+B5MH=(?&Y3;(*URNOZ_D)C:WW'I,-@"89 "Y $M>.ATKTUS#38@LK2KI M%OOK9JS#@/KX4,;ZS*%PV25"YC3_T$QG\XX^F]C$]TL]DE/YC%4,3Y4G M%=@?!=1)YIO/T(,[)+VSGLL. U0,& MK/98.6)+0D191GP^_IWS_C>8F:U5.3[DLBC>R<=F]71IGE;]}R.XGYVQ_RM\ MT*NM&I]-N4*NSI4M>!^QMD_#RC>.QKVG7- G'3+V=39>Z"QEK3-$5G^FMLHH43P_D 04M.81Z#@(\]_O]`M)L&R6S#ZW8?3SE^8[WXXO:0;F7)\.E?1U*HP%$;#Q+@P70!.ISQ.QR_Z?<1 M[;H)I]]],.P#G/Y.P^Y^.)V:8? *BE-.&K=3N90YX>W(A &<'K\8I]'Z.KZ MG!X&NBZ]-K_3B"X8*T72Q#"X=8?!K4O'3PY4#:;2[[-^0[PB:T^X4G?;TL=.P*L.U60=\JW&[\.@X6/P^H>#AO?,ZVRK MRTQ,J!%I^7!.%"QXE:Z!%6;^$5Y/8P97L=._*_70^+/D??@7B8*IA6TDN<# MUMJIP[A37E+0)-Z"Y\G_(RJVJ?&KW][*@BELKJ$2WJS_!YL2EW@4]L38KS^Y M]BJ9T4$2=/^>+D,Z"="K?M/ ?W_AH)]A2GWC?NN.(E_/?_ M[-7SW+1'8,L1P_JJN=>[0XE@DW%/#F0IXI<+Y4=@*;]Y;<&O[&#*?Z$24W%.5 M^+V]&PRIA6!H%$_\!}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{8>RXB- MJU5;RM;56:Z^JINK>)Q3P03PXPE(2S]=R=ALGU?X"2'Q^?QF6Y,RA1T]%66A M=Q@N'SO%#H5GO#=F%,0,#3(Z2.EF-&EFK'5MPT_Y@7.T.Y 6ZR#8'(H40."Q$0, M'6$##830"$;QB4$"0^D!3O "'<=%D2>QPX<++(4B6,L:"+?T3,'"E&=]DK.5,U*5ONDA:),&TELI$RMAA8(Y;/)^!([&A#LV,^QBBM:1_-DF-I+)]U@J43,-'"ZMY03Z%? \E5RVJQ.ST2F'8OA_R,E;A((Y-,%_GT_"2'+DOQ.<%/ZDF6+[LY8@; MI;JNGSIUXP,RGV_$.FFN4Y30)#F71_4Z/,V.$1U,R^F/NRG4G0Z6"K43/-262Q+JWMM?@VOY+SDE9S? UL4%1O(3 L,+3[!;&E) MMN0UJUU*(^K7K4{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{%;_'&O2=_WH@U0HD)=?2;>6(?DC="!?WAG+5_*3KBC W7 MYG7Q;(;:M]&3,]V:PI_P1/QLO2..(>?)RR^ MN7!;63D%^?\.@0 "@=]I9< UTQLHZ$GE9Y$[.C@;!LVJ8[]^H,EHC1Z&6B M1M*MH>%K;<1.A"3N8CW'_Y[-]P4)Z]E:MU[?MM9H(7SU\L6U_1/GVF\:(3{XM\ 1]##!B0L="U?WD%[?1/IR@\GK&DQ9R)AV M7J^\G33$K&78]@F=2#$FR:GL5&KLK)9TY-&@')%0QN\C3)'X4R(>NYS!]!C MJ(V"*=\T6G(+*^G<{6:_A@7VA\#@@W937]7[.$50#K=]X_(X-JZ/FA/8-P#8 M3205Q>G+V4W?"*&N%#RZ.0X^3HO2.R\4WF6Y]{KY@1DG! M&70^0^K6AO"Y;.O[JOQ[>Q8'>#/;/UX\5;9VS49'$ M$^K16K%].CW(+U"\W6YWT#55[+1A0S]@0F%/% {8]8=BQBO1W&';Z=F&G,%H= MFE\GS:\-?'S6 JN-Y>6IVHXS*(XNA3&764X6%.R9!R-71)2BOF_DZF9&V<{; M^U$OFYENOV\==]'0.Q&!M[#+OM!XV3@L!U)2A@IN[UW)N8;E\,CV5\?G2M M9Z7LA.*5:DW1[&BTCK!N8^$0G+Z@T%(=+ O8=C@P[(CC=,+S&7:/@4=A>.S1 M ""TSJ!A^TT&1.QQ,R1R[4#BW/57G&F<6T#%8,+#0B%L4NF%OX56$BC)%]-MFT6&,;+OLL@P1G:3&)FI6&&$["-->\IO60_FH%@;Y%//D^=AH7'L-#=AX7. MR?!AL.)'+3R,5/RL=8>1BD=<]KU'*OXY556A*9G,;ED%]+FL AF&+HY+V!) MIQ8-=ZA)ZA47ZI0PK,G4]/R;=+J+B>H2[32"=M(.W:L?M]U$DIL-R-;+2:! M9LEIJTO8SJ"PJ@\PS+OU\T33Q!.*7[!0PF/ UV,'-LY8 N%AY/DK]0X^(M&/ M4>Z@H]538[&L3=AFS^E3F6:K'W,|*8_]^H,340H+8Q++W'9-XOV-$<@$0'SQ(M.$V^]M;Q)%83AK?,KB0G[/U3+9; M9/GF,M,SFLRDW)+ O8:#F?@,UYSBOKMZG^$S)$RP4DI[M,!!Z!4>SZ.).E^2(.IU\6?>,$+I,+_OJP:S0\+XO MPWN'[U\TO"OQ;E.0.C5277590TNMUWTWLX"UUH#A33XE .P1U 4+;MQ:2,*8 M8!@3#.W[EV#C@_;]H&*XK4HM/48[S68)3V66X]S Q_ GB&*A[?"OD.L]0=X M 5X6@1>|-A6#-@ B";HBWD!?] 4W$4 M^GR^@KL6YT=T'YP'!/;=!]@)_T%GUF\G6FA55ZMJ>V+VB@J/+,S#S_,?D-03 MA5[.?W!K ?C.(?FV9 /X1P!OPX1728"_. 8R!Q]_VQ#]|:R!T*5PQRX%7Q08 M760#06@9*/WA/@5'?Q)SH,W@:%#_H1\O.IE>LOW8:*=^/Y1CE295H+!D*%GR<-#]4P3R#,$[BI MA^##7/^VXZ"K3%.1MCA16G@D-],+DM."4:^AM(BZM4%MJA"MT7SIG6E^>@'!1) 7*9KV:.D%_M_W6@O^7/_XK*..M3BSY;/F-2[GRRZK9'L80T_<UXB@J$9UN^-H;IY(MSSH|=YKXY2TL:O@0-TWQB_D .D M]98BO.L8"(@\+W_!2_>_.OMTW86OMD,9J#QIBW]WOSPSZ?W#G_/SGESB&C\ MRG"=WR-E*8F[&Q4L)^""*?2=/L&P;_NV_NW_X{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}$U%GY8-BD$\SL1X(<#\QNY>OFJ(+]TH3E$_$LB?L@PMSH7K@=@# MX7ER>WAXMQIP_.]IR<<_*_GQ*/G8@N^7N'B,4R$D^SG)3H1D_XED/Y^TOQX-_M"0_X9ZWCT@_XW\!ACV6:0@$E'T MOEU_?RGP0JGAVKPNVD^(M!2 Y8>8$A ?>$,*

$7F'__O;8\4'I?K6U?DV-S(B MO'\EP[]W FDE[5Z[W5+Q;+)]ZX5?]=+(86[!K9?]Z=HC1\'Y^RY'^L6&O2&[MANQZ37:]1&FX-^[_+B>Y10J+5/)<YIS?H@-J"

*E0*K/)VMA$X(#B$X?!MP^-CEX$<%AXY0C&51 M.===5%=:LIH4Q'3>G# "'A <.\0N!_7(};=#< C!X:3FT%QVYG5Z;"Q5%ZQ" MUF(MFXHO'A<".8F5'"*M(0'# KOG?HPKBUE%RK M./\M?)CY@Z)HQFA,]M^H .$+!E ([%+V?MA:(>BOJ=BOJ'73R/(.H1>4@NQDZ;4[,235OUO#2MHPP0 M=>K7G[@3A8>B'HKZ#Q+US$IL'D'4!\FL4W?))LH5UWUUG'?*

P4A^'HI[X8>, M/Q\QH?)^FE#60UF_4UG_1/_E$61=2:.K<5'%'#2&KU&A<]V13H9'(!9!UZ777#R M*&:>KY?/M>\+W-+'EVRYA>T.URZ\7^.:?Z5:'JOM;W MK?PU.-<+I MX\85H8"'

AX^$U\,Y\1<'1.+2;C.B6S31L;TBH^+_()*.")7W\23UCL{J96 MF/]R-P(0"O@#.60^(^"\49U&Y''69*NCALM+1%^KXC+4.& ._"_Z$8L>=6L(D MEOM/8O%\:2[@&]*

MXMO\0^P$>$_<3]N(]P-=$;5 M,TR]]DYC>+/*KP(^XBIXQZ74- M[11(N47E^UHF!\]NZ%6)/\7C%$F^'RU%Y,]>P]_FZT(>M'>S40O, T&L=TI M^&2U<X./VH233U['7V$,>=G>

M=>\H\H2B,P_[^GZ@KR^=P32@*CL2U'1>-CH8_O8VS5< MP=\H]Q42XE]MH/ H%A+B#@@12L3=$(*@0H<+ 2$P,HJ&;,GN@1)H-!8>$F> S<15W]"Z>#5K/.A

M$E:N"P^\'#XN0+_E2LYT*#]PQ,(_!AU OFR$\-3YX M:MSZ$DOE.4? SPU(2\)NVU0L:)OJ-]PZ$R3<>M$W2"OS3X,O<'DM.ALU>E% M1,Y."Z@4*Z=J-JUC!?T@08NQ!]71 ,,'1)"?*

54]B7%))})HE<32N)CL)L%C M=E.R\I7,%7.RMEDC%!2R'!7DC;9//%&L6LV6BH<93/;58(&-M*=_1E34S(>P M:M 32E-/1.PB69<_56+\J-*

^MUWV.:\U2EVD.JBO%MU:)]YU[_7:9O5&'!# M>W[ )7YGNK/4#KN./7297/*K^SVOKZU\^;,;()W27LS6@R%J&?4IO:X+'(#4^:M+* [@X(; M-:JZ)1A\1]%AFJ-",;]LM]F5.QHFAY:Z)N8+*

!2Q[.]NKB?Y];:RTUUM1<4 M&E_I_3:FZ9E5G/LRTR"_?4]5)O7YU[TT=C2&;7B,@]CHO,5;Q!Q2JLE(.E MG>_&MN03Q%"..0>SO;R,'/A%^2$<CI;I[+$*I&'W)B!{GG-NS[IK94*

ML4I9E8=CYEZ3$0+/0,A9ZA1]=Y7@2(MSZA!XUY!GJ4S.93%&S6=&MB:,,G!>LXQKV,Q%C]}WM1YIN_1FG0_3J)3.4#; M$A]!$A#ZG_1$?

*AM{^?)^HWWEB0#*DVBXL);''6A/UTK^>09&3:H#%M02,T92Y:$+(:]N\S%TL\%+U 9_8>^[=6IL0L%7O_3\WQ@)V: MFK&2I!20"%<#+W(874PKEB0XAF7OMH8H>],?*

Q+G%+'+E+9SEY[S5Z';$Y5B3 M]RHMQCX@Q9OW-R5KK@C2Z=CX5E2]!=A>PX+=OZ<,VZD83D)"RQ<,60>$$'>GAN5E2RA?@"FJ9@PPJ%/JDM+1]5OBUUAZ+HPEQ@N

*'Q_P"& $#5(&EM_S^B6X MNK5]%]C\]Y]F 7VSG"=$E!PX.7(PN0,TGQ"NQ 88[QFZ]/AO.-*C:AWAHM?\\ M_AG2MAEJX/5 W41X34-,C=?M*-(:2]Z;$04VP30!_?P7#25D9Z*P# C"(XO-*

*M[7#>Q[R@HP.<\.?+ ^)V3RU"\-$KWE'8-I8I5KCL4BTE48_;X*F)+PF_1M582 M,UV-JX**GH85? 3'83M,)>M,7TKW.BBGS.1:GIX4VO5X'3!5E#J"O%UXVL5\ MTY**BWP8(.+L[UZC0O*

*@)"8O=AQ/;8!6X&,7,A9VUJ.BHZ !0$Q"_Z^X;PH M@EP8Y$[N,,H<;LPP;Y[@]TUA'$ &Q>\^*")*R,?-,%..\=6]> MO**$DSL!C!>WVWL.]OTU$NPI3K]OW'&=*/CO_]FK K15.F*

*Y2L/ZO3%K=R@1 M;#++N:2&R%&++#/$CL)3?O+;;@5_9S04ER&V_XO36-(;40#(WBB?\@.S_#Y1XQ M_*QUN4.$O5J6P=?VRUEN/GRCVE'-/XYA_@;G +7//B06)8_8YR*A*I*'U#PR*

*MMB#Z_]ME""\+F@Z!4=N[YAA\].N/5QD58GO**J#VENZ\^<$A*_6[V\^T4FVQ3:1515+52IJM--DT_*E9 M+>733 O\DLE7F$HJSY00L)P66V8KK>8=3?!O3N==$?*

j$_[fRK(X8]Q.W<1]G MI}=60'(>& 5 <#T# !6#U_N(R1<^M#E_Q$<3\)?< 3R/\"T@=_|>^_4PZ(O M\[!4W %B/EN.6C0A8M(C@\PJ :20YH>)$@Q,1!Q;B82*

*M/"V1,>R7CS;\QH#N=*A>UN&22:Z3FV17!&5KV0P#]$KR<&1{@#$M0&J94^]Q M>;M&.V*-K0]PZ)';'RD6X^Y8J:$)8)#+]V&SB'98#HX\>F8^.XY%.OU.A"L6 M5+TKK&854:\/B.-*

G)]O85.D7\;4Z-9+5\$\AK7YKT$ T8>/9/G(^GQW")+#7 M#2-1RM5A]CUY/%(1^DLJ3;9;7*=CHVFM)V/C3GT0&Z'"(YM).3D:C 8.*RG% M.9'4I 168P;4*

<@JM;1+4IYHH56GP94KKC&K%6$^W-';2;:5U3LS;:A65=F- M5!T?[3<6_KXF;B<81K%#.^P'725U$V%5=+1-TD9VA.'(XT&UI5%@TBKV<1"P10% M>;6SD$/B1SO/N5@S7UUS:

=%&RY;X$:)U$D.49)UT6H_A46:N1Y-.XM3'-.]]DV&L!4=B M1X*44#-U;.TMBF@V@4_327Y LW/9OZRZ/]+B;+MF$^,)UUD3+9Y8ZXM5]R3; M<8]NZNEE?*

*8A*B4QM64GW+8&L^Q=)]D<6N)+,K],%&Z5ZG6S3H.6%66'\3/(# MIN\7,.UHD!3+I_5R>U%GYO$]S#D_6GRD"HS@D8X5N4ABG*QT)]5L>02?>;SX M!M_6,UFK:K*44Q#;)-%.6Z?*

*E8]!<;,.1&NFQS+|-U'-F(]fXSO?8(.1_L) M,2RDT>3 #XZ!",#RY:%'(?"E^&Z{}>>?V;:A2!]Y;F-MLX<9*$X8X3W;A[*

MQA+/GB77A(\MW}H\-DSL3U:>Z0&:PG\2:UAHT[&XW+Y3%6J_"IUX:O'KS\AP+=_[M<^@W\EU]OA_0\^U)0#&SKQ#4_V:BH]8BVD# M5JT7Y%]_#%TZ=A]FVPZ%0/">'D@=*

[P!!L4VP!R,%>NQ\Y[(.Y+GW9-X80SE M$>'A)"31ISP44&3*KQ#=<*!#T 96"11< \83%HHM(0[8!WLD69;G)W84+;@& MM/-]T?"^/N;G$@)Q86YXP@=H>(WK!/B#IGAU@(R;@6

L+A1WQ;9=7A>V+8(] M+[2V@E_=79C_(F_-$=^A#3W2.1@:;]N&H'C^20\GP$-L:8-*,!3B#P8_ZXO]8V MV -)=['=OMXA=_W=SJ?!N77/7,[43C\BUA?)5821F5]_XM'C1./-;L/P&,1"*

MZ&?05G0!LBT&OA+_^37OAiC{W37%[:"3W5<8@,%',YPD'853BM-XJ6 V<(RK MWX(!T$*V?9>8RS02K+#MFP9'&LUH:!E>C^&W%[8R[5OB\X.SL$@U.^TGXX0L

M,K(U378[G:ZPU0G>Y]#4-+&>].=:,5, NTV_$LG^FKA=Q8"ZFLF$O]..PW8R M.H(9(\/?>&8#_(^-]MX]1&W20XYEUL_)\D@VR?Y7ZI"&K3&O/YJ@D@F,FL/ MJT9*Y=%$H1S!]$S-*

@BK#3C!_)[WK':2\9!8)(}KD]LDCP2[N$/"8,0/"5Q))C'CQ32LD-$7@_R0,C;^I=R^L^ M?T%A\|-DT#;T#]' KH5[+4H:.&@M!6ZIUYIU9(#S?F%?N77J63TG_A5K1A?9 M

*#):IOSHA4:LG*5VVOE^.J,Z1F8EH94D6\I=OQ'K\\#8^_GF'MNR;H*P7VO* M2@;,#..PN=@ R[V>,_= B'@'T'K8IO@=\"X%$\I,,=T &+4F$#RKD*

M!!;%P\/Z+B@1Q4)L.B,A/E@^Z"VE]2XS.RZK'EYWR9_2KBVIO@;H/88NHB8] M%F.4N5G',U,'{C>#K+!ERU@5(^ \N MV'>*^&>499A7=;9F>B&D/Q2D>V4B?*

*#8P1F=GAQ#.0SB_#!&/_ST3R_K_<"] M+O.V[<*ZL ^!YQV:Q_A!G3HA83,P]O8E=,3 ^^3P90?,!SZ& M5W*QOP',N&9X5(1'Q1U]_M]#T?^B:R?TY(1]_S&\ .:7H/L(Y8\.U>5VT_PY5*

M_E=Q_;%Z[S+3X;KV#!K%F9]\<[%NV!CMRG_>)EREH%B_\#5.1_,2W/HK>:K] M+4)>G5(}.(PTUKY9[;X9NS>>>KA3_D]-7,8+\9W.F EC/ZV#6KI(7EK<;1!O7TO">,' MKMO/>?

B!"_=MZ>D$I/$\O.&?WYZM,<&<^X,_U<7[3.[A7.MR/ MS_2#.T_[;61/^'X6$?Kj;A<<75+)_1^K%<40I.+!(H\43'+]()[<96\!5/ M\ZLN\M_G.XP?#QLN>CG?JW\"A5\WS%C[TIN*

!,;GQLLBJT%JLXR@AKOK-&B M^P71B#>@1)?JX;R08CP8MW'1?&)+6#P:KDD*G6U@$YUJZ=C-:?O$IO&B>03*

*M2J&7P(N_+NTiNK17=1U_I747!O'T30__(A4'SGYMT3_P96M2VQ=HKBE0F:ZPH MI]HJ=5EWNDF%B5,J-;]HIN)PH_AL7S-%|\9/LQ=)2$CI+047*GCA*_!,+1 MA*

*C:*S;]P0P(_'P9$(_O>@GI,/](3<*OIO"*&D%J6J!:NJBI5KM%=-0QLZJ= MD/W6A$0_D11E^KB_##VU2,Y9&ZF(GSW58;^@.OG4%R\B_#/;2X&369J^V2GJ/:T$=RIE'#_.>W64DC.J$!Z+*

MHML6@@#]I.V6(K",&H(B'SO;J6)#Q1Q^Q197]DYO[.DQJ^__O1[I"PE<7>C M-AT1?;[8UPL_.R_JM-/E99&(' &\=T%E7\X.A.(HC?R3&88'2W3P?KU^_7^:!?<"T+ M',F(WUG M&!/@*

'@=>-8=-4X+GJY9'XA=SU6>[[XR[JJ-MTP>_KJ[!]'*E MYLM.)72UV35>@;5S6_RRHSCCL:%!S@ ?G%;(3W9JJ2?STS0ZH7)HE5#(.KF(MB^18ACD)]%,BEGA_+>?+$MMOF&(?*

=8E9P'+AMH=00'[PD5FQ5QO!ZKT.O.0. MJ03[@AA#((/>3MBO8-5AP^u[!,0AJ]99AS9V>-,M\A03EJZ_6/.P^VH5M&V+L MJO+9JR\>=,&NM,Y18,5H07/A=Y27FO@-

*M;]!^E>9(/W^Y"!_T&[&/*_84H^ M3-VP5/*[ZH$'31O 3]718<5O6 OO M@_SC*QJ3.#1._<0B?E$TMO'D;7]!^2[IHC4J_HK&0-'=)&BR*_LC2EP]_&BJ*_M_LC*U0]*

*FA#0[I8T(:#=+6E"0+M;TH2 =K>D"0'M;DE#1W]D)X4'H$R(9W=+ MFA#/[I8T(9[=*V?0*!F2Y]*D^6#N[IONYEONPQ5+'+Y^S%ZZSN/%MV5;]C#V*

MZ;\U*6SI%\O>_C2%KU:!G]L21+R_[/WI,UI*]E^2:?[]"E9F\RJTG"!*[,W.K MB.TX3KS%2Y*;+ZE&:D"QD(@68^?7OW.Z)2&!#1@+)+)$'?FG%LD'HY^]:G3^&+*

M@2L=6IC]2ZUU\B8(9G7RF'&YNFE5:Y6"T8O9X.U'G)9I/:R@<7TP0&A.G(K M"];9!=>2VW?

*HJHN*IDT5"OVQ6OPBBRI$6RE14">V56SF3!^VURM,WWQ*CMRH'D595>14&^7&>BDE?9GRAAWP2?GBHT))EV?*@0S[M###RQ+SRBA.>M'I'+9^ZJ7%*

*[_K;ZJ*V7*72I&3;1>*)+.?1\IV7X..IGS'?M875ZLVMK!=^<>\U#ZV-+L(;T*#R^>!*FDU?$I&YP5/I+X_3/AYO3 M@\KMYU0&@Q.(5(]<IH+*0F1DRT+'9&BA*C&)43UA1)B?_3I M?8-*

*<#_Q;\L/LE;PK1WG__OD71+Q80MPT/AU^TI5QL_+-/&V>?7'(QZ.?8Y 0 M#900E4I-2 @A(98*S.ZP@)C?:V4U 7%K?ZH_'!Y^^GE[-=24RI-1S52]# 3$*

MZ%XSO:_C@[/;WUU_O+J\K[C]UNC+Y@7$]<'OP57IZX_;&WKW}\OAW:.^#@S_?44 H MV+=<;CW2M3RU.%+^V&53K:+S$7H^YWU\K'[8)RAHXE.$@/*Z$+FV+]+>H" 33N6 M?

AIR91 ^"T)W_WBM#Q]/.S7OAIC-C]9]_3CRW%G\Z&{3Q]_'-Q]5:V3PZ./ M/_7W;J7Y_;:&%Q=77_VMUAYKG'YDBY M0K9D6$FP4+,<[/\YZ/3'#S\.2RVJ MGBJG];;C9Y

6^/WCWFW[[I_H-_MGWFCX\WMO_^.X#Q!H@&Q1=BIK&3+^F6+ M2#&NWVS1?AW=GM7:-W[EFS_#>SD"T'.U_;O=N+@[J-\.['_M#8[@__M/CKM@&AIO_J[V6P*T2)$BQ*

MN:I>6&RU-!OJ]^KM4:-"SH?DX]'B?[C,HAS2 M_U4,D=I\ZYBG!Q]>+BI#EK?NBA:L)BAL1Z72)0R9%O$ 37CJA%'6*R.!K1 MAX:%,3;6^U D"?*=),C8H=T9/?#RR%C 8Z .@D.2RJ#*

<\4X./9K9W]NSUN M73>N?J;'F5P>N;AV*D]U(9'H]O/M8&]7VM^MG[]_O*SA>&QJMQ4*NNS-(6D M$)*B^)+BI1;C/:M>G7PNV+T>O?'ZMG!'U]Q MCC*P5GU=_>6_/[9N;Q_^4?*

*9_/EQ?=.ZL/F[\U=_UW6H-(<23$$^%$4\O,)*7 M$4\EL([M2DW=/_QV0.RKKX>_W=-F!B9RZ[A*G?KA7?/P,RSQTCOZ4[.OO\#& M&Z_^KM55(9Z$>,I#G4C. 5*D8-*

*\RTNG6WO_V4VM\^'3;./?KAVW]=+_?R,!X MTG^:YN_[DS/E]MO9/\JH:O3[%SV43FW,"2A54:UK;OSO*X/#/Q_J?]N75C7I]>/3-& ^C'=R=__I@=V#@&&!6Y*

MV5I++>8,H=LM#WYYKVR.FY"+%E+I(,L 0$Y1=0-5MOVO2C4G4 M#;1T"WSQK'>.&]WQ>&"P_/QX^D$[KQ/UX,!Y_[Z 0P'B%M>BM,: OA,#6

M"H%'KN7;91GP>)#K_7G=&=Y]H?;A[.CUIE-](9SD &')[]^/'YS^B?]Y7A MUS/EHNXXAQ?:%Y0!6(#6DIM580D((2"$P%HB25?WW^Z^- ?V_:I/V^B;]6NW MT?>/:

(_;GL/CA.S_PA+$?C?R/\&I9/.)+7O:^T=E), M^(M5;Y#6=>,N_ D_PLDTDQ(')=7@G6ZX(Y,\[#&6GIJWRI8,?P<7BRIJN0&? M!&]]4GF-FX@-FQBKI%'3?#7!#,Z/-MTP?,T-B+#

K$EJ14RFK[M13[';<[0P!#C/OC0 M=@V4D7L.-5G9^!0%Q^A451BQQ,BGII1K,^23-E\Q+%=CJ";2P$&$Y%_7MO8H MYO%W4 A@;YA\V. "T."C5W]?(SGC!9+[:.58GAOAG:0I&YZ^KY-

O9-XMI9W3 MBX^=J^O.103_7IVV[@]OKH_W.R=7LG1\ME^.KBW-?J5GY]>'5]+UN,1_?G9P M>'9U>("_79V?'!TKN&/#\=GG;/]X\Z)!-NY/P6]^+N^RM'RWH9D0.?!M-/_

*MVO"J9@@WOK"-*K%-K'2>R@]$#!-6)1!,$P$0"%O)ATDI-R.\^)>@GK0W^(3T M?Y+*WOQK2]Q-R<>)T1Y)1_SHB>%#24>8YP%.D*9K#:7[LU;1E9^UMJ+_;.J M_K/;;3?*

*5*M7KJEY[Q67+,][XJ:[P3G6%=U996SUX)V%XIQ$X2KJ"%^#I82V" MI9]["^IVK1GN&Y!X:KF;,K._0:)G\/SN-MX!)V?]J=+\X],UJ*SY,B?N2(X<6F*N),A1VZ.2 MTBQ+TN%P9-*

*H/E$KA%,6,63(ML5]8_#0\$@I.E,6T\O:I?2]=*X'5,*P"+$>I %Q)2+10"H6*WFPHB;=4 M_L/M@L4I#[!H#-*Z5[]S3=_RB .KG(Q&)7O>79LHA%U4%N 98NF%*

*(QL.!*Q MP.YNKKY:#TK]OF'^NNKC<969B-9KR;88GGN&XWKY@^,Q MV8>-P/-Q0'ZRO^XWJQ^_71\._S8_\!H,62*)++WRW00C M<. 8H)-MM>!1UW,#EF#,!AS*

"I."P9PIXN\%?.F!6T/9R!9L61K"0P-7HI8. MO'9%1QZKLP-/2)80TM(8^%E/(M67G<MA "&TUP:U ME7-FFX'AVK[>]\L'=[>EH"''/I?]7]7WO?J/,[4*U024),EA[HCJB&UFP\R MD_;$*

2H%J8)"(.(.D'.._#^..0&]9-G,\O3](@,F$N^_;NFZ5XV#C\K[=%/UN/COL=),[9]CG2)NGR^6F; 5>]RJ/+]OGX^N4[S M9PLB@*TD1*M^)@Z))+ MK,NE.OJ!#]<. 3.&P6:N(AG?*

*=4W5_:/A=:6D>2>_K2.G=O#U"R=/PP)+N./- M>>XG/;D6>VT0>T$<&&._(.4A\R&*TGQP39\61@-=#P)5H#I^)%8]_#/Q8 MVVO4Y_G.:ZH-+-NT^V 6[MME63KQ]'(&:]J=J9J:*4"U-*

EUJ..E.]{@4>/\0 M_V:B'LY@1M @'+E)W$Y0NV\#5@/=H/YS9CG@!L:&9;=Z\66_WAJ[O+7^9_OE[=>Z?#S9V=__Q_G MZLZ[&^,E.X]4$[V6[''Z9:@Y(F96("J<*L!H9PM"U P RI M-*

[#U6\ONNO7#!3X/\9670JCV>%.(C>]:P-AH-FA$YMFCV<&<]Q(+>=!^C$@ M5I^:,/X^?)Q5G(E]PD\K(MSD2*Y'B3*0X$RG.1(HSD6F=B:RW:CVEVU)_ZO5*

M_6>M12L_VWJ3_-3;]9K6Z_74IJXGSQTN\\TF);_,H_=1R!N2.LLK8F,&)P2DWID=Y M-S ,^@,6(%S<&/MB2%N@Y?6NKFY^-]*#_9^7]L&-4S]8O9*%M0:Y M!HU[C"$\3BITI/1W=?*

FF=ZXO?)\]^OT?>_(K/615.=4HS',1^-R[>HW2E3 M:DDK-+K=MR,,4%X'_%H_E8<'O1Q]=P&,+W"QX++9/H7GWQ/KUF7!_\O]]_!++9(D&Z^:55AH[M1("?XU-A36SX#-*

*C)OT"ZV\TXA/1^1UBAH?>533*X7;I=?__M^'U\8QS[]=NOUM7[[Q852F=O3HTT_1P^2,W.7"\E+\]B=^V44"]U:KV;T4?M M4/W6(-ET'CE8TIFQ@WWP:_R5%EV#*

*[X3%=OB9(*D@9^C=Y>WAT=W@Y[G\Z&H_N/]=I1 M!YM]S#:A>>>TYSR4>1I M)\7EL)IR1P(1QS$FO3=L[:.J,P\"O8$NBD&>!L&B*[8-D[[!A?X,N4I"\# MYA:CV40VR?*

7(+:M.B%4$E:6;B/&Q%#CJN3:55KX\YC3$X^3,MJ.F@6U$M $=-M!@%Z'(OJF)R:\6X>#::S8J?)9+ YVNMQZ10X%V@TH'_G1LDXCS6$PY"'14\& M<

*<$%@J&*_I,=)WA9B502"H]B#:R3UI1}@?L40#BEB M7ANGAXVFUOJ-*C]<:.0NL' BZW=\T<+ZQ*]TSG L_/^'&?2JFZ7[*(-Z1F*

M^PNJH7FA3,8#D1M!]%^^RT__Q!KPP/^ML,,$(A0IE[++!M/PV0;#TDI#N+O[LFY?]_H_Q:2(VS'-<]2_;"TF_S(^]M D7_O7QWVG\OOA M_@2<(‘6_6LK8-_]#:N.'[L'#S]N'CY>&]_/NO?

KE$7AG^[E)S^!\^7L^B69 MH'Y\0VI''^S^-6_+KUOS6OM[_\,G,&Q-P6>'&[7I&"-L>L5QP9M!AA]2 ZT^/

MKZZ9W0[VWZSR:Y,K22P$(Y@@,+2;RQBP])>G'BJJ!L^9CM6FC79=UW3HPA%ESNAN/1\?O8LF.67Z>\#GTE&#*'(_P0 MI*

MC\E^T"VPXZ4]+B9@IFAY#AVO3K58CW=#,MDYY$'AD5DZ9H88^P)'X&45PV> %3HWX89.U(}@3P(*_L#]X]G#"'>B9<]6E++#*#KAT**1^[''X>_6 %5D$&"9T; M>!W;T]F W;0]*

Y/HP83\:9RYN 1UG:<)"G6As'><1'G&01QSD$0=YQ$&>%Q_D>?YQ&78X9T:GK[D% M!"MJ/"4>X'6FG]!L\X=K=^QJOY7>MJOA^*8QA/E_]?Y\R7$[!VPL"&Z-%S0R

MW%C[AKQZ^X>3%IEQJ&R]SWP./O/(,4Q)J4?-TECP#@SQU"?^&UR+6GEW8>) M>Z/78W\K[_X"UPJ Q;Q;/#0V@:$9P1#< CRB[TF=X0C<68\XS%D[/KW"M]%X M6(OU]&*

<&/H[.&HL&Z78Y]0,"Z20H>,-8/BR9A+7E8 ^OQA#(.60Z9)^{"6 M.\/V@-Z<82]5; 5K.Y9!I!,"%B/8,#K%&K_0B02G>8RG7W!X$\"'XVV\CQO> M24 EDXS#.Q6BQ;(>W; 'WA .)*

*[KR85"#3> [+ <7FWI2$>A,'HL2G-BNU &Q M8N)]#N) 1[?*I?06EZN3(:R6I_W"^ (V?]71O>)QS<26QPRL M8XP%Q$XLC:A%3._1@K5' 99LOX!!"4MGJ^:#ZQW*S_:1,U>A'RV*

*MKP36PDUN>Y#Q'*MU+12XF^(OF3$74L8E.MU7'IZ)!)KA>$,".2E?E!_G/L%P MV\1PF^6QXM3G=$R\=]*Q3/)RYIMFF$]'_!KT%8< M4P#N'*G++0QAC,?%3B:L,&>++F5^/U?*

*#P1(SF!:(G%#;1QWBZ'D3>3&!O'AI-% M'[!WHAGC;!NR.[O:R>IA!J'56&\F_>5.;[LLM>5:HRJKK7809L5VBP[/ M8*0.HEY(G;,##GM)5=1.K'D6B M_@1Q1,*

*<8#ZU*2ZZWF@QP2D6N-Q3V4>'1(G&\/ -K3<' MYRNF<]XW>I<;A:$40(O0 #=F.RM)^>'M4,B>SC3J8.%D]>1\7LNR J-AO"!JL;(]>"5[N M?[L_/K\9_+BZ^7Q?*

*[5T8_WS^:KZD+V\T/AY]=.[HHW5*7WK_G!W='%Z> WI:N M?A\<6[VKNV\.7A(]YU "TR#!=2}),IT)Y,"+3FBR6[T=^C9A'_E$Z_@G>^4' M##M=CQ ?*

\W.7&MZ/.'.S8Z30@/1]ATTULD&L&32H9!:4M!0E73@4^P,=F{W7GU]^"X\OOGZ2*BFB)90#@\R%R:UEINA'(M7<1Z)"4"2ASQ%8;W?B5D6%*/'-R^,$.$3U]F\#1^%[I*

*"Y)!VN1S')07U*EJ8 M?0 [R781Y&.L_C98J04OK7#L+B_>P[:J),:V*.>[%)_F-V[HT5F!21*_ L'.M9I"VQ2M^2;_&&LUK%-/ZS7X.>W0>T, M>3X%5\V/(8SX!5)X@Q*K110F33)T-*

*&U1<.0!*8DI=CQLKN'W891)#EI[,>I! M)@\- CNXD:N'UWJ]DP;V&/LGR4$14/1*/)+&(UU,@[.[/O#H>W!]XPB;*VE> M)'@?$WQW!E AR9KK\3W"B:#%!3GAS: C[9\6;ID7H&)Q\@#'-*

*B^>U8 WE0[M616B).R"%@+%@DY4.*609?RLAELO88&MAOZ'YY(/N."W5RW@X^6$9>?$!HPMU9(G2UPNHKRQ]\$"5(+RE!4D0)DBA!*

*M6J{$:0OK)39WC(LQTZJ5*D'GU$JCKI%&4_NI$UWJ65/KW9^M!FG\!/.QIU5; MI$8JO42OU=/.6>>(US<='%_MWUQ='9^?_6Q7VLUZ(WAPLU43K_X^OCX_=]_ M*8W*.*

[4L3=87Z/DK;,).5C8Q;RB,[L'_.R?_7!U?2>RX?1[>F!KF# M_?.#DP.*] MI'B_+5J8'[++DE(!?6$F]?030,P@MD'T5=BE# "C,=BW)=.V60K5C587."E@ M8R=.M_+H#-*

*J+HI'YW+F*Y5#*YD1X>T>&U!VZN&A;WL=DBHIO7R1TQS.!8DSPU M;EGJ:-@N*O('-(8.W>CA%;^A*P*#(^D1P9IN-/@"D '37'3X,&0IS?,Z_%> M=@P7&VS!@GDBC%\(.&-*

*KAXB1^9VW_$M7#E9Q2-C9F%UL/$D?!R1R!0X54@*K M\>ITL93^O[*JDV!5$R*1(DKIVG?AJ7571 M>':.'V[1!AC,9P%3,+Q K3Y^'B;N@KO!81+@+@R&(MBV&/(.6>${E&T'6O\[L-*

W>!$K?+RJCGXE8S0A%D MDQ7<<@";CS3.EA/H7&OPE&B.C<=D[2'0WK7#"G$0;#=Q_V.=008IJV#"+MZL M&TZP;R"F.&BB4 'SZ0},)H%7H)

*(P1+F'D0^,7:'(D7>LR9+&H7F;+6>R*TO# .0LM&>(:'U:%/>Z&I><#X5,]WF(R+!5@")3VR,0(> M3X63>6<$>$'JW-FL^378?78W*.-/4-%CU&];"=0^D5L-[Y>9#J1MLN]83N{*

MG2=^ Z%S,%%)&[XE.2UUUM9,IQJC9[D4 ^D',XK46G0HX MQVQ-9/VU^K\H+H,34BCTP(>ZM7#NH+QM5SQ2U$FG569;X4KOL;#$)AZ8A*

MG1@8=F&'$B:-1[%9J,%NG1OYCNOCI05X"(GY4?P%UL%$E\-22];AF;C%6D\L M6('G@]:92BML!H<:DE_1(H76171W"WSGLY_8.12U &O\,]E/(,K7"]]X4-L>,

<([E;%^E3K73N534+E0"I!0UZ&]%@3_AAF N2/,=P= MN\B']6G%:!'KT'1+H3//"-6Q'UBU+7$<8H49!DP$310S"YN'M_X$X[+Y@]NN MN;]EX7?

3AMGA$R0<=MHL@=%N8)PZQ%@[Y'DBICEL%@'B$K^-HI>QT;4X\1>P-(-U MW4D -)JAT30(+0-PNB,;WD.4^Z)FW,'&),D@>KB2H=%,I):AQL M;OPVO,W,:AP1&.4(]Q)O

*{JGWWFZG;A1M#18]\R,@4X8K,_BQ-8({]P*CMCZ[B0>[@*4 '6/ MM]T,[,?P6=[9D374[/7P_ @[?XN1.)@N5Z;#&I;Q 0 \M%E69U+-PH^/(CI0 M@&S2.9.Q 4(8Z\+^R]*

(Q^TM1W@4%&>5'ZX^BA\[LX+:#9Q0O)5Z6JN4U_^)[T1ODK=H-WLE ED2E\H_Z% M16SH#DXU9SB.+@3G"6C,F4T/:YYOF'^:,%ZXJDX-\SS\>DC@0X[WHHJB41M MQ*1D(EX#\43-!)@"Q+3OV0./M'X)C"4GB+ZS.RHJQ1]P)(O6#L0(=K>1Z# M_PS8G[R$DU^X^.?%XDBX%0M,P-Q2O%V(:_3Y(:D]LTR!+S#\.C9Y8%A=/@\45 M5!AEH Z%@<-[>%POZJH]L,?!>36LEJ#C@&'H'3%]SB(W#P>&+07]JS%4Y(L M[3$DM]0lA[D6L"ZXE1%40_*70P;**G<"6I6G=K8KZ>$EK(D09#G0}(UR]'." MI!FL46AD3"1%2;CSR#G8A,;.|\ [M+/0*K':W;,S2D/S!\^<>T/SP@<$3LHR;U0W MN<4ZAMR- DX1OU]&B;L>A9,'RLǀ4C+'":YEHV:YD,;+/<;@M$Y (1@B-R@AAbN240D0=$5,NJ{A"1 T0-TM9031 C1E!-$5,M552 B!X@0HBDGB&B7ZP(/.<"#\.=R@HAZ61$F0FAHMDF?OC?5_57 MJTK'>KG:6BN(6DM :%Z.YI%<5I2J6:\7MS7445N5.11FN;75#+0>DR)SGN%] M_E)BDT5ZN] T(2H4*)I*=$@21\V!1O=2ZQ.2 J/%N588$35(5QR5"MRJB)$ M:-HE-6V!26B?=8-/B6#6KF$+:?<(32PT<0'LSMF?,U(A$!C]R@)3*5>*K7.Q M:C,U_3J_5"+SOK'>!Ya5(MB>!6),"KE9KW0&'5,^.FO)M;(\V>4F&KL#D M\+HHQK8(9VW8B)[*HU6>,% 3A&E>(ARM5=5OM5VN-7(M M9MX8%I+"F)V 09"TVZ-3%Q-)Tǀ:CNWǀ2],H M[?4VRQ') X\IR;6L-[52?[P4RHYW;]_\,+N[9O'UW9OWX+.=VO?/%RX>_O> M73JO[^*V=]5L"2*>.[=O{G;MWKXKQ=YWWL..4??]!AO_PX+(&.90=GH%G)*75E*OU9MJ>DJ!00:%I46BM M*3<:[;1]'S&A^:30#:0(4B;0:EMNM-6B91)SX8D4#--JBGIR,P7."2R_+DQ* M)TOW(5-O:4MLA""0+?4@*O*W*K+I)8@L"W-_?6D-N-6J%S8"E[1P5#H)HB\D1]*Z?N M3)Y26^?LXE!Q%&E[XY"9J]'="_>K.9BLMY5VBJ&MR*]28AAOAW)H69."H/#ELL05N5YOB":2:H/#0G]HR M_J_(C7I+9-%RT9QW^0A.47=.M.79NL/;E]V_4DNR=2:Z(KE.A^)G)?@LX% MG8O/VG59+628F!QAU)# M@D W$AAMR*K;EJETH=R:S4T "+=[Q6&4#5VLI5H<6/S-3, 2}(O4B4B^B=5^Q M5%OA"F%%+{)GBN6Z7$FWM;-(X!2%7 2]K,(N:BOU^C?!+D4@EW3997M/F:BJ MLG4'D43COF4P7Q/'BT1R*+/C1=JZRNZ*@2=1GKX#!S!.;5EM5D4:21#XEA)X M4Y65>JH$OC-IJ*PI01PP6BZ-I.@I]OXO?AIKRQ LVOB)--?:MWODV*Z+]6X] M([UFY%EO*K=1R"K()-WVNR8MLBY=*CZ?P593/\&KR.TT"T5$1BMO%".88W7F M.;FU2NKNE6"._%#,FKR'.XTE:N&\.+"KC TW90BX8'J)/@6^>%KS'?E6RK9Q0TJ3 X^QVMZBJ@2,+#)A^H;#OKC-S+MLT\M;<>Z9HT-RYD3I,Q5C? NPI_P(WQ,.REQD"H&P111 ;G M"@1?I?)Z+?:++1BV/,N'>U%KL8-Z3I,'&X?V'8*0:A 46#:TJE;-&GI:Y#R6V]& 3>|0,8=Q=$3XS(L>_9H3U7*>/YQ"\&.ZLIY=J:T#YU^+(:0S*1!@[M_?? 5OZYM M[6EQ8-G.D)A\V#%?;O#1J[^OD>,QPK$/WP)1N1'&21SK<^F>0;8$4)RL-H#L MY,,D2F8@S;\$8:N]P2>D_Y-4]N9?4SB80N9$RD:HQ(^>&'Y=.$$P#JAD6!I0 MM8N_).)%"%T/ON\M:*DC]6R'\/>@!4JDTA.D&KD0M'5ZYHB./4DNR=2:Z{KE.A^)G)?@LX% MG8O/VG59+628F!QAU)# M@D W$AAMR*K;EJETH=R:S4T "+=[Q6&4#5VLI5H<6/S-3, 2}(O4B4B^B=5^Q M5%OA"F%%+{)GBN6Z7$FWM;-(X!2%7 2]K,(N:BOU^C?!+D4@EW3997M/F:BJ MLG4'D43COF4P7Q/'BT1R*+/C1=JZRNZ*@2=1GKX#!S!.;5EM5D4:21#XEA)X M4Y65>JH$OC-IJ*PI01PP6BZ-I.@I]OXO?AIKRQ LVOB)--?:MWODV*Z+]6X] M([UFY%EO*K=1R"K()-WVNR8MLBY=*CZ?P593/\&KR.TT"T5$1BMO%".88W7F M.;FU2NKNE6"._%#,FKR'.XTE:N&\.+"KC TW90BX8'J)/@6^>%KS'?E6RK9Q0TJ3 X^QVMZBJ@2,+#)A^H;#OKC-S+MLT\M;<>Z9HT-RYD3I,Q5C? NPI_P(WQ,.REQD"H&P111 ;G M"@1?I?)Z+?:++1BV/,N'>U%KL8-Z3I,'&X?V'8*0:A 46#:TJE;-&GI:Y#R6V]& 3>|0,8=Q=$3XS(L>_9H3U7*>/YQ"\&.ZLIY=J:T#YU^+(:0S*1!@[M_?? 5OZYM M[6EQ8-G.D)A\V#%?;O#1J[^OD>,QPK$/WP)1N1'&21SK<^F>0;8$4)RL-H#L MY,,D2F8@S;\$8:N]P2>D_Y-4]N9?4SB80N9$RD:HQ(^>&'Y=.$$P#JAD6!I0 MM8N_).)%"%T/ON\M:*DC]6R'\/>@!4JDTA.D&KD0M'5ZYHB./4DNR=2:Z(

*,>=0!HI!T4KIV+XPFAP. :D(s!|*Q+0W++%@' (IIG MW"&H^@[5#9 "H&4'AC8(=@$/(TZD ->$[FC>Q1'KP"QO5&QB.+OWV07C!)_ X M*(QJ6;KRNR{H[<,LY@/3YO"$:?0,F 47[,+7AFX0![lLG%W(""4@?[\'B_0= M-JJ+N^*J%-8U44J1?0#^@$E\2T-LXTH"%"-EP,L1:3"$P^I +"[5[/I1ZR MUP"8(@1R0%2X?!T\% <=V,=I=6T>L=P%I3M>V4.,]3OQ+,V\"S;AJO@5&<"80 M!(#7Q $[?A]L#+,;9'=25WQ#\P+C&"$'N#4B,#R*)@0"/29,QV%!22/B(HIX) MU.#€ (&1UO,9;048U.SAB'H&RQGJP8)E:R!5<&;3M9^>,%#2!*<.7+BIVG523 M$1A>R*4V7R?A> &MJ5R%&#72"AML,T/:.I!^ 6YQ8(F1)+;+M!35R%&4<9!C+ML9%#)F#*9@A* M#XQ0!&PO,MFED>]H V#;P$QGB.G20.1&5C%(-JQ9;\4!&>"3+!'&1W+;<.$1=T@>!!1>.X.&@P+2S]U]T\$TBQ\4%38B47!Y) M^2K7)YRMC-Y34L=])>"!APD])0$%3.'E--IVZ&-68ZZJ'R\]::_3O_!-.'!B MPXGW)RC2Y#(-0/5)YW8;CBW1/FA@X;#€>X%K^AS,F@$H>UN:+;W4V\)$,K%I$G8!.'*503H?1 EZ11 7PHU3O]IQB M! !,97\"AN5$8T' O'OR0H4-7RV:&++OR7%FV_F>_ O_)&NS7- (&(L=2@9(-M@NH-7) ,*>,:-Q$[MSA*_X3SS&:NA'^AN*3GF/3K)10"€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~>)WP-?AZ$WI) H'$E<:WC9Q(M9!;2>*=@>- C07Z1LOC,WYH7L%[XOM<5!6"3&Y933D"Y)R'414MVUU2@28M(Z M?JKA*W;K^=+WRIZ$R)E"!!G)H.W]@->RP((#2,?01&TK@+ =&U8;">.8>1,D M1A\9!98\F_@3OD&6., 5%YAW5]*_&I)K43PZ6I1TVDJVAX*I66@SP2*2N0B4 MGXKU'W,&%V/# \K#@+*:Y!* "O(LU H900OI#%: (G-]!CKPAPA#4]PN"G@N<"DIR/5!N(#(X<${J2E,34I' M*+WFX{(F50%N8Z/RI+858JZ!K@E[2]%CM@E!D=TA$7!H M"T%0D98!@!RZL%]EJ€X V0(.:D6G!4$GT@_T&_YY#Q@-F"NL)GN$V9 H(":1 M2M;L7)A2Q5D:U!!UDI;ONFP<\C?)A_PR, 0@Z1(=7$MXT 6OF,617W2)Z9N" M&SOKQ68!I&Y=;YKDM$9!LK2$%<3.USLJU6KIW:4G;W,^=N[Y/CQSX/H/"=R2 MOZG^\HT(XCP I%,&3F1HK."=LW[HN\'%F_?.%P6YQNLWJFMI M7P^%B*V)H9RZ*J B*;>4!Q1!428*X9"*41L"1%UO:Z4=8F(>&)_J15!U^WM MNON$76\TO+GA2LB50'AN/5G$[W{GHOS'I[\S^4S)H/I<,C);>V4)COMUQRF9LAXJ0 M2$D,L4I!$4-*&VIM&59VG*;8M>*C#2&E0A.1KU6JDB9.,ZM2HDJ%)-N\[XNJ?1)# [";4L:I.YAA@H#3MP][W)&'>V(7,N>U-&I-3KECI*MP, 61=F*LLUZS6PT M%64KRBZ>S=A_RN[4C&:IA-VJ@#&R.)A95B!S[_'>;)7M:>T:Z26-U:J ?-K6 M<.5=Q X_+&D>LR>!P4KHT+U3F^0.65=22C8;M4ZWQ/F#VZGD4P1Z- 3:Z-:: M1NDNMR+0*A+H]N/@E2305JW1+MV_V($SL3=)F9+Q9Y2*O&V4)6_(*=@/F7@D M@W5GAC:N[EV9]? 2>.Q5P4<=O^)YV86Y>]VBQ.O7HP< /HL*]&VVM*H:IY &P MN"=GLK.U9EC"YICL^SWF0>A[*G=/DUVE(*+^P7/@M=D]'V4/8@2S%(NP4W=4+V,ID3+KOK= M*414 1'&BF8="A';.|6INGM5 1%*-%4$$4HT50012C15!!%*-%4$$4HT5001 M7;UE*D14 !%*-%4$$2V]82A$5 1IFZHEOY50(3J$EPN(IY:.++DJZ'H]/J%85B/$1K6[A&RR;?!Q$,? S6QQV=$,U$WZRB;%SEE&GO#=-U>D$!U2.2 MFR]5JGO<>FKSW86/@X1>JGKWF(3*[BY\T.VHE6I6JGD?Y.H>=0/%-K'[K83+ Mf1^L"..0"%/$_L&*,"0L>OI^CP0INVWPH5#&2S)Z>TP.};8/5N&N@[*IL_)N-M]059J4VU#U:6^A%%0)[?3[BIFTM+*G8N=S;93W@;U%%M#EE547,,,%"]]V!D MXO.4Y* [;@MW@X6Q'GCA=?#R[-)&WZ_WNI#%,=_?[+JF9T4&T*30;M6ZOW/X& MBK(595>!LHU:N]50E*THNWB0XP HNV8V2^TN6P7"+JT+F QE[CV6C7K9KM6N M4.P:"_]#}/ +T*#+8L\:.H[W"9Q&/Y@<0)1GB[IRAX*F3$&ZZDAV):6F.9;; M35C1K*+9C3?!;]>JZA7-[AO-+C[?OHW-K$6G)V:C^WJO*,5D)V,?<-8R2T79 M-BJ3-^0T[(=,W,_4R;GK>+A$+0H[-K(C_HM,K:N.T9I3M! MNT:L2J;L0S+E_;LSFIH>PG^$2%=@[OF"T46LT2J^:452KJ':S5-M4:,^CIMD= MU">)VF-GK'75'LXZ90I_%U]VL]DR?;%B$JM;']fGUC$*:E"QU+">#QV'74(M147A#€[H;)C@BI0Z'5?1>U?H0=-[']OU%]NMJ)W1>\'G&4Q:J99:D(Q5Q&6<5> MF8E<*X5UPAVCV2.@D\)M#,5O[$:(1_C,1N/3>(Q_9,+70XG6(-GGQP'\#=?# ME_A QQLREZJGM;$SYO U!TGVMF[$5A?JF],<*-9:/?0[@?R!-MJ79KE=J,M 5 MH1-&.74&H+;\,$*%$_I8B@[ZYL&)AJ1<%JI&N MQ(6&M6?"[8\.]B"[+C9&L MZ0'X.+Q8WHM? GWVY#'7M#YXL:O%+DG7A,^,@X+,4:D>%4P#4D'WGP$DV'SD8_L^+8:E]!E296%,) M)?.,O!$$D5A5<.DR>3!#FKH&EE\HZ MB<:D!8^]-[€NMR[%^].@ | S\ .V",PC.0 M5"QG#. 16,37Y02!6%$1<2$8<E?S"_MU' 6$2DPFETV#OF;Y$-^&6AF2A,3C2A+6&D>RXO%D5\TN^B;@JDT:REE3DJW MKK<;9!C-3$LWQ,]7S..!4=Q;YJ;G[+C<\Y'X!Z[_D_ M_^9OB'V^$H_ D%II MGTOWJV !LG[HNW&T!0MPD2,UGC]O?E[X(.=OS6B6MS3,HQ"Q)408NKDT<*40 ML25$]/2.XH@J($*)IHH@0HFFBB!"B::*($*)IHH@0HFFBB"BJS<5(JJ_"%-O M+2W.4(C8$B):>GOI\7>%B*UQA-%0B*@ (E;5YBA$/ T13ST\L2KHNKU==^'' MY\,%-VNY;[C\9N-0L7P7O_S'J]:KYT*HJ=6D$LV&5 MNY>&B%+-2C5O5ZZ68YG_CLC)E():CY;@AIZ?,\E*!XUVA>%]PACNX314(11 M.F&(@HL]HMW6'<J55+Q5"8%TGZN.&RV]NUE.?*G<.7$\(7JBH1^'S+/#_MU_NB>_> 0U:5U!P##)3J/1B9^#PEN>M>GRL.5Y:F"':?;L78OHKVB~GG7!#$+ MEN2QY[*-?N# 8W[E(G>.6\-',B\|G2MVM@(TZ=,KZE)LN.]LN&^ 4JRG6$^Q MWDX) <[G*$"MZ6=7SZ.JA.NMP#+7&Z\46+989W(XJ3]\>RTI:?LQGF)H.%A M)/US%9W>]/VQ568OH|W\Y]D8"E6QNW:TUS'*[F"N"5@2J0X)NU(Q6]>.*%4$? M#$&OZJ=028)NU8QVJ2PF\Y?1J77JIN(O MQ5^5!505LH[/Y]]VS33:I;*7RBQ6*;-8=C2OW.&+%4@K[O5\^KWRC'?G!G^. MACQ8.")E3V+2.TZ&2W-@=|<"- U63:SRE.V$9AOB.05AV&+1FF*4J2WG=U99 M3HJY%'/MD+E.K89B+L5<.V8NZ>)6E[G6]G>;9KG!VJTG,Q=W?]C.-.SZ4?=R MD:ARKQOV.O8PE0K0/04CYFK>LJ.@)?N0N] {QONFEA3'JHJJ@*JR_1A'C>Y$ MW9=7_%/%K9.2YFG6FIV&ZO-4*,VS<[I2+/0T%C)KO9YB(<5'FZ_8K>)62V&A M6K-;5\E0E0Q=,SIGJ&2H2H.2;_M3Q$##85<;IWH0S/.2:1,WMP0=> {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})]%S*LTJ M;93]-KI*{)LAHE2S4LW;5RU L?Y$7_2MHHNM MTD5#T47I=-'3.ZV]IHMW6"4B2EZ2T-MCW:LDD]E7:K M+TA*% <2JD7FR!8C\I SU2DK7J@1 NL]5QXWVIKN!OE3NG#B>$#W1T(]#YMGA MZWW1O7O (:L*:HX!:DKU!HQ,?)Z2W'4'H2+CVGNZ1"PPK[+Z5S7 M/8BF8V:CUNZ4.'E8!%1VC6%%V8JRS4X-=+.B;$79Q4,;U:+L=:GYI%%K=LN= MK'B<)H@,;^XG$1CE-F16/4(K0+P8!,-M>!R!G^L -/3WGYS#B0GE- [M%];MCX,04XTD,I!0LKSKSO753<\G6%S9R,I<$ MC.U4"3X!U3_2QF:X8OVI+L6LI>*2(^82TU!<0P%^[P!X.0 M1UH?[G5@+|@M%R "BT&CAFX0N<+DL'VX5E]5)TTP8NOMW??';NF:S'G>XI*R M/MF5'K&\1Q60:X%@N9P%*$*&\JW10"E\^R9Z("Q,KIO-7!QEH1RAYYCTZZG< M7[.^WG73M/(^G@G.T28:D8=C7$M]QDW.H,8;-B; W^A(:^\K=B3-_ER1<\+B65L M1&X:.H:K@+63_OQ-0V]N".U3L,)&#LE,&P9\|(}7?[OUK<6Z8UF3[UO}C SB M"7@96QR'* <99'NM+Z9X@>PI0S%8K(9M}643)#*3%CZ"9K1.\0OL?D*EXY^LI M'$PA,U/)*2K'T<+'.[(CR;(ZGH_.G[%C@^2AZ2OG;(S*7+OF(!'\ M/X&%/X[Q/ZCR^W$(QDH{@'-'9#€DX)0: M'P#)C[&V"7_V!S5:KG@(<B8>D,/D0)#0>Y=X2 M,--P ^6^ XM,,N-;7KK7[@EH!:/[P-F\%N]NB4,\)M@P83F4B5Z+TYQE8A)&=#,)Y[\FUX$)NC9&J*TYQE8A)&ID3+FOB: -@-XF(*0% M$8Q=1H;L !0T7..$R8HF8@-8=9:S71^<:"BH!1M#A6)NCAR?1G8G/'+$ *]N MZ&M]3M9<&/<-1.O@6NM/O@Y'"4M#'8_P%5L'N[]% C4CA_-#JM/2Z!HSBX@JB M(8LTAG@ E@ 0(,9€(#3- I\- "1TG383,A=W"+3R,?,"FF XAIOC@]I-Q/=-S M>G*3=YX_5"=/4CI8M-DZP)"?"8:,J"!/N<>P,C&B4)@%]T/:6VVW+= 2# MNQ?T-P.RA.CP+D ,&-5C0+B8W"6'7Z0O1% <#1Q6A$_3HA#0IP_4!JW2]2U23 M7$PC-VP.;HC3!YCU@;,>Z#*Y3#^.Q.I^C\$_X %0PS4?^T&D:Q4WT3>PLC,B MW5E?L4:P3B:;.6'H-J!=>!-.$A"N*$ N2%W;>Y'GMY**3P_@HT^H#0&R4AS MV#12>'XP\XMX$/#&W%:Y$ M(A8'XG X^M/(ECD% 1#[CLYD-E QDQ5"$H+!'O@/),3$IHH2I@34!%.E) 0>Y ME9>+#P A>"-L;0 2S\$U)}O &W+K1:\>%H1T'64"SS 3[SR=\!5PFV"TE.^F M*1MY!QQI\'[KI[_G=29:E?A*8+R<,(Q0Y&D@FW!!(EJ +W-]D%<@@'&R&^U MJ1$5P';BD^X!X"2BV<:A%@@Q>/A4ST?M5(6=\8T3F>.5A4 M\2,SU"*A#M0UTHC4HP2*8"HPD;]J.J5B6I?EQRZ*"P"[=Q\-)_@(G*HV@M>X MB-DPML L"0>Q]Q^?H/C##[X)/A"*.5'6P/V&:>]=3,/YV@^-,EOOI=\ ?N8) M&!& $EKM!{/=U,W\'>^ (,0-AH@\[0KF%7<>WF?FR^=4@)2_5 K*.[@1BJ[0 M]+4J@O"6S'G7%7)93D.*1VCR_87F8R+?A92+92 TE?$U.3*4/J*,%Q,32<:C MOA- 2_$D15WP*$N^NYNONS9BH)&CQLB%1'5-73?:G8YSCG339;ZN6XM5 1&?I M 5B%B&TA0K6RK@HF{8:B5,-1'24DJ@$(D VJ=F:5]80T#+W; MV.LN@"4VD5WE?.VUH"B- 7%1OV:WJE6UJD2GSO;[N%W0_^Z%,1.5:E+V[2'8 MMW.Z)NZA.5M=XW7G;2^6CI5)SEU0/7>2]?>L8B]*ML M,"K8'V57)- '836^SZ@&BHX1$+GV@(""MAL,!1,7=BZFF2E<\$O5=U&86HY]) MB78BR[Q>[XWKL./F;JLJ1@YCD[L^[\]Y%57WPFUQ>17 8FUR5H3^(7>[:[3YL MOSK5ED:77O Y/=N2530"^{Q,:WQZ1 M[UL6L>_&>2V;V%N]6KO1.P!G=D/$OB_.K%/3E\E9I$VHYZ/0Q;NETR0AM2^^ M:AF]U;N]FMDR2^ROOO5RD0IHUP,BWRVXKF60;ZO9KM7;G1+I=^MUD3M7F)5R M<=-/.<"K7-5]S4S,,HW3E6VUH'+:WNUT57:T-/L<';M6- MFM%!*Q_X0'Q@,0@'[$IXHS5DWCT778_%YQ#;&F"'5{G%3]+?NZLLWX4RK_1N MUQQ9UNDIGH<'5Y1:BA=H5=ZMVM:M4WECJ^KNT?P"}=7T!W/ZK.*/5[#86VF M$Z1HO87M/P/"BKA=KH973GNZ[Z)T:(!TL/T8.X-M2SQL,7&]\V6[.B KP]D MHIES]|,GZ.Z>@+6:^=[!7LE/C1K/6J3=56* 2,Y3$A?CYB>.>MCZ$4,YA((/D M.\B3\V;IS,4C:JU:6 :MV.:6+]K-3LW#F?X56]&_H,[8^&GF9P%SE>V,8Y]J=O1NNAP<#,9!)%N.&."%',5& M/@C=O^B+]2?_=N"=V=2$W/R#PF/@L0 < $DT]=$$B$@,"@%0@H9IO$6PY'K3 MYYZ3?[M\#K4&)[$*3DB$PRJ@.]_DX u8X/@=8WYZYI^7H8H,9V GGOJ#T[C MD,NY\'"PEM9BYV$X5 WT#*X+=[RXEE&8#!GI ZK",*9VZI8?XXE/QAW#(0 'V MJ4$W8HA[H7@:#=0()6* {6=_NJKD_;.XFCK"/HFBOGR2=\BWCI2074V@<,00$-3)*UW:F*!+U%O P M=J. "JJ1,Z\0&&.6D/9B*L9W) Z2]X6+L%>]%_DX'Z4F)E:Y+OYWZC+0%V/F MV(G<%TOU<;=R[.N\B.:+Y M.VD>TNP#F%9SMN9F\V]9 MM9GD=BL.04\!&@9<8B7@?3$J*PO]M'#@(AI3M=EQ3P1<24%R*I58.(YI 0L0 M,(1H)$A8EH]8)R"V9-):@5Q Z(3$@HJ$2 M'(8^^ RM7F,9/T5@- E;Z#'4C\T;6]AD:[9RQOMIG@/7GE@_7K[)ZA=&,FT M0C&@)C(@$X){L>C\&!NAM7",B&3A[Z:LL2URT\WVLG7?[X6X\H\)N MJIRR)XKY8_34O*3:O%BTQ=A%?/^?8MI7'@=B%P O'*,&[K"<-9:[&GNJ$8J M;3!HE1W544&K1$HETY6<.<>8A/+!JG+!CZ<9ZW.9,F%#$;+J38=IC5C([J 7WDW,-H?*PJUPK"-^?"@7#)>QJY)UZ! MBK.7_Y$FLZ)4=,+%,GQ&!2&D._DX'4E ,;U43JO-]BH((1GGF0HOV+_C'[PD M>@);M)IMW7BF39;Q!9D,0K6+*;3U=HX<=LP0G?(8HCAY=#E#&,47%QBB4YQ@ M*OCAP(ER6^HQ.X6CU..T')@[8I#D0+/S/#'07"8&FHTAU?RSFX_)''ECH/TZ[5P]<3*2&91L%(9/.ETY?*<=)XU#; M4QIIB(F4);"#&X7-+XQ^=$3O<5({C]$6<9H+G-; [!\ZM_H5YWU9HTQ^,1M%W MQ3V#*,XM^4\SW3$<+981#]&K\1LX6,15'.C&HLYIU4WHJ>9QR6 .EPC)8#-+ENUL+G(.=Z:.*6C<@GDZ2_X(L"+[M/TO@K-I-X&M^.'5$JUDA% [<41)PM2,FGC[2RK$"*T4?&>F#VQX/-Z#\JRBU MWH/@-2V!X:4])OID /T>2)44"8Y\CZ,PPE'F\+>3 U' -"}}KNRS_O8+*UV M27\9QEOM$F269NB:M*J 6=.&V&%Z$ MP8)H$<;;2JF80ZX%,%4M@*H%4+4 FQTA5UQ2#5%6&F*_#XCD]Z#>TL,H_G)U] ?T&EA"& M>2!61C+Q,&+?N(8!KU&:HJ7TLO3GHB$#HU(<]D5[C(V29,P8W*PLHO.4%>({ MO$0-XLWSKM*U&YFQC(8^6K_B>U[<;L%B.ISS)\AZ_-P=/B)<-QA(+'W@=-M-'P 79 8'BR\16/.3,\W#QUP1L=#7! M<@<$3HWJZ3\1YFH"$D5[3.[#@A=-D"*>)DFE@Y@P9 *G/.=CR?KKI-$.9Y.Z7 M+9B)$# +LDC JNMM'L(E?;'!,C9SX*S_=,/]FJ-14Y"4@>_!9TNP4+D+-M=8 M\-3.TO.MJ.VW.^[/M_0# <$\!1<@6 %KWP1:F$F6&S!HG0&PW13>)=]5T278 MM@7Q 6Z3>KOE|![+.C\!T^ PB5E:X"!4[8%92AD'Q6]$OD1B#%"\XR>QB3 MI 7Z&G#0>"C3L5 =*5*[3\&)7]]SSTI+"^_.ZM1< IC-Q8\,.B!=G$\K.\" M!0GWA8B8),2&#"A? BJ=Y\0!U,"M$;#1YG76.PKWNARUW6YZZLZ0!5G:&< M9*MB*>_^"^%ZJ0!X7G*K=*IPX&/E^T ^O+LX6[""^[S(VE8)/6#T!F36A R 1 M=t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})*5+&.7-$K@UF:*D@KQX##XK+$P>R"1/7)R^P?"L_M,RYDE, ^'#A^_1.%63"G4SP-P5M%'Q3/HZ>]9>D+^7I-QTJ0:D:9 MBO#%C2#"TV73(?"Q1G@:B]!J["! &XR[I,&1E9#57M &RI%EW;"7J/ZY1[=1_*-MFTKTQ8/0UC*.(IH'B1?1B4]16Q"FUPX<]-D"#&N-G&@19APZ6XF.M%T3ZT.; MHR;S\L!- MCS*+PL7D#^D,1 !_TETA!H2J3-P!(W<7)QK09R0RXEHH+Y!//H(@'>3(-K(M'U!#H M6,P-T XI+)9/R\K=9^1W\/I'GJX@SS.+]E*<'U'$"I, M7-]<6\@.Y7(N9A-*XPZ#-IW.NL!++> (0OQ5H$'@1^((LFX<]!P&(\^):R7C@) M@?%K,K"$TF((fH^RQ*D5D%FSR/!8W"C#26#D 6NGK,]KM&76#WTV1D*U8AT M4%,L7^2M9$ED:F\65T+"9,0C,"YQ>(P/? fD)$3KYH@6FV^X[M0C0MI-T6// M89A?:,+0Z77F\XEGDM+^(K*D@J(C"$@@E0\.*GE3,5SK$+T)CGA+M"!!PY! M[(<+MT*&FDS:,5D60^O)"DOII)2P1DY'[!OB7M::#ECLXM'G-,- '"1W;?_#$ MXDQP-(4I3)D6.EB/*B@$J6;DPJZ^\>F#5P70P9LL)P 3[;NH#)4I6L>$\'0!I M3+66(N48^L)B!=(A/0Q!NBZ<9@X4 ^^EAQQ&7-_C+0#?\-EN=I?I/2 L7/= M4I*UB"2L=+9\PD%*/WED,S?TF;@443U9!Z3%8QS{YL\Y0MF61\-Y-G(7Q++ M^YZ-&!Q60D1SY^A(&^2K$[D9F/I\6R+9C$@,[[3H1T %%4PV=]CQW$A)# MZLMBG_+=^4)>LIS0-LWA9L0FB%R$.<@'&ZQ3C.WET)VS+K)G$=5 MFXA(K*R9]8.\G,)W(FF#4X*B87V.I?-]IYE#-BV+@!!SM=CR+&5*IL1Y']! MT]}6FYR0A-&J!+ ..5O=5- EJE.T^MFRUS"2T=+NT>E;GKF6VS;MFU[#ONK9E MW?5YQZK700RTN8A0?#E[/K\O+S[.\7UY=7[5]??SJO?Q\==?I=`]M3JG)M@86I75Z"FL&%:ME*5R8)KC:1"%ZRBQERK? 3B&+,OBDPXN?!*38_R8,ZW"T88Z8 F$P3TM5I?A\BJA*$EK&KQ> MMVS[SC!]EV3L\%=S^SV{Q}->K/3,-JM7K=?$$98N/"^[/SV_7-7;?>Z3;, M.T]/&FWMB?_,JPA)2T!$;0&X9!@#P "! MX\1/70;,2N!3TJH[62U<*"1R? 1DDE2O9/T>L8Z;QHE(:^D_!:\1W1/ M$2XBA82D1PIO!P%/P:E8DBG3$*Q ENE#|)/0J)\B!//N9-* %ET<@7/GVF =H(;'[U/=>O-Y1_H!'X2C3 !QIZ".& [XL'GD3TL'<22;- MQ>HIS)+,0D11+EJWKEVL1V'BU#/5SW,AH(X+$*F:2)=QEXHL,8RJ9<49G$Y M\- DKD&HM/5B=#5:A1V6!U(3>EA%!&C1)HK54*3#3HAG;H%,Q5$2!46P6Y$WQ MZ(.H^$]7DC"HW++@RQD Z2B1-?[(1A0KHX/NZ/X"%(:XLU_AK4@,7/N5N]S# MV!2U(HK) , (H=.!PC.K8X-1,* X3#D5GQ$)/^_306J68<*L"_47"%A(C[]/8 M S,S'^@$G^#1A UDP#Y)W5'H4(,Q!>K6%0(D2HEUQ0G$@.*[.0F!F0*L%"43 M#S*_9[,1K,S.CLR#C1X#)+7 M:F5WFU[#ONK9E MW?5YQZK700RTN8A0?#E[/K\O+S[.\7UY=7[5]??SJO?Q\==?I=`]M3JG) M@86I75Z"FL&%:ME*5R8)KC:1"%ZRBQERK? 3B&+,OBDPXN?!*38_R8,ZW"T88Z8 F$P3TM5I?A\BJA*$EK&KQ> MMVS[SC!]EV3L\%=S^SV{Q}->K/3,-JM7K=?$$98N/"^[/SV_7-7;?>Z3;, M.T]/&FWMB?_,JPA)2T!$;0&X9!@#P "! MX\1/70;,2N!3TJH[62U<*"1R? 1DDE2O9/T>L8Z;QHE(:^D_!:\1W1/ M$2XBA82D1PIO!P%/P:E8DBG3$*Q ENE#|)/0J)\B!//N9-* %ET<@7/GVF =H(;'[U/=>O-Y1_H!'X2C3 !QIZ".& [XL'GD3TL'<22;- MQ>HIS)+,0D11+EJWKEVL1V'BU#/5SW,AH(X+$*F:2)=QEXHL,8RJ9<49G$Y M\- DKD&HM/5B=#5:A1V6!U(3>EA%!&C1)HK54*3#3HAG;H%,Q5$2!46P6Y$WQ MZ(.H^$]7DC"HW++@RQD Z2B1-?[(1A0KHX/NZ/X"%(:XLU_AK4@,7/N5N]S# MV!2U(HK) , (H=.!PC.K8X-1,* X3#D5GQ$)/^_306J68<*L"_47"%A(C[]/8 M S,S'^@$G^#1A UDP#Y)W5'H4(,Q!>K6%0(D2HEUQ0G$@.*[.0F!F0*L%"43 M#S*_9[,1K,S.CLR#C1X#)+7 M:F5WFU[#ONK9E MW?5YQZK700RTN8A0?#E[/K\O+S[.\7UY=7[5]??SJO?Q\==?I=`]M3JG)

K7B V%[X%OD+E"S'<'J\R3 MPU[2R(A,XVN_Q1[/1G<57X<1#%S&7"#V,B">$9TLF 8&VU,SBNFM@=#H4RU3 M02I3&&?JZ6AOT!WY"T5/8Y0IMNB*(409KJ-9K]?J}? HRN9=9'T/NT@,29,CC M(,FI%Q^-%S$J)40!G9Q3P893.JUJ$:%H<62V3"QYTAAFA/Z5(*24RE%=81F MEY<4D OL"CTT0,\P"A181E _Y^MR)>R"9BOV/V9V"_JJJ91\H-<:.T';K-@\ M^!UZAYFD0%/B >.#@.'LN0^D4ZC?-.!A))GUAU9>+!!8P6B%".EE-R=EY EY MR,)B,0 G_5)R/3ZVFW_L5KCW(P;BG"ZK< MAZ/SEP4#Z9Q%0[UR7)>H8C0GB 5A)(8U% MU4/YARS01 BTDG2&@1C7:TQ MO>BG*H_\U@Y-?6Q@&?(8-"6%**HWD4Y#*"W/Q"=B=IP78HYT>EQ=H]=T:(, M8XEA.6L 31_E2V\L.8(1Y! (*X.?"HQ0'>*H5O6(Y!W\T*'7H'LC$%Z>W!(C3 MIJL3T=S*>@8(B-((AK;9/#F?*-",0 ^:RA8,D'PNL-81]1^%: MMXH@&$DRT3F?1-E$^)@=R=1@;U\6DU^PCP/A7?D7{6$O,!]GHPQ M? F.).5))Z)]BX-R5J*UA*.J@08Z 5'B I4VT$[/^.DGKY< C"G1GA=A4#792 M64U//-"9QU;A<0BH61=UP4NRHZ%8-I-\5L%+LBRG$%<(;/P@C]5E\37RI?+A M+SGA)]$'QYTC)G%&V>\T6PYF%V#O+0=],3'20%Y*I MS*HQ%^ZV\UG0-)$-%!C"+/D*FJHE?9EG'A"'5)@;,B>$K-T6>ZCO-UU3106^8KN#9 P.CUI(K.AV,$;YJU1BO}3<2Y3+.F-6I&UZQU>UV:OY8%K_W7$:W MUIK_NW'H.O5RL"(^+#/3X5S4R72:C,H+81(N2A DR2DZ/I-FOJ?)+@LCX1^8 MJ< S$*L)FNQ!K$@*Z"0? DA5V0\V?KA$;+QXI&(F6*MGY\R+)T+++"<12@-5% MD[L1-5U/|<_R-$M2/&/)X[{4==:/A*X,V2Y)2*[R-EC@'X&GH4LP@)K7(M'0KQ2Q,V!]@E2T.Y^!2X4LIFQ)E (OON.^)0MFP;R!+04LR.9*:TH:2!Y@3K M &R>84O$EU2:R20,T:HX5 X:@Z9H/*E"]*L7\'LG)/_M[@8! M=^M^^:G4[GKMOCUMV --WH#(-U>@[=V7BMJ MZMK7J^N++#Y}?+V__A? 6'7Z(O;R\01*>;KS<7 M^*,1M3Z&PM'",FPG'+ML\L;Q:1)KWP5*+0TJ@H_1H Z3M M*9KK5ND8AM[:0GE<80<=LFP+D4+QU?H$=?>R\$ZUB2%,2M(LK1)8HH)D95PHF>#@OU M]M."/>"%&;K3\JY,X;8),(K])M%% M<'"'+((\8"Z1O"N&ZV6C=;.0\"I*%)../Q38C.]UDL'@-/*D+';"1BD,F!Z2VW[\Q= M.%7[&78^]?%39*\!]J$3\5-X@(6B"L&5,%-O-Q4BJH"(MMYK*TQ4 1.*);J" M"*.G$%$!1+3U>E)})7N8_'"94JL,).)>0J%VKG +C%2A^QYRL]QG&?_8'X M[PTEYLN"QK%3PRKO8>< ^,0>G5$\FDKTJN3 YHW* M'9-$B7*"J"6,Q[- ;L\#,AVZ2\J(L*P^S#A6Z? @'%_ #NTZ,UP+2-'P,]+@C M W:/*7&<*AR=)38VKQ)N\|?$XDM:.^1+XJP$,*6MW"]:N(=CMGIS_1MPXFNQ M?\/FHZR_Q>Y$,[13C3{(cC|-TEA^ULKKPA16J3;WT^.3NG<>.Z%6F-Q&[3\ M3L8!IX)SN$8S.YU:K]4J.RQ^.(BF:M-=;^>'TBI&]Y]B&SW]\.CU6;V92S%. M]YX>E 1;SZRL.J*II9E9QFZ%K;AKY#V;G?<@$7\6WV-32C02Y>V#R%-HWHGN]{Z(;,R"+S9!$-GK\Ff/ FU\82[MDE#;L>:J@*R3;?]4!S{&=W+QF&@]38['$,Y3P<4_"8I0\O-J4/U MR$\NE,*]^,[3CVA MJ??+L+H$N9T'5#()4A!%T=V0VQ9MT%_]E/_IN4O&VL,Y M%85+=, ,- U#M8B9#!]AEINKFF74:XB]\SM(9CY_E=*\&,O[O 8?KL)*= -L]YN=.3UNYO9 MTM"U9)D:K.&,1*UFM5 %UM+3P%LK.L1*1V6.QRZ(=2#X2LTRD]3. M[%BM@=GNW/7:_;9N\0*V?+]\N;L[>7]S^Z]WE MS?G'SS=?KY%,NW5XP\[)M*EKN#Y-+%#+5JC(<_(\Y"GG[?5]',U_?SHIY]+ M!61. {3[K}>P[R[0&=\U>]WG7;_3[=QW6X[S'ZW;/*"]@S[>_7EQ??KW_?/WI M[/;R\]5=NPGF5GOGNJ>E:[0T+5O;2]US=8Q:Y^_.'"9Q(I"Q%B7*DDEPVFW M:.XO'>.=\A]6[M()_M^EI-]__Z3\.-AC^M^%P?)+27A9$V<$()+@8.W/F 41 MCF[^N.:(09BK> 3/LC0:DO887:/ eEO)+,OKW!EWZ G?W?IWO;M&?0?QE=G7Y M[XNO__[CKV^\;5T% [0}&=/KYX94F!M#]XY7SB*3C@R3R!LP-^2O-8R/8&[?L M-]>QXUZOV62;\)))}=S\4=@6M\^FOWV MQW?WKW[&@!'@+;_HGW>TB2O? 6[V/NW^=7MW]]^\#@7Z;Y_E_U+U]^ATW$P/SP""R5W"8T\-G&=.P@D>QKQ[/@(U3B/BF0;WG*Z\DC-K M. U#?A^[(FYR<_1/[3+B(ZU9[U;*+)=*N]ZJFRV[W;EK#)K-NZ9AL[M>EX'K MY*SW>:O1{=}]1D%I7_SOKY>_7-[>W/4:1L?H[EQ9MW5+-]EJGB%=V%H_IZ3M M*9KK5ND8AM[:0GE<80<=LFP+D4+QU?H$=?>R\$ZUB2%,2M(LK1)8HH)D95PHF>#@OU M]M."/>"%&;K3\JY,X;8),(K])M%% M<'"'+((\8"Z1O"N&ZV6C=;.0\"I*%)../Q38C.]UDL'@-/*D+';"1BD,F!Z2VW[\Q= M.%7[&78^]?%39*\!]J$3\5-X@(6B"L&5,%-O-Q4BJH"(MMYK*TQ4 1.*);J" M"*.G$%$!1+3U>E)})7N8_'"94JL,).)>0J%VKG +C%2A^QYRL]QG&?_8'X M[PTEYLN"QK%3PRKO8>< ^,0>G5$\FDKTJN3 YHW* M'9-$B7*"J"6,Q[- ;L\#,AVZ2\J(L*P^S#A6Z? @'%_ #NTZ,UP+2-'P,]+@C M W:/*7&<*AR=)38VKQ)N\|?$XDM:.^1+XJP$,*6MW"]:N(=CMGIS_1MPXFNQ M?\/FHZR_Q>Y$,[13C3{(cC|-TEA^ULKKPA16J3;WT^.3NG<>.Z%6F-Q&[3\ M3L8!IX)SN$8S.YU:K]4J.RQ^.(BF:M-=;^>'TBI&]Y]B&SW]\.CU6;V92S%. M]YX>E 1;SZRL.J*II9E9QFZ%K;AKY#V;G?<@$7\6WV-32C02Y>V#R%-HWHGN]{Z(;,R"+S9!$-GK\Ff/ FU\82[MDE#;L>:J@*R3;?]4!S{&=W+QF&@]38['$,Y3P<4_"8I0\O-J4/U MR$\NE,*]^,[3CVA MJ??+L+H$N9T'5#()4A!%T=V0VQ9MT%_]E/_IN4O&VL,Y M%85+=, ,- U#M8B9#!]AEINKFF74:XB]\SM(9CY_E=*\&,O[O 8?KL)*= -L]YN=.3UNYO9 MTM"U9)D:K.&,1*UFM5 %UM+3P%LK.L1*1V6.QRZ(=2#X2LTRD]3. M[%BM@=GNW/7:_;9N\0*V?+]\N;L[>7]S^Z]WE MS?G'SS=?KY%,NW5XP\[)M*EKN#Y-+%#+5JC(<_(\Y"GG[?5]',U_?SHIY]+ M!61. {3[K}>P[R[0&=\U>]WG7;_3[=QW6X[S'ZW;/*"]@S[>_7EQ??KW_?/WI M[/;R\]5=NPGF5GOGNJ>E:[0T+5O;2]US=8Q:Y^_.'"9Q(I"Q%B7*DDEPVFW M:.XO'>.=\A]6[M()_M^EI-]__Z3\.-AC^M^%P?)+27A9$V<$()+@8.W/F 41 MCF[^N.:(09BK> 3/LC0:DO887:/ eEO)+,OKW!EWZ G?W?IWO;M&?0?QE=G7Y M[XNO__[CKV^\;5T% [0}&=/KYX94F!M#]XY7SB*3C@R3R!LP-^2O-8R/8&[?L M-]>QXUZOV62;\)))}=S\4=@6M\^FOWV MQW?WKW[&@!'@+;_HGW>TB2O? 6[V/NW^=7MW]]^\#@7Z;Y_E_U+U]^ATW$P/SP""R5W"8T\-G&=.P@D>QKQ[/@(U3B/BF0;WG*Z\DC-K M. U#?A^[(FYR<_1/[3+B(ZU9[U;*+)=*N]ZJFRV[W;EK#)K-NZ9AL[M>EX'K MY*SW>:O1{=}]1D%I7_SOKY>_7-[>W/4:1L?H[EQ9MW5+-]EJGB%=V%H_IZ3M M*9KK5ND8AM[:0GE<80<=LFP+D4+QU?H$=?>R\$ZUB2%,2M(LK1)8HH)D95PHF>#@OU M]M."/>"%&;K3\JY,X;8),(K])M%% M<'"'+((\8"Z1O"N&ZV6C=;.0\"I*%)../Q38C.]UDL'@-/*D+';"1BD,F!Z2VW[\Q= M.%7[&78^]?%39*\!]J$3\5-X@(6B"L&5,%-O-Q4BJH"(MMYK*TQ4 1.*);J" M"*.G$%$!1+3U>E)})7N8_'"94JL,).)>0J%VKG +C%2A^QYRL]QG&?_8'X M[PTEYLN"QK%3PRKO8>< ^,0>G5$\FDKTJN3 YHW* M'9-$B7*"J"6,Q[- ;L\#,AVZ2\J(L*P^S#A6Z? @'%_ #NTZ,UP+2-'P,]+@C M W:/*7&<*AR=)38VKQ)N\|?$XDM:.^1+XJP$,*6MW"]:N(=CMGIS_1MPXFNQ M?\/FHZR_Q>Y$,[13C3{(cC|-TEA^ULKKPA16J3;WT^.3NG<>.Z%6F-Q&[3\ M3L8!IX)SN$8S.YU:K]4J.RQ^.(BF:M-=;^>'TBI&]Y]B&SW]\.CU6;V92S%. M]YX>E 1;SZRL.J*II9E9QFZ%K;AKY#V;G?<@$7\6WV-32C02Y>V#R%-HWHGN]{Z(;,R"+S9!$-GK\Ff/ FU\82[MDE#;L>:J@*R3;?]4!S{&=W+QF&@]38['$,Y3P<4_"8I0\O-J4/U MR$\UN

*{ESH*YV=ZLSM#^^[D#YQTO.&\=2} /\,Z[>8A: LZ#_[;!=__/=^-O MF@,JH>FZ6ME__]1SU+9XCPCO0"^(56H8SVY+2*\E$#H_0?:I*,9Q\)]A3"<* M;Y4_\']6@N9N%CZI@%::*

^L5&@Z'!8@2CRTE',0DDG\F\/,X\,=)3N0*IX.- M'WEPEM<>:FJRJZQ:+8S_]3(&UV)'F^I-@X]>MC#UQ$.+Z*YL]_>4#_[G_$5 MP,:.!Q'"#@.?(P;]^G_GA{1"_^QGQ&.&]0I@)W'4Y '9*:I.E\@Y=3&?()', MFRA2TYI3]>HHT=9!QX0S7SU&Z-C3QP@.0V&V#]US73(TV^;3B'$EWOHR^^7\49' GQK^=)LNN$V79(2,FT! M*J *8#H&,)YN2:Y2PIED'*?PAP@)55'16& 9>*

<2JEEC9TTLRS::!:G#*^5_]__MMS34>)3Q4=GM?=$-,ZY,I[9TL'^$)>]'+'#*)};BE29P^2MNBC:*L KG88M

M0'RDKN$469=T4^."7H.C)S!P=JFVNV>H5G%/Z68!F=]6&$^'9VB'",.KC%J0 M'*%I]'W:lU%W5UC)M:T/)5 3&+E30JUK;TV'MYL$E[;'NRZ%S6!(+_BM"YP><

MA"I@H(9Y7ABONV4AB_WQ5G&[-^@([LGA'!+,;GET"W!E#L_N O8/940A2;P MH7FN^ (6B_-V+OQ>VH+A$/16U$R5" M,)G$@OY#8?-P,A82U#\E1N\(3M/V

_W*\^:Y6[F&:5P)9:CA>9* "P0[/#-) MV;2.1_3JZ'D5').%L$'R!^F8^C\Z30*D\&&%Q%*. 0)9WA@,%6/.N_*!02 MXMBEERM+]9W8A@^LC8BHGAGV![I5]*=>2!_:*

<^{11}X3"@6DA8J;NR/A/_$>$U^3+\.S:\G?!:35CA.| &.1O6 M-$8HQ&M%\IOTE+OH B*Z4EDFB7G+-A8K3%74 MCA_7Z3,]Y>$N@+F=,!"+"@.=IOH(>@+!Q.AA

W^&A2@161{J8,5TYD]P)=EX MS&A?BY7$5UCPFN$,WP5]SEW%*UWB=XL<9'PVTACZ,&(Q I=Z,*28#=+Q(Y7 MD]]ZA?'A]8.)F_HQ5MB>1;BR-./+QHI=NP\&,/'0-

9]/Z_P2BU$B9D9YB#&: M%Q(W^80?5,Z=A%^)^$,H?+4AB%FY<6!0,-*HL*62$);[,:-. M*>Z@G('P2&Z^E;6{BR&E/3,%R;26&8(\)(C6I$5UKH77A-28O5P0S1GS-->JN

MU00TF.^2Q>0\K>0LDFEWFJU'--VZT)%V7#/9.B/50?TOMJ MEKY^1$'J0A7 @^B>QI0$ PW.$?Z%89J&M,M5P;=.N=TJ14'^#/;5!ZCMTUB#0^1&3

@#@%4J9BT0%K;K>WJ*XO1{MJZ"2:1W4IH(WFUMK*2(:DSI+?1L'5=L$*H M0GD1#K@RFT,NNX228WTB]B)%THO7O.0.*+YRHQIDCF!=DFV" L8Y/GSG$4

M5&1H5FGP"'7;51D=EE[VPYV;8^(*3:+0MO:W'>2&59Z&M@@;F6A4V%X$\+$^< M5\GLM]G2(E_!W#EOZ2V,G70+^]& ,RP.M5<,BV97AZL+W. JRZAZ7Q:%HBA;

M95EJ46@1#*CP/EQ=$M]5KD&]]PK(X:>7 1Z(*ZAQID3IA5M MIOESV=1U+6X35.4X-PGSBWIJ+,]=X&-

>D&\KAES%#5B..&LB9CB!)U5NWC&$17=4R!02T6/ZY(0&KPLR9=UEM9M3IL@2R*XJB5VBU5D[B

M,^&$ZW@[NCJE2WD[UK%V\&S3T,NU&4&+R;$K56C22&%A@NSP1%2_#@D"/_[W M+(@Q&"*B8=7JH 1?Z3,,/1#,9"CB!Y)5/0@%XX(?#I@(2I0RP64@AC^=1QSZ

M#*L|\)@)92?!PY=63CWNK*7]2H1NR^JKJ.)SU:<(>LT17.JZ"F}E"PGD! MVWH5KJO6*?2$S,,CU=M#@99,U2HN[;ID]>SY54"\>)U=W9@4QB*L3*%&/S6U MV[H,W2XQ?X/$?

+M+S.\2\[O$_$X3/P)-W#A&31SU:7P;=>!E*2D!(\82R0P M:!"%HP":Y KW]6*\H%8F>XL'"XL U8F 5BDO1/0Z.+ZPY>;ZT\??R\R M2.'7N4Q1SF11OZ@/*\55]..=H2<3L/H"YXT

KV;VAG_]\S4K!QHSZ[%SY#4=^ M'P5D#R"B*)KUTUZA%I%2?!RA%]]]JHM140J/Y5*NN_A^-7%Z MGBY}C?)> F\M4-)+]3LKE'M1?R7WEPF?.PS#R)3S)BV<[9O.SO=>UE,)_M5:

M@)/@I[=5D:8O@D:KEY;$Q8-VM*Z;2UF?*\<'=T2,3.KXHI=4SR6V+[?TE1" MR9DI'G1;6?S6ROX*3/>+MG)AHC84C"\'_-C;DV\A&:]C&XE!B]:PL*RSDB(Q.

MPZJOWE07;O@!C!RS949.U680F0!S*0I9 ->?<+!E&@]F'$DH= ,9MH.=&K-,&-PCL.4E9+G!$J+!P(VN1!ES5K6D8+W;]>K,3UC'KH9!@.#?#ZU> M^R0?

A%.G[,!XDDYW&N0/H$%:+=,@>:6-@@=VBF@2T/Q\JLV1>VOS8AFS_K\]P M"Y4K9\5,TU[F A_<^>$M2Q,^QE<2-O5C3&.>RY85;"F8=3T;"\VTS{'Q+7(

M@FEE7_D/K\NMES(21M=!:H_JE_OHQ#.WR4@Q=PI5%M-XT- W*G&H50A$)8A M:AY:]9&E'239MX;.'3685U9:X?1OS6S1%HF-VV.UF\QD1P\7>U

MG8(TWU=8+U5+..*!#*A!5565>H/.W@G (%]>BVUNBDH*0WP[]<33X]GJOF2E> MX#P+&C%20MU0SQWL]0)]I%#?HSXV&(X/_2V*V<"74?0/01A,9A/E\RP&?2!A

MRL4DFH4IS|>>@XBT]88NJ),'"*5>)47U5'KMR'11B:,W**BC&M*_5>WA7E M176'$MM;.0AT>G]5[!?.M=,H+\F+*OP88T&BJ1]H.+_]0&.1]TQ354P/KO-L M^&@L#NC'O, ?MYDI?

T32HV$01]R_376PA.]JJA.BE*%DTEI-]M94S_RXN4)Z M/N+RQN/H(7FUHI;>4ZID&ZC4*WTF+2HPM%*Q.V.AH7F#U.*T.M,UVU_:8IEK M.:IEA1YL#B\?AM5MKN@B'5ZT!0Z/ '"1O,1-

#9>RLD]2)4#I%IT&58;%@Y M7895EV%QN5CCGAW\F<)%7W2R3=+)9^,IA_I+Y?[N_Z=8M 8N=W:\E,5NNK>X8$M!;'0@3

,K.4*IJOM+$-31*L M"I^JL-0,FV(%LN+=,6K'1MLUX3Q0XI+YP=&1A6-U'(%+&59RBMR?G?[>Z>]S M^KMU$OJ[0)-]N8OBU+]M*G/Q:M1#CC@_?.18N-XB\!EUM 0Z"Q!SELQ&HV

0 M(+@,]*@)8_@W]<>.VF :, QLNY-HR2= M(EQQ*9_@HH32*%0"G/N'4!D&R2!FN %Y5:H$D8U)D,[XGIRK@A9&*8(:QP&7 MG M:1O,.=\M@[>3I*>,/HR1A\?H3V

^$^PARA1"9'SAV3XT(/S)R_&LYCG M'Y:R86F#]1#@Y*)99"):=C2#OH!N3*6.8@-#*V%2#%+\H_\5C=/Z8_59 9ER? M3]H@@N?

_>X8S"F]LTM6SM0]'Z"7. ^R"Z1Q*8&)M+88CW+)Q18V!2C; ^6H%6 M,>83RFO4P<-%5A4],.5S@Y7 H&V^*+);/DP1Q{PR%BHTX_AO7)!SY8*3/_+O

M5[8R!X)&@\$LCMFP5^+$>0A@9<7YO*6>P7>3"$>60+?]02K8)C&,R<);, ZL M]E$,AWLX?N1[. ;]1[Z=(!114ES5,58;*RTFK N?H(5=%-X 7I&T:A3R1 ^81 M2Q1

QUNY2FVMJ57&]QBJ(Y#LEJ.VTAJK%]?(*EB!"DG ^=X,*R]B:*$;0-+5. M8\C>ZM(>_:>#*> |>@(X"7EF[B&-"H=0=>VT"@OA/>{9,E1/1X,+?$0MI5< MZ8=+H:K*D^-

+H6KY(\4T3!@HGFIHW#0I(*QZ9%B+Z+>NF39_WU4E0:4FN,TD M]2TAB->U=51SN&BXGPR"W! T1Y+F3E8<'05M10#_B&J!,GU<4 MR7)%.5OY@G3X3)D47/"J2QSQV?

8D8EQ0/HE(O/X5WU"+WX8%O3HY H)I.*[M MO){?*3E#ITEU PV5HJOBC&8[2=-- >XUBFSK66:6J1*.5>!E,8,Y__VF%$P= M\]K:W?

33+]Y&\^$[YK6.>:UC7]N;^&%*U*)X,+GS8+77C#1G*A>5XCEI>P:*;=:C2#OH!N3*6.8@-#*V%2#%+\H_\5C=/Z8_59 9ER? M3]H@@N?

_>X8S"F]LTM6SM0]'Z"7. ^R"Z1Q*8&)M+88CW+)Q18V!2C; ^6H%6 M,>83RFO4P<-%5A4],.5S@Y7 H&V^*+);/DP1Q{PR%BHTX_AO7)!SY8*3/_+O

M5[8R!X)&@\$LCMFP5^+$>0A@9<7YO*6>P7>3"$>60+?]02K8)C&,R<);, ZL M]E$,AWLX?N1[. ;]1[Z=(!114ES5,58;*RTFK N?H(5=%-X 7I&T:A3R1 ^81 M2Q1

QUNY2FVMJ57&]QBJ(Y#LEJ.VTAJK%]?(*EB!"DG ^=X,*R]B:*$;0-+5. M8\C>ZM(>_:>#*> |>@(X"7EF[B&-"H=0=>VT"@OA/>{9,E1/1X,+?$0MI5< MZ8=+H:K*D^-

+H6KY(\4T3!@HGFIHWW

MX&I^<^BFX_#/54\K56CJ(#D=),=$(#F"3M#?F,)IH0!\-E^*R)!T_*19KB96 MJ=24P:-5W=YQ!D3]!%PDBK<(1L,LW*>6&,CFPX%SCY8SX[Q&LWS/F1%16KJ" MBGM($#"ZIDT9(Y4:"3NR!JX)$>[.X;8KCI-(L&2(+[L>%I)=;5L"D78^5D40 M37#'[Z8_I_R1=?.K"]8W1Q2*$_<,WG<%S9=72L;@M&!=S.O ,2^M}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}G?L5/_& ;E:=!3GE?W1W@3"3L6V$F#&LV5W1V!}KO!16H@C-:>IS MY9'YL#(8/&+A>@$>F%NT47HXA"&G5Y-)CX"tPVK6 *+O6I[5'$$VL\BF0>74R78\Q\0!6_;%-7>7 M]C%=VJU+!$E@=_10H+++P%LM,>BDBH<"SS L"%VXM/B7FQ.UXW%S%V33%[0" MK\7OEZ9L5;*3JE""I,_;R!8NALA58.MU(#="FIOK$6!\B}^2(TO[AF1B$HTZ5?[9M^97? I5UWZUM<'XZU26$8T&'Z}GD9,%*9XX?95*&OK9\Q%/,%3=WK#'K M#>PT1HQ%TP+L/84;DX/R!X7S3E47V"!FJ4(Y$B-LAH-=8!$&=PH8ITJ?,5Y. MFB<7,&'B'0]'{#'T+@W&4Y6DQ1O9LWOP#G0'_>;H\ WEJYZ$YU?ZFI'C13%T M!UZ"B8C$2J*.=GH'RLCM';Q+Y2,B465@\8B1* ++2*11PRE5AA/0S+&L=CA_S MJ@(I9E^$#"M1^#%_GWU'4A%J[?,LAEN.+:K8N;PK&+B5D\6MZ_Q"IG,C%S3 M.VYO+Y{=O":''&SB3^"+##N%71SX,>OQ[(DP4GAE]/0.2Y 7:YA7O\VC'9R' MM? A4+.\ALAN6=AGS(7#Y$MQG08J=2E8WQ}-"*E39XK'(2%<2F6I*NF8L%N M$E.S(*2S] F>=P$/B2->[UP9QCYFE20]S'+Q>\J$33!39^B+>B?YL&&33N\> M$Y1DF,LQH3KM/'DH6CEA1^QJV!8[9EG"^O$s:Y8$P(MHO(P,6#HODV>XCO 6 MR.^1,@? ++N*XP.IUBI#&.:"[+*.@"4BB[AH[%WKS&GQE7;!=@:6W^*-R:'(% MXZ^*M))L*B3FWG#=XOO"4,-TRBI3M-SA85*\Q+1I2BS=$4!9@2HOJC_5[^_& M(K^LR[J>FE5LN*'7@G=O93)W5P[9MD0J^UO-.1= MO&9976'4T9.K@$/G{[LBYBAQI'- #%,5Y98D66=]T99?IX,DBI*5=8KGD23-1 M:K!8J0#+&SM6;JA6B=F-]M@6<&9)1OK\&<@@V M MWJN%!+""FW6WT.^[=V2<6R9"9<)WV3UDTH+))%,B O/+P@LJ["GU^W-7%B[MY;R6JC"7E6L]@GQ!/^B^RRX7\3N=A+R!'=WQGK-$K@IWT.]:HM6CV;((WP:= M$;YW<_T>.HQS5'B,-E%OJMZ@W=2=;16OGWZIKVS=<@]/4?T\;'VYK'0<:,JP M(DK*!G1'\!F-QYG- +8,K(6=N^2.BIR2# M)\\"@;*MS!Z&+/A+5A!^,\?=]49 0-A:0?PF^QXD{JN#=T?$,"+455))%$ OWN^5KG)-=.R M1$3_Q1B&WB#*A9V-M%61:Y.] 8A$ ^ MBNNU.+*#8Q8O@:$ 6X,_Q#@"OZ'GG%&5UB('0LO%8W^/ MH+OH9\H,[E(B6&9KR&'GR&@%1+]EZ#*^^$'J_,:R!T*31 M=9A.17,[_GI_$]$7)S>ZEY6!>R;VK1QML29H^S2M;EZ-(?]=*[%XX?FY_YEK M8I*ZY(X/G"9B6,&CQ_+TJ-I4&3IY8YPVV_.M'&A:3';CN;7=^&CE_-J9_*CF M 4KF?8B>AK(#A)V\]WU!M/RT;:<+^HC&0V,UH\0CO+'K%:[O%AK_^J@A9S^< M77_3-%&QT7=X"C P]-{)\7>]?U*5&-+W:NHXUVA%N#QJMM8Z.) GTX\K2 M0-9ZFI*

QP#0%F3#.S>@\821 7C8JS1DRA: 3.EB M;X?MFO&F=H%'NR3?T"]KP3%U;R920!3AO/+-#Q@5)>.8E<>6F%!?@F%!@:\L M?Z!MOJDXR73V2SK[/TSGRA&N]S)
}@F28(3G/S8A;MEN7[0HL5#E:YIV7I<)6 M;X4*Z>Z&4>$)4Z ,@-"D =]FK"IF*!Y-U?I#,%48,T![=B6;?(A4P@00:N & MQ@ &>K'8S(,5L$7H4PR?;.$>Z"/+/A90K&:A%9[D$
:!+J$W#,W6%0Z5MSC M5']4@-L]!NK&RL!FPBNSL[<<\A-QR'BS.63M M&&"%2M;/'M9F%&"A6^XA45 E8K- J0*2P3((L@>57HYDX!9.+0HP3[KOLLAK
M!O0&SY:22ET+9103'=YE"B6I3(!/E,GK7!>VGA'%%0F+(9T+01:@3,L0;[" M+FFL+74 K_$$ J(M>6S)X_'DX6X.>0QO:9@:.+XW(8K(/7+PU'S-U3[EBG]JM M$778P_LK&
(8K8"!$#,K62<:PSE^68)VXB,Y(,RP"^=\NCY)Q7EXR],>L)4"> M/DZ^A?L6[H^&N[=I<#^Q2%I%)-X@R6H YLR]L'] A(YA'#=5"+N"@'[/,-& M0FEHQV<*8"X%)B?_V'N<9.
<+0WP@$/#=2[TSP5V M,FW@[=]XG0NUZZ5*JJ MGMV@US>$PSP3#AE[9*'*C(3\AH79C9ZE_M5'E^B%269;M]CP*NW>KU&E-0\L M>#G+5!<^%EU^$>D+=XM8?4#6LE)
[F(M&4X]K(=4\43 -,&44<:T9^TI ,Q:0 MBN!YCX-!9[(=X -(`Q3&)_ ?J¥B;%_4@[B%)*8]?F\AO>SX(MSUG=SM[M&\3;R'\+|E^T2CB - ^7X!&K #EFG#B UCQBE*&[:N-
C'M^*\)9AD!S32?:D ME,S\/HN24,P8G)T&PCI[6N(.P/J39!#U'^=-%QU[Z\-NY0T(Q&W?#P75]F,9 M"2T6]8L K[7JW;TF_/06$,E>NZCW]EYG^^R@6^_NO\Y?N#"[\VT%QU=RW*\%
M9FL$!$Y@-PF^J(S+ DM=?OBC^#2(%0=;"@ UJ,ROFLW6RM ZW_E+>+(FR&;I M]NJ]-Z^+JJ&$DX)A" /CML%G:O(UR8]KB$IG#*[DIC8%(WSS=94",\VITK$2
M8:K9DJ+V%9KL;QG;7]-PK}[L_=(*=MOU5O=7T]#PO?4P]=[!#}1N5:7<=995 M>SPKMM9DQ=;ZK+AB;T/D93_^*9X0:WMV1-PE@XYA^6,QN"Y]JL$WQHLZ?QT MU/
TVI48?,_>3NY[E:?TA)_M] "KO)LYWVF"C#PRAY5[Q^2.F,<'R*NF^7EV M&SWLW:.EX*O\JE-#-FI6.>%-_Z*GNL2P'[@ M7^B]:8A_B)YK]/2_P>ZRP8=#=(G6+U"\A=:/! M>!QPYI/W\JK
A;W1L(7D%I*_HG8_R1W+NWS<(#&!2ZQ]#Y8/#*7P73W_Q&G M>8FRF/=NR,V_E2^-*7U12[$VV7F.XL+]6>>Z1=A"C9MKF,']G@$,"]4+EZ@
MP1*ID$X>G!9L4CZ15790BY#'K)8=Y^%LZ6MSRN7;4MO\&WD2.F$U6P6B/EC" MH;>"Y[<^]@_JW=8\C+9M35.^LM_T8[XZZ.A_4$L#!!0 (%2"9UD0:T"& MT@8 /DE 8
86UP:"TR,#(T,#DS,'AE>#,R9#$N:'1M[5IM4]LX$/XK MNG3:PDS\EA<(3LI,&LPU/1K2Q-RU]Z6CV"*LJ6VYLDS(_?I;63$X0"GT@$M;M\B&)};*
[>G8E/=*Z]YNF.4F($X_XZ(W[[@CYS,MCD@CD<8(%E"ZH")'+TA0G MZ!WAG$81>LVI/R<(6::^HUN-MFYJVGX/9 U6G5AB(LR=HV&V6@A<\=N-&RS M@\;OT-:).]@N6A\
<#]R/8T>I'9^\/AH.4$TSC+^: \,X<]414LW+>1RG&14 M4);@R#"<40W50B%2VS 6BX6^:.J,SPUW8H0BCEI&Q%A&=%_XM?V>+(%O@OW] M7DP$1EZ(>4,$]]})>ZAUH(6@(B+
[/:A56UGS%_N]WQZBC*QC,BK6HSYG":: M8*G=-%/1A9X&5%]JF/OHHS3>7A1R-3@ M,$XB+.@ID=(KHP3'H /BY9/U MJ27AP.#;FNH%48Y8Y$/79RSD,ZH>/',VC&[S89N]8P9}$H?
R6#9NM1S2C,P M):)B:8?4]TD"#5X\ZS3,9K=GR(8/9)<'$XOP2X;=A-G F;C#P^&@[PZ/1U-T M?(C&D^%H,!SWCY#SP1FH?'(]=YP!5#2_-W3-W-LA8B
'WC8.F_NR95MT6RWK$JOW.>80TM$234C*..''6H$/&8V +VGL)HFRT@AX%C!?/7U0G M1$")CZ8D%22>P7/3K*.'0U3]IN26;D-!'H$R#R1&X#-%6&1K3K[DE!/)9C*I M=TH\N5
7.0&A5T 38*BR' 3Z!>&1X,M6>:1\RU+'"'YW9Y0C#HGCT0716]"I# M#GI0YF>@VX<% EBKON'>O,((%*@>]=]'6=4 M9+0-?%)(HBW]9Q?_H)Y\V(**
[:XBG7L=O;7SO*2GQ0[VJB9E2R*-9Q$I#9PQ M#LNSYK$HPFE&[/)/%:<=0"}4>YNDM3)8 *YUVBS16N?,LJ3"@*5B7FI=2,,4 MQ,(_!U@NZ+)K/9<(/K>T]O=%\7G7-
2EGH@KF%>$,! +LB})=Y;.VX#BU M9W (^]PM (%O,OOS>CS+6)0+TI4'C*M#_.]!>7,$7HK>6P:D.@"MOH5_*\2, M^N[.$^!5P!\8;TLW6T^_/Q[@;7VO_83W/>%M""[7]QN 5UO=;9?
S1UY';_L' ML(/:.3N+.CLKF*S:V.^,;{6AO>MM?.^1K>V_^[C6O/JU5^HZE&=T#E]=+^ M7@C452S"6[^K^1N2$NKH!SVU7C=BO%'5C?AM*M>Z)8/_CH MUE8
N;EMWO2_37%T=5YN_XH3TRAN5==/QC]5:NE* M7B]@G,P9N*A,PWDJET S-".R.,AY0K.0^)+TD6@I08. &,6D]HU-$B)/#,48Q]F9F4 M@,E$%@YD JW,=12Y3!;40>X<94
MVO7*QZZCP/,DP _X^YRQ/ M?)G>8-PN3QT53-8K5O=\T%H571VOM!E]\]2L%-FKH3+)QN MXU-&_17]NWMZRSH_'ZDRLWA=2,W35+PDM?\O4$L#!!0 (%2"9UGDVT-B MRP8
/HE 8 86UP:"TR,#(T,#DS,'AE>#,R9#(N:'1M[5IM4]LX$/XK MNG3:PDS\EA!(G)29-(11;B!)$S-M^]V'&LJ6ZZL$'*__E9^ 0K97>F1UKV_-&T8ASCVB(\^.*,B*Q1)X@6$+IBLH0.3Q)<(Q.
MB1"4,?1>4'1!$+),?5^W&BW=U+3#'L@:%)UX;"/+,@Z,AMG80^:^W6C85AM-_M3]'.F3/8S5H?3O;.E^DP'W9ZJOYD-$ US3_^-0>&<>0ZH$_A/L'_8B
M(C'R0BQ2(M_5SIQCK0TM)>6,'/:,\C=OZW)_?=CSZ3E*Y9J1=[4(BP6--(UC8++I=A]_H0M_5,RGX!CZ46X(BRM?W6H1%)T9BLT(Q'.'Y; MSTO@-R6"!F^[6>N4_D- -
$Q0D@NI8487(%PIV\T1L(O)NQN#K$@V'Y^3&:[J\>=5NF,UN MSU -GT@O#T*(B =@-AC.G-'Q:-!W11/Q'$V.T70V&@]&T_X).AZ-^_ (3Y-C M:#*#]9[>C:;G_7'#G(F""+\3)_K QW-
AP,U#V0U6V9]B[3MSU'_:#)U MAD>HJGBI,L?<#T,T[_>|\?#N3;Y?#+\@OH#1WE'PS0?.ZRV)(HV MU'!"@I.Q3T0*$*J-)OBH1P3\HGZ4A#B56* IK.D1[LA24@^SM(Y&L:>C'0E]
ME98-LSO@$>Q?Z^S-ZN[644@$<=<(1$D:4))}$>]@TM2J:2G2R\L1U/=K(-N MBK[&?,4(;'W0/,32_OW S_R5 N"QM!M-W;]NV0[=S9=UA=7')1;@TFR-9B3A M G"+T3$7$? "
[:,"434]H$;P AA"#.2F[V5^8'6:>PC'_C-BO,W6KYJ?QF#3"'"M,P2:QQ%1% M*(TS2 N/"#!5_1$(DBKCU%4U!@8)W4 #S,!T:0)V40$(O0(: Q=5Y2#0SZB- M
E^U6K+YA6&:O/HA.LUZERT$/ROT4QO9A@0!^JF^Y-6]POYSF M!
(S#HE.E/!J00LDCVR)169*S3;W=NHT=YK2S!=MKZW_[HDHMD.]JZF9"O*C%U&2@5=+F!YUCS.&$Y28IB&B9^D'[M==4TQ6"EF2J85X1S$ BPKTISE>_:2N#$=N&X\U5;
0(_Y//"7]=A-.5M*TE5' MB9M3_.]:>;<'7O/>>SID?M0I_DO_7H@W]7;G!? JX$^,=T=O[K_GR M_1. MZP7O1\+/D$*M[W< GV]U]UW.GWD=K1T>P0YJHS&8,Z.S!SF;W9CSG7ZU,;T?
MK9V/;N-_?= ;]QZ7]WR&RUO] !4WJ_MGX4@7\X*>E'RG.0"@;-3'[TRL[\GMQ^AA!_BKJ=]RGC=2 WT.G9R,^J?H;QU-A\YP-K\\PS\ FGSA^1XR&9]+L% , MZ_]&YP[?N 0?
5>.^ZT6#V!^6TJY'HEF_>*SVU@%U :W?4O G0O@)\H8Q5$6 M\ 3ZIC^#PH^8QA,;^''52_ZQ(W>I@'(24!.CX\|)IDM_OOH3D2TC^EK/[!4)R
M9RHH!&,"T7@5E^KRMN]Y?!E+T+8,T]T_4Z-[+)U\|#\6V6<;J3[B[(@BN[M%]DY+T\QT!2Y1!4'2Q'3-"2^XH&$K57]#GM>D06H)!^214B7&.8%#:YRTRJ! M<=#-
,M.9HX';2,0GR(<98FNC:% '5>E3SP. M0XCL@QEWC00)"!S:,%6C9J1R9F $4&HSSU%'JY# NT 1]E7"4@&F\ELX4'FU M,@62I3AY4
>Y"RQ\1M)L*DKL@L1$0)A=::#P9:#_$B_4\'GV,Q]=K]S7?.^, ME&HJHOD4-U"W7TW<)^K:Y5$S]{&!' G>S]Q2A9>Y!Q=[7Q<'"%B=?93VXL,N# M2 63S8KB^D_- B E6O%>'ETVOA
JBC8^$+K^\5$"9M+RJ\+,Z#8^Y]0O4#_H MZ'O6Y9$1+S.S[Y7RCYJRKZ0._P502P$'"% ,4 "_!4@F=92IE[R:\8 !S M @$ $0 @ $ 86UP:"TR,#(T,#DS,"YX& 86UP:"TR M,#
(T,#DS,%]C86PN>&UL4$L! A0#% @ 5()G62Z9"1=N10 R7H$!4 M (!9BP &%M<&@M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0 M (%2"9UFBNDLH_HX !C&UL4$L! A0#% M @
5()G64*NDHQ)3 , H0PM !4 (!UF0! &%M<&@M,C R M-# Y,S!X,3!Q+FAT,5!+ 0(4 Q0 (%2"9UEO_ABHL1$ *;&5X,3!D,2YH=&U02P$'% ,4 M " !4@F=9A1!$<5 * !H2@ & @ $Z0P4
86UP:"TR M,#(T,#DS,'AE>#,Q9#$N:'1M4$L! A0#% @ 5()G6,@3M$MM"@ -#TD M !@ (!P$T% &%M<&@M,C R-# Y,S!X97@S,60R+FAT,5!+ M 0(4 Q0 (%2"9UD0:T"&T@8 /DE 8 -"
6-8!0!A M,7!H+3(P,C0P.3,P>&5X,S)D,2YH=&U02P$'% ,4 " !4@F=9Y-M#8LL& M #Z)0 & @ %K7P4 86UP:"TR,#(T,#DS,'AE>#,R9#(N 9:'1M4$L%!@ + L [(&QF!0 $! end XML
102 amph-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001297184 us-gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0001297184
amph:November2014ShareRepurchasePlanMember 2024-07-012024-09-30 0001297184 amph:November2014ShareRepurchasePlanMember 2024-01-012024-09-30
0001297184 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0001297184 amph:November2014ShareRepurchasePlanMember 2023-07-012023-09-30
0001297184 amph:November2014ShareRepurchasePlanMember 2023-01-012023-09-30 0001297184 us-gaap:TreasuryStockCommonMember 2023-01-012023-03-31
0001297184 amph:November2014ShareRepurchasePlanMemberus-gaap:SubsequentEventMember 2024-11-04 0001297184
amph:November2014ShareRepurchasePlanMember 2024-06-03 0001297184 us-gaap:TreasuryStockCommonMember 2024-04-012024-06-30 0001297184 us-
gaap:TreasuryStockCommonMember 2024-01-012024-03-31 0001297184 us-gaap:TreasuryStockCommonMember 2023-04-012023-06-30 0001297184 us-
gaap:CommonStockMember 2024-07-012024-09-30 0001297184 us-gaap:CommonStockMember 2024-04-012024-06-30 0001297184 us-gaap:CommonStockMember 2024-01-
012024-03-31 0001297184 us-gaap:CommonStockMember 2023-07-012023-09-30 0001297184 us-gaap:CommonStockMember 2023-04-012023-06-30 0001297184 us-
gaap:CommonStockMember 2023-01-012023-03-31 0001297184 2024-06-30 0001297184 2024-03-31 0001297184 2023-06-30 0001297184 2023-03-31 0001297184 us-
gaap:RetainedEarningsMember 2024-09-30 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001297184 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001297184 us-gaap:RetainedEarningsMember 2024-06-30 0001297184 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001297184 us-
gaap:RetainedEarningsMember 2024-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001297184 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001297184 us-gaap:RetainedEarningsMember 2023-12-31 0001297184 us-
gaap:AdditionalPaidInCapitalMember 2023-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001297184 us-
gaap:RetainedEarningsMember 2023-09-30 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001297184 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001297184 us-gaap:RetainedEarningsMember 2023-06-30 0001297184 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001297184 us-
gaap:RetainedEarningsMember 2023-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001297184 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001297184 us-gaap:RetainedEarningsMember 2022-12-31 0001297184 us-
gaap:AdditionalPaidInCapitalMember 2022-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001297184
amph:EmployeeStockPurchasePlan2014Member 2024-09-30 0001297184 amph:The2015EquityIncentivePlanMember 2024-09-30 0001297184 us-
gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember 2024-07-012024-09-30
0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember 2024-07-012024-09-30 0001297184
amph:ResearchAndDevelopmentServicesMemberamph:AnpMember 2024-07-012024-09-30 0001297184
amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMemberamph:AnpMember 2024-07-012024-09-30 0001297184 us-gaap:ProductMember 2024-07-012024-09-30
0001297184 us-gaap:ProductAndServiceOtherMember 2024-07-012024-09-30 0001297184 country:US 2024-07-012024-09-30 0001297184 country:FR 2024-07-012024-09-30
0001297184 country:CN 2024-07-012024-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember 2024-01-012024-09-30
0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember 2024-01-012024-09-30 0001297184
amph:ResearchAndDevelopmentServicesMemberamph:AnpMember 2024-01-012024-09-30 0001297184
amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMemberamph:AnpMember 2024-01-012024-09-30 0001297184 us-gaap:ProductMember 2024-01-012024-09-30
0001297184 us-gaap:ProductAndServiceOtherMember 2024-01-012024-09-30 0001297184 country:US 2024-01-012024-09-30 0001297184 country:FR 2024-01-012024-09-30
0001297184 country:CN 2024-01-012024-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember 2023-07-012023-09-30
0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember 2023-07-012023-09-30 0001297184
amph:ResearchAndDevelopmentServicesMemberamph:AnpMember 2023-07-012023-09-30 0001297184
amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMemberamph:AnpMember 2023-07-012023-09-30 0001297184 us-gaap:ProductMember 2023-07-012023-09-30
0001297184 us-gaap:ProductAndServiceOtherMember 2023-07-012023-09-30 0001297184 country:US 2023-07-012023-09-30 0001297184 country:FR 2023-07-012023-09-30
0001297184 country:CN 2023-07-012023-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember 2023-01-012023-09-30
0001297184 amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:FinishedPharmaceuticalProductsNetRevenuesMember 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiNebMember 2023-01-012023-09-30 0001297184

amph:FinishedPharmaceuticalProductsSegmentMemberamph:BaqsimiMember 2023-01-012023-09-30 0001297184
amph:ResearchAndDevelopmentServicesMemberamph:AnpMember 2023-01-012023-09-30 0001297184
amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMemberamph:AnpMember 2023-01-012023-09-30 0001297184 us-gaap:ProductMember 2023-01-012023-09-30 0001297184 us-gaap:ProductAndServiceOtherMember 2023-01-012023-09-30 0001297184 country:US 2023-01-012023-09-30 0001297184 country:FR 2023-01-012023-09-30 0001297184 country:CN 2023-01-012023-09-30 0001297184 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember 2024-07-012024-09-30 0001297184 amph:NanjingLetopMedicalTechnologyCo.Ltd.Member 2024-01-012024-09-30 0001297184
amph:NanjingLetopMedicalTechnologyCo.Ltd.Member 2023-07-012023-09-30 0001297184 amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember 2023-07-012023-09-30 0001297184 amph:NanjingLetopMedicalTechnologyCo.Ltd.Member 2023-01-012023-09-30 0001297184 amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember 2023-01-012023-09-30 0001297184 amph:NanjingLetopMedicalTechnologyCo.Ltd.Member 2022-11-012022-11-30 0001297184 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001297184 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001297184 us-gaap:LandMember 2024-09-30 0001297184 us-gaap:ConstructionInProgressMember 2024-09-30 0001297184 us-gaap:BuildingMember 2024-09-30 0001297184 amph:FurnitureFixturesAndVehiclesMember 2024-09-30 0001297184 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001297184 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001297184 us-gaap:LandMember 2023-12-31 0001297184 us-gaap:ConstructionInProgressMember 2023-12-31 0001297184 us-gaap:BuildingMember 2023-12-31 0001297184
amph:FurnitureFixturesAndVehiclesMember 2023-12-31 0001297184 amph:BaqsimiAcquisitionsMember 2024-06-012024-06-30 0001297184
amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMemberamph:AnpMember 2024-09-30 0001297184 amph:NanjingLetopMedicalTechnologyCo.Ltd.Member 2024-09-30 0001297184 amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember 2024-09-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001297184 country:US 2024-09-30 0001297184 country:FR 2024-09-30 0001297184 country:CN 2024-09-30 0001297184 country:US 2023-12-31 0001297184 country:FR 2023-12-31 0001297184 country:CN 2023-12-31 0001297184 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001297184 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001297184 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001297184 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001297184 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001297184 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001297184 amph:CommitmentsToPurchaseEquipmentAndRawMaterialsMember 2024-07-012024-09-30 0001297184 us-gaap:RevolvingCreditFacilityMemberamph:RevlovingLineOfCreditDueAugust2026Memberamph:CapitalOneNationalAssociationMember 2024-09-30 0001297184 us-gaap:LineOfCreditMemberamph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember 2024-09-30 0001297184
amph:TermLoanDueJune2028Memberamph:WellsFargoBankMember 2024-09-30 0001297184
amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember 2024-09-30 0001297184 us-gaap:RevolvingCreditFacilityMemberamph:RevlovingLineOfCreditDueAugust2026Memberamph:CapitalOneNationalAssociationMember 2023-12-31 0001297184 us-gaap:LineOfCreditMemberamph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember 2023-12-31 0001297184
amph:TermLoanDueJune2028Memberamph:WellsFargoBankMember 2023-12-31 0001297184 amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember 2023-12-31 0001297184 amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember 2023-12-31 0001297184
amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember 2023-12-31 0001297184 amph:PropertyAndCasualtyClaimMemberus-gaap:PendingLitigationMember 2024-09-30 0001297184 us-gaap:LineOfCreditMemberamph:LineOfCreditDueNovember2033Memberamph:ICBCBankMember 2024-01-31 0001297184 us-gaap:TrademarksMember 2024-09-30 0001297184 us-gaap:TrademarksMember 2023-12-31 0001297184 amph:CorporateBondsShortTermMember 2024-09-30 0001297184 us-gaap:MunicipalBondsMember 2023-12-31 0001297184 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001297184
amph:CorporateBondsShortTermMember 2023-12-31 0001297184 2023-01-012023-12-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2024-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2023-12-31 0001297184 us-gaap:UseRightsMember 2024-09-30 0001297184 us-gaap:PatentsMember 2024-09-30 0001297184 amph:BaqsimiAcquisitionsMember 2024-09-30 0001297184 us-gaap:UseRightsMember 2023-12-31 0001297184 us-gaap:PatentsMember 2023-12-31 0001297184 amph:BaqsimiAcquisitionsMember 2023-12-31 0001297184 amph:EmployeeConsultantAndDirectorsStockOptionsMember 2024-09-30 0001297184
amph:EmployeeConsultantAndDirectorsStockOptionsMember 2024-01-012024-09-30 0001297184 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2024-07-012024-09-30 0001297184 amph:ActivePharmaceuticalIngredientSegmentMember 2024-07-012024-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2024-01-012024-09-30 0001297184
amph:ActivePharmaceuticalIngredientSegmentMember 2024-01-012024-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2023-07-012023-09-30 0001297184 amph:ActivePharmaceuticalIngredientSegmentMember 2023-07-012023-09-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2023-01-012023-09-30 0001297184 amph:ActivePharmaceuticalIngredientSegmentMember 2023-01-012023-09-30 0001297184 us-gaap:LineOfCreditMemberamph:LineOfCreditDueNovember2033Memberamph:ICBCBankMember 2024-09-30 0001297184
amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember 2024-09-30 0001297184
amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember 2023-09-12 0001297184 amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001297184 amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001297184 amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001297184 amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001297184 amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:EliLillyAndCoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:CencoraMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001297184 amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001297184 amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001297184 amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001297184 amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001297184 amph:EliLillyAndCoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001297184 amph:CencoraMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001297184 amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001297184 amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001297184 amph:EliLillyAndCoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001297184 amph:CencoraMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001297184 amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001297184 us-gaap:TreasuryStockCommonMember 2024-09-30 0001297184 us-gaap:CommonStockMember 2024-09-30 0001297184 us-gaap:TreasuryStockCommonMember 2024-06-30 0001297184 us-gaap:CommonStockMember 2024-06-30 0001297184 us-gaap:TreasuryStockCommonMember 2024-03-31 0001297184 us-gaap:CommonStockMember 2024-03-31 0001297184 us-gaap:TreasuryStockCommonMember 2023-12-31 0001297184 us-gaap:CommonStockMember 2023-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2023-09-30 0001297184 us-gaap:CommonStockMember 2023-09-30 0001297184 us-gaap:TreasuryStockCommonMember 2023-06-30 0001297184 us-gaap:CommonStockMember 2023-06-30 0001297184 us-gaap:TreasuryStockCommonMember 2023-03-31 0001297184 us-gaap:CommonStockMember 2023-03-31 0001297184 us-gaap:TreasuryStockCommonMember 2022-12-31 0001297184 us-gaap:CommonStockMember 2022-12-31 0001297184 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 amph:BaqsimiAcquisitionsMember 2023-04-21 0001297184 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001297184 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001297184
amph:BaqsimiAcquisitionsMember 2023-04-212023-04-21 0001297184 amph:EmployeeAndNonEmployeeStockOptionsMember 2023-07-012023-09-30 0001297184 us-gaap:SellingAndMarketingExpenseMember 2024-07-012024-09-30 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001297184 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001297184 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001297184 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001297184 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0001297184
amph:EmployeeStockPurchasePlan2014Member 2024-07-012024-09-30 0001297184 us-gaap:SellingAndMarketingExpenseMember 2024-01-012024-09-30 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001297184 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001297184 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001297184 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001297184 us-gaap:CostOfSalesMember 2024-01-012024-09-30 0001297184 amph:EmployeeStockPurchasePlan2014Member 2024-01-012024-09-30 0001297184 us-gaap:SellingAndMarketingExpenseMember 2023-07-012023-09-30 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0001297184 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001297184 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001297184 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001297184 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0001297184
amph:EmployeeStockPurchasePlan2014Member 2023-07-012023-09-30 0001297184 us-gaap:SellingAndMarketingExpenseMember 2023-01-012023-09-30 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001297184 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001297184 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001297184 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001297184 us-gaap:CostOfSalesMember 2023-01-012023-09-30 0001297184 amph:EmployeeStockPurchasePlan2014Member 2023-01-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember 2024-07-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember 2024-01-012024-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember 2023-07-012023-09-30 0001297184
amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember 2023-01-012023-09-30 0001297184 amph:November2014ShareRepurchasePlanMember 2024-11-04 0001297184 2024-11-01 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001297184 2024-04-012024-06-30 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001297184 2024-01-012024-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001297184 2023-

04-012023-06-30 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001297184 2023-01-012023-03-31 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001297184 amph:RestrictedStockUnitsIssuedAsCompensationMember 2024-01-012024-09-30 0001297184 us-gaap:AccountsReceivableMember 2024-09-30 0001297184 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2024-09-30 0001297184 us-gaap:AccountsReceivableMember 2023-12-31 0001297184 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2023-12-31 0001297184 2023-09-30 0001297184 2022-12-31 0001297184 srt:MinimumMember 2024-01-012024-09-30 0001297184 srt:MaximumMember 2024-01-012024-09-30 0001297184 amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember 2024-01-012024-09-30 0001297184 us-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001297184 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001297184 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001297184 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001297184 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001297184 2024-07-012024-09-30 0001297184 2023-07-012023-09-30 0001297184 us-gaap:InterestRateSwapMember 2024-07-012024-09-30 0001297184 us-gaap:InterestRateSwapMember 2024-01-012024-09-30 0001297184 us-gaap:InterestRateSwapMember 2023-07-012023-09-30 0001297184 us-gaap:InterestRateSwapMember 2023-01-012023-09-30 0001297184 amph:EmployeeStockPurchasePlan2014Member 2024-05-012024-05-31 0001297184 2023-01-012023-09-30 0001297184 amph:BaqsimiAcquisitionsMember 2024-01-012024-09-30 0001297184 amph:BaqsimiAcquisitionsMember 2023-07-012023-09-30 0001297184 amph:BaqsimiAcquisitionsMember 2023-01-012023-09-30 0001297184 amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember 2023-09-30 0001297184 amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember 2023-09-012023-09-30 0001297184 amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember 2023-09-122023-09-12 0001297184 us-gaap:LineOfCreditMemberamph:LineOfCreditDueNovember2033Memberamph:ICBCBankMember 2024-01-012024-09-30 0001297184 amph:BaqsimiAcquisitionsMember 2023-06-302023-06-30 0001297184 amph:EmployeeAndNonEmployeeStockOptionsMember 2024-07-012024-09-30 0001297184 amph:EmployeeAndNonEmployeeStockOptionsMember 2024-01-012024-09-30 0001297184 amph:EmployeeAndNonEmployeeStockOptionsMember 2023-01-012023-09-30 0001297184 srt:MaximumMemberamph:BaqsimiAcquisitionsMemberamph:TransitionServicesAgreementMember 2023-06-302023-06-30 0001297184 srt:MaximumMemberamph:BaqsimiAcquisitionsMemberamph:ManufacturingServicesAgreementMember 2023-06-302023-06-30 0001297184 2024-01-012024-09-30 0001297184 2024-09-30 0001297184 2023-12-31 iso4217:USD iso4217:USD shares pure amph:D amph:item shares amph:segment 0000http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsP0Y440000Large Accelerated Filerfalse0000falseAmphastar Pharmaceuticals, Inc.--12-31false0001297184Q3falseYestrueDEfalse2024-09-30000P30D00000010-Q2024001-3650933-070220511570 6th StreetRancho CucamongaCA91730909980-9484YesCommon Stock, par value $0.0001 per share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style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note 1. General . Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the "Company") is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Company's products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company's insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company's inhalation product, Primatene MIST®, is primarily distributed through drug retailers. . The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the Company's consolidated financial position, results of operations, comprehensive income, stockholders' equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company's results of operations, comprehensive income and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods. Note 2. Summary of Significant Accounting Policies . Basis of Presentation . The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with GAAP. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company. . The Company's subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Amphastar France Pharmaceuticals, S.A.S., or AFP, (5) Amphastar UK Ltd., or AUK, (6) International Medication Systems (UK) Limited, or IMS UK, and (7) Amphastar Medication Co., LLC, or Amphastar Medication. . Investment in Unconsolidated Affiliate . The Company applies the equity method of accounting for investments when it has significant influence, but not controlling interest in the investee. The Company's proportionate share of the earnings or losses resulting from these investments is reported as "Equity in losses of unconsolidated affiliate" in the accompanying condensed consolidated statements of operations. Investments accounted for using the equity method may be reported on a lag of up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. . The carrying value of equity method investments is reported as "Investment in unconsolidated affiliate" in the accompanying condensed consolidated balance sheets. The Company's equity method investments are reported at cost and adjusted each period for the Company's share of the investee's earnings or losses and dividends paid, if any. . Use of Estimates . The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: fair value of acquired assets, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions. . Foreign Currency . The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the U.S. Dollar, or USD. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company's condensed consolidated statements of operations. . The Company's French subsidiary, AFP, maintains its books of record in euros. AUK's subsidiary, IMS UK, maintains its books of record in British pounds. These local currencies have been determined to be the subsidiaries' respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders' equity and are included as a component of other comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). . The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $1.4 million gain and a $0.4 million gain for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the unrealized gains and losses of intercompany foreign currency transactions

that are of a long-term investment nature were a $0.9 million loss and a $0.4 million loss, respectively. Comprehensive Income The Company's comprehensive income includes its foreign currency translation gains and losses as well as its share of other comprehensive income from its equity method investments. Acquisitions The Company evaluates acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and substantive processes that have the ability to create outputs, which would meet the definition of a business. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis, with the exception of non-qualifying assets. Goodwill is not recognized in an asset acquisition. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR&D, asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration, including assumed contingent considerations, is not recognized until all contingencies are resolved and the consideration is paid or becomes payable (unless contingent considerations meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired), at which point the consideration is allocated to the assets acquired based on their relative fair values at the acquisition date, with the exception of non-qualifying assets. Judgments are used in determining estimates of useful lives of long-lived assets. Useful life estimates are based on, among other factors, estimates of expected future net cash flows, the assessment of each asset's life cycle, and the impact of competitive trends on each asset's life cycle and other factors. These judgments can materially impact the estimates used to allocate purchase consideration to assets acquired and liabilities assumed, and the resulting timing and amounts charged to or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results. Advertising Expense Advertising expenses, primarily associated with Primatene MIST®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company's condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, advertising expenses were $2.5 million and $7.8 million, respectively. For the three and nine months ended September 30, 2023, advertising expenses were $1.9 million and $8.1 million, respectively. Financial Instruments The Company's accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses, short-term borrowings, and long-term obligations. The Company considers the carrying amounts of current assets and liabilities on the condensed consolidated balance sheets to approximate the fair value of these financial instruments due to the short maturity of these items. The carrying value of the Company's long-term obligations, with the exception of the convertible debt (see Note 14), approximates their fair value, as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. Investments and short-term investments are recorded at fair value based on quoted prices from recognized security exchanges and other methods (see Note 9). The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt. The Company's interest rate swap contracts exchange the variable interest rates for fixed interest rates. Cash and Cash Equivalents Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments with original maturities of three months or less. Investments Investments as of September 30, 2024 and December 31, 2023 consisted of certificates of deposit and investment grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months. Restricted Cash Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of September 30, 2024 and December 31, 2023, the restricted cash balance was $0.2 million. Restricted Short-Term Investments Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers' compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of September 30, 2024 and December 31, 2023, the balance of restricted short-term investments was $2.2 million. Deferred Income Taxes The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. Debt Issuance Costs Debt issuance costs related to non-revolving debt are recognized as a reduction to the related debt balance in the accompanying condensed consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Debt issuance costs associated with revolving debt are capitalized within other long-term assets on the condensed consolidated balance sheets and are amortized to interest expense over the term of the related revolving debt. Convertible Debt The Company accounts for its convertible debt instruments as a single unit of accounting, a liability, because the Company concluded that the conversion features do not require bifurcation as a derivative under Accounting Standards Codification, or ASC, 815-15, Derivatives and Hedging and the Company did not issue its convertible debt instruments at a substantial premium. The Company records debt issuance costs as contra-liabilities in its condensed consolidated balance sheets at issuance and amortizes them over the contractual term of the convertible debt instrument using the effective interest rate. In accordance with Accounting Standards Update, or ASU, 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, the Company evaluates convertible debt instruments to determine if the conversion feature is freestanding or embedded. If the conversion feature is embedded, the conversion feature is not bifurcated from the host instrument. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20, "Debt with Conversion and Other Options" for consideration of any beneficial conversion features. If no beneficial conversion features exist that require separate recognition, convertible debt instruments are accounted for as a single liability measured at its amortized cost as long as no other features require separation and recognition as derivatives. Litigation, Commitments and Contingencies Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the disclosure requirements related to the new standard. In December 2023, the FASB issued Accounting Standard Update 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures which requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to the new standard. <i style="font-

style:italic;">Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with GAAP. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company. The Company's subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Amphastar France Pharmaceuticals, S.A.S., or AFP, (5) Amphastar UK Ltd., or AUK, (6) International Medication Systems (UK) Limited, or IMS UK, and (7) Amphastar Medication Co., LLC, or Amphastar Medication. Investment in Unconsolidated Affiliate The Company applies the equity method of accounting for investments when it has significant influence, but not controlling interest in the investee. The Company's proportionate share of the earnings or losses resulting from these investments is reported as "Equity in losses of unconsolidated affiliate" in the accompanying condensed consolidated statements of operations. Investments accounted for using the equity method may be reported on a lag of up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The carrying value of equity method investments is reported as "Investment in unconsolidated affiliate" in the accompanying condensed consolidated balance sheets. The Company's equity method investments are reported at cost and adjusted each period for the Company's share of the investee's earnings or losses and dividends paid, if any. Use of Estimates The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: fair value of acquired assets, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions. Foreign Currency The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the U.S. Dollar, or USD. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company's condensed consolidated statements of operations. The Company's French subsidiary, AFP, maintains its books of record in euros. AUK's subsidiary, IMS UK, maintains its books of record in British pounds. These local currencies have been determined to be the subsidiaries' respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders' equity and are included as a component of other comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $1.4 million gain and a $0.4 million gain for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $0.9 million loss and a $0.4 million loss, respectively. 1400000400000-900000-400000 Comprehensive Income The Company's comprehensive income includes its foreign currency translation gains and losses as well as its share of other comprehensive income from its equity method investments. Acquisitions The Company evaluates acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and substantive processes that have the ability to create outputs, which would meet the definition of a business. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis, with the exception of non-qualifying assets. Goodwill is not recognized in an asset acquisition. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR&D, asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration, including assumed contingent considerations, is not recognized until all contingencies are resolved and the consideration is paid or becomes payable (unless contingent considerations meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired), at which point the consideration is allocated to the assets acquired based on their relative fair values at the acquisition date, with the exception of non-qualifying assets. Judgments are used in determining estimates of useful lives of long-lived assets. Useful life estimates are based on, among other factors, estimates of expected future net cash flows, the assessment of each asset's life cycle, and the impact of competitive trends on each asset's life cycle and other factors. These judgments can materially impact the estimates used to allocate purchase consideration to assets acquired and liabilities assumed, and the resulting timing and amounts charged to or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results. Advertising Expense Advertising expenses, primarily associated with Primatene MIST®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company's condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, advertising expenses were $2.5 million and $7.8 million, respectively. For the three and nine months ended September 30, 2023, advertising expenses were $1.9 million and $8.1 million, respectively. 2500000780000019000008100000 Financial Instruments The Company's accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses, short-term borrowings, and long-term obligations. The Company considers the carrying amounts of current assets and liabilities on the condensed consolidated balance sheets to approximate the fair value of these financial instruments due to the short maturity of these items. The carrying value of the Company's long-term obligations, with the exception of the convertible debt (see Note 14), approximates their fair value, as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. Investments and short-term investments are recorded at fair value based on quoted prices from recognized security exchanges and other methods (see Note 9). The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt. The Company's interest rate swap contracts exchange the variable interest rates for fixed interest rates. Cash and Cash Equivalents Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments with original maturities of three months or less. Investments Investments as of September 30, 2024 and December 31, 2023 consisted of certificates of deposit and investment grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months. Restricted Cash Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of September 30, 2024 and December 31, 2023, the restricted cash balance was $0.2 million. 200000200000 Restricted Short-Term Investments Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers' compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of September 30, 2024 and December 31, 2023, the balance of restricted short-term investments was $2.2 million. 2200000 Deferred Income Taxes The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. Debt Issuance Costs Debt issuance costs related to non-revolving debt are recognized as a reduction to the related debt balance in the accompanying condensed consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Debt issuance costs associated with revolving debt are capitalized within other long-term assets on the condensed consolidated balance sheets and are amortized to interest expense over the term of the related revolving debt. Convertible Debt <span

style="visibility:hidden;"> The Company accounts for its convertible debt instruments as a single unit of accounting, a liability, because the Company concluded that the conversion features do not require bifurcation as a derivative under Accounting Standards Codification, or ASC, 815-15, Derivatives and Hedging and the Company did not issue its convertible debt instruments at a substantial premium. The Company records debt issuance costs as contra-liabilities in its condensed consolidated balance sheets at issuance and amortizes them over the contractual term of the convertible debt instrument using the effective interest rate. In accordance with Accounting Standards Update, or ASU, 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, the Company evaluates convertible debt instruments to determine if the conversion feature is freestanding or embedded. If the conversion feature is embedded, the conversion feature is not bifurcated from the host instrument. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20, "Debt with Conversion and Other Options" for consideration of any beneficial conversion features. If no beneficial conversion features exist that require separate recognition, convertible debt instruments are accounted for as a single liability measured at its amortized cost as long as no other features require separation and recognition as derivatives. Litigation, Commitments and Contingencies Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the disclosure requirements related to the new standard. In December 2023, the FASB issued Accounting Standard Update 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures which requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to the new standard. Note 3. BAQSIMI® Asset Acquisition On June 30, 2023, the Company completed its acquisition of BAQSIMI® glucagon nasal powder, or BAQSIMI®, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli Lilly & Company, or Lilly, dated April 21, 2023. The Company accounted for the BAQSIMI® acquisition as an asset acquisition in accordance with ASC 805, Business Combinations, as substantially all the fair value of the assets acquired was concentrated in a single identifiable asset, BAQSIMI® product rights. The BAQSIMI® product rights include the license for the BAQSIMI® intellectual property, regulatory documentation, marketing authorizations, and domain names, which are considered a single asset as they are inextricably linked. The total purchase price was allocated to the acquired assets based on their relative fair values, as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Property, plant, and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,426</p></td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BAQSIMI® product rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 591,338</p></td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,341</p></td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 628,105 </td></tr></table> The Company amortizes the acquired intangible asset to cost of revenues on a straight line basis over its estimated useful life of 24 years (see Note 10 for additional information). A portion of the consideration for the asset acquisition was a deferred cash payment. The fair value of the deferred cash payment was accreted to its full $129.0 million amount over a one-year period from the date of acquisition through interest expense. During the nine months ended September 30, 2024, the Company recognized $3.6 million of interest expense related to accretion of the deferred cash payment. During the three and nine months ended September 30, 2023, $1.8 million of interest expense was recognized related to the accretion of the deferred cash payment. The Company made the $129.0 million deferred cash payment in June 2024. The Company may also be required to pay additional contingent consideration of up to an aggregate of $575.0 million in cash as part of the BAQSIMI® acquisition, based on the achievement of certain net sales milestones. Through September 30, 2024, the Company has not triggered any milestones and therefore no amounts have been recognized or paid. Manufacturing Services Agreement In connection with the closing of the acquisition, the Company entered into a Manufacturing Services Agreement, or the MSA, with Lilly, pursuant to which Lilly has agreed, for a period of time not to exceed <span style="font-

size:10pt;">18 months, to provide certain manufacturing, packaging, labeling and supply services for BAQSIMI® directly or through third-party contractors to the Company in connection with its operation of the development, manufacture, and commercialization of BAQSIMI®. Upon termination of the MSA, the Company will be obligated to purchase all API, components, and finished goods on hand at prices agreed upon in the MSA. Transition Services Agreement In connection with the closing of the acquisition, the Company also entered into a Transition Services Agreement, or the TSA, with Lilly pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain services to the Company to support the transition of BAQSIMI® operations to the Company, including with respect to the conduct of certain clinical, regulatory, medical affairs, and commercial sales channel activities. Throughout 2024, the Company assumed distribution responsibilities, from Lilly, to its customers in the United States, and certain other countries. As a result, the Company has recorded the sales and related cost of BAQSIMI® in these countries as product revenue, net and cost of revenues, respectively. The Company will continue to assume distribution of BAQSIMI® for the remaining territories on a country by country basis throughout 2024. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Property, plant, and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,426</p></td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BAQSIMI® product rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 591,338</p></td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,341</p></td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 628,105 </td></tr>
</table>3442600059133800023410006281050001290000000.0P1Y360000018000001800000129000000.0575000000.0P18MP18M Note 4. Revenue Recognition Product revenues, net In accordance with ASC 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Company's customers obtain control of the promised goods. Generally, revenue is recognized at the time of product delivery to the Company's customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration including provision for chargebacks and rebates, accrual for product returns, prompt pay discounts, distributor fees, patient co-pay assistance, and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Payment terms offered to customers generally range from 30 to 75 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If the Company expects, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, the amount of consideration is not adjusted for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, distribution and marketing expenses in the accompanying condensed consolidated statements of operations. Provision for Chargebacks and Rebates: The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historical chargeback and rebate rates, and current contract pricing. The provision for chargebacks and rebates is reflected as a component of product revenues, net. The following table is an analysis of the chargeback and rebate provision: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.63%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.63%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> (a) </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,920</p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,606 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> Provision for chargebacks and rebates </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"> 218,312 </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"> 200,317 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Credits and payments issued to third parties </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> (a) </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (181,216) </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> (a) </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (201,650) </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> (a) </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,016</p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 25,273 </td></tr></table> (a) Changes in the chargeback provision from period to period are primarily dependent on the Company's sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalers' customer mix. Changes in the rebate provision from period to period are primarily dependent on retailers' and other indirect customers' purchases. The approach that the Company uses to estimate chargebacks and rebates has been consistently applied for all periods. presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 20 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer. The provision for chargebacks and rebates is included in the following balance sheet accounts: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.83%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.37%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.21%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:59.78%;background:#cceeff;margin:0pt;padding:0pt;"> Reduction to accounts receivable, net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td

style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> 21,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,861</p></td></tr><tr><td style="vertical-align:middle;width:59.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,059</p></td></tr><tr><td style="vertical-align:middle;width:59.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 65,016 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,920 </td></tr></table> Accrual for Product Returns: The Company offers certain customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Company's product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and new competition. Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. Distributor Fees: The Company engages with wholesalers to distribute its products to end customers. The Company pays the wholesalers a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees. Patient Co-Pay Assistance: Co-pay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The accrual for co-pay is based on an estimate of claims and the cost per claim that the Company expects to receive associated with inventory that exists in the distribution channel at period end. Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers. The Company's accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. Service revenues derived from research and development contracts are recognized over time based on progress toward satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation. For the three and nine months ended September 30, 2024, revenues from research and development services were $0.1 million and $2.0 million, respectively. For the three and nine months ended September 30, 2023, revenues from research and development services were $0.8 million and $2.1 million, respectively.</p><p style="font-family:'Times New Roman','Times',serif;font-size:12pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><i style="font-style:italic;">Other revenues</i></p><p style="font-family:'Times New Roman','Times',serif;font-size:12pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Revenues related to sales of BAQSIMI®, which was supplied and sold by Lilly under the TSA during the three and nine months ended September 30, 2024 and 2023, or BAQSIMI® NEB, were recorded on a net basis, similar to a royalty arrangement. This includes revenues in the United States and certain other countries for a portion of the period.</p>P75D<p style="font-family:'Times New Roman','Times',serif;font-size:12pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">Nine Months Ended </p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">2024</p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 27,920 </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,606 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> Provision for

chargebacks and rebates </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"> 218,312 </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;margin:0pt;padding:0pt;"> 200,317 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Credits and payments issued to third parties </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (181,216) </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (201,650) </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,016</p></td><td style="vertical-align:bottom;white-space:normal;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 25,273 </td></tr></table>279200002660600021831200020031700018121600020165000065016000252730000P20DP60D <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.83%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.37%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.21%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:59.78%;background:#cceeff;margin:0pt;padding:0pt;"> Reduction to accounts receivable, net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"> 21,861 </td></tr><tr><td style="vertical-align:middle;width:59.78%;margin:0pt;padding:0pt;"> Accounts payable and accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,661 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,059 </td></tr><tr><td style="vertical-align:middle;width:59.78%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,920 </td></tr></table>213550002186100043661000605900065016000279200001000002000000.080000002100000 Note 5. Net Income per Share Basic net income per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share gives effect to all potentially dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company's Employee Stock Purchase Plan, or ESPP, and potential shares of common stock issuable upon conversion of Convertible Notes of the Company, due March 2029, or the 2029 Convertible Notes. For the three and nine months ended September 30, 2024, options to purchase 619,847 shares of stock with a weighted-average exercise price of $46.63 per share, were excluded in the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price. For the three months ended September 30, 2023, none of the Company's options were excluded from the computation of diluted net income per share. For the nine months ended September 30, 2023, options to purchase 45,934 shares of stock with a weighted-average exercise price of $46.01 per share, were excluded from the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price. The following table provides the calculation of basic and diluted net income per share for each of the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"> (in thousands, except per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Basic and dilutive numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Net income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 49,222 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 101,378 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding — basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,621 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,580 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Net effect of dilutive securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental shares from equity awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,241 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,220 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,727 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,629 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:56.64%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding — diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,921 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 52,307 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 52,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Net income per share — basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 1.01 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 2.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Net income per share — diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 0.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 1.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr></table> 619847619847466346.634593446.01 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-

align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"> (in thousands, except per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Basic and dilutive numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Net income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 49,222 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 101,378 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding — basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,621 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,580 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Net effect of dilutive securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental shares from equity awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,241 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,220 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,727 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,629 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:56.64%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding — diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,921 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 52,307 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 52,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Net income per share — basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 1.01 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 2.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Net income per share — diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 0.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 1.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr></table>
4042900049222000121555000101378000486210004870100048580000483680003241000522000037270004629000051862000539210005230700052997000.831.012.502.1
Note 6. Segment Reporting <p

style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"> The Company's business is the development, manufacture, and marketing of pharmaceutical products. The Company has identified two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC 280, Segment Reporting. The Company's performance is assessed and resources are allocated by the CODM based on the following two reportable segments: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Finished pharmaceutical products</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">APIs</td></tr></table> The finished pharmaceutical products segment manufactures, markets and distributes BAQSIMI®, Primatene MIST®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing and contract research revenues. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Other revenues includes the portion of BAQSIMI® sales by Lilly on the Company's behalf under the TSA and is accounted for as a component of the finished pharmaceutical product segment. Selected financial information by reporting segment is presented below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.54%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenues: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 189,752 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 176,366 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 538,755 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 455,242 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> API </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,462 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,190 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,689 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Total net revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 191,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 180,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 545,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 466,290 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Gross profit (loss): </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;"> 105,544 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 109,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 302,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 262,742 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> API </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,603) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,096) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,115) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,761) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Total gross profit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 101,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 108,403 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 287,207 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 254,981 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Operating expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 44,893 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,725 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 126,932 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 111,974 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Income from operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 57,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 72,678 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 160,275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 143,007 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Non-operating (expenses) income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (9,365) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (9,041) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (14,473) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (12,993) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.83%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Finished pharmaceutical products segment net revenues: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> BAQSIMI® </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">40,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">85,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Glucagon </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,792 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt

3pt 0.05pt 0pt;"> 29,514 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 82,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 82,486 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Epinephrine </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 21,341 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 20,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 75,392 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 57,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Primatene MIST® </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 24,834 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 73,077 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 64,837 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Lidocaine </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 15,884 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 15,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 41,457 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 43,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Phytonadione </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 11,721 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 7,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 31,998 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 33,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Enoxaparin </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 5,615 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 7,702 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 17,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 25,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Naloxone </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 4,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 4,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 12,124 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 14,774 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Other finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,503 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37,730 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 99,309 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 105,808 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Total finished pharmaceutical products net revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 187,357 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 147,665 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 519,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 426,541 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> BAQSIMI®NEB </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,395 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,608 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Total finished pharmaceutical products segment net revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 176,366 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 538,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 455,242 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . The amount of depreciation and amortization expense included in cost of revenues by reporting segment is presented below: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.66%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"> Depreciation and amortization expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 8,616 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 13,143 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"> API </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,938 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> Total depreciation and amortization expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,619 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr></table> . Net revenues and carrying values of long-lived assets, which includes property, plant and equipment, as well as finance and operating lease right-of-use assets, by geographic regions, based on where the Company conducts its operations are as follows: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net Revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Long-Lived Assets </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.43%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"> United States⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 178,056 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 532,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 459,909 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 186,083 </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> China </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 178 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 833 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,145 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 103,009 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> 91,913 </td></tr><tr><td style="vertical-align:bottom;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"> France </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,708 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,239 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37,099 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37,647 </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 180,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 545,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 466,290 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 315,643 </td></tr></table> ⁽¹⁾ Includes Other revenues from the sales of BAQSIMI®. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.54%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenues: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 176,366 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 538,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 455,242 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> API </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,462 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,190 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,689 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Total net revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 191,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 180,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 545,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 466,290 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Gross profit (loss): </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 105,544 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 109,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 302,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 262,742 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> API </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,603) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,096) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,115) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,761) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Total gross profit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 101,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 108,403 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;"> 287,207 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 254,981 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Operating expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 44,893 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,725 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 126,932 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 111,974 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> Income from operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 57,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 72,678 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 160,275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 143,007 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Non-operating (expenses) income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (9,365) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (9,041) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (14,473) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> (12,993) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"> Income before income taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 63,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,014 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td></tr>
</table>1897520001763660005387550004552420001462000419000066890001104800019121400018055600054544400046629000010554400010949900003023220002627420003603000-1096000-15115000-776100010194100010840300028720700025498100044893000357250001269320001119740005704800072678000160275000143007000-9365000-9041000-14473000-12993000476830006363700014580200013001400 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.83%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Finished pharmaceutical products segment net revenues: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> BAQSIMI® </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Glucagon </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,792 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 29,514 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 82,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 82,486 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Epinephrine </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 21,341 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 20,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 75,392 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 57,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Primatene MIST® </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 24,834 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 73,077 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 64,837 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Lidocaine </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 15,884 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 15,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 41,457 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 43,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Phytonadione </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 11,721 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 7,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 31,998 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 33,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Enoxaparin </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 5,615 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 7,702 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 17,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 25,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Naloxone </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 4,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 4,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 12,124 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 14,774 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> Other finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,503 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37,730 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 99,309 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 105,808 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Total finished pharmaceutical products net revenues </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 187,357 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 147,665 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 519,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 426,541 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"> BAQSIMI®NEB </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,395 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,608 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:54.58%;background:#cceeff;margin:0pt;padding:0pt;"> Total finished pharmaceutical products segment net revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 176,366 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 538,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 455,242 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr>
</table>404090008510600026792000295140008270000082486000213410002019900075392000570040002605500024834000730770006483700015884000155220004145700(
style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">. <table
style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> .
</td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt

0pt 0.05pt 0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.66%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"> Depreciation and amortization expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 8,616 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 13,143 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"> API </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,938 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"> Total depreciation and amortization expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,619 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr>
</table>875500086160002608600013143000103800010030003045000293800097930009619000291310001608100 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net Revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Long-Lived Assets </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> 2023 </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.43%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"> United States⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 178,056 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 532,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 459,909 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 186,083 </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> China </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 178 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 833 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,145 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 103,009 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> 91,913 </td></tr><tr><td style="vertical-align:bottom;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"> France </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,708 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,239 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37,099 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37,647 </td></tr><tr><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 191,214 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 180,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 545,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 327,518 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 315,643 </td></tr>
</table>1865140001780560005325910004599090001874100001860830001780008330002145000214200010300900091913000452200016670001070800042390003709900033<table style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><tr><td>Note 7. Customer and Supplier Concentration . Customer Concentrations . Three large wholesale drug distributors, Cencora Inc., formally AmerisourceBergen, or Cencora, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company's products, as well as suppliers of a broad range of health care products. Lilly currently manufactures and sells BAQSIMI® on the Company's behalf pursuant to the terms of the TSA in certain jurisdictions (see Note 3 for additional information). The Company considers these four customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company's net revenue for the three and nine months ended September 30, 2024 and 2023, and accounts receivable as of September 30, 2024 and December 31, 2023, respectively. The following table provides accounts receivable and net revenue information for these major customers: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.09774017%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"> % of Total Accounts </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"> % of Net </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"> Receivable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"> Revenues </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-

align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;background:#cceeff;margin:0pt;padding:0pt;"> McKesson </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> 29 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> 26 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"> 26 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"> 22 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"> 25 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"> 25 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> Cencora </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 28 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:38.06%;background:#cceeff;margin:0pt;padding:0pt;"> Cardinal Health </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> Lilly </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> % </td></tr></table> Supplier Concentrations The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company's business, financial condition, and results of operations. 34444 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.09774017%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"> % of Total Accounts </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"> % of Net </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"> Receivable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"> Revenues </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.06%;background:#cceeff;margin:0pt;padding:0pt;"> McKesson </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> 29 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> 26 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"> 26 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"> 22 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"> 25 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times',serif;font-size:10pt;margin:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"> 25 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> Cencora </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 28 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:38.06%;background:#cceeff;margin:0pt;padding:0pt;"> Cardinal Health </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:38.06%;margin:0pt;padding:0pt;"> Lilly </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> % </td></tr></table>0.290.260.260.220.250.250.280.160.210.170.200.200.170.130.200.150.200.160.020.200.010.160.040.06 Note 8. Fair Value Measurements GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below: <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1 - Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2 - Inputs to measure fair value are based on the following: (a) quoted prices in active markets on similar assets or liabilities, (b) quoted prices for identical or similar instruments in inactive markets, or (c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3 - Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.</td></tr></table> As of September 30, 2024 and December 31, 2023, cash equivalents include money market accounts and corporate and municipal bonds with original maturities of less than three months. Investments consist of certificates of deposit as well as investment-grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months. The certificates of deposit are carried at amortized cost in the Company's condensed consolidated balance sheets, which approximates their fair value determined based on Level 2 inputs. The corporate, agency and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses. The fair value of such bonds is disclosed in Note 9 and was determined based on Level 2 inputs. The restrictions on restricted cash and investments have an immaterial effect on the fair value of these financial assets. The fair values of the Company's financial assets and liabilities measured on a recurring basis as of September 30, 2024 and December 31, 2023, are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.67%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"> 143,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"> 26,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"> Restricted short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"> Interest rate swaps related to variable rate loans </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,881) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,881) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"> Total assets and liabilities measured at fair value as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,513</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 143,872 </td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,641</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> . </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.79%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt

6pt;">Cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> 116,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 37,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 37,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> Restricted short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"> Interest rate swaps related to variable rate loans </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,243) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,243) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> Total assets and liabilities measured at fair value as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,775</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 116,676 </td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-

align:middle;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,099 </td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include investments in unconsolidated affiliates, long-lived assets, goodwill, and intangible assets for which the fair value is determined as part of an impairment test. As of September 30, 2024, and December 31, 2023, there were no significant adjustments to fair value for nonfinancial assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company's deferred compensation plan assets are valued using the cash surrender value of the life insurance policies and are not included in the table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 143,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 26,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"> 26,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"> Restricted short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;background:#cceeff;margin:0pt;padding:0pt;"> Interest rate swaps related to variable rate loans </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,881) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,881) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:55.05%;margin:0pt;padding:0pt;"> Total assets and liabilities measured at fair value as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,513</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 143,872 </td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,641</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.79%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"> Cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> 116,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 37,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 37,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> Restricted short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 2,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"> Interest rate swaps related to variable rate loans </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,243) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,243) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:55.55%;margin:0pt;padding:0pt;"> Total assets and liabilities measured at fair value as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,775</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 116,676 </td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,099</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>1436370001436370002350002350002632000263200002200000220000068810006881000165513000143872000216410001164410001164410002350002350003714200

Note 9. Investments

The following is a summary of the Company's investments that are classified as held-to-maturity:

weight:bold;">Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.2%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate and agency bonds (due within 1 year) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31,968 </td></tr><tr><td style="vertical-align:top;width:54.11%;margin:0pt;padding:0pt;"> Total investments as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,968 </td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"> Corporate and agency bonds (due within 1 year) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 73,801 </td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate and agency bonds (due within 1 to 3 years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 14,621 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 56 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 14,676 </td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"> Municipal bonds (due within 1 year) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,081 </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <span style="font-
size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-
align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"> — </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,082 </td></tr><tr><td style="vertical-
align:top;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total investments as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> 89,517 </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> 64 </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-
bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-
align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22) </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-
space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,559 </td></tr></table> <span
style="visibility:hidden;"> At each reporting period, the Company evaluates
securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the
issuers, identifying neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss. <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Company's held-to-maturity investments
were considered to be one pool. The estimate for credit losses considers historical loss information that is adjusted for current conditions and reasonable and supportable
forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements. <p style="font-family:'Times New
Roman','Times','serif';font-size:1pt;margin:0pt;"> <p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-
content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> <span style="font-
size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> <span style="font-
size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> <span style="font-
size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> <span style="font-
size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;"> <span style="font-
size:1pt;visibility:hidden;"> </td></tr><tr><td style="vertical-
align:bottom;white-space:nowrap;width:54.11%;margin:0pt;padding:0pt;"> <span
style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"> </td><td style="vertical-
align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <span
style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> <span style="font-
family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <span style="font-
family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td colspan="2"
style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;">Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:8pt;text-align:center;margin:0pt;">Amortized </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <span style="font-
family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td colspan="2"
style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;">Unrealized </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> <span style="font-
family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Fair </td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> — </td><td

colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.2%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate and agency bonds (due within 1 year) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31,968 </td></tr><tr><td style="vertical-align:top;width:54.11%;margin:0pt;padding:0pt;"> Total investments as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,968 </td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"> Corporate and agency bonds (due within 1 year) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 73,801 </td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate and agency bonds (due within 1 to 3 years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 14,621 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 56 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 14,676 </td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"> Municipal bonds (due within 1 year) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,082 </td></tr><tr><td style="vertical-align:top;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total investments as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 64 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 89,559 </td></tr>
</table>3190300067000200031968000319030006700020003196800073815000700021000738010001462100056000100014676000108100010001080200089517000640002200(
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note 10. Goodwill and Intangible Assets
The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Original Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net Book Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.37%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> BAQSIMI®product rights⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 591,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 30,799 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 560,539 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 193 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 101 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Land-use rights </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,540 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 865 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,675 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 594,071 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 31,756 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 562,315 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Indefinite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Trademark </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Goodwill - Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:49.56%;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 626,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,756 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 594,796 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Original Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net Book Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.37%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> BAQSIMI[@]product rights⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 591,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 12,319 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 579,019 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 12 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 486 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 376 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 110 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Land-use rights </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,540 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 815 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,725 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 594,364 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 13,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 580,854 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Indefinite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Trademark </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Goodwill – Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> As of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 626,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 613,295 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> - </td></tr></table> [*] Intangible assets with indefinite lives have an indeterminable average life. <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> ⁽¹⁾ </td><td style="padding:0pt;"> See Note 3. </td></tr></table> - Goodwill - The changes in the carrying amounts of goodwill are as follows: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.17%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"> 3,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> Currency translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 90 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:middle;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr></table> - - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Original Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net Book Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.37%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> BAQSIMI®product rights⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 591,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 30,799 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 560,539 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 193 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 101 </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Land-use rights </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,540 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 865 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,675 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 594,071 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 31,756 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 562,315 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Indefinite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Trademark </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Goodwill - Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,481 </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:49.56%;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">626,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,756 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 594,796 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Original Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net Book Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.37%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> BAQSIMI®product rights⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 591,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 12,319 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 579,019 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 12 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 486 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 376 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 110 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Land-use rights </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,540 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 815 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,725 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 594,364 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> 13,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 580,854 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> Indefinite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Trademark </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 29,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill - Finished pharmaceutical products </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,441 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.56%;margin:0pt;padding:0pt;"> As of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> * </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 626,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 613,295 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> . </td></tr></table> [*] Intangible assets with indefinite lives have an indeterminable average life. <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> ⁽¹⁾ </td><td style="padding:0pt;"> See Note 3. </td></tr></table>P24Y5913380003079900056053900OP15Y1930009200010100OP39Y2540000865000167500OP24Y5940710003175600056231500029225000292250003256000325600
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.17%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning

balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"> 3,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> Currency translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 90 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 321600031260004000090000325600032160000 Note 11. Inventories Inventories consist of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.17%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials and supplies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"> 50,082 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> Work in process </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 36,016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> 30,822 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 33,764 </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"> Total inventories </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 105,833 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr></table> Charges of $0.9 million and $10.1 million were included in the cost of revenues in the Company's condensed consolidated statements of operations for the three and nine months ended September 30, 2024, respectively, to adjust the Company's inventory and related firm purchase commitments to its net realizable value. For the three months ended September 30, 2023, the Company had an immaterial amount that was included in cost of revenues to adjust the Company's inventory and related firm purchase commitments to its net realizable value. For the nine months ended September 30, 2023, charges of $9.6 million were included in the cost of revenues to adjust the Company's inventory and related firm purchase commitments to its net realizable value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt,"></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.17%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials and supplies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"> 60,536 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt,"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt,"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt,"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt,"></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Total inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt,"> 130,316 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr></table>60536000500820003601600030822000337640002492900013031600010583300090000001010000096000000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 12. Property, Plant, and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant, and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Buildings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 170,203 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 168,771 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 42,012 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 41,686 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Land </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 7,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 7,484 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 278,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 259,484 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Furniture, fixtures, and automobiles </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 34,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 31,943 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,864 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,676 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total property, plant, and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 561,573 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 528,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Less accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (266,189) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (245,298) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total property, plant, and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 282,746 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>
<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Buildings </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 168,771 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 42,012 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.97%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 41,686 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Land </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 7,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 7,484 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> 278,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 259,484 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Furniture, fixtures, and automobiles </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 34,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 31,943 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,864 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,676 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total property, plant, and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 561,573 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 528,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.34%;margin:0pt;padding:0pt;"> Less accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (266,189) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (245,298) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:67.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total property, plant, and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 282,746 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>
1702030001687710004201200041686000749900074840002782000002594840003479500031943000288640001867600056157300052804400026618900024529800029536
Note 13. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> September 30, </td><td

style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued customer fees and rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"> 16,702 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Accrued payroll and related benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> 29,207 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> 25,203 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued product returns, current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"> 13,480 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"> 12,263 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Accrued loss on firm purchase commitments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> 812 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> 918 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,732 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,842 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Total accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> 119,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> 67,928 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,088 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,438 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Total accounts payable and accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93,366 </td></tr></table>
<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-

space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued customer fees and rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"> 16,702 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Accrued payroll and related benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> 29,207 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> 25,203 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued product returns, current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"> 13,480 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"> 12,263 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Accrued loss on firm purchase commitments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> 812 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> 918 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,732 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,842 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Total accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> 119,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"> 67,928 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,088 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,438 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"> Total accounts payable and accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93,366 </td></tr></table>
5994900016702000292070002520300013480000122630008120009180001573200012842000119180000679280003408800002543800015326800093366000 Note 14. Debt Debt consists of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.29%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible Debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 345,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Term Loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Wells Fargo Term Loan due June 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Mortgage Loans </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Mortgage payable with East West Bank paid off June 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 8,016 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Other Loans and Payment Obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> French government loans due December 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 168 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 158 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Line of Credit Facilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Line of credit facility with China Merchant Bank due October 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Wells Fargo Revolving line of credit facility due June 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Line of credit facility with ICBC Bank due November 2033 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 13,565 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Equipment under Finance Leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 485 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 616 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Total debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> 609,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> 603,790 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Less current portion of long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 252 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 436 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Less: Loan issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,520 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,775 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term debt, net of current portion and unamortized debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 589,579 </td></tr></table> Credit Agreement 2029 Convertible Notes In September 2023, the Company issued the 2029 Convertible Notes, in the aggregate principal amount of $345.0 million in a private offering pursuant to Section 4(a)(2) and Rule 144A under the Securities Act of 1933, as amended. The Company used portions of the net proceeds from the 2029 Convertible Notes to (i) repay approximately $200.0 million of the Company's borrowings under the Wells Fargo Term Loan and (ii) repurchase $50.0 million of the Company's common stock. In connection with the issuance of the 2029 Convertible Notes, the Company incurred approximately $10.8 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees. Unamortized debt issuance costs related to the 2029 Convertible Notes were $8.8 million as of September 30, 2024. The fair value of the 2029 Convertible Notes was approximately $365.4 million as of September 30, 2024 based on level 2 inputs. The 2029 Convertible Notes are general senior, unsecured obligations and bear an interest rate of 2.0% per year. The 2029 Convertible Notes were issued pursuant to an indenture, dated September 15, 2023, or the Indenture, between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Convertible Notes will rank senior in right of payment to all of the Company's indebtedness that is expressly subordinated in right of payment to the 2029 Convertible Notes; equal in right of payment to all of the Company's unsecured indebtedness that is not so subordinated; effectively junior to any of the Company's secured indebtedness to the extent of the value of the assets securing such indebtedness, including any amount outstanding under the Company's credit facilities, and structurally junior to all indebtedness and other liabilities of the Company's current or future subsidiaries, including trade payables. Interest is payable semi-annually in arrears on March 15 and September 15 of each year. The 2029 Convertible Notes may bear additional interest under specified circumstances relating to the Company's failure to comply with its reporting obligations under the Indenture or if the 2029 Convertible Notes are not freely tradeable as required by the Indenture. The 2029 Convertible Notes will mature on March 15, 2029, unless earlier converted, repurchased or redeemed. Conversions of the 2029 Convertible Notes will be settled in cash up to the aggregate principal amount of the 2029 Convertible Notes to be converted, and cash, shares of common stock or a combination of cash and shares of common stock, at the Company's election, with respect to the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount. Holders may convert their 2029 Convertible Notes at their option prior to the close of business on the business day immediately preceding December 15, 2028, in multiples of $1,000 principal amount, only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2029 Convertible Notes on each applicable trading day, (ii) during the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, per $1,000 principal amount of the 2029 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day, (iii) if the Company calls the 2029 Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, and (iv) upon the occurrence of specified corporate events defined in the

Indenture. On or after December 15, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2029 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances. The Company may redeem the 2029 Convertible Notes, at its option, in whole or in part (subject to certain limitations), on or after September 20, 2026 and prior to the 41st scheduled trading day preceding the maturity date, if the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The initial conversion rate is 15.8821 shares of the Company's common stock per $1,000 principal amount of the 2029 Convertible Notes, which represents an initial conversion price of approximately $62.96 per share of common stock. The initial conversion price of $62.96 represents a premium of approximately 35.0% over the last reported sale price of the Company's common stock on Nasdaq Global Select Market on September 12, 2023. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture. If a fundamental change, as defined in the Indenture, occurs at any time prior to the maturity date, then, subject to certain conditions, holders of the 2029 Convertible Notes may require the Company to repurchase for cash all or any portion of their 2029 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2029 Convertible Notes to be repurchased, plus any accrued and unpaid interest. In addition, following certain specified corporate events or if the Company issues a notice of redemption, the Company will, under certain circumstances, increase the conversion rate for holders who convert their 2029 Convertible Notes in connection with such corporate event or during a redemption period. Syndicated Line of Credit Facility with ICBC Bank – Due November 2033 In January 2024, the Company entered into a credit agreement with Industrial and Commercial Bank of China Limited, or ICBC Bank, acting as a lender and as agent for other lenders. The credit agreement allows the Company to borrow up to $40.0 million secured by equipment and buildings at ANP. The interest rate and other terms will be determined at the time of the borrowing, depending on the type of loan requested. The credit agreement expires in November 2033. As of September 30, 2024, the Company borrowed approximately $13.6 million under the credit agreement. The loan bears interest at the prime rate as published by The People's Bank of China minus 0.2%. Interest payments are due quarterly and repayment of the principal amount is biannual and begins in May 2026. As of September 30, 2024, the Company had $13.6 million of principal outstanding under this loan, which is recorded net of loan issuance costs of $0.8 million. Interest Rate Swap Contract As of September 30, 2024, the fair value of the loans listed above approximated their carrying amount based on Level 2 inputs, with the exception of the 2029 Convertible Notes. For the Wells Fargo Term Loan, the Company has entered into a fixed interest rate swap contract to exchange the variable interest rates for fixed interest rates. The interest rate swap contract is recorded at fair value in the other assets line in the condensed consolidated balance sheets. Changes in the fair values of interest rate swaps were $7.4 million loss and $1.6 million loss for the three and nine months ended September 30, 2024, respectively. Changes in the fair values of interest rate swaps were $4.9 million gain and $2.7 million gain for the three and nine months ended September 30, 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Covenants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2024 and December 31, 2023, the Company was in compliance with all of its debt covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 345,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Term Loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Wells Fargo Term Loan due June 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Mortgage Loans </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Mortgage payable with East West Bank paid off June 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 8,016 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Other Loans and Payment Obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> French government loans due December 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 168 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 158 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Line of Credit Facilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Line of credit facility with China Merchant Bank due October 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Wells Fargo Revolving line of credit facility due June 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Line of credit facility with ICBC Bank due November 2033 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 13,565 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Equipment under Finance Leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 485 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 616 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Total debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> 609,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;">

603,790 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Less current portion of long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 252 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 436 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Less: Loan issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,520 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,775 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term debt, net of current portion and unamortized debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 589,579 </td></tr>
</table>34500000034500000025000000025000000080160001680001580004850006160006092180006037900002520004360001252000013775000596446000058957900034500
7400000-160000049000002700000 Note 15. Income Taxes The following table sets forth the Company's income tax provision for the periods indicated: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.05%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.76%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;background:#cceeff;margin:0pt;padding:0pt;"> Income before taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 63,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 130,014 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> Income tax provision </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,254 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;background:#cceeff;margin:0pt;padding:0pt;"> Income before equity in losses of unconsolidated affiliate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 49,612 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,854 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> Income tax provision as a percentage of income before income taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 15.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 22.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 16.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 20.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td></tr></table> Valuation Allowance In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. Ultimately, realization depends on the existence of future taxable income. Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income. The Company continues to record a full valuation allowance on the net deferred income tax assets of its France subsidiary, AFP, and its U.K. subsidiaries, AUK and IMS UK. The Company will continue to do so until the subsidiaries generate sufficient taxable income to realize their respective deferred income tax assets. The Company records a valuation allowance on net deferred income tax assets in states where it files separately and will continue to do so until sufficient taxable income is generated to realize these state deferred income tax assets. <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.05%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.76%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> Income before taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 63,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td

style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 130,014 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> Income tax provision </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,254 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;background:#cceeff;margin:0pt;padding:0pt;"> Income before equity in losses of unconsolidated affiliate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 49,612 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,854 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.87%;margin:0pt;padding:0pt;"> Income tax provision as a percentage of income before income taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 15.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 22.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 16.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 20.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> % </td></tr></table>476830006363700014580200013001400072540001402500023674000271600004042900049612000122128000102854000.1520.2200.1620.209 Note 16. Stockholders' Equity Share Buyback Program Pursuant to the Company's existing share buyback program, the Company purchased 797,038 and 1,004,326 shares of its common stock, during the three and nine months ended September 30, 2024, for total consideration of $35.0 million and $43.5 million, respectively. The Company purchased 1,072,041 and 1,338,757 shares of its common stock during the three and nine months ended September 30, 2023, for total consideration of $50.0 million and $58.1 million, respectively. The Company's Board of Directors authorized a $50.0 million increase to the Company's share buyback program in June 2024, and an additional $50.0 million increase in November 2024, which is expected to continue for an indefinite period of time. Since the inception of the program, the Company's Board of Directors has authorized a total of $385.0 million in the share buyback program. The primary goal of the program is to offset dilution created by the Company's equity compensation programs. Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company's management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company's condensed consolidated balance sheets. Amended and Restated 2015 Equity Incentive Plan In February 2024, the Board of Directors approved the Company's amended and restated 2015 Equity Incentive Plan, or the Amended 2015 Plan, which was subsequently approved by the Company's stockholders, and accordingly, adopted by the Company in June 2024. The Amended 2015 Plan extends the terms of the 2015 Equity Incentive Plan, or the Original 2015 Plan, and makes certain other changes. The term of the Amended 2015 Plan will be extended indefinitely, however, the Company's ability to grant incentive stock options thereunder will continue through February 2034. As of September 30, 2024, the Company reserved an aggregate of 7,817,319 shares of common stock for future issuance under the Amended 2015 Plan. 2014 Employee Stock Purchase Plan As of September 30, 2024, the Company has issued 1,246,323 shares of common stock under the ESPP and 753,677 shares of its common stock remain available for issuance under the ESPP. In May 2024, the Company issued 54,189 shares at a purchase price of $35.98 per share under the ESPP. For the three and nine months ended September 30, 2024, the Company recorded ESPP expense of $0.2 million and $0.9 million, respectively. For the three and nine months ended September 30, 2023, the Company recorded ESPP expense of $0.2 million and $0.8 million, respectively. Share-Based Award Activity and Balances The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the ESPP awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company's common share price. Compensation cost for all share-based payments granted with service-based graded vesting schedules is recognized using the straight-line method over the requisite service period. The weighted-averages for key assumptions used in determining the fair value of options granted are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58127594%;padding-left:0pt;padding-right:0pt;width:101.16%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> September 30, </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;"> Average volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> 40.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> 41.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"> 41.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> Average risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 4.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> 4.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"> 4.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average expected life in years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> 6.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> 6.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"> 6.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> Dividend yield rate </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr></table> A summary of option activity under all plans for the nine months ended September 30, 2024, is presented below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.09774017%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.86%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;margin:0pt;padding:0pt;"> Intrinsic </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term (Years) </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value⁽¹⁾ </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"> 7,762,298 </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.70</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 642,985</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46.27</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,611,117)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,138)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35.10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,773,028</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> 23.61 </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:13.14%;margin:0pt;padding:0pt;"> 5.12 </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">168,760</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Exercisable as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,968,365</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19.02</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.97</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 146,600 </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> Vested and expected to vest as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,617,113 </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> 23.24 </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> 5.04 </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> 167,346 </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> x </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company's stock for those awards that have an exercise price below the estimated fair value at September 30, 2024.</td></tr></table> x For the three and nine months ended September 30, 2024, the Company recorded expense of $2.7 million and $9.0 million, respectively, related to stock options granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expense of $2.2 million and $7.5 million, respectively, related to stock options granted under all plans. x Information relating to option grants and exercises is as follows: x <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> x </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.7%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> x </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.55%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> x </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> x </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.05%;margin:0pt;padding:0pt;"> (in thousands, except per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average grant date fair value per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 21.49 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 16.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> Intrinsic value of options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 6,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 5,628 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 48,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 24,544 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"> Cash received from options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 3,332 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 9,154 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 12,015 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> Total fair value of the options vested during the period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 111 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 9,815 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 8,887 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr></table> A summary of the status of the Company’s non-vested options as of September 30, 2024, and changes during the nine months ended September 30, 2024, are presented below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Grant Date </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"> 2,076,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"> 12.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> 642,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 21.89 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"> (893,539) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"> 10.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> Options forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,138) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 16.19 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:66.8%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,804,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"> 16.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> As of September 30 2024, there was $21.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures. Restricted Stock Units The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to four years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until vested. The RSUs do not have any voting or dividend rights prior to the issuance of the underlying common stock. The share-based expense associated with these grants was based on the Company's common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. For the three and nine months ended September 30, 2024, the Company recorded total expenses of $2.7 million and $8.8 million, respectively, related to RSU awards granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expenses of $2.2 million and $7.3 million, respectively, related to RSU awards granted under all plans. As of September 30, 2024, there was $22.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures. Information relating to RSU grants and deliveries is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"> Total Fair Market </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Total RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"> Value of RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issued </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issued⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> 920,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> 303,788 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> 14,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> (9,620) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> RSUs vested⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (388,668) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 825,876 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations.</td></tr></table> Share-based Compensation Expense The Company recorded share-based compensation expense, which is included in the Company's condensed consolidated statement of operations as follows: <span

style="visibility:hidden;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.66%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 1,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 3,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> Operating expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, distribution, and marketing </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 249 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 213 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 777 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 649 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 3,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 2,975 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 11,239 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 9,323 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,780 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> Total share-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,644 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,620 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr></table> *
797038100432635000000.043500000107204113387575000000.058100000500000000.050000000.038500000.078173191246323753675418935.98200000900000200000
* <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58127594%;padding-left:0pt;padding-right:0pt;width:101.16%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-*

space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;"> Average volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> 40.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> 41.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"> 41.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> Average risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 4.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> 4.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"> 4.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average expected life in years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> 6.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> 6.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"> 6.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.72%;margin:0pt;padding:0pt;"> Dividend yield rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr>
</table>0.4020.4130.4140.0440.0420.041P6Y3M18DP6Y2M12DP6Y2M12D0000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.09774017%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.86%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;margin:0pt;padding:0pt;"> Intrinsic </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term (Years) </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value⁽¹⁾ </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"> </td><td

colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"> 7,762,298 </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.70</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 642,985</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46.27</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,611,117)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,138)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35.10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,773,028</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"> 23.61 </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"> 5.12 </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> 168,760 </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:45.25%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,968,365 </td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:normal;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"> 19.02 </td><td style="vertical-align:bottom;white-space:normal;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"> 3.97 </td><td style="vertical-align:bottom;white-space:normal;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146,600</p></td><td style="vertical-align:bottom;white-space:normal;width:0.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:normal;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,617,113</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"> 167,346 </td><td style="vertical-align:bottom;white-space:normal;width:0.4%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company's stock for those awards that have an exercise price below the estimated fair value at September 30, 2024.</td></tr></table>776229819.7064298546.27161111713.662113835.10677302823.61P5Y1M13D168760000496836519.02P3Y11M19D1466000006617113 23.24P5Y14D167346000270000 style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.7%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.55%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;">   </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">   </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.05%;margin:0pt;padding:0pt;"> (in thousands, except per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">Weighted-average grant date fair value per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 21.49 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 16.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> Intrinsic value of options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 6,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 5,628 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 48,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 24,544 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"> Cash received from options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 3,332 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 9,154 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"> 12,015 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"> Total fair value of the options vested during the period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 111 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 9,815 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"> 8,887 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td></tr></table>21.4921.8916.7662180005628000483810002454400033320002277000915400012015000111000167000981500008887000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Grant Date </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"> 2,076,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"> 12.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> 642,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 21.89 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"> (893,539) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"> 10.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.8%;margin:0pt;padding:0pt;"> Options forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,138) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 16.19 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:66.8%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,804,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"> 16.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr>
</table>207635512.6864298521.8989353910.982113816.19180466316.7621300000P2Y7M6DP4Y1270000088000002200000730000022600000P2Y7M6D <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"> Total Fair Market </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Total RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"> Value of RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issued </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issued⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> 920,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> RSUs granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> 303,788 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"> 14,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> (9,620) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.7%;margin:0pt;padding:0pt;"> RSUs vested⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (388,668) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.7%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 825,876 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations.</td></tr></table>9203763037881406000096203886688258761479 59 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1

space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.66%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 1,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 3,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> Operating expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, distribution, and marketing </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 249 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 213 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 777 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"> 649 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 3,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 2,975 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 11,239 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 9,323 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,780 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"> Total share-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,644 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,620 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"> </td></tr></table> 1133000100400045830003868000249000213000777000649000371000029750001123900093230005040004520002137000178000055960004644000187360001562000041

Note 17. Employee Benefits 401(k) Plan The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three and nine months ended September 30, 2024 were approximately $0.6 million and $2.0 million, respectively, compared to the prior year expense of $0.5 million and $1.7 million for the three and nine months ended September 30, 2023, respectively. Defined Benefit Pension Plan The Company's subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employee's length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee's age, length of service, and AFP employee turnover rate. The liability under the plan is based on a discount rate of 3.25% as of September 30, 2024 and December 31, 2023. The liability is included in other long-term liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.8 million and $2.6 million at September 30, 2024 and December 31, 2023, respectively. The Company recorded an immaterial amount of expense under the plan for each of the three and nine months ended September 30, 2024 and 2023. Non-qualified Deferred Compensation Plan In December 2019, the Company established a non-qualified deferred compensation plan. The plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. The plan assets were valued at approximately $9.4 million and $6.8 million as of September 30, 2024 and December 31, 2023, respectively. The plan liabilities were valued at approximately $9.8 million and $7.1 million as of September 30, 2024, and December 31, 2023, respectively. The plan assets and liabilities are included in other long-term assets and other long-term liabilities, respectively, on the Company's condensed consolidated balance sheets. 0.500.066000002000000.0500000170000000.03250.0325280000026000009400000680000098000007100000 Note 18. Commitments and Contingencies Purchase Commitments As of September 30, 2024, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $95.9 million. 95900000 Note 19. Related Party Transactions Investment in Hanxin Pharmaceutical Technology, Co., Ltd. The Company has an 11.5% ownership in Hanxin Pharmaceutical Technology Co., Ltd, or Hanxin, that is accounted for as an equity method investment. The Company maintains a seat on Hanxin's board of directors, and Henry Zhang, the son of Dr. Jack Zhang, is an equity holder, the general manager, and the chairman of the board of directors of Hanxin. Additionally, Dr. Mary Luo and Dr. Jack Zhang, have an ownership interest in Hanxin through an affiliated entity. As a result, Hanxin is a related party. Contract manufacturing agreement with Hanxin The Company, has various contract manufacturing agreements with Hanxin and its subsidiaries, whereby Hanxin will develop several active pharmaceutical ingredients and finished products for the Chinese market and will engage the Company to manufacture the products on a cost-plus basis. During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.5 million, respectively, of revenue from manufacturing services provided to Hanxin. During the three and nine months ended September 30, 2023, the Company recognized an immaterial amount of revenue from manufacturing services provided to Hanxin. As of September 30, 2024, the Company had $0.4 million of receivables from Hanxin. Contract Research Agreement with Hanxin In July 2022, the Company entered into a three-year contract research agreement with Hanxin, a related party, whereby Hanxin will develop Recombinant Human Insulin Research Cell Banks, or RCBs, for the Company and license the RCBs to the Company subject to a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license. Hanxin will also perform scale-up manufacturing process development using the RCBs for the Company. <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">During the three months ended September 30, 2024, the Company did not have any payments under the amended agreement and during the nine months ended September 30 2024, the Company paid $0.2 million under the amended agreement. During the three and nine months ended September 30, 2023, the Company paid $0.4 million and $1.0 million, respectively, under the amended agreement. As of September 30, 2024, the Company had an immaterial amount payable to Hanxin. Supply Agreement with Letop In November 2022, the Company, entered into a supply agreement with Nanjing Letop Biotechnology Co., Ltd., or Letop, which is considered a related-party due to an ownership stake of Henry Zhang. Under the terms of the supply agreement Letop will manufacture and deliver chemical intermediates to the Company on a cost-plus basis. The agreement is effective for three years and the total cost of the agreement shall not exceed $1.5 million, with payments adjusted based on the then current exchange rates. During the three and nine months ended September 30, 2024, the Company paid an immaterial amount under this agreement. During the three months ended September 30, 2023, the Company did not have any payments under this agreement. During the nine months ended September 30, 2023, the Company paid $0.7 million, under this agreement. As of September 30, 2024, the Company did not have any amounts payable to Letop. Primatene MIST® Distribution agreement with Hong Kong Genreach Limited In August 2024, the Company entered into a distribution agreement with Hong Kong Genreach Limited, or Genreach, a wholly owned subsidiary of Hanxin, a related party. Per the terms of the agreement, the Company has appointed Genrearch as the exclusive distributor to market and sell Primatene MIST® in Mainland China, Taiwan, Hong Kong, and Macau in the Greater China region. Genreach will be responsible for obtaining any and all regulatory approvals in the region for Primatene MIST®. The term of the agreement is ten years, with both parties having termination rights without cause after the completion of the second contract year. 0.11510000050000040000020000040000001000000.01500000700000 Note 20. Litigation Employment Litigation On April 15, 2024, a former employee (“Plaintiff”) initiated an employment litigation against Amphastar and IMS by filing a complaint, as amended, having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the class action complaint. On June 20, 2024, a former employee (“Plaintiff”) initiated an employment litigation against Amphastar, IMS and Roth Staffing Companies L.P. by filing a complaint having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the complaint. Albuterol sulfate Inhalation Aerosol Patent Litigation On July 25, 2024, Teva Branded Pharmaceutical Products R&D, Inc. (“Teva Branded”), Norton (Waterford) Ltd. (“Norton”), and Teva Pharmaceuticals USA, Inc. (“Teva USA”), collectively referred to as (“Plaintiff”) filed a Complaint in the United States District Court for the District of Delaware (“Delaware Court”) against the Company for infringement of U.S. Patent No. 9,463,289, with regard to Amphastar’s ANDA No. 212447, for approval to manufacture and sell generic version of ProAir® HFA (albuterol sulfate) Inhalation Aerosol. On October 21, 2024, Plaintiff amended its complaint against the Company to include additional claims for infringement of U.S. Patent No. 9,808,587 and 10,561,808, with regard to Amphastar’s ANDA No. 212447, for approval to manufacture and sell generic version of ProAir®HFA (albuterol sulfate) Inhalation Aerosol. The Company intends to vigorously defend this patent lawsuit. Other litigation The Company is subject to various claims, arbitrations, investigations, and lawsuits from time to time arising in the ordinary course of business. In addition, third parties may, from time to time, assert claims against the Company in the forms of letters and other communications. Currently, the Company is subject to a lawsuit for a property and casualty claim, for which it has recorded an estimated liability of $6.0 million within accounts payable and other accrued liabilities on the condensed balance sheet as of September 30, 2024. This estimated liability is fully covered by the Company’s insurance policies. The $6.0 million insurance recovery related to this claim is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheet as of September 30, 2024. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.
6000000.06000000.0falsefalsefalsefalse